20667451
D003474_D003072 NONE Curcumin_0/NN (r_nsubj) ameliorates_1/VBZ (l_dobj) dysfunction_3/NN
D003474_D003072 NONE curcumin_14/NNP (r_compound) administration_15/NNP (r_pobj) of_12/IN (r_prep) effect_11/NN (l_prep) on_16/IN (l_pobj) impairment_23/NN
D003474_D003072 NONE curcumin_1/NN (r_compound) administration_2/NN (r_nsubj) prevented_3/VBD (l_dobj) impairment_6/NN
D003474_D003072 NONE curcumin_4/NN (r_nsubj) has_5/VBZ (l_dobj) effect_7/NN (l_prep) in_8/IN (l_pcomp) mitigating_9/VBG (l_dobj) deterioration_11/NN (l_prep) of_12/IN (l_pobj) functions_14/NNS
D003474_D003072 NONE curcumin_4/NN (r_nsubjpass) considered_7/VBN (l_prep) as_8/IN (l_pobj) adjuvant_14/NN (l_prep) to_15/IN (l_pobj) phenobarbitone_16/NN (l_conj) therapy_19/NN (l_prep) in_20/IN (l_pcomp) preventing_21/VBG (l_dobj) impairment_23/NN
D010634_D003072 CID phenobarbitone_8/NN (r_pobj) in_7/IN (r_prep) dysfunction_3/NN
D010634_D003072 CID phenobarbitone_4/NN (r_appos) drugs_2/NNS (r_nsubj) are_7/VBP (l_acomp) known_9/VBN (l_xcomp) cause_11/VB (l_dobj) impairment_13/NN
D010634_D003072 CID phenobarbitone-_17/NNP (r_dep) and_18/CC (r_cc) induced_21/VBN (r_amod) impairment_23/NN
D010634_D003072 CID phenobarbitone_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) caused_8/VBD (l_dobj) impairment_11/NN (l_prep) of_12/IN (l_pobj) learning_13/NN (l_conj) memory_15/NN
D010634_D003072 CID phenobarbitone_22/NN (r_pobj) with_21/IN (r_prep) treated_20/VBN (r_acl) rats_19/NNS (r_pobj) in_18/IN (r_prep) damage_17/NN (r_conj) functions_14/NNS
D010634_D003072 CID phenobarbitone_16/NN (l_conj) therapy_19/NN (l_prep) in_20/IN (l_pcomp) preventing_21/VBG (l_dobj) impairment_23/NN
D002220_D003072 CID carbamazepine_10/NN (r_conj) phenobarbitone_8/NN (r_pobj) in_7/IN (r_prep) dysfunction_3/NN
D002220_D003072 CID carbamazepine_6/NN (r_conj) phenobarbitone_4/NN (r_appos) drugs_2/NNS (r_nsubj) are_7/VBP (l_acomp) known_9/VBN (l_xcomp) cause_11/VB (l_dobj) impairment_13/NN
D002220_D003072 CID carbamazepine_19/NN (r_npadvmod) induced_21/VBN (r_amod) impairment_23/NN
D002220_D003072 CID carbamazepine_5/NNP (r_conj) phenobarbitone_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) caused_8/VBD (l_dobj) impairment_11/NN (l_prep) of_12/IN (l_pobj) learning_13/NN (l_conj) memory_15/NN
D002220_D003072 CID carbamazepine_24/NN (r_conj) phenobarbitone_22/NN (r_pobj) with_21/IN (r_prep) treated_20/VBN (r_acl) rats_19/NNS (r_pobj) in_18/IN (r_prep) damage_17/NN (r_conj) functions_14/NNS
D002220_D003072 CID carbamazepine_18/NN (r_compound) therapy_19/NN (l_prep) in_20/IN (l_pcomp) preventing_21/VBG (l_dobj) impairment_23/NN
3827439
D000666_D058186 CID amphotericin_6/NNS (r_pobj) from_5/IN (r_prep) failure_4/NN
D000666_D058186 CID B_18/NNP (r_pobj) of_16/IN (r_prep) administration_15/NN (r_dobj) following_13/VBG (r_acl) failure_11/NN
D000666_D058186 CID amphotericin_3/NN (r_dobj) propose_1/VBP (l_conj) activate_15/VB (l_advcl) contributing_20/VBG (l_prep) to_21/IN (l_pobj) failure_24/NN
D000666_D005355 NONE B_18/NNP (r_pobj) of_16/IN (r_prep) administration_15/NN (r_dobj) following_13/VBG (r_acl) failure_11/NN (r_dobj) developed_8/VBD (l_nsubj) patient_1/NN (l_prep) with_2/IN (l_pobj) cirrhosis_4/NN
D000666_D013174 NONE B_18/NNP (r_pobj) of_16/IN (r_prep) administration_15/NN (r_dobj) following_13/VBG (r_acl) failure_11/NN (r_dobj) developed_8/VBD (l_nsubj) patient_1/NN (l_conj) sporotrichosis_7/NNP
1601297
D003042_D009202 NONE cocaine_8/NN (r_compound) abusers_9/NNS (r_pobj) in_5/IN (r_prep) injury_4/NN
D003042_D009202 NONE cocaine_3/NN (r_compound) abusers_4/NNS (r_pobj) of_1/IN (r_prep) Eleven_0/CD (r_nsubj) had_10/VBD (l_dobj) evidence_12/NN (l_prep) of_13/IN (l_pobj) injury_16/NN
D003042_D012559 NONE cocaine_7/NN (r_npadvmod) abusing_9/VBG (r_amod) patients_10/NNS (r_pobj) of_5/IN (r_prep) electrocardiograms_1/NNS (r_nsubjpass) compared_12/VBN (l_prep) with_13/IN (l_pobj) ECGs_15/NNS (l_prep) of_16/IN (l_pobj) controls_19/NNS (l_amod) schizophrenic_18/JJ
D003042_D009203 CID cocaine_3/NN (r_compound) abusers_4/NNS (r_pobj) of_1/IN (r_prep) Eleven_0/CD (r_nsubj) had_10/VBD (l_dobj) evidence_12/NN (l_prep) of_13/IN (l_pobj) injury_16/NN (l_acl) defined_17/VBN (l_prep) as_18/IN (l_pobj) infarction_20/NN
D003042_D007511 NONE cocaine_3/NN (r_compound) abusers_4/NNS (r_pobj) of_1/IN (r_prep) Eleven_0/CD (r_nsubj) had_10/VBD (l_dobj) evidence_12/NN (l_prep) of_13/IN (l_pobj) injury_16/NN (l_acl) defined_17/VBN (l_prep) as_18/IN (l_pobj) infarction_20/NN (l_conj) ischemia_22/NN
D003042_D002037 CID cocaine_3/NN (r_compound) abusers_4/NNS (r_pobj) of_1/IN (r_prep) Eleven_0/CD (r_nsubj) had_10/VBD (l_dobj) evidence_12/NN (l_prep) of_13/IN (l_pobj) injury_16/NN (l_acl) defined_17/VBN (l_prep) as_18/IN (l_pobj) infarction_20/NN (l_conj) ischemia_22/NN (l_conj) block_27/NN
6133211
D012460_D015212 NONE sulphasalazine_15/NNP (r_pobj) with_14/IN (r_prep) treatment_13/NN (r_dobj) received_12/VBD (r_relcl) mothers_6/NNS (l_prep) with_7/IN (l_pobj) disease_10/NN
D012460_D000013 NONE sulphasalazine_15/NNP (r_pobj) with_14/IN (r_prep) treatment_13/NN (r_dobj) received_12/VBD (r_relcl) mothers_6/NNS (r_pobj) of_4/IN (r_prep) born_3/VBN (r_acl) infants_1/NNS (r_nsubjpass) found_20/VBN (l_xcomp) have_22/VB (l_dobj) anomalies_25/NNS
11007689
D016572_D057049 CID Cyclosporine_0/NN (r_nmod) microangiopathy_6/NN
D016572_D057049 CID cyclosporine_13/NN (r_pobj) of_12/IN (r_prep) use_11/NN (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) TMA_6/NNP (r_appos) microangiopathy_4/NNP
D016572_D057049 CID cyclosporine_13/NN (r_pobj) of_12/IN (r_prep) use_11/NN (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) TMA_6/NNP
D016572_D057049 CID cyclosporine_20/NN (r_npadvmod) induced_22/VBN (r_amod) TMA_23/NNP
D016572_D057049 CID cyclosporine_16/NN (r_pobj) to_15/IN (r_prep) exposed_13/VBN (r_acl) patients_12/NNS (r_pobj) in_11/IN (r_prep) recurrence_8/NN (l_prep) of_9/IN (l_pobj) TMA_10/NNP
D016572_D057049 CID cyclosporine_13/NN (r_npadvmod) induced_15/VBN (r_amod) TMA_16/NNP
D016572_D057049 CID cyclosporine_23/NN (r_pobj) of_22/IN (r_prep) withdrawal_21/NN (r_pobj) to_19/IN (r_prep) responded_18/VBD (r_relcl) TMA_16/NNP
D016572_D057049 CID cyclosporine_5/NN (r_pobj) from_4/IN (r_prep) switched_3/VBN (r_relcl) Patients_0/NNS (r_nsubjpass) monitored_14/VBN (l_prep) for_15/IN (l_pobj) signs_17/NNS (l_prep) of_20/IN (l_pobj) TMA_22/NNP
D016559_D057049 CID tacrolimus_2/NN (r_npadvmod) associated_4/VBN (r_conj) Cyclosporine_0/NN (r_nmod) microangiopathy_6/NN
D016559_D057049 CID tacrolimus_6/NN (r_pobj) to_5/IN (r_prep) switching_4/VBG (r_csubjpass) reported_9/VBN (l_xcomp) be_11/VB (l_attr) option_15/NN (l_prep) in_16/IN (l_pobj) setting_18/NN (l_prep) of_19/IN (l_pobj) TMA_23/NNP
D016559_D057049 CID tacrolimus_6/NN (r_pobj) of_5/IN (r_prep) application_4/NN (r_pobj) With_0/IN (r_prep) recognized_18/VBN (l_nsubjpass) TMA_14/NNP
D016559_D057049 CID tacrolimus_11/NN (r_npadvmod) associated_13/VBN (r_amod) TMA_14/NNP
D016559_D057049 CID tacrolimus_18/NN (r_nsubj) is_19/VBZ (l_nsubj) literature_2/NN (l_prep) regarding_3/VBG (l_pobj) incidence_5/NN (l_prep) of_6/IN (l_pobj) recurrence_8/NN (l_prep) of_9/IN (l_pobj) TMA_10/NNP
D016559_D057049 CID tacrolimus_2/NN (r_pobj) of_1/IN (r_prep) Introduction_0/NN (r_nsubj) resulted_8/VBD (l_prep) in_9/IN (l_pobj) recurrence_11/NN (l_prep) of_12/IN (l_pobj) TMA_13/NNP
D016559_D057049 CID tacrolimus_7/NN (r_pobj) to_6/IN (r_prep) switched_3/VBN (r_relcl) Patients_0/NNS (r_nsubjpass) monitored_14/VBN (l_prep) for_15/IN (l_pobj) signs_17/NNS (l_prep) of_20/IN (l_pobj) TMA_22/NNP
18329269
D006220_D002375 CID haloperidol_36/NN (r_npadvmod) induced_38/VBN (r_amod) model_40/NN (l_compound) catalepsy_39/NN
D006220_D010300 NONE haloperidol_36/NN (r_npadvmod) induced_38/VBN (r_amod) model_40/NN (l_prep) for_41/IN (l_pobj) disease_44/NN
20003049
C031942_D013921 NONE argatroban_4/NNP (r_pobj) of_2/IN (r_prep) elevation_1/NN (l_prep) in_5/IN (l_pobj) patient_9/NN (l_prep) with_10/IN (l_pobj) history_13/NN (l_prep) of_14/IN (l_pobj) thrombocytopenia_18/NN
C031942_D013921 NONE argatroban_20/NNP (r_oprd) administered_19/VBN (l_nsubjpass) patient_11/NN (l_prep) with_12/IN (l_pobj) history_15/NN (l_prep) of_16/IN (l_pobj) HITT_17/NNP
C031942_D013927 NONE argatroban_4/NNP (r_pobj) of_2/IN (r_prep) elevation_1/NN (l_prep) in_5/IN (l_pobj) patient_9/NN (l_prep) with_10/IN (l_pobj) history_13/NN (l_prep) with_19/IN (l_pobj) thrombosis_20/NN
C031942_D013927 NONE argatroban_20/NNP (r_oprd) administered_19/VBN (l_nsubjpass) patient_11/NN (l_prep) with_12/IN (l_pobj) history_15/NN (l_prep) of_16/IN (l_pobj) HITT_17/NNP
D006493_D013921 NONE heparin_15/NN (r_npadvmod) induced_17/VBN (r_amod) thrombocytopenia_18/NN
D006493_D013921 NONE heparin_18/NN (r_npadvmod) induced_20/VBN (r_amod) thrombocytopenia_21/NN
D006493_D013921 NONE heparin_18/NN (r_npadvmod) induced_20/VBN (r_amod) thrombocytopenia_21/NN (l_appos) HIT_23/NN
D006493_D013921 NONE heparin_18/NN (r_npadvmod) induced_20/VBN (r_amod) thrombocytopenia_21/NN (r_pobj) of_17/IN (r_prep) history_16/NN (r_pobj) with_14/IN (r_prep) patients_13/NNS (r_pobj) for_12/IN (r_prep) method_9/NN (r_dobj) provide_6/VB (l_conj) HIT_26/VB
D006493_D013921 NONE heparin_18/NN (r_npadvmod) induced_20/VBN (r_amod) thrombocytopenia_21/NN (r_pobj) of_17/IN (r_prep) history_16/NN (r_pobj) with_14/IN (r_prep) patients_13/NNS (r_pobj) for_12/IN (r_prep) method_9/NN (r_dobj) provide_6/VB (l_conj) HIT_26/VB (l_prep) with_27/IN (l_pobj) thrombosis_28/NN (l_appos) HITT_30/NNP
D006493_D013927 NONE heparin_15/NN (r_npadvmod) induced_17/VBN (r_amod) thrombocytopenia_18/NN (r_pobj) of_14/IN (r_prep) history_13/NN (l_prep) with_19/IN (l_pobj) thrombosis_20/NN
D006493_D013927 NONE heparin_18/NN (r_npadvmod) induced_20/VBN (r_amod) thrombocytopenia_21/NN (r_pobj) of_17/IN (r_prep) history_16/NN (r_pobj) with_14/IN (r_prep) patients_13/NNS (r_pobj) for_12/IN (r_prep) method_9/NN (r_dobj) provide_6/VB (l_conj) HIT_26/VB (l_prep) with_27/IN (l_pobj) thrombosis_28/NN
D006493_D013927 NONE heparin_18/NN (r_npadvmod) induced_20/VBN (r_amod) thrombocytopenia_21/NN (r_pobj) of_17/IN (r_prep) history_16/NN (r_pobj) with_14/IN (r_prep) patients_13/NNS (r_pobj) for_12/IN (r_prep) method_9/NN (r_dobj) provide_6/VB (l_conj) HIT_26/VB (l_prep) with_27/IN (l_pobj) thrombosis_28/NN (l_appos) HITT_30/NNP
C031942_D016638 NONE argatroban_20/NNP (r_oprd) administered_19/VBN (l_nsubjpass) patient_11/NN (l_amod) ill_10/JJ
C031942_D001778 NONE argatroban_3/NNP (r_compound) concentration_4/NN (r_pobj) of_1/IN (r_prep) Correlation_0/NN (r_nsubj) suggest_14/VBP (l_ccomp) contributed_24/VBN (l_prep) to_25/IN (l_pobj) coagulopathy_30/NN
C031942_D001778 NONE argatroban_21/NNP (r_pobj) of_19/IN (r_prep) levels_18/NNS (r_nsubj) contributed_24/VBN (l_prep) to_25/IN (l_pobj) coagulopathy_30/NN
C031942_D001778 NONE argatroban_8/NNP (r_compound) concentration_9/NN (r_dobj) measure_6/VB (l_conj) extended_16/JJ (l_dobj) coagulopathy_17/NN
3676049
D007530_D007022 CID isoflurane_6/RB (r_advmod) induced_8/VBN (r_amod) hypotension_9/NN
D007530_D007022 CID isoflurane_12/NN (r_advmod) induced_14/VBN (r_amod) hypotension_15/NN
D007530_D002532 NONE isoflurane_6/RB (r_advmod) induced_8/VBN (r_amod) hypotension_9/NN (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_acl) subjected_12/VBN (l_prep) for_15/IN (l_pobj) aneurysms_17/NNS
D007530_D002532 NONE isoflurane_12/NN (r_advmod) induced_14/VBN (r_amod) hypotension_15/NN (l_prep) in_16/IN (l_pobj) patients_18/NNS (l_acl) subjected_19/VBN (l_prep) for_22/IN (l_pobj) clipping_23/NN (l_prep) of_24/IN (l_pobj) aneurysm_27/NN
D010100_D007022 NONE oxygen_8/NN (r_pobj) for_7/IN (r_prep) rate_6/NN (r_conj) flow_2/NN (r_nsubjpass) measured_10/VBN (l_prep) during_11/IN (l_pobj) hypotension_15/NN
D010100_D002532 NONE oxygen_8/NN (r_pobj) for_7/IN (r_prep) rate_6/NN (r_conj) flow_2/NN (r_nsubjpass) measured_10/VBN (l_prep) during_11/IN (l_pobj) hypotension_15/NN (l_prep) in_16/IN (l_pobj) patients_18/NNS (l_acl) subjected_19/VBN (l_prep) for_22/IN (l_pobj) clipping_23/NN (l_prep) of_24/IN (l_pobj) aneurysm_27/NN
D014978_D013345 NONE xenon-133_24/NNP (r_compound) Anaesthesia_26/NNP (r_dobj) using_23/VBG (r_acl) technique_22/NN (r_pobj) of_16/IN (r_prep) modification_15/NN (r_pobj) by_13/IN (r_prep) haemorrhage_12/NN
D007530_D013345 NONE isoflurane_32/NN (r_amod) concentration_33/NN (r_pobj) with_29/IN (r_prep) maintained_28/VBN (l_nsubjpass) haemorrhage_12/NN
D009609_D013345 NONE oxide_42/NN (r_conj) %_36/NN (r_pobj) of_34/IN (r_prep) concentration_33/NN (r_pobj) with_29/IN (r_prep) maintained_28/VBN (l_nsubjpass) haemorrhage_12/NN
D010100_D013345 NONE oxygen_44/NN (r_pobj) in_43/IN (r_prep) oxide_42/NN (r_conj) %_36/NN (r_pobj) of_34/IN (r_prep) concentration_33/NN (r_pobj) with_29/IN (r_prep) maintained_28/VBN (l_nsubjpass) haemorrhage_12/NN
D007530_D000783 NONE isoflurane_7/NN (r_compound) concentration_8/NN (r_nsubjpass) reduced_10/VBN (l_prep) After_0/IN (l_pobj) clipping_2/NN (l_prep) of_3/IN (l_pobj) aneurysm_5/NN
2096243
C017367_D019965 CID Carmofur_0/NN (r_npadvmod) induced_2/VBN (r_amod) disorders_5/NNS
C017367_D019965 CID carmofur_19/NN (r_npadvmod) induced_21/VBN (r_amod) leukoencephalopathy_22/NNP (r_pobj) of_18/IN (r_prep) onset_17/NN (r_pobj) after_15/IN (r_prep) period_14/NN (r_pobj) in_11/IN (r_prep) observed_4/VBN (l_nsubjpass) disorder_2/NN
C017367_D056784 CID carmofur_19/NN (r_npadvmod) induced_21/VBN (r_amod) leukoencephalopathy_22/NNP
C017367_D056784 CID carmofur_2/NN (r_npadvmod) induced_4/VBN (r_amod) leukoencephalopathy_5/NNS
C017367_D010554 NONE carmofur_2/NN (r_npadvmod) induced_4/VBN (r_amod) leukoencephalopathy_5/NNS (r_nsubj) result_8/VB (l_prep) in_9/IN (l_pobj) syndrome_12/NN
8638206
D001279_D010243 CID atracurium_6/NN (r_pobj) of_5/IN (r_prep) use_4/NN (r_pobj) after_2/IN (r_prep) paralysis_1/NN
D001279_D010243 CID besylate_1/NNP (r_nsubjpass) associated_22/VBN (l_prep) with_23/IN (l_pobj) paralysis_25/NN
D001279_D010243 CID atracurium_5/NN (r_npadvmod) related_7/VBN (r_amod) paralysis_8/NN
D014673_D010243 CID bromide_21/NN (r_pobj) as_19/IN (r_prep) NMBAs_17/NNP (r_dobj) involved_13/VBN (l_nsubj) Reports_0/NNS (l_prep) of_1/IN (l_pobj) paralysis_3/NN
-1_D010243 NONE benzylisoquinolinium_7/NN (r_compound) NMBA_8/NNS (r_appos) besylate_1/NNP (r_nsubjpass) associated_22/VBN (l_prep) with_23/IN (l_pobj) paralysis_25/NN
18410508
D008694_D020258 NONE Methamphetamine_0/NN (r_npadvmod) induced_2/VBN (r_amod) activation_6/NN (l_nmod) neurotoxicity_3/NN
D008694_D020258 NONE METH_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) damage_3/NN (r_nsubj) is_9/VBZ (l_prep) for_12/IN (l_pobj) system_16/NN (l_prep) in_17/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) neurotoxicity_21/NN
D008694_D020258 NONE METH_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) damage_3/NN (r_nsubj) is_9/VBZ (r_advcl) hypothesized_24/VBD (l_ccomp) plays_28/VBZ (l_dobj) role_30/NN (l_prep) in_31/IN (l_pobj) activation_38/NN (l_nmod) neurotoxicity_35/NN
D008694_D020258 NONE METH_32/NN (r_npadvmod) induced_34/VBN (r_amod) neurotoxicity_35/NN (r_nmod) activation_38/NN (r_pobj) in_31/IN (r_prep) role_30/NN (r_dobj) plays_28/VBZ (r_ccomp) hypothesized_24/VBD (l_advcl) is_9/VBZ (l_prep) for_12/IN (l_pobj) system_16/NN (l_prep) in_17/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) neurotoxicity_21/NN
D008694_D020258 NONE METH_32/NN (r_npadvmod) induced_34/VBN (r_amod) neurotoxicity_35/NN
D008694_D020258 NONE METH_25/NNS (r_pobj) with_24/IN (r_prep) treated_23/VBN (l_conj) examined_27/VBN (l_prep) for_28/IN (l_pobj) neurotoxicity_30/NN
D008694_D020258 NONE METH_11/NNS (r_compound) neurotoxicity_12/NN
D015632_D009422 CID MPTP_23/NNP (r_npadvmod) induced_25/VBN (r_amod) neurodegeneration_26/NN
D015632_D009422 CID MPTP_8/NNP (r_conj) METH_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) damage_3/NN
D004298_D009422 NONE DA_28/NNP (r_compound) neurons_29/NNS (r_pobj) of_27/IN (r_prep) mediator_21/NN (l_prep) of_22/IN (l_pobj) neurodegeneration_26/NN
D004298_D009422 NONE DA_14/NNP (r_nmod) system_16/NN (r_pobj) for_12/IN (r_prep) is_9/VBZ (l_nsubj) damage_3/NN
D008694_D009422 CID METH_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) damage_3/NN
D008694_D009422 CID METH_32/NN (r_npadvmod) induced_34/VBN (r_amod) neurotoxicity_35/NN (r_nmod) activation_38/NN (r_pobj) in_31/IN (r_prep) role_30/NN (r_dobj) plays_28/VBZ (r_ccomp) hypothesized_24/VBD (l_advcl) is_9/VBZ (l_nsubj) damage_3/NN
D015632_D020258 NONE MPTP_8/NNP (r_conj) METH_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) damage_3/NN (r_nsubj) is_9/VBZ (l_prep) for_12/IN (l_pobj) system_16/NN (l_prep) in_17/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) neurotoxicity_21/NN
D015632_D020258 NONE MPTP_8/NNP (r_conj) METH_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) damage_3/NN (r_nsubj) is_9/VBZ (r_advcl) hypothesized_24/VBD (l_ccomp) plays_28/VBZ (l_dobj) role_30/NN (l_prep) in_31/IN (l_pobj) activation_38/NN (l_nmod) neurotoxicity_35/NN
D004298_D020258 NONE DA_14/NNP (r_nmod) system_16/NN (l_prep) in_17/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) neurotoxicity_21/NN
D004298_D020258 NONE DA_14/NNP (r_nmod) system_16/NN (r_pobj) for_12/IN (r_prep) is_9/VBZ (r_advcl) hypothesized_24/VBD (l_ccomp) plays_28/VBZ (l_dobj) role_30/NN (l_prep) in_31/IN (l_pobj) activation_38/NN (l_nmod) neurotoxicity_35/NN
16858720
D014859_D002543 CID warfarin_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) haemorrhage_1/NN
D014859_D002543 CID warfarin_11/NN (r_advmod) induced_13/VBN (r_amod) haemorrhages_15/NNS
D014859_D002543 CID warfarin_18/NN (r_nmod) interactions_23/NNS (r_pobj) due_16/JJ (r_prep) evaluate_3/VB (l_dobj) frequency_5/NN (l_prep) of_10/IN (l_pobj) haemorrhages_15/NNS
D014859_D002543 CID warfarin_20/NN (r_amod) drug_22/NN (r_conj) warfarin_18/NN (r_nmod) interactions_23/NNS (r_pobj) due_16/JJ (r_prep) evaluate_3/VB (l_dobj) frequency_5/NN (l_prep) of_10/IN (l_pobj) haemorrhages_15/NNS
D014859_D002543 CID warfarin_8/NN (r_amod) interactions_13/NNS (r_nsubj) caused_16/VBN (l_dobj) haemorrhage_19/NN
D014859_D002543 CID warfarin_10/NN (r_amod) drug_12/NN (r_compound) interactions_13/NNS (r_nsubj) caused_16/VBN (l_dobj) haemorrhage_19/NN
D014859_D002543 CID warfarin_17/NN (r_amod) treatment_18/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (r_advcl) assessed_13/VBN (l_prep) Among_0/IN (l_pobj) patients_2/NNS (l_prep) with_3/IN (l_pobj) haemorrhage_5/NN
D014859_D002543 CID Warfarin_0/NN (r_npadvmod) induced_2/VBN (r_amod) haemorrhages_4/NNS
D014859_D002543 CID warfarin_4/NN (r_advmod) related_6/VBN (r_amod) haemorrhages_8/NNS
D014859_D002543 CID warfarin_26/NN (r_pobj) with_25/IN (r_prep) interact_24/VB (r_xcomp) known_22/VBN (r_acl) drugs_21/NNS (r_dobj) prescribing_20/VBG (r_advcl) taken_18/VBN (r_advcl) prevented_12/VBN (l_nsubjpass) proportion_2/NN (l_prep) of_3/IN (l_pobj) haemorrhages_8/NNS
D014859_D006470 NONE warfarin_1/NN (r_amod) drug_3/NN (r_compound) interaction_4/NN (r_nsubj) contributed_7/VBN (l_prep) to_8/IN (l_pobj) haemorrhage_10/NN
D014859_D006470 NONE warfarin_19/NN (r_amod) patients_20/NNS (r_pobj) of_17/IN (r_prep) %_15/NN (r_pobj) in_11/IN (r_prep) haemorrhage_10/NN
9495837
C087567_D000647 NONE /-)-PG-9_2/CD (r_punct) was_11/VBD (l_acomp) able_12/JJ (l_xcomp) prevent_14/VB (l_dobj) amnesia_15/NN
C087567_D000647 NONE /-)-PG-9_5/NNP (r_punct) +_4/CC (r_pobj) of_2/IN (r_prep) profiles_1/NNS (r_nsubj) shown_44/VBN (l_dobj) ratio_50/NN (l_relcl) be_55/VB (l_acomp) responsible_56/JJ (l_prep) for_57/IN (l_pobj) antinociception_59/NN (l_conj) effect_65/NN (l_amod) amnesic_64/JJ
C087567_D000647 NONE /-)-PG-9_70/NFP (r_punct) through_71/IN (r_prep) be_55/VB (l_acomp) responsible_56/JJ (l_prep) for_57/IN (l_pobj) antinociception_59/NN (l_conj) effect_65/NN (l_amod) amnesic_64/JJ
D012601_D000647 CID scopolamine_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) amnesia_15/NN
D004025_D000647 CID dicyclomine_26/NNP (r_conj) scopolamine_18/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) amnesia_15/NN
D000109_D000647 NONE acetylcholine_75/NN (r_compound) levels_77/NNS (r_pobj) in_74/IN (r_prep) increase_73/NN (r_pobj) through_71/IN (r_prep) be_55/VB (l_acomp) responsible_56/JJ (l_prep) for_57/IN (l_pobj) antinociception_59/NN (l_conj) effect_65/NN (l_amod) amnesic_64/JJ
18791946
D002939_D013921 CID ciprofloxacin_7/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) anaemia_4/NN (r_conj) thrombocytopenia_1/NN
D002939_D013921 CID ciprofloxacin_5/NN (r_nsubj) precipitate_7/VB (l_dobj) thrombocytopenia_11/NN
D002939_D000743 CID ciprofloxacin_7/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) anaemia_4/NN
D002939_D000743 CID ciprofloxacin_5/NN (r_nsubj) precipitate_7/VB (l_dobj) thrombocytopenia_11/NN (l_conj) anaemia_14/NN
D002939_D015746 CID ciprofloxacin_16/NNP (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) after_11/IN (r_prep) reported_5/VBN (l_prep) with_6/IN (l_pobj) pain_8/NN
D002939_D007565 CID ciprofloxacin_16/NNP (r_pobj) of_14/IN (r_prep) administration_13/NN (r_pobj) after_11/IN (r_prep) reported_5/VBN (l_prep) with_6/IN (l_pobj) pain_8/NN (l_conj) jaundice_10/NN
D002939_D014552 NONE ciprofloxacin_16/NNP (r_pobj) of_14/IN (r_prep) administration_13/NN (l_prep) for_17/IN (l_pobj) suspect_19/NN (l_prep) of_20/IN (l_pobj) infection_23/NN
9401499
D013988_D000741 CID Ticlopidine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) anemia_4/NN
D013988_D000741 CID ticlopidine_8/NN (r_npadvmod) induced_10/VBN (r_amod) anemia_12/NN
D013988_D000741 CID ticlopidine_2/NN (r_npadvmod) induced_4/VBN (r_amod) anemia_6/NN
D013988_D000380 CID ticlopidine_9/NN (r_pobj) of_8/IN (r_prep) initiation_7/NN (r_pobj) after_6/IN (r_prep) occurred_1/VBD (l_nsubj) Agranulocytosis_0/NN
15899738
D003401_D001281 CID creatine_5/NN (r_compound) supplementation_7/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) fibrillation_2/NN
D003401_D001145 NONE creatine_5/NN (r_dobj) linked_4/VBN (l_prep) to_6/IN (l_pobj) development_8/NN (l_prep) of_9/IN (l_pobj) arrhythmia_10/NN
9869257
C087567_D000647 NONE PG-9_8/NNP (r_dep) In_0/IN (r_prep) administered_18/VBD (l_conj) prevented_26/VBD (l_dobj) amnesia_27/NN
C087567_D000647 NONE PG-9_6/NNP (r_dep) microg_11/NNS (r_nsubj) was_17/VBD (l_acomp) able_19/JJ (l_xcomp) prevent_21/VB (l_dobj) amnesia_25/NN
D012601_D000647 CID scopolamine_36/NN (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) amnesia_27/NN
C098725_D000647 CID S-(-)-ET-126_41/NNP (r_conj) scopolamine_36/NN (r_pobj) by_29/IN (r_agent) induced_28/VBN (r_acl) amnesia_27/NN
1616457
D010424_D000647 CID pentobarbital_7/NN (r_pobj) by_6/IN (r_agent) caused_5/VBN (r_acl) amnesia_4/NN
D010424_D000647 CID pentobarbital_15/NN (r_pobj) by_14/IN (r_agent) produced_13/VBN (r_acl) state_10/NN (l_prep) of_11/IN (l_pobj) amnesia_12/NN
16574712
D018817_D003072 CID MDMA_0/NNP (r_compound) polydrug_1/NN (r_compound) users_2/NNS (r_nsubj) show_3/VBP (l_dobj) impairments_9/NNS (l_acl) coupled_10/VBN (l_prep) with_11/IN (l_pobj) processes_17/NNS
D018817_D008569 NONE MDMA_12/NNP (r_pobj) of_11/IN (r_prep) users_10/NNS (r_pobj) in_9/IN (r_prep) reported_8/VBN (l_nsubjpass) deficits_5/NNS
D018817_D008569 NONE 3,4-methylenedioxymethamphetamine_14/CD (r_appos) MDMA_12/NNP (r_pobj) of_11/IN (r_prep) users_10/NNS (r_pobj) in_9/IN (r_prep) reported_8/VBN (l_nsubjpass) deficits_5/NNS
D018817_D008569 NONE ecstasy_16/NN (r_npadvmod) 3,4-methylenedioxymethamphetamine_14/CD (r_appos) MDMA_12/NNP (r_pobj) of_11/IN (r_prep) users_10/NNS (r_pobj) in_9/IN (r_prep) reported_8/VBN (l_nsubjpass) deficits_5/NNS
3403780
D000082_D003128 NONE Paracetamol_0/NN (r_npadvmod) associated_2/VBN (r_amod) coma_3/NN
D000082_D000138 CID Paracetamol_0/NN (r_npadvmod) associated_2/VBN (r_amod) coma_3/NN (l_appos) failure_11/NN (l_nmod) acidosis_6/NN
D000082_D000138 CID paracetamol_13/NN (r_nmod) ingestion_14/NN (r_pobj) following_12/VBG (r_prep) failure_8/NN (r_nsubjpass) presented_16/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) acidosis_4/NN
D000082_D058186 CID paracetamol_13/NN (r_nmod) ingestion_14/NN (r_pobj) following_12/VBG (r_prep) failure_8/NN (l_conj) failure_11/NN
D000082_D058186 NONE Paracetamol_0/NN (r_npadvmod) associated_2/VBN (r_amod) coma_3/NN (l_appos) failure_11/NN
D000082_D017093 NONE Paracetamol_0/NN (r_npadvmod) associated_2/VBN (r_amod) coma_3/NN (l_appos) failure_11/NN
D000082_D017114 CID paracetamol_13/NN (r_nmod) ingestion_14/NN (r_pobj) following_12/VBG (r_prep) failure_8/NN (l_conj) failure_11/NN
1664218
D000677_D002289 NONE amsacrine_5/NNP (r_compound) analogue_6/NN (r_pobj) of_3/IN (r_prep) study_2/NN (l_prep) in_12/IN (l_pobj) cancer_18/NN
C042315_D002289 NONE CI-921_7/NNP (r_appos) analogue_6/NN (r_pobj) of_3/IN (r_prep) study_2/NN (l_prep) in_12/IN (l_pobj) cancer_18/NN
C042315_D002289 NONE 343499_10/CD (r_nummod) NSC_9/NNP (r_appos) analogue_6/NN (r_pobj) of_3/IN (r_prep) study_2/NN (l_prep) in_12/IN (l_pobj) cancer_18/NN
12653683
D012964_D009404 NONE sodium_1/NN (r_compound) channel_2/NN (l_appos) expression_10/NN (l_prep) in_11/IN (l_pobj) rats_12/NNS (l_prep) with_13/IN (l_pobj) puromycin_14/NNP (l_appos) syndrome_19/NN
D012964_D009404 NONE sodium_6/NN (r_compound) excretion_7/NN (r_nsubjpass) decreased_9/VBN (l_prep) In_0/IN (l_pobj) syndrome_3/NN
D011692_D009404 CID aminonucleoside_15/RB (r_advmod) induced_17/VBN (r_amod) syndrome_19/NN
D011692_D009404 CID aminonucleoside_12/RB (l_appos) syndrome_16/NN
D011692_D009404 CID PAN)-induced_14/VBN (r_nummod) syndrome_16/NN
D011692_D009404 CID PAN_22/NN (r_npadvmod) induced_24/VBN (r_amod) syndrome_26/NN
D012964_D011507 NONE sodium_5/NN (r_compound) excretion_6/NN (r_pobj) of_3/IN (r_prep) courses_2/NNS (r_nsubjpass) studied_14/VBN (l_nsubjpass) concentration_10/NN (l_conj) proteinuria_12/NN
D012964_D011507 NONE sodium_4/NN (r_compound) excretion_5/NN (r_pobj) of_2/IN (r_prep) kinetics_1/NNS (l_conj) appearance_8/NN (l_prep) of_9/IN (l_pobj) proteinuria_10/NN
D000450_D011507 NONE aldosterone_9/NN (r_compound) concentration_10/NN (l_conj) proteinuria_12/NN
D011692_D011507 CID PAN_28/NN (r_pobj) of_26/IN (r_prep) dose_25/NN (r_pobj) with_22/IN (r_prep) treated_21/VBN (r_acl) rats_20/NNS (r_pobj) in_15/IN (r_prep) studied_14/VBN (l_nsubjpass) concentration_10/NN (l_conj) proteinuria_12/NN
D000450_D009404 NONE aldosterone_38/NN (r_pobj) by_37/IN (r_prep) regulation_36/NN (r_pobj) from_34/IN (r_prep) escape_33/VB (r_xcomp) appears_31/VBZ (r_conj) increased_11/VBN (l_prep) in_12/IN (l_pobj) phase_16/NN (l_prep) of_17/IN (l_pobj) model_20/NN (l_prep) of_21/IN (l_pobj) syndrome_26/NN
10457883
11263551
D016572_D010146 CID cyclosporine-_3/NN (r_pobj) of_2/IN (r_prep) reduction_1/NN (r_nsubj) tacrolimus_5/NN (l_advcl) led_15/VBD (l_prep) to_16/IN (l_pobj) relief_17/NN (l_prep) of_18/IN (l_pobj) pain_19/NN
D016572_D010146 CID cyclosporine_18/NN (r_pobj) of_17/IN (r_prep) effect_16/NN (r_attr) is_10/VBZ (l_nsubj) Syndrome_6/NNP (l_compound) Pain_5/NNP
D016559_D010146 CID tacrolimus_5/NN (l_advcl) led_15/VBD (l_prep) to_16/IN (l_pobj) relief_17/NN (l_prep) of_18/IN (l_pobj) pain_19/NN
D016559_D010146 CID tacrolimus_20/NN (r_conj) cyclosporine_18/NN (r_pobj) of_17/IN (r_prep) effect_16/NN (r_attr) is_10/VBZ (l_nsubj) Syndrome_6/NNP (l_compound) Pain_5/NNP
D002118_D010146 NONE calcium_12/NNP (r_compound) channel_13/NN (r_compound) blockers_14/NNS (r_pobj) of_11/IN (r_prep) administration_10/NN (r_conj) levels_7/NNS (r_dobj) tacrolimus_5/NN (l_advcl) led_15/VBD (l_prep) to_16/IN (l_pobj) relief_17/NN (l_prep) of_18/IN (l_pobj) pain_19/NN
D016572_-1 NONE cyclosporine_18/NN (r_pobj) of_17/IN (r_prep) effect_16/NN (r_attr) is_10/VBZ (l_nsubj) Syndrome_6/NNP (l_appos) CIPS_8/NNP
D016559_-1 NONE tacrolimus_20/NN (r_conj) cyclosporine_18/NN (r_pobj) of_17/IN (r_prep) effect_16/NN (r_attr) is_10/VBZ (l_nsubj) Syndrome_6/NNP (l_appos) CIPS_8/NNP
7628595
D014805_D064420 NONE B12_6/NNP (l_conj) supplementation_10/NN (l_prep) in_11/IN (l_pcomp) preventing_12/VBG (l_dobj) toxicity_14/NN
D002955_D064420 NONE acid_9/NN (r_compound) supplementation_10/NN (l_prep) in_11/IN (l_pcomp) preventing_12/VBG (l_dobj) toxicity_14/NN
D015215_D064420 NONE zidovudine_16/NN (r_pobj) of_15/IN (r_prep) toxicity_14/NN
D014805_D001855 NONE B12_13/NNP (l_conj) supplementation_17/NN (l_prep) in_18/IN (l_pcomp) preventing_19/VBG (l_dobj) suppression_25/NN
D014805_D001855 NONE B12_6/NN (l_conj) levels_9/NNS (l_prep) of_12/IN (l_pobj) myelosuppression_13/NN
D014805_D001855 NONE B12_1/NNP (r_nmod) supplementation_5/NN (r_nsubj) seem_11/VB (l_oprd) useful_12/JJ (l_prep) in_13/IN (l_pcomp) preventing_14/VBG (l_conj) reducing_16/VBG (l_dobj) myelotoxicity_20/NN
D002955_D001855 NONE acid_16/NN (r_compound) supplementation_17/NN (l_prep) in_18/IN (l_pcomp) preventing_19/VBG (l_dobj) suppression_25/NN
D002955_D001855 NONE acid_4/JJ (r_conj) B12_1/NNP (r_nmod) supplementation_5/NN (r_nsubj) seem_11/VB (l_oprd) useful_12/JJ (l_prep) in_13/IN (l_pcomp) preventing_14/VBG (l_conj) reducing_16/VBG (l_dobj) myelotoxicity_20/NN
D015215_D001855 CID zidovudine_20/CC (r_nmod) suppression_25/NN
D015215_D001855 CID ZDV)-induced_22/JJ (r_nummod) suppression_25/NN
D015215_D001855 CID ZDV_7/NNP (r_compound) therapy_8/NN (r_pobj) of_6/IN (r_prep) supplementation_5/NN (r_nsubj) seem_11/VB (l_oprd) useful_12/JJ (l_prep) in_13/IN (l_pcomp) preventing_14/VBG (l_conj) reducing_16/VBG (l_dobj) myelotoxicity_20/NN
D015215_D001855 CID ZDV_17/NN (r_npadvmod) induced_19/VBN (r_amod) myelotoxicity_20/NN
D005492_D001855 NONE folate_8/JJ (r_amod) levels_9/NNS (l_prep) of_12/IN (l_pobj) myelosuppression_13/NN
10739826
D003276_D054556 CID contraceptives_5/NNS (l_conj) risk_8/NN (l_prep) of_9/IN (l_pobj) thromboembolism_11/NN
D003276_D054556 CID contraceptives_17/NNS (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) studies_2/NNS (l_relcl) assessed_4/VBD (l_dobj) risk_6/NN (l_prep) of_7/IN (l_pobj) thromboembolism_9/NN
D003276_D054556 CID contraceptives_17/NNS (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) studies_2/NNS (l_appos) VTE_11/NNP
D003276_D054556 CID OC_19/NNP (r_appos) contraceptives_17/NNS (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) studies_2/NNS (l_relcl) assessed_4/VBD (l_dobj) risk_6/NN (l_prep) of_7/IN (l_pobj) thromboembolism_9/NN
D003276_D054556 CID OC_19/NNP (r_appos) contraceptives_17/NNS (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) studies_2/NNS (l_appos) VTE_11/NNP
D003276_D054556 CID OC_27/NNP (r_compound) use_28/NN (r_pobj) of_26/IN (r_prep) patterns_25/NNS (r_pobj) between_24/IN (r_prep) distinguish_23/VB (l_nsubj) studies_2/NNS (l_relcl) assessed_4/VBD (l_dobj) risk_6/NN (l_prep) of_7/IN (l_pobj) thromboembolism_9/NN
D003276_D054556 CID OC_27/NNP (r_compound) use_28/NN (r_pobj) of_26/IN (r_prep) patterns_25/NNS (r_pobj) between_24/IN (r_prep) distinguish_23/VB (l_nsubj) studies_2/NNS (l_appos) VTE_11/NNP
D003276_D054556 CID OC_12/NNP (r_pobj) of_9/IN (r_prep) users_8/NNS (r_pobj) for_6/IN (r_prep) ratio_3/NN (l_prep) of_4/IN (l_pobj) VTE_5/NNP
2572625
C084599_D056486 CID Clotiazepam_0/NN (r_npadvmod) induced_2/VBN (r_amod) hepatitis_4/NN
C084599_D056486 CID clotiazepam_24/NNP (r_pobj) of_23/IN (r_prep) administration_22/NN (r_pobj) of_21/IN (r_prep) onset_20/NN (r_pobj) after_18/IN (r_prep) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) patient_6/NN (l_relcl) developed_8/VBD (l_dobj) hepatitis_10/NN
C084599_D056486 CID clotiazepam_9/NNP (r_pobj) to_8/IN (r_prep) related_7/JJ (r_acl) benzodiazepines_4/NNS (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) interfere_13/VB (l_conj) induce_19/VB (l_dobj) relapse_21/NN (l_prep) of_22/IN (l_pobj) hepatitis_23/NN
C084599_D056486 CID clotiazepam_4/NN (r_nsubj) induce_6/VB (l_dobj) hepatitis_8/NN
C084599_D056486 CID clotiazepam_4/NN (r_nsubj) induce_6/VB (r_ccomp) shows_2/VBZ (l_conj) suggests_10/VBZ (l_ccomp) is_13/VBZ (l_attr) hepatotoxicity_16/NN
C084599_D056486 CID clotiazepam_18/NN (r_pobj) between_17/IN (r_prep) hepatotoxicity_16/NN (r_attr) is_13/VBZ (r_ccomp) suggests_10/VBZ (r_conj) shows_2/VBZ (l_ccomp) induce_6/VB (l_dobj) hepatitis_8/NN
C084599_D056486 CID clotiazepam_18/NN (r_pobj) between_17/IN (r_prep) hepatotoxicity_16/NN
C084599_D047508 NONE clotiazepam_24/NNP (r_pobj) of_23/IN (r_prep) administration_22/NN (r_pobj) of_21/IN (r_prep) onset_20/NN (r_pobj) after_18/IN (r_prep) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) patient_6/NN (l_relcl) developed_8/VBD (l_dobj) hepatitis_10/NN (l_prep) with_11/IN (l_pobj) necrosis_14/NN
C013295_D056486 NONE thienodiazepine_27/NN (r_compound) derivative_28/NN (r_appos) administration_22/NN (r_pobj) of_21/IN (r_prep) onset_20/NN (r_pobj) after_18/IN (r_prep) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) patient_6/NN (l_relcl) developed_8/VBD (l_dobj) hepatitis_10/NN
C013295_D047508 NONE thienodiazepine_27/NN (r_compound) derivative_28/NN (r_appos) administration_22/NN (r_pobj) of_21/IN (r_prep) onset_20/NN (r_pobj) after_18/IN (r_prep) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) patient_6/NN (l_relcl) developed_8/VBD (l_dobj) hepatitis_10/NN (l_prep) with_11/IN (l_pobj) necrosis_14/NN
D001569_D056486 NONE benzodiazepines_4/NNS (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) interfere_13/VB (l_conj) induce_19/VB (l_dobj) relapse_21/NN (l_prep) of_22/IN (l_pobj) hepatitis_23/NN
D001569_D056486 NONE benzodiazepines_21/NNS (r_conj) clotiazepam_18/NN (r_pobj) between_17/IN (r_prep) hepatotoxicity_16/NN (r_attr) is_13/VBZ (r_ccomp) suggests_10/VBZ (r_conj) shows_2/VBZ (l_ccomp) induce_6/VB (l_dobj) hepatitis_8/NN
D001569_D056486 NONE benzodiazepines_21/NNS (r_conj) clotiazepam_18/NN (r_pobj) between_17/IN (r_prep) hepatotoxicity_16/NN
9390208
D008942_D001943 NONE mitoxantrone_8/NN (r_pobj) by_7/IN (r_prep) cancer_6/NN
D008942_D001943 NONE mitoxantrone_20/NN (r_pobj) by_19/IN (r_prep) treated_8/VBD (l_dobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) cancer_18/NN
D008942_D064420 NONE mitoxantrone_8/NN (l_conj) infusion_12/NN (l_conj) leucovorin_19/NN (l_conj) benefit_26/NN (l_conj) toxicity_32/NN
D005472_D001943 NONE 5-FU_17/CD (r_pobj) of_13/IN (r_prep) infusion_12/NN (r_conj) mitoxantrone_8/NN (r_pobj) by_7/IN (r_prep) cancer_6/NN
D005472_D001943 NONE 5-FU_34/CD (r_pobj) of_33/IN (r_prep) infusion_32/NN (r_conj) day_28/NN (r_pobj) on_27/IN (r_prep) treated_8/VBD (l_dobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) cancer_18/NN
D005472_D064420 NONE 5-FU_17/CD (r_pobj) of_13/IN (r_prep) infusion_12/NN (l_conj) leucovorin_19/NN (l_conj) benefit_26/NN (l_conj) toxicity_32/NN
D002955_D001943 NONE leucovorin_19/NN (r_conj) infusion_12/NN (r_conj) mitoxantrone_8/NN (r_pobj) by_7/IN (r_prep) cancer_6/NN
D002955_D001943 NONE leucovorin_43/NN (r_pobj) with_42/IN (r_prep) treated_8/VBD (l_dobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) cancer_18/NN
D002955_D064420 NONE leucovorin_19/NN (l_conj) benefit_26/NN (l_conj) toxicity_32/NN
C085788_D001943 NONE MFL_21/NNP (r_appos) leucovorin_19/NN (r_conj) infusion_12/NN (r_conj) mitoxantrone_8/NN (r_pobj) by_7/IN (r_prep) cancer_6/NN
C085788_D064420 NONE MFL_21/NNP (r_appos) leucovorin_19/NN (l_conj) benefit_26/NN (l_conj) toxicity_32/NN
C085788_D064420 NONE regimen_2/NN (r_nsubj) achieves_3/VBZ (l_conj) induces_8/VBZ (l_dobj) toxicity_10/NN
20588063
D011692_D009401 CID aminonucleoside_17/JJ (r_compound) nephrosis_18/NN
D011692_D009401 CID aminonucleoside_2/JJ (r_compound) nephrosis_3/NN
7468724
D013726_D002318 CID terbutaline_4/JJ (r_compound) treatment_5/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) complications_1/NNS
D013726_D002318 CID terbutaline_11/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) patients_8/NNS (r_pobj) in_4/IN (r_prep) occurred_3/VBD (l_nsubj) complications_2/NNS
D013726_D007752 NONE terbutaline_4/JJ (r_compound) treatment_5/NN (l_prep) for_6/IN (l_pobj) labor_8/NN
D013726_D007752 NONE terbutaline_11/NN (l_prep) for_12/IN (l_pobj) labor_14/NN
7919560
D000667_D004892 CID ampicillin_7/NN (r_pobj) by_6/IN (r_agent) caused_5/VBN (l_nsubj) multiforme_1/NN
D000667_D004892 CID ampicillin_12/NN (r_pobj) by_11/IN (r_agent) caused_10/VBN (r_acl) case_3/NN (l_prep) of_4/IN (l_pobj) multiforme_6/NN
D000667_D009205 CID ampicillin_7/NN (r_pobj) by_6/IN (r_agent) caused_5/VBN (l_nsubj) multiforme_1/NN (l_conj) myocarditis_4/NN
D000667_D009205 CID ampicillin_12/NN (r_pobj) by_11/IN (r_agent) caused_10/VBN (r_acl) case_3/NN (l_prep) of_4/IN (l_pobj) multiforme_6/NN (l_conj) myocarditis_9/NN
D000667_D018805 NONE ampicillin_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (l_prep) because_11/IN (l_pobj) septicemia_14/NN
D005839_D018805 NONE gentamicin_10/NNS (r_conj) treated_6/VBN (l_prep) because_11/IN (l_pobj) septicemia_14/NN
D010406_D009205 NONE penicillins_11/NNS (r_pobj) to_10/IN (r_prep) manifestation_7/NN (r_attr) is_2/VBZ (l_nsubj) myocarditis_1/NN
D010406_D004342 NONE penicillins_11/NNS (r_pobj) to_10/IN (r_prep) manifestation_7/NN (l_prep) of_8/IN (l_pobj) allergy_9/NN
11250767
D011441_D014657 NONE Propylthiouracil_0/NNP (r_npadvmod) induced_2/VBN (r_amod) vasculitis_11/NN
D011441_D014657 NONE propylthiouracil_5/NN (r_npadvmod) induced_7/VBN (r_amod) vasculitis_8/NN
D011441_D014657 NONE uracil_20/NN (r_compound) therapy_21/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) vasculitis_16/NN
D011441_D014657 NONE uracil_14/NN (r_compound) therapy_15/NN (r_pobj) to_12/IN (r_prep) attributable_11/JJ (r_amod) manifestation_5/NN (l_prep) of_6/IN (l_pobj) vasculitis_10/NN
D011441_D010493 CID Propylthiouracil_0/NNP (r_npadvmod) induced_2/VBN (r_amod) vasculitis_11/NN (l_prep) in_12/IN (l_pobj) conjunction_13/NN (l_prep) with_14/IN (l_pobj) pericarditis_15/NN
D011441_D010493 CID propylthiouracil_5/NN (r_npadvmod) induced_7/VBN (r_amod) vasculitis_8/NN (l_acl) manifesting_9/VBG (l_prep) with_10/IN (l_pobj) pericarditis_11/NN
D011441_D010493 CID propylthiouracil_13/NNP (l_relcl) developed_25/VBD (l_nsubj) syndrome_17/NN (l_prep) of_18/IN (l_pobj) pericarditis_19/NN
D011441_D010493 CID uracil_20/NN (r_compound) therapy_21/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) vasculitis_16/NN (r_pobj) in_9/IN (r_prep) reports_6/NNS (l_prep) of_7/IN (l_pobj) pericarditis_8/NN
D011441_D010493 CID uracil_14/NN (r_compound) therapy_15/NN (r_pobj) to_12/IN (r_prep) attributable_11/JJ (r_amod) manifestation_5/NN (r_attr) be_2/VB (l_nsubj) Pericarditis_0/NNP
D011441_D006980 NONE propylthiouracil_13/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) hyperthyroidism_10/NN
D011441_D005334 CID propylthiouracil_13/NNP (l_relcl) developed_25/VBD (l_nsubj) syndrome_17/NN (l_prep) of_18/IN (l_pobj) pericarditis_19/NN (l_conj) fever_21/NN
D011441_D005921 CID propylthiouracil_13/NNP (l_relcl) developed_25/VBD (l_nsubj) syndrome_17/NN (l_prep) of_18/IN (l_pobj) pericarditis_19/NN (l_conj) fever_21/NN (l_conj) glomerulonephritis_24/NN
6286738
D002762_D064420 NONE D3_1/NN (r_compound) toxicity_2/NN
D002762_D064420 NONE D3_3/NN (r_compound) toxicity_4/NN
D002762_D064420 NONE D3_3/NN (r_compound) toxicity_4/NN (r_pobj) of_1/IN (r_prep) Signs_0/NNS (r_nsubjpass) observed_7/VBN (r_ccomp) developed_18/VBN (l_dobj) signs_20/NNS (l_prep) of_21/IN (l_pobj) toxicity_24/NN
D002762_D064420 NONE D3_23/NN (r_compound) toxicity_24/NN (r_pobj) of_21/IN (r_prep) signs_20/NNS (r_dobj) developed_18/VBN (l_ccomp) observed_7/VBN (l_nsubjpass) Signs_0/NNS (l_prep) of_1/IN (l_pobj) toxicity_4/NN
D002762_D064420 NONE D3_23/NN (r_compound) toxicity_24/NN
D002762_D064420 NONE D3_7/NN (r_pobj) of_5/IN (r_prep) toxicity_4/NN
D002762_D064420 NONE D3_22/NN (r_pobj) of_20/IN (r_prep) doses_19/NNS (r_pobj) between_18/IN (r_prep) margin_15/NN (r_conj) cows_11/NNS (r_pobj) in_8/IN (r_prep) toxicity_4/NN
D002762_D064420 NONE D3_38/NNP (r_nsubjpass) used_42/VBN (r_ccomp) concluded_35/VBD (l_prep) Because_0/IN (l_pobj) toxicity_4/NN
D002762_D006934 CID D3_2/NNP (r_nsubjpass) associated_5/VBN (l_prep) with_6/IN (l_pobj) hypercalcemia_8/NN
D002762_D006934 CID D3_17/NN (r_pobj) of_15/IN (r_prep) increases_14/NNS (r_conj) hyperphosphatemia_10/NNP (r_conj) hypercalcemia_8/NN
D002762_D054559 CID D3_2/NNP (r_nsubjpass) associated_5/VBN (l_prep) with_6/IN (l_pobj) hypercalcemia_8/NN (l_conj) hyperphosphatemia_10/NNP
D002762_D054559 CID D3_17/NN (r_pobj) of_15/IN (r_prep) increases_14/NNS (r_conj) hyperphosphatemia_10/NNP
D002762_D010319 NONE D3_7/NNP (r_pobj) with_5/IN (r_prep) treated_4/VBN (r_acl) cows_3/NNS (r_pobj) of_1/IN (r_prep) None_0/NN (r_nsubj) showed_8/VBD (l_dobj) signs_9/NNS (l_prep) of_10/IN (l_pobj) fever_12/NN
D002762_D010319 NONE D3_7/NNP (r_pobj) with_5/IN (r_prep) treated_4/VBN (r_acl) cows_3/NNS (r_pobj) of_1/IN (r_prep) None_0/NN (r_nsubj) showed_8/VBD (r_ccomp) developed_26/VBD (l_dobj) signs_28/NNS (l_prep) of_29/IN (l_pobj) fever_31/NN
D002762_D010319 NONE D3_7/NN (r_pobj) of_5/IN (r_prep) toxicity_4/NN (l_prep) in_8/IN (l_pobj) cows_11/NNS (l_conj) margin_15/NN (l_prep) between_18/IN (l_pobj) doses_19/NNS (l_prep) of_20/IN (l_pobj) D3_22/NN (l_relcl) prevent_24/VBP (l_dobj) fever_26/NN
D002762_D010319 NONE D3_7/NN (r_pobj) of_5/IN (r_prep) toxicity_4/NN (l_prep) in_8/IN (l_pobj) cows_11/NNS (l_conj) margin_15/NN (l_prep) between_18/IN (l_pobj) doses_19/NNS (l_prep) of_20/IN (l_pobj) D3_22/NN (l_relcl) prevent_24/VBP (l_ccomp) induce_30/VBP (l_dobj) fever_32/NN
D002762_D010319 NONE D3_7/NN (r_pobj) of_5/IN (r_prep) toxicity_4/NN (r_pobj) Because_0/IN (r_prep) concluded_35/VBD (l_ccomp) used_42/VBN (l_xcomp) prevent_45/VB (l_dobj) fever_47/NN
D002762_D010319 NONE D3_22/NN (l_relcl) prevent_24/VBP (l_dobj) fever_26/NN
D002762_D010319 NONE D3_22/NN (l_relcl) prevent_24/VBP (l_ccomp) induce_30/VBP (l_dobj) fever_32/NN
D002762_D010319 NONE D3_22/NN (r_pobj) of_20/IN (r_prep) doses_19/NNS (r_pobj) between_18/IN (r_prep) margin_15/NN (r_conj) cows_11/NNS (r_pobj) in_8/IN (r_prep) toxicity_4/NN (r_pobj) Because_0/IN (r_prep) concluded_35/VBD (l_ccomp) used_42/VBN (l_xcomp) prevent_45/VB (l_dobj) fever_47/NN
D002762_D010319 NONE D3_38/NNP (r_nsubjpass) used_42/VBN (r_ccomp) concluded_35/VBD (l_prep) Because_0/IN (l_pobj) toxicity_4/NN (l_prep) in_8/IN (l_pobj) cows_11/NNS (l_conj) margin_15/NN (l_prep) between_18/IN (l_pobj) doses_19/NNS (l_prep) of_20/IN (l_pobj) D3_22/NN (l_relcl) prevent_24/VBP (l_dobj) fever_26/NN
D002762_D010319 NONE D3_38/NNP (r_nsubjpass) used_42/VBN (r_ccomp) concluded_35/VBD (l_prep) Because_0/IN (l_pobj) toxicity_4/NN (l_prep) in_8/IN (l_pobj) cows_11/NNS (l_conj) margin_15/NN (l_prep) between_18/IN (l_pobj) doses_19/NNS (l_prep) of_20/IN (l_pobj) D3_22/NN (l_relcl) prevent_24/VBP (l_ccomp) induce_30/VBP (l_dobj) fever_32/NN
D002762_D010319 NONE D3_38/NNP (r_nsubjpass) used_42/VBN (l_xcomp) prevent_45/VB (l_dobj) fever_47/NN
18996674
D004837_D011317 NONE epinephrine_1/NN (l_appos) treatment_6/NN (l_prep) for_7/IN (l_pobj) priapism_8/NN
D003042_D011317 CID cocaine_9/NN (r_compound) user_10/NN (r_appos) man_4/NN (l_acl) presented_12/VBN (l_prep) on_20/IN (l_pobj) occasions_23/NNS (l_prep) with_24/IN (l_pobj) history_26/NN (l_prep) of_27/IN (l_pobj) priapism_28/NN
D003042_D011317 CID cocaine_30/NN (r_compound) use_31/NN (r_pobj) after_29/IN (r_prep) history_26/NN (l_prep) of_27/IN (l_pobj) priapism_28/NN
3828020
D010665_D002544 CID phenylpropanolamine_8/NN (r_pobj) of_7/IN (r_prep) dose_6/NN (r_pobj) with_2/IN (r_prep) infarction_1/NN
D010665_D002544 CID PPA_20/NNP (r_pobj) of_19/IN (r_prep) dose_18/NN (r_dobj) taking_14/VBG (r_pcomp) after_13/IN (r_prep) suffered_9/VBD (l_dobj) infarction_12/NN
16740173
1967484
D013469_D004421 CID Sulpiride_0/NN (r_npadvmod) induced_2/VBN (r_amod) dystonia_4/NN
D013469_D004421 CID sulpiride_17/NN (r_compound) therapy_18/NN (r_dobj) starting_16/VBG (r_pcomp) after_15/IN (r_prep) developed_8/VBD (l_dobj) dystonia_11/NN
D013469_D004421 CID sulpiride_8/NN (r_npadvmod) induced_10/VBN (r_amod) dystonia_12/NN
D013469_D004409 NONE sulpiride_11/NN (r_npadvmod) induced_13/VBN (r_amod) dyskinesia_15/NN
D013469_D010302 NONE sulpiride_11/NN (r_npadvmod) induced_13/VBN (r_amod) dyskinesia_15/NN (l_conj) parkinsonism_17/NN
869641
D007980_D001919 NONE dopa_9/NNP (r_pobj) by_6/IN (r_prep) Mediation_0/NN (l_prep) of_1/IN (l_pobj) bradycardia_5/NN
D007980_D001919 NONE dopa_15/NNP (r_pobj) by_12/IN (r_agent) enhanced_11/VBN (l_nsubjpass) bradycardia_4/NNS
D007980_D001919 NONE dopa_28/NNP (r_pobj) of_25/IN (r_prep) effect_24/NN (r_conj) bradycardia_19/JJ
D007980_D001919 NONE dopa_4/NNP (r_nsubj) restored_5/VBD (l_dobj) bradycardia_7/NN
D007980_D001919 NONE dopa_6/NNP (r_nsubj) enhances_7/VBZ (l_dobj) bradycardia_9/NNS
D004298_D001919 NONE dopamine_12/NN (r_compound) formation_13/NN (r_pobj) via_10/IN (r_prep) Mediation_0/NN (l_prep) of_1/IN (l_pobj) bradycardia_5/NN
D004298_D001919 NONE dopamine_3/NN (r_compound) oxidase_7/NN (r_compound) inhibitor_8/NN (r_nsubj) have_12/VB (l_dobj) effect_14/NN (l_prep) on_15/IN (l_pobj) hypotension_17/NN (l_conj) bradycardia_19/JJ
D009638_D001919 CID norepinephrine_8/NN (r_pobj) by_6/IN (r_agent) caused_5/VBN (r_acl) bradycardia_4/NNS
D009638_D001919 CID norepinephrine_10/NN (r_pobj) by_9/IN (r_agent) caused_8/VBN (r_acl) bradycardia_7/NN
D009638_D001919 CID norepinephrine_12/NN (r_pobj) to_11/IN (r_prep) decreased_7/VBD (l_dobj) bradycardia_10/NNS
D005406_D007022 NONE FLA-63_0/NNP (r_dep) ,_1/, (r_punct) inhibitor_8/NN (r_nsubj) have_12/VB (l_dobj) effect_14/NN (l_prep) on_15/IN (l_pobj) hypotension_17/NN
D005406_D001919 NONE FLA-63_0/NNP (r_dep) ,_1/, (r_punct) inhibitor_8/NN (r_nsubj) have_12/VB (l_dobj) effect_14/NN (l_prep) on_15/IN (l_pobj) hypotension_17/NN (l_conj) bradycardia_19/JJ
D004298_D007022 NONE dopamine_3/NN (r_compound) oxidase_7/NN (r_compound) inhibitor_8/NN (r_nsubj) have_12/VB (l_dobj) effect_14/NN (l_prep) on_15/IN (l_pobj) hypotension_17/NN
D007980_D007022 NONE dopa_28/NNP (r_pobj) of_25/IN (r_prep) effect_24/NN (r_conj) bradycardia_19/JJ (r_conj) hypotension_17/NN
1085609
D011736_D012640 NONE pyridoxine_1/NN (r_nmod) convulsions_3/NNS
D011736_D012640 NONE pyridoxine_9/NN (r_dobj) administering_7/VBG (r_pcomp) of_6/IN (r_prep) hours_5/NNS (r_pobj) within_3/IN (r_prep) ceased_2/VBD (l_nsubj) fits_1/NNS
D011736_D012640 NONE pyridoxine_15/NN (r_compound) deficiency_16/NN (r_pobj) of_14/IN (r_prep) aetiology_13/NN (r_dobj) suggesting_11/VBG (r_advcl) ceased_2/VBD (l_nsubj) fits_1/NNS
D007538_D012640 CID isoniazid_6/NN (r_compound) therapy_7/NN (r_pobj) to_5/IN (r_prep) due_4/JJ (r_amod) convulsions_3/NNS
D007538_D012640 CID isoniazid_6/NNP (r_compound) therapy_7/NN (r_pobj) on_5/IN (r_prep) infant_4/NN (r_nsubjpass) admitted_18/VBN (l_prep) after_19/IN (l_pobj) days_21/NNS (l_prep) of_22/IN (l_pobj) fits_24/NNS
D007538_D012640 CID isoniazid_19/NNP (r_compound) medication_20/NN (r_pobj) to_18/IN (r_prep) secondary_17/JJ (r_amod) deficiency_16/NN (r_pobj) of_14/IN (r_prep) aetiology_13/NN (r_dobj) suggesting_11/VBG (r_advcl) ceased_2/VBD (l_nsubj) fits_1/NNS
D007538_D014376 NONE isoniazid_6/NNP (r_compound) therapy_7/NN (r_pobj) on_5/IN (r_prep) infant_4/NN (l_prep) because_13/IN (l_pobj) tuberculosis_16/NN
2334618
D009020_D001049 NONE morphine_17/NN (r_pobj) of_16/IN (r_prep) infusion_15/NN (r_dobj) receiving_11/VBG (r_acl) patients_10/NNS (r_pobj) between_8/IN (r_prep) compared_7/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) apnoea_5/NN
D002045_D001049 NONE bupivacaine_34/NN (r_pobj) of_31/IN (r_prep) infusion_30/NN (r_dobj) receiving_26/VBG (r_acl) patients_25/NNS (r_conj) patients_10/NNS (r_pobj) between_8/IN (r_prep) compared_7/VBN (l_nsubjpass) incidence_1/NN (l_prep) of_2/IN (l_pobj) apnoea_5/NN
D009020_D020181 CID morphine_25/NN (r_compound) infusion_26/NN (r_dobj) had_23/VBD (r_relcl) patients_21/NNS (r_pobj) in_20/IN (r_prep) occurred_17/VBD (l_nsubj) apnoea_10/NN
D009020_D020182 CID morphine_25/NN (r_compound) infusion_26/NN (r_dobj) had_23/VBD (r_relcl) patients_21/NNS (r_pobj) in_20/IN (r_prep) occurred_17/VBD (l_nsubj) apnoea_10/NN
D009020_D013610 NONE morphine_26/NN (r_compound) group_28/NN (r_pobj) in_24/IN (r_prep) incidence_5/NN (l_prep) of_6/IN (l_pobj) tachyarrhythmias_7/NNP
D009020_D018879 CID morphine_26/NN (r_compound) group_28/NN (r_pobj) in_24/IN (r_prep) incidence_5/NN (l_conj) beats_17/NNS
11875660
D001374_D009436 NONE 5-azacytidine_6/CD (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) exencephaly_3/NNS
2304736
D011224_D014550 CID Prazosin_0/NN (r_npadvmod) induced_2/VBN (r_amod) incontinence_4/NN
D011224_D014550 CID prazosin_8/NN (r_pobj) due_6/IN (r_amod) case_1/NN (l_prep) of_2/IN (l_pobj) incontinence_5/NN
D011224_D014550 CID prazosin_8/NN (r_dobj) taking_7/VBG (r_advcl) present_2/VBP (l_prep) with_3/IN (l_pobj) incontinence_5/NN
D011224_D014549 NONE prazosin_8/NN (r_dobj) taking_7/VBG (r_advcl) present_2/VBP (r_relcl) Patients_0/NNS (r_nsubj) change_10/VB (l_advcl) resolve_22/VB (l_nsubj) incontinence_20/NN
7444978
D013307_D020258 NONE streptomycin_11/NNS (r_pobj) of_10/IN (r_prep) effects_9/NNS (l_amod) neurotoxic_8/JJ
D013307_D004409 CID streptomycin_48/NNS (r_pobj) to_47/IN (r_prep) sensitive_46/JJ (r_acomp) is_44/VBZ (r_ccomp) indicating_40/VBG (r_advcl) occurred_23/VBD (l_ccomp) occurred_4/VBD (l_nsubj) movements_1/NNS
D013307_D004409 CID streptomycin_48/NNS (l_prep) than_49/IN (l_pobj) site_51/NN (l_amod) responsible_57/JJ (l_prep) for_58/IN (l_pobj) dyskinesias_60/NNP
D013307_D003638 CID streptomycin_48/NNS (r_pobj) to_47/IN (r_prep) sensitive_46/JJ (r_acomp) is_44/VBZ (r_ccomp) indicating_40/VBG (r_advcl) occurred_23/VBD (l_ccomp) occurred_4/VBD (l_nsubj) movements_1/NNS (l_conj) deafness_3/NN
230316
D006912_D020258 NONE hydroxyquinolines_3/NNPS (r_pobj) of_1/IN (r_prep) Neurotoxicity_0/NN
D006912_D020258 NONE hydroxyquinolines_13/NNS (r_pobj) to_11/IN (r_prep) reactions_10/NNS (l_amod) neurotoxic_9/JJ
D007464_D009422 NONE clioquinol_25/NN (r_pobj) of_24/IN (r_prep) dose_23/NN (r_pobj) of_20/IN (r_prep) ingestion_19/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acl) encephalopathy_14/NN (r_pobj) of_10/IN (r_prep) consisted_9/VBN (l_nsubj) disturbance_8/NN
D007464_D001927 CID clioquinol_25/NN (r_pobj) of_24/IN (r_prep) dose_23/NN (r_pobj) of_20/IN (r_prep) ingestion_19/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acl) encephalopathy_14/NN
D007464_C538178 NONE clioquinol_13/NN (r_dobj) received_12/VBN (l_prep) as_14/IN (l_pobj) treatment_15/NN (l_prep) for_16/IN (l_pobj) enteropathica_18/NNP
2484011
D000547_D003866 NONE amantadine_4/NN (r_nmod) activity_7/NN (l_amod) depressed_5/JJ
D000547_D011596 CID amantadine_2/NNP (r_pobj) of_1/IN (r_prep) Readministration_0/NN (l_appos) motility_13/NN (l_prep) with_21/IN (l_pobj) exception_22/NN (l_prep) of_23/IN (l_pobj) mice_28/NNS (l_relcl) occurred_33/VBD (l_nsubj) suppression_30/NN (l_prep) of_31/IN (l_pobj) motility_32/NN
D000547_D011596 CID amantadine_45/NNP (r_pobj) by_44/IN (r_agent) caused_43/VBN (r_acl) depression_42/NN
D000588_D011596 NONE amines_6/NNS (r_pobj) of_3/IN (r_prep) results_2/NNS (r_nsubj) suggest_13/VBP (l_dobj) decrease_16/NN (l_conj) metabolism_22/NN (l_conj) increase_29/NN (l_prep) in_30/IN (l_pobj) methylation_33/NN (l_relcl) account_38/VB (l_prep) for_39/IN (l_pobj) depression_42/NN
D002395_D011596 NONE catecholamine_18/NN (r_compound) rate_20/NN (r_pobj) of_17/IN (r_prep) decrease_16/NN (l_conj) metabolism_22/NN (l_conj) increase_29/NN (l_prep) in_30/IN (l_pobj) methylation_33/NN (l_relcl) account_38/VB (l_prep) for_39/IN (l_pobj) depression_42/NN
D009638_D011596 NONE norepinephrine_35/NN (r_pobj) of_34/IN (r_prep) methylation_33/NN (l_relcl) account_38/VB (l_prep) for_39/IN (l_pobj) depression_42/NN
3371379
D014700_D020258 CID Verapamil_0/NN (r_npadvmod) induced_2/VBN (r_amod) neurotoxicity_4/NN
D014700_D020258 CID verapamil_11/NN (r_pobj) with_10/IN (r_prep) treatment_9/NN (r_pobj) after_7/IN (r_prep) patients_1/NNS (l_prep) with_2/IN (l_pobj) signs_3/NNS (l_prep) of_4/IN (l_pobj) neurotoxicity_6/NN
D002220_D020258 CID carbamazepine_3/NN (r_compound) neurotoxicity_4/NN
D002220_D020258 CID carbamazepine_5/NN (r_compound) neurotoxicity_6/NN
D002118_D020258 NONE calcium_19/NN (r_compound) blocker_21/NN (r_pobj) of_17/IN (r_prep) discontinuation_16/NN (r_pobj) after_15/IN (r_prep) recovery_14/NN (r_dobj) showed_12/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) signs_3/NNS (l_prep) of_4/IN (l_pobj) neurotoxicity_6/NN
15737522
D002443_D001660 CID Ceftriaxone_0/NN (r_npadvmod) associated_2/VBN (r_amod) pseudolithiasis_4/NN
D002443_D001660 CID ceftriaxone_5/NN (r_nsubj) leads_6/VBZ (l_prep) to_7/IN (l_pobj) pseudolithiasis_8/NN
D002443_D001660 CID ceftriaxone_19/NN (r_compound) treatment_20/NN (r_dobj) receiving_18/VBG (r_acl) patients_17/NNS (r_pobj) in_14/IN (r_prep) evaluated_6/VBD (l_dobj) incidence_8/NN (l_prep) of_12/IN (l_pobj) pseudolithiasis_13/NNP
18083142
D009638_D001008 NONE Norepinephrine_0/NN (r_nsubj) signaling_1/VBG (r_csubj) is_7/VBZ (l_acomp) critical_8/JJ (l_prep) for_9/IN (l_pobj) expression_10/NN (l_prep) of_11/IN (l_pobj) anxiety_15/NN
D009638_D001008 NONE norepinephrine_22/NN (r_dobj) lack_21/VBP (r_relcl) mice_18/NNS (r_appos) knockout_13/NN (r_pobj) of_8/IN (r_prep) performance_7/NN (r_dobj) evaluated_5/VBD (l_advcl) examine_36/VB (l_dobj) contribution_38/NN (l_prep) of_39/IN (l_pobj) signaling_41/NN (l_prep) to_42/IN (l_pobj) anxiety_46/NN
D009638_D001008 NONE NE_24/NNP (r_appos) norepinephrine_22/NN (r_dobj) lack_21/VBP (r_relcl) mice_18/NNS (r_appos) knockout_13/NN (r_pobj) of_8/IN (r_prep) performance_7/NN (r_dobj) evaluated_5/VBD (l_advcl) examine_36/VB (l_dobj) contribution_38/NN (l_prep) of_39/IN (l_pobj) signaling_41/NN (l_prep) to_42/IN (l_pobj) anxiety_46/NN
D003042_D001008 CID cocaine_12/NN (r_npadvmod) induced_14/VBN (r_amod) anxiety_15/NN
D003042_D001008 CID cocaine_4/NN (r_poss) effects_7/NNS (r_appos) mechanisms_2/NNS (r_nsubjpass) studied_10/VBN (r_advcl) paid_17/VBN (l_prep) to_18/IN (l_pobj) states_22/NNS (l_acl) induced_23/VBN (l_agent) by_24/IN (l_pobj) cocaine_25/NN (l_prep) as_28/IN (l_pobj) anxiety_29/NN
D003042_D001008 CID cocaine_25/NN (l_prep) as_28/IN (l_pobj) anxiety_29/NN
D003042_D001008 CID cocaine_43/NN (r_npadvmod) induced_45/VBN (r_amod) anxiety_46/NN
D003042_D001008 CID cocaine_3/NN (r_nsubj) increased_7/VBN (r_amod) behavior_11/NN (l_amod) like_10/JJ (l_npadvmod) anxiety_8/NN
D003042_D001008 CID Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) anxiety_3/NN
D003042_D001008 CID cocaine_20/NN (r_npadvmod) induced_22/VBN (r_amod) behavior_26/NN (l_amod) like_25/JJ (l_npadvmod) anxiety_23/NN
D003042_D001008 CID cocaine_14/NN (r_npadvmod) induced_16/VBN (r_amod) anxiety_17/NN
D004298_D001008 NONE dopamine_9/NN (r_compound) knockout_13/NN (r_pobj) of_8/IN (r_prep) performance_7/NN (r_dobj) evaluated_5/VBD (l_advcl) examine_36/VB (l_dobj) contribution_38/NN (l_prep) of_39/IN (l_pobj) signaling_41/NN (l_prep) to_42/IN (l_pobj) anxiety_46/NN
D011433_D001008 NONE propranolol_18/FW (r_appos) antagonist_17/NN (l_conj) behavior_26/NN (l_amod) like_25/JJ (l_npadvmod) anxiety_23/NN
2440413
D001556_D012640 NONE hexachlorocyclohexane_5/NNP (r_nmod) lindane_7/NNP (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_9/IN (l_pobj) seizures_13/NNS
D001556_D012640 NONE lindane_7/NNP (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_9/IN (l_pobj) seizures_13/NNS
D001556_D012640 NONE hexachlorocyclohexane_2/NNP (r_nsubjpass) shown_19/VBN (l_xcomp) decrease_21/VB (l_dobj) threshold_23/NN (l_compound) seizure_22/NN
D001556_D012640 NONE hexachlorocyclohexane_2/NNP (r_nsubjpass) shown_19/VBN (l_xcomp) decrease_21/VB (l_conj) increase_39/VB (l_dobj) threshold_40/NN (l_prep) to_41/IN (l_pobj) seizures_45/NNS
D001556_D012640 NONE HCH_6/NNP (r_appos) hexachlorocyclohexane_2/NNP (r_nsubjpass) shown_19/VBN (l_xcomp) decrease_21/VB (l_dobj) threshold_23/NN (l_compound) seizure_22/NN
D001556_D012640 NONE HCH_6/NNP (r_appos) hexachlorocyclohexane_2/NNP (r_nsubjpass) shown_19/VBN (l_xcomp) decrease_21/VB (l_conj) increase_39/VB (l_dobj) threshold_40/NN (l_prep) to_41/IN (l_pobj) seizures_45/NNS
D001556_D012640 NONE lindane_15/NN (r_pobj) of_12/IN (r_prep) ingredient_11/NN (r_appos) hexachlorocyclohexane_2/NNP (r_nsubjpass) shown_19/VBN (l_xcomp) decrease_21/VB (l_dobj) threshold_23/NN (l_compound) seizure_22/NN
D001556_D012640 NONE lindane_15/NN (r_pobj) of_12/IN (r_prep) ingredient_11/NN (r_appos) hexachlorocyclohexane_2/NNP (r_nsubjpass) shown_19/VBN (l_xcomp) decrease_21/VB (l_conj) increase_39/VB (l_dobj) threshold_40/NN (l_prep) to_41/IN (l_pobj) seizures_45/NNS
D001556_D012640 NONE HCH_36/NNP (r_pobj) to_33/IN (r_prep) exposure_32/NN (r_pobj) after_31/IN (r_prep) h_30/NN (r_appos) pentylenetrazol_25/NN (r_pobj) to_24/IN (r_prep) decrease_21/VB (l_dobj) threshold_23/NN (l_compound) seizure_22/NN
D001556_D012640 NONE HCH_36/NNP (r_pobj) to_33/IN (r_prep) exposure_32/NN (r_pobj) after_31/IN (r_prep) h_30/NN (r_appos) pentylenetrazol_25/NN (r_pobj) to_24/IN (r_prep) decrease_21/VB (l_conj) increase_39/VB (l_dobj) threshold_40/NN (l_prep) to_41/IN (l_pobj) seizures_45/NNS
D001556_D012640 NONE HCH_53/NNP (r_pobj) to_50/IN (r_prep) exposure_49/NN (r_pobj) after_48/IN (r_prep) increase_39/VB (r_conj) decrease_21/VB (l_dobj) threshold_23/NN (l_compound) seizure_22/NN
D001556_D012640 NONE HCH_53/NNP (r_pobj) to_50/IN (r_prep) exposure_49/NN (r_pobj) after_48/IN (r_prep) increase_39/VB (l_dobj) threshold_40/NN (l_prep) to_41/IN (l_pobj) seizures_45/NNS
D001556_D012640 NONE HCH_30/NNP (r_npadvmod) mg/kg_27/CD (r_pobj) of_25/IN (r_prep) administration_24/NN (r_pobj) after_22/IN (r_prep) tested_15/VBN (l_nsubjpass) severity_5/NN (l_prep) of_6/IN (l_pobj) response_7/NN (l_prep) to_8/IN (l_pobj) agents_13/NNS (l_amod) inducing_12/VBG (l_npadvmod) seizure_10/NN
D001556_D012640 NONE HCH_8/NNP (l_appos) activity_11/NN (l_prep) of_12/IN (l_pobj) agents_16/NNS (l_amod) inducing_15/VBG (l_npadvmod) seizure_13/NN
D001556_D012640 NONE HCH_31/NNP (r_pobj) after_28/IN (r_mark) observed_36/VBN (r_advcl) increased_18/VBN (l_nsubjpass) administration_4/NN (l_prep) of_5/IN (l_pobj) HCH_8/NNP (l_appos) activity_11/NN (l_prep) of_12/IN (l_pobj) agents_16/NNS (l_amod) inducing_15/VBG (l_npadvmod) seizure_13/NN
D001556_D012640 NONE HCH_22/NNP (r_pobj) after_19/IN (r_prep) induced_12/VBN (r_acl) activity_11/NN (l_compound) seizure_10/JJ
D001556_D012640 NONE HCH_22/NNP (r_pobj) after_19/IN (r_prep) induced_12/VBN (r_acl) activity_11/NN (r_pobj) to_9/IN (r_prep) occur_8/VB (l_advcl) decreased_36/VBN (l_nsubjpass) response_26/NN (l_prep) to_27/IN (l_pobj) agents_34/NNS (l_amod) inducing_33/VBG (l_npadvmod) seizure_31/NN
D001556_D012640 NONE HCH_20/NNP (r_nsubj) be_22/VB (l_nsubj) site_7/NN (l_amod) responsible_8/JJ (l_prep) for_9/IN (l_pobj) decrease_11/NN (l_prep) in_12/IN (l_pobj) activity_14/NN (l_compound) seizure_13/NN
D010433_D012640 CID PTZ_27/NNP (r_appos) pentylenetrazol_25/NN (r_pobj) to_24/IN (r_prep) decrease_21/VB (l_dobj) threshold_23/NN (l_compound) seizure_22/NN
D010433_D012640 CID PTZ_27/NNP (r_appos) pentylenetrazol_25/NN (r_pobj) to_24/IN (r_prep) decrease_21/VB (l_conj) increase_39/VB (l_dobj) threshold_40/NN (l_prep) to_41/IN (l_pobj) seizures_45/NNS
D010433_D012640 CID PTZ_42/NNP (r_npadvmod) induced_44/VBN (r_amod) seizures_45/NNS (r_pobj) to_41/IN (r_prep) threshold_40/NN (r_dobj) increase_39/VB (r_conj) decrease_21/VB (l_dobj) threshold_23/NN (l_compound) seizure_22/NN
D010433_D012640 CID PTZ_42/NNP (r_npadvmod) induced_44/VBN (r_amod) seizures_45/NNS
D010433_D012640 CID PTZ_4/NNP (r_pobj) due_2/IN (r_amod) activity_1/NN (l_compound) Seizure_0/NN
D010433_D012640 CID PTZ_4/NNP (r_pobj) due_2/IN (r_amod) activity_1/NN (r_nsubjpass) decreased_12/VBN (r_ccomp) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
D010433_D012640 CID PTZ_14/NNP (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) activity_11/NN (l_compound) seizure_10/JJ
D010433_D012640 CID PTZ_14/NNP (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) activity_11/NN (r_pobj) to_9/IN (r_prep) occur_8/VB (l_advcl) decreased_36/VBN (l_nsubjpass) response_26/NN (l_prep) to_27/IN (l_pobj) agents_34/NNS (l_amod) inducing_33/VBG (l_npadvmod) seizure_31/NN
D010852_D012640 CID picrotoxin_6/NNP (r_conj) PTZ_4/NNP (r_pobj) due_2/IN (r_amod) activity_1/NN (l_compound) Seizure_0/NN
D010852_D012640 CID picrotoxin_6/NNP (r_conj) PTZ_4/NNP (r_pobj) due_2/IN (r_amod) activity_1/NN (r_nsubjpass) decreased_12/VBN (r_ccomp) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
D010852_D012640 CID PTX_8/NNP (r_appos) picrotoxin_6/NNP (r_conj) PTZ_4/NNP (r_pobj) due_2/IN (r_amod) activity_1/NN (l_compound) Seizure_0/NN
D010852_D012640 CID PTX_8/NNP (r_appos) picrotoxin_6/NNP (r_conj) PTZ_4/NNP (r_pobj) due_2/IN (r_amod) activity_1/NN (r_nsubjpass) decreased_12/VBN (r_ccomp) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
D010852_D012640 CID PTX_16/NNP (r_nmod) h_18/NN (r_conj) PTZ_14/NNP (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) activity_11/NN (l_compound) seizure_10/JJ
D010852_D012640 CID PTX_16/NNP (r_nmod) h_18/NN (r_conj) PTZ_14/NNP (r_pobj) by_13/IN (r_agent) induced_12/VBN (r_acl) activity_11/NN (r_pobj) to_9/IN (r_prep) occur_8/VB (l_advcl) decreased_36/VBN (l_nsubjpass) response_26/NN (l_prep) to_27/IN (l_pobj) agents_34/NNS (l_amod) inducing_33/VBG (l_npadvmod) seizure_31/NN
D015097_D012640 CID acid_21/NN (r_intj) 3-mercaptopropionic_20/CD (r_pobj) to_19/IN (r_pcomp) due_18/IN (r_prep) activity_17/NN (r_nsubj) was_46/VBD (l_ccomp) decreased_12/VBN (l_nsubjpass) activity_1/NN (l_compound) Seizure_0/NN
D015097_D012640 CID acid_21/NN (r_intj) 3-mercaptopropionic_20/CD (r_pobj) to_19/IN (r_pcomp) due_18/IN (r_prep) activity_17/NN (l_compound) seizure_16/JJ
D015097_D012640 CID MPA_23/NNP (r_appos) acid_21/NN (r_intj) 3-mercaptopropionic_20/CD (r_pobj) to_19/IN (r_pcomp) due_18/IN (r_prep) activity_17/NN (r_nsubj) was_46/VBD (l_ccomp) decreased_12/VBN (l_nsubjpass) activity_1/NN (l_compound) Seizure_0/NN
D015097_D012640 CID MPA_23/NNP (r_appos) acid_21/NN (r_intj) 3-mercaptopropionic_20/CD (r_pobj) to_19/IN (r_pcomp) due_18/IN (r_prep) activity_17/NN (l_compound) seizure_16/JJ
D001640_D012640 CID bicuculline_26/NNP (r_nsubj) was_46/VBD (l_ccomp) decreased_12/VBN (l_nsubjpass) activity_1/NN (l_compound) Seizure_0/NN
D001640_D012640 CID bicuculline_26/NNP (r_nsubj) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
D001640_D012640 CID BCC_28/NNP (r_appos) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_ccomp) decreased_12/VBN (l_nsubjpass) activity_1/NN (l_compound) Seizure_0/NN
D001640_D012640 CID BCC_28/NNP (r_appos) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
C034818_D012640 CID carboline-3-carboxylate_36/NN (r_conj) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_ccomp) decreased_12/VBN (l_nsubjpass) activity_1/NN (l_compound) Seizure_0/NN
C034818_D012640 CID carboline-3-carboxylate_36/NN (r_conj) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
C034818_D012640 CID DMCM_38/NNP (r_appos) carboline-3-carboxylate_36/NN (r_conj) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_ccomp) decreased_12/VBN (l_nsubjpass) activity_1/NN (l_compound) Seizure_0/NN
C034818_D012640 CID DMCM_38/NNP (r_appos) carboline-3-carboxylate_36/NN (r_conj) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
D013331_D012640 CID strychnine_42/NN (r_conj) carboline-3-carboxylate_36/NN (r_conj) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_ccomp) decreased_12/VBN (l_nsubjpass) activity_1/NN (l_compound) Seizure_0/NN
D013331_D012640 CID strychnine_42/NN (r_conj) carboline-3-carboxylate_36/NN (r_conj) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
D013331_D012640 CID STR_44/NNP (r_appos) strychnine_42/NN (r_conj) carboline-3-carboxylate_36/NN (r_conj) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_ccomp) decreased_12/VBN (l_nsubjpass) activity_1/NN (l_compound) Seizure_0/NN
D013331_D012640 CID STR_44/NNP (r_appos) strychnine_42/NN (r_conj) carboline-3-carboxylate_36/NN (r_conj) bicuculline_26/NNP (r_nsubj) was_46/VBD (l_nsubj) activity_17/NN (l_compound) seizure_16/JJ
D005680_D012640 NONE GABA_24/NNP (r_compound) A_26/DT (r_nmod) channel_31/NN (r_attr) be_22/VB (l_nsubj) site_7/NN (l_amod) responsible_8/JJ (l_prep) for_9/IN (l_pobj) decrease_11/NN (l_prep) in_12/IN (l_pobj) activity_14/NN (l_compound) seizure_13/NN
18217897
D013792_D008228 NONE Thalidomide_0/NNP (r_nsubj) limited_2/VBN (l_prep) in_7/IN (l_pobj) lymphomas_15/NNS
D013792_D009369 NONE Thalidomide_0/NNP (r_nsubj) limited_2/VBN (l_dobj) trial_20/NN (l_prep) of_21/IN (l_pobj) B._27/NNP (l_compound) Group_26/NNP (l_nmod) Cancer_23/NNP
D013792_D007938 NONE Thalidomide_0/NNP (r_nsubj) limited_2/VBN (l_dobj) trial_20/NN (l_prep) of_21/IN (l_pobj) B._27/NNP (l_compound) Group_26/NNP (l_nmod) Cancer_23/NNP (l_conj) Leukemia_25/NNP
D013792_D009101 NONE Thalidomide_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_4/NN (l_prep) with_5/IN (l_pobj) activity_7/NN (l_prep) in_8/IN (l_pobj) myeloma_10/NN
D013792_D020522 NONE Thalidomide_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_4/NN (l_prep) with_5/IN (l_pobj) activity_7/NN (l_prep) in_8/IN (l_pobj) myeloma_10/NN (l_conj) lymphoma_14/NN
D013792_D008223 NONE Thalidomide_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_4/NN (l_prep) with_5/IN (l_pobj) activity_7/NN (l_prep) in_8/IN (l_pobj) myeloma_10/NN (l_conj) lymphoma_14/NN (l_conj) lymphoma_17/NN
D013792_D008223 NONE thalidomide_16/NN (r_dative) received_15/VBD (l_nsubj) patients_8/NNS (l_prep) with_9/IN (l_pobj) lymphomas_14/NNS
D013792_D008223 NONE thalidomide_12/NN (r_pobj) to_9/IN (r_prep) rate_8/NN (l_prep) in_13/IN (l_pobj) lymphomas_15/NNS
C467567_D008223 NONE lenalidomide_31/JJ (r_appos) agent_29/NN (r_pobj) with_24/IN (r_prep) reported_23/VBN (r_acl) level_22/NN (r_pobj) with_18/IN (r_prep) contrast_17/NN (r_conj) rate_8/NN (l_prep) in_13/IN (l_pobj) lymphomas_15/NNS
7504976
D002231_D056486 CID carbimazole_16/NNP (r_pobj) between_15/IN (r_prep) reactivity_14/NN (r_pobj) with_11/IN (r_prep) one_10/CD (r_pobj) including_9/VBG (r_prep) cases_8/NNS (r_appos) hepatitis_1/NN
D002231_D056486 CID carbimazole_8/NNP (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) hepatitis_5/NN
D002231_D056486 CID omercazole_11/NNP (r_appos) carbimazole_8/NNP (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) hepatitis_5/NN
D002231_D056486 CID carbimazole_12/NNP (r_pobj) following_11/VBG (r_acl) hepatitis_10/NNP
D002231_D056486 CID carbimazole_21/NNP (r_dobj) replaced_20/VBN (l_nsubj) experienced_7/VBD (l_dobj) hepatitis_10/NN
C019269_D056486 NONE benzylthiouracil_18/NNP (r_conj) carbimazole_16/NNP (r_pobj) between_15/IN (r_prep) reactivity_14/NN (r_pobj) with_11/IN (r_prep) one_10/CD (r_pobj) including_9/VBG (r_prep) cases_8/NNS (r_appos) hepatitis_1/NN
C019269_D056486 NONE Benzylthiouracil_14/NNP (r_pobj) after_13/IN (r_prep) appeared_12/VBD (r_relcl) hepatitis_10/NN
C019269_D056486 NONE ne_17/XX (r_appos) Benzylthiouracil_14/NNP (r_pobj) after_13/IN (r_prep) appeared_12/VBD (r_relcl) hepatitis_10/NN
D002231_D002779 CID carbimazole_8/NNP (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) hepatitis_5/NN
D002231_D002779 CID omercazole_11/NNP (r_appos) carbimazole_8/NNP (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) hepatitis_5/NN
D002231_D002779 CID carbimazole_12/NNP (r_pobj) following_11/VBG (r_acl) hepatitis_10/NNP (l_det) a_3/DT (l_amod) mixed_4/JJ (l_conj) cholestatic_6/NNP
21029050
D013390_D001049 CID succinylcholine_9/NN (r_pobj) after_8/IN (r_prep) apnea_7/NN
D013390_D001049 CID succinylcholine_11/NN (r_pobj) of_10/IN (r_prep) action_9/NN (r_pobj) of_8/IN (r_prep) duration_7/NN (r_pobj) with_4/IN (r_prep) patients_3/NNS (r_nsubj) had_12/VBD (l_advcl) indicating_17/VBG (l_ccomp) is_20/VBZ (l_attr) reason_23/NN (l_prep) for_24/IN (l_pobj) period_27/NN (l_prep) of_28/IN (l_pobj) apnea_29/NN
9034419
C047426_D012640 CID venlafaxine_4/NN (r_compound) overdose_5/NN (r_pobj) from_2/IN (r_prep) resulting_1/VBG (r_acl) Seizure_0/NN
C047426_D012640 CID venlafaxine_5/NN (r_compound) tablets_7/NNS (r_pobj) of_3/IN (r_prep) ingestion_2/NN (r_pobj) After_0/IN (r_prep) experienced_11/VBD (l_dobj) seizure_15/NN
C047426_D012640 CID venlafaxine_11/NN (r_compound) overdose_12/NN (l_relcl) resulted_14/VBD (l_prep) in_15/IN (l_pobj) seizure_18/NN
C047426_D012640 CID venlafaxine_1/NN (r_compound) overdose_2/NN (r_nsubj) resulted_6/VBD (l_prep) in_7/IN (l_pobj) episode_10/NN (l_prep) of_11/IN (l_pobj) seizure_13/NN
C047426_D062787 CID venlafaxine_4/NN (r_compound) overdose_5/NN
C047426_D062787 CID venlafaxine_5/NN (r_compound) overdose_6/NN
C047426_D062787 CID venlafaxine_12/NN (r_pobj) of_11/IN (r_prep) overdose_10/NN
C047426_D062787 CID venlafaxine_11/NN (r_compound) overdose_12/NN
C047426_D062787 CID venlafaxine_1/NN (r_compound) overdose_2/NN
C047426_D003865 NONE venlafaxine_12/NN (r_pobj) of_11/IN (r_prep) overdose_10/NN (r_dobj) took_8/VBD (l_nsubj) woman_4/NN (l_prep) with_5/IN (l_pobj) depression_7/NN
11419773
D002110_D001145 NONE Caffeine_0/NN (r_npadvmod) induced_2/VBN (r_amod) arrhythmia_4/NN
D002110_D008945 NONE caffeine_34/NN (r_pobj) of_33/IN (r_prep) concentration_32/NN (r_dobj) containing_29/VBG (r_acl) drink_28/NN (r_dobj) consuming_20/VBG (r_pcomp) after_19/IN (r_prep) developed_15/VBD (r_relcl) prolapse_13/NN
D002110_D014693 CID caffeine_34/NN (r_pobj) of_33/IN (r_prep) concentration_32/NN (r_dobj) containing_29/VBG (r_acl) drink_28/NN (r_dobj) consuming_20/VBG (r_pcomp) after_19/IN (r_prep) developed_15/VBD (l_dobj) fibrillation_18/NN
10706004
D012964_D006973 NONE sodium_2/NN (r_pobj) of_1/IN (r_prep) Changes_0/NNS (l_appos) K)-ATPase_12/NNP (l_prep) during_13/IN (l_conj) after_15/IN (l_pobj) hypertension_19/NN
D012964_D006973 NONE Na_10/NNP (r_appos) cardiac_8/JJ (r_pobj) of_6/IN (r_prep) affinities_5/NNS (r_conj) Changes_0/NNS (l_appos) K)-ATPase_12/NNP (l_prep) during_13/IN (l_conj) after_15/IN (l_pobj) hypertension_19/NN
D012964_D006973 NONE sodium_9/NN (r_compound) level_10/NN (r_pobj) of_7/IN (r_prep) elevation_6/NN (r_nsubjpass) documented_12/VBN (l_prep) In_0/IN (l_pobj) models_2/NNS (l_prep) of_3/IN (l_pobj) hypertension_4/NN
D012964_D006973 NONE Na+_11/NN (r_pobj) of_10/IN (r_prep) transport_9/NN (r_pobj) in_7/IN (r_prep) disturbances_6/NNS (r_pobj) of_5/IN (r_prep) basis_4/NN (r_dobj) assess_1/VB (r_advcl) studied_14/VBD (l_dobj) response_16/NN (l_prep) to_23/IN (l_pobj) hypertension_27/NN
D012964_D006973 NONE Na_20/NNP (r_appos) cardiac_18/NN (r_pobj) of_17/IN (r_prep) response_16/NN (l_prep) to_23/IN (l_pobj) hypertension_27/NN
D012964_D006973 NONE Na_9/NNP (r_pobj) of_7/IN (r_prep) activity_6/NN (r_nsubj) increased_12/VBD (l_prep) After_0/IN (l_pobj) recovery_1/NN (l_prep) from_2/IN (l_pobj) hypertension_3/NN
D012964_D006973 NONE Na+-extrusion_12/NN (r_pobj) by_10/IN (r_agent) accompanied_9/VBN (r_acl) hypertension_8/NN
D012964_D006973 NONE Na+-binding_21/VBG (r_amod) properties_22/NNS (r_pobj) of_19/IN (r_prep) consequence_18/NN (r_pobj) as_16/IN (r_prep) accompanied_9/VBN (r_acl) hypertension_8/NN
D012964_D006973 NONE Na_26/NNP (r_pobj) of_23/IN (r_prep) properties_22/NNS (r_pobj) of_19/IN (r_prep) consequence_18/NN (r_pobj) as_16/IN (r_prep) accompanied_9/VBN (r_acl) hypertension_8/NN
D000255_D006973 NONE ATP_4/NNP (r_conj) sodium_2/NN (r_pobj) of_1/IN (r_prep) Changes_0/NNS (l_appos) K)-ATPase_12/NNP (l_prep) during_13/IN (l_conj) after_15/IN (l_pobj) hypertension_19/NN
D000255_D006973 NONE ATP_20/NNP (r_npadvmod) binding_22/VBG (r_amod) site_23/NN (r_pobj) of_18/IN (r_prep) affinity_17/NN (r_pobj) due_14/IN (r_prep) increased_12/VBD (l_prep) After_0/IN (l_pobj) recovery_1/NN (l_prep) from_2/IN (l_pobj) hypertension_3/NN
D000255_D006973 NONE ATP_33/NNP (r_pobj) for_32/IN (r_prep) value_31/NN (r_pobj) from_27/IN (r_prep) revealed_26/VBN (r_advcl) increased_12/VBD (l_prep) After_0/IN (l_pobj) recovery_1/NN (l_prep) from_2/IN (l_pobj) hypertension_3/NN
D011188_D006973 NONE K)-ATPase_12/NNP (l_prep) during_13/IN (l_conj) after_15/IN (l_pobj) hypertension_19/NN
D011188_D006973 NONE K)-ATPase_22/NNP (r_appos) cardiac_18/NN (r_pobj) of_17/IN (r_prep) response_16/NN (l_prep) to_23/IN (l_pobj) hypertension_27/NN
D011188_D006973 NONE K)-ATPase_11/NNP (r_conj) Na_9/NNP (r_pobj) of_7/IN (r_prep) activity_6/NN (r_nsubj) increased_12/VBD (l_prep) After_0/IN (l_pobj) recovery_1/NN (l_prep) from_2/IN (l_pobj) hypertension_3/NN
D011188_D006973 NONE K)-ATPase_28/NNP (r_appos) Na_26/NNP (r_pobj) of_23/IN (r_prep) properties_22/NNS (r_pobj) of_19/IN (r_prep) consequence_18/NN (r_pobj) as_16/IN (r_prep) accompanied_9/VBN (r_acl) hypertension_8/NN
D009569_D006973 CID oxide_17/NN (r_npadvmod) deficient_18/JJ (r_amod) hypertension_19/NN
D009569_D006973 CID NO_2/DT (r_det) synthesis_3/NN (r_pobj) of_1/IN (r_prep) Inhibition_0/NN (r_nsubj) induces_4/VBZ (l_dobj) hypertension_6/NN
D009569_D006973 CID NO_24/DT (r_advmod) deficient_26/JJ (r_amod) hypertension_27/NN
D009569_D006973 CID NO_32/JJ (r_compound) synthase_34/NN (r_compound) inhibition_35/NN (r_pobj) by_31/IN (r_agent) induced_28/VBN (r_acl) hypertension_27/NN
D009569_D006973 CID NO_2/JJ (r_compound) synthase_4/NN (r_pobj) of_1/IN (r_prep) Inhibition_0/NN (r_nsubj) induced_5/VBD (l_dobj) hypertension_8/NN
D019331_D006973 NONE ester_49/NN (r_pobj) with_36/IN (r_prep) induced_28/VBN (r_acl) hypertension_27/NN
D019331_D006973 NONE NAME_53/NNP (r_appos) ester_49/NN (r_pobj) with_36/IN (r_prep) induced_28/VBN (r_acl) hypertension_27/NN
D009569_D003866 NONE NO_2/JJ (r_compound) synthase_4/NN (r_pobj) of_1/IN (r_prep) Inhibition_0/NN (r_nsubj) induced_5/VBD (l_dobj) hypertension_8/NN (l_acl) accompanied_9/VBN (l_agent) by_10/IN (l_pobj) Na+-extrusion_12/NN (l_amod) depressed_11/JJ
D012964_D003866 NONE Na+-extrusion_12/NN (l_amod) depressed_11/JJ
D012964_D003866 NONE Na+-binding_21/VBG (r_amod) properties_22/NNS (r_pobj) of_19/IN (r_prep) consequence_18/NN (r_pobj) as_16/IN (r_prep) accompanied_9/VBN (l_agent) by_10/IN (l_pobj) Na+-extrusion_12/NN (l_amod) depressed_11/JJ
D012964_D003866 NONE Na_26/NNP (r_pobj) of_23/IN (r_prep) properties_22/NNS (r_pobj) of_19/IN (r_prep) consequence_18/NN (r_pobj) as_16/IN (r_prep) accompanied_9/VBN (l_agent) by_10/IN (l_pobj) Na+-extrusion_12/NN (l_amod) depressed_11/JJ
D011188_D003866 NONE K)-ATPase_28/NNP (r_appos) Na_26/NNP (r_pobj) of_23/IN (r_prep) properties_22/NNS (r_pobj) of_19/IN (r_prep) consequence_18/NN (r_pobj) as_16/IN (r_prep) accompanied_9/VBN (l_agent) by_10/IN (l_pobj) Na+-extrusion_12/NN (l_amod) depressed_11/JJ
6308277
D002110_D064420 NONE caffeine_2/NN (r_compound) toxicity_3/NN
D002110_D064420 NONE caffeine_11/NN (r_pobj) of_10/IN (r_prep) effects_9/NNS (r_dobj) augment_6/VB (r_xcomp) reported_4/VBN (r_advcl) focused_18/VBN (l_prep) on_19/IN (l_pobj) possibility_21/NN (l_acl) reduced_33/VBD (l_dobj) toxicity_36/NN
D002110_D064420 NONE caffeine_38/NN (r_pobj) of_37/IN (r_prep) toxicity_36/NN
D000082_D064420 NONE acetaminophen_5/NN (r_pobj) by_4/IN (r_prep) Reduction_0/NN (l_prep) in_1/IN (l_pobj) toxicity_3/NN
D000082_D064420 NONE acetaminophen_26/NNP (r_pobj) of_25/IN (r_prep) presence_24/NN (r_nsubj) reduced_33/VBD (l_dobj) toxicity_36/NN
D000082_D012640 NONE acetaminophen_8/NN (r_pobj) with_7/IN (r_prep) pretreatment_6/NN (r_nsubj) increased_13/VBD (l_dobj) interval_15/NN (l_conj) onset_30/NN (l_prep) of_31/IN (l_pobj) convulsions_33/NNS
D000082_D012640 NONE acetaminophen_8/NN (r_pobj) with_7/IN (r_prep) pretreatment_6/NN (r_nsubj) increased_13/VBD (l_advcl) reduced_51/VBD (l_dobj) incidence_53/NN (l_prep) of_54/IN (l_pobj) seizures_56/NNS
D000082_D012640 NONE acetaminophen_46/NN (r_pobj) with_45/IN (r_prep) pretreatment_44/NN (r_conj) onset_30/NN (l_prep) of_31/IN (l_pobj) convulsions_33/NNS
D000082_D012640 NONE acetaminophen_46/NN (r_pobj) with_45/IN (r_prep) pretreatment_44/NN (r_conj) onset_30/NN (r_conj) interval_15/NN (r_dobj) increased_13/VBD (l_advcl) reduced_51/VBD (l_dobj) incidence_53/NN (l_prep) of_54/IN (l_pobj) seizures_56/NNS
D000082_D012640 NONE acetaminophen_21/NN (r_pobj) by_20/IN (r_prep) reduced_14/VBN (l_nsubjpass) frequency_1/NN (l_prep) of_2/IN (l_pobj) seizures_6/NNS
D000082_D012640 NONE acetaminophen_6/NN (r_advmod) mg/kg_11/CD (r_pobj) In_0/IN (r_prep) modify_15/VB (l_dobj) seizures_17/NNS
D002110_D012640 CID caffeine_20/NNP (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) between_16/IN (r_prep) interval_15/NN (l_conj) onset_30/NN (l_prep) of_31/IN (l_pobj) convulsions_33/NNS
D002110_D012640 CID caffeine_20/NNP (r_pobj) of_19/IN (r_prep) administration_18/NN (r_pobj) between_16/IN (r_prep) interval_15/NN (r_dobj) increased_13/VBD (l_advcl) reduced_51/VBD (l_dobj) incidence_53/NN (l_prep) of_54/IN (l_pobj) seizures_56/NNS
D002110_D012640 CID caffeine_62/NN (r_pobj) of_61/IN (r_prep) presence_60/NN (r_pobj) in_58/IN (r_prep) produced_57/VBN (r_acl) seizures_56/NNS (r_pobj) of_54/IN (r_prep) incidence_53/NN (r_dobj) reduced_51/VBD (r_advcl) increased_13/VBD (l_dobj) interval_15/NN (l_conj) onset_30/NN (l_prep) of_31/IN (l_pobj) convulsions_33/NNS
D002110_D012640 CID caffeine_62/NN (r_pobj) of_61/IN (r_prep) presence_60/NN (r_pobj) in_58/IN (r_prep) produced_57/VBN (r_acl) seizures_56/NNS
D002110_D012640 CID caffeine_12/NN (r_pobj) after_7/IN (r_prep) frequency_1/NN (l_prep) of_2/IN (l_pobj) seizures_6/NNS
D002110_D012640 CID caffeine_4/NN (r_pobj) of_3/IN (r_prep) absence_2/NN (r_pobj) In_0/IN (r_prep) modify_15/VB (l_dobj) seizures_17/NNS
D010433_D012640 CID pentylenetetrezol_30/NN (r_pobj) of_29/IN (r_prep) dose_28/NN (r_dobj) alter_25/VB (r_conj) modify_15/VB (l_dobj) seizures_17/NNS
17600377
C524754_D003072 NONE coumarate_7/NNP (r_appos) compound_2/NN (r_nsubj) attenuates_9/VBZ (l_dobj) deficits_11/NNS
C524754_D003072 NONE coumarate_11/NNP (r_nsubj) improve_13/VB (l_dobj) decline_15/NN
C524754_D003072 NONE coumarate_3/NNP (r_nsubjpass) found_5/VBN (l_xcomp) attenuate_7/VB (l_dobj) deficits_9/NNS
C524754_D003072 NONE coumarate_17/NNP (r_nsubj) is_18/VBZ (l_attr) candidate_22/NN (l_relcl) characterized_29/VBN (l_agent) by_30/IN (l_pobj) death_34/NN (l_conj) decline_37/NN (l_prep) of_38/IN (l_pobj) function_40/NN
C524754_D003704 NONE coumarate_7/NNP (r_appos) compound_2/NN (r_nsubj) attenuates_9/VBZ (l_conj) shows_13/VBZ (l_prep) in_16/IN (l_conj) in_19/IN (l_pobj) models_22/NNS (l_compound) dementia_21/NN
D012601_D003072 CID scopolamine_17/NN (r_npadvmod) injected_19/VBN (r_amod) rats_20/NNS (r_pobj) in_16/IN (r_prep) decline_15/NN
C544092_D003072 NONE 42)-infused_27/CD (r_appos) amyloid_23/NN (r_nmod) rats_28/NNS (r_pobj) in_22/IN (r_conj) in_16/IN (r_prep) decline_15/NN
C544092_D003072 NONE beta_31/NN (r_appos) amyloid_30/NN (r_pobj) of_28/IN (r_prep) hippocampus_27/NN (r_pobj) in_25/IN (r_prep) observed_24/VBN (r_acl) deficits_9/NNS
C524754_D000544 NONE coumarate_17/NNP (r_nsubj) is_18/VBZ (l_attr) candidate_22/NN (l_prep) against_23/IN (l_pobj) disease_26/NN
C524754_D009410 NONE coumarate_17/NNP (r_nsubj) is_18/VBZ (l_attr) candidate_22/NN (l_relcl) characterized_29/VBN (l_agent) by_30/IN (l_pobj) death_34/NN
14568327
D007980_D004409 CID levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) dyskinesias_5/NN
D007980_D004409 CID Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NNP
D007980_D004409 CID Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NNP (l_appos) LIDs_5/NNP
D007980_D004409 CID levodopa_34/NN (r_compound) therapy_35/NN (r_pobj) of_33/IN (r_prep) duration_32/NN (r_conj) response_29/NN (r_conj) severity_26/NN (r_conj) progression_23/NN (r_pobj) of_21/IN (r_prep) rate_20/NN (r_nsubjpass) involved_38/VBN (l_prep) in_39/IN (l_pobj) development_41/NN (l_prep) of_42/IN (l_pobj) LIDs_43/NNP
D007980_D004409 CID levodopa_22/NNP (r_compound) therapy_23/NN (r_pobj) of_21/IN (r_prep) initiation_20/NN (r_pobj) to_19/IN (r_prep) prior_18/RB (r_advmod) Monkeys_0/NNS (r_nsubj) developed_24/VBD (l_dobj) dyskinesia_25/NN
D007980_D004409 CID levodopa_33/NNP (r_compound) administration_34/NN (r_pobj) of_31/IN (r_prep) days_30/NNS (r_pobj) between_26/IN (r_prep) dyskinesia_25/NN
D007980_D004409 CID levodopa_22/NN (r_compound) therapy_23/NN (r_pobj) of_21/IN (r_prep) initiation_20/NN (r_pobj) to_19/IN (r_prep) prior_18/RB (r_advmod) progression_13/NN (r_conj) monkeys_3/NNS (r_nsubj) were_24/VBD (l_acomp) resistant_26/JJ (l_prep) to_27/IN (l_pcomp) developing_28/VBG (l_dobj) LIDs_29/NNS
D007980_D004409 CID levodopa_22/NN (r_compound) therapy_23/NN (r_pobj) of_21/IN (r_prep) initiation_20/NN (r_pobj) to_19/IN (r_prep) prior_18/RB (r_advmod) progression_13/NN (r_conj) monkeys_3/NNS (r_nsubj) were_24/VBD (l_acomp) resistant_26/JJ (l_prep) to_27/IN (l_pcomp) developing_28/VBG (l_dobj) LIDs_29/NNS (l_parataxis) developed_34/VBD (l_nsubj) dyskinesia_33/NN
D007980_D004409 CID levodopa_42/NNP (r_compound) administration_43/NNP (r_pobj) of_40/IN (r_prep) days_39/NNS (r_dobj) developing_28/VBG (l_dobj) LIDs_29/NNS
D007980_D004409 CID levodopa_42/NNP (r_compound) administration_43/NNP (r_pobj) of_40/IN (r_prep) days_39/NNS (r_dobj) developing_28/VBG (l_dobj) LIDs_29/NNS (l_parataxis) developed_34/VBD (l_nsubj) dyskinesia_33/NN
D007980_D004409 CID levodopa_24/NN (r_pobj) to_23/IN (r_prep) prior_22/RB (r_advmod) develop_9/VB (l_dobj) LIDs_10/NNP
D007980_D004409 CID levodopa_24/NN (r_pobj) to_23/IN (r_prep) prior_22/RB (r_advmod) develop_9/VB (l_conj) demonstrate_26/VB (l_prep) for_32/IN (l_pcomp) studying_34/VBG (l_dobj) pathophysiology_36/NN (l_prep) of_37/IN (l_pobj) LIDs_38/NNS
D007980_D010300 NONE levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) dyskinesias_5/NN (l_prep) in_6/IN (l_pobj) monkeys_8/NNS (l_amod) parkinsonian_7/NNP
D007980_D010300 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NNP (r_nsubj) present_7/VB (l_dobj) problem_10/NN (l_prep) for_11/IN (l_pobj) management_16/NN (l_prep) of_17/IN (l_pobj) disease_20/NN
D007980_D010300 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NNP (r_nsubj) present_7/VB (l_dobj) problem_10/NN (l_prep) for_11/IN (l_pobj) management_16/NN (l_prep) of_17/IN (l_pobj) disease_20/NN (l_appos) patients_24/NNS (l_nmod) PD_22/NNP
D015632_D010302 CID MPTP_7/NNP (r_npadvmod) induced_9/VBN (r_amod) parkinsonism_10/NN
D015632_D004409 NONE MPTP_7/NNP (r_npadvmod) induced_9/VBN (r_amod) parkinsonism_10/NN (r_pobj) of_6/IN (r_prep) types_5/NNS (r_pobj) with_3/IN (r_prep) Using_0/VBG (r_advcl) evaluated_15/VBD (l_dobj) degree_17/NN (l_relcl) involved_38/VBN (l_prep) in_39/IN (l_pobj) development_41/NN (l_prep) of_42/IN (l_pobj) LIDs_43/NNP
D015632_D004409 NONE MPTP_8/NNP (r_compound) exposure_9/NN (r_pobj) with_1/IN (r_prep) Monkeys_0/NNS (r_nsubj) developed_24/VBD (l_dobj) dyskinesia_25/NN
D015632_D004409 NONE MPTP_8/NNP (r_compound) exposure_9/NN (r_pobj) with_4/IN (r_prep) monkeys_3/NNS (r_nsubj) were_24/VBD (l_acomp) resistant_26/JJ (l_prep) to_27/IN (l_pcomp) developing_28/VBG (l_dobj) LIDs_29/NNS
D015632_D004409 NONE MPTP_8/NNP (r_compound) exposure_9/NN (r_pobj) with_4/IN (r_prep) monkeys_3/NNS (r_nsubj) were_24/VBD (l_acomp) resistant_26/JJ (l_prep) to_27/IN (l_pcomp) developing_28/VBG (l_dobj) LIDs_29/NNS (l_parataxis) developed_34/VBD (l_nsubj) dyskinesia_33/NN
D007980_D010302 NONE levodopa_34/NN (r_compound) therapy_35/NN (r_pobj) of_33/IN (r_prep) duration_32/NN (r_conj) response_29/NN (r_conj) severity_26/NN (r_conj) progression_23/NN (r_pobj) of_21/IN (r_prep) rate_20/NN (r_nsubjpass) involved_38/VBN (r_relcl) degree_17/NN (r_dobj) evaluated_15/VBD (l_advcl) Using_0/VBG (l_prep) with_3/IN (l_pobj) types_5/NNS (l_prep) of_6/IN (l_pobj) parkinsonism_10/NN
15804801
D017239_D003323 CID paclitaxel_6/NN (r_compound) eluting_8/VBG (r_compound) stent_9/NN (r_pobj) of_4/IN (r_prep) implantation_3/NN (r_pobj) after_2/IN (r_prep) aneurysm_1/NN
D017239_D003323 CID paclitaxel_22/NN (r_compound) eluting_24/VBG (r_compound) stent_25/NN (r_dobj) receiving_20/VBG (r_pcomp) after_19/IN (r_prep) developed_8/VBD (l_dobj) aneurysm_11/NN
2355241
D007980_D002543 NONE levodopa_23/NN (r_pobj) of_22/IN (r_prep) effect_21/NN (r_dobj) reflect_18/VB (l_nsubj) incidence_2/NN (l_prep) of_3/IN (l_pobj) haemorrhage_5/NN
D007980_D003643 NONE levodopa_23/NN (r_pobj) of_22/IN (r_prep) effect_21/NN (r_dobj) reflect_18/VB (l_nsubj) incidence_2/NN (l_prep) as_6/IN (l_pobj) cause_8/NN (l_prep) of_9/IN (l_pobj) death_10/NN
D007980_D010300 NONE levodopa_23/NN (r_pobj) of_22/IN (r_prep) effect_21/NN (r_dobj) reflect_18/VB (l_nsubj) incidence_2/NN (l_prep) as_6/IN (l_pobj) cause_8/NN (l_prep) in_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) disease_16/NN
D007980_D010300 NONE levodopa_23/NN (l_conj) mechanism_27/NN (l_amod) due_28/JJ (l_pcomp) to_29/IN (l_pobj) levels_32/NNS (l_prep) in_33/IN (l_pobj) brain_36/NN (l_amod) parkinsonian_35/NNP
D007980_D007022 CID levodopa_23/NN (r_pobj) of_22/IN (r_prep) effect_21/NN (l_amod) hypotensive_20/JJ
D007980_D007022 CID levodopa_23/NN (l_conj) mechanism_27/NN (l_amod) hypotensive_26/JJ
D009638_D002543 NONE noradrenaline_31/NN (r_compound) levels_32/NNS (r_pobj) to_29/IN (r_pcomp) due_28/JJ (r_amod) mechanism_27/NN (r_conj) levodopa_23/NN (r_pobj) of_22/IN (r_prep) effect_21/NN (r_dobj) reflect_18/VB (l_nsubj) incidence_2/NN (l_prep) of_3/IN (l_pobj) haemorrhage_5/NN
D009638_D003643 NONE noradrenaline_31/NN (r_compound) levels_32/NNS (r_pobj) to_29/IN (r_pcomp) due_28/JJ (r_amod) mechanism_27/NN (r_conj) levodopa_23/NN (r_pobj) of_22/IN (r_prep) effect_21/NN (r_dobj) reflect_18/VB (l_nsubj) incidence_2/NN (l_prep) as_6/IN (l_pobj) cause_8/NN (l_prep) of_9/IN (l_pobj) death_10/NN
D009638_D010300 NONE noradrenaline_31/NN (r_compound) levels_32/NNS (r_pobj) to_29/IN (r_pcomp) due_28/JJ (r_amod) mechanism_27/NN (r_conj) levodopa_23/NN (r_pobj) of_22/IN (r_prep) effect_21/NN (r_dobj) reflect_18/VB (l_nsubj) incidence_2/NN (l_prep) as_6/IN (l_pobj) cause_8/NN (l_prep) in_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) disease_16/NN
D009638_D010300 NONE noradrenaline_31/NN (r_compound) levels_32/NNS (l_prep) in_33/IN (l_pobj) brain_36/NN (l_amod) parkinsonian_35/NNP
D009638_D007022 NONE noradrenaline_31/NN (r_compound) levels_32/NNS (r_pobj) to_29/IN (r_pcomp) due_28/JJ (r_amod) mechanism_27/NN (r_conj) levodopa_23/NN (r_pobj) of_22/IN (r_prep) effect_21/NN (l_amod) hypotensive_20/JJ
D009638_D007022 NONE noradrenaline_31/NN (r_compound) levels_32/NNS (r_pobj) to_29/IN (r_pcomp) due_28/JJ (r_amod) mechanism_27/NN (l_amod) hypotensive_26/JJ
16337777
D010862_D004827 NONE pilocarpine_12/NNP (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) model_7/NN (l_prep) of_8/IN (l_pobj) epilepsy_9/NN
D010862_D013226 NONE pilocarpine_49/NNP (r_compound) model_50/NN (r_pobj) of_47/IN (r_prep) phase_46/NN (r_pobj) in_43/IN (r_conj) in_23/IN (r_prep) be_15/VB (l_nsubj) generation_8/NN (l_prep) during_11/IN (l_pobj) epilepticus_13/NN
D010862_D004833 CID pilocarpine_49/NNP (r_compound) model_50/NN (l_prep) of_51/IN (l_pobj) epilepsy_54/NN
12202650
D002211_D063806 NONE Capsaicin_0/NN (r_npadvmod) induced_2/VBN (r_amod) pain_4/NN
D002211_D010146 CID Capsaicin_0/NN (r_nsubjpass) injected_7/VBN (l_advcl) induce_13/VB (l_dobj) pain_14/NN
7453952
D008094_D003919 CID lithium_3/NN (r_npadvmod) induced_5/VBN (r_amod) diabetes_6/NN (r_nmod) like_10/JJ (r_amod) syndrome_11/NN
D008094_D003919 CID lithium_9/NN (r_npadvmod) induced_11/VBN (r_amod) diabetes_12/NN (r_nmod) like_16/JJ (r_amod) syndrome_17/NN
D008094_D003919 CID lithium_30/NN (r_compound) concentration_31/NN (r_pobj) between_28/IN (r_prep) ratio_27/NN (r_pobj) of_25/IN (r_prep) reduction_24/NN (r_pobj) by_22/IN (r_agent) accompanied_21/VBN (l_nsubjpass) attenuation_6/NN (l_prep) of_7/IN (l_pobj) syndrome_17/NN
D000584_D003919 NONE amiloride_13/NN (r_pobj) by_12/IN (r_prep) syndrome_11/NN
D000584_D003919 NONE amiloride_19/NN (r_pobj) by_18/IN (r_prep) syndrome_17/NN
D000584_D059606 NONE amiloride_3/NN (l_prep) on_4/IN (l_pobj) polydipsia_8/NN
D000584_D059606 NONE amiloride_5/NNP (r_compound) administration_6/NN (l_prep) to_7/IN (l_pobj) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) polydipsia_14/NN
D000584_D059606 NONE amiloride_23/NN (r_compound) supplementation_24/NN (r_nsubj) result_26/VB (r_conj) relieve_18/VB (l_nsubj) administration_6/NN (l_prep) to_7/IN (l_pobj) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) polydipsia_14/NN
D000584_D011141 NONE amiloride_3/NN (l_prep) on_4/IN (l_pobj) polydipsia_8/NN (l_conj) polyuria_10/NN
D000584_D011141 NONE amiloride_5/NNP (r_compound) administration_6/NN (l_prep) to_7/IN (l_pobj) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) polydipsia_14/NN (l_conj) polyuria_16/NN
D000584_D011141 NONE amiloride_23/NN (r_compound) supplementation_24/NN (r_nsubj) result_26/VB (r_conj) relieve_18/VB (l_nsubj) administration_6/NN (l_prep) to_7/IN (l_pobj) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) polydipsia_14/NN (l_conj) polyuria_16/NN
D008094_D059606 NONE lithium_5/NN (r_npadvmod) induced_7/VBN (r_amod) polydipsia_8/NN
D008094_D059606 NONE lithium_14/NN (r_compound) concentration_15/NN (r_pobj) on_12/IN (r_conj) on_4/IN (l_pobj) polydipsia_8/NN
D008094_D059606 NONE lithium_8/NN (r_npadvmod) treated_10/VBN (r_amod) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) polydipsia_14/NN
D008094_D059606 NONE lithium_29/NN (r_compound) levels_30/NNS (r_pobj) in_27/IN (r_prep) result_26/VB (r_conj) relieve_18/VB (l_nsubj) administration_6/NN (l_prep) to_7/IN (l_pobj) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) polydipsia_14/NN
D008094_D011141 NONE lithium_5/NN (r_npadvmod) induced_7/VBN (r_amod) polydipsia_8/NN (l_conj) polyuria_10/NN
D008094_D011141 NONE lithium_14/NN (r_compound) concentration_15/NN (r_pobj) on_12/IN (r_conj) on_4/IN (l_pobj) polydipsia_8/NN (l_conj) polyuria_10/NN
D008094_D011141 NONE lithium_8/NN (r_npadvmod) treated_10/VBN (r_amod) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) polydipsia_14/NN (l_conj) polyuria_16/NN
D008094_D011141 NONE lithium_29/NN (r_compound) levels_30/NNS (r_pobj) in_27/IN (r_prep) result_26/VB (r_conj) relieve_18/VB (l_nsubj) administration_6/NN (l_prep) to_7/IN (l_pobj) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) polydipsia_14/NN (l_conj) polyuria_16/NN
D018021_D059606 NONE LiCl_37/NNP (r_pobj) with_36/IN (r_prep) treated_35/VBN (r_advcl) investigated_30/VBN (l_nsubjpass) effect_1/NN (l_prep) of_2/IN (l_pobj) amiloride_3/NN (l_prep) on_4/IN (l_pobj) polydipsia_8/NN
D018021_D011141 NONE LiCl_37/NNP (r_pobj) with_36/IN (r_prep) treated_35/VBN (r_advcl) investigated_30/VBN (l_nsubjpass) effect_1/NN (l_prep) of_2/IN (l_pobj) amiloride_3/NN (l_prep) on_4/IN (l_pobj) polydipsia_8/NN (l_conj) polyuria_10/NN
D011188_D003919 NONE potassium_48/NN (r_compound) level_49/NN (r_pobj) in_45/IN (r_prep) elevation_44/NN (r_conj) levels_38/NNS (r_conj) medulla_35/NN (r_pobj) in_32/IN (r_prep) reduction_24/NN (r_pobj) by_22/IN (r_agent) accompanied_21/VBN (l_nsubjpass) attenuation_6/NN (l_prep) of_7/IN (l_pobj) syndrome_17/NN
2505783
C004656_D006470 CID chloroacetaldehyde_7/NNP (r_nsubj) is_11/VBZ (r_ccomp) indicating_5/VBG (r_advcl) carried_23/VBN (l_prep) in_25/IN (l_pobj) order_26/NN (l_acl) elucidate_28/VB (l_dobj) role_30/NN (l_prep) in_33/IN (l_pobj) development_35/NN (l_prep) of_36/IN (l_pobj) cystitis_38/NN
C004656_D006470 CID CAA_9/NNP (r_appos) chloroacetaldehyde_7/NNP (r_nsubj) is_11/VBZ (r_ccomp) indicating_5/VBG (r_advcl) carried_23/VBN (l_prep) in_25/IN (l_pobj) order_26/NN (l_acl) elucidate_28/VB (l_dobj) role_30/NN (l_prep) in_33/IN (l_pobj) development_35/NN (l_prep) of_36/IN (l_pobj) cystitis_38/NN
C004656_D006470 CID CAA_32/NNP (r_pobj) of_31/IN (r_prep) role_30/NN (l_prep) in_33/IN (l_pobj) development_35/NN (l_prep) of_36/IN (l_pobj) cystitis_38/NN
C004656_D003556 CID chloroacetaldehyde_7/NNP (r_nsubj) is_11/VBZ (r_ccomp) indicating_5/VBG (r_advcl) carried_23/VBN (l_prep) in_25/IN (l_pobj) order_26/NN (l_acl) elucidate_28/VB (l_dobj) role_30/NN (l_prep) in_33/IN (l_pobj) development_35/NN (l_prep) of_36/IN (l_pobj) cystitis_38/NN
C004656_D003556 CID CAA_9/NNP (r_appos) chloroacetaldehyde_7/NNP (r_nsubj) is_11/VBZ (r_ccomp) indicating_5/VBG (r_advcl) carried_23/VBN (l_prep) in_25/IN (l_pobj) order_26/NN (l_acl) elucidate_28/VB (l_dobj) role_30/NN (l_prep) in_33/IN (l_pobj) development_35/NN (l_prep) of_36/IN (l_pobj) cystitis_38/NN
C004656_D003556 CID CAA_32/NNP (r_pobj) of_31/IN (r_prep) role_30/NN (l_prep) in_33/IN (l_pobj) development_35/NN (l_prep) of_36/IN (l_pobj) cystitis_38/NN
C004656_D001745 NONE CAA_4/NNP (r_nsubj) contribute_10/VB (l_prep) to_11/IN (l_pobj) damage_13/NN
7053303
D002927_D003704 CID cimetidine_10/NN (r_pobj) to_9/IN (r_prep) due_8/JJ (r_amod) case_4/NN (l_prep) of_5/IN (l_pobj) dementia_6/NN
D002927_D003704 CID cimetidine_40/NN (r_compound) levels_41/NNS (r_dobj) had_39/VBD (r_relcl) group_29/NN (r_pobj) in_27/IN (r_prep) due_8/JJ (r_amod) case_4/NN (l_prep) of_5/IN (l_pobj) dementia_6/NN
D002927_D003704 CID cimetidine_3/NN (r_compound) levels_4/NNS (r_nsubj) induce_9/VB (l_dobj) dementia_10/NN
D002927_D008107 NONE cimetidine_10/NN (r_pobj) to_9/IN (r_prep) due_8/JJ (l_prep) in_27/IN (l_pobj) group_29/NN (l_prep) without_33/IN (l_pobj) disease_37/NN
D002927_D008107 NONE cimetidine_40/NN (r_compound) levels_41/NNS (r_dobj) had_39/VBD (r_relcl) group_29/NN (l_prep) without_33/IN (l_pobj) disease_37/NN
D002927_D007674 NONE cimetidine_10/NN (r_pobj) to_9/IN (r_prep) due_8/JJ (l_prep) in_27/IN (l_pobj) group_29/NN (l_prep) without_33/IN (l_pobj) disease_37/NN
D002927_D007674 NONE cimetidine_40/NN (r_compound) levels_41/NNS (r_dobj) had_39/VBD (r_relcl) group_29/NN (l_prep) without_33/IN (l_pobj) disease_37/NN
9727773
D001067_D006976 CID suppressants_9/NNS (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) hypertension_5/NN
D001067_D006976 CID suppressant_21/NN (r_compound) drugs_22/NNS (r_pobj) of_19/IN (r_prep) intake_18/NN (r_pobj) with_16/IN (r_prep) associated_15/VBN (r_relcl) disease_10/NN (r_attr) is_3/VBZ (l_nsubj) hypertension_2/NN
D001067_D006976 CID suppressants_18/NNS (r_dobj) taken_16/VBN (r_conj) was_9/VBD (l_nsubj) diagnosis_4/NN (l_prep) of_5/IN (l_pobj) hypertension_8/NN
D001067_D006976 CID suppressants_7/NNS (r_pobj) of_5/IN (r_prep) prescription_4/NN (r_pobj) of_2/IN (r_prep) policy_1/NN (r_nsubj) lead_9/VB (l_prep) to_10/IN (l_pobj) incidence_13/NN (l_prep) of_14/IN (l_pobj) hypertension_18/NN
20080419
D010862_D004827 CID pilocarpine_24/NNP (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) epilepsy_21/NN
6692345
D001241_D001749 NONE aspirin_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_nsubj) resulted_13/VBD (l_prep) in_14/IN (l_pobj) incidence_17/NN (l_prep) of_18/IN (l_pobj) carcinomas_23/NNS
D001241_D013274 NONE aspirin_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_nsubj) resulted_13/VBD (l_prep) in_14/IN (l_pobj) incidence_17/NN (l_conj) induction_27/NN (l_prep) of_28/IN (l_pobj) tumors_30/NNS
D005200_D001749 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7/NNP (r_pobj) with_6/IN (r_prep) aspirin_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_nsubj) resulted_13/VBD (l_prep) in_14/IN (l_pobj) incidence_17/NN (l_prep) of_18/IN (l_pobj) carcinomas_23/NNS
D005200_D001749 CID FANFT_9/NNP (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7/NNP (r_pobj) with_6/IN (r_prep) aspirin_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_nsubj) resulted_13/VBD (l_prep) in_14/IN (l_pobj) incidence_17/NN (l_prep) of_18/IN (l_pobj) carcinomas_23/NNS
D005200_D001749 CID FANFT_19/NNP (r_npadvmod) induced_21/VBN (r_amod) carcinomas_23/NNS
D005200_D013274 CID N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7/NNP (r_pobj) with_6/IN (r_prep) aspirin_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_nsubj) resulted_13/VBD (l_prep) in_14/IN (l_pobj) incidence_17/NN (l_conj) induction_27/NN (l_prep) of_28/IN (l_pobj) tumors_30/NNS
D005200_D013274 CID FANFT_9/NNP (r_appos) N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide_7/NNP (r_pobj) with_6/IN (r_prep) aspirin_5/NN (r_pobj) of_4/IN (r_prep) administration_3/NN (r_nsubj) resulted_13/VBD (l_prep) in_14/IN (l_pobj) incidence_17/NN (l_conj) induction_27/NN (l_prep) of_28/IN (l_pobj) tumors_30/NNS
D005200_D013274 CID FANFT_19/NNP (r_npadvmod) induced_21/VBN (r_amod) carcinomas_23/NNS (r_pobj) of_18/IN (r_prep) incidence_17/NN (l_conj) induction_27/NN (l_prep) of_28/IN (l_pobj) tumors_30/NNS
D005200_D063646 NONE FANFT_16/NNP (r_compound) carcinogenesis_17/NN
D005200_D063646 NONE FANFT_30/NNP (r_pobj) on_29/IN (r_prep) effect_28/NN (r_nsubj) is_34/VBZ (r_conj) are_3/VBP (l_acomp) consistent_4/JJ (l_prep) with_5/IN (l_pobj) experiment_8/NN (l_acl) suggesting_9/VBG (l_ccomp) involved_14/VBN (l_prep) in_15/IN (l_pobj) carcinogenesis_17/NN
D001241_D063646 NONE aspirin_26/NN (r_poss) effect_28/NN (r_nsubj) is_34/VBZ (r_conj) are_3/VBP (l_acomp) consistent_4/JJ (l_prep) with_5/IN (l_pobj) experiment_8/NN (l_acl) suggesting_9/VBG (l_ccomp) involved_14/VBN (l_prep) in_15/IN (l_pobj) carcinogenesis_17/NN
1527456
D008012_D014012 NONE lignocaine_7/NNP (r_pobj) of_6/IN (r_prep) instillation_5/NN (r_pobj) by_3/IN (r_prep) Treatment_0/NN (l_prep) of_1/IN (l_pobj) tinnitus_2/NN
D008012_D014012 NONE lidocaine_9/NN (r_appos) lignocaine_7/NNP (r_pobj) of_6/IN (r_prep) instillation_5/NN (r_pobj) by_3/IN (r_prep) Treatment_0/NN (l_prep) of_1/IN (l_pobj) tinnitus_2/NN
D008012_D014012 NONE lignocaine_12/NNP (r_pobj) of_11/IN (r_prep) instillation_10/NN (r_pobj) by_8/IN (r_prep) treating_6/VBG (l_dobj) IST_7/NNP
D008012_D014012 NONE lidocaine_14/NN (r_appos) lignocaine_12/NNP (r_pobj) of_11/IN (r_prep) instillation_10/NN (r_pobj) by_8/IN (r_prep) treating_6/VBG (l_dobj) IST_7/NNP
8437969
D002927_D054138 CID cimetidine_7/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) arrest_1/NN
D002927_D054138 CID cimetidine_27/NN (r_dobj) receiving_23/VBG (r_advcl) developed_13/VBD (l_dobj) episodes_17/NNS (l_prep) of_18/IN (l_pobj) arrest_21/NN
D002927_D054138 CID cimetidine_14/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) arrest_8/NN
D002927_D001919 CID cimetidine_7/NN (r_pobj) of_6/IN (r_prep) infusions_5/NNS (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubjpass) associated_10/VBN (l_prep) with_11/IN (l_pobj) development_13/NN (l_prep) of_14/IN (l_pobj) bradyarrhythmias_15/NNP
D002927_D007938 NONE cimetidine_27/NN (r_dobj) receiving_23/VBG (r_advcl) developed_13/VBD (l_nsubj) man_4/NN (l_prep) with_5/IN (l_pobj) leukemia_6/NN
D002927_D006331 NONE cimetidine_27/NN (r_dobj) receiving_23/VBG (r_advcl) developed_13/VBD (l_nsubj) man_4/NN (l_conj) history_9/NN (l_prep) of_10/IN (l_pobj) disease_12/NN
D002927_D001145 NONE cimetidine_6/NNP (r_compound) administration_7/NN (r_pobj) to_5/IN (r_prep) related_4/VBN (r_acomp) were_2/VBD (l_nsubj) arrhythmias_1/NNS
D011899_D001145 NONE ranitidine_18/NN (r_compound) treatment_19/NN (r_pobj) during_17/IN (r_prep) recur_16/VB (r_conj) disappeared_9/VBD (r_dep) were_2/VBD (l_nsubj) arrhythmias_1/NNS
3629586
D015790_D006402 NONE cefonicid_4/NNP (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_appos) model_13/NN (l_prep) of_14/IN (l_pobj) hematotoxicity_16/NNP
D015790_D006402 NONE cefonicid_23/NN (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) of_16/IN (r_prep) %_15/NN (r_pobj) in_12/IN (r_prep) occurred_11/VBD (r_conj) was_3/VBD (l_attr) compromising_6/NN (l_prep) of_7/IN (l_pobj) cytopenias_9/NNS
D015790_D006402 NONE cefonicid_16/NNP (r_conj) reproduced_10/VBN (l_nsubjpass) syndrome_8/NN
D015790_D006402 NONE cefonicid_9/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_pobj) of_5/IN (r_prep) administration_4/NN (r_nsubj) induce_15/VB (l_dobj) hematotoxicity_16/NN
D015790_D006402 NONE cefonicid_9/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_pobj) of_5/IN (r_prep) administration_4/NN (r_nsubj) induce_15/VB (l_dobj) hematotoxicity_16/NN (l_amod) similar_17/JJ (l_prep) to_18/IN (l_pobj) dyscrasias_24/NNS
C021341_D006402 NONE cefazedone_6/NNP (r_conj) cefonicid_4/NNP (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_appos) model_13/NN (l_prep) of_14/IN (l_pobj) hematotoxicity_16/NNP
C021341_D006402 NONE cefazedone_29/NN (r_npadvmod) occurred_11/VBD (r_conj) was_3/VBD (l_attr) compromising_6/NN (l_prep) of_7/IN (l_pobj) cytopenias_9/NNS
C021341_D006402 NONE cefazedone_11/NN (r_conj) cefonicid_9/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_pobj) of_5/IN (r_prep) administration_4/NN (r_nsubj) induce_15/VB (l_dobj) hematotoxicity_16/NN
C021341_D006402 NONE cefazedone_11/NN (r_conj) cefonicid_9/NN (r_pobj) of_8/IN (r_prep) doses_7/NNS (r_pobj) of_5/IN (r_prep) administration_4/NN (r_nsubj) induce_15/VB (l_dobj) hematotoxicity_16/NN (l_amod) similar_17/JJ (l_prep) to_18/IN (l_pobj) dyscrasias_24/NNS
D002511_D006402 NONE cephalosporin_15/NNP (r_amod) hematotoxicity_16/NNP
D002511_D006402 NONE Cephalosporin_0/NNP (r_compound) antibiotics_1/NNS (r_nsubj) cause_2/VBP (l_ccomp) remain_17/VBP (l_nsubj) variety_4/NN (l_prep) of_5/IN (l_pobj) disturbances_7/NNS
D002511_D006402 NONE cephalosporin_4/NN (r_pobj) with_2/IN (r_prep) rechallenge_1/NN (r_pobj) Upon_0/IN (r_prep) reproduced_10/VBN (l_nsubjpass) syndrome_8/NN
D002511_D006402 NONE cephalosporin_20/NN (r_amod) induced_22/VBN (r_amod) dyscrasias_24/NNS (r_pobj) to_18/IN (r_prep) similar_17/JJ (r_amod) hematotoxicity_16/NN
D002511_D006402 NONE cephalosporin_20/NN (r_amod) induced_22/VBN (r_amod) dyscrasias_24/NNS
D015790_D064420 NONE cefonicid_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) caused_16/VBD (l_prep) In_0/IN (l_pobj) studies_4/NNS (l_compound) toxicity_3/NN
D015790_D000740 CID cefonicid_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) caused_16/VBD (l_dobj) incidence_21/NN (l_prep) of_22/IN (l_pobj) anemia_23/NN
D015790_D000740 CID cefonicid_23/NN (r_dobj) receiving_18/VBG (r_acl) dogs_17/NNS (r_pobj) of_16/IN (r_prep) %_15/NN (r_pobj) in_12/IN (r_prep) occurred_11/VBD (r_conj) was_3/VBD (l_nsubj) anemia_2/NN
D015790_D009503 CID cefonicid_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) caused_16/VBD (l_dobj) incidence_21/NN (l_prep) of_22/IN (l_pobj) anemia_23/NN (l_conj) neutropenia_25/NN
D015790_D013921 CID cefonicid_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) caused_16/VBD (l_dobj) incidence_21/NN (l_prep) of_22/IN (l_pobj) anemia_23/NN (l_conj) neutropenia_25/NN (l_conj) thrombocytopenia_28/NN
C021341_D064420 NONE cefazedone_12/NNP (r_conj) cefonicid_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) caused_16/VBD (l_prep) In_0/IN (l_pobj) studies_4/NNS (l_compound) toxicity_3/NN
C021341_D000740 CID cefazedone_12/NNP (r_conj) cefonicid_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) caused_16/VBD (l_dobj) incidence_21/NN (l_prep) of_22/IN (l_pobj) anemia_23/NN
C021341_D000740 CID cefazedone_29/NN (r_npadvmod) occurred_11/VBD (r_conj) was_3/VBD (l_nsubj) anemia_2/NN
C021341_D009503 CID cefazedone_12/NNP (r_conj) cefonicid_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) caused_16/VBD (l_dobj) incidence_21/NN (l_prep) of_22/IN (l_pobj) anemia_23/NN (l_conj) neutropenia_25/NN
C021341_D013921 CID cefazedone_12/NNP (r_conj) cefonicid_10/NNP (r_pobj) of_9/IN (r_prep) administration_8/NN (r_nsubj) caused_16/VBD (l_dobj) incidence_21/NN (l_prep) of_22/IN (l_pobj) anemia_23/NN (l_conj) neutropenia_25/NN (l_conj) thrombocytopenia_28/NN
8953972
D004837_D013345 CID epinephrine_8/NN (r_pobj) of_7/IN (r_prep) use_6/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) bleeding_2/VBG
D004837_D012128 NONE epinephrine_26/NN (r_dobj) administer_24/VB (r_advcl) led_16/VBD (l_nsubj) onset_2/NN (l_prep) of_3/IN (l_pobj) distress_5/NN
D004837_D005076 NONE epinephrine_26/NN (r_dobj) administer_24/VB (r_advcl) led_16/VBD (l_nsubj) onset_2/NN (l_prep) of_3/IN (l_pobj) distress_5/NN (l_conj) rash_7/JJ
D004837_D006323 CID Epinephrine_0/NN (r_nsubj) has_1/VBZ (l_dobj) role_4/NN (l_prep) in_5/IN (l_pobj) arrest_7/NN
D004837_D004342 NONE Epinephrine_0/NN (r_nsubj) has_1/VBZ (r_ccomp) viewed_28/VBN (l_nsubjpass) use_14/NN (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) reaction_22/NN
D004837_D006973 NONE Epinephrine_0/NN (r_nsubj) has_1/VBZ (r_ccomp) viewed_28/VBN (l_nsubjpass) use_14/NN (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) reaction_22/NN (l_conj) hypertension_25/NN
7516729
D014700_D001919 CID verapamil_6/NN (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) bradycardia_3/NNS
2273650
D012601_D000647 CID scopolamine_3/NN (r_pobj) by_2/IN (r_agent) produced_1/VBN (r_acl) Amnesia_0/NN
D012601_D000647 CID scopolamine_5/NN (r_nsubj) reversed_7/VBD (l_dobj) amnesia_12/NN
D012601_D000647 CID scopolamine_5/NN (r_nsubj) reversed_7/VBD (l_conj) failed_23/VBD (l_xcomp) reverse_25/VB (l_dobj) amnesia_30/NN
D012601_D000647 CID scopolamine_9/NN (r_npadvmod) induced_11/VBN (r_amod) amnesia_12/NN
D012601_D000647 CID scopolamine_9/NN (r_npadvmod) induced_11/VBN (r_amod) amnesia_12/NN (r_dobj) reversed_7/VBD (l_conj) failed_23/VBD (l_xcomp) reverse_25/VB (l_dobj) amnesia_30/NN
D003513_D000647 CID cycloheximide_5/NN (r_conj) scopolamine_3/NN (r_pobj) by_2/IN (r_agent) produced_1/VBN (r_acl) Amnesia_0/NN
D003513_D000647 CID cycloheximide_22/NN (r_nsubj) failed_23/VBD (r_conj) reversed_7/VBD (l_dobj) amnesia_12/NN
D003513_D000647 CID cycloheximide_22/NN (r_nsubj) failed_23/VBD (l_xcomp) reverse_25/VB (l_dobj) amnesia_30/NN
D003513_D000647 CID cycloheximide_27/NN (r_npadvmod) induced_29/VBN (r_amod) amnesia_30/NN (r_dobj) reverse_25/VB (r_xcomp) failed_23/VBD (r_conj) reversed_7/VBD (l_dobj) amnesia_12/NN
D003513_D000647 CID cycloheximide_27/NN (r_npadvmod) induced_29/VBN (r_amod) amnesia_30/NN
D009020_D000647 NONE morphine_9/NN (r_pobj) by_8/IN (r_agent) reversed_7/VBN (l_nsubjpass) Amnesia_0/NN
D009020_D000647 NONE morphine_27/NN (r_nsubj) facilitated_29/VBD (r_conj) reversed_7/VBN (l_nsubjpass) Amnesia_0/NN
D009270_D000647 NONE naloxone_37/NN (r_dobj) administered_36/VBD (r_ccomp) facilitated_29/VBD (r_conj) reversed_7/VBN (l_nsubjpass) Amnesia_0/NN
10807237
D003042_D000783 NONE cocaine_12/NN (r_npadvmod) related_14/VBN (r_amod) aneurysms_15/NNS
D003042_D000783 NONE cocaine_16/NN (r_npadvmod) related_18/VBN (r_amod) aneurysms_19/NNS
D003042_D000783 NONE Cocaine_0/NN (r_compound) use_1/VBP (l_prep) at_5/IN (l_conj) in_11/IN (l_pobj) aneurysms_14/NNS
D003042_D017542 CID Cocaine_0/NN (r_compound) use_1/VBP (l_dobj) rupture_4/NN
8919272
D014635_D001927 CID valproate_11/RB (l_nsubj) features_1/NNS (l_prep) of_2/IN (l_pobj) encephalopathy_3/NN
D014635_D001927 CID valproate_12/FW (r_amod) encephalopathy_13/NN
D014635_D001927 CID valproate_15/NN (r_amod) encephalopathy_16/NN
D014635_D009422 NONE valproate_12/FW (r_amod) encephalopathy_13/NN (r_npadvmod) revealed_4/VBD (l_dobj) disorders_6/NNS
D014635_D002526 NONE valproate_12/FW (r_amod) encephalopathy_13/NN (r_npadvmod) revealed_4/VBD (l_dobj) disorders_6/NNS (l_acl) indicating_7/VBG (l_dobj) damage_9/NN
D014635_D056486 NONE valproate_15/NN (r_amod) encephalopathy_16/NN (r_pobj) of_14/IN (r_prep) development_13/NN (r_pobj) upon_11/IN (r_prep) discussed_18/VBN (l_nsubjpass) influence_2/NN (l_prep) of_3/IN (l_pobj) damage_6/NN
D014635_D022124 NONE valproate_15/NN (r_amod) encephalopathy_16/NN (r_pobj) of_14/IN (r_prep) development_13/NN (r_pobj) upon_11/IN (r_prep) discussed_18/VBN (l_nsubjpass) influence_2/NN (l_appos) hyperammonemia_9/NNP
16005948
-1_D062787 NONE GNC92H2_6/NNP (r_pobj) of_1/IN (r_prep) Evaluation_0/NN (l_prep) as_7/IN (l_pobj) immunotherapy_9/NN (l_prep) for_10/IN (l_pobj) overdose_12/NN
-1_D062787 NONE GNC92H2_7/NNP (r_pobj) of_3/IN (r_prep) potential_2/NN (r_nsubjpass) examined_9/VBN (l_advcl) using_10/VBG (l_dobj) model_12/NN (l_prep) of_13/IN (l_pobj) overdose_15/NN
-1_D062787 NONE GNC92H2_7/NNS (r_pobj) of_6/IN (r_prep) potential_5/NN (l_prep) as_8/IN (l_pobj) tool_11/NN (l_prep) against_12/IN (l_pobj) overdose_14/NN
D003042_D062787 NONE cocaine_4/NN (r_pobj) of_3/IN (r_prep) use_2/NN (r_nsubj) continues_5/VBZ (l_prep) in_6/IN (l_pobj) proportions_8/NNS (l_prep) for_11/IN (l_pobj) overdose_13/NN
D003042_D064420 NONE cocaine_3/NN (r_compound) toxicity_4/NN
D003042_D012640 CID cocaine_3/NN (r_compound) toxicity_4/NN (r_pobj) of_2/IN (r_prep) blockade_1/NN (r_nsubjpass) observed_6/VBN (l_dobj) seizures_28/NNS
D003042_D003643 NONE cocaine_3/NN (r_compound) toxicity_4/NN (r_pobj) of_2/IN (r_prep) blockade_1/NN (r_nsubjpass) observed_6/VBN (l_dobj) seizures_28/NNS (l_conj) death_34/NN
D003042_D003643 NONE cocaine_8/JJ (r_amod) injection_9/NN (r_appos) death_4/NN
-1_D064420 NONE GNC92H2_12/NNS (r_pobj) of_11/IN (r_prep) dose_10/NN (r_pobj) with_7/IN (r_prep) observed_6/VBN (l_nsubjpass) blockade_1/NN (l_prep) of_2/IN (l_pobj) toxicity_4/NN
-1_D012640 NONE GNC92H2_12/NNS (r_pobj) of_11/IN (r_prep) dose_10/NN (r_pobj) with_7/IN (r_prep) observed_6/VBN (l_dobj) seizures_28/NNS
-1_D003643 NONE GNC92H2_12/NNS (r_pobj) of_11/IN (r_prep) dose_10/NN (r_pobj) with_7/IN (r_prep) observed_6/VBN (l_dobj) seizures_28/NNS (l_conj) death_34/NN
-1_D003643 NONE GNC92H2_2/NNS (r_nsubj) prevented_3/VBN (l_dobj) death_4/NN
2696505
D007741_D007022 CID labetalol_4/NNP (r_pobj) of_3/IN (r_prep) comparison_2/NN (l_prep) for_7/IN (l_pobj) hypotension_9/NN
D007741_D007022 CID labetalol_5/NN (r_npadvmod) induced_7/VBN (r_amod) hypotension_8/NN
D007741_D007022 CID labetalol_5/NN (r_npadvmod) induced_7/VBN (r_amod) hypotension_8/NN (l_conj) hypotension_13/NN
D009599_D007022 CID nitroprusside_6/RB (r_conj) labetalol_4/NNP (r_pobj) of_3/IN (r_prep) comparison_2/NN (l_prep) for_7/IN (l_pobj) hypotension_9/NN
D009599_D007022 CID nitroprusside_10/RB (r_npadvmod) induced_12/VBN (r_amod) hypotension_13/NN (r_conj) hypotension_8/NN
D009599_D007022 CID nitroprusside_10/RB (r_npadvmod) induced_12/VBN (r_amod) hypotension_13/NN
D009599_D016534 CID nitroprusside_31/NNP (r_pobj) of_30/IN (r_prep) discontinuation_29/NN (r_pobj) after_28/IN (r_prep) observed_24/VBN (l_ccomp) associated_3/VBN (l_nsubjpass) infusion_1/NN (l_acl) increase_13/NN (l_prep) in_14/IN (l_pobj) rate_16/NN (l_conj) output_19/NN
D009599_D006973 NONE nitroprusside_31/NNP (r_pobj) of_30/IN (r_prep) discontinuation_29/NN (r_pobj) after_28/IN (r_prep) observed_24/VBN (l_nsubjpass) hypertension_22/NN
6538499
D011092_D064420 NONE 400_4/CD (l_prep) on_5/IN (l_pobj) toxicity_7/NN
D004317_D064420 NONE adriamycin_6/NN (r_compound) toxicity_7/NN
D004317_D009202 CID ADR_8/NNP (r_npadvmod) induced_10/VBN (r_amod) alterations_13/NNS
D004317_D007939 NONE ADR_6/NNP (r_compound) activity_8/NN (l_prep) in_9/IN (l_pobj) leukemia_11/NN
D004317_D002286 NONE ADR_6/NNP (r_compound) activity_8/NN (l_prep) in_9/IN (l_conj) in_13/IN (l_pobj) tumor_16/NN
8739323
D008466_D007674 NONE nitrogranulogen_8/NNP (r_pobj) as_7/IN (r_prep) drugs_5/NNS (r_pobj) of_3/IN (r_prep) action_2/NN (l_compound) nephrotoxic_1/JJ
D008466_D007674 NONE NG_10/NNP (r_appos) nitrogranulogen_8/NNP (r_pobj) as_7/IN (r_prep) drugs_5/NNS (r_pobj) of_3/IN (r_prep) action_2/NN (l_compound) nephrotoxic_1/JJ
D008727_D007674 NONE methotrexate_13/NNP (r_conj) nitrogranulogen_8/NNP (r_pobj) as_7/IN (r_prep) drugs_5/NNS (r_pobj) of_3/IN (r_prep) action_2/NN (l_compound) nephrotoxic_1/JJ
D008727_D007674 NONE MTX_15/NNP (r_appos) methotrexate_13/NNP (r_conj) nitrogranulogen_8/NNP (r_pobj) as_7/IN (r_prep) drugs_5/NNS (r_pobj) of_3/IN (r_prep) action_2/NN (l_compound) nephrotoxic_1/JJ
D008727_D007674 NONE MTX_6/NNP (r_pobj) of_5/IN (r_prep) nephrotoxicity_4/NN
D005472_D007674 NONE 5-fluorouracil_18/CD (r_punct) action_2/NN (l_compound) nephrotoxic_1/JJ
D005472_D007674 NONE 5-FU_20/CD (r_appos) action_2/NN (l_compound) nephrotoxic_1/JJ
D005472_D007674 NONE 5-FU_8/CD (r_conj) MTX_6/NNP (r_pobj) of_5/IN (r_prep) nephrotoxicity_4/NN
D003520_D006470 CID CY_0/NNP (r_nsubj) caused_1/VBD (l_dobj) cystitis_3/NN
D003520_D003556 CID CY_0/NNP (r_nsubj) caused_1/VBD (l_dobj) cystitis_3/NN
D005472_D006470 NONE 5-FU_20/CD (r_pobj) with_19/IN (r_prep) combined_18/VBN (r_advcl) cause_14/VB (r_conj) caused_1/VBD (l_dobj) cystitis_3/NN
D005472_D003556 NONE 5-FU_20/CD (r_pobj) with_19/IN (r_prep) combined_18/VBN (r_advcl) cause_14/VB (r_conj) caused_1/VBD (l_dobj) cystitis_3/NN
D008727_D006470 NONE MTX_22/NNP (r_conj) 5-FU_20/CD (r_pobj) with_19/IN (r_prep) combined_18/VBN (r_advcl) cause_14/VB (r_conj) caused_1/VBD (l_dobj) cystitis_3/NN
D008727_D003556 NONE MTX_22/NNP (r_conj) 5-FU_20/CD (r_pobj) with_19/IN (r_prep) combined_18/VBN (r_advcl) cause_14/VB (r_conj) caused_1/VBD (l_dobj) cystitis_3/NN
D003520_D007674 NONE CY_10/NNP (r_conj) nephrotoxicity_4/NN
11027905
D007649_D009369 NONE ketamine_4/NN (l_prep) in_5/IN (l_pobj) patients_7/NNS (l_compound) cancer_6/NN
D007649_D009369 NONE ketamine_7/NN (r_pobj) of_6/IN (r_prep) doses_5/NNS (r_pobj) of_3/IN (r_prep) bolus_2/NN (r_nsubjpass) given_16/VBN (l_dative) to_17/IN (l_pobj) patients_20/NNS (l_compound) cancer_19/NN
D009020_D009369 NONE morphine_9/NN (r_compound) therapy_10/NN (r_pobj) on_8/IN (r_prep) effect_1/NN (l_prep) of_2/IN (l_pobj) ketamine_4/NN (l_prep) in_5/IN (l_pobj) patients_7/NNS (l_compound) cancer_6/NN
D009020_D009369 NONE morphine_26/NN (r_pobj) by_25/IN (r_prep) unrelieved_24/JJ (r_acomp) was_23/VBD (r_relcl) patients_20/NNS (l_compound) cancer_19/NN
D009020_D010146 NONE morphine_4/NN (r_pobj) to_3/IN (r_prep) responsive_2/JJ (r_amod) Pain_0/NN
D009020_D010146 NONE morphine_26/NN (r_pobj) by_25/IN (r_prep) unrelieved_24/JJ (r_acomp) was_23/VBD (l_nsubj) pain_22/NN
D009020_D010146 NONE morphine_3/NN (r_compound) analgesia_4/NN (r_dobj) improve_2/VB (l_prep) in_5/IN (l_pobj) syndromes_8/NNS (l_compound) pain_7/NN
D016202_D010146 NONE aspartate_13/NN (r_nsubj) be_24/VB (l_acomp) effective_25/JJ (l_prep) in_26/IN (l_pcomp) improving_27/VBG (l_prep) in_30/IN (l_pobj) syndromes_33/NNS (l_compound) pain_32/NN
D016202_D010146 NONE NMDA_15/NNP (r_appos) aspartate_13/NN (r_nsubj) be_24/VB (l_acomp) effective_25/JJ (l_prep) in_26/IN (l_pcomp) improving_27/VBG (l_prep) in_30/IN (l_pobj) syndromes_33/NNS (l_compound) pain_32/NN
D016202_D009437 NONE aspartate_13/NN (r_nsubj) be_24/VB (l_acomp) effective_25/JJ (l_prep) in_26/IN (l_pcomp) improving_27/VBG (l_prep) in_30/IN (l_pobj) syndromes_33/NNS (l_prep) as_36/IN (l_pobj) pain_38/NN
D016202_D009437 NONE NMDA_15/NNP (r_appos) aspartate_13/NN (r_nsubj) be_24/VB (l_acomp) effective_25/JJ (l_prep) in_26/IN (l_pcomp) improving_27/VBG (l_prep) in_30/IN (l_pobj) syndromes_33/NNS (l_prep) as_36/IN (l_pobj) pain_38/NN
D007649_D010146 NONE ketamine_21/NN (r_pobj) as_20/IN (r_prep) aspartate_13/NN (r_nsubj) be_24/VB (l_acomp) effective_25/JJ (l_prep) in_26/IN (l_pcomp) improving_27/VBG (l_prep) in_30/IN (l_pobj) syndromes_33/NNS (l_compound) pain_32/NN
D007649_D010146 NONE ketamine_7/NN (r_pobj) of_6/IN (r_prep) doses_5/NNS (r_pobj) of_3/IN (r_prep) bolus_2/NN (r_nsubjpass) given_16/VBN (l_dative) to_17/IN (l_pobj) patients_20/NNS (l_relcl) was_23/VBD (l_nsubj) pain_22/NN
D007649_D010146 NONE Ketamine_0/NNP (r_nsubj) reduced_8/VBD (l_dobj) intensity_11/NN (l_compound) pain_10/NN
D007649_D010146 NONE Ketamine_0/NNP (r_nsubj) improve_2/VB (l_prep) in_5/IN (l_pobj) syndromes_8/NNS (l_compound) pain_7/NN
D007649_D009437 NONE ketamine_21/NN (r_pobj) as_20/IN (r_prep) aspartate_13/NN (r_nsubj) be_24/VB (l_acomp) effective_25/JJ (l_prep) in_26/IN (l_pcomp) improving_27/VBG (l_prep) in_30/IN (l_pobj) syndromes_33/NNS (l_prep) as_36/IN (l_pobj) pain_38/NN
D007649_D009437 NONE Ketamine_0/NNP (r_nsubj) improve_2/VB (l_prep) in_5/IN (l_pobj) syndromes_8/NNS (l_prep) as_11/IN (l_pobj) pain_13/NN
D009020_D009437 NONE morphine_3/NN (r_compound) analgesia_4/NN (r_dobj) improve_2/VB (l_prep) in_5/IN (l_pobj) syndromes_8/NNS (l_prep) as_11/IN (l_pobj) pain_13/NN
19889778
17439425
D019820_D006973 NONE xanthine_2/NN (r_compound) oxidase_3/NN (l_prep) in_4/IN (l_pobj) hypertension_8/NN
D019820_D006973 NONE xanthine_5/NN (r_compound) oxidase_6/NN (l_relcl) implicated_13/VBN (l_prep) in_22/IN (l_pobj) hypertension_26/NN
D019820_D006973 NONE xanthine_5/NN (r_compound) oxidase_6/NN (l_relcl) implicated_13/VBN (l_prep) in_22/IN (l_pobj) hypertension_26/NN (l_appos) HT_30/NNP
D003907_D006973 CID dexamethasone_5/NN (r_npadvmod) induced_7/VBN (r_amod) hypertension_8/NN
D003907_D006973 CID dexamethasone_23/NN (r_npadvmod) induced_25/VBN (r_amod) hypertension_26/NN
D003907_D006973 CID dexamethasone_23/NN (r_npadvmod) induced_25/VBN (r_amod) hypertension_26/NN (l_appos) HT_30/NNP
D003907_D006973 CID dex_28/NNP (r_compound) HT_30/NNP (r_appos) hypertension_26/NN
D003907_D006973 CID dex_28/NNP (r_compound) HT_30/NNP
D003907_D006973 CID Dex_0/NNP (r_nmod) SBP_2/NNP
D003907_D006973 CID dex_4/NN (r_compound) HT_6/NNP
D003907_D015431 CID Dex_0/NNP (r_nmod) SBP_2/NNP (l_conj) thymus_19/NN (l_conj) bodyweights_26/NNS
D000493_D006973 NONE Allopurinol_0/NNP (r_nsubj) prevent_3/VB (l_dobj) HT_6/NNP
D000493_D006973 NONE allopurinol_8/NN (r_nsubj) failed_9/VBD (l_xcomp) prevent_11/VB (l_dobj) hypertension_15/NN
D000493_D006973 NONE allopurinol_8/NN (r_nsubj) failed_9/VBD (r_acl) findings_6/NNS (r_pobj) with_3/IN (r_prep) suggests_17/VBZ (l_ccomp) is_21/VBZ (l_attr) determinant_25/NN (l_prep) of_26/IN (l_pobj) HT_29/NNP
7269015
D002066_D006470 CID Busulfan_0/NNP (r_npadvmod) induced_2/VBN (r_amod) cystitis_4/NN
D002066_D006470 CID busulfan_4/NN (r_npadvmod) induced_6/VBN (r_amod) hemorrhage_7/NN (r_compound) cystitis_8/NN
D002066_D003556 CID Busulfan_0/NNP (r_npadvmod) induced_2/VBN (r_amod) cystitis_4/NN
D002066_D003556 CID busulfan_4/NN (r_npadvmod) induced_6/VBN (r_amod) hemorrhage_7/NN (r_compound) cystitis_8/NN
D002066_D003556 CID busulfan_7/NNP (r_compound) cystitis_8/NNP
D002066_D003556 CID busulfan_7/NNP (r_compound) cystitis_8/NNP (l_conj) radiation_11/NN (l_conj) cystitis_16/NN
D003520_D003556 NONE cyclophosphamide_13/NN (r_npadvmod) induced_15/VBN (r_amod) cystitis_16/NN (r_conj) radiation_11/NN (r_conj) cystitis_8/NNP
D003520_D003556 NONE cyclophosphamide_13/NN (r_npadvmod) induced_15/VBN (r_amod) cystitis_16/NN
D002066_D002277 NONE busulfan_7/NNP (r_pobj) of_6/IN (r_prep) tendency_5/NN (r_pobj) of_2/IN (r_prep) view_1/NN (r_pobj) In_0/IN (l_pcomp) induce_9/VB (l_dobj) atypia_11/NN (l_conj) carcinoma_13/NN
3856631
D008727_D008577 NONE methotrexate_10/NN (r_pobj) with_5/IN (r_prep) induction_1/NN (l_prep) of_2/IN (l_pobj) leukemia_4/NN
D008727_D054198 NONE methotrexate_18/NN (r_compound) regimen_19/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (l_nsubjpass) children_1/NNS (l_prep) with_2/IN (l_pobj) leukemia_5/NN
D008727_D054198 NONE methotrexate_28/NNP (r_compound) concentrations_29/NNS (r_dobj) maintain_26/VB (r_conj) achieve_24/VB (r_xcomp) designed_22/VBN (r_relcl) regimen_19/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (l_nsubjpass) children_1/NNS (l_prep) with_2/IN (l_pobj) leukemia_5/NN
D008727_D054198 NONE methotrexate_4/NN (r_nsubj) is_5/VBZ (l_prep) after_14/IN (l_pobj) relapse_16/NN (l_prep) in_17/IN (l_pobj) leukemia_20/NN
D008727_D002493 NONE methotrexate_18/NN (r_compound) regimen_19/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (l_nsubjpass) children_1/NNS (l_prep) with_2/IN (l_pobj) leukemia_5/NN (l_relcl) developed_7/VBD (l_dobj) disease_9/NN
D008727_D002493 NONE methotrexate_28/NNP (r_compound) concentrations_29/NNS (r_dobj) maintain_26/VB (r_conj) achieve_24/VB (r_xcomp) designed_22/VBN (r_relcl) regimen_19/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (l_nsubjpass) children_1/NNS (l_prep) with_2/IN (l_pobj) leukemia_5/NN (l_relcl) developed_7/VBD (l_dobj) disease_9/NN
D001663_D064420 NONE bilirubin_10/NN (r_amod) elevations_11/NNS (r_conj) transaminase_8/NN (r_attr) were_5/VBD (l_nsubj) toxicities_3/NNS
D001663_D009503 NONE bilirubin_10/NN (r_amod) elevations_11/NNS (r_conj) transaminase_8/NN (l_conj) neutropenia_13/NN
D001663_D052016 NONE bilirubin_10/NN (r_amod) elevations_11/NNS (r_conj) transaminase_8/NN (l_conj) neutropenia_13/NN (l_conj) mucositis_16/NNP
18162529
D012313_D006966 NONE acid_5/NN (r_compound) levels_6/NNS (r_appos) prolactin_1/NN (r_nsubj) signaling_9/NN (l_conj) are_19/VBP (l_nsubj) inhibition_13/NN (l_compound) hyperprolactinemic_12/NN
D004958_D006966 NONE estradiol_22/NN (r_pobj) on_21/IN (r_prep) dependent_20/JJ (r_acomp) are_19/VBP (l_nsubj) inhibition_13/NN (l_compound) hyperprolactinemic_12/NN
D004958_D006966 NONE estradiol_30/NN (r_pobj) of_29/IN (r_prep) levels_28/NNS (r_pobj) of_25/IN (r_prep) presence_24/NN (r_pobj) in_22/IN (r_conj) caused_8/VBD (l_nsubj) hyperprolactinemia_1/NN
D004967_D006966 NONE estrogen_20/NN (r_npadvmod) induced_22/VBN (r_amod) surge_24/NN (r_conj) secretion_17/NN (r_appos) parameters_9/NNS (r_dobj) inhibited_6/VBD (l_nsubj) hyperprolactinemia_5/NN
D004298_D006966 NONE dopamine_5/NN (r_compound) antagonist_6/NN (r_compound) sulpiride_7/NNP (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) hyperprolactinemia_1/NN
D013469_D006966 CID sulpiride_7/NNP (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) hyperprolactinemia_1/NN
D013256_D006966 NONE steroid_14/NN (r_npadvmod) dependent_16/JJ (r_amod) manner_17/NN (r_pobj) in_12/IN (r_prep) inhibited_8/VBN (l_agent) by_9/IN (l_pobj) hyperprolactinemia_11/NN
9653867
D013974_D013971 CID Thyroxine_0/JJ (r_compound) abuse_1/NN (l_appos) case_5/NN (l_prep) of_6/IN (l_pobj) thyrotoxicosis_7/NN
D013974_D013971 CID thyroxine_28/JJ (r_amod) abuse_29/NN (r_nsubjpass) considered_32/VBN (l_advcl) remains_25/VBZ (l_nsubj) cause_22/NN (l_prep) for_23/IN (l_pobj) thyrotoxicosis_24/NNP
D013974_D001068 NONE thyroxine_28/JJ (r_amod) abuse_29/NN (r_nsubjpass) considered_32/VBN (r_ccomp) reminds_17/VBZ (r_conj) illustrates_3/VBZ (l_dobj) derangements_5/NNS (l_prep) of_6/IN (l_pobj) function_8/NN (l_acl) seen_9/VBN (l_prep) in_10/IN (l_pobj) women_12/NNS (l_prep) with_13/IN (l_pcomp) eating_14/VBG (l_dobj) disorders_15/NNS
6640832
D004317_D001749 NONE adriamycin_2/NNS (l_prep) in_3/IN (l_pobj) carcinoma_6/NN
D004317_D001749 NONE Adriamycin_0/NN (r_nsubjpass) administered_7/VBN (l_prep) after_12/IN (l_pobj) resection_14/NN (l_prep) of_15/IN (l_pobj) tumors_25/NNS
D004317_D002277 NONE adriamycin_2/NNS (l_prep) in_3/IN (l_pobj) carcinoma_6/NN
15233872
C007145_D009203 NONE Crataegus_5/NNP (r_pobj) of_4/IN (r_prep) tincture_3/NN (l_prep) on_6/IN (l_pobj) infarction_11/NN
C007145_D009203 NONE TCR_11/NNP (r_pobj) of_10/IN (r_prep) effect_9/NN (r_dobj) investigate_6/VB (l_prep) on_12/IN (l_pobj) infarction_16/NN
D007545_D009203 CID isoproterenol_7/NN (r_npadvmod) induced_9/VBN (r_amod) infarction_11/NN
20084309
D008874_D020521 NONE MZ_35/NNP (r_compound) dose_36/NN (r_conj) regurgitation_29/NN (r_conj) duration_23/NN (r_conj) used_2/VBN (l_xcomp) test_4/VB (l_dobj) influence_6/NN (l_appos) age_12/NN (l_conj) sex_14/NN (l_conj) stroke_16/NN
D008874_D009202 NONE MZ_35/NNP (r_compound) dose_36/NN (r_conj) regurgitation_29/NN (r_conj) duration_23/NN (r_conj) used_2/VBN (l_xcomp) test_4/VB (l_dobj) influence_6/NN (l_appos) age_12/NN (l_conj) sex_14/NN (l_conj) stroke_16/NN (l_conj) myocardiopathy_18/NNP
D008874_D009202 NONE MZ_35/NNP (r_compound) dose_36/NN (r_conj) regurgitation_29/NN (r_conj) duration_23/NN (r_conj) used_2/VBN (l_xcomp) test_4/VB (l_dobj) influence_6/NN (l_appos) age_12/NN (l_conj) sex_14/NN (l_conj) stroke_16/NN (l_conj) myocardiopathy_18/NNP (l_appos) MP_20/NNP
D008874_D009202 NONE MZ_17/NNP (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_conj) %_11/NN (l_nmod) MP_8/NNP
D008874_D008944 NONE MZ_35/NNP (r_compound) dose_36/NN (r_conj) regurgitation_29/NN
D008874_D008944 NONE MZ_35/NNP (r_compound) dose_36/NN (r_conj) regurgitation_29/NN (l_appos) MR_31/NNP
D008874_D008944 NONE MZ_17/NNP (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_conj) %_11/NN (l_nmod) MP_8/NNP (l_nmod) MR_6/NNP
D008874_D000860 CID MZ_44/NNP (r_compound) use_45/NN (r_pobj) by_43/IN (r_agent) caused_42/VBN (r_acl) 8_34/CD (r_conj) obstruction_29/NN (r_pobj) due_25/IN (r_prep) presented_22/VBD (l_ccomp) was_6/VBD (l_nsubj) hypoxia_1/NN
D008874_D000860 CID MZ_44/NNP (r_compound) use_45/NN (r_pobj) by_43/IN (r_agent) caused_42/VBN (r_acl) 8_34/CD (r_conj) obstruction_29/NN (r_pobj) due_25/IN (r_prep) presented_22/VBD (l_dobj) hypoxia_24/NN
D008874_D000860 CID MZ_44/NNP (r_compound) use_45/NN (r_pobj) by_43/IN (r_agent) caused_42/VBN (r_acl) 8_34/CD (l_prep) due_39/JJ (l_pobj) hypoxia_41/NN
D008874_D000402 NONE MZ_44/NNP (r_compound) use_45/NN (r_pobj) by_43/IN (r_agent) caused_42/VBN (r_acl) 8_34/CD (r_conj) obstruction_29/NN
18182964
D003000_D001289 NONE Clonidine_0/NN (l_prep) for_1/IN (l_pobj) disorder_7/NN
D003000_D001289 NONE clonidine_7/NN (r_pobj) of_6/IN (r_prep) safety_3/NN (r_dobj) examine_1/VB (l_prep) with_11/IN (l_pobj) methylphenidate_12/NN (l_prep) in_13/IN (l_pobj) children_14/NNS (l_prep) with_15/IN (l_pobj) disorder_21/NN
D003000_D001289 NONE clonidine_7/NN (r_pobj) of_6/IN (r_prep) safety_3/NN (r_dobj) examine_1/VB (l_prep) with_11/IN (l_pobj) methylphenidate_12/NN (l_prep) in_13/IN (l_pobj) children_14/NNS (l_prep) with_15/IN (l_pobj) disorder_21/NN (l_appos) ADHD_23/NNP
D003000_D001289 NONE clonidine_18/NN (r_pobj) to_17/IN (r_prep) assigned_16/VBN (l_nsubjpass) children_11/NNS (l_prep) with_12/IN (l_pobj) ADHD_13/NNP
D003000_D001289 NONE clonidine_32/NN (r_conj) methylphenidate_25/NNP (r_conj) assigned_16/VBN (l_nsubjpass) children_11/NNS (l_prep) with_12/IN (l_pobj) ADHD_13/NNP
D003000_D001289 NONE Clonidine_0/NNP (r_nsubj) appears_8/VBZ (l_oprd) tolerated_12/VBN (l_prep) in_13/IN (l_pobj) ADHD_15/NNP
D008774_D001289 NONE methylphenidate_12/NN (l_prep) in_13/IN (l_pobj) children_14/NNS (l_prep) with_15/IN (l_pobj) disorder_21/NN
D008774_D001289 NONE methylphenidate_12/NN (l_prep) in_13/IN (l_pobj) children_14/NNS (l_prep) with_15/IN (l_pobj) disorder_21/NN (l_appos) ADHD_23/NNP
D008774_D001289 NONE methylphenidate_25/NNP (r_conj) assigned_16/VBN (l_nsubjpass) children_11/NNS (l_prep) with_12/IN (l_pobj) ADHD_13/NNP
D008774_D001289 NONE methylphenidate_34/NN (r_conj) clonidine_32/NN (r_conj) methylphenidate_25/NNP (r_conj) assigned_16/VBN (l_nsubjpass) children_11/NNS (l_prep) with_12/IN (l_pobj) ADHD_13/NNP
D008774_D001289 NONE methylphenidate_6/NN (r_pobj) with_5/IN (r_conj) used_2/VBN (r_acl) Clonidine_0/NNP (r_nsubj) appears_8/VBZ (l_oprd) tolerated_12/VBN (l_prep) in_13/IN (l_pobj) ADHD_15/NNP
D003000_D001919 CID clonidine_10/NN (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) subjects_7/NNS (r_pobj) in_6/IN (r_prep) incidents_3/NNS (l_prep) of_4/IN (l_pobj) bradycardia_5/NNS
D003000_D001919 CID clonidine_17/NN (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) those_13/DT (r_pobj) with_12/IN (r_prep) compared_11/VBN (r_prep) were_1/VBD (l_attr) incidents_3/NNS (l_prep) of_4/IN (l_pobj) bradycardia_5/NNS
D003000_D001919 CID clonidine_2/NN (r_dobj) prescribing_1/VBG (r_acl) Physicians_0/NNS (r_nsubj) monitor_4/VB (l_prep) for_5/IN (l_pobj) bradycardia_6/NN
D003000_D006970 NONE clonidine_4/NN (r_pobj) on_3/IN (r_prep) was_1/VBD (l_nsubj) Drowsiness_0/NN
D003000_D006970 NONE clonidine_2/NN (r_dobj) prescribing_1/VBG (r_acl) Physicians_0/NNS (r_nsubj) monitor_4/VB (l_conj) advise_8/VB (l_prep) about_10/IN (l_pobj) likelihood_13/NN (l_prep) of_14/IN (l_pobj) drowsiness_16/NN
17042910
C065179_D006973 NONE atorvastatin_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) in_6/IN (l_pobj) hypertension_10/NN
C065179_D006973 NONE Atorvastatin_0/NNP (r_nsubj) possesses_4/VBZ (l_dobj) properties_6/NNS (l_relcl) reported_10/VBN (l_xcomp) improve_12/VB (l_prep) through_15/IN (l_pobj) availability_17/NN (l_prep) in_24/IN (l_pobj) forms_26/NNS (l_prep) of_27/IN (l_pobj) hypertension_28/NN
C065179_D006973 NONE Ato_2/NNP (r_appos) Atorvastatin_0/NNP (r_nsubj) possesses_4/VBZ (l_dobj) properties_6/NNS (l_relcl) reported_10/VBN (l_xcomp) improve_12/VB (l_prep) through_15/IN (l_pobj) availability_17/NN (l_prep) in_24/IN (l_pobj) forms_26/NNS (l_prep) of_27/IN (l_pobj) hypertension_28/NN
D003907_D006973 CID dexamethasone_7/NN (r_npadvmod) induced_9/VBN (r_amod) hypertension_10/NN
D003907_D006973 CID Dexamethasone_0/NN (l_parataxis) characterized_5/VBN (l_nsubjpass) hypertension_3/NN
D003907_D006973 CID Dex)-induced_2/NNP (r_nmod) hypertension_3/NN
D009569_D006973 NONE oxide_12/NN (r_nmod) deficiency_16/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) dysfunction_8/NN (r_pobj) by_6/IN (r_agent) characterized_5/VBN (l_nsubjpass) hypertension_3/NN
D009569_D006973 NONE NO_14/NN (r_nmod) deficiency_16/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) dysfunction_8/NN (r_pobj) by_6/IN (r_agent) characterized_5/VBN (l_nsubjpass) hypertension_3/NN
D009569_D006973 NONE NO_19/DT (r_amod) production_23/NN (r_pobj) of_18/IN (r_prep) availability_17/NN (l_prep) in_24/IN (l_pobj) forms_26/NNS (l_prep) of_27/IN (l_pobj) hypertension_28/NN
D013481_D006973 NONE superoxide_19/NN (r_nmod) production_23/NN (r_conj) deficiency_16/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) dysfunction_8/NN (r_pobj) by_6/IN (r_agent) characterized_5/VBN (l_nsubjpass) hypertension_3/NN
D013481_D006973 NONE O2-_21/NNP (r_nmod) production_23/NN (r_conj) deficiency_16/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) dysfunction_8/NN (r_pobj) by_6/IN (r_agent) characterized_5/VBN (l_nsubjpass) hypertension_3/NN
D013481_D006973 NONE O2-_22/NN (r_compound) production_23/NN (r_pobj) of_18/IN (r_prep) availability_17/NN (l_prep) in_24/IN (l_pobj) forms_26/NNS (l_prep) of_27/IN (l_pobj) hypertension_28/NN
11135224
C056507_D002289 NONE gemcitabine_0/NNP (r_compound) combination_1/NN (r_compound) chemotherapy_2/NN (l_prep) within_3/IN (l_pobj) approach_7/NN (l_prep) in_8/IN (l_pobj) carcinoma_13/NN
C056507_D002289 NONE gemcitabine_23/JJ (r_conj) cisplatin_20/NN (r_appos) paclitaxel_18/NN (r_nmod) combination_24/NN (l_relcl) treat_26/VB (l_dobj) NSCLC_28/NNP
C056507_D002289 NONE gemcitabine_65/NNP (r_conj) given_54/VBN (r_acl) combination_28/NN (r_pobj) with_26/IN (r_prep) treated_25/VBN (l_nsubjpass) patients_7/NNS (l_prep) with_8/IN (l_pobj) NSCLC_11/NNP
C056507_D002289 NONE gemcitabine_8/NNP (r_conj) paclitaxel_3/NN (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubj) is_9/VBZ (l_acomp) tolerated_11/VBN (l_conj) shows_13/VBZ (l_dobj) activity_15/NN (l_prep) in_16/IN (l_pobj) NSCLC_18/NNP
D002945_D002289 NONE Cisplatin_0/NN (r_npadvmod) based_2/VBN (r_amod) combinations_4/NNS (r_nsubj) improve_5/VBP (l_dobj) quality_6/NN (l_prep) in_11/IN (l_pobj) carcinoma_16/NN
D002945_D002289 NONE Cisplatin_0/NN (r_npadvmod) based_2/VBN (r_amod) combinations_4/NNS (r_nsubj) improve_5/VBP (l_dobj) quality_6/NN (l_prep) in_11/IN (l_pobj) carcinoma_16/NN (l_appos) NSCLC_18/NNP
D002945_D002289 NONE cisplatin_20/NN (r_appos) paclitaxel_18/NN (r_nmod) combination_24/NN (l_relcl) treat_26/VB (l_dobj) NSCLC_28/NNP
D002945_D002289 NONE cisplatin_47/NN (r_amod) combination_28/NN (r_pobj) with_26/IN (r_prep) treated_25/VBN (l_nsubjpass) patients_7/NNS (l_prep) with_8/IN (l_pobj) NSCLC_11/NNP
D002945_D002289 NONE cisplatin_5/NN (r_appos) paclitaxel_3/NN (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubj) is_9/VBZ (l_acomp) tolerated_11/VBN (l_conj) shows_13/VBZ (l_dobj) activity_15/NN (l_prep) in_16/IN (l_pobj) NSCLC_18/NNP
D017239_D064420 NONE paclitaxel_18/NN (r_nmod) combination_24/NN (r_pobj) of_16/IN (r_prep) toxicity_15/NN
D017239_D002289 NONE paclitaxel_18/NN (r_nmod) combination_24/NN (l_relcl) treat_26/VB (l_dobj) NSCLC_28/NNP
D017239_D002289 NONE paclitaxel_30/NN (r_pobj) of_29/IN (r_prep) combination_28/NN (r_pobj) with_26/IN (r_prep) treated_25/VBN (l_nsubjpass) patients_7/NNS (l_prep) with_8/IN (l_pobj) NSCLC_11/NNP
D017239_D002289 NONE paclitaxel_3/NN (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubj) is_9/VBZ (l_acomp) tolerated_11/VBN (l_conj) shows_13/VBZ (l_dobj) activity_15/NN (l_prep) in_16/IN (l_pobj) NSCLC_18/NNP
D002945_D064420 NONE cisplatin_20/NN (r_appos) paclitaxel_18/NN (r_nmod) combination_24/NN (r_pobj) of_16/IN (r_prep) toxicity_15/NN
C056507_D064420 NONE gemcitabine_23/JJ (r_conj) cisplatin_20/NN (r_appos) paclitaxel_18/NN (r_nmod) combination_24/NN (r_pobj) of_16/IN (r_prep) toxicity_15/NN
7292072
D003891_D017180 CID desipramine_4/JJ (r_compound) toxicity_5/NN (r_pobj) in_3/IN (r_prep) tachycardia_2/NN
D003891_D017180 CID desipramine_10/JJ (r_compound) toxicity_11/NN (r_pobj) by_9/IN (r_agent) induced_8/VBN (r_acl) tachycardia_7/NN
D003891_D064420 NONE desipramine_4/JJ (r_compound) toxicity_5/NN
D003891_D064420 NONE desipramine_10/JJ (r_compound) toxicity_11/NN
12905102
D003024_D003693 CID clozapine_2/NN (r_compound) treatment_3/NN (r_pobj) during_1/IN (r_prep) Delirium_0/NN
D003024_D003693 CID clozapine_7/NN (r_compound) treatment_8/NN (r_pobj) during_6/IN (r_prep) factors_3/NNS (l_prep) for_4/IN (l_pobj) delirium_5/NN
D003024_D003693 CID clozapine_13/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) inpatients_10/NNS (r_dobj) identify_6/VB (r_xcomp) used_1/VBD (l_conj) reviewed_20/VBD (l_advcl) score_25/VB (l_dobj) incidence_26/NN (l_prep) of_29/IN (l_pobj) delirium_30/NN
D003024_D003693 CID clozapine_7/NN (r_npadvmod) treated_9/VBN (r_amod) inpatients_10/NNS (r_pobj) of_6/IN (r_prep) %_5/NN (r_pobj) in_3/IN (r_prep) found_2/VBN (l_nsubjpass) Delirium_0/NNP
D003024_D001523 NONE clozapine_13/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) inpatients_10/NNS (l_amod) psychiatric_9/JJ
1592014
D003042_D012640 CID cocaine_4/NN (r_compound) benzoylecgonine_6/NNP (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Seizures_0/NNS
D003042_D012640 CID cocaine_8/NN (r_pobj) of_7/IN (r_prep) t1/2_5/NNP (r_nsubj) is_9/VBZ (l_conj) occur_29/VB (l_nsubj) some_14/DT (l_prep) of_15/IN (l_pobj) consequences_17/NNS (l_prep) of_18/IN (l_pobj) use_20/NN (l_prep) as_23/IN (l_pobj) seizures_24/NNS
D003042_D012640 CID cocaine_9/NN (r_pobj) of_8/IN (r_prep) metabolite_7/NN (r_pobj) of_4/IN (r_prep) potential_3/NN (r_dobj) evaluated_1/VBD (l_advcl) cause_17/VB (l_dobj) seizures_18/NNS
D003042_D012640 CID cocaine_19/NN (r_pobj) of_18/IN (r_prep) amounts_17/NNS (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_acl) those_13/DT (r_pobj) than_12/IN (r_prep) latencies_11/NNS (r_dobj) had_8/VBD (r_conj) occurred_4/VBD (l_nsubj) seizures_3/NNS
D003042_D012640 CID cocaine_1/NN (r_npadvmod) induced_3/VBN (r_amod) seizures_4/NNS
D003042_D012640 CID cocaine_15/NN (r_npadvmod) injected_17/VBN (r_amod) animals_18/NNS (r_pobj) than_14/IN (r_prep) activity_13/NN (r_dobj) had_9/VBD (l_nsubj) rats_3/NNS (l_relcl) have_7/VB (l_dobj) seizures_8/NNS
D003042_D012640 CID cocaine_15/NN (r_npadvmod) injected_17/VBN (r_amod) animals_18/NNS (r_pobj) than_14/IN (r_prep) activity_13/NN (r_dobj) had_9/VBD (l_prep) without_19/IN (l_pobj) seizures_20/NNS
D003042_D012640 CID cocaine_14/NN (r_npadvmod) induced_16/VBN (r_amod) seizures_17/NNS (r_pobj) for_13/IN (r_prep) mechanism_12/NN (r_dobj) suggests_8/VBZ (l_ccomp) differ_4/VBP (l_nsubj) seizures_3/NNS
D003042_D012640 CID cocaine_14/NN (r_npadvmod) induced_16/VBN (r_amod) seizures_17/NNS
D003042_D012640 CID cocaine_24/NN (r_compound) metabolite_25/NN (r_pobj) of_22/IN (r_prep) importance_21/NN (r_dobj) emphasizes_19/VBZ (r_conj) suggests_8/VBZ (l_ccomp) differ_4/VBP (l_nsubj) seizures_3/NNS
D003042_D012640 CID cocaine_24/NN (r_compound) metabolite_25/NN (r_pobj) of_22/IN (r_prep) importance_21/NN (r_dobj) emphasizes_19/VBZ (r_conj) suggests_8/VBZ (l_dobj) mechanism_12/NN (l_prep) for_13/IN (l_pobj) seizures_17/NNS
C005618_D012640 CID benzoylecgonine_6/NNP (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Seizures_0/NNS
C005618_D012640 CID benzoylecgonine_11/NNP (r_appos) metabolite_7/NN (r_pobj) of_4/IN (r_prep) potential_3/NN (r_dobj) evaluated_1/VBD (l_advcl) cause_17/VB (l_dobj) seizures_18/NNS
C005618_D012640 CID BE_13/NNP (r_parataxis) benzoylecgonine_11/NNP (r_appos) metabolite_7/NN (r_pobj) of_4/IN (r_prep) potential_3/NN (r_dobj) evaluated_1/VBD (l_advcl) cause_17/VB (l_dobj) seizures_18/NNS
C005618_D012640 CID BE_0/VB (r_compound) Induced_2/VBN (r_amod) seizures_3/NNS
C005618_D012640 CID BE_23/NNS (r_pobj) by_22/IN (r_agent) induced_21/VBN (r_acl) those_20/DT (r_nsubj) were_24/VBD (l_advcl) characterized_7/VBN (l_nsubjpass) seizures_4/NNS
C005618_D012640 CID BE_0/VB (r_auxpass) Injected_2/VBN (r_amod) rats_3/NNS (l_relcl) have_7/VB (l_dobj) seizures_8/NNS
C005618_D012640 CID BE_0/VB (r_auxpass) Injected_2/VBN (r_amod) rats_3/NNS (r_nsubj) had_9/VBD (l_prep) without_19/IN (l_pobj) seizures_20/NNS
C005618_D012640 CID BE_0/VB (r_auxpass) induced_2/VBN (r_amod) seizures_3/NNS
C005618_D012640 CID BE_0/VB (r_auxpass) induced_2/VBN (r_amod) seizures_3/NNS (r_nsubj) differ_4/VBP (r_ccomp) suggests_8/VBZ (l_dobj) mechanism_12/NN (l_prep) for_13/IN (l_pobj) seizures_17/NNS
C005618_D012640 CID BE_27/VB (l_ccomp) suggests_8/VBZ (l_ccomp) differ_4/VBP (l_nsubj) seizures_3/NNS
C005618_D012640 CID BE_27/VB (l_ccomp) suggests_8/VBZ (l_dobj) mechanism_12/NN (l_prep) for_13/IN (l_pobj) seizures_17/NNS
D003042_D020521 NONE cocaine_8/NN (r_pobj) of_7/IN (r_prep) t1/2_5/NNP (r_nsubj) is_9/VBZ (l_conj) occur_29/VB (l_nsubj) some_14/DT (l_prep) of_15/IN (l_pobj) consequences_17/NNS (l_prep) of_18/IN (l_pobj) use_20/NN (l_prep) as_23/IN (l_pobj) seizures_24/NNS (l_conj) strokes_26/NNS
D003042_D003643 NONE cocaine_1/NN (r_npadvmod) induced_3/VBN (r_amod) seizures_4/NNS (r_nsubjpass) characterized_7/VBN (l_conj) resulted_16/VBD (l_prep) in_17/IN (l_pobj) death_18/NN
D003042_D003643 NONE cocaine_1/NN (r_npadvmod) induced_3/VBN (r_amod) seizures_4/NNS (r_nsubjpass) characterized_7/VBN (r_advcl) were_24/VBD (l_conj) resulted_36/VBD (l_prep) in_37/IN (l_pobj) death_38/NN
C005618_D003643 NONE BE_23/NNS (r_pobj) by_22/IN (r_agent) induced_21/VBN (r_acl) those_20/DT (r_nsubj) were_24/VBD (l_advcl) characterized_7/VBN (l_conj) resulted_16/VBD (l_prep) in_17/IN (l_pobj) death_18/NN
C005618_D003643 NONE BE_23/NNS (r_pobj) by_22/IN (r_agent) induced_21/VBN (r_acl) those_20/DT (r_nsubj) were_24/VBD (l_conj) resulted_36/VBD (l_prep) in_37/IN (l_pobj) death_38/NN
12063090
D004177_D003248 NONE Metamizol_0/NNP (r_nsubj) potentiates_1/VBZ (l_dobj) antinociception_3/NN (l_conj) constipation_6/NN
D004177_D003248 NONE metamizol_20/NNP (r_pobj) with_16/IN (r_prep) evaluates_2/VBZ (l_dobj) antinociceptive_4/JJ (l_conj) constipating_6/JJ
D004177_D003248 NONE metamizol_20/NNP (r_nsubj) potentiate_23/VB (l_dobj) constipation_27/NN
D009020_D003248 CID morphine_2/NN (r_compound) antinociception_3/NN (l_conj) constipation_6/NN
D009020_D003248 CID morphine_15/NN (r_pobj) of_11/IN (r_prep) combination_10/NN (r_pobj) of_8/IN (r_prep) effects_7/NNS (r_conj) antinociceptive_4/JJ (l_conj) constipating_6/JJ
D009020_D003248 CID morphine_4/NN (r_nsubj) inhibited_5/VBD (l_advcl) suggesting_23/VBG (l_ccomp) develop_28/VB (l_prep) to_29/IN (l_pobj) effects_32/NNS (l_amod) constipating_31/JJ
D009020_D003248 CID morphine_10/NN (r_pobj) by_9/IN (r_agent) produced_8/VBN (r_acl) that_7/DT (r_pobj) to_6/IN (r_prep) similar_5/JJ (r_amod) transit_4/NN (r_dobj) inhibited_2/VBD (l_advcl) suggesting_18/VBG (l_ccomp) potentiate_23/VB (l_dobj) constipation_27/NN
D009020_D003248 CID morphine_24/NN (r_npadvmod) induced_26/VBN (r_amod) constipation_27/NN
D002606_D010146 NONE charcoal_25/NN (r_compound) meal_26/NN (r_compound) test_27/NN (r_nsubjpass) used_29/VBN (r_conj) assessed_8/VBN (l_conj) model_21/NN (l_amod) induced_18/VBN (l_npadvmod) pain_16/NN
D009020_D059350 NONE morphine_7/NN (r_pobj) between_6/IN (r_prep) interaction_5/NN (r_dobj) show_2/VBP (l_advcl) suggesting_15/VBG (l_ccomp) be_20/VB (l_acomp) useful_21/JJ (l_prep) for_22/IN (l_pobj) treatment_24/NN (l_prep) of_25/IN (l_pobj) pain_27/NN
D004177_D059350 NONE metamizol_9/NN (r_conj) morphine_7/NN (r_pobj) between_6/IN (r_prep) interaction_5/NN (r_dobj) show_2/VBP (l_advcl) suggesting_15/VBG (l_ccomp) be_20/VB (l_acomp) useful_21/JJ (l_prep) for_22/IN (l_pobj) treatment_24/NN (l_prep) of_25/IN (l_pobj) pain_27/NN
2476560
D001556_D012532 NONE lindane_12/NNP (r_dobj) consider_11/VBP (l_ccomp) initiated_5/VBN (l_nsubjpass) Treatment_0/NN (l_prep) for_1/IN (l_pobj) scabies_2/NN
D001556_D012532 NONE hexachloride_16/NN (r_appos) lindane_12/NNP (r_dobj) consider_11/VBP (l_ccomp) initiated_5/VBN (l_nsubjpass) Treatment_0/NN (l_prep) for_1/IN (l_pobj) scabies_2/NN
D001556_D002493 CID lindane_4/NN (r_nsubj) be_6/VB (l_acomp) toxic_7/JJ (l_prep) to_8/IN (l_pobj) system_12/NN
D001556_D000741 CID lindane_4/NN (r_nsubj) be_6/VB (l_conj) associated_16/VBN (l_prep) with_17/IN (l_pobj) anaemia_19/NN
14657095
D000666_D002311 CID B_6/NN (r_compound) therapy_7/NN (r_pobj) to_4/IN (r_prep) related_3/VBN (r_acl) cardiomyopathy_2/NN
D000666_D002311 CID B_20/NNP (r_pobj) with_18/IN (r_prep) months_15/NNS (r_pobj) after_13/IN (r_prep) developed_5/VBD (l_dobj) cardiomyopathy_7/NN
D000666_D002311 CID AmB_22/NN (r_appos) B_20/NNP (r_pobj) with_18/IN (r_prep) months_15/NNS (r_pobj) after_13/IN (r_prep) developed_5/VBD (l_dobj) cardiomyopathy_7/NN
D000666_D006333 CID B_20/NNP (r_pobj) with_18/IN (r_prep) months_15/NNS (r_pobj) after_13/IN (r_prep) developed_5/VBD (l_dobj) cardiomyopathy_7/NN (l_conj) failure_12/NN
D000666_D006333 CID AmB_22/NN (r_appos) B_20/NNP (r_pobj) with_18/IN (r_prep) months_15/NNS (r_pobj) after_13/IN (r_prep) developed_5/VBD (l_dobj) cardiomyopathy_7/NN (l_conj) failure_12/NN
D000666_D006333 CID AmB._12/NNP (r_pobj) for_11/IN (r_prep) substituted_10/VBN (r_advcl) resolved_6/VBN (l_nsubj) abnormalities_2/NNS (l_conj) failure_5/NN
D000666_D003047 NONE B_20/NNP (l_prep) for_24/IN (l_pobj) coccidioidomycosis_26/NNP
D000666_D003047 NONE AmB_22/NN (r_appos) B_20/NNP (l_prep) for_24/IN (l_pobj) coccidioidomycosis_26/NNP
C101425_D006333 NONE posaconazole_8/NNP (r_nsubjpass) substituted_10/VBN (r_advcl) resolved_6/VBN (l_nsubj) abnormalities_2/NNS (l_conj) failure_5/NN
D000666_D064420 NONE AmB._12/NNP (r_pobj) of_11/IN (r_prep) toxicity_10/NN
15188772
D004837_D018487 NONE epinephrine_12/NN (r_compound) overdose_13/NN (r_pobj) due_8/IN (r_prep) dysfunction_7/NN
D004837_D018487 NONE epinephrine_15/NN (r_pobj) of_14/IN (r_prep) mg_13/NN (r_nsubj) developed_16/VBD (l_dobj) stunning_18/JJ (l_relcl) characterized_21/VBN (l_agent) by_22/IN (l_pobj) compromise_25/NN (l_acl) left_32/VBD (l_dobj) dysfunction_37/NN
D004837_D062787 NONE epinephrine_12/NN (r_compound) overdose_13/NN
D002395_D009202 NONE Catecholamine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) cardiomyopathy_3/NN
D002395_D009202 NONE catecholamines_10/NNS (r_pobj) of_8/IN (r_prep) excess_7/NN (r_pobj) due_4/IN (r_prep) cardiomyopathy_3/NN
D004837_D017682 CID epinephrine_15/NN (r_pobj) of_14/IN (r_prep) mg_13/NN (r_nsubj) developed_16/VBD (l_dobj) stunning_18/JJ
D004837_D009202 NONE epinephrine_15/NN (r_pobj) of_14/IN (r_prep) mg_13/NN (r_nsubj) developed_16/VBD (l_dobj) stunning_18/JJ (l_relcl) characterized_21/VBN (l_agent) by_22/IN (l_pobj) compromise_25/NN (l_conj) markers_44/NNS (l_prep) of_45/IN (l_pobj) necrosis_47/NN
2445283
D012254_D006478 NONE ribavirin_5/NN (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) fever_11/NN
D012254_D006478 NONE ribavirin_5/NNP (r_pobj) of_4/IN (r_prep) effect_3/NN (r_conj) Tolerance_0/NN (r_nsubjpass) studied_7/VBN (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) fever_14/NN
D012254_D006478 NONE ribavirin_5/NNP (r_pobj) of_4/IN (r_prep) effect_3/NN (r_conj) Tolerance_0/NN (r_nsubjpass) studied_7/VBN (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) fever_14/NN (l_appos) AHF_16/NNP
D012254_D006478 NONE ribavirin_7/NNP (r_nsubj) has_8/VBZ (l_dobj) effect_11/NN (l_prep) in_12/IN (l_pobj) cases_14/NNS (l_prep) of_15/IN (l_pobj) AHF_16/NNP
D012254_D006478 NONE ribavirin_5/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (l_prep) during_6/IN (l_pobj) days_9/NNS (l_prep) of_10/IN (l_pobj) AHF_11/NNP
D012254_D014766 NONE ribavirin_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) resulted_3/VBD (l_prep) in_4/IN (l_pobj) neutralization_6/NN (l_prep) of_7/IN (l_pobj) viremia_8/NN
D012254_D000740 CID ribavirin_7/NNP (r_nsubj) has_8/VBZ (l_conj) managed_31/VBN (l_dep) anemia_20/NN
12695819
D016559_D020258 NONE tacrolimus_7/NN (r_npadvmod) induced_9/VBN (r_amod) neurotoxicity_10/NN
D016559_D020258 NONE tacrolimus_15/NN (r_npadvmod) induced_17/VBN (r_amod) neurotoxicity_18/NN
D016559_D009422 NONE tacrolimus_17/NN (l_relcl) developed_19/VBD (l_dobj) complications_21/NNS
3173180
D008795_D006463 CID metronidazole_7/NN (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) after_4/IN (r_prep) syndrome_3/NN
D008795_D006463 CID metronidazole_19/NN (r_pobj) with_18/IN (r_prep) treatment_17/NN (r_pobj) after_16/IN (r_prep) developed_10/VBD (l_dobj) syndrome_15/NN
D008795_D006463 CID metronidazole_4/NN (r_pobj) of_3/IN (r_prep) involvement_2/NN (l_prep) in_5/IN (l_pobj) aetiology_7/NN (l_prep) of_8/IN (l_pobj) syndrome_13/NN
D008795_D006463 CID metronidazole_4/NN (r_pobj) of_3/IN (r_prep) involvement_2/NN (r_nsubjpass) established_16/VBN (r_advcl) suggest_43/VBP (l_nsubj) action_20/NN (l_conj) evidence_33/NN (l_prep) of_34/IN (l_pobj) changes_36/NNS (l_prep) in_37/IN (l_pobj) syndrome_42/NN
D008795_D006463 CID metronidazole_4/NN (r_pobj) of_3/IN (r_prep) involvement_2/NN (r_nsubjpass) established_16/VBN (r_advcl) suggest_43/VBP (l_dobj) link_46/NN (l_prep) between_47/IN (l_pobj) treatment_49/NN (l_conj) cases_52/NNS (l_prep) of_53/IN (l_pobj) syndrome_58/NN
D008795_D006463 CID metronidazole_48/NN (r_compound) treatment_49/NN (r_pobj) between_47/IN (r_prep) link_46/NN (r_dobj) suggest_43/VBP (l_advcl) established_16/VBN (l_nsubjpass) involvement_2/NN (l_prep) in_5/IN (l_pobj) aetiology_7/NN (l_prep) of_8/IN (l_pobj) syndrome_13/NN
D008795_D006463 CID metronidazole_48/NN (r_compound) treatment_49/NN (r_pobj) between_47/IN (r_prep) link_46/NN (r_dobj) suggest_43/VBP (l_nsubj) action_20/NN (l_conj) evidence_33/NN (l_prep) of_34/IN (l_pobj) changes_36/NNS (l_prep) in_37/IN (l_pobj) syndrome_42/NN
D008795_D006463 CID metronidazole_48/NN (r_compound) treatment_49/NN (l_conj) cases_52/NNS (l_prep) of_53/IN (l_pobj) syndrome_58/NN
354896
D008012_D006323 CID Lidocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) asystole_4/NN
D008012_D003866 NONE lidocaine_8/NN (r_pobj) of_7/IN (r_prep) bolus_6/NN (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) resulted_15/VBD (l_prep) in_16/IN (l_pobj) depression_18/NN
D008012_D001919 NONE lidocaine_29/NN (r_pobj) to_28/IN (r_prep) idiosyncrasy_27/NN (r_dobj) represented_24/VBD (r_conj) had_2/VBD (l_dobj) conditions_6/NNS (l_relcl) predisposed_10/VBN (l_prep) to_12/IN (l_pobj) development_14/NN (l_prep) of_15/IN (l_pobj) bradyarrhythmias_16/NNP
88336
D002719_D013375 NONE chlormethiazole_6/NN (r_pobj) of_5/IN (r_prep) doses_4/NNS (r_dobj) received_2/VBD (l_prep) for_7/IN (l_pobj) symptoms_10/NNS
D002719_D062787 NONE chlormethiazole_6/NN (r_pobj) of_5/IN (r_prep) doses_4/NNS (r_dobj) received_2/VBD (l_conj) took_14/VBD (l_dobj) overdose_17/NN
D002719_D062787 NONE chlormethiazole_10/JJ (r_compound) intoxication_11/NN (r_pobj) with_9/IN (r_prep) those_8/DT (r_pobj) of_7/IN (r_prep) two_6/CD (r_conj) overdose_4/NN
D000431_D013375 NONE alcohol_8/NN (r_compound) withdrawal_9/NN (r_compound) symptoms_10/NNS
D000431_D062787 NONE alcohol_8/NN (r_compound) withdrawal_9/NN (r_compound) symptoms_10/NNS (r_pobj) for_7/IN (r_prep) received_2/VBD (l_conj) took_14/VBD (l_dobj) overdose_17/NN
D009567_D013375 NONE nitrazepam_19/NN (r_pobj) of_18/IN (r_prep) overdose_17/NN (r_dobj) took_14/VBD (r_conj) received_2/VBD (l_prep) for_7/IN (l_pobj) symptoms_10/NNS
D009567_D062787 CID nitrazepam_19/NN (r_pobj) of_18/IN (r_prep) overdose_17/NN
D009567_D062787 CID nitrazepam_3/NN (r_compound) overdose_4/NN
D009567_D003128 CID nitrazepam_3/NN (r_compound) overdose_4/NN (r_pobj) with_2/IN (r_prep) patient_1/NN (r_nsubj) conformed_12/VBD (l_prep) to_13/IN (l_pobj) criteria_15/NNS (l_prep) of_16/IN (l_pobj) coma_19/NN
D002719_D003128 CID chlormethiazole_10/JJ (r_compound) intoxication_11/NN (r_pobj) with_9/IN (r_prep) those_8/DT (r_pobj) of_7/IN (r_prep) two_6/CD (r_conj) overdose_4/NN (r_pobj) with_2/IN (r_prep) patient_1/NN (r_nsubj) conformed_12/VBD (l_prep) to_13/IN (l_pobj) criteria_15/NNS (l_prep) of_16/IN (l_pobj) coma_19/NN
11752354
D003276_D009203 CID contraceptives_1/NNS (l_conj) risk_4/NN (l_prep) of_5/IN (l_pobj) infarction_7/NN
D003276_D009203 CID contraceptives_7/NNS (r_pobj) of_5/IN (r_prep) use_4/NN (l_conj) risk_10/NN (l_prep) of_11/IN (l_pobj) infarction_13/NN
D003276_D009203 CID contraceptive_15/NN (r_pobj) of_12/IN (r_prep) type_11/NN (r_dobj) used_9/VBD (r_relcl) women_7/NNS (r_pobj) among_6/IN (r_prep) infarction_5/NN
D003276_D009203 CID contraceptives_5/NNS (r_dobj) used_3/VBD (r_relcl) women_1/NNS (r_pobj) Among_0/IN (r_prep) was_10/VBD (l_conj) increased_53/VBN (l_nsubjpass) risk_48/NN (l_prep) of_49/IN (l_pobj) infarction_51/NN
D003276_D009203 CID contraceptives_62/NNS (r_dobj) used_57/VBD (r_relcl) women_55/NNS (r_pobj) among_54/IN (r_prep) increased_53/VBN (l_nsubjpass) risk_48/NN (l_prep) of_49/IN (l_pobj) infarction_51/NN
D003276_D009203 CID contraceptives_12/NNS (r_dobj) used_10/VBD (r_relcl) women_8/NNS (r_pobj) among_7/IN (r_prep) similar_6/JJ (r_acomp) was_5/VBD (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) infarction_4/NN
8073369
C007112_D001176 CID coniine_2/NNP (r_nsubj) failed_4/VBN (l_xcomp) produce_6/VB (l_dobj) arthrogryposis_7/NN
C007112_D001176 CID coniine_15/NN (r_npadvmod) induced_17/VBN (r_amod) arthrogryposis_18/NN
C007112_D009140 NONE coniine_5/NN (r_nmod) sulfate_8/NN (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) deformations_1/NNS
C007112_D009140 NONE coniine_5/NN (r_nmod) sulfate_8/NN (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) deformations_1/NNS (r_nsubj) were_9/VBD (l_attr) flexion_11/NN (l_prep) of_14/IN (l_pobj) toes_18/NNS
D009538_D009140 NONE nicotine_7/NN (r_conj) coniine_5/NN (r_nmod) sulfate_8/NN (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) deformations_1/NNS
D009538_D009140 NONE nicotine_7/NN (r_conj) coniine_5/NN (r_nmod) sulfate_8/NN (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) deformations_1/NNS (r_nsubj) were_9/VBD (l_attr) flexion_11/NN (l_prep) of_14/IN (l_pobj) toes_18/NNS
D009538_D002543 CID nicotine_30/NN (r_nmod) chicks_34/NNS (r_pobj) in_28/IN (r_prep) occurred_27/VBD (l_nsubj) hemorrhage_26/NN
2348231
D010431_D006940 NONE Pentoxifylline_0/NNP (r_nsubj) inhibit_6/VB (l_dobj) hyperemia_11/NN
D010431_D006940 NONE Trental_2/NNP (r_appos) Pentoxifylline_0/NNP (r_nsubj) inhibit_6/VB (l_dobj) hyperemia_11/NN
D010431_D006940 NONE pentoxifylline_1/NNP (r_nsubj) inhibits_2/VBZ (l_dobj) hyperemia_7/NN
D010431_D006940 NONE pentoxifylline_3/NNP (r_pobj) of_2/IN (r_prep) dose_1/NN (r_nsubj) decreased_5/VBD (l_dobj) hyperemia_10/NN
D010431_D006940 NONE pentoxyifylline_3/NNP (r_nsubj) inhibit_6/VB (l_dobj) hyperemia_11/NN
D004176_D006940 CID dipyridamole_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperemia_11/NN
D004176_D006940 CID dipyridamole_15/NNP (r_compound) thallium-201_17/NNP (r_nmod) imaging_19/NN (r_pobj) for_14/IN (r_prep) implications_13/NNS (r_appos) hyperemia_11/NN
D004176_D006940 CID dipyridamole_3/NN (r_npadvmod) induced_5/VBN (r_amod) hyperemia_7/NN
D004176_D006940 CID dipyridamole_20/NNP (r_compound) thallium-201_22/NNP (r_compound) imaging_23/NN (r_nsubj) is_24/VBZ (l_advcl) inhibits_2/VBZ (l_dobj) hyperemia_7/NN
D004176_D006940 CID dipyridamole_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperemia_10/NN
D004176_D006940 CID dipyridamole_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperemia_11/NN
D013793_D006940 NONE thallium-201_17/NNP (r_nmod) imaging_19/NN (r_pobj) for_14/IN (r_prep) implications_13/NNS (r_appos) hyperemia_11/NN
D013793_D006940 NONE thallium-201_22/NNP (r_compound) imaging_23/NN (r_nsubj) is_24/VBZ (l_advcl) inhibits_2/VBZ (l_dobj) hyperemia_7/NN
D004176_D016491 NONE Dipyridamole_0/NNP (r_nmod) imaging_3/NN (r_nsubjpass) performed_6/VBN (l_prep) because_12/IN (l_pobj) disease_16/NN
D013793_D016491 NONE thallium-201_2/NNP (r_compound) imaging_3/NN (r_nsubjpass) performed_6/VBN (l_prep) because_12/IN (l_pobj) disease_16/NN
D010431_D007383 CID pentoxifylline_6/NNP (l_appos) derivative_13/NN (l_relcl) improve_16/VB (l_dobj) claudication_18/NN
D010431_D007383 CID Trental_8/NNP (r_appos) pentoxifylline_6/NNP (l_appos) derivative_13/NN (l_relcl) improve_16/VB (l_dobj) claudication_18/NN
C008514_D007383 NONE methylxanthine_12/NN (r_compound) derivative_13/NN (l_relcl) improve_16/VB (l_dobj) claudication_18/NN
C008514_D006940 NONE methylxanthines_10/NNS (r_pobj) like_8/IN (r_prep) hyperemia_7/NN
D013806_D006940 NONE theophylline_13/NN (r_pobj) as_12/IN (r_prep) methylxanthines_10/NNS (r_pobj) like_8/IN (r_prep) hyperemia_7/NN
D013806_D006940 NONE theophylline_21/NN (r_pobj) after_20/IN (r_prep) was_17/VBD (r_advcl) decreased_5/VBD (l_dobj) hyperemia_10/NN
11679859
D011346_D017109 CID prochlorperazine_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) affect_12/VB (l_dobj) incidence_14/NN (l_prep) of_15/IN (l_pobj) akathisia_16/NN
D011346_D017109 CID prochlorperazine_12/NNP (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) after_8/IN (r_prep) compare_3/VB (l_dobj) rate_5/NN (l_prep) of_6/IN (l_pobj) akathisia_7/NN
D011346_D017109 CID prochlorperazine_10/NNP (r_nsubjpass) administered_12/VBN (r_advcl) reduction_3/NN (l_prep) in_4/IN (l_pobj) incidence_6/NN (l_prep) of_7/IN (l_pobj) akathisia_8/NN
D011346_D006261 NONE prochlorperazine_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (l_prep) for_9/IN (l_pobj) headache_10/NN
D011346_D006261 NONE prochlorperazine_3/NN (r_pobj) of_2/IN (r_prep) efficacy_1/NN (l_prep) in_4/IN (l_pobj) treatment_6/NN (l_prep) of_7/IN (l_pobj) headache_8/NN
D011346_D009325 NONE prochlorperazine_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (l_prep) for_9/IN (l_pobj) headache_10/NN (l_conj) nausea_12/NN
D011346_D009325 NONE prochlorperazine_3/NN (r_pobj) of_2/IN (r_prep) efficacy_1/NN (l_prep) in_4/IN (l_pobj) treatment_6/NN (l_prep) of_7/IN (l_pobj) headache_8/NN (l_conj) nausea_10/NN
D011346_D014839 NONE prochlorperazine_8/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (l_prep) for_9/IN (l_pobj) headache_10/NN (l_conj) nausea_12/NN (l_conj) vomiting_15/NN
11961407
D014443_D009401 NONE tyrosine_2/NN (r_compound) phosphatase_3/NN (r_appos) receptor_1/NN (l_prep) in_7/IN (l_pobj) nephrosis_10/NN
D011692_D009401 CID PAN_9/NNP (r_compound) nephrosis_10/NN
D011692_D009401 CID aminonucleoside_1/JJ (r_compound) nephrosis_2/NN
D011692_D009401 CID aminonucleoside_11/RB (r_advmod) induced_4/VBN (l_nsubjpass) nephrosis_2/NN
D011692_D009401 CID PAN_13/NNP (r_appos) aminonucleoside_11/RB (r_advmod) induced_4/VBN (l_nsubjpass) nephrosis_2/NN
D011692_D011507 CID PAN_21/NNP (r_compound) injection_22/NN (r_pobj) after_20/IN (r_prep) analyzed_2/VBN (l_advcl) include_26/VB (l_dobj) phase_30/NN (l_prep) of_31/IN (l_pobj) proteinuria_32/NN
D011692_D011507 CID PAN_21/NNP (r_compound) injection_22/NN (r_pobj) after_20/IN (r_prep) analyzed_2/VBN (l_advcl) include_26/VB (l_dobj) phase_30/NN (l_conj) phase_47/NN (l_prep) of_48/IN (l_pobj) proteinuria_49/NN
D011692_D005921 NONE PAN_21/NNP (r_compound) injection_22/NN (r_pobj) after_20/IN (r_prep) analyzed_2/VBN (l_advcl) include_26/VB (l_dobj) phase_30/NN (l_conj) phase_47/NN (l_acl) associated_50/VBN (l_prep) with_51/IN (l_pobj) glomerulosclerosis_52/NNP
6386793
D004308_D003866 NONE hydrochloride_12/NN (r_pobj) of_10/IN (r_prep) efficacy_7/NN (l_prep) in_13/IN (l_pobj) treatment_15/NN (l_prep) of_16/IN (l_pobj) disorder_19/NN
D004308_D003866 NONE dothiepin_10/NN (r_conj) study_8/NN (r_pobj) In_0/IN (r_prep) compared_14/VBN (l_prep) to_15/IN (l_pobj) placebo_16/NN (l_prep) in_17/IN (l_pobj) treatment_19/NN (l_prep) of_20/IN (l_pobj) outpatients_23/NNS (l_amod) depressed_22/JJ
D004308_D003866 NONE Dothiepin_0/NNP (r_nsubj) were_3/VBD (l_acomp) effective_5/JJ (l_prep) in_6/IN (l_pcomp) alleviating_7/VBG (l_dobj) symptoms_9/NNS (l_prep) of_10/IN (l_pobj) illness_12/NN
D004308_D003866 NONE Dothiepin_0/NNP (r_nsubjpass) found_3/VBN (l_xcomp) be_5/VB (l_attr) drug_9/NN (l_acl) associated_10/VBN (l_prep) with_11/IN (l_pobj) effects_14/NNS (l_prep) in_17/IN (l_pobj) treatment_19/NN (l_prep) of_20/IN (l_pobj) outpatients_22/NNS (l_amod) depressed_21/JJ
D000639_D003866 NONE amitriptyline_12/NN (r_conj) dothiepin_10/NN (r_conj) study_8/NN (r_pobj) In_0/IN (r_prep) compared_14/VBN (l_prep) to_15/IN (l_pobj) placebo_16/NN (l_prep) in_17/IN (l_pobj) treatment_19/NN (l_prep) of_20/IN (l_pobj) outpatients_23/NNS (l_amod) depressed_22/JJ
D000639_D003866 NONE amitriptyline_2/NN (r_conj) Dothiepin_0/NNP (r_nsubj) were_3/VBD (l_acomp) effective_5/JJ (l_prep) in_6/IN (l_pcomp) alleviating_7/VBG (l_dobj) symptoms_9/NNS (l_prep) of_10/IN (l_pobj) illness_12/NN
D000639_D003866 NONE amitriptyline_16/NN (r_pobj) than_15/IN (r_prep) effects_14/NNS (l_prep) in_17/IN (l_pobj) treatment_19/NN (l_prep) of_20/IN (l_pobj) outpatients_22/NNS (l_amod) depressed_21/JJ
D004308_D014786 NONE dothiepin_24/NN (r_pobj) with_23/IN (r_prep) less_22/JJR (r_acomp) were_20/VBD (l_nsubj) incidence_2/NN (l_conj) frequency_8/NN (l_prep) of_11/IN (l_pobj) vision_13/NN
D004308_D014987 NONE dothiepin_24/NN (r_pobj) with_23/IN (r_prep) less_22/JJR (r_acomp) were_20/VBD (l_nsubj) incidence_2/NN (l_conj) frequency_8/NN (l_prep) of_11/IN (l_pobj) vision_13/NN (l_conj) mouth_16/NN
D000639_D014786 CID amitriptyline_27/NN (r_pobj) with_26/IN (r_prep) than_25/IN (r_prep) less_22/JJR (r_acomp) were_20/VBD (l_nsubj) incidence_2/NN (l_conj) frequency_8/NN (l_prep) of_11/IN (l_pobj) vision_13/NN
D000639_D014987 CID amitriptyline_27/NN (r_pobj) with_26/IN (r_prep) than_25/IN (r_prep) less_22/JJR (r_acomp) were_20/VBD (l_nsubj) incidence_2/NN (l_conj) frequency_8/NN (l_prep) of_11/IN (l_pobj) vision_13/NN (l_conj) mouth_16/NN
D000928_D003866 NONE antidepressant_8/NN (r_compound) drug_9/NN (l_acl) associated_10/VBN (l_prep) with_11/IN (l_pobj) effects_14/NNS (l_prep) in_17/IN (l_pobj) treatment_19/NN (l_prep) of_20/IN (l_pobj) outpatients_22/NNS (l_amod) depressed_21/JJ
7582165
D000305_D004342 NONE corticosteroids_5/NNS (r_pobj) to_4/IN (r_prep) reactions_3/NNS
D010248_D004342 NONE paramethasone_3/NN (r_pobj) from_2/IN (r_prep) different_1/JJ (r_amod) Corticosteroids_0/NNS (r_nsubj) produced_5/VBD (l_dobj) reactions_7/NNS (l_compound) hypersensitivity_6/NN
D010248_D004342 NONE paramethasone_16/NN (r_pobj) by_15/IN (r_agent) caused_14/VBN (r_acl) allergy_13/NN
9931093
D016559_D006973 CID 506-induced_3/CD (r_nummod) hypertension_4/NN
D016559_D006973 CID 506_5/CD (r_nummod) FK_4/NNP (r_pobj) of_3/IN (r_prep) utility_2/NN (r_nsubj) is_6/VBZ (r_auxpass) complicated_7/VBN (l_agent) by_8/IN (l_pobj) hypertension_10/NN
D016559_D006973 CID 506-induced_6/CD (r_nummod) hypertension_7/NN
D016559_D006973 CID 506_16/CD (r_nummod) FK_15/NNP (r_pobj) of_14/IN (r_prep) effects_13/NNS (r_dobj) studied_10/VBD (l_advcl) clarify_1/VB (l_dobj) mechanisms_3/NNS (l_prep) of_4/IN (l_pobj) hypertension_7/NN
D016559_D006973 CID 506-induced_17/CD (r_nummod) hypertension_18/NN
D016559_D006973 CID 506-induced_14/CD (r_nummod) hypertension_15/NN
D016559_D007674 NONE 506_5/CD (r_nummod) FK_4/NNP (r_pobj) of_3/IN (r_prep) utility_2/NN (r_nsubj) is_6/VBZ (r_auxpass) complicated_7/VBN (l_agent) by_8/IN (l_pobj) hypertension_10/NN (l_conj) nephrotoxicity_12/NN
D009569_D006973 NONE oxide_44/NN (r_compound) synthase_45/NN (r_appos) mRNA_29/NN (r_pobj) of_28/IN (r_prep) expression_27/NN (r_npadvmod) studied_10/VBD (l_advcl) clarify_1/VB (l_dobj) mechanisms_3/NNS (l_prep) of_4/IN (l_pobj) hypertension_7/NN
C079574_D006973 NONE 139317_14/CD (r_nummod) FR_13/NNP (r_appos) antagonist_12/NN (l_prep) on_15/IN (l_pobj) hypertension_18/NN
C079574_D006973 NONE 139317_4/CD (r_nummod) FR_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubj) prevented_12/VBD (l_dobj) hypertension_15/NN
10901305
D007649_D050723 NONE Ketamine_0/NNP (r_compound) sedation_1/NN (l_prep) for_2/IN (l_pobj) reduction_4/NN (l_prep) of_5/IN (l_pobj) fractures_8/NNS
D007649_D050723 NONE ketamine_14/NN (r_pobj) of_13/IN (r_prep) safety_10/NN (r_dobj) examine_8/VB (l_prep) for_15/IN (l_pobj) sedation_16/NN (l_prep) in_17/IN (l_pobj) treatment_19/NN (l_prep) of_20/IN (l_pobj) fractures_23/NNS
D007649_D050723 NONE ketamine_7/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) from_3/IN (r_prep) time_2/NN (l_prep) to_8/IN (l_pobj) manipulation_9/NN (l_prep) of_10/IN (l_pobj) fracture_12/NN
D007649_D050723 NONE Ketamine_0/NNP (l_conj) provided_7/VBD (l_advcl) facilitate_12/VB (l_dobj) reduction_14/NN (l_prep) of_15/IN (l_pobj) fractures_18/NNS
D007649_D004204 NONE ketamine_7/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) from_3/IN (r_prep) time_2/NN (l_prep) to_8/IN (l_pobj) manipulation_9/NN (l_prep) of_10/IN (l_pobj) fracture_12/NN (l_conj) dislocation_14/NN
3409645
D008727_D007172 CID methotrexate_23/NN (r_pobj) of_22/IN (r_prep) taking_21/NN (r_conj) morbidity_18/NN (r_pobj) with_15/IN (r_prep) associated_14/VBN (r_xcomp) found_11/VBN (r_conj) was_1/VBD (l_nsubj) Impotence_0/NN
10683478
D001058_D007035 CID Apomorphine_0/NNP (l_appos) ability_17/NN (l_acl) induce_19/VB (l_dobj) hypothermia_20/NN
D001058_D007035 CID apomorphine_11/NNP (l_prep) as_13/IN (l_pobj) hypothermia_17/NN
D018491_D007035 NONE agonist_5/NN (r_appos) Apomorphine_0/NNP (l_appos) ability_17/NN (l_acl) induce_19/VB (l_dobj) hypothermia_20/NN
D004298_D007035 NONE dopamine_28/NN (r_compound) turnover_29/NN (r_pobj) to_27/IN (r_prep) produce_24/VB (r_conj) induce_19/VB (l_dobj) hypothermia_20/NN
D001058_D006948 CID apomorphine_5/NN (r_npadvmod) induced_7/VBN (r_amod) hyperactivity_8/NN
8423889
D005473_D009069 CID fluoxetine_5/NNP (r_compound) medication_6/NN (r_pobj) after_4/IN (r_prep) Increase_0/NN (l_prep) of_1/IN (l_pobj) disability_3/NN
D005473_D009069 CID fluoxetine_21/NN (r_pobj) to_18/IN (r_prep) exposure_17/NN (r_pobj) after_16/IN (r_prep) report_1/VBP (l_dobj) amount_4/NN (l_prep) of_5/IN (l_pobj) disability_7/NN
D000928_D009069 NONE antidepressant_20/NN (r_compound) fluoxetine_21/NN (r_pobj) to_18/IN (r_prep) exposure_17/NN (r_pobj) after_16/IN (r_prep) report_1/VBP (l_dobj) amount_4/NN (l_prep) of_5/IN (l_pobj) disability_7/NN
D000928_D010300 NONE antidepressant_20/NN (r_compound) fluoxetine_21/NN (r_pobj) to_18/IN (r_prep) exposure_17/NN (r_pobj) after_16/IN (r_prep) report_1/VBP (l_dobj) amount_4/NN (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) disease_15/NN
D005473_D010300 NONE fluoxetine_21/NN (r_pobj) to_18/IN (r_prep) exposure_17/NN (r_pobj) after_16/IN (r_prep) report_1/VBP (l_dobj) amount_4/NN (l_prep) in_8/IN (l_pobj) patients_10/NNS (l_prep) with_11/IN (l_pobj) disease_15/NN
D005473_D010300 NONE fluoxetine_11/NN (r_pobj) of_10/IN (r_prep) capacity_9/NN (l_prep) in_12/IN (l_pobj) patients_16/NNS (l_compound) disease_15/NN
D004298_D010300 NONE dopamine_6/NN (r_npadvmod) antagonistic_8/JJ (r_amod) capacity_9/NN (l_prep) in_12/IN (l_pobj) patients_16/NNS (l_compound) disease_15/NN
18081909
C026098_D001927 CID levetiracetam_3/NNS (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Encephalopathy_0/NN
C026098_D001927 CID levetiracetam_7/NNP (r_nmod) encephalopathy_10/NN
C026098_D001927 CID LEV)-induced_9/VBN (r_parataxis) levetiracetam_7/NNP (r_nmod) encephalopathy_10/NN
D014635_D001927 CID valproate_6/VB (r_xcomp) added_4/VBD (l_nsubj) Encephalopathy_0/NN
C026098_C562694 NONE LEV_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (l_nsubjpass) man_4/NN (l_acl) suffering_5/VBG (l_prep) from_6/IN (l_pobj) epilepsy_8/NN
C026098_D012640 NONE LEV_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (l_nsubjpass) man_4/NN (l_acl) suffering_5/VBG (l_prep) with_9/IN (l_pobj) seizures_11/NNS
C026098_D012640 NONE LEV_3/NNP (r_pobj) of_2/IN (r_prep) discontinuation_1/NN (r_pobj) Following_0/VBG (r_prep) improved_9/VBD (l_conj) decreased_13/VBD (l_nsubj) frequency_12/NN (l_compound) seizure_11/NN
D014635_C562694 NONE valproate_22/VB (r_xcomp) added_20/VBN (r_conj) treated_13/VBN (l_nsubjpass) man_4/NN (l_acl) suffering_5/VBG (l_prep) from_6/IN (l_pobj) epilepsy_8/NN
D014635_C562694 NONE VPA_24/NNP (r_npadvmod) valproate_22/VB (r_xcomp) added_20/VBN (r_conj) treated_13/VBN (l_nsubjpass) man_4/NN (l_acl) suffering_5/VBG (l_prep) from_6/IN (l_pobj) epilepsy_8/NN
D014635_D012640 NONE valproate_22/VB (r_xcomp) added_20/VBN (r_conj) treated_13/VBN (l_nsubjpass) man_4/NN (l_acl) suffering_5/VBG (l_prep) with_9/IN (l_pobj) seizures_11/NNS
D014635_D012640 NONE VPA_24/NNP (r_npadvmod) valproate_22/VB (r_xcomp) added_20/VBN (r_conj) treated_13/VBN (l_nsubjpass) man_4/NN (l_acl) suffering_5/VBG (l_prep) with_9/IN (l_pobj) seizures_11/NNS
2802551
D012964_D007674 NONE Sodium_0/NN (r_compound) status_1/NN (r_nsubj) influences_2/VBZ (l_dobj) nephrotoxicity_6/NN
D000666_D007674 CID B_5/NN (r_compound) nephrotoxicity_6/NN
D000666_D007674 CID B_5/NNP (r_pobj) of_3/IN (r_prep) potential_2/NN (l_compound) nephrotoxic_1/JJ
17466854
D008775_D002386 NONE methylprednisolone_13/NNP (r_pobj) of_12/IN (r_prep) administration_11/NN (r_pobj) after_9/IN (r_prep) incidence_3/NN (r_dobj) assess_1/VB (l_conj) gentamicin_15/NNS (l_prep) at_24/IN (l_pobj) end_26/NN (l_prep) of_27/IN (l_pobj) surgery_30/NN (l_compound) cataract_29/NN
D005839_D002386 NONE gentamicin_15/NNS (l_prep) at_24/IN (l_pobj) end_26/NN (l_prep) of_27/IN (l_pobj) surgery_30/NN (l_compound) cataract_29/NN
D008775_D020250 CID methylprednisolone_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubjpass) related_15/VBN (l_prep) to_16/IN (l_pobj) incidence_19/NN (l_prep) of_20/IN (l_pobj) effects_22/NNS (l_prep) including_23/VBG (l_pobj) nausea_24/NN (l_conj) vomiting_26/NN
D008775_D006261 CID methylprednisolone_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubjpass) related_15/VBN (l_prep) to_16/IN (l_pobj) incidence_19/NN (l_prep) of_20/IN (l_pobj) effects_22/NNS (l_prep) including_23/VBG (l_pobj) nausea_24/NN (l_conj) vomiting_26/NN (l_conj) headache_29/NN
D005839_D020250 CID gentamicin_5/NNS (r_conj) methylprednisolone_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubjpass) related_15/VBN (l_prep) to_16/IN (l_pobj) incidence_19/NN (l_prep) of_20/IN (l_pobj) effects_22/NNS (l_prep) including_23/VBG (l_pobj) nausea_24/NN (l_conj) vomiting_26/NN
D005839_D006261 CID gentamicin_5/NNS (r_conj) methylprednisolone_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubjpass) related_15/VBN (l_prep) to_16/IN (l_pobj) incidence_19/NN (l_prep) of_20/IN (l_pobj) effects_22/NNS (l_prep) including_23/VBG (l_pobj) nausea_24/NN (l_conj) vomiting_26/NN (l_conj) headache_29/NN
1428568
D013999_D005901 NONE timolol_6/NNS (r_compound) 0.5%/12h_7/CD (r_pobj) with_5/IN (r_prep) treated_4/VBN (l_nsubj) patients_2/NNS (l_amod) glaucomatous_1/JJ
D013999_D003866 CID timolol_6/NNS (r_compound) 0.5%/12h_7/CD (r_pobj) with_5/IN (r_prep) treated_4/VBN (l_advcl) suffering_9/VBG (l_prep) from_10/IN (l_pobj) depression_11/NN
D013999_D003866 CID timolol_15/NNS (r_compound) treatment_16/NN (r_pobj) under_14/IN (r_prep) patients_13/NNS (r_nsubj) presented_17/VBD (l_dobj) values_20/NNS (l_compound) depression_19/NN
D013999_D003866 CID timolol_14/NNS (r_pobj) than_13/IN (r_prep) inducer_12/NN (l_compound) depression_10/NN
D015784_D003866 NONE betaxolol_4/NNS (r_nsubj) be_6/VB (l_attr) less_7/JJR (l_prep) of_8/IN (l_pobj) inducer_12/NN (l_compound) depression_10/NN
9249847
D014700_D013611 CID verapamil_7/NN (r_nmod) ablation_10/NN (r_pobj) after_6/IN (r_prep) induced_1/VBD (l_dobj) tachycardia_5/NN
D014700_D013611 CID verapamil_10/NN (r_pobj) after_9/IN (r_prep) beats_8/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) QRS_0/NNP (r_nsubj) established_22/VBD (l_dobj) attack_25/NN (l_compound) AVRT_24/NNP
D014700_D014927 NONE verapamil_7/NN (r_nmod) ablation_10/NN (l_prep) in_11/IN (l_pobj) patient_13/NN (l_prep) with_14/IN (l_pobj) syndrome_20/NN
D014700_D002311 NONE verapamil_7/NN (r_nmod) ablation_10/NN (l_prep) in_11/IN (l_pobj) patient_13/NN (l_prep) with_14/IN (l_pobj) syndrome_20/NN (l_conj) cardiomyopathy_24/NN
15515654
D003676_D006311 NONE DFO_6/NNP (r_pobj) than_5/IN (r_prep) other_4/JJ (r_amod) factor_2/NN (l_amod) ototoxic_1/JJ
D003676_D006319 CID DFO_6/NNP (r_compound) reduction_7/NN (r_pobj) to_5/IN (r_prep) submitted_4/VBN (l_nsubjpass) Subjects_0/NNS (l_prep) with_1/IN (l_pobj) SNHL_2/NNP
D003676_D034381 NONE DFO_5/NNP (r_poss) role_8/NN (l_prep) in_9/IN (l_pobj) development_11/NN (l_prep) of_12/IN (l_pcomp) hearing_13/NN (l_dobj) impairment_14/NN
15130900
D003520_D001749 CID cyclophosphamide_12/NN (r_pobj) to_11/IN (r_prep) risks_8/NNS (r_appos) cancer_2/NN
D003520_D001749 CID cyclophosphamide_14/NN (r_pobj) to_13/IN (r_prep) relation_12/NN (r_conj) assess_1/VB (l_conj) characterise_3/VB (l_dobj) risk_5/NN (l_prep) of_6/IN (l_pobj) cancer_8/NN
D003520_D001749 CID cyclophosphamide_18/NN (l_conj) cancer_21/NN
D003520_D001749 CID cyclophosphamide_12/NN (r_pobj) in_11/IN (r_prep) increment_10/NN (r_pobj) for_6/IN (r_prep) doubled_5/VBD (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) cancer_4/NN
D003520_D001749 CID cyclophosphamide_9/NN (l_conj) risk_12/NN (l_prep) of_13/IN (l_pobj) cancer_15/NN
D003520_D014890 NONE cyclophosphamide_12/NN (r_pobj) to_11/IN (r_prep) risks_8/NNS (r_appos) cancer_2/NN (l_prep) in_3/IN (l_pobj) granulomatosis_6/NN
D003520_D014890 NONE cyclophosphamide_14/NN (r_pobj) to_13/IN (r_prep) relation_12/NN (r_conj) assess_1/VB (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) granulomatosis_21/NN
D003520_D014890 NONE cyclophosphamide_9/NN (l_conj) risk_12/NN (l_prep) of_13/IN (l_pobj) cancer_15/NN (l_appos) risks_19/NNS (l_conj) possibility_28/NN (l_prep) before_34/IN (l_pobj) granulomatosis_37/NN
20470218
D008727_D056784 NONE methotrexate_32/NNP (r_nmod) 2_37/CD (r_appos) syndrome_6/NN (l_compound) leukoencephalopathy_5/NNP
D008727_D020521 NONE methotrexate_32/NNP (r_nmod) 2_37/CD (r_appos) syndrome_6/NN (l_appos) stroke_13/NN
D008727_D004833 NONE methotrexate_32/NNP (r_nmod) 2_37/CD (r_appos) syndrome_6/NN (l_appos) epilepsy_22/NN
D008727_D064420 NONE methotrexate_32/NNP (r_nmod) 2_37/CD (l_nmod) toxicity_33/NN
D008727_D007177 NONE methotrexate_32/NNP (r_nmod) 2_37/CD (r_appos) syndrome_6/NN (l_appos) syndrome_40/NN (l_prep) of_41/IN (l_pobj) secretion_45/NN
9522152
D002045_D009461 NONE bupivacaine_11/NN (r_pobj) of_7/IN (r_prep) injection_6/NN (r_pobj) following_4/VBG (r_prep) deficit_3/NN
D002045_D009461 NONE bupivacaine_21/NN (r_pobj) of_17/IN (r_prep) mg_16/CD (r_pobj) with_14/IN (r_prep) anaesthesia_13/NN (r_pobj) after_10/IN (r_prep) occurred_9/VBD (r_relcl) deficit_7/NN
1833784
D004298_D006948 NONE dopamine_8/NN (r_compound) receptors_9/NNS (l_prep) in_10/IN (l_pcomp) mediating_11/VBG (l_dobj) hyperactivity_15/NN
D009538_D006948 CID nicotine_12/NN (r_npadvmod) induced_14/VBN (r_amod) hyperactivity_15/NN
D009538_D006948 CID Nicotine_0/NNP (r_nsubj) caused_5/VBD (l_dobj) increase_8/NN (l_prep) in_9/IN (l_pobj) activity_11/NN
D009538_D006948 CID Nicotine_0/NN (r_npadvmod) induced_2/VBN (r_amod) hyperactivity_3/NN
D009538_D006948 CID nicotine_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperactivity_10/NN
D009538_D006948 CID nicotine_5/NN (r_compound) injection_6/NN (r_nsubj) induces_7/VBZ (l_dobj) hyperactivity_10/NN
C534628_D006948 NONE 23390_12/CD (r_nummod) SCH_11/NNP (r_appos) antagonist_10/NN (r_pobj) by_6/IN (r_agent) blocked_5/VBN (l_nsubjpass) hyperactivity_3/NN
D020891_D006948 NONE raclopride_18/NN (r_appos) antagonist_10/NN (r_pobj) by_6/IN (r_agent) blocked_5/VBN (l_nsubjpass) hyperactivity_3/NN
D005476_D006948 NONE fluphenazine_25/NN (r_conj) raclopride_18/NN (r_appos) antagonist_10/NN (r_pobj) by_6/IN (r_agent) blocked_5/VBN (l_nsubjpass) hyperactivity_3/NN
-1_D006948 NONE PHNO_5/NNP (r_nmod) hyperactivity_10/NN
D015647_D006948 NONE 38393_17/CD (r_nummod) SKF_16/NNP (r_nsubj) had_18/VBD (r_advcl) Pretreatment_0/NN (l_prep) with_1/IN (l_pobj) agonist_4/NN (l_appos) hyperactivity_10/NN
9351491
D018967_D011618 NONE risperidone_6/NNP (r_poss) profile_9/NN (r_nsubj) produce_11/VB (l_dobj) efficacy_13/NN (l_prep) for_14/IN (l_pobj) symptoms_17/NNS
D018967_D010302 CID risperidone_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) subjects_7/NNS (r_pobj) in_6/IN (r_prep) observed_5/VBN (l_nsubjpass) parkinsonism_3/NN
D006220_D010302 CID haloperidol_16/NNP (r_conj) risperidone_10/NNP (r_pobj) with_9/IN (r_prep) treated_8/VBN (r_acl) subjects_7/NNS (r_pobj) in_6/IN (r_prep) observed_5/VBN (l_nsubjpass) parkinsonism_3/NN
18821488
C080436_D064420 NONE 8-aminoquinoline_8/CD (r_nmod) methylbutyl)amino]-_13/JJ (r_nmod) WR242511_18/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) following_4/VBG (r_prep) Toxicity_0/NN
C068820_D064420 NONE hexyloxy)-6-methoxy-4-methylquinoline_16/NNP (r_nmod) WR242511_18/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) following_4/VBG (r_prep) Toxicity_0/NN
C068820_D064420 NONE WR242511_18/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) following_4/VBG (r_prep) Toxicity_0/NN
C068820_D064420 NONE WR242511_4/NNP (r_nsubjpass) pursued_8/VBN (l_advcl) dissociated_27/VBN (l_prep) from_28/IN (l_pobj) those_29/DT (l_acl) producing_30/VBG (l_dobj) toxicity_32/NN
C068820_D008708 NONE WR242511_4/NNP (r_pobj) of_3/IN (r_prep) doses_2/NNS (l_relcl) produced_7/VBD (l_dobj) methemoglobinemia_9/NN
C068820_D006456 CID WR242511_11/NNP (r_pobj) of_10/IN (r_prep) postinjection_9/NN (r_oprd) noted_5/VBN (l_nsubjpass) hemoglobinuria_3/NN
C068820_D011041 NONE WR242511_4/NNP (r_nsubjpass) pursued_8/VBN (l_prep) as_9/IN (l_pobj) pretreatment_11/NN (l_prep) for_12/IN (l_pobj) poisoning_14/NN
8649546
D007980_D004409 CID levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) dyskinesia_5/NN
D007980_D004409 CID levodopa_14/NN (r_npadvmod) induced_16/VBN (r_amod) ballistic_17/JJ (l_conj) choreic_19/VBZ (l_dobj) dyskinesia_20/NN
D007980_D010300 NONE levodopa_2/NN (r_npadvmod) induced_4/VBN (r_amod) dyskinesia_5/NN (r_pobj) of_1/IN (r_prep) Improvement_0/NN (l_prep) in_8/IN (l_pobj) disease_11/NN
D007980_D010300 NONE levodopa_14/NN (r_npadvmod) induced_16/VBN (r_amod) ballistic_17/JJ (l_conj) choreic_19/VBZ (l_prep) in_21/IN (l_pobj) PD_22/NNP
D011433_D004409 NONE propranolol_7/NN (r_pobj) by_6/IN (r_prep) Improvement_0/NN (l_prep) of_1/IN (l_pobj) dyskinesia_5/NN
D011433_D004409 NONE propranolol_18/NN (r_dobj) received_14/VBD (l_nsubj) dyskinesia_13/NN
D011433_D010300 NONE propranolol_7/NN (r_pobj) by_6/IN (r_prep) Improvement_0/NN (l_prep) in_8/IN (l_pobj) disease_11/NN
D011433_D010300 NONE propranolol_18/NN (r_dobj) received_14/VBD (l_nsubj) patients_1/NNS (l_acl) suffering_2/VBG (l_prep) from_3/IN (l_pobj) disease_6/NN
D011433_D010300 NONE propranolol_18/NN (r_dobj) received_14/VBD (l_nsubj) patients_1/NNS (l_acl) suffering_2/VBG (l_prep) from_3/IN (l_pobj) disease_6/NN (l_appos) PD_8/NNP
11773892
D016572_D007674 CID cyclosporine_3/VBP (r_appos) inhibitors_2/NNS (r_nsubjpass) known_8/VBN (l_xcomp) be_10/VB (l_attr) nephrotoxic_11/JJ
D016559_D007674 CID tacrolimus_5/NN (r_conj) inhibitors_2/NNS (r_nsubjpass) known_8/VBN (l_xcomp) be_10/VB (l_attr) nephrotoxic_11/JJ
D003404_D007676 NONE creatinine_20/NN (r_appos) CRF_16/NNP (r_appos) Controls_7/NNS (l_appos) CRF_10/NNP
D003404_D007676 NONE creatinine_20/NN (r_appos) CRF_16/NNP (r_appos) Controls_7/NNS (l_appos) CRF_10/NNP (l_conj) ESRD_12/NNP
D003404_D007676 NONE creatinine_20/NN (r_appos) CRF_16/NNP
D003404_D007676 NONE creatinine_13/NN (r_compound) levels_14/NNS (r_dobj) had_9/VBD (l_nsubj) patients_8/NNS (l_nmod) CRF_5/NNP
D003404_D007676 NONE creatinine_13/NN (r_compound) levels_14/NNS (r_dobj) had_9/VBD (l_nsubj) patients_8/NNS (l_nmod) CRF_5/NNP (l_conj) ESRD_7/NNP
D003404_D007676 NONE creatinine_42/NN (r_conj) requirement_27/NN (r_appos) percentage_18/NN (r_appos) levels_14/NNS (r_dobj) had_9/VBD (l_nsubj) patients_8/NNS (l_nmod) CRF_5/NNP
D003404_D007676 NONE creatinine_42/NN (r_conj) requirement_27/NN (r_appos) percentage_18/NN (r_appos) levels_14/NNS (r_dobj) had_9/VBD (l_nsubj) patients_8/NNS (l_nmod) CRF_5/NNP (l_conj) ESRD_7/NNP
D003404_D007676 NONE creatinine_16/NN (r_pobj) of_14/IN (r_prep) increase_13/NN (r_nsubj) were_31/VBD (l_attr) factors_34/NNS (l_prep) for_35/IN (l_pobj) development_37/NN (l_prep) of_38/IN (l_pobj) CRF_39/NNP
D003404_D007676 NONE creatinine_16/NN (r_pobj) of_14/IN (r_prep) increase_13/NN (r_nsubj) were_31/VBD (l_attr) factors_34/NNS (l_prep) for_35/IN (l_pobj) development_37/NN (l_prep) of_38/IN (l_pobj) CRF_39/NNP (l_conj) ESRD_41/NNP
D003404_D007676 NONE creatinine_11/NN (r_dobj) have_4/VBP (l_nsubj) Patients_0/NNS (l_relcl) develop_2/VBP (l_dobj) ESRD_3/NNP
D003404_D007676 NONE creatinine_6/NN (r_pobj) of_4/IN (r_prep) increase_3/NN (r_nsubj) is_11/VBZ (l_attr) predictive_13/JJ (l_prep) of_14/IN (l_pobj) development_16/NN (l_prep) of_17/IN (l_pobj) CRF_18/NNP
D003404_D007676 NONE creatinine_6/NN (r_pobj) of_4/IN (r_prep) increase_3/NN (r_nsubj) is_11/VBZ (l_attr) predictive_13/JJ (l_prep) of_14/IN (l_pobj) development_16/NN (l_prep) of_17/IN (l_pobj) CRF_18/NNP (l_conj) ESRD_20/NNP
D003404_D006530 NONE creatinine_13/NN (r_compound) levels_14/NNS (l_appos) percentage_18/NN (l_prep) of_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) syndrome_23/NN
D003404_D006530 NONE creatinine_42/NN (r_conj) requirement_27/NN (r_appos) percentage_18/NN (l_prep) of_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) syndrome_23/NN
D003404_D006530 NONE creatinine_11/NN (r_dobj) have_4/VBP (l_conj) are_13/VBP (l_acomp) likely_15/JJ (l_xcomp) have_17/VB (l_dobj) syndrome_19/NN
6534871
D007545_D009203 CID isoproterenol_8/NN (r_npadvmod) induced_10/VBN (r_amod) infarction_12/NN
16330293
435349
D013390_D005207 CID Suxamethonium_0/NN (r_compound) rate_2/NN (l_conj) fasciculations_5/NNS
D013390_D013746 NONE Sch_20/NNP (r_nsubjpass) exceeded_24/VBN (r_conj) was_7/VBD (l_attr) response_10/NN (l_prep) to_11/IN (l_pobj) stimulation_13/NN (l_compound) tetanic_12/JJ
9100294
D002118_D018376 NONE calcium_7/NN (r_compound) blockers_9/NNS (r_pobj) to_6/IN (r_prep) exposed_5/VBN (r_acl) alterations_1/NNS
D002118_D018376 NONE calcium_7/NN (r_compound) channel_8/NN (r_compound) blocker_9/NN (r_nsubj) induced_16/VBD (l_dobj) alterations_18/NNS
D002118_D018376 NONE calcium_10/NN (r_compound) channel_11/NN (r_compound) blockers_12/NNS (r_nsubj) induce_15/VBP (l_dobj) malformations_17/NNS
D002118_D018376 NONE calcium_7/NN (r_compound) channel_8/NN (r_compound) blockers_9/NNS (r_pobj) of_5/IN (r_prep) one_4/CD (r_dobj) administered_3/VBN (l_conj) offspring_18/NN (l_acl) examined_19/VBD (l_prep) for_25/IN (l_pobj) malformations_27/NNS
D002118_D018376 NONE calcium_15/NN (r_compound) channel_16/NN (r_compound) blockers_17/NNS (r_pobj) of_12/IN (r_prep) each_11/DT (r_pobj) to_10/IN (r_prep) exposure_9/NN (r_pobj) after_8/IN (r_prep) observed_7/VBN (l_nsubjpass) incidence_2/NN (l_prep) of_3/IN (l_pobj) malformations_5/NNS
D020748_D018376 CID 5967_14/CD (r_appos) blocker_9/NN (r_nsubj) induced_16/VBD (l_dobj) alterations_18/NNS
D014700_D018376 CID verapamil_27/NN (r_pobj) for_26/IN (r_prep) significant_24/JJ (r_acomp) was_22/VBD (r_conj) observed_7/VBN (l_nsubjpass) incidence_2/NN (l_prep) of_3/IN (l_pobj) malformations_5/NNS
D009543_D018376 CID nifedipine_29/NN (r_conj) verapamil_27/NN (r_pobj) for_26/IN (r_prep) significant_24/JJ (r_acomp) was_22/VBD (r_conj) observed_7/VBN (l_nsubjpass) incidence_2/NN (l_prep) of_3/IN (l_pobj) malformations_5/NNS
12757899
D004958_D012640 NONE Estradiol_0/NN (r_nsubj) reduces_1/VBZ (l_dobj) injury_6/NN (l_amod) induced_4/VBN (l_npadvmod) seizure_2/NN
D004958_D012640 NONE estradiol_7/NN (l_prep) on_8/IN (l_pobj) threshold_10/NN (l_compound) seizure_9/NN
D004958_D001930 NONE Estradiol_0/NN (r_nsubj) reduces_1/VBZ (l_dobj) injury_6/NN
D007608_D001930 NONE acid_10/NN (r_npadvmod) induced_12/VBN (r_amod) status_13/NN (r_nmod) SE_16/NNP (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) injury_6/NN
D007608_D013226 NONE acid_10/NN (r_npadvmod) induced_12/VBN (r_amod) status_13/NN (r_nmod) SE_16/NNP (l_nmod) epilepticus_14/NN
D007608_D013226 NONE acid_10/NN (r_npadvmod) induced_12/VBN (r_amod) status_13/NN (r_nmod) SE_16/NNP
D004958_D013226 NONE estradiol_7/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_dobj) compared_1/VBD (l_conj) ovariectomized_12/JJ (l_dobj) rats_14/NNS (l_acl) subjected_15/VBN (l_prep) to_16/IN (l_pobj) SE_22/NNP
D008094_D013226 CID lithium_17/NN (r_compound) pilocarpine_19/NN (r_npadvmod) induced_21/VBN (r_amod) SE_22/NNP
D010862_D013226 CID pilocarpine_19/NN (r_npadvmod) induced_21/VBN (r_amod) SE_22/NNP
D012834_D013226 NONE silver_3/NN (r_npadvmod) stained_5/VBN (r_amod) CA3_6/NNP (r_pobj) of_2/IN (r_prep) extent_1/NN (r_nsubjpass) evaluated_12/VBN (l_prep) after_15/IN (l_pobj) SE_16/NNP
10193204
C009438_D013927 NONE tetrandrine_2/NNP (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_5/IN (l_pobj) thrombosis_7/NN
C009438_D013927 NONE TET_10/NNP (r_pobj) of_9/IN (r_prep) effects_8/NNS (l_prep) on_13/IN (l_pobj) thrombosis_16/NN
C009438_D013927 NONE TET_15/NNP (r_pobj) of_14/IN (r_prep) administration_7/NN (r_nsubj) showed_20/VBD (l_dobj) inhibition_22/NN (l_prep) of_23/IN (l_pobj) thrombosis_24/NN
C009438_D001791 NONE tetrandrine_2/NNP (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) in_8/IN (l_pobj) aggregation_13/NN
C009438_D001791 NONE TET_10/NNP (r_pobj) of_9/IN (r_prep) effects_8/NNS (r_dobj) investigate_6/VB (r_advcl) undertaken_4/VBN (l_conj) aggregation_30/NN
C009438_D001791 NONE TET_14/NNP (r_nsubj) showed_17/VBD (l_prep) In_0/IN (l_pobj) aggregations_5/NNS
C060802_D013927 NONE fangchinoline_4/NNP (r_conj) tetrandrine_2/NNP (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_5/IN (l_pobj) thrombosis_7/NN
C060802_D013927 NONE FAN_12/NNP (r_conj) TET_10/NNP (r_pobj) of_9/IN (r_prep) effects_8/NNS (l_prep) on_13/IN (l_pobj) thrombosis_16/NN
C060802_D013927 NONE FAN_17/NNP (r_conj) TET_15/NNP (r_pobj) of_14/IN (r_prep) administration_7/NN (r_nsubj) showed_20/VBD (l_dobj) inhibition_22/NN (l_prep) of_23/IN (l_pobj) thrombosis_24/NN
C060802_D001791 NONE fangchinoline_4/NNP (r_conj) tetrandrine_2/NNP (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) in_8/IN (l_pobj) aggregation_13/NN
C060802_D001791 NONE FAN_12/NNP (r_conj) TET_10/NNP (r_pobj) of_9/IN (r_prep) effects_8/NNS (r_dobj) investigate_6/VB (r_advcl) undertaken_4/VBN (l_conj) aggregation_30/NN
C060802_D001791 NONE FAN_16/NNP (r_conj) TET_14/NNP (r_nsubj) showed_17/VBD (l_prep) In_0/IN (l_pobj) aggregations_5/NNS
C009438_D001778 NONE TET_10/NNP (r_pobj) of_9/IN (r_prep) effects_8/NNS (r_dobj) investigate_6/VB (r_advcl) undertaken_4/VBN (l_conj) aggregation_30/NN (l_conj) coagulation_33/NN
C060802_D001778 NONE FAN_12/NNP (r_conj) TET_10/NNP (r_pobj) of_9/IN (r_prep) effects_8/NNS (r_dobj) investigate_6/VB (r_advcl) undertaken_4/VBN (l_conj) aggregation_30/NN (l_conj) coagulation_33/NN
D004837_D013927 CID epinephrine_21/NN (r_conj) collagen_19/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) thrombosis_16/NN
D004837_D013927 CID EP_23/NNP (r_appos) collagen_19/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) thrombosis_16/NN
D004837_D001791 NONE epinephrine_21/NN (r_conj) collagen_19/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) thrombosis_16/NN (r_pobj) on_13/IN (r_prep) effects_8/NNS (r_dobj) investigate_6/VB (r_advcl) undertaken_4/VBN (l_conj) aggregation_30/NN
D004837_D001791 NONE EP_23/NNP (r_appos) collagen_19/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) thrombosis_16/NN (r_pobj) on_13/IN (r_prep) effects_8/NNS (r_dobj) investigate_6/VB (r_advcl) undertaken_4/VBN (l_conj) aggregation_30/NN
D004837_D001778 NONE epinephrine_21/NN (r_conj) collagen_19/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) thrombosis_16/NN (r_pobj) on_13/IN (r_prep) effects_8/NNS (r_dobj) investigate_6/VB (r_advcl) undertaken_4/VBN (l_conj) aggregation_30/NN (l_conj) coagulation_33/NN
D004837_D001778 NONE EP_23/NNP (r_appos) collagen_19/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) thrombosis_16/NN (r_pobj) on_13/IN (r_prep) effects_8/NNS (r_dobj) investigate_6/VB (r_advcl) undertaken_4/VBN (l_conj) aggregation_30/NN (l_conj) coagulation_33/NN
D001241_D013927 NONE acid_36/NN (r_nsubj) showed_50/VBD (r_advcl) showed_20/VBD (l_dobj) inhibition_22/NN (l_prep) of_23/IN (l_pobj) thrombosis_24/NN
D001241_D013927 NONE ASA_38/NNP (r_appos) acid_36/NN (r_nsubj) showed_50/VBD (r_advcl) showed_20/VBD (l_dobj) inhibition_22/NN (l_prep) of_23/IN (l_pobj) thrombosis_24/NN
8590259
C016986_D015814 CID apraclonidine_8/NN (r_npadvmod) treated_10/VBN (r_amod) eyes_11/NNS (r_pobj) for_7/IN (r_prep) were_4/VBD (l_nsubj) effects_3/NNS (l_amod) hypotensive_2/JJ
C016986_D015814 CID apraclonidine_31/NN (r_pobj) of_28/IN (r_prep) administration_27/NN (r_pobj) after_25/IN (r_prep) from_22/IN (r_prep) significant_18/JJ (r_acomp) were_4/VBD (l_nsubj) effects_3/NNS (l_amod) hypotensive_2/JJ
9625142
D002443_D056486 CID ceftriaxone_11/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) erythroblastocytopenia_8/NNP (r_conj) hepatitis_1/NN
D002443_D056486 CID ceftriaxone_12/NN (r_dobj) ingesting_10/VBG (r_pcomp) after_9/IN (r_prep) developed_5/VBD (l_dobj) hepatitis_7/NN
D002443_D000744 CID ceftriaxone_11/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) erythroblastocytopenia_8/NNP (r_conj) hepatitis_1/NN (l_appos) anemia_5/NN
D002443_-1 NONE ceftriaxone_11/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) erythroblastocytopenia_8/NNP
D047090_D000744 NONE lactam_11/NN (r_compound) antibiotic_12/NN (r_dobj) withholding_8/VBG (r_pcomp) after_7/IN (r_prep) returned_4/VBD (r_advcl) was_15/VBD (l_attr) increase_18/NN (l_conj) decrease_24/NN (l_prep) in_25/IN (l_pobj) concentration_27/NN (l_acl) caused_28/VBN (l_agent) by_29/IN (l_pobj) anemia_33/NN
D047090_-1 NONE lactam_11/NN (r_compound) antibiotic_12/NN (r_dobj) withholding_8/VBG (r_pcomp) after_7/IN (r_prep) returned_4/VBD (r_advcl) was_15/VBD (l_attr) increase_18/NN (l_conj) decrease_24/NN (l_prep) in_25/IN (l_pobj) concentration_27/NN (l_acl) caused_28/VBN (l_agent) by_29/IN (l_pobj) anemia_33/NN (l_conj) erythroblastocytopenia_35/NNP
D001663_D000744 NONE bilirubin_21/NN (r_pobj) in_19/IN (r_prep) increase_18/NN (l_conj) decrease_24/NN (l_prep) in_25/IN (l_pobj) concentration_27/NN (l_acl) caused_28/VBN (l_agent) by_29/IN (l_pobj) anemia_33/NN
D001663_-1 NONE bilirubin_21/NN (r_pobj) in_19/IN (r_prep) increase_18/NN (l_conj) decrease_24/NN (l_prep) in_25/IN (l_pobj) concentration_27/NN (l_acl) caused_28/VBN (l_agent) by_29/IN (l_pobj) anemia_33/NN (l_conj) erythroblastocytopenia_35/NNP
18726058
D010208_D020301 NONE hydrochloride_1/NN (r_nsubj) is_2/VBZ (l_attr) vasodilator_7/NN (l_acl) used_8/VBD (l_xcomp) manage_10/VB (l_dobj) vasospasm_11/NN
D010208_D020301 NONE papaverine_18/NN (r_dobj) received_16/VBD (l_prep) for_19/IN (l_pobj) vasospasm_20/NN
D010208_D020301 NONE papaverine_1/NN (r_nsubjpass) used_3/VBN (l_prep) as_4/IN (l_pobj) action_8/NN (l_acl) manage_10/VB (l_dobj) vasospasm_11/NN
D010208_D020301 NONE papaverine_1/NN (l_prep) for_2/IN (l_pobj) treatment_4/NN (l_prep) of_5/IN (l_pobj) vasospasm_6/NN
D010208_D003389 NONE papaverine_13/NN (r_pobj) with_11/IN (r_prep) cases_10/NNS (r_pobj) in_7/IN (r_prep) described_6/VBN (l_nsubjpass) dysfunction_3/NN
D010208_D003389 NONE papaverine_8/NN (r_pobj) from_7/IN (r_prep) deficits_6/NNS
17111419
C102006_D064420 NONE citrate_1/NN (r_compound) toxicity_2/NN
C102006_D064420 NONE citrate_6/NN (r_compound) toxicity_7/NN
C102006_D064420 NONE citrate_22/NN (r_compound) toxicity_23/NN
D002125_C536214 NONE gluconate_5/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_nsubjpass) initiated_7/VBN (l_conj) subsided_13/VBD (l_nsubj) contractions_11/NNS
D002118_D006996 NONE calcium_9/NN (r_compound) chelation_10/NN (r_pobj) to_8/IN (r_prep) reaction_7/NN (l_prep) by_11/IN (l_pobj) anticoagulant_14/NN (l_acl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) hypocalcemia_19/NN
C102006_D006996 CID citrate_13/NN (r_compound) anticoagulant_14/NN (l_acl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) hypocalcemia_19/NN
C102006_D006996 CID citrate_22/NN (r_compound) toxicity_23/NN (r_pobj) to_21/IN (r_pcomp) due_20/JJ (r_amod) reactions_19/NNS (r_dobj) prevent_17/VB (r_xcomp) help_16/VB (r_xcomp) recommended_14/VBN (l_nsubjpass) screening_4/NN (l_acl) predisposing_10/VBG (l_prep) to_11/IN (l_pobj) hypocalcemia_12/NN
D002034_D006996 NONE bumetanide_9/NNP (r_nsubj) is_10/VBZ (l_attr) diuretic_13/NN (l_relcl) cause_16/VB (l_dobj) hypocalcemia_18/NN
D049994_D006996 NONE diuretic_13/NN (l_relcl) cause_16/VB (l_dobj) hypocalcemia_18/NN
8955532
D001920_D006973 NONE bradykinin_4/NN (r_amod) B2_5/NN (r_compound) receptors_6/NNS (r_pobj) of_3/IN (r_prep) activation_2/NN (l_prep) in_7/IN (l_pobj) disruption_8/NN (l_prep) during_15/IN (l_pobj) hypertension_17/NN
D001920_D006973 NONE bradykinin_15/NN (r_pobj) of_14/IN (r_prep) release_13/NN (r_pobj) of_10/IN (r_prep) role_9/NN (r_dobj) determine_7/VB (l_xcomp) activate_17/VB (l_prep) in_20/IN (l_pobj) disruption_21/NN (l_prep) during_28/IN (l_pobj) hypertension_30/NN
D001920_D006973 NONE bradykinin_23/NN (r_pobj) of_22/IN (r_prep) release_21/NN (r_pobj) to_17/IN (r_prep) related_16/VBN (r_acomp) is_14/VBZ (l_nsubj) disruption_4/NN (l_prep) during_11/IN (l_pobj) hypertension_13/NN
D003911_D006973 NONE dextran_15/NN (r_pobj) of_11/IN (r_prep) clearance_10/NN (r_pobj) by_9/IN (r_agent) quantitated_8/VBN (l_prep) before_16/IN (l_conj) during_18/IN (l_pobj) hypertension_23/NN
D010656_D006973 CID phenylephrine_19/NN (r_npadvmod) induced_21/VBN (r_amod) hypertension_23/NN
C065679_D006973 NONE Hoe-140_30/NNS (r_conj) hypertension_23/NN
10520387
D004809_D007022 NONE ephedrine_11/NN (r_pobj) of_10/IN (r_prep) doses_9/NNS (r_dobj) adding_7/VBG (l_prep) in_14/IN (l_pobj) order_15/NN (l_acl) obtund_17/VB (l_dobj) response_20/NN (l_amod) hypotensive_19/JJ
D004809_D007022 NONE ephedrine_3/NN (r_pobj) of_2/IN (r_prep) addition_1/NN (r_nsubj) appears_6/VBZ (l_xcomp) be_8/VB (l_attr) method_11/NN (l_prep) of_12/IN (l_pcomp) obtunding_13/VBG (l_dobj) response_16/NN (l_amod) hypotensive_15/JJ
D015742_D007022 CID propofol_13/NN (r_pobj) to_12/IN (r_prep) adding_7/VBG (l_prep) in_14/IN (l_pobj) order_15/NN (l_acl) obtund_17/VB (l_dobj) response_20/NN (l_amod) hypotensive_19/JJ
D015742_D007022 CID propofol_5/NN (r_pobj) to_4/IN (r_prep) addition_1/NN (r_nsubj) appears_6/VBZ (l_xcomp) be_8/VB (l_attr) method_11/NN (l_prep) of_12/IN (l_pcomp) obtunding_13/VBG (l_dobj) response_16/NN (l_amod) hypotensive_15/JJ
D015742_D007022 CID propofol_18/NN (r_pobj) to_17/IN (r_prep) response_16/NN (l_amod) hypotensive_15/JJ
D004809_D013610 CID ephedrine_9/NN (r_pobj) of_8/IN (r_prep) use_7/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) tachycardia_3/NN
D004809_D013610 CID ephedrine_24/NN (r_nmod) mixtures_28/NNS (r_pobj) of_22/IN (r_prep) any_21/DT (r_pobj) of_20/IN (r_prep) patients_19/NNS (r_pobj) in_17/IN (r_prep) use_16/NN (r_dobj) recommend_14/VB (l_prep) Due_0/IN (l_pobj) risk_3/NN (l_prep) of_4/IN (l_pobj) tachycardia_6/NN
D015742_D013610 CID propofol_13/NN (r_pobj) with_12/IN (r_prep) combination_11/NN (r_pobj) in_10/IN (r_prep) use_7/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) tachycardia_3/NN
D015742_D013610 CID propofol_26/NN (r_nmod) mixtures_28/NNS (r_pobj) of_22/IN (r_prep) any_21/DT (r_pobj) of_20/IN (r_prep) patients_19/NNS (r_pobj) in_17/IN (r_prep) use_16/NN (r_dobj) recommend_14/VB (l_prep) Due_0/IN (l_pobj) risk_3/NN (l_prep) of_4/IN (l_pobj) tachycardia_6/NN
D004809_D017202 NONE ephedrine_24/NN (r_nmod) mixtures_28/NNS (r_pobj) of_22/IN (r_prep) any_21/DT (r_pobj) of_20/IN (r_prep) patients_19/NNS (r_pobj) in_17/IN (r_prep) use_16/NN (r_dobj) recommend_14/VB (l_prep) Due_0/IN (l_pobj) risk_3/NN (l_prep) of_4/IN (l_pobj) tachycardia_6/NN (l_acl) inducing_7/VBG (l_dobj) ischemia_9/NN
D015742_D017202 NONE propofol_26/NN (r_nmod) mixtures_28/NNS (r_pobj) of_22/IN (r_prep) any_21/DT (r_pobj) of_20/IN (r_prep) patients_19/NNS (r_pobj) in_17/IN (r_prep) use_16/NN (r_dobj) recommend_14/VB (l_prep) Due_0/IN (l_pobj) risk_3/NN (l_prep) of_4/IN (l_pobj) tachycardia_6/NN (l_acl) inducing_7/VBG (l_dobj) ischemia_9/NN
2673163
D003042_D020521 NONE cocaine_3/NN (r_compound) use_4/NN (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Stroke_0/NN
D003042_D020521 NONE cocaine_6/NN (r_compound) use_7/NN (r_nsubjpass) related_9/VBN (l_prep) to_10/IN (l_pobj) stroke_11/NN
D003042_D020521 NONE cocaine_2/NN (r_compound) use_3/NN (r_dobj) followed_1/VBD (l_nsubj) Stroke_0/NN
D003042_D020521 NONE cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN
D003042_D020521 NONE cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN (r_pobj) of_10/IN (r_prep) incidence_9/NN (r_nsubj) increasing_17/VBG (r_ccomp) indicate_2/VBP (r_ccomp) occurs_26/VBZ (l_nsubj) stroke_25/NN
D003042_D020521 NONE cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN (r_pobj) of_10/IN (r_prep) incidence_9/NN (r_nsubj) increasing_17/VBG (r_ccomp) indicate_2/VBP (r_ccomp) occurs_26/VBZ (r_ccomp) follow_37/VB (l_nsubj) stroke_35/NN
D003042_D020521 NONE cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN (r_pobj) of_10/IN (r_prep) incidence_9/NN (r_nsubj) increasing_17/VBG (r_ccomp) indicate_2/VBP (r_ccomp) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN
D003042_D020521 NONE cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN (r_pobj) of_10/IN (r_prep) incidence_9/NN (r_nsubj) increasing_17/VBG (r_ccomp) indicate_2/VBP (r_ccomp) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_meta) 5_63/CD (l_prep) in_65/IN (l_pobj) stroke_69/NN
D003042_D020521 NONE cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN (r_nsubj) occurs_26/VBZ (l_ccomp) indicate_2/VBP (l_ccomp) increasing_17/VBG (l_nsubj) incidence_9/NN (l_prep) of_10/IN (l_pobj) stroke_11/NN
D003042_D020521 NONE cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN
D003042_D020521 NONE cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN (r_nsubj) occurs_26/VBZ (r_ccomp) follow_37/VB (l_nsubj) stroke_35/NN
D003042_D020521 NONE cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN (r_nsubj) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN
D003042_D020521 NONE cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN (r_nsubj) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_meta) 5_63/CD (l_prep) in_65/IN (l_pobj) stroke_69/NN
D003042_D020521 NONE cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_ccomp) occurs_26/VBZ (l_ccomp) indicate_2/VBP (l_ccomp) increasing_17/VBG (l_nsubj) incidence_9/NN (l_prep) of_10/IN (l_pobj) stroke_11/NN
D003042_D020521 NONE cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_ccomp) occurs_26/VBZ (l_nsubj) stroke_25/NN
D003042_D020521 NONE cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_nsubj) stroke_35/NN
D003042_D020521 NONE cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_dep) stroke_47/NN
D003042_D020521 NONE cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_meta) 5_63/CD (l_prep) in_65/IN (l_pobj) stroke_69/NN
D003042_D020521 NONE cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (r_advcl) stroke_47/NN (r_dep) follow_37/VB (l_ccomp) occurs_26/VBZ (l_ccomp) indicate_2/VBP (l_ccomp) increasing_17/VBG (l_nsubj) incidence_9/NN (l_prep) of_10/IN (l_pobj) stroke_11/NN
D003042_D020521 NONE cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (r_advcl) stroke_47/NN (r_dep) follow_37/VB (l_ccomp) occurs_26/VBZ (l_nsubj) stroke_25/NN
D003042_D020521 NONE cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (r_advcl) stroke_47/NN (r_dep) follow_37/VB (l_nsubj) stroke_35/NN
D003042_D020521 NONE cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (r_advcl) stroke_47/NN
D003042_D020521 NONE cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (r_advcl) stroke_47/NN (l_conj) exceeds_76/VBZ (l_meta) 5_63/CD (l_prep) in_65/IN (l_pobj) stroke_69/NN
D003042_D020521 NONE cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN (r_pobj) in_65/IN (r_prep) 5_63/CD (r_meta) exceeds_76/VBZ (r_conj) stroke_47/NN (r_dep) follow_37/VB (l_ccomp) occurs_26/VBZ (l_ccomp) indicate_2/VBP (l_ccomp) increasing_17/VBG (l_nsubj) incidence_9/NN (l_prep) of_10/IN (l_pobj) stroke_11/NN
D003042_D020521 NONE cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN (r_pobj) in_65/IN (r_prep) 5_63/CD (r_meta) exceeds_76/VBZ (r_conj) stroke_47/NN (r_dep) follow_37/VB (l_ccomp) occurs_26/VBZ (l_nsubj) stroke_25/NN
D003042_D020521 NONE cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN (r_pobj) in_65/IN (r_prep) 5_63/CD (r_meta) exceeds_76/VBZ (r_conj) stroke_47/NN (r_dep) follow_37/VB (l_nsubj) stroke_35/NN
D003042_D020521 NONE cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN (r_pobj) in_65/IN (r_prep) 5_63/CD (r_meta) exceeds_76/VBZ (r_conj) stroke_47/NN
D003042_D020521 NONE cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN
D003042_D002532 NONE cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN (r_pobj) of_10/IN (r_prep) incidence_9/NN (r_nsubj) increasing_17/VBG (r_ccomp) indicate_2/VBP (r_ccomp) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_advcl) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS
D003042_D002532 NONE cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN (r_nsubj) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_advcl) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS
D003042_D002532 NONE cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_dep) stroke_47/NN (l_advcl) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS
D003042_D002532 NONE cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS
D003042_D002532 NONE cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN (r_pobj) in_65/IN (r_prep) 5_63/CD (r_meta) exceeds_76/VBZ (r_conj) stroke_47/NN (l_advcl) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS
D003042_D001165 NONE cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN (r_pobj) of_10/IN (r_prep) incidence_9/NN (r_nsubj) increasing_17/VBG (r_ccomp) indicate_2/VBP (r_ccomp) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_advcl) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS (l_conj) malformations_59/NNS
D003042_D001165 NONE cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN (r_nsubj) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_advcl) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS (l_conj) malformations_59/NNS
D003042_D001165 NONE cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_dep) stroke_47/NN (l_advcl) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS (l_conj) malformations_59/NNS
D003042_D001165 NONE cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS (l_conj) malformations_59/NNS
D003042_D001165 NONE cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN (r_pobj) in_65/IN (r_prep) 5_63/CD (r_meta) exceeds_76/VBZ (r_conj) stroke_47/NN (l_advcl) associated_53/VBN (l_prep) with_54/IN (l_pobj) aneurysms_56/NNS (l_conj) malformations_59/NNS
D003042_D020300 NONE cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN (r_pobj) of_10/IN (r_prep) incidence_9/NN (r_nsubj) increasing_17/VBG (r_ccomp) indicate_2/VBP (r_ccomp) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_nsubj) frequency_72/NN (l_prep) of_73/IN (l_pobj) hemorrhage_75/NN
D003042_D020300 NONE cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN (r_nsubj) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_nsubj) frequency_72/NN (l_prep) of_73/IN (l_pobj) hemorrhage_75/NN
D003042_D020300 NONE cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_nsubj) frequency_72/NN (l_prep) of_73/IN (l_pobj) hemorrhage_75/NN
D003042_D020300 NONE cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (r_advcl) stroke_47/NN (l_conj) exceeds_76/VBZ (l_nsubj) frequency_72/NN (l_prep) of_73/IN (l_pobj) hemorrhage_75/NN
D003042_D020300 NONE cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN (r_pobj) in_65/IN (r_prep) 5_63/CD (r_meta) exceeds_76/VBZ (l_nsubj) frequency_72/NN (l_prep) of_73/IN (l_pobj) hemorrhage_75/NN
D003042_D002544 CID cocaine_14/NN (r_compound) use_15/NN (r_pobj) to_13/IN (r_prep) related_12/VBN (r_acl) stroke_11/NN (r_pobj) of_10/IN (r_prep) incidence_9/NN (r_nsubj) increasing_17/VBG (r_ccomp) indicate_2/VBP (r_ccomp) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_dobj) that_77/IN (l_prep) of_78/IN (l_pobj) infarction_80/NN
D003042_D002544 CID cocaine_22/NN (r_npadvmod) associated_24/VBN (r_amod) stroke_25/NN (r_nsubj) occurs_26/VBZ (r_ccomp) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_dobj) that_77/IN (l_prep) of_78/IN (l_pobj) infarction_80/NN
D003042_D002544 CID cocaine_41/NN (r_compound) administration_42/NN (r_pobj) of_40/IN (r_prep) route_39/NN (r_dobj) follow_37/VB (l_dep) stroke_47/NN (l_conj) exceeds_76/VBZ (l_dobj) that_77/IN (l_prep) of_78/IN (l_pobj) infarction_80/NN
D003042_D002544 CID cocaine_49/NN (r_compound) use_50/NN (r_nsubjpass) associated_53/VBN (r_advcl) stroke_47/NN (l_conj) exceeds_76/VBZ (l_dobj) that_77/IN (l_prep) of_78/IN (l_pobj) infarction_80/NN
D003042_D002544 CID cocaine_66/NN (r_npadvmod) associated_68/VBN (r_amod) stroke_69/NN (r_pobj) in_65/IN (r_prep) 5_63/CD (r_meta) exceeds_76/VBZ (l_dobj) that_77/IN (l_prep) of_78/IN (l_pobj) infarction_80/NN
9088814
D000527_D007022 CID E1-induced_5/VBN (r_compound) hypotension_6/NN
D000527_D007022 CID E1_5/NN (l_appos) hypotension_8/NN
D000527_D007022 CID PGE1)-induced_7/VBN (r_nummod) hypotension_8/NN
D000527_D007022 CID PGE1-induced_13/JJ (r_compound) hypotension_14/NN
D000527_D020141 NONE E1-induced_5/VBN (r_compound) hypotension_6/NN (l_conj) haemodilution_8/NN
D000527_D020141 NONE E1_5/NN (l_appos) hypotension_8/NN (l_conj) haemodilution_10/NN
D000527_D020141 NONE PGE1)-induced_7/VBN (r_nummod) hypotension_8/NN (l_conj) haemodilution_10/NN
D000527_D020141 NONE PGE1-induced_13/JJ (r_compound) hypotension_14/NN (l_conj) haemodilution_17/NN
D003911_D020141 NONE dextran_23/NN (r_amod) solution_24/NN (r_pobj) of_22/IN (r_prep) amount_21/NN (r_pobj) with_18/IN (r_prep) replacing_16/VBG (r_conj) withdrawing_9/VBG (r_pcomp) by_8/IN (r_prep) produced_7/VBN (l_nsubjpass) Haemodilution_0/NN
D001663_D007022 NONE bilirubin_50/NN (r_conj) LDH_47/NNP (r_conj) SGPT_45/NNP (r_conj) SGOT_43/NNP (r_nsubj) showed_51/VBD (l_prep) at_17/IN (l_prep) after_24/IN (l_pobj) start_26/NN (l_prep) of_27/IN (l_pobj) hypotension_28/NN
D000527_D008107 CID PGE1-induced_13/JJ (r_compound) hypotension_14/NN (r_pobj) of_12/IN (r_prep) min_11/NN (r_pobj) of_7/IN (r_prep) combination_6/NN (r_nsubj) cause_19/VB (l_dobj) impairment_20/NN (l_prep) of_21/IN (l_pobj) function_23/NN
3125768
D015760_D009127 CID alfentanil_4/NN (r_npadvmod) induced_6/VBN (r_amod) rigidity_7/NN
D015760_D009127 CID alfentanil_8/NN (r_npadvmod) induced_10/VBN (r_amod) rigidity_11/NN
D015760_D009127 CID alfentanil_9/NN (r_nsubjpass) used_19/VBN (r_advcl) prevented_7/VBN (l_nsubjpass) rigidity_4/NN
C032943_D009127 NONE metocurine_10/NNP (r_pobj) with_9/IN (r_prep) abolished_8/VBN (l_nsubjpass) rigidity_6/NN
4008111
D000638_D012848 CID Amiodarone_0/NN (r_npadvmod) induced_2/VBN (r_amod) block_4/NN
D000638_D012848 CID amiodarone_7/NNP (r_compound) administration_8/NN (r_pobj) due_4/IN (r_amod) block_3/NN
D000638_D012848 CID amiodarone_5/NN (r_pobj) of_4/IN (r_prep) dosage_3/NN (r_pobj) in_1/IN (r_prep) Reduction_0/NN (r_nsubj) resulted_6/VBD (l_prep) in_7/IN (l_pobj) disappearance_9/NN (l_prep) of_10/IN (l_pobj) block_13/NN
D000638_D009202 NONE amiodarone_7/NNP (r_compound) administration_8/NN (r_pobj) due_4/IN (r_amod) block_3/NN (l_prep) in_9/IN (l_pobj) boy_14/NN (l_prep) with_15/IN (l_pobj) cardiomyopathy_17/NN
D000638_D014927 NONE amiodarone_7/NNP (r_compound) administration_8/NN (r_pobj) due_4/IN (r_amod) block_3/NN (l_prep) in_9/IN (l_pobj) boy_14/NN (l_prep) with_15/IN (l_pobj) cardiomyopathy_17/NN (l_appos) syndrome_24/NN
D000638_D013617 NONE amiodarone_7/NNP (r_compound) administration_8/NN (r_pobj) due_4/IN (r_amod) block_3/NN (l_prep) in_9/IN (l_pobj) boy_14/NN (l_prep) with_15/IN (l_pobj) cardiomyopathy_17/NN (l_appos) syndrome_24/NN (l_conj) tachycardia_27/NN
D000638_D012804 NONE amiodarone_5/NN (r_pobj) of_4/IN (r_prep) dosage_3/NN (r_pobj) in_1/IN (r_prep) Reduction_0/NN (r_nsubj) resulted_6/VBD (l_prep) in_7/IN (l_pobj) disappearance_9/NN (l_conj) persistence_16/NN (l_prep) of_17/IN (l_pobj) bradycardia_20/NN
8092427
D000658_D004342 CID amoxicillin_4/NNP (r_pobj) to_3/IN (r_prep) reactions_2/NNS
D000658_D004342 CID amoxicillin_39/NNP (r_pobj) to_38/IN (r_prep) responses_37/NNS (r_dobj) had_33/VBD (l_nsubj) patients_26/NNS (l_amod) allergic_27/JJ
D000658_D004342 CID amoxicillin_39/NNP (r_pobj) to_38/IN (r_prep) responses_37/NNS (l_amod) allergic_36/JJ
D000658_D004342 CID AX_41/NNP (r_appos) amoxicillin_39/NNP (r_pobj) to_38/IN (r_prep) responses_37/NNS (r_dobj) had_33/VBD (l_nsubj) patients_26/NNS (l_amod) allergic_27/JJ
D000658_D004342 CID AX_41/NNP (r_appos) amoxicillin_39/NNP (r_pobj) to_38/IN (r_prep) responses_37/NNS (l_amod) allergic_36/JJ
D000658_D004342 CID AX_11/NN (r_compound) allergy_12/NN
D000658_D004342 CID AX_3/NNP (r_pobj) with_2/IN (r_prep) tests_1/NNS (r_nsubjpass) performed_5/VBN (l_advcl) establish_14/VB (l_dobj) diagnosis_16/NN (l_prep) of_17/IN (l_pobj) reaction_20/NN
D000658_D004342 CID AX_22/NNP (r_pobj) to_21/IN (r_prep) reaction_20/NN
D000658_D004342 CID AX_38/NNP (r_pobj) for_37/IN (r_prep) RAST_36/NNP (r_nsubj) were_39/VBD (r_conj) performed_5/VBN (l_advcl) establish_14/VB (l_dobj) diagnosis_16/NN (l_prep) of_17/IN (l_pobj) reaction_20/NN
D000658_D004342 CID AX_6/NN (r_npadvmod) allergic_8/JJ
D047090_D004342 NONE lactam_12/NN (r_compound) antibiotics_13/NNS (r_pobj) to_9/IN (r_prep) reactions_8/NNS
D047090_D004342 NONE lactam_31/NN (r_compound) antibiotics_32/NNS (r_pobj) to_28/IN (r_prep) allergic_27/JJ
D047090_D004342 NONE lactam_31/NN (r_compound) antibiotics_32/NNS (r_pobj) to_28/IN (r_prep) allergic_27/JJ (r_amod) patients_26/NNS (r_nsubj) had_33/VBD (l_dobj) responses_37/NNS (l_amod) allergic_36/JJ
D047090_D004342 NONE lactam_12/NN (r_compound) antibiotics_13/NNS (r_pobj) to_9/IN (r_prep) allergic_8/JJ
D010406_D004342 NONE penicillin_50/NN (r_compound) derivatives_51/NNS (r_pobj) with_48/IN (r_prep) reacting_47/VBG (r_acomp) were_44/VBD (r_conj) had_33/VBD (l_nsubj) patients_26/NNS (l_amod) allergic_27/JJ
D010406_D004342 NONE penicillin_50/NN (r_compound) derivatives_51/NNS (r_pobj) with_48/IN (r_prep) reacting_47/VBG (r_acomp) were_44/VBD (r_conj) had_33/VBD (l_dobj) responses_37/NNS (l_amod) allergic_36/JJ
D010400_D004342 NONE PG_17/NNP (r_pobj) of_16/IN (r_prep) tolerance_15/NN (r_pobj) with_13/IN (r_prep) allergy_12/NN
D010400_D004342 NONE PG_13/NNP (r_dobj) tolerated_12/VBN (r_relcl) group_4/NN (l_prep) of_5/IN (l_pobj) patients_9/NNS (l_amod) allergic_8/JJ
-1_D007645 NONE BPO_8/NNP (r_pobj) to_7/IN (r_prep) negative_6/JJ (r_amod) test_5/NN (r_attr) were_3/VBD (r_ccomp) were_17/VBD (l_acomp) negative_19/JJ (l_prep) to_20/IN (l_pobj) MDM_21/NNP
D010400_D007645 NONE PG_32/NNP (r_pobj) to_31/IN (r_prep) 44_24/CD (r_conj) were_17/VBD (l_acomp) negative_19/JJ (l_prep) to_20/IN (l_pobj) MDM_21/NNP
6203452
D002945_D002277 NONE cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (r_acl) microangiopathy_6/NNP (r_dobj) developed_4/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) carcinoma_3/NN
D002945_D057049 NONE cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (r_acl) microangiopathy_6/NNP
D002945_D051437 NONE cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN
D002945_D051437 NONE cisplatin_30/XX (r_compound) nephrotoxicity_31/NN (r_pobj) to_29/IN (r_prep) ascribed_28/VBN (l_nsubjpass) failure_25/NN
D002945_D000743 NONE cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN (l_conj) anemia_15/NN
D002945_D013921 NONE cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN (l_conj) anemia_15/NN (l_conj) thrombocytopenia_19/JJ
D002945_D013921 NONE cisplatin_30/XX (r_compound) nephrotoxicity_31/NN (r_pobj) to_29/IN (r_prep) ascribed_28/VBN (l_conj) thrombocytopenia_36/NN
D001761_D002277 NONE bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (r_acl) microangiopathy_6/NNP (r_dobj) developed_4/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) carcinoma_3/NN
D001761_D057049 NONE bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (r_acl) microangiopathy_6/NNP
D001761_D051437 NONE bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN
D001761_D000743 NONE bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN (l_conj) anemia_15/NN
D001761_D013921 NONE bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN (l_conj) anemia_15/NN (l_conj) thrombocytopenia_19/JJ
D014748_D002277 NONE alkaloid_31/NN (r_conj) bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (r_acl) microangiopathy_6/NNP (r_dobj) developed_4/VBN (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) carcinoma_3/NN
D014748_D057049 NONE alkaloid_31/NN (r_conj) bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (r_acl) microangiopathy_6/NNP
D014748_D051437 NONE alkaloid_31/NN (r_conj) bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN
D014748_D000743 NONE alkaloid_31/NN (r_conj) bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN (l_conj) anemia_15/NN
D014748_D013921 NONE alkaloid_31/NN (r_conj) bleomycin_26/NN (r_conj) cisplatin_24/NN (r_pobj) with_23/IN (r_prep) treatment_22/NN (r_pobj) after_21/IN (r_prep) characterized_8/VBN (l_agent) by_9/IN (l_pobj) insufficiency_11/NN (l_conj) anemia_15/NN (l_conj) thrombocytopenia_19/JJ
D002945_D007674 CID cisplatin_30/XX (r_compound) nephrotoxicity_31/NN
D002945_D000740 NONE cisplatin_30/XX (r_compound) nephrotoxicity_31/NN (l_conj) anemia_34/NN
D002945_D001855 NONE cisplatin_30/XX (r_compound) nephrotoxicity_31/NN (r_pobj) to_29/IN (r_prep) ascribed_28/VBN (l_conj) thrombocytopenia_36/NN (l_prep) to_37/IN (l_pobj) suppression_43/NN
9855119
D016559_D005922 NONE FK506_27/NN (r_compound) nephropathy_28/NN (r_appos) nephropathy_8/NN
D016559_D007674 NONE FK506_27/NN (r_compound) nephropathy_28/NN
D016559_D007674 NONE FK506_0/NNP (r_compound) nephropathy_1/NN
D016559_D007674 NONE FK506_18/NN (r_compound) nephropathy_19/NN
D016559_D007674 NONE FK506_1/JJ (r_compound) nephropathy_2/NN
D016559_D007674 NONE FK506_12/NNP (r_compound) group_14/NN (l_compound) nephropathy_13/NN
D016559_D007674 NONE FK506_12/NNP (r_compound) group_14/NN (r_pobj) in_6/IN (r_prep) patients_5/NNS (r_pobj) of_4/IN (r_prep) levels_3/NNS (r_nsubj) were_22/VBD (l_acomp) higher_24/JJR (l_prep) than_25/IN (l_pobj) those_26/DT (l_prep) in_27/IN (l_pobj) group_34/NN (l_compound) FK506-nephropathy_33/NNP
D016559_D007674 NONE FK506-nephropathy_33/NNP (r_compound) group_34/NN (r_pobj) in_27/IN (r_prep) those_26/DT (r_pobj) than_25/IN (r_prep) higher_24/JJR (r_acomp) were_22/VBD (l_nsubj) levels_3/NNS (l_prep) of_4/IN (l_pobj) patients_5/NNS (l_prep) in_6/IN (l_pobj) group_14/NN (l_compound) nephropathy_13/NN
D016559_D007674 NONE FK506-nephropathy_33/NNP
D016559_D007674 NONE FK506_5/JJ (r_compound) nephropathy_6/NN
D016559_D007674 NONE FK506_5/JJ (r_compound) nephropathy_6/NN (r_nsubj) consists_7/VBZ (r_ccomp) demonstrates_2/VBZ (l_conj) suggests_21/VBZ (l_ccomp) is_29/VBZ (l_nsubj) nephropathy_28/NN
D016559_D007674 NONE FK506_27/NN (r_compound) nephropathy_28/NN (r_nsubj) is_29/VBZ (r_ccomp) suggests_21/VBZ (r_conj) demonstrates_2/VBZ (l_ccomp) consists_7/VBZ (l_nsubj) nephropathy_6/NN
D016559_D007674 NONE FK506_27/NN (r_compound) nephropathy_28/NN
D016559_D005923 CID FK506_1/JJ (r_compound) nephropathy_2/NN (r_nsubj) consisted_3/VBD (l_prep) of_4/IN (l_pobj) vacuolization_9/NN (l_conj) arteriolopathy_15/NNP (l_conj) biopsies_24/NNS (l_conj) glomerulosclerosis_29/NN
D016559_D005355 NONE FK506_1/JJ (r_compound) nephropathy_2/NN (r_nsubj) consisted_3/VBD (l_prep) of_4/IN (l_pobj) vacuolization_9/NN (l_conj) arteriolopathy_15/NNP (l_conj) biopsies_24/NNS (l_conj) glomerulosclerosis_29/NN (l_conj) form_37/NN (l_prep) of_38/IN (l_pobj) fibrosis_40/NN
D003404_D007674 NONE creatinine_2/NN (r_compound) levels_3/NNS (l_prep) of_4/IN (l_pobj) patients_5/NNS (l_prep) in_6/IN (l_pobj) group_14/NN (l_compound) nephropathy_13/NN
D003404_D007674 NONE creatinine_2/NN (r_compound) levels_3/NNS (r_nsubj) were_22/VBD (l_acomp) higher_24/JJR (l_prep) than_25/IN (l_pobj) those_26/DT (l_prep) in_27/IN (l_pobj) group_34/NN (l_compound) FK506-nephropathy_33/NNP
3015567
D009599_D007022 CID Nitroprusside_0/NNP (r_npadvmod) induced_2/VBN (r_amod) hypotension_3/NN
D009599_D007022 CID nitroprusside_7/NN (r_npadvmod) induced_9/VBN (r_amod) hypotension_10/NN
D003345_D007022 NONE corticosterone_18/NN (r_compound) level_19/NN (r_pobj) at_15/IN (r_prep) occurs_14/VBZ (r_conj) observed_12/VBN (l_nsubjpass) Suppression_0/NN (l_prep) in_4/IN (l_pobj) response_5/NN (l_prep) to_6/IN (l_pobj) hypotension_10/NN
18343374
D002996_D012170 CID clomiphene_6/NN (r_npadvmod) induced_8/VBN (r_amod) ovulation_9/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) occlusion_3/NN
D002996_D012170 CID citrate_12/NNP (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) occlusion_8/NN
D002996_D012170 CID CC_14/NNP (r_appos) citrate_12/NNP (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) occlusion_8/NN
D002996_D012170 CID CC_8/NNP (r_pobj) with_7/IN (r_prep) induction_6/NN (r_pobj) after_4/IN (r_prep) occlusion_3/NN
D002996_D012170 CID CC_15/NN (r_pobj) of_14/IN (r_prep) courses_13/NNS (r_pobj) after_11/IN (r_prep) developed_6/VBD (l_dobj) occlusion_10/NN
D002996_D012170 CID CC_15/NNP (r_pobj) with_14/IN (r_prep) treatment_13/NN (r_pobj) after_12/IN (r_prep) case_6/NN (l_prep) of_7/IN (l_pobj) occlusion_11/NN
D002996_D013923 NONE CC_10/NNP (r_pobj) of_9/IN (r_prep) complications_8/NNS (l_amod) thromboembolic_7/JJ
D002996_D013923 NONE CC_24/NN (r_compound) intake_25/NN (r_nsubj) is_26/VBZ (r_advcl) include_13/VB (l_nsubj) search_1/NN (l_prep) on_5/IN (l_pobj) complications_8/NNS (l_amod) thromboembolic_7/JJ
D002996_D014786 CID CC_10/NNP (r_pobj) of_9/IN (r_prep) complications_8/NNS (r_pobj) on_5/IN (r_prep) search_1/NN (r_nsubj) include_13/VB (l_advcl) is_26/VBZ (l_nsubj) disturbance_22/NN
D002996_D014786 CID CC_24/NN (r_compound) intake_25/NN (r_nsubj) is_26/VBZ (l_nsubj) disturbance_22/NN
D002996_D007247 NONE CC_9/NNP (r_pobj) with_8/IN (r_prep) treating_5/VBG (l_dobj) patients_7/NNS (l_compound) infertility_6/NN
12684739
D020888_D019966 NONE GVG_35/NNP (r_pobj) of_29/IN (r_prep) effects_28/NNS (r_dobj) explored_26/VBD (l_prep) Given_0/VBN (l_pobj) success_3/NN (l_prep) for_4/IN (l_pcomp) treating_5/VBG (l_dobj) abuse_7/NN
D020888_D005128 CID GVG_35/NNP (r_pobj) of_29/IN (r_prep) effects_28/NNS (r_dobj) explored_26/VBD (l_prep) Given_0/VBN (l_pobj) success_3/NN (l_prep) for_4/IN (l_pcomp) treating_5/VBG (l_dobj) abuse_7/NN (l_conj) risk_11/NN (l_prep) of_12/IN (l_pobj) defects_15/NNS
D020888_D005128 CID GVG_35/NNP (r_pobj) of_29/IN (r_prep) effects_28/NNS (r_dobj) explored_26/VBD (l_prep) Given_0/VBN (l_pobj) success_3/NN (l_prep) for_4/IN (l_pcomp) treating_5/VBG (l_dobj) abuse_7/NN (l_appos) VFD_17/NNP
D003042_D019966 NONE cocaine_37/NN (r_npadvmod) induced_39/VBN (r_amod) increases_40/NNS (r_pobj) on_36/IN (r_prep) effects_28/NNS (r_dobj) explored_26/VBD (l_prep) Given_0/VBN (l_pobj) success_3/NN (l_prep) for_4/IN (l_pcomp) treating_5/VBG (l_dobj) abuse_7/NN
D003042_D005128 NONE cocaine_37/NN (r_npadvmod) induced_39/VBN (r_amod) increases_40/NNS (r_pobj) on_36/IN (r_prep) effects_28/NNS (r_dobj) explored_26/VBD (l_prep) Given_0/VBN (l_pobj) success_3/NN (l_prep) for_4/IN (l_pcomp) treating_5/VBG (l_dobj) abuse_7/NN (l_conj) risk_11/NN (l_prep) of_12/IN (l_pobj) defects_15/NNS
D003042_D005128 NONE cocaine_37/NN (r_npadvmod) induced_39/VBN (r_amod) increases_40/NNS (r_pobj) on_36/IN (r_prep) effects_28/NNS (r_dobj) explored_26/VBD (l_prep) Given_0/VBN (l_pobj) success_3/NN (l_prep) for_4/IN (l_pcomp) treating_5/VBG (l_dobj) abuse_7/NN (l_appos) VFD_17/NNP
16755009
D012601_D000647 CID scopolamine-_1/JJ (r_intj) served_7/VBD (l_nsubj) amnesia_6/NN
D012601_D000647 CID scopolamine_8/NN (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) amnesia_5/NN
D010936_D000647 NONE DCE_2/NNP (r_nsubj) reversed_3/VBD (l_dobj) amnesia_5/NN
D003975_D000647 CID diazepam_16/NN (r_conj) mg/kg_11/CD (r_appos) scopolamine_8/NN (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) amnesia_5/NN
D010936_D003072 NONE DCE_2/NNP (r_nsubj) prove_4/VB (l_xcomp) be_6/VB (l_attr) remedy_9/NN (l_prep) for_10/IN (l_pobj) management_12/NN (l_prep) of_13/IN (l_pobj) dysfunctions_15/NNS
D002784_D003072 NONE cholesterol_30/NN (r_nsubj) lowering_31/VBG (r_conj) improving_27/VBG (r_pcomp) as_24/IN (r_prep) effects_22/NNS (r_pobj) of_18/IN (r_prep) account_17/NN (r_pobj) on_16/IN (r_prep) management_12/NN (l_prep) of_13/IN (l_pobj) dysfunctions_15/NNS
14698717
D010672_D011605 NONE phenytoin_6/NN (r_pobj) with_5/IN (r_prep) treatment_4/NN (r_pobj) due_2/IN (r_prep) psychosis_1/NN
D010672_D011605 NONE phenytoin_10/NN (r_compound) treatment_11/NN (r_pobj) following_9/VBG (r_prep) developed_7/VBD (l_dobj) psychosis_8/NN
D010672_D011605 NONE phenytoin_10/NN (r_amod) treatment_11/NN (r_pobj) following_9/VBG (r_prep) occur_8/VBP (r_relcl) symptoms_6/NNS
D010672_D014277 NONE phenytoin_10/NN (r_compound) treatment_11/NN (l_prep) for_12/IN (l_pobj) neuralgia_14/NNP
D010672_D004827 NONE phenytoin_10/NN (r_amod) treatment_11/NN (l_prep) in_12/IN (l_pobj) patients_15/NNS (l_amod) epileptic_14/JJ
D010672_D012640 NONE phenytoin_10/NN (r_amod) treatment_11/NN (r_pobj) following_9/VBG (r_prep) occur_8/VBP (r_relcl) symptoms_6/NNS (r_nsubj) be_17/VB (l_attr) result_20/NN (l_amod) unrelated_24/JJ (l_prep) to_25/IN (l_pobj) seizures_26/NNS
1639466
D002118_D009400 NONE calcium_4/NN (r_compound) channel_5/NN (r_compound) nitrendipine_7/NNP (l_prep) on_8/IN (l_pobj) nephrosclerosis_9/NNP
D002118_D006978 NONE calcium_4/NN (r_compound) channel_5/NN (r_compound) nitrendipine_7/NNP (l_prep) on_8/IN (l_pobj) nephrosclerosis_9/NNP (l_prep) in_10/IN (l_pobj) rats_11/NNS (l_prep) with_12/IN (l_pobj) hypertension_14/NN
D002118_D006978 NONE calcium_8/NN (r_compound) channel_9/NN (r_compound) nitrendipine_11/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_35/VBN (l_prep) with_38/IN (l_pobj) kidney_41/NN (l_conj) clip_44/NN (l_dobj) hypertension_46/NN
D009568_D009400 CID nitrendipine_7/NNP (l_prep) on_8/IN (l_pobj) nephrosclerosis_9/NNP
D009568_D006978 NONE nitrendipine_7/NNP (l_prep) on_8/IN (l_pobj) nephrosclerosis_9/NNP (l_prep) in_10/IN (l_pobj) rats_11/NNS (l_prep) with_12/IN (l_pobj) hypertension_14/NN
D009568_D006978 NONE nitrendipine_11/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_35/VBN (l_prep) with_38/IN (l_pobj) kidney_41/NN (l_conj) clip_44/NN (l_dobj) hypertension_46/NN
D002118_D000419 NONE calcium_8/NN (r_compound) channel_9/NN (r_compound) nitrendipine_11/NNP (l_conj) angiotensin_14/FW (l_acl) converting_15/VBG (l_prep) on_19/IN (l_pobj) pressure_21/NN (l_conj) albuminuria_23/NNP
D009568_D000419 CID nitrendipine_11/NNP (l_conj) angiotensin_14/FW (l_acl) converting_15/VBG (l_prep) on_19/IN (l_pobj) pressure_21/NN (l_conj) albuminuria_23/NNP
D009568_D000419 CID nitrendipine_5/NN (r_npadvmod) treated_7/VBN (r_amod) group_8/NN (r_compound) albuminuria_9/NNP
D000809_D000419 NONE angiotensin_14/FW (l_acl) converting_15/VBG (l_prep) on_19/IN (l_pobj) pressure_21/NN (l_conj) albuminuria_23/NNP
D000809_D006978 NONE angiotensin_14/FW (r_conj) nitrendipine_11/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_35/VBN (l_prep) with_38/IN (l_pobj) kidney_41/NN (l_conj) clip_44/NN (l_dobj) hypertension_46/NN
D004656_D000419 NONE enalapril_18/NN (r_dobj) converting_15/VBG (l_prep) on_19/IN (l_pobj) pressure_21/NN (l_conj) albuminuria_23/NNP
D004656_D006978 NONE enalapril_18/NN (r_dobj) converting_15/VBG (r_acl) angiotensin_14/FW (r_conj) nitrendipine_11/NNP (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) studied_35/VBN (l_prep) with_38/IN (l_pobj) kidney_41/NN (l_conj) clip_44/NN (l_dobj) hypertension_46/NN
D004656_D006973 NONE enalapril_33/NN (r_npadvmod) treated_35/VBN (r_amod) 8)_39/CD (r_appos) controls_27/NNS (r_appos) groups_23/NNS (r_pobj) to_21/IN (r_prep) assigned_20/VBN (l_nsubjpass) rats_10/NNS (l_amod) hypertensive_9/JJ
D004656_D006973 NONE enalapril_33/NN (r_npadvmod) treated_35/VBN (r_amod) 8)_39/CD (r_appos) controls_27/NNS (l_amod) hypertensive_26/JJ
D004656_D006973 NONE enalapril_25/RB (r_npadvmod) treated_27/VBN (r_amod) group_28/NN (r_pobj) in_23/IN (r_prep) lower_22/JJR (l_prep) compared_37/VBN (l_prep) with_38/IN (l_pobj) controls_41/NNS (l_amod) hypertensive_40/JJ
D009568_D006973 NONE nitrendipine_42/NN (r_npadvmod) treated_44/VBN (r_conj) 8)_39/CD (r_appos) controls_27/NNS (r_appos) groups_23/NNS (r_pobj) to_21/IN (r_prep) assigned_20/VBN (l_nsubjpass) rats_10/NNS (l_amod) hypertensive_9/JJ
D009568_D006973 NONE nitrendipine_42/NN (r_npadvmod) treated_44/VBN (r_conj) 8)_39/CD (r_appos) controls_27/NNS (l_amod) hypertensive_26/JJ
D009568_D006973 NONE nitrendipine_5/NN (r_npadvmod) treated_7/VBN (r_amod) group_8/NN (r_compound) albuminuria_9/NNP (r_nsubj) increased_10/VBD (l_prep) compared_20/VBN (l_prep) with_21/IN (l_pobj) hr_26/NN (l_prep) in_27/IN (l_pobj) controls_30/NNS (l_amod) hypertensive_29/JJ
D009568_D006973 NONE nitrendipine_9/NN (r_npadvmod) treated_11/VBN (r_amod) group_12/NN (r_pobj) in_7/IN (r_prep) increased_6/VBN (l_prep) compared_13/VBN (l_prep) with_14/IN (l_pobj) controls_17/NNS (l_amod) hypertensive_16/JJ
D009568_D006973 NONE nitrendipine_9/NN (r_npadvmod) treated_11/VBN (r_amod) group_12/NN (r_pobj) in_7/IN (r_prep) was_5/VBD (l_conj) lower_22/JJR (l_prep) compared_37/VBN (l_prep) with_38/IN (l_pobj) controls_41/NNS (l_amod) hypertensive_40/JJ
D004656_D005921 NONE enalapril_14/NNP (r_compound) treatment_15/NN (r_pobj) after_13/IN (r_prep) change_12/VB (l_nsubj) excretion_7/NN (l_conj) glomerulosclerosis_9/NNP
D009568_D005921 NONE nitrendipine_9/NN (r_npadvmod) treated_11/VBN (r_amod) group_12/NN (r_pobj) in_7/IN (r_prep) increased_6/VBN (l_nsubjpass) index_3/NN (l_compound) glomerulosclerosis_2/NNP
17242861
D010862_D012640 NONE pilocarpine_4/NN (r_npadvmod) induced_6/VBN (r_amod) seizures_7/NNS
D010862_D012640 NONE pilocarpine_4/NN (r_npadvmod) induced_6/VBN (r_amod) seizures_7/NNS (r_pobj) to_3/IN (r_prep) susceptibility_2/NN (r_pobj) for_1/IN (r_prep) QTLs_0/NNP (r_nsubjpass) reported_19/VBN (l_conj) used_27/VBN (l_xcomp) localize_29/VB (l_dobj) genes_32/NNS (l_compound) susceptibility_31/NN (l_compound) seizure_30/NN
D010862_D012640 NONE pilocarpine_16/NN (r_npadvmod) induced_18/VBN (r_amod) seizures_19/NNS
D010862_D012640 NONE pilocarpine_23/NN (r_npadvmod) induced_25/VBN (r_amod) seizures_26/NNS
D010862_D004833 CID pilocarpine_4/NN (r_npadvmod) induced_6/VBN (r_amod) seizures_7/NNS (r_pobj) to_3/IN (r_prep) susceptibility_2/NN (r_pobj) for_1/IN (r_prep) QTLs_0/NNP (l_appos) model_10/NN (l_prep) of_11/IN (l_pobj) epilepsy_14/NN
3750012
D010396_D009157 CID penicillamine_4/NNP (r_nmod) therapy_7/NN (r_pobj) by_3/IN (r_agent) caused_2/VBN (l_nsubj) gravis_1/FW
D010396_D009157 CID penicillamine_16/NNP (r_nmod) therapy_19/NN (r_pobj) after_15/IN (r_prep) had_7/VBD (l_dobj) gravis_14/NN
D010396_D001172 NONE penicillamine_4/NNP (r_nmod) therapy_7/NN (l_prep) for_8/IN (l_pobj) arthritis_10/NN
D010396_D001172 NONE penicillamine_16/NNP (r_nmod) therapy_19/NN (l_prep) for_20/IN (l_pobj) arthritis_22/NN
D002738_D009157 CID chloroquine_6/NN (r_conj) penicillamine_4/NNP (r_nmod) therapy_7/NN (r_pobj) by_3/IN (r_agent) caused_2/VBN (l_nsubj) gravis_1/FW
D002738_D009157 CID chloroquine_18/NN (r_conj) penicillamine_16/NNP (r_nmod) therapy_19/NN (r_pobj) after_15/IN (r_prep) had_7/VBD (l_dobj) gravis_14/NN
D002738_D001172 NONE chloroquine_6/NN (r_conj) penicillamine_4/NNP (r_nmod) therapy_7/NN (l_prep) for_8/IN (l_pobj) arthritis_10/NN
D002738_D001172 NONE chloroquine_18/NN (r_conj) penicillamine_16/NNP (r_nmod) therapy_19/NN (l_prep) for_20/IN (l_pobj) arthritis_22/NN
17919553
C106791_D056486 CID telithromycin_6/NNS (r_pobj) to_5/IN (r_prep) exposure_4/NN (r_pobj) after_3/IN (r_prep) attack_2/NN (l_compound) hepatitis_1/NN
C106791_D056486 CID telithromycin_19/NN (r_compound) usage_20/NN (r_pobj) after_18/IN (r_prep) occurred_17/VBD (l_ccomp) suffered_3/VBN (l_dobj) episode_6/NN (l_prep) of_7/IN (l_pobj) hepatitis_10/NN
C106791_D056486 CID telithromycin_15/NNP (r_nsubj) was_16/VBD (l_attr) cause_19/NN (l_prep) of_20/IN (l_pobj) hepatitis_22/NN
C106791_D056486 CID telithromycin_15/NNP (r_nsubj) was_16/VBD (l_conj) suggested_30/VBD (l_dobj) hepatitis_35/NN
C106791_D056486 CID telithromycin_21/NNS (r_dobj) prescribed_20/VBD (r_relcl) physician_18/NN (r_pobj) to_15/IN (r_prep) communicated_14/VBN (r_advcl) avoided_7/VBN (l_nsubjpass) Recurrence_0/NN (l_prep) of_1/IN (l_pobj) attack_3/NN (l_compound) hepatitis_2/NN
C106791_D056486 CID telithromycin_14/NNP (r_pobj) of_13/IN (r_prep) administration_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) hepatitis_7/NN
C106791_D012141 NONE telithromycin_4/NNS (r_dobj) prescribed_3/VBN (l_advcl) treat_11/VB (l_dobj) infection_16/NN
C106791_D064420 NONE telithromycin_15/NNP (r_nsubj) was_16/VBD (l_prep) Based_0/VBN (l_prep) on_1/IN (l_pobj) score_3/NN (l_prep) on_6/IN (l_pobj) scale_13/NN (l_compound) probability_12/NN (l_compound) reaction_11/NN
2071257
D005997_D000647 NONE phosphorylcholine_8/NN (l_prep) on_9/IN (l_pobj) amnesia_10/NN
D012601_D000647 NONE scopolamine_13/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) Effect_0/NN (l_prep) of_1/IN (l_pobj) phosphorylcholine_8/NN (l_prep) on_9/IN (l_pobj) amnesia_10/NN
D005997_D008569 NONE glycerylphosphorylcholine_15/NNP (r_pobj) of_10/IN (r_prep) effects_9/NNS (l_prep) on_23/IN (l_pobj) impairment_25/NN
D005997_D008569 NONE GFC_21/NNP (r_appos) glycerylphosphorylcholine_15/NNP (r_pobj) of_10/IN (r_prep) effects_9/NNS (l_prep) on_23/IN (l_pobj) impairment_25/NN
D012601_D008569 CID scopolamine_28/NN (r_pobj) by_27/IN (r_agent) induced_26/VBN (r_acl) impairment_25/NN
D012601_D008569 CID scopolamine_20/NN (r_pobj) by_19/IN (r_agent) induced_18/VBN (r_acl) attention_15/NN (l_conj) memory_17/NN
1130930
D002512_D007674 NONE cephalothin_3/NN (r_compound) gentamicin_5/NN (r_compound) regimen_6/NN (r_pobj) of_1/IN (r_prep) Nephrotoxicity_0/NNP
D005839_D007674 NONE gentamicin_5/NN (r_compound) regimen_6/NN (r_pobj) of_1/IN (r_prep) Nephrotoxicity_0/NNP
D002512_D007683 CID sodium_23/NN (r_pobj) of_21/IN (r_prep) combination_20/NN (r_dobj) receiving_18/VBG (r_advcl) developed_2/VBD (l_dobj) necrosis_5/NN
D002512_D009846 NONE sodium_23/NN (r_pobj) of_21/IN (r_prep) combination_20/NN (r_dobj) receiving_18/VBG (r_advcl) developed_2/VBD (l_advcl) characterized_7/VBN (l_agent) by_9/IN (l_pobj) failure_13/NN
D002512_D051437 NONE sodium_23/NN (r_pobj) of_21/IN (r_prep) combination_20/NN (r_dobj) receiving_18/VBG (r_advcl) developed_2/VBD (l_advcl) characterized_7/VBN (l_agent) by_9/IN (l_pobj) failure_13/NN
D005839_D007683 CID sulfate_26/NN (r_compound) therapy_27/NN (r_conj) sodium_23/NN (r_pobj) of_21/IN (r_prep) combination_20/NN (r_dobj) receiving_18/VBG (r_advcl) developed_2/VBD (l_dobj) necrosis_5/NN
D005839_D009846 NONE sulfate_26/NN (r_compound) therapy_27/NN (r_conj) sodium_23/NN (r_pobj) of_21/IN (r_prep) combination_20/NN (r_dobj) receiving_18/VBG (r_advcl) developed_2/VBD (l_advcl) characterized_7/VBN (l_agent) by_9/IN (l_pobj) failure_13/NN
D005839_D051437 NONE sulfate_26/NN (r_compound) therapy_27/NN (r_conj) sodium_23/NN (r_pobj) of_21/IN (r_prep) combination_20/NN (r_dobj) receiving_18/VBG (r_advcl) developed_2/VBD (l_advcl) characterized_7/VBN (l_agent) by_9/IN (l_pobj) failure_13/NN
567256
D004054_D006394 CID diethylstilbestrol_6/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) Angiosarcoma_0/NNP (l_prep) of_1/IN (l_pobj) liver_3/NN
D004054_D006394 CID diethylstilbestrol_25/NN (r_pobj) with_24/IN (r_prep) liver_23/NN (r_pobj) of_21/IN (r_prep) adenocarcinoma_20/NN (r_pobj) for_15/IN (r_prep) treated_14/VBN (r_relcl) man_10/NN (r_pobj) in_5/IN (r_prep) occurred_4/VBD (l_nsubj) Angiosarcoma_0/NNP (l_prep) of_1/IN (l_pobj) liver_3/NN
D004054_D008113 CID diethylstilbestrol_6/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) Angiosarcoma_0/NNP (l_prep) of_1/IN (l_pobj) liver_3/NN
D004054_D008113 CID diethylstilbestrol_25/NN (r_pobj) with_24/IN (r_prep) liver_23/NN (r_pobj) of_21/IN (r_prep) adenocarcinoma_20/NN (r_pobj) for_15/IN (r_prep) treated_14/VBN (r_relcl) man_10/NN (r_pobj) in_5/IN (r_prep) occurred_4/VBD (l_nsubj) Angiosarcoma_0/NNP (l_prep) of_1/IN (l_pobj) liver_3/NN
D004054_D008113 NONE diethylstilbestrol_25/NN (r_pobj) with_24/IN (r_prep) liver_23/NN
D004054_D000230 NONE diethylstilbestrol_25/NN (r_pobj) with_24/IN (r_prep) liver_23/NN
18768591
D004317_D009404 CID doxorubicin_8/NN (r_npadvmod) induced_10/VBN (r_amod) syndrome_12/NN
D004317_D007674 NONE Doxorubicin_0/NNS (r_npadvmod) induced_2/VBN (r_amod) nephropathy_3/NN
D004317_D016055 NONE Doxorubicin_0/NNS (r_npadvmod) induced_2/VBN (r_amod) nephropathy_3/NN (r_nsubj) leads_4/VBZ (l_prep) to_5/IN (l_pobj) channel_8/NN (l_appos) retention_12/NN
D004317_D005355 NONE Doxorubicin_0/NNS (r_npadvmod) induced_2/VBN (r_amod) nephropathy_3/NN (r_nsubj) leads_4/VBZ (l_prep) to_5/IN (l_pobj) channel_8/NN (l_appos) retention_12/NN (l_conj) fibrosis_15/NN
D012964_D007674 NONE sodium_7/NN (r_compound) channel_8/NN (r_pobj) to_5/IN (r_prep) leads_4/VBZ (l_nsubj) nephropathy_3/NN
D012964_D016055 NONE sodium_7/NN (r_compound) channel_8/NN (l_appos) retention_12/NN
D012964_D005355 NONE sodium_7/NN (r_compound) channel_8/NN (l_appos) retention_12/NN (l_conj) fibrosis_15/NN
D000450_D005355 NONE aldosterone_1/NN (r_npadvmod) sensitive_3/JJ (r_amod) serum-_4/NN (r_nmod) SGK1_10/NNP (r_nsubjpass) shown_13/VBN (l_xcomp) participate_15/VB (l_conj) mediate_23/VB (l_dobj) fibrosis_25/NN
D004317_D011507 CID Doxorubicin_0/NNS (r_compound) treatment_1/NN (r_nsubj) resulted_2/VBD (l_prep) in_3/IN (l_pobj) proteinuria_5/NN
D000450_D009404 NONE aldosterone_1/NN (r_compound) levels_2/NNS (r_nsubj) increased_3/VBD (l_prep) in_4/IN (l_pobj) mice_6/NNS (l_amod) nephrotic_5/JJ
D014508_D009404 NONE urea_8/NN (r_compound) concentrations_9/NNS (r_nsubj) increased_10/VBD (l_prep) During_0/IN (l_pobj) course_2/NN (l_prep) of_3/IN (l_pobj) syndrome_5/NN
16904497
D013256_D011128 NONE steroid_5/NN (r_compound) injection_6/NN (r_pobj) after_3/IN (r_prep) syndrome_2/NN
D013256_D011843 NONE steroid_11/NN (r_compound) injections_12/NNS (r_appos) therapy_8/NN (r_attr) are_6/VBP (l_nsubj) methods_2/NNS (l_prep) of_3/IN (l_pobj) radiculopathy_5/NNP
D014221_D011128 NONE triamcinolone_16/NN (r_pobj) of_15/IN (r_prep) injection_14/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) syndrome_9/NN
D002045_D011128 CID bupivacaine_18/NN (r_conj) triamcinolone_16/NN (r_pobj) of_15/IN (r_prep) injection_14/NN (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) syndrome_9/NN
D013256_D017116 NONE steroid_16/NN (r_compound) injection_17/NN (r_pobj) for_14/IN (r_prep) scheduled_13/VBN (l_nsubjpass) woman_4/NN (l_prep) with_5/IN (l_pobj) pain_11/NN
D013256_D010146 NONE steroid_16/NN (r_compound) injection_17/NN (r_pobj) for_14/IN (r_prep) scheduled_13/VBN (l_nsubjpass) woman_4/NN (l_prep) with_5/IN (l_pobj) pain_11/NN
D013256_D009422 NONE steroid_10/NN (r_compound) injections_11/NNS (r_nsubj) is_12/VBZ (l_nsubj) examination_1/NN (l_conj) vigilance_4/NN (l_prep) for_5/IN (l_pobj) deterioration_7/NN
8319760
D019808_D009401 NONE 753_1/CD (r_nummod) Dup_0/NNP (r_nsubj) prevents_2/VBZ (l_dobj) development_4/NN (l_prep) of_5/IN (l_pobj) puromycin_6/NNP (l_appos) nephrosis_10/NN
D011692_D009401 NONE aminonucleoside_7/RB (r_advmod) induced_9/VBN (r_amod) nephrosis_10/NN
D011692_D009401 NONE aminonucleoside_17/RB (r_advmod) induced_19/VBN (r_amod) nephrosis_20/NN
D001806_D009404 NONE urea_17/NN (r_pobj) in_14/IN (r_prep) increase_13/VB (r_conj) hypercholesterolemia_11/NN (r_conj) hypoalbuminemia_9/NNP (r_conj) proteinuria_7/NN (r_pobj) as_6/IN (r_prep) syndromes_4/NNS
D001806_D011507 NONE urea_17/NN (r_pobj) in_14/IN (r_prep) increase_13/VB (r_conj) hypercholesterolemia_11/NN (r_conj) hypoalbuminemia_9/NNP (r_conj) proteinuria_7/NN
D001806_D034141 NONE urea_17/NN (r_pobj) in_14/IN (r_prep) increase_13/VB (r_conj) hypercholesterolemia_11/NN (r_conj) hypoalbuminemia_9/NNP
D001806_D006937 NONE urea_17/NN (r_pobj) in_14/IN (r_prep) increase_13/VB (r_conj) hypercholesterolemia_11/NN
D011692_D009404 CID aminonucleoside_26/NNP (r_advmod) induced_19/VBN (r_acl) syndromes_4/NNS
D011692_D011507 CID aminonucleoside_26/NNP (r_advmod) induced_19/VBN (r_acl) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN
D011692_D034141 CID aminonucleoside_26/NNP (r_advmod) induced_19/VBN (r_acl) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN (l_conj) hypoalbuminemia_9/NNP
D011692_D006937 CID aminonucleoside_26/NNP (r_advmod) induced_19/VBN (r_acl) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN (l_conj) hypoalbuminemia_9/NNP (l_conj) hypercholesterolemia_11/NN
D019808_D009404 NONE 753_35/CD (r_nummod) Dup_34/NNP (r_nmod) losartan_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) by_30/IN (r_agent) inhibited_29/VBN (l_nsubjpass) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS
D019808_D009404 NONE losartan_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) by_30/IN (r_agent) inhibited_29/VBN (l_nsubjpass) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS
D019808_D011507 NONE 753_35/CD (r_nummod) Dup_34/NNP (r_nmod) losartan_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) by_30/IN (r_agent) inhibited_29/VBN (l_nsubjpass) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN
D019808_D011507 NONE losartan_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) by_30/IN (r_agent) inhibited_29/VBN (l_nsubjpass) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN
D019808_D034141 NONE 753_35/CD (r_nummod) Dup_34/NNP (r_nmod) losartan_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) by_30/IN (r_agent) inhibited_29/VBN (l_nsubjpass) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN (l_conj) hypoalbuminemia_9/NNP
D019808_D034141 NONE losartan_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) by_30/IN (r_agent) inhibited_29/VBN (l_nsubjpass) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN (l_conj) hypoalbuminemia_9/NNP
D019808_D006937 NONE 753_35/CD (r_nummod) Dup_34/NNP (r_nmod) losartan_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) by_30/IN (r_agent) inhibited_29/VBN (l_nsubjpass) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN (l_conj) hypoalbuminemia_9/NNP (l_conj) hypercholesterolemia_11/NN
D019808_D006937 NONE losartan_37/NN (r_pobj) of_33/IN (r_prep) administration_32/NN (r_pobj) by_30/IN (r_agent) inhibited_29/VBN (l_nsubjpass) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN (l_conj) hypoalbuminemia_9/NNP (l_conj) hypercholesterolemia_11/NN
D000804_D009404 NONE II_43/NNP (r_compound) antagonist_45/NN (r_appos) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS
D000804_D011507 NONE II_43/NNP (r_compound) antagonist_45/NN (r_appos) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN
D000804_D034141 NONE II_43/NNP (r_compound) antagonist_45/NN (r_appos) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN (l_conj) hypoalbuminemia_9/NNP
D000804_D006937 NONE II_43/NNP (r_compound) antagonist_45/NN (r_appos) appearance_1/NN (l_prep) of_2/IN (l_pobj) syndromes_4/NNS (l_prep) as_6/IN (l_pobj) proteinuria_7/NN (l_conj) hypoalbuminemia_9/NNP (l_conj) hypercholesterolemia_11/NN
D000809_D009401 NONE angiotensin_10/NN (r_compound) system_11/NN (r_pobj) of_6/IN (r_prep) involvement_5/NN (l_prep) in_12/IN (l_pobj) development_14/NN (l_prep) of_15/IN (l_pobj) puromycin_16/NNP (l_appos) nephrosis_20/NN
7248170
D010634_D006529 CID Phenobarbitone_0/NN (r_npadvmod) induced_2/VBN (r_amod) enlargement_3/NN (l_prep) of_4/IN (l_pobj) liver_6/NN
D010634_D006529 CID phenobarbitone_60/NN (r_npadvmod) primed_62/VBN (r_amod) rat_63/NN (r_pobj) in_58/IN (r_prep) given_56/VBN (r_advcl) splenomegaly_35/JJ (r_nsubjpass) increased_65/VBN (l_prep) by_72/IN (l_pcomp) giving_73/VBG (l_prep) at_83/IN (l_pobj) peak_85/NN (l_prep) of_86/IN (l_pobj) enlargement_91/NN (l_prep) of_92/IN (l_pobj) liver_94/NN
D010634_D006529 CID phenobarbitone_88/NN (r_npadvmod) induced_90/VBN (r_amod) enlargement_91/NN (l_prep) of_92/IN (l_pobj) liver_94/NN
D010634_D005355 NONE Phenobarbitone_0/NN (r_npadvmod) induced_2/VBN (r_amod) enlargement_3/NN (l_appos) relationship_12/NN (l_acl) carbon_14/NN (l_dobj) cirrhosis_18/NN
D002251_D006529 NONE tetrachloride_15/NN (r_npadvmod) induced_17/VBN (r_amod) cirrhosis_18/NN (r_dobj) carbon_14/NN (r_acl) relationship_12/NN (r_appos) enlargement_3/NN (l_prep) of_4/IN (l_pobj) liver_6/NN
D002251_D006529 NONE tetrachloride_55/NN (r_pobj) of_53/IN (r_prep) doses_52/NNS (r_nsubj) given_56/VBN (r_advcl) splenomegaly_35/JJ (r_nsubjpass) increased_65/VBN (l_prep) by_72/IN (l_pcomp) giving_73/VBG (l_prep) at_83/IN (l_pobj) peak_85/NN (l_prep) of_86/IN (l_pobj) enlargement_91/NN (l_prep) of_92/IN (l_pobj) liver_94/NN
D002251_D006529 NONE tetrachloride_82/NN (r_dobj) giving_73/VBG (l_prep) at_83/IN (l_pobj) peak_85/NN (l_prep) of_86/IN (l_pobj) enlargement_91/NN (l_prep) of_92/IN (l_pobj) liver_94/NN
D002251_D005355 NONE tetrachloride_15/NN (r_npadvmod) induced_17/VBN (r_amod) cirrhosis_18/NN
D002251_D008103 CID tetrachloride_55/NN (r_pobj) of_53/IN (r_prep) doses_52/NNS (r_nsubj) given_56/VBN (r_advcl) splenomegaly_35/JJ (l_nsubj) yield_1/NN (l_prep) of_2/IN (l_pobj) cirrhosis_4/NN (l_prep) of_5/IN (l_pobj) liver_7/NN
D002251_D008103 CID tetrachloride_82/NN (r_dobj) giving_73/VBG (r_pcomp) by_72/IN (r_prep) increased_65/VBN (l_nsubjpass) splenomegaly_35/JJ (l_nsubj) yield_1/NN (l_prep) of_2/IN (l_pobj) cirrhosis_4/NN (l_prep) of_5/IN (l_pobj) liver_7/NN
D002251_D001201 NONE tetrachloride_55/NN (r_pobj) of_53/IN (r_prep) doses_52/NNS (r_nsubj) given_56/VBN (r_advcl) splenomegaly_35/JJ (l_nsubj) yield_1/NN (l_prep) of_2/IN (l_pobj) cirrhosis_4/NN (l_prep) of_5/IN (l_pobj) liver_7/NN (l_acl) defined_9/VBN (l_prep) as_10/IN (l_pobj) liver_15/NN (l_prep) with_16/IN (l_pobj) histology_18/NNP (l_appos) ascites_20/NNS
D002251_D001201 NONE tetrachloride_82/NN (r_dobj) giving_73/VBG (r_pcomp) by_72/IN (r_prep) increased_65/VBN (l_nsubjpass) splenomegaly_35/JJ (l_nsubj) yield_1/NN (l_prep) of_2/IN (l_pobj) cirrhosis_4/NN (l_prep) of_5/IN (l_pobj) liver_7/NN (l_acl) defined_9/VBN (l_prep) as_10/IN (l_pobj) liver_15/NN (l_prep) with_16/IN (l_pobj) histology_18/NNP (l_appos) ascites_20/NNS
D002251_D013163 NONE tetrachloride_55/NN (r_pobj) of_53/IN (r_prep) doses_52/NNS (r_nsubj) given_56/VBN (r_advcl) splenomegaly_35/JJ
D002251_D013163 NONE tetrachloride_82/NN (r_dobj) giving_73/VBG (r_pcomp) by_72/IN (r_prep) increased_65/VBN (l_nsubjpass) splenomegaly_35/JJ
D002251_D001284 NONE tetrachloride_55/NN (r_pobj) of_53/IN (r_prep) doses_52/NNS (r_nsubj) given_56/VBN (r_advcl) splenomegaly_35/JJ (l_dobj) atrophy_44/NN
D002251_D001284 NONE tetrachloride_82/NN (r_dobj) giving_73/VBG (r_pcomp) by_72/IN (r_prep) increased_65/VBN (l_nsubjpass) splenomegaly_35/JJ (l_dobj) atrophy_44/NN
D010634_D008103 CID phenobarbitone_60/NN (r_npadvmod) primed_62/VBN (r_amod) rat_63/NN (r_pobj) in_58/IN (r_prep) given_56/VBN (r_advcl) splenomegaly_35/JJ (l_nsubj) yield_1/NN (l_prep) of_2/IN (l_pobj) cirrhosis_4/NN (l_prep) of_5/IN (l_pobj) liver_7/NN
D010634_D008103 CID phenobarbitone_88/NN (r_npadvmod) induced_90/VBN (r_amod) enlargement_91/NN (r_pobj) of_86/IN (r_prep) peak_85/NN (r_pobj) at_83/IN (r_prep) giving_73/VBG (r_pcomp) by_72/IN (r_prep) increased_65/VBN (l_nsubjpass) splenomegaly_35/JJ (l_nsubj) yield_1/NN (l_prep) of_2/IN (l_pobj) cirrhosis_4/NN (l_prep) of_5/IN (l_pobj) liver_7/NN
D010634_D001201 NONE phenobarbitone_60/NN (r_npadvmod) primed_62/VBN (r_amod) rat_63/NN (r_pobj) in_58/IN (r_prep) given_56/VBN (r_advcl) splenomegaly_35/JJ (l_nsubj) yield_1/NN (l_prep) of_2/IN (l_pobj) cirrhosis_4/NN (l_prep) of_5/IN (l_pobj) liver_7/NN (l_acl) defined_9/VBN (l_prep) as_10/IN (l_pobj) liver_15/NN (l_prep) with_16/IN (l_pobj) histology_18/NNP (l_appos) ascites_20/NNS
D010634_D001201 NONE phenobarbitone_88/NN (r_npadvmod) induced_90/VBN (r_amod) enlargement_91/NN (r_pobj) of_86/IN (r_prep) peak_85/NN (r_pobj) at_83/IN (r_prep) giving_73/VBG (r_pcomp) by_72/IN (r_prep) increased_65/VBN (l_nsubjpass) splenomegaly_35/JJ (l_nsubj) yield_1/NN (l_prep) of_2/IN (l_pobj) cirrhosis_4/NN (l_prep) of_5/IN (l_pobj) liver_7/NN (l_acl) defined_9/VBN (l_prep) as_10/IN (l_pobj) liver_15/NN (l_prep) with_16/IN (l_pobj) histology_18/NNP (l_appos) ascites_20/NNS
D010634_D013163 NONE phenobarbitone_60/NN (r_npadvmod) primed_62/VBN (r_amod) rat_63/NN (r_pobj) in_58/IN (r_prep) given_56/VBN (r_advcl) splenomegaly_35/JJ
D010634_D013163 NONE phenobarbitone_88/NN (r_npadvmod) induced_90/VBN (r_amod) enlargement_91/NN (r_pobj) of_86/IN (r_prep) peak_85/NN (r_pobj) at_83/IN (r_prep) giving_73/VBG (r_pcomp) by_72/IN (r_prep) increased_65/VBN (l_nsubjpass) splenomegaly_35/JJ
D010634_D001284 NONE phenobarbitone_60/NN (r_npadvmod) primed_62/VBN (r_amod) rat_63/NN (r_pobj) in_58/IN (r_prep) given_56/VBN (r_advcl) splenomegaly_35/JJ (l_dobj) atrophy_44/NN
D010634_D001284 NONE phenobarbitone_88/NN (r_npadvmod) induced_90/VBN (r_amod) enlargement_91/NN (r_pobj) of_86/IN (r_prep) peak_85/NN (r_pobj) at_83/IN (r_prep) giving_73/VBG (r_pcomp) by_72/IN (r_prep) increased_65/VBN (l_nsubjpass) splenomegaly_35/JJ (l_dobj) atrophy_44/NN
1749407
D003042_D009203 CID Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) infarction_4/NN
D003042_D009203 CID cocaine_13/NN (r_nsubj) result_15/VB (l_prep) in_16/IN (l_pobj) infarction_19/NN
D003042_D009203 CID cocaine_26/NN (r_npadvmod) induced_28/VBN (r_amod) increase_29/NN (r_pobj) with_25/IN (r_prep) associated_24/VBN (r_acl) demand_23/NN (r_pobj) in_20/IN (r_prep) increase_19/NN (r_pobj) from_17/IN (r_prep) result_16/VB (l_nsubj) infarction_14/NN
D010100_D009203 NONE oxygen_22/NN (r_compound) demand_23/NN (r_pobj) in_20/IN (r_prep) increase_19/NN (r_pobj) from_17/IN (r_prep) result_16/VB (l_nsubj) infarction_14/NN
D003042_D013035 NONE cocaine_16/NN (r_npadvmod) induced_18/VBN (r_amod) vasoconstriction_19/NN (r_pobj) of_15/IN (r_prep) locus_14/NN (r_nsubj) remains_20/VBZ (r_conj) are_8/VBP (l_prep) With_0/IN (l_pobj) regard_1/NN (l_prep) to_2/IN (l_pobj) spasm_3/NN
D003042_D013927 NONE cocaine_11/NN (r_pobj) of_10/IN (r_prep) effect_9/NN (l_amod) thrombotic_8/JJ
17612891
D003024_D009205 CID clozapine_4/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) myocarditis_1/NN
D003024_D009205 CID clozapine_10/NNP (r_pobj) of_9/IN (r_prep) commencement_8/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) case_1/NN (l_prep) of_2/IN (l_pobj) myocarditis_4/NN
D003024_D009205 CID clozapine_16/NN (r_pobj) of_15/IN (r_prep) commencement_14/NN (r_pobj) after_13/IN (r_prep) developed_7/VBD (l_dobj) onset_10/NN (l_prep) of_11/IN (l_pobj) myocarditis_12/NN
D003024_D009205 CID clozapine_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) complication_5/NN (r_attr) is_1/VBZ (l_nsubj) Myocarditis_0/NN
D003024_D012559 NONE clozapine_16/NN (r_pobj) of_15/IN (r_prep) commencement_14/NN (r_pobj) after_13/IN (r_prep) developed_7/VBD (l_nsubj) male_4/NN (l_prep) with_5/IN (l_pobj) schizophrenia_6/NN
D003024_D011618 NONE clozapine_2/NN (r_nsubj) remains_3/VBZ (l_attr) standard_6/NN (l_prep) in_7/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) psychosis_11/NN
11166519
D003042_D012640 CID cocaine_1/NN (r_npadvmod) induced_3/VBN (r_amod) seizures_4/NNS
D003042_D012640 CID cocaine_22/NN (r_pobj) of_21/IN (r_prep) injection_20/NN (r_pobj) by_17/IN (r_agent) induced_16/VBN (r_acl) seizures_15/NNS
D003042_D012640 CID cocaine_14/NN (r_npadvmod) induced_16/VBN (r_amod) seizures_17/NNS
9862868
D004997_D002780 CID estradiol_9/NNP (r_nmod) treatment_13/NN (r_pobj) by_7/IN (r_prep) used_1/VBD (l_dobj) models_3/NNS (l_prep) of_4/IN (l_pobj) cholestasis_6/NN
D004997_D002780 CID EE_11/NNP (r_appos) estradiol_9/NNP (r_nmod) treatment_13/NN (r_pobj) by_7/IN (r_prep) used_1/VBD (l_dobj) models_3/NNS (l_prep) of_4/IN (l_pobj) cholestasis_6/NN
D004997_D001651 NONE estradiol_9/NNP (r_nmod) treatment_13/NN (l_conj) cholestasis_16/NN
D004997_D001651 NONE EE_11/NNP (r_appos) estradiol_9/NNP (r_nmod) treatment_13/NN (l_conj) cholestasis_16/NN
3997294
D000638_D010996 CID amiodarone_9/NN (r_compound) therapy_10/NN (r_pobj) during_8/IN (r_prep) Pneumonitis_0/VB (l_prep) with_1/IN (l_pobj) effusion_5/NN
D000638_D010490 CID amiodarone_9/NN (r_compound) therapy_10/NN (r_pobj) during_8/IN (r_prep) Pneumonitis_0/VB (l_prep) with_1/IN (l_pobj) effusion_5/NN
D000638_D009422 NONE amiodarone_9/NN (r_compound) therapy_10/NN (r_pobj) during_8/IN (r_prep) Pneumonitis_0/VB (l_prep) with_1/IN (l_pobj) effusion_5/NN (l_conj) neuropathy_7/NN
D000638_D002318 NONE amiodarone_11/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_conj) patient_1/NN (l_prep) with_2/IN (l_pobj) disease_4/NN
D000638_D011014 CID amiodarone_14/NN (r_compound) pneumonitis_15/NN
D000638_D011014 CID amiodarone_20/NN (r_pobj) of_19/IN (r_prep) withdrawal_18/NN (r_conj) need_9/NN (l_prep) for_10/IN (l_pobj) diagnosis_12/NN (l_prep) of_13/IN (l_pobj) pneumonitis_15/NN
D013256_D011014 NONE steroid_26/NN (r_compound) therapy_27/NN (r_conj) prompt_23/VB (r_conj) withdrawal_18/NN (r_conj) need_9/NN (l_prep) for_10/IN (l_pobj) diagnosis_12/NN (l_prep) of_13/IN (l_pobj) pneumonitis_15/NN
20477932
D003042_D008569 CID Cocaine_0/NN (r_nsubj) causes_1/VBZ (l_dobj) impairments_5/NNS
D003042_D007859 CID Cocaine_0/NN (r_nsubj) causes_1/VBZ (l_dobj) impairments_5/NNS
D003042_D064420 NONE cocaine_6/NN (r_compound) toxicity_7/NN
D003042_D064420 NONE cocaine_24/NN (r_conj) brain_22/NN (r_nmod) behaviour_27/NN (r_pobj) in_20/IN (r_prep) status_19/NN (r_pobj) between_17/IN (r_prep) association_16/NN (r_nsubjpass) understood_30/VBN (l_ccomp) suggested_4/VBN (l_prep) for_5/IN (l_pobj) toxicity_7/NN
D009569_D019970 NONE oxide_9/NN (r_compound) synthase_10/NN (r_conj) stress_5/NN (r_appos) activity_2/NN (l_appos) effect_24/NN (l_prep) of_25/IN (l_pobj) topiramate_26/NNP (l_appos) therapy_31/NN (l_prep) for_32/IN (l_pobj) addiction_34/NN
C052342_D019970 NONE topiramate_26/NNP (l_appos) therapy_31/NN (l_prep) for_32/IN (l_pobj) addiction_34/NN
D003042_D019970 NONE cocaine_43/NN (r_compound) administration_44/NN (r_pobj) of_42/IN (r_prep) model_41/NN (r_pobj) in_38/IN (r_prep) evaluated_37/VBN (l_nsubjpass) activity_2/NN (l_appos) effect_24/NN (l_prep) of_25/IN (l_pobj) topiramate_26/NNP (l_appos) therapy_31/NN (l_prep) for_32/IN (l_pobj) addiction_34/NN
2522601
D002220_D004342 CID carbamazepine_2/NN (r_pobj) to_1/IN (r_prep) Hypersensitivity_0/NN
D002220_D004342 CID carbamazepine_8/NN (r_pobj) to_7/IN (r_prep) hypersensitivity_6/NN
D002220_D007955 CID carbamazepine_2/NN (l_acl) presenting_3/VBG (l_prep) with_4/IN (l_pobj) reaction_7/NN
D002220_D007955 CID carbamazepine_8/NN (r_pobj) to_7/IN (r_prep) hypersensitivity_6/NN (r_nsubj) presented_9/VBN (l_prep) with_10/IN (l_pobj) erythroderma_12/NNP (l_appos) reaction_17/NN
D002220_D004802 NONE carbamazepine_2/NN (l_acl) presenting_3/VBG (l_prep) with_4/IN (l_pobj) reaction_7/NN (l_appos) eosinophilia_9/NNP
D002220_D004802 NONE carbamazepine_8/NN (r_pobj) to_7/IN (r_prep) hypersensitivity_6/NN (r_nsubj) presented_9/VBN (l_prep) with_10/IN (l_pobj) erythroderma_12/NNP (l_appos) reaction_17/NN (l_conj) eosinophilia_19/NN
D002220_D003873 CID carbamazepine_2/NN (l_acl) presenting_3/VBG (l_prep) with_4/IN (l_pobj) reaction_7/NN (l_appos) eosinophilia_9/NNP (l_conj) erythroderma_11/NNP
D002220_D003873 CID carbamazepine_8/NN (r_pobj) to_7/IN (r_prep) hypersensitivity_6/NN (r_nsubj) presented_9/VBN (l_prep) with_10/IN (l_pobj) erythroderma_12/NNP
D002220_D051437 CID carbamazepine_2/NN (l_acl) presenting_3/VBG (l_prep) with_4/IN (l_pobj) reaction_7/NN (l_appos) eosinophilia_9/NNP (l_conj) erythroderma_11/NNP (l_conj) failure_15/NN
D002220_D051437 CID carbamazepine_8/NN (r_pobj) to_7/IN (r_prep) hypersensitivity_6/NN (r_nsubj) presented_9/VBN (l_prep) with_10/IN (l_pobj) erythroderma_12/NNP (l_appos) reaction_17/NN (l_conj) eosinophilia_19/NN (l_conj) hyponatremia_21/NN (l_conj) failure_25/NN
D002220_D007010 CID carbamazepine_8/NN (r_pobj) to_7/IN (r_prep) hypersensitivity_6/NN (r_nsubj) presented_9/VBN (l_prep) with_10/IN (l_pobj) erythroderma_12/NNP (l_appos) reaction_17/NN (l_conj) eosinophilia_19/NN (l_conj) hyponatremia_21/NN
2024540
D004656_D006333 NONE enalapril_11/NNP (r_pobj) of_10/IN (r_prep) safety_9/NN (r_appos) Design_0/NN (l_prep) in_14/IN (l_pobj) phase_18/NN (l_prep) of_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) failure_24/NN
D011224_D006333 NONE prazosin_13/NN (r_conj) enalapril_11/NNP (r_pobj) of_10/IN (r_prep) safety_9/NN (r_appos) Design_0/NN (l_prep) in_14/IN (l_pobj) phase_18/NN (l_prep) of_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) failure_24/NN
D000806_D006333 NONE inhibitors_10/NNS (r_appos) enzyme_6/NNS (r_pobj) of_3/IN (r_prep) introduction_2/NN (l_prep) into_11/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) failure_20/NN
D000806_D007022 CID inhibitors_10/NNS (r_appos) enzyme_6/NNS (r_pobj) of_3/IN (r_prep) introduction_2/NN (r_pobj) Since_0/IN (r_prep) reported_38/VBN (l_nsubjpass) cases_22/NNS (l_prep) of_23/IN (l_pobj) hypotension_25/NN
D004656_D007022 NONE enalapril_0/NNP (r_nmod) trial_9/NN (r_nsubjpass) designed_11/VBN (l_ccomp) compared_13/VBD (l_pobj) incidence_15/NN (l_prep) of_18/IN (l_pobj) hypotension_20/NN
D004656_D007022 NONE enalapril_3/NNP (r_dobj) received_2/VBD (r_relcl) Patients_0/NNS (r_nsubj) experienced_4/VBN (l_dobj) hypotension_11/NN
D011224_D007022 CID prazosin_6/NN (r_npadvmod) controlled_8/VBN (r_amod) trial_9/NN (r_nsubjpass) designed_11/VBN (l_ccomp) compared_13/VBD (l_pobj) incidence_15/NN (l_prep) of_18/IN (l_pobj) hypotension_20/NN
D011224_D007022 CID prazosin_21/NN (r_dobj) received_20/VBD (r_relcl) patients_18/NNS (r_pobj) than_16/IN (r_prep) hypotension_11/NN
9195768
D018170_D010292 CID sumatriptan_7/NNP (r_pobj) of_5/IN (r_prep) use_4/NN (r_pobj) following_2/VBG (r_prep) sensations_1/NNS
1992636
D009853_D000743 CID omeprazole_7/NN (r_pobj) of_6/IN (r_prep) use_5/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) anemia_1/NN
D009853_D000743 CID omeprazole_17/NN (l_appos) anemia_20/NN
D009853_D000743 CID omeprazole_4/NN (r_nsubj) caused_5/VBD (r_relcl) mechanism_1/NN (r_nsubj) is_11/VBZ (l_nsubj) anemia_10/NN
D009853_D053609 CID omeprazole_17/NNP (r_pobj) with_16/IN (r_prep) therapy_15/NN (r_dobj) starting_14/VBG (r_pcomp) after_13/IN (r_prep) weakness_3/NN (l_conj) lethargy_5/NN
D009853_D004417 CID omeprazole_17/NNP (r_pobj) with_16/IN (r_prep) therapy_15/NN (r_dobj) starting_14/VBG (r_pcomp) after_13/IN (r_prep) weakness_3/NN (l_conj) lethargy_5/NN (l_conj) shortness_8/NN (l_prep) of_9/IN (l_pobj) breath_10/NN
18754075
D004164_D011507 NONE bisphosphonate_8/NNP (r_nmod) administration_12/NN (r_pobj) after_6/IN (r_prep) proteinuria_1/NN
D004164_D011507 NONE bisphosphonates_11/NNS (r_conj) intravenous_6/JJ (r_nsubj) aggravate_13/VB (l_dobj) proteinuria_14/NN
D004164_D058186 NONE bisphosphonate_8/NNP (r_nmod) administration_12/NN (r_pobj) after_6/IN (r_prep) proteinuria_1/NN (l_conj) failure_5/NN
D004164_D058186 NONE bisphosphonate_18/NNP (r_nmod) administration_23/NN (r_pobj) of_15/IN (r_prep) days_14/NNS (r_pobj) Within_12/IN (r_prep) decreased_6/VBD (l_conj) increased_31/VBD (l_prep) with_37/IN (l_pobj) failure_40/NN
D004164_D058186 NONE bisphosphonates_11/NNS (r_conj) intravenous_6/JJ (r_nsubj) aggravate_13/VB (l_dobj) proteinuria_14/NN (l_conj) failure_18/NN
D004164_D005923 NONE bisphosphonate_8/NNP (r_nmod) administration_12/NN (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) glomerulosclerosis_19/NN
D019386_D011507 CID alendronate_10/NNP (r_nmod) administration_12/NN (r_pobj) after_6/IN (r_prep) proteinuria_1/NN
D019386_D058186 CID alendronate_10/NNP (r_nmod) administration_12/NN (r_pobj) after_6/IN (r_prep) proteinuria_1/NN (l_conj) failure_5/NN
D019386_D058186 CID sodium_21/NN (r_nmod) administration_23/NN (r_pobj) of_15/IN (r_prep) days_14/NNS (r_pobj) Within_12/IN (r_prep) decreased_6/VBD (l_conj) increased_31/VBD (l_prep) with_37/IN (l_pobj) failure_40/NN
D019386_D005923 NONE alendronate_10/NNP (r_nmod) administration_12/NN (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) glomerulosclerosis_19/NN
D013256_D009404 NONE steroid_19/NN (r_compound) therapy_20/NN (r_pobj) to_18/IN (r_prep) responding_16/VBG (l_nsubj) man_5/NN (l_prep) with_6/IN (l_pobj) syndrome_8/NN
D013256_D005923 NONE steroid_19/NN (r_compound) therapy_20/NN (r_pobj) to_18/IN (r_prep) responding_16/VBG (l_nsubj) man_5/NN (l_prep) due_9/IN (l_pobj) glomerulosclerosis_13/NN
12716030
D006493_D002543 NONE heparin_7/NNP (r_nsubj) enhanced_8/VBD (l_prep) In_0/IN (l_pobj) induction_2/NN (l_compound) ICH_1/NNP
D006493_D002543 NONE heparin_7/NNP (r_nsubj) enhanced_8/VBD (l_dobj) animals_19/NNS (l_compound) ICH_18/NNP
D006493_D006406 CID heparin_7/NNP (r_nsubj) enhanced_8/VBD (l_dobj) volume_11/NN (l_compound) hematoma_10/NN
D006493_D006470 NONE heparin_7/NNP (r_nsubj) enhanced_8/VBD (l_dobj) animals_19/NNS (l_conj) 7.6-fold_23/CD (l_amod) bleeding_22/VBG
7988234
D008790_D000799 CID metoprolol_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) following_1/VBG (r_prep) Angioedema_0/NNP
D008790_D000799 CID metoprolol_12/NNP (r_nsubjpass) given_14/VBN (l_advcl) resulting_16/VBG (l_prep) in_17/IN (l_pobj) angioedema_19/NN
D017706_D000799 CID lisinopril_6/NNP (r_compound) therapy_7/NN (r_pobj) to_5/IN (r_prep) secondary_4/JJ (r_amod) angioedema_3/NN
D013256_D000799 NONE steroids_7/NNS (r_pobj) with_5/IN (r_prep) therapy_4/NN (r_pobj) after_3/IN (r_prep) resolved_2/VBD (l_nsubj) angioedema_1/NN
D004155_D000799 NONE diphenhydramine_9/NN (r_compound) hydrochloride_10/NN (r_conj) steroids_7/NNS (r_pobj) with_5/IN (r_prep) therapy_4/NN (r_pobj) after_3/IN (r_prep) resolved_2/VBD (l_nsubj) angioedema_1/NN
8372922
9293063
D003613_D001650 CID danazol_12/NNP (r_pobj) with_11/IN (r_prep) treatment_10/NN (r_pobj) with_6/IN (r_prep) association_5/NN (r_pobj) in_4/IN (r_prep) occurring_3/VBG (l_nsubj) hamartoma_2/NN
D003613_D001650 CID danazol_20/NN (r_compound) treatment_21/NN (r_pobj) on_16/IN (r_prep) been_15/VBN (r_relcl) patient_12/NN (r_pobj) in_10/IN (r_prep) developed_9/VBD (r_relcl) hamartoma_7/NN
D003613_D006222 CID danazol_12/NNP (r_pobj) with_11/IN (r_prep) treatment_10/NN (r_pobj) with_6/IN (r_prep) association_5/NN (r_pobj) in_4/IN (r_prep) occurring_3/VBG (l_nsubj) hamartoma_2/NN
D003613_D006222 CID danazol_20/NN (r_compound) treatment_21/NN (r_pobj) on_16/IN (r_prep) been_15/VBN (r_relcl) patient_12/NN (r_pobj) in_10/IN (r_prep) developed_9/VBD (r_relcl) hamartoma_7/NN
19356053
D020123_D011507 CID sirolimus_7/NNP (r_pobj) of_6/IN (r_prep) administration_5/NN (r_pobj) following_3/VBG (r_prep) proteinuria_2/NN
D020123_D011507 CID sirolimus_16/NN (r_pobj) of_15/IN (r_prep) use_14/NN (r_pobj) with_12/IN (r_prep) linked_11/VBN (r_acl) proteinuria_10/NN
D020123_D011507 CID sirolimus_11/NN (r_compound) use_12/NN (r_pobj) with_10/IN (r_prep) associated_9/VBN (r_acl) proteinuria_8/NN
D020123_D011507 CID sirolimus_12/NN (r_compound) therapy_13/NN (l_conj) proteinuria_15/NN
D020123_D011507 CID sirolimus_12/NN (r_compound) therapy_13/NN (r_pobj) of_11/IN (r_prep) commencement_10/NN (r_pobj) between_8/IN (r_prep) association_7/NN (r_nsubj) implicated_16/VBN (l_prep) as_18/IN (l_pobj) etiology_22/NN (l_prep) of_23/IN (l_pobj) proteinuria_25/NN
D020123_D011507 CID sirolimus_17/NN (r_dobj) implicated_16/VBN (l_nsubj) association_7/NN (l_prep) between_8/IN (l_pobj) commencement_10/NN (l_prep) of_11/IN (l_pobj) therapy_13/NN (l_conj) proteinuria_15/NN
D020123_D011507 CID sirolimus_17/NN (r_dobj) implicated_16/VBN (l_prep) as_18/IN (l_pobj) etiology_22/NN (l_prep) of_23/IN (l_pobj) proteinuria_25/NN
D020123_D011507 CID sirolimus_16/NNP (r_pobj) of_15/IN (r_prep) initiation_14/NN (l_conj) development_19/NN (l_prep) of_20/IN (l_pobj) proteinuria_24/NN
D020123_D011507 CID sirolimus_5/NN (r_compound) therapy_6/NN (r_pobj) with_4/IN (r_prep) correlated_1/VBD (l_nsubj) Proteinuria_0/NNP
D020123_D011507 CID sirolimus_6/NNP (r_pobj) of_5/IN (r_prep) discontinuation_4/NN (r_nsubj) resulted_7/VBD (l_conj) resolution_14/NN (l_prep) of_16/IN (l_pobj) proteinuria_17/NN
D020123_D011507 CID Sirolimus_0/NN (r_nsubj) induces_1/VBZ (l_conj) aggravates_3/VBZ (l_dobj) proteinuria_7/NN
D020123_D011507 CID sirolimus_10/NNP (r_nsubjpass) withdrawn_12/VBN (r_advcl) resolve_7/VB (r_conj) improve_2/VB (l_nsubj) Proteinuria_0/NNP
D020123_D007674 NONE Sirolimus_0/NNP (r_nsubj) is_1/VBZ (l_conj) have_13/VB (l_dobj) nephrotoxicity_15/NN
D003404_D011507 NONE creatinine_22/NN (r_compound) ratios_23/NNS (r_appos) magnitude_5/NN (l_prep) of_6/IN (l_pobj) proteinuria_7/NN
D003404_D011507 NONE creatinine_22/NN (r_compound) ratios_23/NNS (l_appos) estimate_26/NN (l_prep) of_27/IN (l_pobj) grams_28/NNS (l_prep) of_29/IN (l_pobj) proteinuria_30/NN
D020123_D009404 NONE sirolimus_16/NNP (r_pobj) of_15/IN (r_prep) initiation_14/NN (l_conj) development_19/NN (l_prep) of_20/IN (l_pobj) proteinuria_24/NN (l_compound) range_23/NN (l_amod) nephrotic_21/JJ
2611118
D004008_D006521 NONE sodium_6/NN (r_compound) therapy_7/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) hepatitis_2/NN
D004008_D006521 NONE sodium_13/NN (r_pobj) with_11/IN (r_prep) therapy_10/NN (r_pobj) after_7/IN (r_prep) hepatitis_6/NN
D004008_D056486 CID diclofenac_4/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) hepatitis_1/NN
6287825
D013831_D010523 CID thiamine_7/NN (r_pobj) of_6/IN (r_prep) deficiency_5/NN (r_pobj) due_2/JJ (r_amod) neuropathy_1/NN
D013831_D010523 CID thiamine_7/NN (r_pobj) of_6/IN (r_prep) deficiency_5/NN (r_pobj) due_2/JJ (r_amod) neuropathy_1/NN (r_nsubj) was_10/VBD (l_conj) presented_17/VBN (l_prep) as_19/IN (l_pobj) neuropathy_25/NN
D013831_D044342 NONE thiamine_7/NN (r_pobj) of_6/IN (r_prep) deficiency_5/NN
D012256_D010523 CID riboflavin_9/NN (r_nsubj) was_10/VBD (l_nsubj) neuropathy_1/NN
D012256_D010523 CID riboflavin_9/NN (r_nsubj) was_10/VBD (l_conj) presented_17/VBN (l_prep) as_19/IN (l_pobj) neuropathy_25/NN
D012256_D044342 NONE riboflavin_9/NN (r_nsubj) was_10/VBD (l_nsubj) neuropathy_1/NN (l_amod) due_2/JJ (l_pobj) deficiency_5/NN
D007538_D009422 NONE Isoniazid_0/NNP (r_nsubj) was_1/VBD (l_attr) agent_5/NN (l_prep) in_6/IN (l_pobj) neuropathy_10/NN
11807648
D014148_D004827 NONE acid_10/NN (r_dobj) containing_8/VBG (r_acl) sealants_7/NNS (r_pobj) of_5/IN (r_prep) application_4/NN (r_pobj) following_2/VBG (r_acl) seizures_1/NNS
D014148_D004827 NONE tAMCA_2/NNP (r_nsubjpass) shown_5/VBN (l_xcomp) cause_7/VB (l_dobj) seizures_9/NNS
D014148_D012640 CID tAMCA_5/NNP (r_nsubj) retains_6/VBZ (l_dobj) action_9/NN (l_amod) convulsive_8/JJ
D014148_D012640 CID tAMCA_2/NN (r_dobj) containing_1/VBG (r_acl) FS_0/NNP (r_nsubj) caused_3/VBD (l_dobj) activity_6/NN (l_relcl) associated_9/VBN (l_prep) with_10/IN (l_pobj) behaviours_13/NNS (l_amod) convulsive_12/JJ
D014148_D012640 CID tAMCA_10/NNP (r_pobj) of_9/IN (r_prep) concentration_8/NN (r_pobj) with_6/IN (r_prep) increased_5/VBD (l_nsubj) degree_1/NN (l_prep) of_2/IN (l_pobj) seizures_4/NNS
D014148_D012640 CID tAMCA_15/NNP (r_pobj) of_14/IN (r_prep) concentration_13/NN (r_nsubj) evoked_23/VBD (r_advcl) evoked_0/VBN (l_dobj) seizures_2/NNS
D014148_D012640 CID tAMCA_15/NNP (r_pobj) of_14/IN (r_prep) concentration_13/NN (r_nsubj) evoked_23/VBD (l_dobj) episodes_25/NNS (l_prep) of_26/IN (l_pobj) potentials_31/NNS (l_amod) convulsive_30/JJ
D014148_D012640 CID acid_1/NN (r_nsubj) retains_2/VBZ (l_dobj) action_5/NN (l_amod) convulsive_4/JJ
9746003
D002220_D004832 CID carbamazepine_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (l_prep) in_6/IN (l_pobj) seizures_9/NNS
D002220_D004832 CID Carbamazepine_0/NN (r_nsubjpass) contraindicated_4/VBN (l_prep) in_5/IN (l_pobj) seizures_8/NNS
D020888_D004832 CID vigabatrin_5/NN (r_conj) carbamazepine_3/NN (r_pobj) of_2/IN (r_prep) use_1/NN (l_prep) in_6/IN (l_pobj) seizures_9/NNS
D020888_D004832 CID vigabatrin_2/NNP (r_conj) Carbamazepine_0/NN (r_nsubjpass) contraindicated_4/VBN (l_prep) in_5/IN (l_pobj) seizures_8/NNS
D002220_D009207 CID carbamazepine_9/NN (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_acl) children_6/NNS (r_pobj) in_4/IN (r_prep) increased_3/VBD (l_conj) two_11/CD (l_prep) of_12/IN (l_pobj) jerks_16/NNS
D002220_D009207 CID carbamazepine_23/NN (r_pobj) of_22/IN (r_prep) withdrawal_21/NN (r_pobj) on_20/IN (r_prep) resolved_19/VBD (r_relcl) two_11/CD (l_prep) of_12/IN (l_pobj) jerks_16/NNS
8741744
D009538_D009069 NONE nicotine_29/NN (r_pobj) by_28/IN (r_agent) caused_27/VBN (r_acl) hypoactivity_26/NN
D009538_D009069 NONE nicotine_48/NN (r_npadvmod) induced_50/VBN (r_amod) hyperactivity_51/NN (r_dobj) enhanced_39/VBD (r_conj) blunted_14/VBD (l_dobj) early_16/JJ (l_appos) hypoactivity_26/NN
D009538_D006948 CID nicotine_29/NN (r_pobj) by_28/IN (r_agent) caused_27/VBN (r_acl) hypoactivity_26/NN (r_appos) early_16/JJ (r_dobj) blunted_14/VBD (l_conj) enhanced_39/VBD (l_dobj) hyperactivity_51/NN
D009538_D006948 CID nicotine_48/NN (r_npadvmod) induced_50/VBN (r_amod) hyperactivity_51/NN
3187073
D005472_D002637 CID 5-FU_6/CD (r_compound) treatment_7/NN (r_pobj) on_5/IN (r_prep) patients_4/NNS (r_nsubj) be_9/VB (l_conj) discontinued_19/VBN (l_advcl) observed_26/VBN (l_nsubjpass) pain_22/NN
D005472_D013610 NONE 5-FU_6/CD (r_compound) treatment_7/NN (r_pobj) on_5/IN (r_prep) patients_4/NNS (r_nsubj) be_9/VB (l_conj) discontinued_19/VBN (l_advcl) observed_26/VBN (l_nsubjpass) pain_22/NN (l_conj) tachyarrhythmia_24/NN
10791295
D001058_D010554 CID apomorphine_2/NNP (r_npadvmod) induced_4/VBN (r_amod) behavior_6/NN
D001058_D010554 CID apomorphine_3/NNP (r_npadvmod) induced_5/VBN (r_amod) behavior_14/NN
D001058_D010554 CID apomorphine_5/JJ (r_compound) treatment_6/NN (r_nsubj) induced_7/VBD (l_dobj) development_10/NN (l_prep) of_11/IN (l_pobj) behavior_13/NN
D001058_D010554 CID apomorphine_5/JJ (r_compound) treatment_6/NN (r_nsubj) induced_7/VBD (l_dobj) development_10/NN (l_advcl) evidenced_15/VBN (l_agent) by_16/IN (l_pobj) intensity_19/NN (l_prep) of_20/IN (l_pobj) aggressiveness_21/NN
D001058_D010554 CID apomorphine_14/NN (r_npadvmod) induced_16/VBN (r_amod) behavior_18/NN
18544179
D005283_D009325 NONE fentanyl_1/NN (r_dobj) Omitting_0/VBG (r_csubj) reduces_2/VBZ (l_dobj) nausea_3/NN
D005283_D009325 NONE fentanyl_2/NN (r_pobj) of_1/IN (r_prep) Omission_0/NN (r_nsubj) reduce_5/VB (l_conj) reduce_17/VB (l_conj) moderate_23/JJ (l_prep) to_24/IN (l_pobj) nausea_26/NN
D005283_D009325 NONE fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (l_conj) moderate_23/JJ (l_prep) to_24/IN (l_pobj) nausea_26/NN
D005283_D009325 NONE fentanyl_39/NN (r_compound) dexamethasone_41/NN (r_conj) fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (l_conj) moderate_23/JJ (l_prep) to_24/IN (l_pobj) nausea_26/NN
D005283_D009325 NONE fentanyl_3/NN (r_compound) groups_4/NNS (r_dobj) Combining_0/VBG (r_csubj) revealed_5/VBD (l_advcl) reducing_15/VBG (l_dobj) nausea_17/NN (l_conj) vomiting_19/NN (l_conj) nausea_21/NN
D005283_D009325 NONE fentanyl_3/NN (r_compound) groups_4/NNS (r_dobj) Combining_0/VBG (r_csubj) revealed_5/VBD (l_advcl) reducing_15/VBG (l_advcl) decreased_57/VBN (l_nsubjpass) nausea_50/NN
D005283_D014839 NONE fentanyl_1/NN (r_dobj) Omitting_0/VBG (r_csubj) reduces_2/VBZ (l_dobj) nausea_3/NN (l_conj) vomiting_5/NN
D005283_D014839 NONE fentanyl_2/NN (r_pobj) of_1/IN (r_prep) Omission_0/NN (r_nsubj) reduce_5/VB (l_conj) reduce_17/VB (l_dobj) incidence_19/NN (l_prep) of_20/IN (l_pobj) vomiting_21/NN
D005283_D014839 NONE fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (l_dobj) incidence_19/NN (l_prep) of_20/IN (l_pobj) vomiting_21/NN
D005283_D014839 NONE fentanyl_39/NN (r_compound) dexamethasone_41/NN (r_conj) fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (l_dobj) incidence_19/NN (l_prep) of_20/IN (l_pobj) vomiting_21/NN
D005283_D010146 NONE fentanyl_1/NN (r_dobj) Omitting_0/VBG (r_csubj) reduces_2/VBZ (l_prep) without_7/IN (l_pcomp) increasing_8/VBG (l_dobj) pain_9/NN
D005283_D010146 NONE fentanyl_11/NN (r_pobj) of_10/IN (r_prep) omission_9/NN (r_pobj) by_7/IN (r_prep) unaffected_6/JJ (r_acomp) were_5/VBD (l_nsubj) severity_1/NN (l_compound) Pain_0/NN
C009250_D009325 NONE sevoflurane_12/NNP (r_pobj) after_11/IN (r_prep) reduces_2/VBZ (l_dobj) nausea_3/NN
C009250_D014839 NONE sevoflurane_12/NNP (r_pobj) after_11/IN (r_prep) reduces_2/VBZ (l_dobj) nausea_3/NN (l_conj) vomiting_5/NN
C009250_D010146 NONE sevoflurane_12/NNP (r_pobj) after_11/IN (r_prep) reduces_2/VBZ (l_prep) without_7/IN (l_pcomp) increasing_8/VBG (l_dobj) pain_9/NN
C009250_D010146 NONE sevoflurane_23/NNP (r_compound) anaesthesia_24/NN (r_pobj) after_22/IN (r_prep) examined_5/VBD (l_dobj) incidence_7/NN (l_prep) of_10/IN (l_pobj) nausea_12/NN (l_conj) vomiting_14/NN (l_conj) pain_16/NN
C009250_D020250 NONE sevoflurane_9/NNP (r_pobj) with_8/IN (r_prep) anaesthesia_7/NN (r_pobj) of_6/IN (r_prep) induction_3/NN (r_pobj) of_2/IN (r_prep) advantages_1/NNS (r_pobj) Despite_0/IN (r_prep) occurs_15/VBZ (l_nsubj) nausea_12/NN (l_conj) vomiting_14/NN
C009250_D020250 NONE sevoflurane_23/NNP (r_compound) anaesthesia_24/NN (r_pobj) after_22/IN (r_prep) examined_5/VBD (l_dobj) incidence_7/NN (l_prep) of_10/IN (l_pobj) nausea_12/NN (l_conj) vomiting_14/NN
C009250_D020250 NONE sevoflurane_31/NNP (r_relcl) supplement_29/NN (r_attr) be_23/VB (r_xcomp) appears_21/VBZ (l_advcl) exacerbated_2/VBD (l_dobj) nausea_4/NN (l_conj) vomiting_6/NN
D005283_D020250 CID fentanyl_2/NN (r_pobj) of_1/IN (r_prep) Omission_0/NN (r_nsubj) reduce_5/VB (l_dobj) incidence_8/NN (l_prep) of_9/IN (l_pobj) nausea_11/NN (l_conj) vomiting_13/NN
D005283_D020250 CID fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (r_conj) reduce_5/VB (l_dobj) incidence_8/NN (l_prep) of_9/IN (l_pobj) nausea_11/NN (l_conj) vomiting_13/NN
D005283_D020250 CID fentanyl_39/NN (r_compound) dexamethasone_41/NN (r_conj) fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (r_conj) reduce_5/VB (l_dobj) incidence_8/NN (l_prep) of_9/IN (l_pobj) nausea_11/NN (l_conj) vomiting_13/NN
D005283_D020250 CID fentanyl_3/NN (r_compound) groups_4/NNS (r_dobj) Combining_0/VBG (r_csubj) revealed_5/VBD (l_advcl) reducing_15/VBG (l_dobj) nausea_17/NN (l_conj) vomiting_19/NN
D005283_D020250 CID fentanyl_1/NN (r_nsubj) exacerbated_2/VBD (l_dobj) nausea_4/NN (l_conj) vomiting_6/NN
D003907_D020250 NONE dexamethasone_41/NN (r_conj) fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (r_conj) reduce_5/VB (l_dobj) incidence_8/NN (l_prep) of_9/IN (l_pobj) nausea_11/NN (l_conj) vomiting_13/NN
D003907_D020250 NONE Dexamethasone_0/NN (r_nsubj) had_1/VBD (l_dobj) effect_4/NN (l_prep) on_5/IN (l_pobj) incidence_7/NN (l_prep) of_10/IN (l_pobj) nausea_12/NN (l_conj) vomiting_14/NN
D003907_D014839 NONE dexamethasone_41/NN (r_conj) fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (l_dobj) incidence_19/NN (l_prep) of_20/IN (l_pobj) vomiting_21/NN
D003907_D009325 NONE dexamethasone_41/NN (r_conj) fentanyl_37/NN (r_pobj) with_36/IN (r_prep) from_30/IN (r_prep) discharge_29/VB (r_advcl) reduce_17/VB (l_conj) moderate_23/JJ (l_prep) to_24/IN (l_pobj) nausea_26/NN
D005283_D012131 CID Fentanyl_0/NN (r_nsubj) reduce_2/VB (l_conj) had_7/VBD (l_conj) depression_16/NN
D005283_D007022 CID Fentanyl_0/NN (r_nsubj) reduce_2/VB (l_conj) had_7/VBD (l_conj) depression_16/NN (l_conj) hypotension_18/NN
D005283_D001919 CID Fentanyl_0/NN (r_nsubj) reduce_2/VB (l_conj) had_7/VBD (l_conj) depression_16/NN (l_conj) hypotension_18/NN (l_conj) bradycardia_20/NN
C009250_D012131 NONE sevoflurane_9/NN (r_npadvmod) sparing_11/VBG (r_amod) effect_12/NN (r_dobj) had_7/VBD (l_conj) depression_16/NN
C009250_D007022 NONE sevoflurane_9/NN (r_npadvmod) sparing_11/VBG (r_amod) effect_12/NN (r_dobj) had_7/VBD (l_conj) depression_16/NN (l_conj) hypotension_18/NN
C009250_D001919 NONE sevoflurane_9/NN (r_npadvmod) sparing_11/VBG (r_amod) effect_12/NN (r_dobj) had_7/VBD (l_conj) depression_16/NN (l_conj) hypotension_18/NN (l_conj) bradycardia_20/NN
D005283_D010149 NONE fentanyl_1/NN (r_nsubj) exacerbated_2/VBD (l_prep) without_7/IN (l_pobj) improvement_9/NN (l_prep) in_10/IN (l_pobj) pain_12/NN
C009250_D010149 NONE sevoflurane_31/NNP (r_relcl) supplement_29/NN (r_attr) be_23/VB (r_xcomp) appears_21/VBZ (l_advcl) exacerbated_2/VBD (l_prep) without_7/IN (l_pobj) improvement_9/NN (l_prep) in_10/IN (l_pobj) pain_12/NN
15957009
C507242_D008569 NONE Ro4368554_5/NNPS (r_nsubj) restores_6/VBZ (l_dobj) performance_8/NN (l_prep) in_9/IN (l_pobj) models_13/NNS (l_prep) of_14/IN (l_pobj) deficiency_16/NN
C507242_D008569 NONE Ro4368554_4/NNP (r_nsubj) improve_7/VB (r_advcl) reversed_16/VBD (l_dobj) cholinergic_18/JJ (l_conj) deficit_23/NN
C507242_D008569 NONE Ro4368554_39/NNP (r_pobj) by_38/IN (r_prep) facilitation_34/NN (r_pobj) in_32/IN (r_prep) involved_31/VBN (r_ccomp) suggesting_25/VBG (r_advcl) reversed_16/VBD (l_dobj) cholinergic_18/JJ (l_conj) deficit_23/NN
D014236_D008569 NONE metrifonate_1/NNP (r_nsubj) reversed_10/VBD (l_dobj) deficits_12/NNS
D012601_D008569 CID scopolamine_15/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) deficits_12/NNS
D014364_D008569 NONE TRP_17/NN (r_compound) depletion_18/NN (r_conj) scopolamine_15/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) deficits_12/NNS
D012701_D008569 NONE 5-HT(6_45/CD (r_appos) facilitation_34/NN (r_pobj) in_32/IN (r_prep) involved_31/VBN (r_ccomp) suggesting_25/VBG (r_advcl) reversed_16/VBD (l_dobj) cholinergic_18/JJ (l_conj) deficit_23/NN
3719553
D005472_D004342 NONE 5-fluorouracil_3/CD (r_punct) infusion_4/NN (r_pobj) to_2/IN (r_prep) reaction_1/NN
D005472_D004342 NONE 5-fluorouracil_11/CD (r_punct) reaction_2/NN
D005472_D000799 CID 5-fluorouracil_11/CD (r_punct) reaction_2/NN (l_acl) consisting_3/VBG (l_prep) of_4/IN (l_pobj) edema_6/NN
D005472_D009062 NONE 5-fluorouracil_11/CD (r_punct) reaction_2/NN (r_nsubj) occurred_12/VBD (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) carcinoma_18/NN (l_prep) of_19/IN (l_pobj) cavity_22/NN
D005472_D005355 NONE 5-fluorouracil_11/CD (r_punct) reaction_2/NN (r_nsubj) occurred_12/VBD (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) carcinoma_18/NN (l_prep) of_19/IN (l_pobj) cavity_22/NN (l_conj) cirrhosis_24/NN
D005472_D007674 NONE 5-fluorouracil_11/CD (r_punct) reaction_2/NN (r_nsubj) occurred_12/VBD (l_prep) in_13/IN (l_pobj) patient_15/NN (l_prep) with_16/IN (l_pobj) carcinoma_18/NN (l_prep) of_19/IN (l_pobj) cavity_22/NN (l_conj) cirrhosis_24/NN (l_conj) function_32/NN
D002945_D004342 NONE cisplatin_27/NN (r_npadvmod) induced_29/VBN (r_amod) function_32/NN (r_conj) cirrhosis_24/NN (r_conj) cavity_22/NN (r_pobj) of_19/IN (r_prep) carcinoma_18/NN (r_pobj) with_16/IN (r_prep) patient_15/NN (r_pobj) in_13/IN (r_prep) occurred_12/VBD (l_nsubj) reaction_2/NN
D002945_D000799 NONE cisplatin_27/NN (r_npadvmod) induced_29/VBN (r_amod) function_32/NN (r_conj) cirrhosis_24/NN (r_conj) cavity_22/NN (r_pobj) of_19/IN (r_prep) carcinoma_18/NN (r_pobj) with_16/IN (r_prep) patient_15/NN (r_pobj) in_13/IN (r_prep) occurred_12/VBD (l_nsubj) reaction_2/NN (l_acl) consisting_3/VBG (l_prep) of_4/IN (l_pobj) edema_6/NN
D002945_D009062 NONE cisplatin_27/NN (r_npadvmod) induced_29/VBN (r_amod) function_32/NN (r_conj) cirrhosis_24/NN (r_conj) cavity_22/NN
D002945_D005355 NONE cisplatin_27/NN (r_npadvmod) induced_29/VBN (r_amod) function_32/NN (r_conj) cirrhosis_24/NN
D002945_D007674 NONE cisplatin_27/NN (r_npadvmod) induced_29/VBN (r_amod) function_32/NN
D004155_D004342 NONE diphenhydramine_1/NN (r_nsubj) were_4/VBD (l_acomp) ineffective_5/JJ (l_prep) in_6/IN (l_pcomp) preventing_7/VBG (l_dobj) recurrence_9/NN (l_prep) of_10/IN (l_pobj) reaction_13/NN
D011241_D004342 NONE prednisone_3/NN (r_conj) diphenhydramine_1/NN (r_nsubj) were_4/VBD (l_acomp) ineffective_5/JJ (l_prep) in_6/IN (l_pcomp) preventing_7/VBG (l_dobj) recurrence_9/NN (l_prep) of_10/IN (l_pobj) reaction_13/NN
17608141
D008694_D020258 NONE methamphetamine_2/NN (r_npadvmod) induced_4/VBN (r_amod) neurotoxicity_7/NN
D008694_D020258 NONE methamphetamine_23/NN (r_npadvmod) induced_25/VBN (r_amod) nigrostriatal_26/JJ (r_compound) neurotoxicity_28/NN
D008694_D020258 NONE methamphetamine_15/NN (r_npadvmod) induced_17/VBN (r_amod) nigrostriatal_18/JJ (r_compound) neurotoxicity_20/NN
D008070_D020258 NONE lipopolysaccharide_11/NN (r_compound) pretreatment_12/NN (r_pobj) by_10/IN (r_prep) neurotoxicity_7/NN
D008070_D020258 NONE lipopolysaccharide_9/NN (l_appos) factor_17/NN (l_conj) treatment_19/NN (l_prep) in_20/IN (l_pcomp) modulating_21/VBG (l_dobj) neurotoxicity_28/NN
D008070_D020258 NONE lipopolysaccharide_8/NN (r_compound) pretreatment_9/NN (r_pobj) for_6/IN (r_prep) window_5/NN (l_prep) in_10/IN (l_pcomp) exerting_11/VBG (l_dobj) protection_13/NN (l_prep) against_14/IN (l_pobj) neurotoxicity_20/NN
D008694_D009422 NONE methamphetamine_10/NN (r_npadvmod) induced_12/VBN (r_amod) damage_15/NN
D004298_D020258 NONE dopamine_27/NN (r_compound) neurotoxicity_28/NN
D004298_D020258 NONE dopamine_19/NN (r_compound) neurotoxicity_20/NN
D008070_D005334 NONE Lipopolysaccharide_0/NNP (r_compound) pretreatment_1/NN (r_nsubj) affect_4/VB (l_dobj) temperature_8/NN (l_conj) hyperthermia_13/NN
D008694_D005334 CID methamphetamine_10/NN (r_npadvmod) elicited_12/VBN (r_amod) hyperthermia_13/NN
7449470
D004317_D066126 NONE doxorubicin_3/NN (r_compound) cardiotoxicity_4/NN
D004317_D066126 NONE adriamycin_11/NNS (r_pobj) of_10/IN (r_prep) use_9/NN (r_dobj) limits_7/VBZ (r_relcl) complication_5/NN (r_attr) is_2/VBZ (l_nsubj) toxicity_1/NN
11581460
D005283_D016055 CID fentanyl_12/NN (r_pobj) of_11/IN (r_prep) infusion_10/NN (r_pobj) of_7/IN (r_prep) result_6/NN (r_pobj) as_4/IN (r_prep) retention_1/NN (l_prep) of_2/IN (l_pobj) urine_3/NN
D005283_D009127 NONE fentanyl_5/NN (r_compound) administration_6/NNP (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_nsubj) include_7/VBP (l_dobj) rigidity_10/NN
D005283_D007022 CID fentanyl_5/NN (r_compound) administration_6/NNP (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_nsubj) include_7/VBP (l_dobj) rigidity_10/NN (l_conj) hypotension_12/NN
D005283_D012131 CID fentanyl_5/NN (r_compound) administration_6/NNP (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_nsubj) include_7/VBP (l_dobj) rigidity_10/NN (l_conj) hypotension_12/NN (l_conj) depression_15/NN
D005283_D001919 CID fentanyl_5/NN (r_compound) administration_6/NNP (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_nsubj) include_7/VBP (l_dobj) rigidity_10/NN (l_conj) hypotension_12/NN (l_conj) depression_15/NN (l_conj) bradycardia_18/NN
D005283_D001745 CID fentanyl_22/NN (r_pobj) of_21/IN (r_prep) infusion_20/NN (r_pobj) of_18/IN (r_prep) result_17/NN (r_pobj) as_15/IN (r_prep) mimicking_13/VBG (r_acl) dilatation_12/NN (r_pobj) to_9/IN (r_prep) leading_8/VBG (r_acl) cases_3/NNS (l_prep) of_4/IN (l_pobj) retention_7/NN
D005283_D006869 NONE fentanyl_22/NN (r_pobj) of_21/IN (r_prep) infusion_20/NN (r_pobj) of_18/IN (r_prep) result_17/NN (r_pobj) as_15/IN (r_prep) mimicking_13/VBG (l_dobj) hydronephrosis_14/NN
10704919
D013629_D006461 CID tamoxifen_6/NN (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) erythrocytes_3/NNS (r_pobj) of_1/IN (r_prep) Hemolysis_0/NNP
D013629_D006461 CID TAM_0/NNP (r_nsubj) induces_1/VBZ (l_dobj) hemolysis_2/NN
D013629_D006461 CID TAM_13/NNP (r_nsubj) induces_14/VBZ (r_conj) is_4/VBZ (l_nsubj) extension_1/NN (l_prep) of_2/IN (l_pobj) hemolysis_3/NN
D013629_D006461 CID TAM_13/NNP (r_nsubj) induces_14/VBZ (l_dobj) hemolysis_16/NN
D013629_D006461 CID TAM_4/NNP (r_pobj) of_3/IN (r_prep) effect_2/NN (l_amod) hemolytic_1/JJ
D013629_D006461 CID TAM_4/NNP (r_pobj) of_3/IN (r_prep) effect_2/NN (r_nsubjpass) prevented_6/VBN (l_advcl) indicating_34/VBG (l_ccomp) related_42/VBN (l_nsubjpass) hemolysis_39/NN
D013629_D006461 CID TAM_36/NN (r_npadvmod) induced_38/VBN (r_amod) hemolysis_39/NN (r_nsubjpass) related_42/VBN (r_ccomp) indicating_34/VBG (r_advcl) prevented_6/VBN (l_nsubjpass) effect_2/NN (l_amod) hemolytic_1/JJ
D013629_D006461 CID TAM_36/NN (r_npadvmod) induced_38/VBN (r_amod) hemolysis_39/NN
D013629_D006461 CID TAM_17/NN (r_npadvmod) induced_19/VBN (r_amod) hemolysis_20/NN
D013629_D006461 CID TAM_3/NNP (r_pobj) by_2/IN (r_agent) caused_1/VBN (r_acl) Hemolysis_0/NNP
D013629_D006461 CID TAM_3/NNP (r_pobj) by_2/IN (r_agent) caused_1/VBN (r_acl) Hemolysis_0/NNP (r_nsubjpass) preceded_6/VBN (l_advcl) excluding_18/VBG (l_dobj) mechanism_24/NN (l_prep) of_25/IN (l_pobj) hemolysis_26/NN
D013629_D006461 CID TAM_15/NN (r_compound) incorporation_16/NN (r_pobj) to_12/IN (r_prep) related_11/VBN (l_nsubjpass) protection_5/NN (l_prep) from_6/IN (l_pobj) hemolysis_7/NN
D013629_D006461 CID TAM_2/NNP (r_npadvmod) induced_4/VBN (r_amod) results_6/NNS (l_compound) hemolysis_5/NN
D013629_D001943 NONE Tamoxifen_0/NNP (l_appos) drug_7/NN (l_acl) prescribed_10/VBN (l_prep) in_11/IN (l_pobj) chemotherapy_13/NN (l_prep) of_14/IN (l_pobj) cancer_16/NN
D013629_D001943 NONE TAM_2/NNP (r_appos) Tamoxifen_0/NNP (l_appos) drug_7/NN (l_acl) prescribed_10/VBN (l_prep) in_11/IN (l_pobj) chemotherapy_13/NN (l_prep) of_14/IN (l_pobj) cancer_16/NN
D013629_D000743 CID Tamoxifen_0/NNP (r_nsubj) induces_18/VBZ (l_dobj) changes_19/NNS (l_prep) in_20/IN (l_pobj) shape_23/NN (l_prep) of_24/IN (l_pobj) erythrocytes_25/NNS (l_conj) anemia_28/NN
D013629_D000743 CID TAM_2/NNP (r_appos) Tamoxifen_0/NNP (r_nsubj) induces_18/VBZ (l_dobj) changes_19/NNS (l_prep) in_20/IN (l_pobj) shape_23/NN (l_prep) of_24/IN (l_pobj) erythrocytes_25/NNS (l_conj) anemia_28/NN
D013629_D000743 CID TAM_6/NNP (r_pobj) of_5/IN (r_prep) effects_4/NNS (r_dobj) evaluates_2/VBZ (l_advcl) attempting_12/VBG (l_xcomp) identify_14/VB (l_dobj) mechanisms_17/NNS (l_prep) on_18/IN (l_pobj) anemia_23/NN
D013629_D000743 CID TAM_19/NN (r_npadvmod) induced_21/VBN (r_amod) anemia_23/NN
D013629_D000743 CID TAM_13/NNP (r_pobj) by_12/IN (r_agent) promoted_11/VBN (r_acl) stability_10/NN (r_dobj) decreased_8/VBD (l_advcl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) anemia_18/NN
D024502_D006461 NONE tocopherol_13/NN (r_pobj) of_10/IN (r_prep) concentrations_9/NNS (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_nsubjpass) effect_2/NN (l_amod) hemolytic_1/JJ
D024502_D006461 NONE tocopherol_13/NN (r_pobj) of_10/IN (r_prep) concentrations_9/NNS (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_advcl) indicating_34/VBG (l_ccomp) related_42/VBN (l_nsubjpass) hemolysis_39/NN
D024502_D006461 NONE T_17/NNP (r_appos) tocopherol_13/NN (r_pobj) of_10/IN (r_prep) concentrations_9/NNS (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_nsubjpass) effect_2/NN (l_amod) hemolytic_1/JJ
D024502_D006461 NONE T_17/NNP (r_appos) tocopherol_13/NN (r_pobj) of_10/IN (r_prep) concentrations_9/NNS (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_advcl) indicating_34/VBG (l_ccomp) related_42/VBN (l_nsubjpass) hemolysis_39/NN
D024502_D006461 NONE acetate_23/NN (r_conj) tocopherol_13/NN (r_pobj) of_10/IN (r_prep) concentrations_9/NNS (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_nsubjpass) effect_2/NN (l_amod) hemolytic_1/JJ
D024502_D006461 NONE acetate_23/NN (r_conj) tocopherol_13/NN (r_pobj) of_10/IN (r_prep) concentrations_9/NNS (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_advcl) indicating_34/VBG (l_ccomp) related_42/VBN (l_nsubjpass) hemolysis_39/NN
D024502_D006461 NONE TAc_27/NN (r_parataxis) acetate_23/NN (r_conj) tocopherol_13/NN (r_pobj) of_10/IN (r_prep) concentrations_9/NNS (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_nsubjpass) effect_2/NN (l_amod) hemolytic_1/JJ
D024502_D006461 NONE TAc_27/NN (r_parataxis) acetate_23/NN (r_conj) tocopherol_13/NN (r_pobj) of_10/IN (r_prep) concentrations_9/NNS (r_pobj) by_7/IN (r_agent) prevented_6/VBN (l_advcl) indicating_34/VBG (l_ccomp) related_42/VBN (l_nsubjpass) hemolysis_39/NN
D017665_D006461 NONE hydroxyl_32/NN (r_npadvmod) prevented_6/VBN (l_nsubjpass) effect_2/NN (l_amod) hemolytic_1/JJ
D017665_D006461 NONE hydroxyl_32/NN (r_npadvmod) prevented_6/VBN (l_advcl) indicating_34/VBG (l_ccomp) related_42/VBN (l_nsubjpass) hemolysis_39/NN
D010100_D006461 NONE oxygen_7/NN (r_compound) consumption_8/NN (r_pobj) of_6/IN (r_prep) absence_5/NN (l_conj) oxidation_11/NN (l_acl) determined_13/VBD (l_prep) in_14/IN (l_pobj) parallel_15/NN (l_prep) with_16/IN (l_pobj) hemolysis_20/NN
D011188_D006461 NONE K(+_11/NNP (r_pobj) of_10/IN (r_prep) leakage_9/NN (r_pobj) by_7/IN (r_agent) preceded_6/VBN (l_nsubjpass) Hemolysis_0/NNP
D011188_D006461 NONE K(+_11/NNP (r_pobj) of_10/IN (r_prep) leakage_9/NN (r_pobj) by_7/IN (r_agent) preceded_6/VBN (l_advcl) excluding_18/VBG (l_dobj) mechanism_24/NN (l_prep) of_25/IN (l_pobj) hemolysis_26/NN
D024505_D006461 NONE tocopherols_9/NNS (r_pobj) by_8/IN (r_prep) hemolysis_7/NN
2224762
C027260_D009369 NONE Pirarubicin_1/NNP (r_nsubjpass) done_4/VBN (l_prep) in_5/IN (l_pobj) patients_7/NNS (l_prep) in_8/IN (l_pobj) status_11/NN (l_prep) with_12/IN (l_pobj) tumors_14/NNS
6209318
D008801_D001145 NONE mexiletine_1/NNP (l_appos) Report_9/NNP (l_prep) on_10/IN (l_pobj) arrhythmia_11/NN
D008801_D009203 NONE mexiletine_9/NNP (r_pobj) of_8/IN (r_prep) form_7/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) evaluated_16/VBN (l_prep) in_17/IN (l_pobj) trial_23/NN (l_prep) in_24/IN (l_pobj) patients_26/NNS (l_prep) with_27/IN (l_pobj) infarction_31/NN
D008801_D009203 NONE Perlongets_13/NNP (r_appos) mexiletine_9/NNP (r_pobj) of_8/IN (r_prep) form_7/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubjpass) evaluated_16/VBN (l_prep) in_17/IN (l_pobj) trial_23/NN (l_prep) in_24/IN (l_pobj) patients_26/NNS (l_prep) with_27/IN (l_pobj) infarction_31/NN
D008801_D003643 NONE mexiletine_6/NN (r_compound) group_7/NN (r_pobj) in_4/IN (r_prep) deaths_3/NNS
D008801_D014202 CID mexiletine_16/NN (r_compound) group_17/NN (r_pobj) in_14/IN (r_prep) frequent_13/JJ (r_acomp) were_11/VBD (l_advcl) recognized_1/VBN (l_dobj) effects_3/NNS (l_appos) tremor_6/NN
D008801_D012817 CID mexiletine_16/NN (r_compound) group_17/NN (r_pobj) in_14/IN (r_prep) frequent_13/JJ (r_acomp) were_11/VBD (l_advcl) recognized_1/VBN (l_dobj) effects_3/NNS (l_appos) tremor_6/NN (l_conj) problems_9/NNS
7088431
D004054_D018262 CID DES_6/NNP (r_npadvmod) exposed_8/VBN (r_amod) offspring_9/NN (r_pobj) in_5/IN (r_prep) Development_0/NN (l_prep) of_1/IN (l_pobj) adenocarcinoma_4/NN
D004054_D018262 CID diethylstilbestrol_21/NN (r_pobj) to_20/IN (r_prep) exposed_17/VBN (r_acl) women_16/NNS (r_pobj) in_14/IN (r_prep) up_13/NN (r_pobj) at_10/IN (r_prep) detected_9/VBN (r_acl) vagina_8/NN
D004054_D014625 CID diethylstilbestrol_21/NN (r_pobj) to_20/IN (r_prep) exposed_17/VBN (r_acl) women_16/NNS (r_pobj) in_14/IN (r_prep) up_13/NN (r_pobj) at_10/IN (r_prep) detected_9/VBN (r_acl) vagina_8/NN
9766615
D003024_D001480 NONE clozapine_40/NNP (r_appos) threshold_37/NN (r_dobj) lowered_35/VBD (r_conj) associated_13/VBN (r_conj) have_4/VBP (l_dobj) risk_7/NN (l_prep) of_8/IN (l_pobj) EPS_9/NNP
D003024_D001480 NONE clozapine_46/NNP (r_appos) agranulocytosis_44/NN (r_conj) lowered_35/VBD (r_conj) associated_13/VBN (r_conj) have_4/VBP (l_dobj) risk_7/NN (l_prep) of_8/IN (l_pobj) EPS_9/NNP
D003024_D015430 NONE clozapine_40/NNP (r_appos) threshold_37/NN (r_dobj) lowered_35/VBD (r_conj) associated_13/VBN (l_prep) in_14/IN (l_pobj) degrees_16/NNS (l_conj) effects_21/NNS (l_conj) effects_24/NNS (l_conj) gain_27/NN
D003024_D015430 NONE clozapine_46/NNP (r_appos) agranulocytosis_44/NN (r_conj) lowered_35/VBD (r_conj) associated_13/VBN (l_prep) in_14/IN (l_pobj) degrees_16/NNS (l_conj) effects_21/NNS (l_conj) effects_24/NNS (l_conj) gain_27/NN
D003024_D012735 NONE clozapine_40/NNP (r_appos) threshold_37/NN (r_dobj) lowered_35/VBD (r_conj) associated_13/VBN (l_prep) in_14/IN (l_pobj) degrees_16/NNS (l_conj) effects_21/NNS (l_conj) effects_24/NNS (l_conj) gain_27/NN (l_conj) dysfunction_30/NN
D003024_D012735 NONE clozapine_46/NNP (r_appos) agranulocytosis_44/NN (r_conj) lowered_35/VBD (r_conj) associated_13/VBN (l_prep) in_14/IN (l_pobj) degrees_16/NNS (l_conj) effects_21/NNS (l_conj) effects_24/NNS (l_conj) gain_27/NN (l_conj) dysfunction_30/NN
D003024_D012640 NONE clozapine_40/NNP (r_appos) threshold_37/NN (l_compound) seizure_36/NN
D003024_D012640 NONE clozapine_46/NNP (r_appos) agranulocytosis_44/NN (r_conj) lowered_35/VBD (l_dobj) threshold_37/NN (l_compound) seizure_36/NN
D003024_D000380 CID clozapine_40/NNP (r_appos) threshold_37/NN (r_dobj) lowered_35/VBD (l_conj) agranulocytosis_44/NN
D003024_D000380 CID clozapine_46/NNP (r_appos) agranulocytosis_44/NN
10342929
D000806_D000799 CID inhibitors_4/NNS (r_pobj) due_1/IN (r_amod) Angioedema_0/NNP
D000806_D000799 CID inhibitor_13/NN (r_compound) treatment_14/NN (r_pobj) during_5/IN (r_prep) incidence_2/NN (l_prep) of_3/IN (l_pobj) angioedema_4/NN
17931375
D006493_D003288 CID heparin_10/NN (r_compound) injection_11/NN (r_pobj) of_8/IN (r_prep) duration_7/NN (l_prep) on_12/IN (l_pobj) bruising_13/NN
D006493_D003288 CID heparin_26/NN (r_pobj) of_25/IN (r_prep) injection_24/NN (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) following_18/VBG (r_prep) determine_8/VB (l_dobj) effect_10/NN (l_prep) of_11/IN (l_pobj) duration_13/NN (l_prep) on_14/IN (l_pobj) bruising_15/NN
D006493_D003288 CID heparin_13/NN (r_pobj) of_12/IN (r_prep) injection_11/NN (r_pobj) following_8/VBG (r_prep) prevent_4/VB (l_dobj) bruising_5/NN
D006493_D003288 CID heparin_13/NN (r_pobj) of_12/IN (r_prep) injection_11/NN (r_pobj) following_8/VBG (r_prep) prevent_4/VB (r_acl) methods_2/NNS (r_nsubjpass) studied_17/VBN (r_advcl) is_33/VBZ (l_nsubj) effect_22/NN (l_prep) of_23/IN (l_pobj) duration_25/NN (l_prep) on_26/IN (l_pobj) occurrence_28/NN (l_prep) of_29/IN (l_pobj) bruising_30/NN
D006493_D003288 CID heparin_6/NN (r_nmod) areas_8/NNS (r_pobj) on_4/IN (r_prep) bruising_3/NN
D006493_D003288 CID heparin_18/NNP (r_pobj) of_17/IN (r_prep) administration_16/NN (r_pobj) following_13/VBG (r_prep) had_6/VBD (l_dobj) effect_8/NN (l_prep) on_9/IN (l_pobj) bruising_10/NN
D006493_D010146 CID heparin_10/NN (r_compound) injection_11/NN (r_pobj) of_8/IN (r_prep) duration_7/NN (l_prep) on_12/IN (l_pobj) bruising_13/NN (l_conj) pain_15/NN
D006493_D010146 CID heparin_26/NN (r_pobj) of_25/IN (r_prep) injection_24/NN (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) following_18/VBG (r_prep) determine_8/VB (l_dobj) effect_10/NN (l_prep) of_11/IN (l_pobj) duration_13/NN (l_prep) on_14/IN (l_pobj) bruising_15/NN (l_conj) pain_17/NN
D006493_D010146 CID heparin_13/NN (r_pobj) of_12/IN (r_prep) injection_11/NN (r_pobj) following_8/VBG (r_prep) prevent_4/VB (l_dobj) bruising_5/NN (l_conj) pain_7/NN
D006493_D010146 CID heparin_13/NN (r_pobj) of_12/IN (r_prep) injection_11/NN (r_pobj) following_8/VBG (r_prep) prevent_4/VB (r_acl) methods_2/NNS (r_nsubjpass) studied_17/VBN (r_advcl) is_33/VBZ (l_nsubj) effect_22/NN (l_prep) of_23/IN (l_pobj) duration_25/NN (l_prep) on_26/IN (l_pobj) occurrence_28/NN (l_prep) of_29/IN (l_pobj) bruising_30/NN (l_conj) pain_32/NN
D006493_D010146 CID heparin_18/NNP (r_pobj) of_17/IN (r_prep) administration_16/NN (r_pobj) following_13/VBG (r_prep) had_6/VBD (l_dobj) effect_8/NN (l_prep) on_9/IN (l_pobj) bruising_10/NN (l_conj) pain_12/NN
19581773
C417083_D009157 CID interferon_6/NN (r_pobj) during_4/IN (r_prep) Development_0/NN (l_prep) of_1/IN (l_pobj) myasthenia_3/NN
C417083_D009157 CID IFN_9/NNP (r_pobj) of_7/IN (r_prep) therapy_6/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) myasthenia_2/NN
C417083_D019698 NONE interferon_6/NN (l_conj) treatment_9/NN (l_prep) for_10/IN (l_pobj) C._13/NNP
C417083_D019698 NONE alpha-2b_19/NNP (r_punct) experienced_5/VBD (l_conj) ribavirin_21/NN (l_prep) for_22/IN (l_pobj) CHC_27/NNP (l_nmod) C_25/NNP
C417083_D019698 NONE alpha-2b_19/NNP (r_punct) experienced_5/VBD (l_conj) ribavirin_21/NN (l_prep) for_22/IN (l_pobj) CHC_27/NNP
C417083_D019698 NONE IFN_24/NNP (r_compound) therapy_25/NN (r_pobj) of_23/IN (r_prep) complications_22/NNS (r_pobj) of_18/IN (r_prep) review_17/NN (r_pobj) with_15/IN (r_prep) present_12/VBP (l_ccomp) reported_7/VBN (l_advcl) ribavirin_1/NN (l_prep) for_2/IN (l_pobj) CHC_3/NNP
D012254_D009157 CID ribavirin_8/JJ (r_compound) treatment_9/NN (r_conj) interferon_6/NN (r_pobj) during_4/IN (r_prep) Development_0/NN (l_prep) of_1/IN (l_pobj) myasthenia_3/NN
D012254_D019698 NONE ribavirin_8/JJ (r_compound) treatment_9/NN (l_prep) for_10/IN (l_pobj) C._13/NNP
D012254_D019698 NONE ribavirin_21/NN (l_prep) for_22/IN (l_pobj) CHC_27/NNP (l_nmod) C_25/NNP
D012254_D019698 NONE ribavirin_21/NN (l_prep) for_22/IN (l_pobj) CHC_27/NNP
D012254_D019698 NONE ribavirin_1/NN (l_prep) for_2/IN (l_pobj) CHC_3/NNP
C417083_D004172 NONE alpha-2b_19/NNP (r_punct) experienced_5/VBD (l_dobj) diplopia_7/NN
D012254_D004172 NONE ribavirin_21/NN (r_conj) experienced_5/VBD (l_dobj) diplopia_7/NN
2008831
D008755_D000788 NONE methylergonovine_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NNP (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_conj) without_11/IN (l_pobj) angina_13/NN
D008755_D000788 NONE methylergonovine_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) studied_8/VBN (l_prep) in_9/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) angina_14/NN
D008755_D000788 NONE methylergonovine_19/NNP (r_pobj) of_18/IN (r_prep) dose_17/NN (r_pobj) of_13/IN (r_prep) injection_12/NN (r_dobj) use_9/VBP (r_relcl) tests_6/NNS (r_nsubj) have_21/VBP (l_dobj) sensitivity_24/NN (l_prep) in_25/IN (l_pobj) angina_27/NN
D008755_D002637 NONE methylergonovine_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) studied_8/VBN (l_prep) in_9/IN (l_pobj) patients_11/NNS (l_conj) patients_17/NNS (l_prep) with_18/IN (l_pobj) pain_21/NN
D008755_D000787 NONE methylergonovine_6/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) studied_8/VBN (l_prep) without_25/IN (l_pobj) pectoris_27/NNP
D008755_D013035 NONE methylergonovine_19/NNP (r_pobj) of_18/IN (r_prep) dose_17/NN (r_pobj) of_13/IN (r_prep) injection_12/NN (r_dobj) use_9/VBP (r_relcl) tests_6/NNS (l_compound) provocation_5/NN (l_compound) spasm_4/NN
9660111
D014299_D007035 NONE TRI_4/NNP (r_nsubj) antagonize_11/VB (l_dobj) hypothermia_14/NN
D012110_D007035 CID reserpine_13/NN (r_compound) hypothermia_14/NN
D006916_D007035 NONE 5-hydroxytryptophan_22/CD (r_nummod) head_23/NN (r_compound) twitches_24/NNS (r_dobj) potentiate_20/VB (r_conj) antagonize_11/VB (l_dobj) hypothermia_14/NN
D014299_D006948 CID TRI_0/NNP (r_nsubj) increases_5/VBZ (l_dobj) hyperactivity_8/NN
D003913_D006948 CID amphetamine_13/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) hyperactivity_8/NN
D019257_D006948 CID quinpirole_15/NNP (r_conj) amphetamine_13/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) hyperactivity_8/NN
D004298_D006948 NONE dopamine_24/NN (r_compound) D2_25/NNP (r_nmod) effects_28/NNS (r_conj) quinpirole_15/NNP (r_conj) amphetamine_13/NN (r_pobj) by_10/IN (r_agent) induced_9/VBN (r_acl) hyperactivity_8/NN
D010656_D010554 NONE phenylephrine_7/NNP (l_acl) evaluated_15/VBN (l_prep) in_16/IN (l_pobj) test_20/NN (l_conj) aggressiveness_25/NN
D003000_D010554 NONE clonidine_28/NN (r_pobj) by_27/IN (r_agent) evoked_26/VBN (r_acl) aggressiveness_25/NN
16787750
D014635_D001927 CID acid_1/NN (r_nsubj) induced_2/VBD (l_dobj) cases_5/NNS (l_amod) encephalopathy--19_3/JJ
D014635_D001927 CID VPA_18/NNP (r_compound) therapy_20/NN (r_pobj) to_17/IN (r_prep) associated_16/VBN (r_acl) effect_15/NN (r_pobj) to_10/IN (r_prep) from_8/IN (r_prep) induced_2/VBD (l_dobj) cases_5/NNS (l_amod) encephalopathy--19_3/JJ
D014635_D001927 CID VPA_17/NNP (r_npadvmod) induced_19/VBN (r_amod) hepatotoxicity_20/NN (l_conj) encephalopathy_25/NN
D014635_D001927 CID VPA_22/NNP (r_npadvmod) induced_24/VBN (r_amod) encephalopathy_25/NN
D014635_D001927 CID VPA_4/NNP (r_npadvmod) induced_6/VBN (r_amod) encephalopathy_7/NNS
D014635_D001927 CID VPA_9/NNP (r_pobj) of_8/IN (r_prep) effect_7/NN (r_pobj) of_5/IN (r_prep) proof_4/NN (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) encephalopathy_13/NN
D014635_D001927 CID VPA_5/NNP (r_npadvmod) associated_7/VBN (r_amod) encephalopathy_8/NN
D014635_D010195 CID VPA_17/NNP (r_npadvmod) induced_19/VBN (r_amod) hepatotoxicity_20/NN (r_conj) patients_7/NNS (l_prep) including_9/VBG (l_pobj) pancreatitis_11/NN
D014635_D010195 CID VPA_22/NNP (r_npadvmod) induced_24/VBN (r_amod) encephalopathy_25/NN (r_conj) hepatotoxicity_20/NN (r_conj) patients_7/NNS (l_prep) including_9/VBG (l_pobj) pancreatitis_11/NN
D014635_D001855 CID VPA_17/NNP (r_npadvmod) induced_19/VBN (r_amod) hepatotoxicity_20/NN (r_conj) patients_7/NNS (l_prep) including_9/VBG (l_pobj) pancreatitis_11/NN (l_conj) suppression_15/NN
D014635_D001855 CID VPA_22/NNP (r_npadvmod) induced_24/VBN (r_amod) encephalopathy_25/NN (r_conj) hepatotoxicity_20/NN (r_conj) patients_7/NNS (l_prep) including_9/VBG (l_pobj) pancreatitis_11/NN (l_conj) suppression_15/NN
D014635_D056486 CID VPA_17/NNP (r_npadvmod) induced_19/VBN (r_amod) hepatotoxicity_20/NN
D014635_D056486 CID VPA_22/NNP (r_npadvmod) induced_24/VBN (r_amod) encephalopathy_25/NN (r_conj) hepatotoxicity_20/NN
D014635_D003244 CID VPA_4/NNP (r_npadvmod) induced_6/VBN (r_amod) encephalopathy_7/NNS (r_pobj) of_3/IN (r_prep) signs_2/NNS (r_nsubj) are_8/VBP (l_attr) consciousness_10/NN
D014635_D012640 NONE VPA_4/NNP (r_npadvmod) induced_6/VBN (r_amod) encephalopathy_7/NNS (r_pobj) of_3/IN (r_prep) signs_2/NNS (r_nsubj) are_8/VBP (l_advcl) slowing_16/VBG (l_dobj) frequency_20/NN (l_compound) seizure_19/NN
D014635_D022124 NONE VPA_4/NNP (r_npadvmod) induced_6/VBN (r_amod) encephalopathy_7/NNS (r_pobj) of_3/IN (r_prep) signs_2/NNS (r_nsubj) are_8/VBP (l_advcl) slowing_16/VBG (l_dobj) frequency_20/NN (l_prep) with_22/IN (l_conj) without_24/IN (l_pobj) hyperammonemia_25/NNP
18752389
C492458_D017093 NONE ezetimibe_2/NNP (r_advmod) induced_4/VBN (r_amod) failure_6/NN
C492458_D017093 NONE ezetimibe_13/RB (r_npadvmod) induced_15/VBN (r_amod) failure_17/NN
C108606_D056486 NONE ezetimibe_10/NNP (r_pobj) with_9/IN (r_prep) published_8/VBN (l_nsubjpass) events_3/NNS (l_amod) hepatotoxic_2/JJ
C108606_D056486 NONE Ezetimibe_0/NNP (r_nsubj) undergoes_1/VBZ (l_conj) inhibited_19/VBN (l_advcl) resulting_27/VBG (l_prep) in_28/IN (l_pobj) exposure_31/NN (l_conj) hepatotoxicity_34/NN
C108606_D056486 NONE ezetimibe_17/JJ (r_compound) inhibition_18/NN (r_pobj) by_16/IN (r_prep) exposure_15/NN (r_attr) is_11/VBZ (l_nsubj) mechanism_4/NN (l_prep) of_5/IN (l_pobj) hepatotoxicity_10/NN
C492458_D056486 CID ezetimibe_17/NNP (r_conj) ezetimibe_10/NNP (r_pobj) with_9/IN (r_prep) published_8/VBN (l_nsubjpass) events_3/NNS (l_amod) hepatotoxic_2/JJ
C492458_D056486 CID Simvastatinezetimibe_0/NNP (r_nsubjpass) discontinued_12/VBN (l_conj) excluded_21/VBN (l_nsubjpass) causes_17/NNS (l_prep) of_18/IN (l_pobj) hepatotoxicity_19/NN
C492458_D056486 CID simvastatinezetimibe_7/NN (r_advmod) induced_9/VBN (r_amod) hepatotoxicity_10/NN
C492458_D056486 CID ezetimibe_10/NNP (r_pobj) with_7/IN (r_prep) hepatotoxicity_6/NN
D019821_D017114 NONE simvastatin_21/RB (r_nmod) day_25/NN (r_pobj) from_20/IN (r_prep) conversion_19/NN (r_pobj) after_18/IN (r_prep) developed_9/VBD (l_dobj) failure_12/NN
C492458_D017114 CID mg_33/NNP (r_nmod) day_35/NN (r_npadvmod) developed_9/VBD (l_dobj) failure_12/NN
D019821_D056486 NONE simvastatin_9/NN (r_pobj) with_8/IN (r_prep) maintained_7/VBN (l_prep) for_10/IN (l_pobj) months_12/NNS (l_prep) before_13/IN (l_pobj) conversion_15/NN (l_prep) without_16/IN (l_pobj) evidence_17/NN (l_prep) of_18/IN (l_pobj) hepatotoxicity_19/NN
D019821_D056486 NONE simvastatin_30/NN (r_compound) exposure_31/NN (l_conj) hepatotoxicity_34/NN
D019821_D056486 NONE simvastatin_14/NN (r_compound) exposure_15/NN (r_attr) is_11/VBZ (l_nsubj) mechanism_4/NN (l_prep) of_5/IN (l_pobj) hepatotoxicity_10/NN
C492458_D003866 NONE Simvastatinezetimibe_0/NNP (l_conj) escitalopram_2/NNP (l_relcl) taking_7/VBG (l_prep) for_8/IN (l_pobj) depression_9/NN
D015283_D003866 NONE escitalopram_2/NNP (l_relcl) taking_7/VBG (l_prep) for_8/IN (l_pobj) depression_9/NN
D015283_D056486 NONE escitalopram_2/NNP (r_conj) Simvastatinezetimibe_0/NNP (r_nsubjpass) discontinued_12/VBN (l_conj) excluded_21/VBN (l_nsubjpass) causes_17/NNS (l_prep) of_18/IN (l_pobj) hepatotoxicity_19/NN
D014530_D056486 NONE diphosphate_6/NNP (r_amod) glucoronosyltransferases_7/NNS (r_pobj) by_4/IN (r_prep) undergoes_1/VBZ (l_conj) inhibited_19/VBN (l_advcl) resulting_27/VBG (l_prep) in_28/IN (l_pobj) exposure_31/NN (l_conj) hepatotoxicity_34/NN
C532833_D056486 NONE acid_25/NN (r_pobj) of_22/IN (r_prep) glucuronidation_21/NN (r_dobj) inhibited_19/VBN (l_advcl) resulting_27/VBG (l_prep) in_28/IN (l_pobj) exposure_31/NN (l_conj) hepatotoxicity_34/NN
3192036
10406016
C007789_D002543 NONE fucoidan_2/NNP (r_compound) treatment_3/NN (l_prep) on_4/IN (l_pobj) hemorrhage_9/NN
C007789_D002543 NONE fucoidan_5/NNP (r_dobj) tested_1/VBD (l_prep) in_17/IN (l_pobj) model_20/NN (l_prep) of_21/IN (l_pobj) hemorrhage_23/NN
C007789_D001925 NONE fucoidan_5/NNP (l_relcl) reported_10/VBN (l_xcomp) reduce_12/VB (l_dobj) damage_15/NN
C007789_D020141 CID Fucoidan_0/NNP (r_npadvmod) treated_2/VBN (r_amod) rats_3/NNS (r_nsubj) exhibited_4/VBD (l_dobj) evidence_5/NN (l_prep) of_6/IN (l_pobj) clotting_9/NN
C007789_D020141 CID Fucoidan_0/NNP (r_npadvmod) treated_2/VBN (r_amod) rats_3/NNS (r_nsubj) exhibited_4/VBD (l_dobj) evidence_5/NN (l_prep) of_6/IN (l_pobj) clotting_9/NN (l_conj) hemodilution_11/NN
C007789_D006406 NONE Fucoidan_0/NNP (r_npadvmod) treated_2/VBN (r_amod) rats_3/NNS (r_nsubj) exhibited_4/VBD (l_conj) had_13/VBD (l_dobj) hematomas_15/NNS
C007789_D006406 NONE Fucoidan_0/NNP (r_npadvmod) treated_2/VBN (r_amod) rats_3/NNS (r_nsubj) exhibited_4/VBD (l_conj) had_13/VBD (l_conj) tended_18/VBD (l_xcomp) have_20/VB (l_prep) in_23/IN (l_pobj) vicinity_25/NN (l_prep) of_26/IN (l_pobj) hematoma_28/NN
C007789_D007249 NONE Fucoidan_0/NNP (r_npadvmod) treated_2/VBN (r_amod) rats_3/NNS (r_nsubj) exhibited_4/VBD (l_conj) had_13/VBD (l_conj) tended_18/VBD (l_xcomp) have_20/VB (l_dobj) inflammation_22/NN
19346865
D008795_D001927 CID metronidazole_5/NN (r_npadvmod) induced_7/VBN (r_amod) encephalopathy_8/NN (r_pobj) in_4/IN (r_prep) lesion_3/NN
D008795_D001927 CID metronidazole_5/NN (r_npadvmod) induced_7/VBN (r_amod) encephalopathy_8/NN
D008795_D001927 CID metronidazole_9/NN (r_npadvmod) induced_11/VBN (r_amod) encephalopathy_12/NN (r_pobj) in_8/IN (r_prep) lesions_7/NNS
D008795_D001927 CID metronidazole_9/NN (r_npadvmod) induced_11/VBN (r_amod) encephalopathy_12/NN
D008795_D001927 CID metronidazole_20/NN (r_npadvmod) induced_22/VBN (r_amod) encephalopathy_23/NN
D008795_D001927 CID metronidazole_11/NN (r_npadvmod) induced_13/VBN (r_amod) encephalopathy_14/NN (r_pobj) for_10/IN (r_prep) characteristic_9/NN (r_pobj) as_7/IN (r_prep) considered_6/VBN (l_nsubjpass) lesions_3/NNS
D008795_D001927 CID metronidazole_11/NN (r_npadvmod) induced_13/VBN (r_amod) encephalopathy_14/NN
18464113
D019259_D006509 NONE Lamivudine_0/NNP (l_prep) for_1/IN (l_pobj) prevention_3/NN (l_prep) of_4/IN (l_pobj) reactivation_8/NN (l_compound) virus_7/NN (l_compound) B_6/NNP
D019259_D006509 NONE lamivudine_20/NNP (r_dobj) received_16/VBD (l_nsubj) patients_5/NNS (l_relcl) have_7/VBP (l_dobj) malignancies_11/NNS (l_prep) with_12/IN (l_pobj) infection_15/NN
D019259_D006509 NONE lamivudine_34/NNP (r_dobj) receive_33/VB (r_relcl) group_29/NN (r_pobj) with_26/IN (r_prep) compared_25/VBN (r_prep) received_16/VBD (l_nsubj) patients_5/NNS (l_relcl) have_7/VBP (l_dobj) malignancies_11/NNS (l_prep) with_12/IN (l_pobj) infection_15/NN
D019259_D009369 NONE Lamivudine_0/NNP (l_prep) for_1/IN (l_pobj) prevention_3/NN (l_prep) of_4/IN (l_pobj) reactivation_8/NN (l_prep) in_9/IN (l_pobj) patients_20/NNS (l_compound) cancer_19/NN
D019259_D009369 NONE lamivudine_20/NNP (r_dobj) received_16/VBD (l_nsubj) patients_5/NNS (l_compound) cancer_4/NN
D019259_D009369 NONE lamivudine_34/NNP (r_dobj) receive_33/VB (r_relcl) group_29/NN (r_pobj) with_26/IN (r_prep) compared_25/VBN (r_prep) received_16/VBD (l_nsubj) patients_5/NNS (l_compound) cancer_4/NN
D019259_D009369 NONE lamivudine_5/NN (r_nsubj) decreases_7/VBZ (l_dobj) incidence_9/NN (l_prep) of_10/IN (l_pobj) reactivation_12/NN (l_conj) morbidity_15/NN (l_prep) in_16/IN (l_pobj) patients_18/NNS (l_compound) cancer_17/NN
D006514_D006509 CID antigen_14/NN (r_nmod) patients_20/NNS (r_pobj) in_9/IN (r_prep) reactivation_8/NN (l_compound) virus_7/NN (l_compound) B_6/NNP
D006514_D006509 CID HBSAG_16/NNP (r_nmod) patients_20/NNS (r_pobj) in_9/IN (r_prep) reactivation_8/NN (l_compound) virus_7/NN (l_compound) B_6/NNP
D006514_D009369 NONE antigen_14/NN (r_nmod) patients_20/NNS (l_compound) cancer_19/NN
D006514_D009369 NONE HBSAG_16/NNP (r_nmod) patients_20/NNS (l_compound) cancer_19/NN
D019259_D019337 NONE lamivudine_20/NNP (r_dobj) received_16/VBD (l_nsubj) patients_5/NNS (l_relcl) have_7/VBP (l_dobj) malignancies_11/NNS
D019259_D019337 NONE lamivudine_34/NNP (r_dobj) receive_33/VB (r_relcl) group_29/NN (r_pobj) with_26/IN (r_prep) compared_25/VBN (r_prep) received_16/VBD (l_nsubj) patients_5/NNS (l_relcl) have_7/VBP (l_dobj) malignancies_11/NNS
D019259_D056486 NONE lamivudine_3/NNP (r_compound) group_4/NNP (l_appos) hepatitis_6/NNP
9721172
D007052_D001649 NONE ibuprofen_30/NN (r_compound) use_31/NN (r_pobj) with_29/IN (r_prep) associated_28/VBN (l_nsubjpass) child_3/NN (l_relcl) developed_5/VBD (l_dobj) syndrome_15/NN
D007052_D013262 CID ibuprofen_30/NN (r_compound) use_31/NN (r_pobj) with_29/IN (r_prep) associated_28/VBN (l_nsubjpass) child_3/NN (l_relcl) developed_5/VBD (l_advcl) described_23/VBN (l_nsubjpass) syndrome_21/NN
D014580_D002779 NONE acid_4/NN (r_pobj) with_2/IN (r_prep) therapy_1/NN (r_pobj) Despite_0/IN (r_prep) was_15/VBD (l_nsubj) disease_14/NN
D014580_D005355 NONE acid_4/NN (r_pobj) with_2/IN (r_prep) therapy_1/NN (r_pobj) Despite_0/IN (r_prep) was_15/VBD (l_prep) with_18/IN (l_pobj) cirrhosis_19/NN
D011241_D002779 NONE prednisone_6/NN (r_conj) acid_4/NN (r_pobj) with_2/IN (r_prep) therapy_1/NN (r_pobj) Despite_0/IN (r_prep) was_15/VBD (l_nsubj) disease_14/NN
D011241_D005355 NONE prednisone_6/NN (r_conj) acid_4/NN (r_pobj) with_2/IN (r_prep) therapy_1/NN (r_pobj) Despite_0/IN (r_prep) was_15/VBD (l_prep) with_18/IN (l_pobj) cirrhosis_19/NN
D016559_D002779 NONE tacrolimus_10/NN (r_conj) prednisone_6/NN (r_conj) acid_4/NN (r_pobj) with_2/IN (r_prep) therapy_1/NN (r_pobj) Despite_0/IN (r_prep) was_15/VBD (l_nsubj) disease_14/NN
D016559_D005355 NONE tacrolimus_10/NN (r_conj) prednisone_6/NN (r_conj) acid_4/NN (r_pobj) with_2/IN (r_prep) therapy_1/NN (r_pobj) Despite_0/IN (r_prep) was_15/VBD (l_prep) with_18/IN (l_pobj) cirrhosis_19/NN
19058010
D010936_D009203 NONE tea_3/NN (r_nmod) combination_7/NN (r_pobj) of_1/IN (r_prep) Effect_0/NN (r_nsubj) induced_10/VBN (l_dobj) infarction_12/NN
D010936_D009203 NONE tea_12/NN (r_pobj) of_10/IN (r_prep) effects_9/NNS (l_prep) on_16/IN (l_pobj) weight_18/NN (l_conj) weight_21/NN (l_conj) enzymes_25/NNS (l_conj) peroxidation_28/NN (l_conj) antioxidants_31/NNS (l_prep) in_36/IN (l_pobj) isoproterenol_37/NNP (l_appos) infarction_41/NN
D010936_D009203 NONE tea_9/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (r_nsubj) induced_15/VBD (l_dobj) infarction_17/NN
D014810_D009203 NONE E_6/NN (r_conj) tea_3/NN (r_nmod) combination_7/NN (r_pobj) of_1/IN (r_prep) Effect_0/NN (r_nsubj) induced_10/VBN (l_dobj) infarction_12/NN
D014810_D009203 NONE E_15/NN (r_conj) tea_12/NN (r_pobj) of_10/IN (r_prep) effects_9/NNS (l_prep) on_16/IN (l_pobj) weight_18/NN (l_conj) weight_21/NN (l_conj) enzymes_25/NNS (l_conj) peroxidation_28/NN (l_conj) antioxidants_31/NNS (l_prep) in_36/IN (l_pobj) isoproterenol_37/NNP (l_appos) infarction_41/NN
D014810_D009203 NONE E_12/NN (r_conj) tea_9/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (r_nsubj) induced_15/VBD (l_dobj) infarction_17/NN
D007545_D009203 CID isoproterenol_9/NNP (r_pobj) in_8/IN (r_prep) combination_7/NN (r_pobj) of_1/IN (r_prep) Effect_0/NN (r_nsubj) induced_10/VBN (l_dobj) infarction_12/NN
D007545_D009203 CID isoproterenol_37/NNP (l_appos) infarction_41/NN
D007545_D009203 CID ISO)-induced_39/NNP (r_det) infarction_41/NN
D007545_D009203 CID ISO_14/NN (r_pobj) during_13/IN (r_prep) effect_6/NN (r_nsubj) induced_15/VBD (l_dobj) infarction_17/NN
15120741
D010862_D013226 CID pilocarpine_5/NN (r_compound) injection_6/NN (r_nsubj) causes_7/VBZ (l_ccomp) SE_11/NNP (l_nmod) epilepticus_9/NN
D010862_D013226 CID pilocarpine_5/NN (r_compound) injection_6/NN (r_nsubj) causes_7/VBZ (l_ccomp) SE_11/NNP
D010862_D013226 CID pilocarpine_34/NN (r_npadvmod) treated_36/VBN (r_amod) mice_37/NNS (l_relcl) experience_41/VB (l_dobj) SE_42/NNP
D010862_D012640 CID pilocarpine_5/NN (r_compound) injection_6/NN (r_nsubj) causes_7/VBZ (l_conj) development_16/NN (l_prep) of_17/IN (l_pobj) seizures_19/NNS
D008274_D013226 NONE Mg(2+)-free_1/CD (r_nummod) bicuculline_5/NNP (r_pobj) In_0/IN (r_prep) resulted_21/VBD (l_prep) in_22/IN (l_pobj) spike_26/NN (l_prep) from_30/IN (l_pobj) mice_32/NNS (l_conj) mice_37/NNS (l_relcl) experience_41/VB (l_dobj) SE_42/NNP
D001640_D013226 NONE bicuculline_5/NNP (r_pobj) In_0/IN (r_prep) resulted_21/VBD (l_prep) in_22/IN (l_pobj) spike_26/NN (l_prep) from_30/IN (l_pobj) mice_32/NNS (l_conj) mice_37/NNS (l_relcl) experience_41/VB (l_dobj) SE_42/NNP
D018698_D013226 NONE glutamate_37/NN (r_compound) antagonists_39/NNS (r_pobj) by_35/IN (r_agent) blocked_34/VBN (r_relcl) duration_30/NN (r_pobj) of_25/IN (r_prep) afterdischarges_24/NNS (r_conj) shifts_21/NNS (r_pobj) by_18/IN (r_agent) resulted_6/VBD (l_prep) In_0/IN (l_pobj) survivors_2/NNS (l_compound) SE_1/NNP
D018698_D013226 NONE glutamate_1/NN (r_compound) photostimulation_2/NN (r_nsubj) resulted_15/VBD (l_prep) in_16/IN (l_pobj) responses_18/NNS (l_prep) of_19/IN (l_pobj) duration_24/NN (l_prep) from_27/IN (l_pobj) survivors_29/NNS (l_compound) SE_28/NNP
150790
D011736_D002653 NONE pyridoxine_1/NN (r_npadvmod) dependent_3/JJ (r_amod) disorder_5/NN
D007538_D002653 CID isoniazid_8/NNS (r_pobj) by_7/IN (r_agent) unmasked_6/VBN (r_acl) disorder_5/NN
D007538_D002653 CID isoniazid_22/NNP (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) after_17/IN (r_prep) had_5/VBD (l_dobj) deterioration_7/NN
D007538_D006948 CID isoniazid_22/NNP (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) after_17/IN (r_prep) had_5/VBD (l_prep) with_9/IN (l_pobj) hyperkinesis_10/NN
D007538_D001523 NONE isoniazid_22/NNP (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) after_17/IN (r_prep) had_5/VBD (l_prep) with_9/IN (l_pobj) hyperkinesis_10/NN (l_conj) irritability_12/NN
D007538_D012893 NONE isoniazid_22/NNP (r_pobj) of_21/IN (r_prep) administration_20/NN (r_pobj) after_17/IN (r_prep) had_5/VBD (l_prep) with_9/IN (l_pobj) hyperkinesis_10/NN (l_conj) irritability_12/NN (l_conj) difficulties_16/NNS
D011736_D006948 NONE pyridoxine_3/NN (r_pobj) of_2/IN (r_prep) withdrawal_1/NN (r_nsubjpass) associated_5/VBN (l_prep) with_6/IN (l_pobj) return_7/NN (l_prep) of_8/IN (l_pobj) hyperkinesis_10/NNP
15863244
C106876_D064420 NONE DFU_17/NNP (r_appos) rats_15/NNS (r_pobj) in_12/IN (r_prep) inhibitors_11/NNS (r_pobj) of_4/IN (r_prep) toxicity_3/NN
C106876_D064420 NONE DFU_22/NNP (r_appos) toxicity_10/NN
C106876_D064420 NONE )_25/-RRB- (r_punct) 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl_24/CD (r_punct) was_5/VBD (l_xcomp) evaluate_7/VB (l_dobj) toxicity_10/NN
C106876_D064420 NONE DFU_10/NNP (r_nmod) toxicity_12/NN
D010894_D064420 NONE piroxicam_19/NNP (r_compound) study_20/NN (r_conj) DFU_17/NNP (r_appos) rats_15/NNS (r_pobj) in_12/IN (r_prep) inhibitors_11/NNS (r_pobj) of_4/IN (r_prep) toxicity_3/NN
D010894_D064420 NONE piroxicam_17/NNP (r_pobj) of_11/IN (r_prep) toxicity_10/NN
D010894_D064420 NONE piroxicam_24/NNP (r_pobj) of_23/IN (r_prep) dose_22/NN (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_acl) rats_17/NNS (r_pobj) in_16/IN (r_prep) found_15/VBN (l_nsubjpass) toxicity_1/NN
D010894_D006345 NONE piroxicam_23/NNP (r_pobj) to_22/IN (r_prep) exposed_21/VBN (r_acl) fetuses_20/NNS (r_pobj) for_18/IN (r_prep) performed_17/VBN (l_nsubjpass) analysis_3/NN (l_prep) for_4/IN (l_pobj) septal_6/JJ (l_conj) defects_15/NNS
D010894_D009436 NONE piroxicam_23/NNP (r_pobj) to_22/IN (r_prep) exposed_21/VBN (r_acl) fetuses_20/NNS (r_pobj) for_18/IN (r_prep) performed_17/VBN (l_nsubjpass) analysis_3/NN (l_prep) for_4/IN (l_pobj) septal_6/JJ (l_conj) defects_15/NNS
D010894_D005317 CID piroxicam_24/NNP (r_pobj) of_23/IN (r_prep) dose_22/NN (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_acl) rats_17/NNS (r_pobj) in_16/IN (r_prep) found_15/VBN (l_nsubjpass) toxicity_1/NN (l_conj) retardation_5/NN
D010894_D009139 CID piroxicam_24/NNP (r_pobj) of_23/IN (r_prep) dose_22/NN (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_acl) rats_17/NNS (r_pobj) in_16/IN (r_prep) found_15/VBN (l_nsubjpass) toxicity_1/NN (l_conj) retardation_5/NN (l_conj) increase_8/NN (l_prep) of_9/IN (l_pobj) variations_13/NNS
19820426
C558899_D066126 NONE ritonavir_10/NNPS (r_compound) therapy_11/NN (r_pobj) to_7/IN (r_prep) related_6/VBN (r_acl) toxicity_5/NN
C558899_D006327 CID ritonavir_15/NNPS (r_compound) therapy_16/NNP (r_pobj) to_12/IN (r_prep) related_11/VBN (r_acl) block_7/NN
C558899_D002311 CID ritonavir_15/NNPS (r_compound) therapy_16/NNP (r_pobj) to_12/IN (r_prep) related_11/VBN (r_acl) block_7/NN (l_conj) cardiomyopathy_10/NN
C558899_D001919 CID ritonavir_15/NNPS (r_compound) therapy_16/NNP (r_pobj) to_12/IN (r_prep) related_11/VBN (r_acl) block_7/NN (r_dobj) developed_4/VBD (l_advcl) developed_29/VBD (l_dobj) bradycardia_31/NNS
20098969
D008694_D001145 NONE Methamphetamine_0/NN (r_nsubj) is_1/VBZ (l_attr) stimulant_7/NN (l_relcl) increases_9/VBZ (l_conj) produce_16/VB (l_dobj) effects_18/NNS (l_prep) as_20/IN (l_pobj) dysrhythmias_22/NNS
D008694_D006973 NONE Methamphetamine_0/NN (r_nsubj) is_1/VBZ (l_attr) stimulant_7/NN (l_relcl) increases_9/VBZ (l_conj) produce_16/VB (l_dobj) effects_18/NNS (l_prep) as_20/IN (l_pobj) dysrhythmias_22/NNS (l_conj) hypertension_24/NN
D008694_D006212 NONE Methamphetamine_0/NN (r_nsubj) is_1/VBZ (l_attr) stimulant_7/NN (l_relcl) increases_9/VBZ (l_conj) produce_16/VB (l_dobj) effects_18/NNS (l_prep) as_20/IN (l_pobj) dysrhythmias_22/NNS (l_conj) hypertension_24/NN (l_conj) hallucinations_26/NNS
D008694_D001523 NONE Methamphetamine_0/NN (r_nsubj) is_1/VBZ (l_attr) stimulant_7/NN (l_relcl) increases_9/VBZ (l_conj) produce_16/VB (l_dobj) effects_18/NNS (l_prep) as_20/IN (l_pobj) dysrhythmias_22/NNS (l_conj) hypertension_24/NN (l_conj) hallucinations_26/NNS (l_conj) behavior_30/NN
D008694_D014987 NONE methamphetamine_3/NN (r_dobj) abusing_2/VBG (r_acl) patients_1/NNS (r_nsubj) present_5/VB (l_prep) with_6/IN (l_pobj) hygiene_9/NN (l_conj) xerostomia_11/NN
D008694_D003731 CID methamphetamine_3/NN (r_dobj) abusing_2/VBG (r_acl) patients_1/NNS (r_nsubj) present_5/VB (l_prep) with_6/IN (l_pobj) hygiene_9/NN (l_conj) xerostomia_11/NN (l_conj) caries_14/NNS
D008694_D003731 CID methamphetamine_5/NN (r_pobj) of_4/IN (r_prep) use_3/NN (r_dobj) reported_1/VBD (l_conj) experienced_12/VBN (l_dobj) episodes_16/NNS
D008694_-1 NONE methamphetamine_3/NN (r_dobj) abusing_2/VBG (r_acl) patients_1/NNS (r_nsubj) present_5/VB (l_prep) with_6/IN (l_pobj) hygiene_9/NN (l_conj) xerostomia_11/NN (l_conj) caries_14/NNS (l_appos) mouth_18/NN
D008694_-1 NONE methamphetamines_23/NNS (r_dobj) abusing_22/VBG (r_relcl) patients_18/NNS (r_dobj) manage_17/VB (r_conj) recognize_15/VB (r_ccomp) help_12/VB (r_advcl) presented_10/VBN (l_nsubjpass) case_2/NN (l_acl) showing_3/VBG (l_dobj) manifestations_5/NNS (l_prep) of_6/IN (l_pobj) mouth_8/NN
D008694_D057085 NONE methamphetamine_3/NN (r_dobj) abusing_2/VBG (r_acl) patients_1/NNS (r_nsubj) present_5/VB (l_conj) wear_25/NN
12639165
D013988_D002779 CID Ticlopidine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) hepatitis_4/NN
D013988_D002779 CID ticlopidine_5/NN (r_npadvmod) induced_7/VBN (r_amod) hepatitis_9/NNP
D013988_D002779 CID ticlopidine_8/NN (r_dobj) receiving_7/VBG (r_pcomp) after_6/IN (r_prep) developed_2/VBD (l_dobj) hepatitis_5/NN
D013988_D002779 CID ticlopidine_10/NN (r_appos) agent_9/NN (r_pobj) of_6/IN (r_prep) complication_5/NN (r_attr) is_2/VBZ (l_nsubj) hepatitis_1/NN
D013988_D002779 CID ticlopidine_7/NN (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) following_4/VBG (r_prep) developed_2/VBD (l_conj) showed_9/VBD (l_dobj) characteristics_14/NNS (l_prep) of_15/IN (l_pobj) hepatitis_17/NNP
D013988_D002779 CID ticlopidine_4/NN (r_npadvmod) induced_6/VBN (r_amod) cholestasis_7/NN
D013988_D002779 CID ticlopidine_8/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (r_attr) is_2/VBZ (l_nsubj) hepatitis_1/NN
D013988_D056486 CID Ticlopidine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) hepatitis_4/NN
D013988_D056486 CID ticlopidine_5/NN (r_npadvmod) induced_7/VBN (r_amod) hepatitis_9/NNP
D013988_D056486 CID ticlopidine_8/NN (r_dobj) receiving_7/VBG (r_pcomp) after_6/IN (r_prep) developed_2/VBD (l_dobj) hepatitis_5/NN
D013988_D056486 CID ticlopidine_10/NN (r_appos) agent_9/NN (r_pobj) of_6/IN (r_prep) complication_5/NN (r_attr) is_2/VBZ (l_nsubj) hepatitis_1/NN
D013988_D056486 CID ticlopidine_7/NN (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) following_4/VBG (r_prep) developed_2/VBD (l_conj) showed_9/VBD (l_dobj) characteristics_14/NNS (l_prep) of_15/IN (l_pobj) hepatitis_17/NNP
D013988_D056486 CID ticlopidine_8/NN (r_pobj) of_7/IN (r_prep) effect_6/NN (r_attr) is_2/VBZ (l_nsubj) hepatitis_1/NN
D013988_D007565 CID ticlopidine_7/NN (r_pobj) with_6/IN (r_prep) treatment_5/NN (r_pobj) following_4/VBG (r_prep) developed_2/VBD (l_dobj) jaundice_3/NN
8864707
D010672_D004827 NONE phenytoin_10/NNP (r_compound) overdosages_11/NNS (r_pobj) after_9/IN (r_prep) volumetry_2/NN (l_prep) in_6/IN (l_pobj) patients_8/NNS (l_amod) epileptic_7/JJ
D010672_D062787 CID phenytoin_10/NNP (r_compound) overdosages_11/NNS
D010672_D062787 CID phenytoin_3/NN (r_compound) overdosage_4/NN
D010672_D062787 CID phenytoin_17/NNP (r_amod) medication_18/NN (r_nsubj) was_19/VBD (r_ccomp) unlikely_15/JJ (r_acomp) is_14/VBZ (r_conj) result_8/VB (l_nsubj) overdosage_4/NN
D010672_D002526 NONE phenytoin_11/NN (r_compound) medication_12/NN (l_conj) atrophy_15/NN
D010672_D002526 NONE phenytoin_3/NN (r_compound) overdosage_4/NN (r_nsubj) result_8/VB (l_prep) in_9/IN (l_pobj) atrophy_11/NN
D010672_D002526 NONE phenytoin_3/NN (r_compound) overdosage_4/NN (r_nsubj) result_8/VB (l_conj) is_14/VBZ (l_acomp) unlikely_15/JJ (l_ccomp) was_19/VBD (l_attr) cause_22/NN (l_prep) of_23/IN (l_pobj) atrophy_25/NN
D010672_D002526 NONE phenytoin_17/NNP (r_amod) medication_18/NN (r_nsubj) was_19/VBD (r_ccomp) unlikely_15/JJ (r_acomp) is_14/VBZ (r_conj) result_8/VB (l_prep) in_9/IN (l_pobj) atrophy_11/NN
D010672_D002526 NONE phenytoin_17/NNP (r_amod) medication_18/NN (r_nsubj) was_19/VBD (l_attr) cause_22/NN (l_prep) of_23/IN (l_pobj) atrophy_25/NN
D010672_D012640 NONE phenytoin_15/NN (r_compound) levels_17/NNS (r_pobj) of_14/IN (r_prep) elevation_13/NN (r_conj) duration_11/NN (l_compound) seizure_10/NN
20698227
D012254_D000743 NONE ribavirin_8/NN (r_nmod) anemia_11/NN
D012254_D006461 NONE ribavirin_1/NNP (r_nsubjpass) found_4/VBN (l_conj) found_21/VBN (l_xcomp) cause_23/VB (l_dobj) hemolysis_25/NN
C473478_D006461 CID sunitinib_16/NNP (r_pobj) as_15/IN (r_prep) inhibitors_13/NNS (r_pobj) of_11/IN (r_prep) number_10/NN (r_conj) angiogenesis_7/NN (r_dobj) inhibit_6/VB (r_xcomp) found_4/VBN (l_conj) found_21/VBN (l_xcomp) cause_23/VB (l_dobj) hemolysis_25/NN
C471405_D006461 CID sorafenib_18/NNP (r_conj) sunitinib_16/NNP (r_pobj) as_15/IN (r_prep) inhibitors_13/NNS (r_pobj) of_11/IN (r_prep) number_10/NN (r_conj) angiogenesis_7/NN (r_dobj) inhibit_6/VB (r_xcomp) found_4/VBN (l_conj) found_21/VBN (l_xcomp) cause_23/VB (l_dobj) hemolysis_25/NN
C100416_D019698 NONE 2a_14/NN (r_pobj) by_10/IN (r_agent) treated_9/VBN (l_nsubjpass) patients_1/NNS (l_acl) infected_3/VBN (l_prep) with_4/IN (l_pobj) virus_7/NN
D012254_D019698 NONE ribavirin_16/NNP (r_conj) treated_9/VBN (l_nsubjpass) patients_1/NNS (l_acl) infected_3/VBN (l_prep) with_4/IN (l_pobj) virus_7/NN
D012254_D019698 NONE ribavirin_16/NN (r_amod) anemia_18/NN (r_conj) markers_14/NNS (r_pobj) between_11/IN (r_prep) link_10/NN (l_prep) in_19/IN (l_pobj) patients_20/NNS (l_prep) with_21/IN (l_pobj) C_23/NNP
D012254_D000740 NONE ribavirin_16/NN (r_amod) anemia_18/NN
20882060
D009496_D002375 NONE neurotensin_3/NNP (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_4/IN (l_pobj) catalepsy_9/NN
D009496_D002375 NONE neurotensin_3/NNP (r_pobj) of_2/IN (r_prep) infusions_1/NNS (r_nsubj) reversed_8/VBD (l_dobj) catalepsy_13/NN
D006220_D002375 CID haloperidol_5/NNP (r_npadvmod) induced_7/VBN (r_amod) catalepsy_9/NN
D006220_D002375 CID haloperidol_9/NNP (r_npadvmod) induced_11/VBN (r_amod) catalepsy_13/NN
D009496_D010302 NONE neurotensin_10/NNP (r_pobj) of_8/IN (r_prep) effects_7/NNS (l_prep) on_11/IN (l_pobj) symptoms_16/NNS
D006220_D010302 NONE haloperidol_12/NNP (r_npadvmod) induced_14/VBN (r_amod) symptoms_16/NNS
17562951
D007479_D051436 NONE iopamidol_14/NN (r_pobj) of_13/IN (r_prep) comparison_12/NN (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) disease_22/NN
C044834_D051436 NONE iodixanol_16/NN (r_conj) iopamidol_14/NN (r_pobj) of_13/IN (r_prep) comparison_12/NN (l_prep) in_17/IN (l_pobj) patients_18/NNS (l_prep) with_19/IN (l_pobj) disease_22/NN
D000111_D003920 NONE acetylcysteine_16/NN (r_pobj) of_13/IN (r_prep) use_12/NN (r_appos) volume_5/NN (l_appos) presence_7/NN (l_prep) of_8/IN (l_pobj) mellitus_10/NN
D007479_D007674 CID iopamidol_23/NNP (r_pobj) of_22/IN (r_prep) administration_21/NN (r_pobj) after_18/IN (r_prep) is_14/VBZ (l_nsubj) rate_1/NN (l_prep) of_2/IN (l_pobj) nephropathy_6/NN
D007479_D003920 NONE iopamidol_23/NNP (r_pobj) of_22/IN (r_prep) administration_21/NN (l_prep) with_32/IN (l_conj) without_34/IN (l_pobj) mellitus_36/NN
C044834_D007674 CID iodixanol_25/NNP (r_conj) iopamidol_23/NNP (r_pobj) of_22/IN (r_prep) administration_21/NN (r_pobj) after_18/IN (r_prep) is_14/VBZ (l_nsubj) rate_1/NN (l_prep) of_2/IN (l_pobj) nephropathy_6/NN
C044834_D003920 NONE iodixanol_25/NNP (r_conj) iopamidol_23/NNP (r_pobj) of_22/IN (r_prep) administration_21/NN (l_prep) with_32/IN (l_conj) without_34/IN (l_pobj) mellitus_36/NN
2670794
D000809_D011665 NONE angiotensin_5/NN (r_compound) converting_6/VBG (r_compound) enzyme_7/NNS (r_pobj) of_4/IN (r_prep) inhibitor_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_11/IN (l_pobj) insufficiency_15/NN
D000809_D011665 NONE angiotensin_11/NN (r_compound) converting_12/VBG (r_compound) enzyme_13/NNS (r_pobj) of_10/IN (r_prep) inhibitor_9/NN (r_appos) Injection_0/NN (r_nsubj) reduced_18/VBD (l_dobj) insufficiency_23/NN
D000809_D051437 NONE angiotensin_5/NN (r_compound) converting_6/VBG (r_compound) enzyme_7/NNS (r_pobj) of_4/IN (r_prep) inhibitor_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_11/IN (l_pobj) insufficiency_15/NN
D000809_D051437 NONE angiotensin_11/NN (r_compound) converting_12/VBG (r_compound) enzyme_13/NNS (r_pobj) of_10/IN (r_prep) inhibitor_9/NN (r_appos) Injection_0/NN (r_nsubj) reduced_18/VBD (l_dobj) insufficiency_23/NN
D000809_D004211 NONE angiotensin_5/NN (r_compound) converting_6/VBG (r_compound) enzyme_7/NNS (r_pobj) of_4/IN (r_prep) inhibitor_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_11/IN (l_pobj) insufficiency_15/NN (l_prep) due_16/IN (l_pobj) coagulation_19/NN
D002216_D011665 NONE Captopril_9/NNP (r_appos) enzyme_7/NNS (r_pobj) of_4/IN (r_prep) inhibitor_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_11/IN (l_pobj) insufficiency_15/NN
D002216_D011665 NONE Captopril_2/NNP (r_pobj) of_1/IN (r_prep) Injection_0/NN (r_nsubj) reduced_18/VBD (l_dobj) insufficiency_23/NN
D002216_D051437 NONE Captopril_9/NNP (r_appos) enzyme_7/NNS (r_pobj) of_4/IN (r_prep) inhibitor_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_11/IN (l_pobj) insufficiency_15/NN
D002216_D051437 NONE Captopril_2/NNP (r_pobj) of_1/IN (r_prep) Injection_0/NN (r_nsubj) reduced_18/VBD (l_dobj) insufficiency_23/NN
D002216_D004211 NONE Captopril_9/NNP (r_appos) enzyme_7/NNS (r_pobj) of_4/IN (r_prep) inhibitor_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_11/IN (l_pobj) insufficiency_15/NN (l_prep) due_16/IN (l_pobj) coagulation_19/NN
D014508_D007674 NONE urea_9/NN (r_pobj) in_7/IN (r_prep) increase_6/NN (r_pobj) by_4/IN (r_agent) reflected_3/VBN (r_advcl) damage_1/NN
D002216_D007674 NONE Captopril_17/NNP (r_pobj) by_16/IN (r_agent) prevented_15/VBN (l_nsubjpass) damage_1/NN
D002216_D007674 NONE Captopril_0/NNP (r_nsubj) reduce_8/VB (l_advcl) diminishing_26/VBG (l_prep) with_36/IN (l_pobj) result_38/NN (l_acl) deposited_44/VBN (l_conj) produced_52/VBN (l_nsubjpass) damage_49/NN
20067456
D016642_D012735 NONE bupropion_5/NNP (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_6/IN (l_pobj) dysfunction_9/NN
D016642_D012735 NONE bupropion_8/NN (r_pobj) of_6/IN (r_prep) safety_3/NN (r_dobj) determine_1/VB (l_aux) sustained_9/VBD (l_prep) on_15/IN (l_pobj) dysfunction_18/NN
D016642_D012735 NONE bupropion_8/NN (r_pobj) of_6/IN (r_prep) safety_3/NN (r_dobj) determine_1/VB (l_aux) sustained_9/VBD (l_prep) on_15/IN (l_pobj) dysfunction_18/NN (l_appos) SD_20/NNP
D016642_D012735 NONE bupropion_8/NN (r_pobj) of_6/IN (r_prep) safety_3/NN (r_dobj) determine_1/VB (l_advcl) is_35/VBZ (l_nsubj) SD_34/NNP
D016642_D012735 NONE Bupropion_0/NNP (r_nsubj) is_1/VBZ (l_attr) treatment_4/NN (l_prep) for_5/IN (l_pobj) SD_7/NN
D017367_D012735 NONE inhibitor_16/NN (r_appos) serotonin_14/NN (r_pobj) by_11/IN (r_agent) induced_10/VBN (r_acl) dysfunction_9/NN
D017367_D012735 NONE inhibitor_28/NN (r_appos) serotonin_26/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) dysfunction_18/NN
D017367_D012735 NONE inhibitor_28/NN (r_appos) serotonin_26/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) dysfunction_18/NN (l_appos) SD_20/NNP
D017367_D012735 NONE inhibitor_28/NN (r_appos) serotonin_26/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) dysfunction_18/NN (r_pobj) on_15/IN (r_prep) sustained_9/VBD (r_aux) determine_1/VB (l_advcl) is_35/VBZ (l_nsubj) SD_34/NNP
D017367_D012735 NONE SSRI_30/NNP (r_appos) inhibitor_28/NN (r_appos) serotonin_26/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) dysfunction_18/NN
D017367_D012735 NONE SSRI_30/NNP (r_appos) inhibitor_28/NN (r_appos) serotonin_26/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) dysfunction_18/NN (l_appos) SD_20/NNP
D017367_D012735 NONE SSRI_30/NNP (r_appos) inhibitor_28/NN (r_appos) serotonin_26/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) dysfunction_18/NN (r_pobj) on_15/IN (r_prep) sustained_9/VBD (r_aux) determine_1/VB (l_advcl) is_35/VBZ (l_nsubj) SD_34/NNP
D017367_D012735 NONE SSRIs_42/NNS (r_pobj) of_41/IN (r_prep) effect_40/NN (r_attr) is_35/VBZ (r_advcl) determine_1/VB (l_aux) sustained_9/VBD (l_prep) on_15/IN (l_pobj) dysfunction_18/NN
D017367_D012735 NONE SSRIs_42/NNS (r_pobj) of_41/IN (r_prep) effect_40/NN (r_attr) is_35/VBZ (r_advcl) determine_1/VB (l_aux) sustained_9/VBD (l_prep) on_15/IN (l_pobj) dysfunction_18/NN (l_appos) SD_20/NNP
D017367_D012735 NONE SSRIs_42/NNS (r_pobj) of_41/IN (r_prep) effect_40/NN (r_attr) is_35/VBZ (l_nsubj) SD_34/NNP
D017367_D012735 NONE SSRI_21/NNP (r_pobj) of_20/IN (r_prep) type_19/NN (r_appos) SD_17/NN
D017367_D012735 NONE SSRIs_10/NNS (r_pobj) by_9/IN (r_agent) induced_8/VBN (r_acl) SD_7/NN
7083920
D000638_D006327 CID amiodarone_13/NN (r_compound) treatment_14/NN (r_pobj) under_12/IN (r_prep) occurring_11/VBG (r_acl) block_10/NN
D000638_D013617 NONE amiodarone_13/NN (r_compound) treatment_14/NN (l_prep) for_15/IN (l_pobj) tachycardia_17/NN
D000638_D006345 NONE amiodarone_13/NN (r_compound) treatment_14/NN (r_pobj) under_12/IN (r_prep) occurring_11/VBG (l_prep) without_21/IN (l_pobj) abnormalities_25/NNS
D000638_D001282 NONE amiodarone_3/NN (r_compound) discontinuation_4/NN (r_pobj) after_2/IN (r_prep) showed_9/VBD (l_dobj) flutter_11/NN
2396046
D002794_D006528 CID choline_13/NN (r_npadvmod) supplemented_15/VBN (r_amod) diet_16/NN (r_dobj) fed_10/VBD (l_nsubj) nodules_3/NNS (l_conj) carcinomas_6/NNS
D002794_D006528 CID choline_13/NN (r_npadvmod) supplemented_15/VBN (r_amod) diet_16/NN (r_dobj) fed_10/VBD (l_advcl) fed_30/VBD (l_nsubj) nodule_21/NN (l_conj) carcinoma_25/NN
D002794_D006528 CID choline_23/NN (r_npadvmod) devoid_25/JJ (r_amod) diet_26/NN (r_dobj) fed_20/VBD (r_advcl) was_9/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_conj) of_6/IN (l_pobj) carcinomas_8/NNS
D002794_D006528 CID choline_42/NN (r_npadvmod) devoid_44/JJ (r_amod) diet_45/NN (r_dobj) fed_37/VBD (r_advcl) fed_20/VBD (r_advcl) was_9/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_conj) of_6/IN (l_pobj) carcinomas_8/NNS
D010634_D006528 NONE phenobarbital_35/NN (r_dobj) containing_34/VBG (r_acl) diet_33/NN (r_dobj) fed_30/VBD (r_advcl) fed_10/VBD (l_nsubj) nodules_3/NNS (l_conj) carcinomas_6/NNS
D010634_D006528 NONE phenobarbital_35/NN (r_dobj) containing_34/VBG (r_acl) diet_33/NN (r_dobj) fed_30/VBD (l_nsubj) nodule_21/NN (l_conj) carcinoma_25/NN
D010634_D006528 NONE phenobarbital_39/NN (r_npadvmod) containing_41/VBG (r_amod) diet_45/NN (r_dobj) fed_37/VBD (r_advcl) fed_20/VBD (r_advcl) was_9/VBD (l_nsubj) incidence_1/NN (l_prep) of_2/IN (l_conj) of_6/IN (l_pobj) carcinomas_8/NNS
12536034
D002220_D004832 CID carbamazepine_13/NN (r_pobj) of_12/IN (r_prep) administration_11/NN (r_pobj) after_10/IN (r_prep) present_2/VBP (l_dobj) patients_4/NNS (l_prep) with_5/IN (l_pobj) epilepsy_9/NN
D020888_D004832 CID vigabatrin_15/NNP (r_conj) carbamazepine_13/NN (r_pobj) of_12/IN (r_prep) administration_11/NN (r_pobj) after_10/IN (r_prep) present_2/VBP (l_dobj) patients_4/NNS (l_prep) with_5/IN (l_pobj) epilepsy_9/NN
D005680_D004832 NONE acid_4/NN (r_npadvmod) transmitted_6/VBN (r_amod) accounts_9/NNS (l_prep) for_10/IN (l_pobj) part_13/NN (l_prep) of_14/IN (l_pobj) neurophysiology_17/NN (l_prep) of_18/IN (l_pobj) epilepsy_21/NN
6229975
D013999_D009203 NONE timolol_8/NNS (r_compound) treatment_9/NN (l_prep) after_10/IN (l_pobj) infarction_12/NN
D013999_D009203 NONE timolol_6/NNS (r_compound) treatment_7/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_advcl) evaluated_15/VBN (l_nsubjpass) infarction_13/NN
D013999_D009203 NONE timolol_33/VBZ (r_appos) patients_28/NNS (r_pobj) including_26/VBG (r_prep) study_25/NN (r_pobj) in_20/IN (r_prep) evaluated_15/VBN (l_nsubjpass) infarction_13/NN
D013999_D001919 NONE timolol_6/NNS (r_npadvmod) induced_8/VBN (r_amod) bradycardia_9/NNS
D013999_D007238 NONE timolol_17/NNS (r_compound) group_18/NN (r_pobj) in_15/IN (r_prep) remained_13/VBD (r_conj) increased_7/VBD (l_prep) After_0/IN (l_pobj) infarction_3/NN
15338796
D000420_D014202 CID salbutamol_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_amod) Tremor_0/JJ
D000420_D014202 CID salbutamol_6/NN (r_pobj) of_5/IN (r_prep) effects_4/NNS (l_amod) tremor_2/NN
D000420_D014202 CID salbutamol_19/NN (r_pobj) of_18/IN (r_prep) doses_17/NNS (r_pobj) of_15/IN (r_prep) administration_14/NN (r_pobj) after_13/IN (r_prep) assessed_4/VBD (l_dobj) tremor_5/NN
D000420_D014202 CID Salbutamol_0/NNP (r_amod) severity_4/NN (l_compound) tremor_3/NN
D000420_D008173 NONE salbutamol_19/NN (r_pobj) of_18/IN (r_prep) doses_17/NNS (r_pobj) of_15/IN (r_prep) administration_14/NN (r_pobj) after_13/IN (r_prep) assessed_4/VBD (l_prep) in_6/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) disease_12/NN
17437408
D010862_D012640 CID pilocarpine_11/NN (r_npadvmod) induced_13/VBN (r_amod) seizures_14/NNS
2559236
D004317_D007674 NONE adriamycin_9/NN (r_npadvmod) induced_11/VBN (r_amod) nephropathy_12/NN
D004317_D007674 NONE adriamycin_24/FW (r_compound) nephrosis_25/NN (r_pobj) in_23/IN (r_prep) injury_22/NN
D004656_D009401 NONE enalapril_10/NNP (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) assessed_12/VBN (l_prep) with_18/IN (l_pobj) nephrosis_21/NN
D004656_D009401 NONE enalapril_17/NN (r_pobj) of_16/IN (r_prep) effect_15/NN (r_dobj) assess_13/VB (l_prep) on_18/IN (l_pobj) progression_19/NN (l_prep) of_20/IN (l_pobj) injury_22/NN (l_prep) in_23/IN (l_pobj) nephrosis_25/NN
D004317_D009401 CID adriamycin_20/IN (r_compound) nephrosis_21/NN
D004317_D009401 CID adriamycin_24/FW (r_compound) nephrosis_25/NN
D004317_D000419 CID adriamycin_7/NN (r_pobj) of_6/IN (r_prep) dose_5/NN (r_dobj) given_2/VBN (l_advcl) divided_12/VBN (l_prep) into_13/IN (l_pobj) groups_15/NNS (l_acl) matched_16/VBN (l_prep) for_17/IN (l_pobj) albuminuria_18/NNP
D004656_D007674 NONE enalapril_17/NN (r_pobj) of_16/IN (r_prep) effect_15/NN (r_dobj) assess_13/VB (l_prep) on_18/IN (l_pobj) progression_19/NN (l_prep) of_20/IN (l_pobj) injury_22/NN
D004656_D000419 NONE enalapril_1/NN (r_compound) treatment_2/NN (r_nsubj) reduced_3/VBN (l_prep) without_6/IN (l_pcomp) reducing_7/VBG (l_dobj) albuminuria_8/NNP
8410052
D019344_D001480 NONE lactate_10/NN (r_pobj) of_9/IN (r_prep) infusion_8/NN (r_pobj) by_7/IN (r_agent) produced_6/VBN (l_nsubjpass) injury_1/NN (l_prep) in_2/IN (l_pobj) cortex_4/NN
D010862_D002544 CID pilocarpine_10/NN (r_npadvmod) induced_12/VBN (r_amod) status_13/NN (r_compound) epilepticus_14/NN (r_pobj) by_8/IN (r_agent) evoked_7/VBN (l_nsubjpass) Infarcts_0/NNS (l_prep) in_1/IN (l_pobj) reticulata_5/NNS
D010862_D013226 CID pilocarpine_10/NN (r_npadvmod) induced_12/VBN (r_amod) status_13/NN (r_compound) epilepticus_14/NN
11426838
-1_D012640 NONE BD1018_10/NNP (l_conj) BD1063_12/NNP (l_conj) convulsions_21/NNS
-1_D012640 NONE LR132_15/NN (r_punct) convulsions_21/NNS
C093337_D012640 NONE BD1063_12/NNP (l_conj) convulsions_21/NNS
D003042_D012640 CID cocaine_18/NN (r_npadvmod) induced_20/VBN (r_amod) convulsions_21/NNS
D003042_D012640 CID cocaine_9/JJ (r_amod) effects_10/NNS (r_nsubj) involved_15/VBD (r_acl) hypothesis_4/NN (r_dobj) validate_2/VB (r_csubjpass) shown_29/VBN (l_xcomp) attenuate_32/VB (l_dobj) effects_38/NNS (l_amod) convulsive_34/JJ
D003042_D012640 CID cocaine_40/NN (r_pobj) of_39/IN (r_prep) effects_38/NNS (l_amod) convulsive_34/JJ
D003042_D064420 NONE cocaine_6/NN (r_pobj) of_5/IN (r_prep) toxicity_4/NN
D009838_D012640 NONE oligodeoxynucleotide_23/NN (r_appos) receptors_19/NNS (r_pobj) of_17/IN (r_prep) antagonism_16/NN (r_dobj) involved_15/VBD (r_acl) hypothesis_4/NN (r_dobj) validate_2/VB (r_csubjpass) shown_29/VBN (l_xcomp) attenuate_32/VB (l_dobj) effects_38/NNS (l_amod) convulsive_34/JJ
17241784
D019821_D009135 CID statin_12/NN (r_compound) therapy_13/NN (r_pobj) with_11/IN (r_prep) associated_10/VBD (l_nsubj) myopathy_1/NN
D019821_D009135 CID Statins_0/NNS (r_nsubj) cause_2/VB (l_dobj) myopathy_5/NN
D019821_D009135 CID statins_9/NNS (r_nsubj) induce_11/VB (l_dobj) myopathy_13/NN
D019821_D009135 CID statins_4/NNS (r_nsubj) initiate_6/VB (l_dobj) myopathy_11/NN
D019821_D009135 CID statins_13/NNS (r_pobj) by_12/IN (r_prep) induction_11/NN (r_dobj) involve_9/VB (r_conj) is_5/VBZ (l_nsubj) mechanism_1/NN (l_prep) of_2/IN (l_pobj) myopathy_4/NN
D019821_-1 NONE Statins_0/NNS (r_nsubj) cause_2/VB (l_dobj) myopathy_5/NN (l_conj) hyperCKaemia_7/NNP
6103707
D005445_D010146 CID flunitrazepam_7/NN (r_pobj) of_6/IN (r_prep) injection_5/NN (r_pobj) on_3/IN (r_prep) pain_2/NN
12084448
D007069_D001927 CID Ifosfamide_0/NNP (r_amod) encephalopathy_1/NN
D007069_D020820 NONE Ifosfamide_0/NNP (r_amod) encephalopathy_1/NN (l_acl) presenting_2/VBG (l_prep) with_3/IN (l_pobj) asterixis_4/NN
D007069_D020820 NONE ifosfamide_3/NNP (r_pobj) of_2/IN (r_prep) administration_1/NN (r_nsubjpass) discontinued_5/VBN (l_conj) resolved_12/VBD (l_nsubj) asterixis_11/NN
D007069_D020820 NONE ifosfamide_12/NNP (r_pobj) of_11/IN (r_prep) infusion_10/NN (r_pobj) during_9/IN (r_prep) presence_6/NN (l_prep) of_7/IN (l_pobj) asterixis_8/NN
D007069_D020820 NONE IFX_41/NNP (r_pobj) of_40/IN (r_prep) use_39/NN (r_pobj) with_37/IN (r_prep) associated_36/VBN (r_ccomp) suggest_31/VBP (l_nsubj) presence_6/NN (l_prep) of_7/IN (l_pobj) asterixis_8/NN
D007069_D009207 CID ifosfamide_27/NNP (r_pobj) of_26/IN (r_prep) infusion_25/NN (r_pobj) after_23/IN (r_prep) disabling_14/VBG (l_dobj) myoclonus_16/NN
D007069_D009207 CID ifosfamide_12/NNP (r_pobj) of_11/IN (r_prep) infusion_10/NN (r_pobj) during_9/IN (r_prep) presence_6/NN (r_nsubj) suggest_31/VBP (l_ccomp) associated_36/VBN (l_nsubjpass) myoclonus_34/NN
D007069_D009207 CID IFX_41/NNP (r_pobj) of_40/IN (r_prep) use_39/NN (r_pobj) with_37/IN (r_prep) associated_36/VBN (l_nsubjpass) myoclonus_34/NN
D007069_D010954 NONE ifosfamide_27/NNP (r_pobj) of_26/IN (r_prep) infusion_25/NN (l_prep) for_28/IN (l_pobj) plasmacytoma_29/NNP
19387625
D002211_D010146 NONE capsaicin_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperalgesia_11/NN (r_pobj) in_6/IN (r_prep) intensity_5/NN (l_compound) pain_4/NN
D002211_D010146 NONE capsaicin_16/NN (r_npadvmod) induced_18/VBN (r_amod) hyperalgesia_20/NN (r_pobj) in_15/IN (r_prep) affected_12/VBN (l_nsubjpass) ratings_10/NNS (l_compound) intensity_9/NN (l_compound) pain_8/NN
D002211_D010146 NONE capsaicin_7/NN (r_compound) treatment_8/NN (r_pobj) between_6/IN (r_prep) interaction_5/NN (r_dobj) showing_3/VBG (r_acl) findings_1/NNS (r_nsubj) suggest_12/VBP (l_ccomp) affect_22/VB (l_dobj) pain_24/NN
D002211_D010146 NONE capsaicin_14/NN (r_npadvmod) induced_16/VBN (r_amod) hyperalgesia_18/NN (r_nsubj) affect_22/VB (l_dobj) pain_24/NN
D002211_D006930 CID capsaicin_7/NN (r_npadvmod) induced_9/VBN (r_amod) hyperalgesia_11/NN
D002211_D006930 CID capsaicin_16/NN (r_npadvmod) induced_18/VBN (r_amod) hyperalgesia_20/NN
D002211_D006930 CID capsaicin_20/NN (r_npadvmod) untreated_22/VBN (r_amod) condition_25/NN (r_pobj) of_19/IN (r_prep) that_18/DT (r_pobj) to_17/IN (r_prep) similar_16/JJ (r_acomp) is_14/VBZ (l_nsubj) magnitude_7/NN (l_prep) in_11/IN (l_pobj) hyperalgesia_13/NN
D002211_D006930 CID capsaicin_7/NN (r_compound) treatment_8/NN (r_pobj) between_6/IN (r_prep) interaction_5/NN (r_dobj) showing_3/VBG (r_acl) findings_1/NNS (r_nsubj) suggest_12/VBP (l_ccomp) affect_22/VB (l_nsubj) hyperalgesia_18/NN
D002211_D006930 CID capsaicin_14/NN (r_npadvmod) induced_16/VBN (r_amod) hyperalgesia_18/NN
10743446
D007649_D006930 NONE ketamine_5/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_8/IN (l_pobj) hyperalgesia_12/NN
D007649_D006930 NONE Ketamine_0/NNP (r_nsubj) reduced_1/VBD (l_dobj) area_4/NN (l_prep) of_5/IN (l_pobj) hyperalgesia_13/NN
D007649_D006930 NONE ketamine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) on_7/IN (l_pobj) hyperalgesia_11/NN
D007649_D006930 NONE ketamine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubj) suggest_12/VBP (l_ccomp) mediated_20/VBN (l_nsubjpass) types_16/NNS (l_prep) of_17/IN (l_pobj) hyperalgesia_18/NN
D008012_D006930 NONE lidocaine_7/NN (r_conj) ketamine_5/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_8/IN (l_pobj) hyperalgesia_12/NN
D008012_D006930 NONE Lidocaine_0/NNP (r_nsubj) reduced_1/VBD (l_dobj) area_3/NN (l_prep) of_4/IN (l_pobj) hyperalgesia_8/NN
D008012_D006930 NONE lidocaine_6/NN (r_conj) ketamine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) on_7/IN (l_pobj) hyperalgesia_11/NN
D008012_D006930 NONE lidocaine_6/NN (r_conj) ketamine_4/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (r_nsubj) suggest_12/VBP (l_ccomp) mediated_20/VBN (l_nsubjpass) types_16/NNS (l_prep) of_17/IN (l_pobj) hyperalgesia_18/NN
D002211_D006930 CID capsaicin_16/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) hyperalgesia_12/NN
D002211_D006930 CID capsaicin_3/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) hyperalgesia_0/NN
D007649_D010146 NONE ketamine_9/NNP (r_pobj) of_8/IN (r_prep) administration_7/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (r_dobj) examined_2/VBN (l_prep) on_12/IN (l_pobj) pain_19/NN
D007649_D010146 NONE Ketamine_0/NNP (r_nsubj) reduced_1/VBD (l_conj) tended_17/VBD (l_xcomp) reduce_19/VB (l_dobj) pain_23/NN
D008012_D010146 NONE lidocaine_11/NN (r_conj) ketamine_9/NNP (r_pobj) of_8/IN (r_prep) administration_7/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (r_dobj) examined_2/VBN (l_prep) on_12/IN (l_pobj) pain_19/NN
7977601
11334364
D000082_D009336 CID acetaminophen_13/NN (r_advmod) induced_15/VBN (r_amod) nephrotoxicity_16/NN (r_pobj) during_12/IN (r_prep) deaths_11/NNS (l_amod) apoptotic_7/JJ (l_conj) necrotic_9/JJ
D000082_D009336 CID AAP_9/NNP (r_pobj) as_7/IN (r_prep) drugs_4/NNS (r_nsubj) induced_14/VBD (l_prep) in_17/IN (l_pobj) addition_18/NN (l_prep) to_19/IN (l_pobj) necrosis_20/NN
D000082_D007674 CID acetaminophen_13/NN (r_advmod) induced_15/VBN (r_amod) nephrotoxicity_16/NN
D000082_D007674 CID acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN
D000082_D007674 CID AAP)-induced_18/VBN (r_nummod) nephrotoxicity_19/NN
D000082_D008171 NONE acetaminophen_13/NN (r_advmod) induced_15/VBN (r_amod) nephrotoxicity_16/NN (l_conj) toxicity_22/NN
D000082_D008171 NONE acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN (l_appos) amiodarone_21/NN (l_conj) toxicity_25/NN
D000082_D008171 NONE AAP)-induced_18/VBN (r_nummod) nephrotoxicity_19/NN (l_appos) amiodarone_21/NN (l_conj) toxicity_25/NN
D000082_D066126 NONE acetaminophen_13/NN (r_advmod) induced_15/VBN (r_amod) nephrotoxicity_16/NN (l_conj) toxicity_22/NN (l_conj) cardiotoxicity_27/NN
D000082_D066126 NONE acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN (l_appos) amiodarone_21/NN (l_conj) toxicity_25/NN (l_conj) doxorubicin_28/NNS (l_parataxis) cardiotoxicity_31/NN
D000082_D066126 NONE AAP)-induced_18/VBN (r_nummod) nephrotoxicity_19/NN (l_appos) amiodarone_21/NN (l_conj) toxicity_25/NN (l_conj) doxorubicin_28/NNS (l_parataxis) cardiotoxicity_31/NN
D000638_D009336 CID amiodarone_18/NN (r_npadvmod) induced_20/VBN (r_amod) toxicity_22/NN (r_conj) nephrotoxicity_16/NN (r_pobj) during_12/IN (r_prep) deaths_11/NNS (l_amod) apoptotic_7/JJ (l_conj) necrotic_9/JJ
D000638_D009336 CID AMI_11/NNP (r_conj) AAP_9/NNP (r_pobj) as_7/IN (r_prep) drugs_4/NNS (r_nsubj) induced_14/VBD (l_prep) in_17/IN (l_pobj) addition_18/NN (l_prep) to_19/IN (l_pobj) necrosis_20/NN
D000638_D007674 NONE amiodarone_18/NN (r_npadvmod) induced_20/VBN (r_amod) toxicity_22/NN (r_conj) nephrotoxicity_16/NN
D000638_D007674 NONE amiodarone_21/NN (r_appos) nephrotoxicity_19/NN
D000638_D007674 NONE AMI)-induced_23/NNP (r_parataxis) amiodarone_21/NN (r_appos) nephrotoxicity_19/NN
D000638_D008171 CID amiodarone_18/NN (r_npadvmod) induced_20/VBN (r_amod) toxicity_22/NN
D000638_D008171 CID amiodarone_21/NN (l_conj) toxicity_25/NN
D000638_D008171 CID AMI)-induced_23/NNP (r_parataxis) amiodarone_21/NN (l_conj) toxicity_25/NN
D000638_D066126 NONE amiodarone_18/NN (r_npadvmod) induced_20/VBN (r_amod) toxicity_22/NN (l_conj) cardiotoxicity_27/NN
D000638_D066126 NONE amiodarone_21/NN (l_conj) toxicity_25/NN (l_conj) doxorubicin_28/NNS (l_parataxis) cardiotoxicity_31/NN
D000638_D066126 NONE AMI)-induced_23/NNP (r_parataxis) amiodarone_21/NN (l_conj) toxicity_25/NN (l_conj) doxorubicin_28/NNS (l_parataxis) cardiotoxicity_31/NN
D004317_D009336 CID doxorubicin_24/NN (r_npadvmod) induced_26/VBN (r_amod) cardiotoxicity_27/NN (r_conj) toxicity_22/NN (r_conj) nephrotoxicity_16/NN (r_pobj) during_12/IN (r_prep) deaths_11/NNS (l_amod) apoptotic_7/JJ (l_conj) necrotic_9/JJ
D004317_D009336 CID DOX_13/NNP (r_conj) AMI_11/NNP (r_conj) AAP_9/NNP (r_pobj) as_7/IN (r_prep) drugs_4/NNS (r_nsubj) induced_14/VBD (l_prep) in_17/IN (l_pobj) addition_18/NN (l_prep) to_19/IN (l_pobj) necrosis_20/NN
D004317_D007674 NONE doxorubicin_24/NN (r_npadvmod) induced_26/VBN (r_amod) cardiotoxicity_27/NN (r_conj) toxicity_22/NN (r_conj) nephrotoxicity_16/NN
D004317_D007674 NONE doxorubicin_28/NNS (r_conj) toxicity_25/NN (r_conj) amiodarone_21/NN (r_appos) nephrotoxicity_19/NN
D004317_D007674 NONE DOX)-induced_30/VBN (r_compound) cardiotoxicity_31/NN (r_parataxis) doxorubicin_28/NNS (r_conj) toxicity_25/NN (r_conj) amiodarone_21/NN (r_appos) nephrotoxicity_19/NN
D004317_D008171 NONE doxorubicin_24/NN (r_npadvmod) induced_26/VBN (r_amod) cardiotoxicity_27/NN (r_conj) toxicity_22/NN
D004317_D008171 NONE doxorubicin_28/NNS (r_conj) toxicity_25/NN
D004317_D008171 NONE DOX)-induced_30/VBN (r_compound) cardiotoxicity_31/NN (r_parataxis) doxorubicin_28/NNS (r_conj) toxicity_25/NN
D004317_D066126 CID doxorubicin_24/NN (r_npadvmod) induced_26/VBN (r_amod) cardiotoxicity_27/NN
D004317_D066126 CID doxorubicin_28/NNS (l_parataxis) cardiotoxicity_31/NN
D004317_D066126 CID DOX)-induced_30/VBN (r_compound) cardiotoxicity_31/NN
C511402_D009336 NONE extract_35/NN (r_pobj) by_28/IN (r_agent) associated_6/VBN (l_dobj) deaths_11/NNS (l_amod) apoptotic_7/JJ (l_conj) necrotic_9/JJ
C511402_D009336 NONE GSPE_31/NNP (r_pobj) by_30/IN (r_agent) blocked_29/VBN (r_relcl) organs_24/NNS (r_pobj) in_21/IN (r_prep) necrosis_20/NN
C511402_D007674 NONE extract_35/NN (r_pobj) by_28/IN (r_agent) associated_6/VBN (l_dobj) deaths_11/NNS (l_prep) during_12/IN (l_pobj) nephrotoxicity_16/NN
C511402_D007674 NONE extract_10/NN (r_pobj) of_5/IN (r_prep) ability_4/NN (l_acl) prevent_15/VB (l_dobj) acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN
C511402_D007674 NONE GSPE_12/NNP (r_appos) extract_10/NN (r_pobj) of_5/IN (r_prep) ability_4/NN (l_acl) prevent_15/VB (l_dobj) acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN
C511402_D008171 NONE extract_35/NN (r_pobj) by_28/IN (r_agent) associated_6/VBN (l_dobj) deaths_11/NNS (l_prep) during_12/IN (l_pobj) nephrotoxicity_16/NN (l_conj) toxicity_22/NN
C511402_D008171 NONE extract_10/NN (r_pobj) of_5/IN (r_prep) ability_4/NN (l_acl) prevent_15/VB (l_dobj) acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN (l_appos) amiodarone_21/NN (l_conj) toxicity_25/NN
C511402_D008171 NONE GSPE_12/NNP (r_appos) extract_10/NN (r_pobj) of_5/IN (r_prep) ability_4/NN (l_acl) prevent_15/VB (l_dobj) acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN (l_appos) amiodarone_21/NN (l_conj) toxicity_25/NN
C511402_D066126 NONE extract_35/NN (r_pobj) by_28/IN (r_agent) associated_6/VBN (l_dobj) deaths_11/NNS (l_prep) during_12/IN (l_pobj) nephrotoxicity_16/NN (l_conj) toxicity_22/NN (l_conj) cardiotoxicity_27/NN
C511402_D066126 NONE extract_10/NN (r_pobj) of_5/IN (r_prep) ability_4/NN (l_acl) prevent_15/VB (l_dobj) acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN (l_appos) amiodarone_21/NN (l_conj) toxicity_25/NN (l_conj) doxorubicin_28/NNS (l_parataxis) cardiotoxicity_31/NN
C511402_D066126 NONE GSPE_12/NNP (r_appos) extract_10/NN (r_pobj) of_5/IN (r_prep) ability_4/NN (l_acl) prevent_15/VB (l_dobj) acetaminophen_16/NNP (l_appos) nephrotoxicity_19/NN (l_appos) amiodarone_21/NN (l_conj) toxicity_25/NN (l_conj) doxorubicin_28/NNS (l_parataxis) cardiotoxicity_31/NN
C511402_D017695 NONE GSPE_30/NNP (r_compound) preexposure_31/NN (r_pobj) of_29/IN (r_prep) absence_28/NN (r_pobj) in_26/IN (r_prep) revealed_9/VBD (l_oprd) moderate_10/JJ (l_prep) to_11/IN (l_pobj) damage_14/NN
1147734
D011441_D008107 NONE propylthiouracil_4/NNS (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) disease_1/NN
D011441_D006521 CID propylthiouracil_29/NNP (r_pobj) of_28/IN (r_prep) administration_27/NNP (r_pobj) by_25/IN (r_agent) caused_24/VBN (r_acl) hepatitis_23/NN
18186898
D019259_D006509 NONE Lamivudine_0/NNP (r_nsubjpass) added_2/VBN (l_prep) because_3/IN (l_pobj) infection_9/NN
D016559_D000138 NONE tacrolimus_1/NN (r_nsubjpass) suspected_3/VBN (l_xcomp) be_5/VB (l_attr) cause_7/NN (l_prep) of_8/IN (l_pobj) acidosis_14/NN
D016559_D000138 NONE tacrolimus_1/NN (r_nsubjpass) suspected_3/VBN (l_conj) replaced_17/VBN (l_agent) by_18/IN (l_pobj) sirolimus_19/NN (l_conj) acidosis_21/NN
D020123_D000138 NONE sirolimus_19/NN (r_pobj) by_18/IN (r_agent) replaced_17/VBN (r_conj) suspected_3/VBN (l_xcomp) be_5/VB (l_attr) cause_7/NN (l_prep) of_8/IN (l_pobj) acidosis_14/NN
D020123_D000138 NONE sirolimus_19/NN (l_conj) acidosis_21/NN
D016559_D005198 CID tacrolimus_20/NN (r_pobj) by_19/IN (r_agent) triggered_18/VBN (r_relcl) dysfunction_15/NN (r_pobj) from_13/IN (r_prep) resulted_12/VBN (l_nsubj) dysfunction_7/NN
D016559_D009135 CID tacrolimus_20/NN (r_pobj) by_19/IN (r_agent) triggered_18/VBN (r_relcl) dysfunction_15/NN (r_pobj) from_13/IN (r_prep) resulted_12/VBN (l_nsubj) dysfunction_7/NN (l_conj) myopathy_9/NN
D016559_D028361 NONE tacrolimus_20/NN (r_pobj) by_19/IN (r_agent) triggered_18/VBN (r_relcl) dysfunction_15/NN
D019259_D005198 CID lamivudine_24/NNP (r_pobj) by_23/IN (r_agent) augmented_22/VBN (r_conj) triggered_18/VBN (r_relcl) dysfunction_15/NN (r_pobj) from_13/IN (r_prep) resulted_12/VBN (l_nsubj) dysfunction_7/NN
D019259_D009135 CID lamivudine_24/NNP (r_pobj) by_23/IN (r_agent) augmented_22/VBN (r_conj) triggered_18/VBN (r_relcl) dysfunction_15/NN (r_pobj) from_13/IN (r_prep) resulted_12/VBN (l_nsubj) dysfunction_7/NN (l_conj) myopathy_9/NN
D019259_D028361 NONE lamivudine_24/NNP (r_pobj) by_23/IN (r_agent) augmented_22/VBN (r_conj) triggered_18/VBN (r_relcl) dysfunction_15/NN
9245658
D009538_D002318 CID nicotine_3/NN (r_pobj) of_2/IN (r_prep) role_1/NN (l_prep) in_4/IN (l_pobj) disease_9/NN
D009538_D002318 CID Nicotine_0/NN (r_nsubj) activates_1/VBZ (l_conj) contribute_11/VB (l_prep) to_12/IN (l_pobj) disease_14/NN
D009538_D050197 CID nicotine_7/NN (r_nsubj) play_9/VB (l_dobj) role_11/NN (l_prep) in_12/IN (l_pcomp) accelerating_13/VBG (l_dobj) atherosclerosis_14/NN
D009538_D013927 NONE Nicotine_0/NN (r_nsubj) appear_3/VB (l_xcomp) enhance_5/VB (l_dobj) thrombosis_6/NN
19269743
D002211_D010146 CID capsaicin_9/NN (r_npadvmod) induced_11/VBN (r_amod) pain_12/NN
D002211_D010146 CID capsaicin_21/NN (r_pobj) of_20/IN (r_prep) doses_19/NNS (r_pobj) of_17/IN (r_prep) injections_16/NNS (r_dobj) received_14/VBD (l_prep) In_0/IN (l_pobj) order_1/NN (l_acl) address_3/VB (l_dobj) memory_8/NN (l_compound) pain_7/NN
D002211_D010146 CID capsaicin_11/NN (r_compound) doses_12/NNS (r_pobj) across_10/IN (r_prep) discriminate_5/VB (l_dobj) magnitude_7/NN (l_compound) pain_6/NN
2951327
D009638_D013610 NONE norepinephrine_7/NN (r_compound) rate_9/NN (r_pobj) of_5/IN (r_prep) augmentation_4/NN (r_conj) tachycardia_1/NN
D009638_D007022 NONE norepinephrine_7/NN (r_compound) rate_9/NN (r_pobj) of_5/IN (r_prep) augmentation_4/NN (r_conj) tachycardia_1/NN (l_relcl) is_24/VBZ (l_prep) in_25/IN (l_pobj) contrast_26/NN (l_prep) to_27/IN (l_pobj) hypotension_29/NN
D006830_D013610 NONE hydralazine_32/NN (r_pobj) by_31/IN (r_agent) induced_30/VBN (r_acl) hypotension_29/NN (r_pobj) to_27/IN (r_prep) contrast_26/NN (r_pobj) in_25/IN (r_prep) is_24/VBZ (r_relcl) tachycardia_1/NN
D006830_D007022 CID hydralazine_32/NN (r_pobj) by_31/IN (r_agent) induced_30/VBN (r_acl) hypotension_29/NN
D005996_D013610 NONE nitroglycerin_34/NN (r_conj) hydralazine_32/NN (r_pobj) by_31/IN (r_agent) induced_30/VBN (r_acl) hypotension_29/NN (r_pobj) to_27/IN (r_prep) contrast_26/NN (r_pobj) in_25/IN (r_prep) is_24/VBZ (r_relcl) tachycardia_1/NN
D005996_D007022 CID nitroglycerin_34/NN (r_conj) hydralazine_32/NN (r_pobj) by_31/IN (r_agent) induced_30/VBN (r_acl) hypotension_29/NN
16160878
D014579_D006973 NONE II_8/NNP (r_pobj) of_5/IN (r_prep) injection_4/NN (r_nsubj) causes_9/VBZ (l_dobj) hypertension_10/NN
D014579_D001919 NONE II_8/NNP (r_pobj) of_5/IN (r_prep) injection_4/NN (r_nsubj) causes_9/VBZ (l_dobj) hypertension_10/NN (l_conj) bradycardia_12/NN
D014579_D010409 NONE II_11/NNP (r_pobj) of_8/IN (r_prep) administration_7/NN (r_nsubj) had_12/VBD (l_dobj) effect_14/NN (l_prep) on_15/IN (l_pobj) temperature_17/NN (l_conj) nociception_19/NN (l_conj) erection_25/NN
D001058_D010409 CID apomorphine_21/NN (r_npadvmod) induced_23/VBN (r_amod) erection_25/NN
D003345_D010409 NONE corticosterone_35/NN (r_compound) level_36/NN (r_conj) erection_25/NN
D014579_D001523 NONE II_6/NNP (r_nsubjpass) involved_9/VBN (l_prep) in_10/IN (l_pobj) aspects_12/NNS (l_prep) of_13/IN (l_pobj) disorders_15/NNS
20880751
D007980_D004409 CID Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NN
D007980_D004409 CID levodopa_17/NN (r_npadvmod) induced_19/VBN (r_amod) dyskinesias_20/NN
D007980_D004409 CID levodopa_41/NN (r_npadvmod) induced_43/VBN (r_amod) dyskinesias_44/NN
D007980_D010300 NONE Levodopa_0/NNP (r_npadvmod) induced_2/VBN (r_amod) dyskinesias_3/NN (l_prep) in_4/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) disease_9/NN
D007980_D010300 NONE Levodopa_0/NNP (r_nsubj) is_1/VBZ (l_attr) drug_5/NN (l_prep) for_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) disease_12/NN
D004298_D004409 NONE dopamine_9/NN (r_compound) precursor_10/NN (r_pobj) of_7/IN (r_prep) use_6/NN (r_nsubj) is_11/VBZ (r_auxpass) complicated_12/VBN (l_agent) by_13/IN (l_pobj) fluctuations_16/NNS (l_conj) dyskinesias_18/NN
D004298_D004409 NONE dopamine_21/NN (r_compound) subtypes_23/NNS (r_conj) presynaptic_16/JJ (r_pobj) of_15/IN (r_prep) role_14/NN (l_prep) in_37/IN (l_pobj) pathophysiology_39/NN (l_prep) of_40/IN (l_pobj) dyskinesias_44/NN
D018698_D004409 NONE glutamate_28/NN (r_compound) receptors_29/NNS (r_conj) subtypes_23/NNS (r_conj) presynaptic_16/JJ (r_pobj) of_15/IN (r_prep) role_14/NN (l_prep) in_37/IN (l_pobj) pathophysiology_39/NN (l_prep) of_40/IN (l_pobj) dyskinesias_44/NN
11391224
D003042_D006974 NONE cocaine_23/NN (r_npadvmod) related_25/VBN (r_amod) failure_28/NN (r_conj) glomerulonephritis_20/NN (r_conj) nephritis_17/NN (r_conj) nephritis_12/NN (r_conj) microangiopathy_9/NN (r_conj) hypertension_6/NN
D003042_D057049 NONE cocaine_23/NN (r_npadvmod) related_25/VBN (r_amod) failure_28/NN (r_conj) glomerulonephritis_20/NN (r_conj) nephritis_17/NN (r_conj) nephritis_12/NN (r_conj) microangiopathy_9/NN
D003042_D008181 NONE cocaine_23/NN (r_npadvmod) related_25/VBN (r_amod) failure_28/NN (r_conj) glomerulonephritis_20/NN (r_conj) nephritis_17/NN (r_conj) nephritis_12/NN
D003042_D011695 NONE cocaine_23/NN (r_npadvmod) related_25/VBN (r_amod) failure_28/NN (r_conj) glomerulonephritis_20/NN (r_conj) nephritis_17/NN
D003042_D005921 NONE cocaine_23/NN (r_npadvmod) related_25/VBN (r_amod) failure_28/NN (r_conj) glomerulonephritis_20/NN
D003042_D058186 CID cocaine_23/NN (r_npadvmod) related_25/VBN (r_amod) failure_28/NN
8669433
D000082_D007676 NONE acetaminophen_3/NN (r_advmod) as_4/IN (l_pobj) factor_7/NN (l_prep) for_8/IN (l_pobj) failure_11/NN
D000082_D007676 NONE acetaminophen_27/NN (r_pobj) of_26/IN (r_prep) use_25/NN (r_nsubjpass) associated_30/VBN (l_prep) with_31/IN (l_pobj) failure_34/NN
D000082_D007676 NONE acetaminophen_27/NN (r_pobj) of_26/IN (r_prep) use_25/NN (r_nsubjpass) associated_30/VBN (l_prep) with_31/IN (l_pobj) failure_34/NN (l_conj) ESRD_36/NNP
D000082_D007676 NONE acetaminophen_7/NNP (r_conj) phenacetin_5/NNP (r_nsubj) contribute_9/VB (l_prep) to_10/IN (l_pobj) burden_12/NN (l_prep) of_13/IN (l_pobj) ESRD_14/NNP
D000082_D007676 NONE acetaminophen_6/NN (r_pobj) of_5/IN (r_prep) use_4/NN (r_nsubj) increases_8/VBZ (l_dobj) risk_10/NN (l_prep) of_11/IN (l_pobj) ESRD_12/NNP
D010615_D007676 CID phenacetin_16/NNP (r_pobj) with_15/IN (r_prep) comparison_14/NN (r_appos) use_1/NN (l_prep) as_4/IN (l_pobj) factor_7/NN (l_prep) for_8/IN (l_pobj) failure_11/NN
D010615_D007676 CID phenacetin_14/NNP (r_pobj) of_13/IN (r_prep) use_12/NN (r_nsubjpass) associated_16/VBN (l_prep) with_17/IN (l_pobj) development_19/NN (l_prep) of_20/IN (l_pobj) failure_23/NN
D010615_D007676 CID phenacetin_14/NNP (r_pobj) of_13/IN (r_prep) use_12/NN (r_nsubjpass) associated_16/VBN (l_prep) with_17/IN (l_pobj) development_19/NN (l_prep) of_20/IN (l_pobj) failure_23/NN (l_conj) disease_29/NN
D010615_D007676 CID phenacetin_14/NNP (r_pobj) of_13/IN (r_prep) use_12/NN (r_nsubjpass) associated_16/VBN (l_prep) with_17/IN (l_pobj) development_19/NN (l_prep) of_20/IN (l_pobj) failure_23/NN (l_conj) disease_29/NN (l_appos) ESRD_31/NNP
D010615_D007676 CID phenacetin_5/NNP (r_nsubj) contribute_9/VB (l_prep) to_10/IN (l_pobj) burden_12/NN (l_prep) of_13/IN (l_pobj) ESRD_14/NNP
4812392
D001379_D011565 NONE azathioprine_4/NN (r_pobj) with_3/IN (r_prep) psoriasis_2/NN
D001379_D011565 NONE Azathioprine_0/JJ (r_intj) benefited_2/VBD (l_prep) out_8/IN (l_prep) of_9/IN (l_pobj) patients_11/NNS (l_acl) suffering_12/VBG (l_prep) from_13/IN (l_pobj) psoriasis_15/NN
D001379_D056486 NONE azathioprine_9/NN (r_compound) therapy_10/NN (r_nsubjpass) continued_12/VBN (l_advcl) detected_20/VBN (l_nsubjpass) damage_17/NN
19843802
D004837_D006973 CID epinephrine_5/NN (r_pobj) of_4/IN (r_prep) bolus_3/NN (r_nsubj) injected_6/VBN (l_conj) provoked_11/VBD (l_dobj) crisis_14/NN (l_amod) hypertensive_13/JJ
1549199
D007980_D064420 NONE levodopa_9/NN (r_compound) therapy_10/NN (r_pobj) for_8/IN (r_prep) dose_7/NN (r_acl) correct_5/JJ (r_attr) is_2/VBZ (r_advcl) started_16/VBN (l_prep) following_27/VBG (l_dobj) rule_30/NN (l_acl) attempt_33/VB (l_xcomp) titrate_35/VB (l_prep) to_39/IN (l_pobj) point_41/NN (l_prep) of_42/IN (l_pobj) normality_44/NN (l_relcl) lead_49/VB (l_prep) to_50/IN (l_pobj) toxicity_51/NN
D007980_D064420 NONE levodopa_38/NNP (r_dobj) titrate_35/VB (l_prep) to_39/IN (l_pobj) point_41/NN (l_prep) of_42/IN (l_pobj) normality_44/NN (l_relcl) lead_49/VB (l_prep) to_50/IN (l_pobj) toxicity_51/NN
D002230_D064420 NONE carbidopa_36/NNP (r_compound) levodopa_38/NNP (r_dobj) titrate_35/VB (l_prep) to_39/IN (l_pobj) point_41/NN (l_prep) of_42/IN (l_pobj) normality_44/NN (l_relcl) lead_49/VB (l_prep) to_50/IN (l_pobj) toxicity_51/NN
D007980_D005767 CID levodopa_13/NN (r_npadvmod) induced_15/VBN (r_amod) psychosis_16/NN (r_conj) hypotension_11/NN (r_conj) disorders_8/NNS
D007980_D007024 CID levodopa_13/NN (r_npadvmod) induced_15/VBN (r_amod) psychosis_16/NN (r_conj) hypotension_11/NN
D007980_D011618 NONE levodopa_13/NN (r_npadvmod) induced_15/VBN (r_amod) psychosis_16/NN
D007980_D012893 NONE levodopa_13/NN (r_npadvmod) induced_15/VBN (r_amod) psychosis_16/NN (r_conj) hypotension_11/NN (r_conj) disorders_8/NNS (r_pobj) as_6/IN (r_prep) effects_3/NNS (r_nsubj) sleep_18/NN (l_dobj) disturbances_19/NNS
D007980_D020447 CID levodopa_13/NN (r_npadvmod) induced_15/VBN (r_amod) psychosis_16/NN (r_conj) hypotension_11/NN (r_conj) disorders_8/NNS (r_pobj) as_6/IN (r_prep) effects_3/NNS (r_nsubj) sleep_18/NN (l_dobj) disturbances_19/NNS (l_conj) parasomnias_21/NNS
9334596
D013739_D007172 NONE testosterone_6/NN (r_pobj) of_4/IN (r_prep) results_3/NNS (l_prep) in_10/IN (l_pobj) patients_12/NNS (l_acl) referred_13/VBN (l_prep) because_14/IN (l_pobj) dysfunction_17/NN
D013739_D007172 NONE testosterone_5/NN (r_compound) levels_6/NNS (r_pobj) of_1/IN (r_prep) Most_0/JJS (r_nsubj) seemed_7/VBD (l_xcomp) result_9/VB (l_conj) have_24/VB (l_dobj) role_28/NN (l_prep) in_29/IN (l_pobj) dysfunction_31/NN
D013739_D007172 NONE testosterone_6/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_conj) prevalences_1/NNS (l_prep) in_10/IN (l_pobj) dysfunction_12/NN
D013739_D020018 CID testosterone_5/NN (r_pobj) for_4/IN (r_prep) screened_3/VBN (l_conj) screened_9/VBN (l_prep) on_12/IN (l_pobj) basis_14/NN (l_prep) of_15/IN (l_pobj) desire_18/NN
D013739_D020018 CID testosterone_22/NN (r_conj) gynecomastia_20/NN (r_conj) desire_18/NN
D013739_D020018 CID testosterone_1/NN (r_dobj) Determining_0/VBG (l_prep) in_3/IN (l_pobj) cases_4/NNS (l_prep) of_5/IN (l_pobj) desire_8/NN
D013739_D020018 CID testosterone_23/NN (r_pobj) with_21/IN (r_prep) missed_15/VBN (l_csubj) Determining_0/VBG (l_prep) in_3/IN (l_pobj) cases_4/NNS (l_prep) of_5/IN (l_pobj) desire_8/NN
D013739_D020018 CID testosterone_8/NN (r_nsubjpass) determined_10/VBN (l_prep) in_12/IN (l_pobj) cases_13/NNS (l_prep) of_14/IN (l_pobj) desire_17/NN
D013739_D020018 CID testosterone_14/NN (r_conj) determined_3/VBN (l_prep) in_5/IN (l_pobj) cases_6/NNS (l_prep) of_7/IN (l_pobj) desire_10/NN
D013739_D006177 NONE testosterone_5/NN (r_pobj) for_4/IN (r_prep) screened_3/VBN (l_conj) screened_9/VBN (l_prep) on_12/IN (l_pobj) basis_14/NN (l_prep) of_15/IN (l_pobj) desire_18/NN (l_conj) gynecomastia_20/NN
D013739_D006177 NONE testosterone_22/NN (r_conj) gynecomastia_20/NN
D013739_D006177 NONE testosterone_14/NN (r_conj) determined_3/VBN (l_prep) in_5/IN (l_pobj) cases_6/NNS (l_prep) of_7/IN (l_pobj) desire_10/NN (l_conj) gynecomastia_12/VB
C004648_D007006 NONE heptylate_5/JJ (l_conj) gonadotropin_9/NN (l_prep) for_10/IN (l_pobj) hypogonadism_11/NN
C004648_D006966 NONE heptylate_5/JJ (r_pobj) of_3/IN (r_prep) consisted_2/VBD (l_prep) for_14/IN (l_pobj) hyperprolactinemia_15/NNP
D001971_D007006 NONE bromocriptine_13/NN (r_conj) hypogonadism_11/NN
D001971_D006966 NONE bromocriptine_13/NN (r_conj) hypogonadism_11/NN (r_pobj) for_10/IN (r_prep) gonadotropin_9/NN (r_conj) heptylate_5/JJ (r_pobj) of_3/IN (r_prep) consisted_2/VBD (l_prep) for_14/IN (l_pobj) hyperprolactinemia_15/NNP
D013739_D010911 NONE testosterone_6/NN (r_compound) determination_7/NN (r_pobj) after_5/IN (r_prep) discovered_4/VBN (l_nsubjpass) tumors_2/NNS
D013739_D007027 NONE testosterone_5/NN (r_compound) levels_6/NNS (r_pobj) of_1/IN (r_prep) Most_0/JJS (r_nsubj) seemed_7/VBD (l_xcomp) result_9/VB (l_prep) from_10/IN (l_pobj) dysfunction_13/NN
19631624
D018817_D007859 CID ecstasy_5/NN (r_compound) users_6/NNS (r_pobj) in_4/IN (r_prep) deficits_3/NNS
D018817_D007859 CID ecstasy_6/NN (r_compound) users_7/NNS (r_nsubj) display_8/VBP (l_dobj) impairments_9/NNS (l_prep) in_10/IN (l_pobj) performance_14/NN (l_nmod) learning_11/NN (l_conj) memory_13/NN
D018817_D008569 CID ecstasy_5/NN (r_compound) users_6/NNS (r_pobj) in_4/IN (r_prep) deficits_3/NNS
D018817_D008569 CID ecstasy_6/NN (r_compound) users_7/NNS (r_nsubj) display_8/VBP (l_dobj) impairments_9/NNS (l_prep) in_10/IN (l_pobj) performance_14/NN (l_nmod) learning_11/NN (l_conj) memory_13/NN
D002188_D007859 NONE cannabis_12/NN (r_compound) users_13/NNS (r_pobj) in_11/IN (r_prep) hyperactivity_7/NN (r_appos) Deficits_0/NNS (l_prep) in_1/IN (l_pobj) learning_2/NN (l_conj) memory_4/NN
D002188_D008569 NONE cannabis_12/NN (r_compound) users_13/NNS (r_pobj) in_11/IN (r_prep) hyperactivity_7/NN (r_appos) Deficits_0/NNS (l_prep) in_1/IN (l_pobj) learning_2/NN (l_conj) memory_4/NN
D002188_D006948 NONE cannabis_12/NN (r_compound) users_13/NNS (r_pobj) in_11/IN (r_prep) hyperactivity_7/NN
D018817_D006948 NONE ecstasy_13/NN (r_npadvmod) specific_15/JJ (r_amod) hyperactivity_16/NN
D018817_D020258 NONE ecstasy_1/NN (r_npadvmod) specific_3/JJ (r_amod) effects_4/NNS (r_nsubjpass) related_7/VBN (l_prep) to_8/IN (l_pobj) vulnerability_10/NN (l_prep) to_16/IN (l_pobj) effects_19/NNS (l_amod) neurotoxic_18/JJ
D018817_D020258 NONE ecstasy_21/NN (r_pobj) of_20/IN (r_prep) effects_19/NNS (l_amod) neurotoxic_18/JJ
347884
D006220_D019967 NONE haloperidol_6/NNP (r_pobj) with_5/IN (r_prep) study_4/NN (r_pobj) In_0/IN (r_prep) found_11/VBN (l_xcomp) be_13/VB (l_acomp) effective_15/JJ (l_prep) in_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) syndromes_21/NNS (l_acl) belonging_22/VBG (l_prep) to_24/IN (l_pobj) group_27/NN
137340
D009020_D006948 CID morphine_5/NN (r_npadvmod) induced_7/VBN (r_amod) increase_8/NN (l_prep) in_9/IN (l_pobj) activity_11/NN
D009020_D006948 CID morphine_7/NN (r_amod) induced_9/VBN (r_amod) increase_10/NN (l_prep) in_11/IN (l_pobj) activity_13/NN
D009020_D006948 CID morphine_7/NN (r_compound) HC1_9/NNP (r_pobj) of_6/IN (r_prep) mg/kg_5/CD (r_pobj) of_3/IN (r_prep) administration_2/NN (r_nsubj) produced_10/VBD (l_dobj) increase_13/NN (l_prep) in_14/IN (l_pobj) activity_16/NN
D009020_D006948 CID morphine_1/NN (r_npadvmod) induced_3/VBN (r_amod) hyperactivity_4/NN
D009020_D006948 CID morphine_26/NN (r_pobj) by_25/IN (r_agent) produced_24/VBN (r_acl) hyperactivity_23/NN
D012601_D006948 CID scopolamine_8/NN (r_pobj) by_7/IN (r_agent) potentiated_6/VBN (l_nsubjpass) hyperactivity_4/NN
D010830_D006948 NONE physostigmine_12/NN (r_pobj) by_11/IN (r_agent) attenuated_10/VBN (r_conj) potentiated_6/VBN (l_nsubjpass) hyperactivity_4/NN
D019832_D006948 NONE methscopolamine_4/NNP (r_nsubj) had_18/VBD (l_dobj) effect_20/NN (l_prep) on_21/IN (l_pobj) hyperactivity_23/NN
D009388_D006948 NONE neostigmine_6/NNP (r_conj) methscopolamine_4/NNP (r_nsubj) had_18/VBD (l_dobj) effect_20/NN (l_prep) on_21/IN (l_pobj) hyperactivity_23/NN
D010134_D006948 NONE chlorophenylalamine_9/NNP (r_pobj) with_6/IN (r_prep) pretreatment_5/NN (r_nsubj) caused_25/VBD (l_dobj) change_28/NN (l_prep) in_29/IN (l_pobj) hyperactivity_31/NN
D012701_D006948 NONE serotonin_22/NN (r_compound) depletor_23/NN (r_appos) chlorophenylalamine_9/NNP (r_pobj) with_6/IN (r_prep) pretreatment_5/NN (r_nsubj) caused_25/VBD (l_dobj) change_28/NN (l_prep) in_29/IN (l_pobj) hyperactivity_31/NN
20722491
-1_D009369 NONE Fluoropyrimidines_5/NNP (r_appos) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS
-1_D015179 NONE Fluoropyrimidines_5/NNP (r_appos) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
-1_D001943 NONE Fluoropyrimidines_5/NNP (r_appos) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
-1_D006258 NONE Fluoropyrimidines_5/NNP (r_appos) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
D005472_D009369 NONE 5-fluorouracil_9/CD (r_punct) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS
D005472_D009369 NONE 5-FU_11/CD (r_appos) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS
D005472_D015179 NONE 5-fluorouracil_9/CD (r_punct) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
D005472_D015179 NONE 5-FU_11/CD (r_appos) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
D005472_D001943 NONE 5-fluorouracil_9/CD (r_punct) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
D005472_D001943 NONE 5-FU_11/CD (r_appos) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
D005472_D006258 NONE 5-fluorouracil_9/CD (r_punct) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
D005472_D006258 NONE 5-FU_11/CD (r_appos) IMPORTANCE_0/NN (r_nsubj) been_15/VBN (l_attr) mainstay_17/NN (l_prep) for_20/IN (l_pobj) tumors_23/NNS (l_prep) including_25/VBG (l_pobj) colorectal_26/JJ (l_conj) breast_28/NN (l_conj) cancers_33/NNS
C110904_D007674 NONE capecitabine_10/NNP (r_pobj) of_9/IN (r_prep) safety_8/NN (l_prep) in_11/IN (l_pobj) populations_13/NNS (l_prep) as_15/IN (l_pobj) patients_16/NNS (l_conj) disease_24/NN
C110904_D007674 NONE Capecitabine_0/NNP (r_nsubj) has_1/VBZ (l_conj) given_11/VBN (l_prep) to_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) age_17/NN (l_appos) dysfunctions_22/NNS
C110904_D003967 CID capecitabine_7/NNP (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) are_8/VBP (l_attr) diarrhea_9/JJ
C110904_D009325 CID capecitabine_7/NNP (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) are_8/VBP (l_attr) diarrhea_9/JJ (l_conj) nausea_11/NN
C110904_D014839 CID capecitabine_7/NNP (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) are_8/VBP (l_attr) diarrhea_9/JJ (l_conj) nausea_11/NN (l_conj) vomiting_13/NN
C110904_D013280 CID capecitabine_7/NNP (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) are_8/VBP (l_attr) diarrhea_9/JJ (l_conj) nausea_11/NN (l_conj) vomiting_13/NN (l_conj) stomatitis_15/NN
C110904_D060831 CID capecitabine_7/NNP (r_pobj) of_6/IN (r_prep) effects_5/NNS (r_nsubj) are_8/VBP (l_attr) diarrhea_9/JJ (l_conj) nausea_11/NN (l_conj) vomiting_13/NN (l_conj) stomatitis_15/NN (l_conj) syndrome_20/NN
C110904_D008107 NONE Capecitabine_0/NNP (r_nsubj) has_1/VBZ (l_conj) given_11/VBN (l_prep) to_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) age_17/NN (l_appos) dysfunctions_22/NNS
6387529
D003975_D016584 NONE diazepam_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) disorder_10/NN
D003975_D016584 NONE diazepam_6/NN (r_pobj) of_5/IN (r_prep) doses_4/NNS (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_appos) dose_9/NN (l_conj) propranolol_27/JJ (l_prep) on_47/IN (l_pobj) performance_49/NN (l_prep) of_50/IN (l_pobj) patients_51/NNS (l_prep) with_52/IN (l_pobj) disorders_54/NNS
D003975_D000379 NONE diazepam_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) disorder_10/NN (l_conj) agoraphobia_12/NN
D003975_D000379 NONE diazepam_6/NN (r_pobj) of_5/IN (r_prep) doses_4/NNS (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_appos) dose_9/NN (l_conj) propranolol_27/JJ (l_prep) on_47/IN (l_pobj) performance_49/NN (l_prep) of_50/IN (l_pobj) patients_51/NNS (l_prep) with_52/IN (l_pobj) disorders_54/NNS (l_conj) agoraphobia_56/NN
D011433_D016584 NONE propranolol_5/NNS (r_conj) diazepam_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) disorder_10/NN
D011433_D016584 NONE propranolol_27/JJ (l_prep) on_47/IN (l_pobj) performance_49/NN (l_prep) of_50/IN (l_pobj) patients_51/NNS (l_prep) with_52/IN (l_pobj) disorders_54/NNS
D011433_D000379 NONE propranolol_5/NNS (r_conj) diazepam_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) in_6/IN (l_pobj) patients_7/NNS (l_prep) with_8/IN (l_pobj) disorder_10/NN (l_conj) agoraphobia_12/NN
D011433_D000379 NONE propranolol_27/JJ (l_prep) on_47/IN (l_pobj) performance_49/NN (l_prep) of_50/IN (l_pobj) patients_51/NNS (l_prep) with_52/IN (l_pobj) disorders_54/NNS (l_conj) agoraphobia_56/NN
D003975_D008569 CID diazepam_12/NN (r_pobj) for_11/IN (r_prep) greater_10/JJR (r_acomp) was_9/VBD (r_conj) impaired_2/VBD (l_dobj) recall_5/NN
D011433_D008569 CID propranolol_14/NN (r_pcomp) than_13/IN (r_prep) diazepam_12/NN (r_pobj) for_11/IN (r_prep) greater_10/JJR (r_acomp) was_9/VBD (r_conj) impaired_2/VBD (l_dobj) recall_5/NN
8996652
D000617_D006311 NONE aminoglycosides_17/NNS (r_appos) drugs_14/NNS (r_pobj) of_12/IN (r_prep) dose_11/NN (r_conj) administration_7/NN (r_pobj) to_4/IN (r_prep) related_3/JJ (r_oprd) appeared_1/VBD (l_nsubj) Ototoxicity_0/NNP
D000617_D006311 NONE aminoglycosides_17/NNS (r_appos) drugs_14/NNS (l_amod) ototoxic_13/JJ
D005665_D006311 NONE furosemide_19/NN (r_conj) aminoglycosides_17/NNS (r_appos) drugs_14/NNS (r_pobj) of_12/IN (r_prep) dose_11/NN (r_conj) administration_7/NN (r_pobj) to_4/IN (r_prep) related_3/JJ (r_oprd) appeared_1/VBD (l_nsubj) Ototoxicity_0/NNP
D005665_D006311 NONE furosemide_19/NN (r_conj) aminoglycosides_17/NNS (r_appos) drugs_14/NNS (l_amod) ototoxic_13/JJ
20520283
C522667_D012559 NONE asenapine_4/NN (r_pobj) of_3/IN (r_prep) Efficacy_0/NN (l_prep) in_5/IN (l_pobj) trial_12/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) exacerbation_17/NN (l_prep) of_18/IN (l_pobj) schizophrenia_19/NN
C522667_D012559 NONE Asenapine_0/NNP (r_nsubjpass) approved_2/VBN (l_prep) in_9/IN (l_pobj) adults_10/NNS (l_prep) for_11/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) schizophrenia_15/NN
C522667_D012559 NONE asenapine_22/NN (r_pobj) with_21/IN (r_prep) assigned_15/VBN (l_nsubjpass) patients_9/NNS (l_prep) with_10/IN (l_pobj) schizophrenia_12/NN
C522667_D012559 NONE asenapine_32/NN (r_appos) patients_9/NNS (l_prep) with_10/IN (l_pobj) schizophrenia_12/NN
D006220_D012559 NONE haloperidol_9/NN (r_npadvmod) controlled_11/VBN (r_amod) trial_12/NN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) exacerbation_17/NN (l_prep) of_18/IN (l_pobj) schizophrenia_19/NN
D006220_D012559 NONE haloperidol_41/NNP (r_conj) placebo_38/NN (r_conj) BID_36/NNS (r_pobj) at_33/IN (r_prep) asenapine_32/NN (r_appos) patients_9/NNS (l_prep) with_10/IN (l_pobj) schizophrenia_12/NN
C522667_D001714 NONE Asenapine_0/NNP (r_nsubjpass) approved_2/VBN (l_prep) in_9/IN (l_pobj) adults_10/NNS (l_prep) for_11/IN (l_conj) of_17/IN (l_pobj) episodes_21/NNS (l_amod) manic_18/JJ
C522667_D001714 NONE Asenapine_0/NNP (r_nsubjpass) approved_2/VBN (l_prep) in_9/IN (l_pobj) adults_10/NNS (l_prep) for_11/IN (l_conj) of_17/IN (l_pobj) episodes_21/NNS (l_acl) associated_22/VBN (l_prep) with_23/IN (l_pobj) disorder_26/VBP
C522667_D011618 NONE Asenapine_0/NNP (r_nsubjpass) approved_2/VBN (l_prep) in_9/IN (l_pobj) adults_10/NNS (l_prep) for_11/IN (l_conj) of_17/IN (l_pobj) episodes_21/NNS (l_acl) associated_22/VBN (l_prep) with_23/IN (l_pobj) disorder_26/VBP (l_prep) with_27/IN (l_conj) without_29/IN (l_pobj) features_31/NNS (l_amod) psychotic_30/JJ
C522667_D001480 CID asenapine_21/NN (r_pobj) of_19/IN (r_prep) %_18/NN (r_conj) occurred_5/VBD (r_advcl) reported_2/VBD (l_nsubj) symptoms_1/NNS
C522667_D001480 CID asenapine_8/NN (r_pobj) with_7/IN (r_prep) similar_6/JJ (r_acomp) was_5/VBD (r_ccomp) indicated_2/VBD (r_ccomp) seen_15/VBN (l_prep) in_16/IN (l_pobj) AEs_17/NNP (l_appos) symptoms_21/NNS
D006220_D001480 CID haloperidol_29/NNP (r_npadvmod) BID_27/NNS (r_pobj) at_22/IN (r_prep) %_18/NN (r_conj) occurred_5/VBD (r_advcl) reported_2/VBD (l_nsubj) symptoms_1/NNS
D006220_D001480 CID haloperidol_10/NN (r_conj) asenapine_8/NN (r_pobj) with_7/IN (r_prep) similar_6/JJ (r_acomp) was_5/VBD (r_ccomp) indicated_2/VBD (r_ccomp) seen_15/VBN (l_prep) in_16/IN (l_pobj) AEs_17/NNP (l_appos) symptoms_21/NNS
2924746
D002220_D064420 NONE carbamazepine_1/NN (r_compound) treatment_2/NN (l_prep) in_3/IN (l_pobj) rat_5/NN (l_appos) efficacy_7/NN (l_conj) toxicity_9/NN
D005492_D064420 NONE folate_17/JJ (r_compound) concentrations_18/NNS (r_pobj) on_13/IN (r_prep) treatment_2/NN (l_prep) in_3/IN (l_pobj) rat_5/NN (l_appos) efficacy_7/NN (l_conj) toxicity_9/NN
D019946_D012640 NONE glycol_13/NN (r_appos) vehicle_10/NN (r_appos) model_6/NN (r_dobj) developing_4/VBG (r_pcomp) of_3/IN (r_prep) course_2/NN (r_pobj) In_0/IN (r_prep) found_22/VBN (l_xcomp) exhibit_24/VB (l_dobj) properties_26/NNS (l_prep) against_27/IN (l_pobj) seizures_29/NNS
D019946_D015430 NONE glycol_13/NN (r_appos) vehicle_10/NN (r_appos) model_6/NN (r_dobj) developing_4/VBG (r_pcomp) of_3/IN (r_prep) course_2/NN (r_pobj) In_0/IN (r_prep) found_22/VBN (l_xcomp) exhibit_24/VB (l_dobj) properties_26/NNS (l_prep) against_27/IN (l_pobj) seizures_29/NNS (l_conj) gain_33/NN
D005481_D012640 CID ether_4/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Seizures_0/NNS
D005481_D012640 CID ether_4/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Seizures_0/NNS (r_nsubjpass) found_10/VBN (l_xcomp) be_12/VB (l_attr) measure_16/NN (l_prep) than_21/IN (l_pobj) seizures_22/NNS
D005481_D012640 CID HFDE_6/NNP (r_appos) ether_4/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Seizures_0/NNS
D005481_D012640 CID HFDE_6/NNP (r_appos) ether_4/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Seizures_0/NNS (r_nsubjpass) found_10/VBN (l_xcomp) be_12/VB (l_attr) measure_16/NN (l_prep) than_21/IN (l_pobj) seizures_22/NNS
D005481_D012640 CID HFDE_13/NNP (r_npadvmod) induced_15/VBN (r_amod) seizures_16/NNS
D002220_D012640 NONE CBZ_20/NNP (r_pobj) by_19/IN (r_prep) protection_18/NN (r_pobj) of_17/IN (r_prep) measure_16/NN (r_attr) be_12/VB (r_xcomp) found_10/VBN (l_nsubjpass) Seizures_0/NNS
D002220_D012640 NONE CBZ_20/NNP (r_pobj) by_19/IN (r_prep) protection_18/NN (r_pobj) of_17/IN (r_prep) measure_16/NN (l_prep) than_21/IN (l_pobj) seizures_22/NNS
D005481_D015430 NONE HFDE_13/NNP (r_npadvmod) induced_15/VBN (r_amod) seizures_16/NNS (r_pobj) against_12/IN (r_prep) protective_11/JJ (r_acomp) was_9/VBD (l_conj) was_18/VBD (l_acomp) toxic_20/JJ (l_advcl) measured_22/VBN (l_agent) by_23/IN (l_pobj) gain_25/NN
6503301
D003606_D006504 CID dacarbazine_6/NNP (r_compound) therapy_7/NNP (r_pobj) after_5/IN (r_prep) disease_4/NN
D003606_D006504 CID DTIC_9/NNP (r_appos) therapy_7/NNP (r_pobj) after_5/IN (r_prep) disease_4/NN
D003606_D006504 CID dacarbazine_14/NNP (r_nmod) therapy_18/NN (r_pobj) after_13/IN (r_prep) outcome_12/NN (r_pobj) with_10/IN (r_prep) case_1/NN (l_prep) of_2/IN (l_pobj) disease_6/NN (l_prep) of_7/IN (l_pobj) liver_9/NN
D003606_D006504 CID DTIC_16/NNP (r_nmod) therapy_18/NN (r_pobj) after_13/IN (r_prep) outcome_12/NN (r_pobj) with_10/IN (r_prep) case_1/NN (l_prep) of_2/IN (l_pobj) disease_6/NN (l_prep) of_7/IN (l_pobj) liver_9/NN
D003606_D008545 NONE dacarbazine_6/NNP (r_compound) therapy_7/NNP (l_prep) for_11/IN (l_pobj) melanoma_12/NN
D003606_D008545 NONE DTIC_9/NNP (r_appos) therapy_7/NNP (l_prep) for_11/IN (l_pobj) melanoma_12/NN
D003606_D008545 NONE dacarbazine_14/NNP (r_nmod) therapy_18/NN (l_prep) for_19/IN (l_pobj) melanoma_20/NN
D003606_D008545 NONE DTIC_16/NNP (r_nmod) therapy_18/NN (l_prep) for_19/IN (l_pobj) melanoma_20/NN
10721819
D007545_D013610 NONE isoproterenol_7/NN (l_prep) on_8/IN (l_pobj) tachycardia_12/NN
D007545_D013610 NONE isoproterenol_33/NN (r_compound) pretreatment_34/NN (r_pobj) by_31/IN (r_agent) reduced_30/VBN (r_acl) is_15/VBZ (l_nsubj) tachycardia_8/NN
D007545_D013610 NONE isoproterenol_10/NN (r_pobj) with_9/IN (r_prep) pretreatment_8/NN (r_nsubj) abolish_12/VB (l_dobj) tachycardia_16/NN
D007545_D013610 NONE isoproterenol_7/NN (r_compound) pretreatment_8/NN (r_pobj) by_6/IN (r_agent) unaffected_5/JJ (r_acomp) was_4/VBD (l_advcl) reversed_13/VBN (l_nsubjpass) tachycardia_11/NN
D007545_D013610 NONE isoproterenol_5/NN (r_compound) pretreatment_6/NN (r_nsubj) abolished_9/VBD (l_conj) reversed_11/VBD (l_dobj) tachycardia_15/NN
D001971_D013610 CID bromocriptine_9/NNP (r_npadvmod) induced_11/VBN (r_amod) tachycardia_12/NN
D001971_D013610 CID bromocriptine_5/NN (r_npadvmod) induced_7/VBN (r_amod) tachycardia_8/NN
D001971_D013610 CID bromocriptine_13/NN (r_npadvmod) induced_15/VBN (r_amod) tachycardia_16/NN
D001971_D013610 CID bromocriptine_5/NNP (r_nsubj) induced_12/VBD (l_dobj) hypotension_14/NN (l_conj) tachycardia_16/NN
D001971_D013610 CID Bromocriptine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) hypotension_3/NN (r_nsubj) was_4/VBD (l_advcl) reversed_13/VBN (l_nsubjpass) tachycardia_11/NN
D001971_D013610 CID bromocriptine_12/NN (r_npadvmod) induced_14/VBN (r_amod) tachycardia_15/NN
D001971_D013610 CID bromocriptine_13/NNP (r_pobj) of_12/IN (r_prep) tachycardia_11/NN
D004298_D013610 NONE dopamine_22/NN (r_compound) D2_23/NN (r_compound) activation_25/NN (r_pobj) by_20/IN (r_agent) mediated_19/VBN (r_acl) i_17/NN (r_attr) is_15/VBZ (l_nsubj) tachycardia_8/NN
D004298_D013610 NONE dopamine_27/NN (r_compound) D2_28/NN (r_compound) receptors_29/NNS (r_pobj) at_25/IN (r_prep) bradycardia_21/NNS (r_dobj) mask_19/VB (r_conj) predominate_16/VB (r_xcomp) appears_14/VBZ (l_nsubj) tachycardia_11/NN
D007545_D006332 CID Isoproterenol_0/NN (r_compound) pretreatment_1/NN (r_nsubj) caused_5/VBD (l_dobj) hypertrophy_7/NN
D001971_D007022 CID bromocriptine_5/NNP (r_nsubj) induced_12/VBD (l_dobj) hypotension_14/NN
D001971_D007022 CID Bromocriptine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) hypotension_3/NN
D001971_D001919 NONE Bromocriptine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) hypotension_3/NN (r_nsubj) was_4/VBD (l_advcl) reversed_13/VBN (l_prep) to_14/IN (l_pobj) bradycardia_16/NNS
D001971_D001919 NONE bromocriptine_12/NN (r_npadvmod) induced_14/VBN (r_amod) tachycardia_15/NN (r_dobj) reversed_11/VBD (l_prep) to_16/IN (l_pobj) bradycardia_17/NN
D001971_D001919 NONE bromocriptine_13/NNP (r_pobj) of_12/IN (r_prep) tachycardia_11/NN (r_nsubj) appears_14/VBZ (l_xcomp) predominate_16/VB (l_conj) mask_19/VB (l_dobj) bradycardia_21/NNS
D007545_D007022 NONE isoproterenol_7/NN (r_compound) pretreatment_8/NN (r_pobj) by_6/IN (r_agent) unaffected_5/JJ (r_acomp) was_4/VBD (l_nsubj) hypotension_3/NN
D007545_D001919 CID isoproterenol_7/NN (r_compound) pretreatment_8/NN (r_pobj) by_6/IN (r_agent) unaffected_5/JJ (r_acomp) was_4/VBD (l_advcl) reversed_13/VBN (l_prep) to_14/IN (l_pobj) bradycardia_16/NNS
D007545_D001919 CID isoproterenol_5/NN (r_compound) pretreatment_6/NN (r_nsubj) abolished_9/VBD (l_conj) reversed_11/VBD (l_prep) to_16/IN (l_pobj) bradycardia_17/NN
D004294_D007022 NONE domperidone_26/NN (r_pobj) by_24/IN (r_agent) reduced_23/VBN (r_relcl) effect_19/NN (r_appos) bradycardia_16/NNS (r_pobj) to_14/IN (r_prep) reversed_13/VBN (r_advcl) was_4/VBD (l_nsubj) hypotension_3/NN
D004294_D013610 NONE domperidone_26/NN (r_pobj) by_24/IN (r_agent) reduced_23/VBN (r_relcl) effect_19/NN (r_appos) bradycardia_16/NNS (r_pobj) to_14/IN (r_prep) reversed_13/VBN (l_nsubjpass) tachycardia_11/NN
D004294_D001919 CID domperidone_26/NN (r_pobj) by_24/IN (r_agent) reduced_23/VBN (r_relcl) effect_19/NN (r_appos) bradycardia_16/NNS
D004298_D001919 NONE dopamine_27/NN (r_compound) D2_28/NN (r_compound) receptors_29/NNS (r_pobj) at_25/IN (r_prep) bradycardia_21/NNS
20528871
C104457_D015458 NONE nelarabine_3/NNP (r_pobj) with_2/IN (r_prep) therapy_1/NN (l_prep) in_9/IN (l_pobj) leukaemia_18/NN (l_conj) lymphoma_20/NN
C104457_D015458 NONE nelarabine_6/NNP (r_pobj) of_5/IN (r_prep) d_4/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
C104457_D015458 NONE AraG_8/NNP (r_appos) nelarabine_6/NNP (r_pobj) of_5/IN (r_prep) d_4/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
C104457_D016399 NONE nelarabine_3/NNP (r_pobj) with_2/IN (r_prep) therapy_1/NN (l_prep) in_9/IN (l_pobj) leukaemia_18/NN (l_conj) lymphoma_20/NN
C104457_D016399 NONE nelarabine_6/NNP (r_pobj) of_5/IN (r_prep) d_4/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
C104457_D016399 NONE AraG_8/NNP (r_appos) nelarabine_6/NNP (r_pobj) of_5/IN (r_prep) d_4/NNP (r_pobj) of_2/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
D005047_D015458 NONE etoposide_5/RB (r_conj) nelarabine_3/NNP (r_pobj) with_2/IN (r_prep) therapy_1/NN (l_prep) in_9/IN (l_pobj) leukaemia_18/NN (l_conj) lymphoma_20/NN
D005047_D015458 NONE etoposide_14/NN (r_pobj) of_13/IN (r_prep) d_12/NN (r_pobj) with_10/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
D005047_D015458 NONE VP_16/NNP (r_appos) etoposide_14/NN (r_pobj) of_13/IN (r_prep) d_12/NN (r_pobj) with_10/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
D005047_D016399 NONE etoposide_5/RB (r_conj) nelarabine_3/NNP (r_pobj) with_2/IN (r_prep) therapy_1/NN (l_prep) in_9/IN (l_pobj) leukaemia_18/NN (l_conj) lymphoma_20/NN
D005047_D016399 NONE etoposide_14/NN (r_pobj) of_13/IN (r_prep) d_12/NN (r_pobj) with_10/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
D005047_D016399 NONE VP_16/NNP (r_appos) etoposide_14/NN (r_pobj) of_13/IN (r_prep) d_12/NN (r_pobj) with_10/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
D003520_D015458 NONE cyclophosphamide_8/RBR (r_conj) etoposide_5/RB (r_conj) nelarabine_3/NNP (r_pobj) with_2/IN (r_prep) therapy_1/NN (l_prep) in_9/IN (l_pobj) leukaemia_18/NN (l_conj) lymphoma_20/NN
D003520_D015458 NONE cyclophosphamide_19/NN (r_conj) d_12/NN (r_pobj) with_10/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
D003520_D015458 NONE CPM_21/NNP (r_appos) cyclophosphamide_19/NN (r_conj) d_12/NN (r_pobj) with_10/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
D003520_D016399 NONE cyclophosphamide_8/RBR (r_conj) etoposide_5/RB (r_conj) nelarabine_3/NNP (r_pobj) with_2/IN (r_prep) therapy_1/NN (l_prep) in_9/IN (l_pobj) leukaemia_18/NN (l_conj) lymphoma_20/NN
D003520_D016399 NONE cyclophosphamide_19/NN (r_conj) d_12/NN (r_pobj) with_10/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
D003520_D016399 NONE CPM_21/NNP (r_appos) cyclophosphamide_19/NN (r_conj) d_12/NN (r_pobj) with_10/IN (r_prep) combination_1/NN (r_nsubjpass) used_28/VBN (l_prep) as_29/IN (l_pobj) therapy_31/NN (l_prep) with_35/IN (l_pobj) leukaemia_42/NN (l_conj) lymphoma_44/NN
C104457_D009422 CID AraG_8/NNP (r_pobj) to_6/IN (r_prep) attributable_5/JJ (r_amod) effects_4/NNS (r_nsubj) included_9/VBD (l_dobj) Grade_10/NN (l_conj) neuropathy_17/NN
C104457_D009422 CID AraG_7/NNP (r_dobj) giving_6/VBG (r_pcomp) of_5/IN (r_prep) safety_4/NN (r_dobj) supports_2/VBZ (l_advcl) monitored_24/VBN (l_nsubjpass) toxicity_20/NN
C104457_D059352 CID AraG_8/NNP (r_pobj) to_6/IN (r_prep) attributable_5/JJ (r_amod) effects_4/NNS (r_nsubj) included_9/VBD (l_dobj) Grade_10/NN (l_conj) neuropathy_17/NN (l_conj) pain_20/NN
C104457_D006402 CID AraG_8/NNP (r_pobj) than_7/IN (r_prep) combination_6/NN (r_pobj) for_4/IN (r_prep) greater_3/JJR (r_acomp) was_2/VBD (l_nsubj) toxicity_1/NN
D005047_D009422 NONE etoposide_14/NN (r_pobj) with_13/IN (r_prep) synchrony_12/NN (r_pobj) in_11/IN (r_prep) therapy_10/NN (r_pobj) as_8/IN (r_prep) giving_6/VBG (r_pcomp) of_5/IN (r_prep) safety_4/NN (r_dobj) supports_2/VBZ (l_advcl) monitored_24/VBN (l_nsubjpass) toxicity_20/NN
D003520_D009422 NONE cyclophosphamide_16/UH (r_conj) etoposide_14/NN (r_pobj) with_13/IN (r_prep) synchrony_12/NN (r_pobj) in_11/IN (r_prep) therapy_10/NN (r_pobj) as_8/IN (r_prep) giving_6/VBG (r_pcomp) of_5/IN (r_prep) safety_4/NN (r_dobj) supports_2/VBZ (l_advcl) monitored_24/VBN (l_nsubjpass) toxicity_20/NN
7199841
C004616_D010243 CID CE_11/NNP (r_nmod) paralysis_21/NN
D002045_D010243 NONE bupivacaine_6/NN (r_dobj) received_5/VBD (r_relcl) animals_3/NNS (r_pobj) of_1/IN (r_prep) None_0/NN (r_nsubj) titrated_14/VBN (l_prep) to_15/IN (l_pobj) paralysis_23/NN
C004616_D013118 CID CE_12/NNP (r_dobj) received_9/VBD (r_relcl) animals_7/NNS (r_pobj) of_5/IN (r_prep) cords_4/NNS (r_pobj) Of_0/IN (r_prep) showed_15/VBD (l_dobj) necrosis_17/NN
19767176
C020972_D013226 NONE dithiocarbamate_1/NNP (r_nsubj) protects_2/VBZ (l_prep) in_6/IN (l_pobj) model_11/NN (l_compound) epilepticus_10/NN
C020972_D013226 NONE PDTC_3/NNP (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) on_4/IN (l_pobj) loss_10/NN (l_amod) associated_8/VBN (l_npadvmod) epilepticus_6/NN
C020972_D013226 NONE PDTC_4/NNS (r_pobj) with_1/IN (r_prep) Treatment_0/NN (l_advmod) before_5/IN (l_conj) following_7/VBG (l_dobj) epilepticus_9/NN
C020972_D013226 NONE PDTC_4/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) exert_12/VB (l_dobj) effects_14/NNS (l_prep) on_15/IN (l_pobj) development_17/NN (l_prep) of_18/IN (l_pobj) epilepticus_21/NN
C020972_D013226 NONE PDTC_1/NNP (r_npadvmod) treated_3/VBN (r_amod) rats_4/NNS (l_prep) following_5/VBG (l_pobj) epilepticus_7/NN
D010862_D013226 CID pilocarpine_8/NN (r_compound) status_9/FW (r_compound) model_11/NN (l_compound) epilepticus_10/NN
D010862_D013226 CID pilocarpine_23/NNP (r_compound) model_24/NN (r_pobj) in_19/IN (r_prep) evaluated_18/VBN (l_nsubjpass) effect_1/NN (l_prep) on_4/IN (l_pobj) loss_10/NN (l_amod) associated_8/VBN (l_npadvmod) epilepticus_6/NN
D010100_D009410 NONE oxygen_5/NN (r_compound) species_6/NNS (r_pobj) of_3/IN (r_prep) production_2/NN (r_nsubjpass) implicated_17/VBN (l_prep) in_18/IN (l_pobj) damage_21/NN
D010100_D009410 NONE oxygen_9/NN (r_compound) species_10/NNS (r_pobj) of_7/IN (r_prep) generation_6/NN (r_nsubj) plays_17/VBZ (l_dobj) role_21/NN (l_prep) in_22/IN (l_pobj) damage_27/NN
C020972_D009410 NONE PDTC_10/NNP (r_conj) inhibitor_7/NN (r_nsubj) protected_11/VBD (l_advcl) affect_20/VB (l_dobj) loss_23/NN
D010100_D012640 NONE oxygen_9/NN (r_compound) species_10/NNS (r_pobj) of_7/IN (r_prep) generation_6/NN (r_nsubj) plays_17/VBZ (l_dobj) role_21/NN (l_prep) in_22/IN (l_pobj) damage_27/NN (l_amod) associated_25/VBN (l_npadvmod) seizure_23/NN
18221780
D016202_D010146 NONE NMDA_3/NNP (r_compound) enhancement_5/NN (l_prep) in_9/IN (l_pobj) model_12/NN (l_prep) of_13/IN (l_pobj) pain_15/NN
D016202_D010146 NONE NMDA_9/NNP (r_compound) antagonists_10/NNS (r_pobj) between_8/IN (r_prep) interaction_7/NN (l_prep) in_13/IN (l_pobj) model_17/NN (l_compound) pain_16/NN
D016202_D059787 NONE NMDA_3/NNP (r_compound) enhancement_5/NN (r_pobj) in_2/IN (r_prep) differences_1/NNS (l_appos) comparisons_17/NNS (l_prep) to_18/IN (l_pobj) models_20/NNS (l_prep) of_21/IN (l_pobj) pain_23/NN
D016202_D059787 NONE aspartate_11/NN (r_nmod) antagonists_15/NNS (r_nsubj) enhance_16/VBP (l_prep) In_0/IN (l_pobj) models_3/NNS (l_compound) pain_2/NN
D016202_D059787 NONE NMDA_13/NNP (r_appos) aspartate_11/NN (r_nmod) antagonists_15/NNS (r_nsubj) enhance_16/VBP (l_prep) In_0/IN (l_pobj) models_3/NNS (l_compound) pain_2/NN
D016202_D059787 NONE NMDA_9/NNP (r_compound) antagonists_10/NNS (r_pobj) between_8/IN (r_prep) interaction_7/NN (l_prep) in_13/IN (l_pobj) model_17/NN (l_relcl) distinguished_21/VBN (l_prep) from_22/IN (l_pobj) those_23/DT (l_acl) observed_24/VBN (l_prep) in_25/IN (l_pobj) models_28/NNS (l_compound) pain_27/NN
D009020_D010146 NONE morphine_7/NN (r_compound) antihyperalgesia_8/NNS (r_pobj) of_6/IN (r_prep) enhancement_5/NN (l_prep) in_9/IN (l_pobj) model_12/NN (l_prep) of_13/IN (l_pobj) pain_15/NN
D009020_D010146 NONE morphine_12/NN (r_conj) antagonists_10/NNS (r_pobj) between_8/IN (r_prep) interaction_7/NN (l_prep) in_13/IN (l_pobj) model_17/NN (l_compound) pain_16/NN
D009020_D059787 NONE morphine_7/NN (r_compound) antihyperalgesia_8/NNS (r_pobj) of_6/IN (r_prep) enhancement_5/NN (r_pobj) in_2/IN (r_prep) differences_1/NNS (l_appos) comparisons_17/NNS (l_prep) to_18/IN (l_pobj) models_20/NNS (l_prep) of_21/IN (l_pobj) pain_23/NN
D009020_D059787 NONE morphine_21/NN (r_pobj) of_20/IN (r_prep) effects_19/NNS (r_dobj) enhance_16/VBP (l_prep) In_0/IN (l_pobj) models_3/NNS (l_compound) pain_2/NN
D009020_D059787 NONE morphine_2/NN (r_compound) antinociception_3/NN (r_pobj) of_1/IN (r_prep) Enhancement_0/NN (r_nsubjpass) seen_7/VBN (l_prep) in_8/IN (l_pobj) males_10/NNS (l_prep) in_13/IN (l_pobj) models_17/NNS (l_compound) pain_16/NN
D009020_D059787 NONE morphine_12/NN (r_conj) antagonists_10/NNS (r_pobj) between_8/IN (r_prep) interaction_7/NN (l_prep) in_13/IN (l_pobj) model_17/NN (l_relcl) distinguished_21/VBN (l_prep) from_22/IN (l_pobj) those_23/DT (l_acl) observed_24/VBN (l_prep) in_25/IN (l_pobj) models_28/NNS (l_compound) pain_27/NN
D002211_D010146 NONE capsaicin_11/NN (r_compound) model_12/NN (l_prep) of_13/IN (l_pobj) pain_15/NN
D002211_D059787 NONE capsaicin_11/NN (r_compound) model_12/NN (r_pobj) in_9/IN (r_prep) enhancement_5/NN (r_pobj) in_2/IN (r_prep) differences_1/NNS (l_appos) comparisons_17/NNS (l_prep) to_18/IN (l_pobj) models_20/NNS (l_prep) of_21/IN (l_pobj) pain_23/NN
D002211_D006930 CID capsaicin_11/NN (r_pobj) of_10/IN (r_prep) administration_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (l_nsubjpass) hyperalgesia_5/NN
D003915_D059787 NONE dextromethorphan_5/NN (r_pobj) by_4/IN (r_prep) Enhancement_0/NN (r_nsubjpass) seen_7/VBN (l_prep) in_8/IN (l_pobj) males_10/NNS (l_prep) in_13/IN (l_pobj) models_17/NNS (l_compound) pain_16/NN
8231633
D002118_D064420 NONE calcium_2/NN (r_compound) channel_3/NN (r_compound) blockers_4/NNS (l_prep) on_5/IN (l_pobj) toxicity_9/NN
D002118_D064420 NONE calcium_11/NN (r_compound) channel_12/NN (r_compound) blockers_13/NNS (l_prep) on_14/IN (l_pobj) toxicity_19/NN
D002045_D064420 NONE bupivacaine_6/NN (r_npadvmod) induced_8/VBN (r_amod) toxicity_9/NN
D002045_D064420 NONE bupivacaine_15/NN (r_npadvmod) induced_17/VBN (r_amod) toxicity_19/NN
D002045_D012640 CID bupivacaine_4/NN (r_pobj) of_3/IN (r_prep) activity_2/NN (r_nsubj) was_5/VBD (l_ccomp) decreased_13/VBD (l_advcl) obtain_19/VB (l_dobj) convulsions_23/NNS
D002045_D012640 CID bupivacaine_20/NN (r_npadvmod) induced_22/VBN (r_amod) convulsions_23/NNS
D002118_D012640 NONE calcium_10/NN (r_compound) channel_11/NN (r_compound) blockers_12/NNS (r_nsubj) decreased_13/VBD (l_advcl) obtain_19/VB (l_dobj) convulsions_23/NNS
D015764_D012640 NONE bepridil_31/NNP (r_pobj) with_30/IN (r_prep) pronounced_29/VBN (r_acomp) was_27/VBD (l_ccomp) was_5/VBD (l_ccomp) decreased_13/VBD (l_advcl) obtain_19/VB (l_dobj) convulsions_23/NNS
3070035
D002216_D051437 NONE captopril_2/NN (r_npadvmod) induced_4/VBN (r_amod) insufficiency_6/NN
D002216_D051437 NONE captopril_4/NN (r_npadvmod) induced_6/VBN (r_amod) failure_8/NN
D002216_D006978 NONE captopril_2/NN (r_npadvmod) induced_4/VBN (r_amod) insufficiency_6/NN (l_prep) after_7/IN (l_pobj) use_9/NN (l_prep) in_10/IN (l_pobj) case_13/NN (l_prep) of_14/IN (l_pobj) hypertension_16/NN
D002216_D006973 NONE captopril_27/NNP (r_pobj) with_26/IN (r_prep) treatment_25/NN (r_pobj) following_24/VBG (r_prep) developed_18/VBD (r_relcl) kidney_15/NN (r_pobj) to_12/IN (r_prep) artery_11/NN (r_pobj) with_7/IN (r_prep) hypertension_6/NN
D002216_D058186 CID captopril_27/NNP (r_pobj) with_26/IN (r_prep) treatment_25/NN (r_pobj) following_24/VBG (r_prep) developed_18/VBD (l_dobj) deterioration_20/NN (l_prep) of_21/IN (l_pobj) function_23/NN
20633755
D013390_D001049 CID Suxamethonium_0/NNP (r_nsubj) induced_1/VBD (l_dobj) apnea_3/NN
D013390_D001049 CID Suxamethonium_0/NN (r_nsubj) causes_1/VBZ (l_dobj) apnea_3/NN
D009943_D001049 CID poisons_17/NNS (r_pobj) by_12/IN (r_agent) deactivated_11/VBN (r_relcl) patients_5/NNS (r_pobj) in_4/IN (r_prep) apnea_3/NN
D009943_D001049 CID compound_14/NN (r_pobj) by_12/IN (r_prep) attempt_11/NN (r_pobj) about_9/IN (r_prep) information_8/NN (r_nsubjpass) concealed_16/VBN (r_advcl) ensued_5/VBD (l_nsubj) apnea_1/NN
1720453
D007069_D007674 CID ifosfamide_7/JJ (r_amod) toxicity_9/NN
D007069_C535700 NONE ifosfamide_7/JJ (r_amod) toxicity_9/NN (l_acl) treated_12/VBN (l_prep) for_13/IN (l_pobj) tumors_16/NNS
D007069_C535700 NONE ifosfamide_19/JJ (r_amod) protocol_21/NN (r_dobj) received_16/VBN (r_relcl) function_2/NN (l_prep) of_3/IN (l_pobj) children_5/NNS (l_prep) with_6/IN (l_pobj) tumors_9/NNS
D007069_C535700 NONE ifosfamide_19/JJ (r_amod) protocol_21/NN (l_appos) Society_24/NNP (l_prep) of_25/IN (l_pobj) Study_31/NNP (l_compound) Tumor_30/NNP
D007069_C535700 NONE ifosfamide_18/NNP (r_pobj) of_17/IN (r_prep) efficacy_16/NN (l_prep) in_19/IN (l_pobj) treatment_21/NN (l_prep) of_22/IN (l_pobj) tumors_24/NNS
D003404_D006030 NONE creatinine_22/NN (r_compound) clearance_23/NN (r_conj) osmolarity_20/NN (r_conj) pH_18/NN (r_conj) aminoaciduria_15/NN (r_conj) proteinuria_13/NN (r_conj) glucosuria_11/NNP
D003404_D011507 NONE creatinine_22/NN (r_compound) clearance_23/NN (r_conj) osmolarity_20/NN (r_conj) pH_18/NN (r_conj) aminoaciduria_15/NN (r_conj) proteinuria_13/NN
D003404_D000608 NONE creatinine_22/NN (r_compound) clearance_23/NN (r_conj) osmolarity_20/NN (r_conj) pH_18/NN (r_conj) aminoaciduria_15/NN
D010710_D006030 NONE phosphate_25/NN (r_nmod) reabsorption_27/NN (r_conj) clearance_23/NN (r_conj) osmolarity_20/NN (r_conj) pH_18/NN (r_conj) aminoaciduria_15/NN (r_conj) proteinuria_13/NN (r_conj) glucosuria_11/NNP
D010710_D011507 NONE phosphate_25/NN (r_nmod) reabsorption_27/NN (r_conj) clearance_23/NN (r_conj) osmolarity_20/NN (r_conj) pH_18/NN (r_conj) aminoaciduria_15/NN (r_conj) proteinuria_13/NN
D010710_D000608 NONE phosphate_25/NN (r_nmod) reabsorption_27/NN (r_conj) clearance_23/NN (r_conj) osmolarity_20/NN (r_conj) pH_18/NN (r_conj) aminoaciduria_15/NN
D010710_D064420 NONE phosphate_51/NN (r_compound) reabsorption_52/NN (r_conj) microglobulinuria_48/NNS (r_pobj) with_44/IN (r_prep) patients_43/NNS (r_dobj) included_41/VBD (l_ccomp) included_13/VBD (l_dobj) patients_15/NNS (l_relcl) developed_25/VBD (l_dobj) toxicity_27/NN
D010710_D005198 NONE phosphate_51/NN (r_compound) reabsorption_52/NN (r_conj) microglobulinuria_48/NNS (r_pobj) with_44/IN (r_prep) patients_43/NNS (r_dobj) included_41/VBD (l_ccomp) included_13/VBD (l_dobj) patients_15/NNS (l_relcl) developed_25/VBD (l_dobj) toxicity_27/NN (l_acl) resulting_28/VBG (l_prep) in_29/IN (l_pobj) syndrome_32/NN
D010710_D005198 NONE phosphate_51/NN (r_compound) reabsorption_52/NN (r_conj) microglobulinuria_48/NNS (r_pobj) with_44/IN (r_prep) patients_43/NNS (r_dobj) included_41/VBD (l_ccomp) included_13/VBD (l_dobj) patients_15/NNS (l_relcl) developed_25/VBD (l_dobj) toxicity_27/NN (l_acl) resulting_28/VBG (l_prep) in_29/IN (l_pobj) syndrome_32/NN (l_appos) TDFS_34/NNP
D007069_D064420 NONE ifosfamide_15/NNP (r_pobj) of_14/IN (r_prep) m2_13/NNP (r_pobj) of_9/IN (r_prep) dose_8/NN (r_pobj) with_4/IN (r_prep) correlated_3/VBN (l_nsubjpass) toxicity_1/NN
D007069_D009369 NONE ifosfamide_15/NNP (r_pobj) of_14/IN (r_prep) m2_13/NNP (r_pobj) of_9/IN (r_prep) dose_8/NN (r_pobj) with_4/IN (r_prep) correlated_3/VBN (l_conj) predominance_31/NN (l_prep) of_32/IN (l_pobj) involvement_35/NN (l_compound) tumor_34/NN
6888657
D004967_D010911 NONE estrogen_2/NN (r_npadvmod) induced_4/VBN (r_amod) tumors_6/NNS
D004054_D010911 CID diethylstilbestrol_12/FW (r_pobj) with_11/IN (r_prep) treatment_10/NN (r_pobj) by_8/IN (r_prep) rats_7/NNS (r_pobj) in_4/IN (r_prep) induced_3/VBN (l_nsubjpass) tumors_1/NNS
D004054_D010911 CID DES_14/NNP (r_appos) diethylstilbestrol_12/FW (r_pobj) with_11/IN (r_prep) treatment_10/NN (r_pobj) by_8/IN (r_prep) rats_7/NNS (r_pobj) in_4/IN (r_prep) induced_3/VBN (l_nsubjpass) tumors_1/NNS
D004054_D009369 NONE DES_12/NNP (r_npadvmod) induced_14/VBN (r_amod) tumor_15/NN
7890216
D015282_D042882 CID octreotide_7/NN (r_pobj) with_6/IN (r_prep) associated_5/VBN (r_acl) stones_4/NNS
D015282_D042882 CID Octreotide_0/NNP (r_nsubj) induces_8/VBZ (l_dobj) stones_11/NNS
D015282_D042882 CID octreotide_28/NN (r_pobj) in_26/IN (r_prep) methods_25/NNS (r_pobj) by_21/IN (r_agent) investigated_20/VBN (r_ccomp) treated_29/VBN (l_prep) with_32/IN (l_pobj) stones_34/NNS
D015282_D042882 CID octreotide_3/NN (r_det) stones_6/NNS
D015282_D042882 CID octreotide_3/NN (r_det) stones_6/NNS (r_nsubj) are_7/VBP (l_advcl) have_31/VB (l_prep) in_18/IN (l_amod) common_19/JJ (l_prep) with_20/IN (l_pobj) disease_24/NN
D015282_D042882 CID octreotide_3/NN (r_det) stones_6/NNS (r_nsubj) are_7/VBP (l_advcl) have_31/VB (l_dobj) duct_35/NN (l_conj) stones_39/NNS
D014580_D042882 NONE acid_13/NN (r_pobj) to_10/IN (r_prep) response_9/NN (r_appos) Composition_0/NN (l_prep) of_1/IN (l_pobj) stones_4/NNS
D015282_D000172 NONE Octreotide_0/NNP (l_appos) treatment_4/NN (l_prep) for_5/IN (l_pobj) acromegaly_6/NN
D015282_D000172 NONE octreotide_28/NN (r_pobj) in_26/IN (r_prep) methods_25/NNS (r_pobj) by_21/IN (r_agent) investigated_20/VBN (r_ccomp) treated_29/VBN (l_dobj) patients_31/NNS (l_compound) acromegalic_30/JJ
D002784_D042882 NONE cholesterol_21/NN (r_dobj) contained_15/VBD (r_ccomp) showed_12/VBD (l_ccomp) retrieved_5/VBN (l_nsubj) analysis_1/NN (l_prep) of_2/IN (l_pobj) stones_4/NNS
D002784_D042882 NONE cholesterol_36/NN (r_npadvmod) rich_37/JJ (r_acomp) were_35/VBD (r_ccomp) suggesting_31/VBG (r_advcl) showed_12/VBD (l_dobj) dissolution_29/NN (l_compound) stone_28/NN
D002784_D042882 NONE cholesterol_14/NN (r_conj) multiple_11/JJ (r_conj) small_9/JJ (r_amod) rich_15/JJ (r_acomp) are_7/VBP (l_nsubj) stones_6/NNS
D002784_D042882 NONE cholesterol_14/NN (r_conj) multiple_11/JJ (r_conj) small_9/JJ (r_amod) rich_15/JJ (r_acomp) are_7/VBP (l_advcl) have_31/VB (l_prep) in_18/IN (l_amod) common_19/JJ (l_prep) with_20/IN (l_pobj) disease_24/NN
D002784_D042882 NONE cholesterol_14/NN (r_conj) multiple_11/JJ (r_conj) small_9/JJ (r_amod) rich_15/JJ (r_acomp) are_7/VBP (l_advcl) have_31/VB (l_dobj) duct_35/NN (l_conj) stones_39/NNS
D002118_D042882 NONE calcium_41/NN (r_dobj) containing_40/VBG (r_acl) stones_39/NNS (r_conj) duct_35/NN (r_dobj) have_31/VB (r_advcl) are_7/VBP (l_nsubj) stones_6/NNS
D002118_D042882 NONE calcium_41/NN (r_dobj) containing_40/VBG (r_acl) stones_39/NNS (r_conj) duct_35/NN (r_dobj) have_31/VB (l_prep) in_18/IN (l_amod) common_19/JJ (l_prep) with_20/IN (l_pobj) disease_24/NN
D002118_D042882 NONE calcium_41/NN (r_dobj) containing_40/VBG (r_acl) stones_39/NNS
19473225
D018698_D010523 NONE glutamate_3/NN (r_compound) supplementation_4/NN (r_nsubj) failed_5/VBD (l_xcomp) protect_7/VB (l_prep) against_8/IN (l_pobj) neurotoxicity_10/NN
D018698_D010523 NONE glutamate_18/NN (r_nsubjpass) claimed_27/VBN (r_advcl) is_3/VBZ (l_nsubj) neuropathy_2/NN
D018698_D010523 NONE glutamine_25/NN (r_conj) glutamate_18/NN (r_nsubjpass) claimed_27/VBN (r_advcl) is_3/VBZ (l_nsubj) neuropathy_2/NN
D018698_D010523 NONE glutamate_9/NN (r_compound) supplementation_10/NN (l_prep) for_11/IN (l_pcomp) preventing_12/VBG (l_dobj) neuropathy_17/NN
D018698_D010523 NONE glutamate_8/NN (r_compound) supplementation_9/NN (r_nsubj) fails_14/VBZ (l_xcomp) protect_16/VB (l_prep) against_17/IN (l_pobj) neurotoxicity_19/NN
D017239_D010523 CID paclitaxel_12/NN (r_pobj) of_11/IN (r_prep) neurotoxicity_10/NN
D017239_D010523 CID paclitaxel_12/NN (r_pobj) with_11/IN (r_prep) chemotherapy_10/NN (r_pobj) for_9/IN (r_prep) factor_8/NN (r_attr) is_3/VBZ (l_nsubj) neuropathy_2/NN
D017239_D010523 CID PAC_14/NNP (r_appos) paclitaxel_12/NN (r_pobj) with_11/IN (r_prep) chemotherapy_10/NN (r_pobj) for_9/IN (r_prep) factor_8/NN (r_attr) is_3/VBZ (l_nsubj) neuropathy_2/NN
D017239_D010523 CID PAC_30/NNP (r_compound) neurotoxicity_31/NN (r_dobj) ameliorate_29/VB (r_xcomp) claimed_27/VBN (r_advcl) is_3/VBZ (l_nsubj) neuropathy_2/NN
D017239_D010523 CID PAC_13/NNP (r_npadvmod) induced_15/VBN (r_amod) neuropathy_17/NN
D017239_D010523 CID PAC_21/NNP (r_pobj) of_20/IN (r_prep) neurotoxicity_19/NN
D017239_D020258 NONE paclitaxel_12/NN (r_pobj) with_11/IN (r_prep) chemotherapy_10/NN (r_pobj) for_9/IN (r_prep) factor_8/NN (r_attr) is_3/VBZ (l_advcl) claimed_27/VBN (l_xcomp) ameliorate_29/VB (l_dobj) neurotoxicity_31/NN
D017239_D020258 NONE PAC_14/NNP (r_appos) paclitaxel_12/NN (r_pobj) with_11/IN (r_prep) chemotherapy_10/NN (r_pobj) for_9/IN (r_prep) factor_8/NN (r_attr) is_3/VBZ (l_advcl) claimed_27/VBN (l_xcomp) ameliorate_29/VB (l_dobj) neurotoxicity_31/NN
D017239_D020258 NONE PAC_30/NNP (r_compound) neurotoxicity_31/NN
D018698_D020258 NONE glutamate_18/NN (r_nsubjpass) claimed_27/VBN (l_xcomp) ameliorate_29/VB (l_dobj) neurotoxicity_31/NN
D018698_D020258 NONE glutamine_25/NN (r_conj) glutamate_18/NN (r_nsubjpass) claimed_27/VBN (l_xcomp) ameliorate_29/VB (l_dobj) neurotoxicity_31/NN
D000596_D010523 NONE acid_24/NN (r_compound) glutamine_25/NN (r_conj) glutamate_18/NN (r_nsubjpass) claimed_27/VBN (r_advcl) is_3/VBZ (l_nsubj) neuropathy_2/NN
D000596_D020258 NONE acid_24/NN (r_compound) glutamine_25/NN (r_conj) glutamate_18/NN (r_nsubjpass) claimed_27/VBN (l_xcomp) ameliorate_29/VB (l_dobj) neurotoxicity_31/NN
D017239_D010051 NONE PAC_16/NNP (r_npadvmod) containing_18/VBG (r_amod) regimen_19/NN (r_pobj) of_13/IN (r_prep) cycles_12/NNS (r_pobj) following_10/VBG (r_prep) analysis_9/NN (r_pobj) for_8/IN (r_prep) available_7/JJ (r_acomp) were_6/VBD (l_nsubj) patients_5/NNS (l_compound) cancer_4/NN
D018698_D010051 NONE glutamate_26/NN (r_pobj) by_25/IN (r_agent) supplemented_24/VBN (l_ccomp) were_6/VBD (l_nsubj) patients_5/NNS (l_compound) cancer_4/NN
11897407
C067171_D009203 NONE glucarate_2/NN (l_prep) for_3/IN (l_pobj) detection_4/NN (l_prep) of_5/IN (l_pobj) infarction_10/NN
C067171_D009203 NONE glucarate_2/NNP (r_nsubj) was_3/VBD (l_conj) used_14/VBN (l_xcomp) study_16/VB (l_prep) with_21/IN (l_pobj) infarction_27/NN
D007545_D009203 CID isoproterenol_6/NN (r_npadvmod) induced_8/VBN (r_amod) infarction_10/NN
D007545_D009203 CID isoproterenol_22/NN (r_npadvmod) induced_24/VBN (r_amod) infarction_27/NN
D007545_D007238 NONE isoproterenol_18/NNP (r_pobj) with_17/IN (r_prep) obtained_16/VBN (r_conj) implies_7/VBZ (l_nsubj) model_2/NN (l_acl) used_3/VBD (l_xcomp) produce_5/VB (l_dobj) infarction_6/NN
D007545_D007238 NONE isoproterenol_12/NNP (r_compound) administration_13/NNP (r_pobj) after_11/IN (r_prep) developed_6/VBD (l_dobj) h_10/NN (l_nmod) infarct_8/NN
D005937_D007238 NONE acid_9/NN (r_pobj) on_7/IN (r_prep) based_6/VBN (r_acl) radiopharmaceutical_5/NN (l_amod) avid_4/JJ (l_npadvmod) infarct_2/NN
4027862
D003891_D003693 CID Desipramine_0/NN (r_npadvmod) induced_2/VBN (r_amod) delirium_3/NN
D003891_D003693 CID Desipramine_7/NNP (r_pobj) with_4/IN (r_prep) treated_3/VBN (r_acl) patient_2/NN (r_nsubj) developed_8/VBD (l_dobj) delirium_10/NN
11279304
D018943_D066126 NONE anthracycline_7/NN (r_npadvmod) induced_9/VBN (r_amod) cardiotoxicity_10/NN
D018943_D066126 NONE Anthracyclines_0/NNS (r_nsubj) are_1/VBP (l_conj) cause_9/VBP (l_dobj) cardiotoxicity_13/NN
D018943_D066126 NONE anthracycline_4/NN (r_compound) therapy_5/NN (r_pobj) of_2/IN (r_prep) cardiotoxicity_1/NN
D018943_D066126 NONE anthracycline_24/NN (r_npadvmod) induced_26/VBN (r_amod) cardiotoxicity_27/NN
D018943_D066126 NONE anthracycline_16/NN (r_npadvmod) induced_18/VBN (r_amod) cardiotoxicity_19/NN
D018943_D006331 NONE anthracycline_4/NN (r_compound) therapy_5/NN (r_pobj) of_2/IN (r_prep) cardiotoxicity_1/NN (r_nsubj) highlights_6/VBZ (l_dobj) need_8/NN (l_acl) search_10/VB (l_prep) for_11/IN (l_pobj) methods_12/NNS (l_relcl) are_14/VBP (l_acomp) sensitive_16/JJ (l_conj) capable_18/JJ (l_prep) of_19/IN (l_pcomp) predicting_20/VBG (l_dobj) dysfunction_22/NN
D018943_D015470 NONE anthracycline_24/NN (r_npadvmod) induced_26/VBN (r_amod) cardiotoxicity_27/NN (r_pobj) of_23/IN (r_prep) indicator_22/NN (l_prep) in_28/IN (l_pobj) patients_29/NNS (l_prep) with_30/IN (l_pobj) leukemia_32/NN
D003630_D066126 NONE daunorubicin_36/NNS (r_pobj) with_34/IN (r_prep) treated_33/VBN (r_acl) indicator_22/NN (l_prep) of_23/IN (l_pobj) cardiotoxicity_27/NN
D003630_D066126 NONE DNR)-containing_38/VBG (r_appos) daunorubicin_36/NNS (r_pobj) with_34/IN (r_prep) treated_33/VBN (r_acl) indicator_22/NN (l_prep) of_23/IN (l_pobj) cardiotoxicity_27/NN
D003630_D015470 NONE daunorubicin_36/NNS (r_pobj) with_34/IN (r_prep) treated_33/VBN (r_acl) indicator_22/NN (l_prep) in_28/IN (l_pobj) patients_29/NNS (l_prep) with_30/IN (l_pobj) leukemia_32/NN
D003630_D015470 NONE DNR)-containing_38/VBG (r_appos) daunorubicin_36/NNS (r_pobj) with_34/IN (r_prep) treated_33/VBN (r_acl) indicator_22/NN (l_prep) in_28/IN (l_pobj) patients_29/NNS (l_prep) with_30/IN (l_pobj) leukemia_32/NN
D003630_D015470 NONE DNR_9/NNP (r_npadvmod) containing_11/VBG (r_amod) regimen_12/NN (r_pobj) with_7/IN (r_prep) treated_6/VBN (l_nsubjpass) patients_1/NNS (l_prep) with_2/IN (l_pobj) leukemia_4/NN
D003630_D006333 CID DNR_16/NNP (r_pobj) given_15/VBN (r_acl) failure_14/NN
19884587
D013449_D000757 CID Sulfonamides_0/NNS (r_nsubjpass) associated_2/VBN (l_prep) with_3/IN (l_pobj) anencephaly_4/NN
D009582_D000853 CID Nitrofurantoins_0/NNP (r_nsubjpass) associated_2/VBN (l_prep) with_3/IN (l_pobj) anophthalmia_4/NNP
D009582_D008850 CID Nitrofurantoins_0/NNP (r_nsubjpass) associated_2/VBN (l_prep) with_3/IN (l_pobj) anophthalmia_4/NNP (l_conj) microphthalmos_6/NNP
D009582_D018636 CID Nitrofurantoins_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) syndrome_24/NN
D009582_D006344 CID Nitrofurantoins_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) syndrome_24/NN (l_appos) defects_41/NNS
D009582_D002971 CID Nitrofurantoins_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) syndrome_24/NN (l_appos) defects_41/NNS (l_conj) CI_49/NNP (l_conj) lip_58/NN
D009582_D002972 CID Nitrofurantoins_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) syndrome_24/NN (l_appos) defects_41/NNS (l_conj) CI_49/NNP (l_conj) lip_58/NN (l_prep) with_59/IN (l_pobj) palate_61/NN
D010406_D000014 NONE penicillins_2/NNS (r_nsubjpass) associated_18/VBN (l_prep) with_19/IN (l_pobj) defects_22/NNS
D004917_D000014 NONE erythromycins_4/NNS (r_conj) penicillins_2/NNS (r_nsubjpass) associated_18/VBN (l_prep) with_19/IN (l_pobj) defects_22/NNS
D002511_D000014 NONE cephalosporins_7/NNS (r_conj) erythromycins_4/NNS (r_conj) penicillins_2/NNS (r_nsubjpass) associated_18/VBN (l_prep) with_19/IN (l_pobj) defects_22/NNS
D013449_D000014 CID Sulfonamides_0/NNS (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) defects_8/NNS
D009582_D000014 CID nitrofurantoins_2/NNP (r_conj) Sulfonamides_0/NNS (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) defects_8/NNS
14976857
D011405_-1 NONE propafenone_9/NN (r_compound) overdose_10/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) syndrome_6/NN
D011405_D062787 NONE propafenone_9/NN (r_compound) overdose_10/NN
D011405_D062787 NONE propafenone_26/NN (r_compound) overdose_27/NN
D011405_D004437 NONE propafenone_9/NN (r_compound) overdose_10/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (l_prep) in_11/IN (l_pobj) woman_14/NN (l_prep) with_15/IN (l_pobj) anomaly_18/NN
D011405_D054092 NONE propafenone_26/NN (r_compound) overdose_27/NN (r_pobj) by_24/IN (r_agent) precipitated_23/VBN (r_conj) occurred_9/VBD (l_nsubj) shunt_1/NN (l_prep) via_4/IN (l_pobj) ovale_8/NN
19759529
D004298_D012559 NONE dopamine_8/NN (r_compound) neurotransmission_9/NN (r_pobj) in_7/IN (r_prep) dysfunction_6/NN (r_pobj) with_5/IN (r_prep) associated_4/VBN (l_nsubjpass) Schizophrenia_0/NN
D018698_D012559 NONE glutamate_8/NN (r_nmod) aspartate_15/NN (r_nmod) receptor_19/NN (r_pobj) of_6/IN (r_prep) antagonists_5/NNS (r_nsubj) produce_20/VBP (l_dobj) symptoms_24/NNS (l_amod) like_23/JJ (l_amod) schizophrenic_21/JJ
D016202_D012559 NONE aspartate_15/NN (r_nmod) receptor_19/NN (r_pobj) of_6/IN (r_prep) antagonists_5/NNS (r_nsubj) produce_20/VBP (l_dobj) symptoms_24/NNS (l_amod) like_23/JJ (l_amod) schizophrenic_21/JJ
D016202_D012559 NONE NMDA_17/NNP (r_appos) aspartate_15/NN (r_nmod) receptor_19/NN (r_pobj) of_6/IN (r_prep) antagonists_5/NNS (r_nsubj) produce_20/VBP (l_dobj) symptoms_24/NNS (l_amod) like_23/JJ (l_amod) schizophrenic_21/JJ
D016202_D012559 NONE NMDA_41/NNP (r_compound) receptor_42/NN (r_pobj) via_39/IN (r_prep) dysfunctioning_34/NN (r_pobj) of_32/IN (r_prep) idea_31/NN (r_pobj) to_29/IN (r_prep) led_28/VBN (l_nsubj) observation_3/NN (l_acl) produce_20/VBP (l_dobj) symptoms_24/NNS (l_amod) like_23/JJ (l_amod) schizophrenic_21/JJ
-1_D006948 NONE SSR103800_12/NNP (r_pobj) of_11/IN (r_prep) properties_10/NNS (r_dobj) investigating_4/VBG (r_pcomp) at_3/IN (r_prep) aimed_2/VBN (r_acl) study_1/NN (l_prep) with_14/IN (l_pobj) focus_17/NN (l_prep) on_18/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) hyperactivity_21/NN
-1_D006948 NONE SSR103800_3/NNP (r_nsubj) blocked_11/VBD (r_amod) hyperactivity_12/NN
-1_D006948 NONE SSR103800_3/NNP (r_nsubj) blocked_11/VBD (r_amod) hyperactivity_12/NN (l_conj) hyperactivity_28/NN
-1_D006948 NONE SSR103800_3/NNP (r_nsubj) failed_4/VBD (l_xcomp) affect_6/VB (l_dobj) hyperactivity_7/NN
D000661_D006948 CID amphetamine_30/NN (r_conj) ie_28/FW (r_appos) challenge_26/NN (r_dobj) involving_23/VBG (r_acl) study_1/NN (l_prep) with_14/IN (l_pobj) focus_17/NN (l_prep) on_18/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) hyperactivity_21/NN
D000661_D006948 CID amphetamine_10/NN (r_pobj) by_9/IN (r_agent) induced_8/VBN (r_acl) hyperactivity_7/NN
D016291_D006948 CID MK-801_32/NNP (r_dep) )_33/-RRB- (r_punct) challenge_26/NN (r_dobj) involving_23/VBG (r_acl) study_1/NN (l_prep) with_14/IN (l_pobj) focus_17/NN (l_prep) on_18/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) hyperactivity_21/NN
D016291_D006948 CID MK-801_23/NNP (r_dep) and_24/CC (r_cc) hyperactivity_12/NN
D016291_D006948 CID MK-801_23/NNP (r_dep) and_24/CC (r_cc) hyperactivity_12/NN (l_conj) hyperactivity_28/NN
D016202_D006948 NONE NMDA_40/NNP (r_appos) challenge_26/NN (r_dobj) involving_23/VBG (r_acl) study_1/NN (l_prep) with_14/IN (l_pobj) focus_17/NN (l_prep) on_18/IN (l_pobj) models_19/NNS (l_prep) of_20/IN (l_pobj) hyperactivity_21/NN
D016202_D006948 NONE NMDA_19/NNP (r_compound) antagonist_21/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) hyperactivity_12/NN
D016202_D006948 NONE NMDA_19/NNP (r_compound) antagonist_21/NN (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) hyperactivity_12/NN (l_conj) hyperactivity_28/NN
D016202_D006948 NONE NMDA_30/NNP (r_nmod) mice_33/NNS (r_pobj) of_29/IN (r_prep) hyperactivity_28/NN (r_conj) hyperactivity_12/NN
D016202_D006948 NONE NMDA_30/NNP (r_nmod) mice_33/NNS (r_pobj) of_29/IN (r_prep) hyperactivity_28/NN
D004298_D006948 NONE dopamine_15/NN (r_compound) transporter_16/NN (r_pobj) in_14/IN (r_prep) observed_13/VBN (r_conj) induced_8/VBN (r_acl) hyperactivity_7/NN
D006220_D006948 NONE haloperidol_5/NNP (r_nmod) antipsychotics_16/NNS (r_nsubj) were_17/VBD (l_acomp) effective_18/JJ (l_prep) in_19/IN (l_pobj) models_22/NNS (l_prep) of_23/IN (l_pobj) hyperactivity_24/NN
C076029_D006948 NONE olanzapine_10/NN (r_intj) (_9/-LRB- (r_punct) atypical_8/JJ (r_conj) haloperidol_5/NNP (r_nmod) antipsychotics_16/NNS (r_nsubj) were_17/VBD (l_acomp) effective_18/JJ (l_prep) in_19/IN (l_pobj) models_22/NNS (l_prep) of_23/IN (l_pobj) hyperactivity_24/NN
D003024_D006948 NONE clozapine_12/NNP (r_conj) olanzapine_10/NN (r_intj) (_9/-LRB- (r_punct) atypical_8/JJ (r_conj) haloperidol_5/NNP (r_nmod) antipsychotics_16/NNS (r_nsubj) were_17/VBD (l_acomp) effective_18/JJ (l_prep) in_19/IN (l_pobj) models_22/NNS (l_prep) of_23/IN (l_pobj) hyperactivity_24/NN
C094645_D006948 NONE aripiprazole_14/NNP (r_conj) clozapine_12/NNP (r_conj) olanzapine_10/NN (r_intj) (_9/-LRB- (r_punct) atypical_8/JJ (r_conj) haloperidol_5/NNP (r_nmod) antipsychotics_16/NNS (r_nsubj) were_17/VBD (l_acomp) effective_18/JJ (l_prep) in_19/IN (l_pobj) models_22/NNS (l_prep) of_23/IN (l_pobj) hyperactivity_24/NN
-1_D002375 NONE SSR103800_6/NNP (r_nsubj) produce_9/VB (l_dobj) catalepsy_10/NN
424937
D008750_D056486 CID methyldopa_6/NNP (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) injury_3/NN
D008750_D056486 CID methyldopa_22/NNP (r_npadvmod) induced_24/VBN (r_amod) hepatitis_25/NN
D008750_D056486 CID methyldopa_14/NNP (r_pobj) between_13/IN (r_prep) relationship_12/NN (r_nsubjpass) proved_19/VBN (l_prep) with_20/IN (l_pobj) recurrence_22/NN (l_prep) of_23/IN (l_pobj) hepatitis_24/NN
D008750_D008107 NONE methyldopa_7/NNP (r_pobj) to_6/IN (r_prep) related_5/VBN (r_acl) disease_4/NN
D008750_D008107 NONE methyldopa_14/NNP (l_conj) dysfunction_17/NN
D008750_D017093 NONE methyldopa_17/NNP (r_dobj) taking_16/VBG (r_relcl) another_11/DT (r_nsubj) showed_22/VBD (r_conj) died_2/VBD (l_advcl) presented_5/VBN (l_prep) in_6/IN (l_pobj) failure_8/NN
D008750_D017114 NONE methyldopa_22/NNP (r_npadvmod) induced_24/VBN (r_amod) hepatitis_25/NN (r_pobj) of_21/IN (r_prep) episode_20/NN (r_pobj) after_17/IN (r_prep) recommenced_14/VBN (r_advcl) developed_6/VBD (l_dobj) hepatitis_8/NN
7420681
D014031_D007674 NONE tobramycin_3/NNS (r_pobj) of_2/IN (r_prep) nephrotoxicity_1/NN
D014031_D007674 NONE sulfate_4/NN (r_nsubj) continue_5/VBP (l_xcomp) demonstrate_7/VB (l_dobj) ototoxicity_8/NN (l_conj) nephrotoxicity_10/NN
D005839_D007674 NONE gentamicin_5/NNS (r_conj) tobramycin_3/NNS (r_pobj) of_2/IN (r_prep) nephrotoxicity_1/NN
D005839_D007674 NONE sulfate_1/NN (r_nmod) sulfate_4/NN (r_nsubj) continue_5/VBP (l_xcomp) demonstrate_7/VB (l_dobj) ototoxicity_8/NN (l_conj) nephrotoxicity_10/NN
D005839_D006311 NONE sulfate_1/NN (r_nmod) sulfate_4/NN (r_nsubj) continue_5/VBP (l_xcomp) demonstrate_7/VB (l_dobj) ototoxicity_8/NN
D014031_D006311 NONE sulfate_4/NN (r_nsubj) continue_5/VBP (l_xcomp) demonstrate_7/VB (l_dobj) ototoxicity_8/NN
D005839_D051437 CID sulfate_25/NN (r_nmod) sulfate_28/NN (r_pobj) of_23/IN (r_prep) day_22/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_conj) patients_5/NNS (r_nsubjpass) followed_36/VBN (l_prep) for_39/IN (l_pobj) development_41/NN (l_prep) of_42/IN (l_pobj) failure_47/NN
D005839_D051437 CID gentamicin_23/NN (r_npadvmod) treated_25/VBN (r_amod) patients_26/NNS (r_pobj) of_21/IN (r_prep) 16_14/CD (r_conj) 33_2/CD (r_nsubj) had_27/VBD (l_dobj) failure_29/NN
D005839_D051437 CID gentamicin_2/NNS (r_nsubjpass) associated_4/VBN (l_prep) with_5/IN (l_pobj) failure_7/NN
D014031_D051437 CID sulfate_28/NN (r_pobj) of_23/IN (r_prep) day_22/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_conj) patients_5/NNS (r_nsubjpass) followed_36/VBN (l_prep) for_39/IN (l_pobj) development_41/NN (l_prep) of_42/IN (l_pobj) failure_47/NN
D014031_D051437 CID tobramycin_9/NNS (r_npadvmod) treated_11/VBN (r_amod) patients_12/NNS (r_pobj) of_7/IN (r_prep) 33_2/CD (r_nsubj) had_27/VBD (l_dobj) failure_29/NN
D014031_D051437 CID tobramycin_16/NNS (r_acomp) was_15/VBD (r_advcl) often_13/RB (r_advmod) associated_4/VBN (l_prep) with_5/IN (l_pobj) failure_7/NN
D000617_D051437 NONE aminoglycoside_43/RB (r_npadvmod) related_45/VBN (r_amod) failure_47/NN
16938416
D013739_D050197 CID testosterone_3/NN (r_nsubjpass) associated_5/VBN (l_prep) with_6/IN (l_pobj) atherosclerosis_7/NN
D013739_D050197 CID testosterone_32/NN (r_compound) therapy_33/NN (l_conj) atherosclerosis_42/NN
D013739_D050197 CID testosterone_7/NN (r_compound) therapy_8/NN (r_nsubj) affect_11/VB (l_dobj) atherosclerosis_12/NN
D004967_D050197 NONE estrogen_30/NN (r_compound) testosterone_32/NN (r_compound) therapy_33/NN (l_conj) atherosclerosis_42/NN
C032109_D050197 NONE esters_38/NNS (r_conj) therapy_33/NN (l_conj) atherosclerosis_42/NN
D002784_D003920 NONE cholesterol_9/NN (r_compound) level_10/NN (r_conj) diabetes_7/NN
D000431_D003920 NONE alcohol_17/NN (r_compound) use_18/NN (r_conj) pressure_14/NN (r_conj) level_10/NN (r_conj) diabetes_7/NN
15145918
D004967_D007022 NONE estrogen_3/NN (l_prep) of_4/IN (l_pobj) hypotension_11/NN
D004967_D007022 NONE estrogen_5/NN (r_nsubj) modulates_7/VBZ (l_dobj) effect_10/NN (l_amod) hypotensive_9/JJ
D004967_D007022 NONE estrogen_4/NN (r_nsubj) downregulates_5/VBZ (l_conj) hypotension_12/NN
D004967_D007022 NONE estrogen_27/NN (r_compound) interaction_28/NN (r_pobj) in_22/IN (r_prep) control_21/NN (r_pobj) for_17/IN (r_prep) role_16/NN (r_dobj) highlight_14/VB (r_conj) downregulates_5/VBZ (l_conj) hypotension_12/NN
D048288_D007022 NONE I1-imidazoline_7/NNP (r_conj) alpha2-adrenergic_5/JJ (r_amod) hypotension_11/NN
D003000_D007022 NONE clonidine_12/NN (r_pobj) of_11/IN (r_prep) effect_10/NN (l_amod) hypotensive_9/JJ
C032302_D007022 CID rilmenidine_6/NN (r_nsubj) elicited_11/VBD (l_dobj) hypotension_13/NN
C032302_D007022 CID rilmenidine_17/JJ (r_compound) hypotension_18/NN (r_pobj) on_16/IN (r_prep) effect_15/NN (r_pobj) to_13/IN (r_prep) contrast_12/NN (r_pobj) in_11/IN (r_prep) enhanced_2/VBD (l_dobj) response_5/NN (l_amod) hypotensive_4/JJ
C032302_D007022 CID rilmenidine_17/JJ (r_compound) hypotension_18/NN
D008750_D007022 CID methyldopa_10/NNP (r_conj) rilmenidine_6/NN (r_nsubj) elicited_11/VBD (l_dobj) hypotension_13/NN
D008750_D007022 CID methyldopa_9/NNP (r_pobj) to_6/IN (r_prep) response_5/NN (l_amod) hypotensive_4/JJ
D008750_D007022 CID methyldopa_9/NNP (r_pobj) to_6/IN (r_prep) response_5/NN (r_dobj) enhanced_2/VBD (l_prep) in_11/IN (l_pobj) contrast_12/NN (l_prep) to_13/IN (l_pobj) effect_15/NN (l_prep) on_16/IN (l_pobj) hypotension_18/NN
D008750_D007022 CID methyldopa_4/NN (r_compound) hypotension_5/NN
D008750_D007022 CID methyldopa_25/NN (r_compound) estrogen_27/NN (r_compound) interaction_28/NN (r_pobj) in_22/IN (r_prep) control_21/NN (r_pobj) for_17/IN (r_prep) role_16/NN (r_dobj) highlight_14/VB (r_conj) downregulates_5/VBZ (l_conj) hypotension_12/NN
D008750_D001523 NONE methyldopa_4/NN (r_compound) hypotension_5/NN (r_nsubjpass) paralleled_10/VBN (l_prep) with_11/IN (l_pobj) reduction_13/NN (l_conj) activity_20/NN
20196116
D000995_D017114 CID Antituberculosis_0/NNP (r_compound) failure_6/NN
D000995_D017114 CID Antituberculosis_0/NN (r_compound) therapy_1/NN (l_appos) failure_6/NN
D000995_D017114 CID Antituberculosis_0/NN (r_compound) therapy_1/NN (l_appos) failure_6/NN (l_appos) ALF_10/NNP
D000995_D017114 CID Antituberculosis_0/NN (r_compound) therapy_1/NN (r_nsubj) is_12/VBZ (l_attr) ALF_18/NNP
10737864
D003000_D001919 CID clonidine_14/NN (r_nsubj) induces_15/VBZ (l_dobj) withdrawal_17/NN (l_conj) bradycardia_19/NN
D003000_D001919 CID clonidine_24/NN (r_poss) effects_27/NNS (r_nsubj) mirror_35/VB (r_ccomp) hypothesized_22/VBD (r_conj) exhibits_5/VBZ (l_conj) given_12/VBN (l_pcomp) induces_15/VBZ (l_dobj) withdrawal_17/NN (l_conj) bradycardia_19/NN
D003000_D001919 CID clonidine_19/NN (r_npadvmod) induced_21/VBN (r_amod) bradycardia_22/NN
11532387
D018967_D013375 CID risperidone_9/NNP (r_pobj) of_8/IN (r_prep) reduction_7/NN (r_pobj) during_5/IN (r_prep) syndrome_4/NN
D018967_D013375 CID risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_nsubjpass) mechanism_2/NN (l_prep) of_3/IN (l_pobj) RS_7/NNS
D018967_D001480 CID risperidone_9/NNP (r_pobj) of_8/IN (r_prep) reduction_7/NN (r_pobj) during_5/IN (r_prep) syndrome_4/NN
D018967_D001480 CID risperidone_8/NNP (r_pobj) of_7/IN (r_prep) reduction_6/NN (r_pobj) during_4/IN (r_prep) developed_2/VBD (l_dobj) RS_3/NN
D018967_D001480 CID risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_nsubjpass) mechanism_2/NN (l_prep) of_3/IN (l_pobj) RS_7/NNS
D018967_D001480 CID risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_advcl) suggesting_29/VBG (l_dobj) influence_32/NN (l_prep) in_37/IN (l_pobj) development_39/NN (l_prep) of_40/IN (l_pobj) RS_41/NN
D012701_D013375 NONE serotonin_24/NN (r_compound) dopamine_26/NN (r_compound) antagonist_27/NN (r_appos) risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_nsubjpass) mechanism_2/NN (l_prep) of_3/IN (l_pobj) RS_7/NNS
D012701_D013375 NONE serotonin_35/NN (r_compound) system_36/NN (r_pobj) of_33/IN (r_prep) influence_32/NN (r_dobj) suggesting_29/VBG (r_advcl) related_15/VBN (l_nsubjpass) mechanism_2/NN (l_prep) of_3/IN (l_pobj) RS_7/NNS
D012701_D001480 NONE serotonin_24/NN (r_compound) dopamine_26/NN (r_compound) antagonist_27/NN (r_appos) risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_nsubjpass) mechanism_2/NN (l_prep) of_3/IN (l_pobj) RS_7/NNS
D012701_D001480 NONE serotonin_24/NN (r_compound) dopamine_26/NN (r_compound) antagonist_27/NN (r_appos) risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_advcl) suggesting_29/VBG (l_dobj) influence_32/NN (l_prep) in_37/IN (l_pobj) development_39/NN (l_prep) of_40/IN (l_pobj) RS_41/NN
D012701_D001480 NONE serotonin_35/NN (r_compound) system_36/NN (r_pobj) of_33/IN (r_prep) influence_32/NN (r_dobj) suggesting_29/VBG (r_advcl) related_15/VBN (l_nsubjpass) mechanism_2/NN (l_prep) of_3/IN (l_pobj) RS_7/NNS
D012701_D001480 NONE serotonin_35/NN (r_compound) system_36/NN (r_pobj) of_33/IN (r_prep) influence_32/NN (l_prep) in_37/IN (l_pobj) development_39/NN (l_prep) of_40/IN (l_pobj) RS_41/NN
D004298_D013375 NONE dopamine_26/NN (r_compound) antagonist_27/NN (r_appos) risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_nsubjpass) mechanism_2/NN (l_prep) of_3/IN (l_pobj) RS_7/NNS
D004298_D001480 NONE dopamine_26/NN (r_compound) antagonist_27/NN (r_appos) risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_nsubjpass) mechanism_2/NN (l_prep) of_3/IN (l_pobj) RS_7/NNS
D004298_D001480 NONE dopamine_26/NN (r_compound) antagonist_27/NN (r_appos) risperidone_21/NNP (r_pobj) of_20/IN (r_prep) profile_19/NN (r_pobj) to_16/IN (r_prep) related_15/VBN (l_advcl) suggesting_29/VBG (l_dobj) influence_32/NN (l_prep) in_37/IN (l_pobj) development_39/NN (l_prep) of_40/IN (l_pobj) RS_41/NN
1835291
D009241_D029424 NONE bromide_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) in_8/IN (l_pobj) disease_12/NN
D009241_D029424 NONE ipratropium_4/NN (r_nsubj) is_5/VBZ (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) obstruction_18/NN
D013806_D029424 NONE theophylline_7/NN (r_conj) bromide_5/NN (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_prep) in_8/IN (l_pobj) disease_12/NN
D013806_D029424 NONE theophylline_12/NN (r_pobj) than_10/IN (r_prep) bronchodilator_9/NN (r_attr) is_5/VBZ (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) obstruction_18/NN
D013806_D002318 CID theophylline_9/NN (r_compound) use_10/NN (r_pobj) after_8/IN (r_prep) experienced_7/VBN (r_acl) those_6/DT (r_nsubj) involve_12/VB (l_dobj) systems_17/NNS
D013806_D005767 CID theophylline_9/NN (r_compound) use_10/NN (r_pobj) after_8/IN (r_prep) experienced_7/VBN (r_acl) those_6/DT (r_nsubj) involve_12/VB (l_dobj) systems_17/NNS
17879945
D019438_D050197 CID ritonavir_5/NNP (r_compound) treatment_6/NN (r_nsubj) increases_7/VBZ (l_dobj) formation_10/NN (l_compound) lesion_9/NN
11198499
C023754_D007022 CID tizanidine_5/NNP (r_pobj) of_4/IN (r_prep) initiation_3/NN (r_pobj) following_1/VBG (r_prep) Hypotension_0/NN
C023754_D007022 CID tizanidine_29/NNP (r_pobj) of_28/IN (r_prep) addition_27/NN (r_pobj) following_25/VBG (r_prep) developed_23/VBD (l_dobj) hypotension_24/NN
C023754_D006973 NONE tizanidine_5/NNP (r_pobj) of_4/IN (r_prep) initiation_3/NN (l_prep) in_6/IN (l_pobj) patient_8/NN (l_acl) treated_9/VBN (l_prep) with_10/IN (l_pobj) angiotensin_12/NN (l_acl) converting_13/VBG (l_prep) for_16/IN (l_pobj) hypertension_18/NN
C023754_D006973 NONE tizanidine_29/NNP (r_pobj) of_28/IN (r_prep) addition_27/NN (r_pobj) following_25/VBG (r_prep) developed_23/VBD (r_relcl) hypertension_21/NN
C023754_D006973 NONE tizanidine_4/NNP (r_pobj) of_3/IN (r_prep) interaction_2/NN (r_nsubjpass) kept_11/VBN (l_advcl) prescribing_15/VBG (l_xcomp) treat_18/VB (l_dobj) hypertension_20/NN
D000809_D007022 NONE angiotensin_12/NN (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) patient_8/NN (r_pobj) in_6/IN (r_prep) initiation_3/NN (r_pobj) following_1/VBG (r_prep) Hypotension_0/NN
D000809_D007022 NONE angiotensin_4/NN (r_npadvmod) converting_5/VBG (r_pcomp) with_3/IN (r_prep) treated_2/VBN (r_csubj) have_9/VB (l_dobj) ability_12/NN (l_acl) respond_14/VB (l_prep) to_15/IN (l_pobj) hypotension_16/NN
D000809_D007022 NONE angiotensin_14/NN (r_appos) lisinopril_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) boy_7/NN (r_dobj) present_2/VBP (l_advcl) control_20/VB (l_dobj) hypertension_21/NN (l_relcl) developed_23/VBD (l_dobj) hypotension_24/NN
D000809_D006973 NONE angiotensin_12/NN (l_acl) converting_13/VBG (l_prep) for_16/IN (l_pobj) hypertension_18/NN
D000809_D006973 NONE angiotensin_14/NN (r_appos) lisinopril_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) boy_7/NN (r_dobj) present_2/VBP (l_advcl) control_20/VB (l_dobj) hypertension_21/NN
D017706_D006973 NONE lisinopril_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) boy_7/NN (r_dobj) present_2/VBP (l_advcl) control_20/VB (l_dobj) hypertension_21/NN
D017706_D007022 CID lisinopril_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) boy_7/NN (r_dobj) present_2/VBP (l_advcl) control_20/VB (l_dobj) hypertension_21/NN (l_relcl) developed_23/VBD (l_dobj) hypotension_24/NN
D017706_D009128 NONE lisinopril_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) boy_7/NN (r_dobj) present_2/VBP (l_advcl) control_20/VB (l_dobj) hypertension_21/NN (l_relcl) developed_23/VBD (l_prep) following_25/VBG (l_pobj) addition_27/NN (l_prep) for_35/IN (l_pobj) treatment_37/NN (l_prep) of_38/IN (l_pobj) spasticity_39/NN
D000809_D009128 NONE angiotensin_14/NN (r_appos) lisinopril_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (r_acl) boy_7/NN (r_dobj) present_2/VBP (l_advcl) control_20/VB (l_dobj) hypertension_21/NN (l_relcl) developed_23/VBD (l_prep) following_25/VBG (l_pobj) addition_27/NN (l_prep) for_35/IN (l_pobj) treatment_37/NN (l_prep) of_38/IN (l_pobj) spasticity_39/NN
C023754_D009128 NONE tizanidine_29/NNP (r_pobj) of_28/IN (r_prep) addition_27/NN (l_prep) for_35/IN (l_pobj) treatment_37/NN (l_prep) of_38/IN (l_pobj) spasticity_39/NN
C023754_D009128 NONE tizanidine_4/NNP (r_pobj) of_3/IN (r_prep) interaction_2/NN (r_nsubjpass) kept_11/VBN (l_advcl) prescribing_15/VBG (l_xcomp) treat_18/VB (l_dobj) hypertension_20/NN (l_conj) spasticity_22/NN
3101906
D007654_D003643 NONE ketoconazole_9/NN (r_amod) treatment_10/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) deaths_5/NNS
D007654_D007565 CID ketoconazole_9/NN (r_amod) treatment_10/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) deaths_5/NNS (r_pobj) of_2/IN (r_prep) two_1/CD (r_pobj) In_0/IN (r_prep) continued_15/VBN (l_prep) after_16/IN (l_pobj) onset_18/NN (l_prep) of_19/IN (l_pobj) jaundice_20/NN
D007654_D056486 CID ketoconazole_9/NN (r_amod) treatment_10/NN (r_pobj) with_8/IN (r_prep) associated_7/VBN (r_acl) deaths_5/NNS (r_pobj) of_2/IN (r_prep) two_1/CD (r_pobj) In_0/IN (r_prep) continued_15/VBN (l_prep) after_16/IN (l_pobj) onset_18/NN (l_prep) of_19/IN (l_pobj) jaundice_20/NN (l_conj) symptoms_23/NNS (l_prep) of_24/IN (l_pobj) hepatitis_25/NN
D007654_D056486 CID ketoconazole_18/NN (r_pobj) with_17/IN (r_prep) treatment_16/NN (r_pobj) during_13/IN (r_prep) advised_12/VBN (l_nsubjpass) monitoring_3/NN (l_prep) for_7/IN (l_pobj) evidence_8/NN (l_prep) of_9/IN (l_pobj) hepatitis_10/NN
D007654_D056486 CID ketoconazole_18/NN (r_pobj) with_17/IN (r_prep) treatment_16/NN (r_pobj) during_13/IN (r_prep) advised_12/VBN (l_xcomp) prevent_20/VB (l_dobj) injury_24/NN
16680561
D003891_D009325 CID desipramine_8/NN (r_pobj) with_7/IN (r_prep) treatment_6/NN (r_dobj) following_5/VBG (r_acl) events_4/NNS (r_dobj) reported_2/VBD (r_ccomp) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN
D003891_D009325 CID desipramine_13/NN (r_dobj) receiving_12/VBG (r_pcomp) than_10/IN (r_prep) alone_9/RB (r_advmod) reported_2/VBD (r_ccomp) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN
D003891_D009325 CID desipramine_41/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (r_acl) patients_37/NNS (r_pobj) for_36/IN (r_prep) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN
D003891_D006261 CID desipramine_8/NN (r_pobj) with_7/IN (r_prep) treatment_6/NN (r_dobj) following_5/VBG (r_acl) events_4/NNS (r_dobj) reported_2/VBD (r_ccomp) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN (l_conj) headache_31/NN
D003891_D006261 CID desipramine_13/NN (r_dobj) receiving_12/VBG (r_pcomp) than_10/IN (r_prep) alone_9/RB (r_advmod) reported_2/VBD (r_ccomp) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN (l_conj) headache_31/NN
D003891_D006261 CID desipramine_41/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (r_acl) patients_37/NNS (r_pobj) for_36/IN (r_prep) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN (l_conj) headache_31/NN
C476217_D009325 CID cinacalcet_15/NNP (r_pobj) with_14/IN (r_prep) receiving_12/VBG (r_pcomp) than_10/IN (r_prep) alone_9/RB (r_advmod) reported_2/VBD (r_ccomp) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN
C476217_D009325 CID cinacalcet_43/NN (r_conj) desipramine_41/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (r_acl) patients_37/NNS (r_pobj) for_36/IN (r_prep) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN
C476217_D006261 CID cinacalcet_15/NNP (r_pobj) with_14/IN (r_prep) receiving_12/VBG (r_pcomp) than_10/IN (r_prep) alone_9/RB (r_advmod) reported_2/VBD (r_ccomp) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN (l_conj) headache_31/NN
C476217_D006261 CID cinacalcet_43/NN (r_conj) desipramine_41/NN (r_pobj) with_39/IN (r_prep) treated_38/VBN (r_acl) patients_37/NNS (r_pobj) for_36/IN (r_prep) reported_35/VBN (l_nsubjpass) frequent_25/JJ (l_parataxis) nausea_29/NN (l_conj) headache_31/NN
18560792
D010479_D006349 NONE pergolide_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_nsubj) disease_2/NN
D010479_D006349 NONE pergolide_17/NNP (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) patients_7/NNS (r_pobj) in_6/IN (r_prep) reported_5/VBN (l_nsubjpass) abnormalities_2/NNS
D010479_D006349 NONE pergolide_12/NNP (r_pobj) of_11/IN (r_prep) role_10/NN (r_pobj) of_8/IN (r_prep) suggestive_7/JJ (r_amod) pattern_2/NN (l_prep) of_3/IN (l_pobj) regurgitation_5/NN
D010479_D006349 NONE Pergolide_0/NNP (r_nsubjpass) discontinued_2/VBN (l_prep) in_3/IN (l_pobj) patients_5/NNS (l_prep) with_6/IN (l_pobj) disease_9/NN
D010479_D006349 NONE pergolide_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) frequency_5/NN (l_prep) of_6/IN (l_pobj) regurgitation_9/NN
D010479_D010300 NONE pergolide_11/NNP (r_pobj) with_10/IN (r_prep) treated_9/VBN (l_nsubj) disease_2/NN (l_prep) in_3/IN (l_pobj) patients_4/NNS (l_prep) with_5/IN (l_pobj) disease_8/NN
D010479_D010300 NONE pergolide_17/NNP (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) patients_7/NNS (l_prep) with_8/IN (l_pobj) disease_11/NN
D010479_D010300 NONE pergolide_17/NNP (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) patients_7/NNS (l_prep) with_8/IN (l_pobj) disease_11/NN (l_appos) PD_13/NNP
D010479_D010300 NONE pergolide_9/NNP (r_pobj) with_8/IN (r_prep) treated_7/VBN (r_acl) patients_2/NNS (l_compound) PD_1/NNP
D010479_D010300 NONE pergolide_15/NNP (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) frequency_5/NN (l_prep) of_6/IN (l_pobj) regurgitation_9/NN (l_prep) in_10/IN (l_pobj) patients_12/NNS (l_compound) PD_11/NNP
D010479_D006333 NONE pergolide_12/NNP (r_pobj) of_11/IN (r_prep) role_10/NN (r_pobj) of_8/IN (r_prep) suggestive_7/JJ (r_amod) pattern_2/NN (r_nsubjpass) observed_15/VBN (l_prep) in_16/IN (l_pobj) patients_22/NNS (l_prep) including_23/VBG (l_pobj) two_24/CD (l_prep) with_25/IN (l_pobj) failure_27/NN
D010479_D006333 NONE Pergolide_0/NNP (r_nsubjpass) discontinued_2/VBN (l_advcl) resulting_11/VBG (l_prep) at_20/IN (l_pobj) echocardiography_24/NN (l_conj) patients_28/NNS (l_prep) with_29/IN (l_pobj) failure_31/NN
D004298_D006349 NONE dopamine_33/NN (r_compound) agonists_34/NNS (r_pobj) to_29/IN (r_prep) converted_28/VBN (r_advcl) is_22/VBZ (r_ccomp) reveals_17/VBZ (r_conj) supports_2/VBZ (l_dobj) frequency_5/NN (l_prep) of_6/IN (l_pobj) regurgitation_9/NN
D004298_D010300 NONE dopamine_33/NN (r_compound) agonists_34/NNS (r_pobj) to_29/IN (r_prep) converted_28/VBN (r_advcl) is_22/VBZ (r_ccomp) reveals_17/VBZ (r_conj) supports_2/VBZ (l_dobj) frequency_5/NN (l_prep) of_6/IN (l_pobj) regurgitation_9/NN (l_prep) in_10/IN (l_pobj) patients_12/NNS (l_compound) PD_11/NNP
7862923
D002220_D012559 NONE Carbamazepine_0/NNP (r_nsubjpass) switched_2/VBN (l_prep) among_8/IN (l_pobj) patients_19/NNS (l_amod) schizophrenic_15/JJ
D002220_D019965 NONE Carbamazepine_0/NNP (r_nsubjpass) switched_2/VBN (l_prep) among_8/IN (l_pobj) patients_19/NNS (l_amod) psychotic_18/JJ
C036006_D012559 NONE oxcarbazepine_7/NN (r_pobj) to_3/IN (r_prep) switched_2/VBN (l_prep) among_8/IN (l_pobj) patients_19/NNS (l_amod) schizophrenic_15/JJ
C036006_D019965 NONE oxcarbazepine_7/NN (r_pobj) to_3/IN (r_prep) switched_2/VBN (l_prep) among_8/IN (l_pobj) patients_19/NNS (l_amod) psychotic_18/JJ
D006220_D012559 NONE haloperidol_22/NNP (r_dobj) using_20/VBG (r_acl) patients_19/NNS (l_amod) schizophrenic_15/JJ
D006220_D019965 NONE haloperidol_22/NNP (r_dobj) using_20/VBG (r_acl) patients_19/NNS (l_amod) psychotic_18/JJ
D002746_D012559 NONE chlorpromazine_24/NNP (r_conj) haloperidol_22/NNP (r_dobj) using_20/VBG (r_acl) patients_19/NNS (l_amod) schizophrenic_15/JJ
D002746_D019965 NONE chlorpromazine_24/NNP (r_conj) haloperidol_22/NNP (r_dobj) using_20/VBG (r_acl) patients_19/NNS (l_amod) psychotic_18/JJ
D003024_D012559 NONE clozapine_26/NN (r_conj) chlorpromazine_24/NNP (r_conj) haloperidol_22/NNP (r_dobj) using_20/VBG (r_acl) patients_19/NNS (l_amod) schizophrenic_15/JJ
D003024_D019965 NONE clozapine_26/NN (r_conj) chlorpromazine_24/NNP (r_conj) haloperidol_22/NNP (r_dobj) using_20/VBG (r_acl) patients_19/NNS (l_amod) psychotic_18/JJ
3564823
D008012_D013035 NONE lidocaine_7/NN (r_pobj) by_6/IN (r_agent) relieved_5/VBN (l_nsubj) spasm_4/NN
D013874_D002545 NONE pentothal_12/NN (r_nsubjpass) infused_15/VBN (l_advcl) minimize_17/VB (l_dobj) ischaemia_19/NN
D008012_D020301 NONE lidocaine_11/NN (r_nsubjpass) given_13/VBN (l_prep) with_18/IN (l_conj) counteract_24/VB (l_dobj) vasospasm_26/NN
1378968
D008094_D007676 CID lithium_8/NN (r_npadvmod) induced_10/VBN (r_amod) failure_13/NN
D008094_D007674 NONE lithium_2/NN (r_npadvmod) induced_4/VBN (r_amod) nephropathy_5/NN
D008094_D007674 NONE Li_4/NNP (r_npadvmod) induced_6/VBN (r_amod) nephropathy_7/NN
D008094_D051437 NONE lithium_2/NN (r_npadvmod) induced_4/VBN (r_amod) nephropathy_5/NN (r_pobj) with_1/IN (r_prep) Rats_0/NNS (r_nsubjpass) subjected_7/VBN (l_prep) in_26/IN (l_pobj) attempt_28/NN (l_acl) induce_30/VB (l_dobj) hyperfiltration_32/NN (l_conj) progression_35/NN (l_prep) of_36/IN (l_pobj) failure_38/NN
D008094_D051437 NONE lithium_21/NN (r_npadvmod) pretreated_22/VBN (r_amod) rats_23/NNS (r_pobj) in_20/IN (r_prep) levels_19/NNS (r_dobj) decrease_16/VB (r_conj) increase_13/VB (r_xcomp) tended_11/VBD (r_conj) failed_1/VBD (l_prep) to_2/TO (l_pobj) progression_4/NN (l_prep) of_5/IN (l_pobj) failure_7/NN
D008094_D011507 CID Lithium_0/NN (r_nsubj) caused_2/VBD (l_dobj) proteinuria_3/NN
D008094_D011507 CID Li_4/NNP (r_npadvmod) induced_6/VBN (r_amod) nephropathy_7/NN (r_nsubjpass) associated_19/VBN (l_prep) with_20/IN (l_pobj) proteinuria_21/NN
D008094_D006973 CID Lithium_0/NN (r_nsubj) caused_2/VBD (l_dobj) proteinuria_3/NN (l_conj) hypertension_6/NN
D008094_D006973 CID Li_4/NNP (r_npadvmod) induced_6/VBN (r_amod) nephropathy_7/NN (r_nsubjpass) associated_19/VBN (l_prep) with_20/IN (l_pobj) proteinuria_21/NN (l_conj) hypertension_25/NN
D008094_D005921 NONE Lithium_0/NN (r_nsubj) caused_2/VBD (l_prep) in_7/IN (l_pobj) absence_8/NN (l_prep) of_9/IN (l_pobj) glomerulosclerosis_10/NNP
D003404_D051437 NONE creatinine_18/NN (r_compound) levels_19/NNS (r_dobj) decrease_16/VB (r_conj) increase_13/VB (r_xcomp) tended_11/VBD (r_conj) failed_1/VBD (l_prep) to_2/TO (l_pobj) progression_4/NN (l_prep) of_5/IN (l_pobj) failure_7/NN
12483326
D016190_D005128 NONE carboplatin_9/NNP (r_pobj) of_8/IN (r_prep) injection_7/NN (r_pobj) after_5/IN (r_prep) toxicity_4/NN
D016190_D005128 NONE carboplatin_2/NNP (r_nsubjpass) said_4/VBN (l_conj) are_18/VBP (l_nsubj) toxicity_17/NN
D016190_D005128 NONE carboplatin_16/NNP (r_pobj) of_15/IN (r_prep) injection_14/NN (r_pobj) after_12/IN (r_prep) experienced_3/VBD (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) toxicity_11/NN
D016190_D005128 NONE carboplatin_5/NNP (r_pobj) of_4/IN (r_prep) injection_3/NN (r_dobj) performing_1/VBG (r_advcl) be_9/VB (l_acomp) aware_10/JJ (l_prep) of_11/IN (l_pobj) toxicity_16/NN
D016190_D009916 NONE carboplatin_9/NNP (r_pobj) of_8/IN (r_prep) injection_7/NN (r_pobj) after_5/IN (r_prep) toxicity_4/NN
D016190_D009916 NONE carboplatin_2/NNP (r_nsubjpass) said_4/VBN (l_conj) are_18/VBP (l_nsubj) toxicity_17/NN
D016190_D009916 NONE carboplatin_16/NNP (r_pobj) of_15/IN (r_prep) injection_14/NN (r_pobj) after_12/IN (r_prep) experienced_3/VBD (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) toxicity_11/NN
D016190_D005909 NONE carboplatin_9/NNP (r_pobj) of_8/IN (r_prep) injection_7/NN (l_prep) for_10/IN (l_pobj) glioblastomas_12/NNS
D016190_D005909 NONE carboplatin_10/NNP (r_pobj) of_9/IN (r_prep) injection_8/NN (r_dobj) received_5/VBD (l_prep) for_11/IN (l_pobj) glioblastomas_13/NNS
D002945_D005128 NONE cisplatin_11/NN (r_pobj) than_10/IN (r_prep) effects_9/NNS (r_dobj) have_6/VB (r_xcomp) said_4/VBN (l_conj) are_18/VBP (l_nsubj) toxicity_17/NN
D002945_D009916 NONE cisplatin_11/NN (r_pobj) than_10/IN (r_prep) effects_9/NNS (r_dobj) have_6/VB (r_xcomp) said_4/VBN (l_conj) are_18/VBP (l_nsubj) toxicity_17/NN
D016190_D064420 NONE carboplatin_7/NNP (r_compound) toxicity_8/NN
15632880
D013148_D051437 CID Spironolactone_0/NN (r_npadvmod) induced_2/VBN (r_amod) insufficiency_4/NN
D013148_D051437 CID spironolactone_9/NN (r_pobj) of_8/IN (r_prep) use_7/NN (r_dobj) evaluating_5/VBG (r_acl) trial_4/NN (r_nsubj) reported_14/VBD (l_dobj) risk_17/NN (l_conj) insufficiency_26/NN
D013148_D051437 CID spironolactone_21/NN (r_pobj) with_20/IN (r_prep) treated_19/VBN (r_acl) patients_18/NNS (r_pobj) in_15/IN (r_prep) associations_9/NNS (l_prep) of_10/IN (l_pobj) hyperkalemia_11/NN (l_conj) insufficiency_14/NN
D013148_D051437 CID spironolactone_13/NN (r_pobj) of_12/IN (r_prep) discontinuation_11/NN (r_dobj) required_10/VBN (l_prep) due_14/IN (l_pobj) hyperkalemia_16/NN (l_conj) failure_24/NN
D013148_D051437 CID Spironolactone_0/NN (r_npadvmod) induced_2/VBN (r_amod) hyperkalemia_3/NN (l_conj) insufficiency_6/NN
D013148_D006947 CID Spironolactone_0/NN (r_npadvmod) induced_2/VBN (r_amod) insufficiency_4/NN (l_conj) hyperkalemia_6/NN
D013148_D006947 CID spironolactone_9/NN (r_pobj) of_8/IN (r_prep) use_7/NN (r_dobj) evaluating_5/VBG (r_acl) trial_4/NN (r_nsubj) reported_14/VBD (l_dobj) risk_17/NN (l_prep) of_18/IN (l_pobj) hyperkalemia_19/NN
D013148_D006947 CID spironolactone_21/NN (r_pobj) with_20/IN (r_prep) treated_19/VBN (r_acl) patients_18/NNS (r_pobj) in_15/IN (r_prep) associations_9/NNS (l_prep) of_10/IN (l_pobj) hyperkalemia_11/NN
D013148_D006947 CID spironolactone_13/NN (r_pobj) of_12/IN (r_prep) discontinuation_11/NN (r_dobj) required_10/VBN (l_prep) due_14/IN (l_pobj) hyperkalemia_16/NN
D013148_D006947 CID Spironolactone_0/NN (r_npadvmod) induced_2/VBN (r_amod) hyperkalemia_3/NN
D013148_D006333 NONE Spironolactone_0/NN (r_npadvmod) induced_2/VBN (r_amod) insufficiency_4/NN (l_prep) in_7/IN (l_pobj) patients_8/NNS (l_prep) with_9/IN (l_pobj) failure_11/NN
D013148_D006333 NONE spironolactone_9/NN (r_pobj) of_8/IN (r_prep) use_7/NN (r_dobj) evaluating_5/VBG (r_acl) trial_4/NN (r_nsubj) reported_14/VBD (l_nsubj) patients_13/NNS (l_compound) failure_12/NN
D013148_D006333 NONE spironolactone_11/NN (r_pobj) of_10/IN (r_prep) benefits_9/NNS (r_nsubjpass) reported_13/VBN (r_advcl) changed_6/VBN (l_nsubj) treatments_1/NNS (l_prep) for_2/IN (l_pobj) failure_4/NN
D013148_D006333 NONE spironolactone_21/NN (r_pobj) with_20/IN (r_prep) treated_19/VBN (r_acl) patients_18/NNS (l_compound) failure_17/NN
D013148_D006333 NONE spironolactone_12/NN (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_acl) study_5/NN (l_prep) of_6/IN (l_pobj) patients_9/NNS (l_compound) failure_8/NN
D011188_D006947 NONE K(+_7/NNP (r_parataxis) were_1/VBD (l_attr) patients_2/NNS (l_relcl) developed_4/VBD (l_dobj) hyperkalemia_5/NN
D011188_D006947 NONE potassium_17/NN (r_compound) levels_18/NNS (r_dobj) had_13/VBD (r_conj) were_4/VBD (l_nsubj) Patients_0/NNS (l_relcl) developed_2/VBD (l_dobj) hyperkalemia_3/NN
D011188_D006947 NONE potassium_22/NN (r_compound) supplement_23/NN (r_compound) doses_24/NNS (r_conj) levels_18/NNS (r_dobj) had_13/VBD (r_conj) were_4/VBD (l_nsubj) Patients_0/NNS (l_relcl) developed_2/VBD (l_dobj) hyperkalemia_3/NN
D011188_D003920 NONE potassium_17/NN (r_compound) levels_18/NNS (r_dobj) had_13/VBD (r_conj) were_4/VBD (l_acomp) older_5/JJR (l_conj) likely_8/JJ (l_xcomp) have_10/VB (l_dobj) diabetes_11/NN
D011188_D003920 NONE potassium_22/NN (r_compound) supplement_23/NN (r_compound) doses_24/NNS (r_conj) levels_18/NNS (r_dobj) had_13/VBD (r_conj) were_4/VBD (l_acomp) older_5/JJR (l_conj) likely_8/JJ (l_xcomp) have_10/VB (l_dobj) diabetes_11/NN
D003404_D051437 NONE creatinine_14/NN (r_conj) weight_9/NN (r_dobj) had_5/VBD (l_nsubj) Patients_0/NNS (l_relcl) developed_2/VBD (l_dobj) insufficiency_4/NN
D049971_D051437 NONE thiazide_31/JJ (r_compound) diuretics_32/NNS (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_xcomp) likely_26/JJ (r_acomp) were_24/VBD (r_conj) required_16/VBD (r_conj) had_5/VBD (l_nsubj) Patients_0/NNS (l_relcl) developed_2/VBD (l_dobj) insufficiency_4/NN
19729346
D010098_D010146 NONE oxycodone_18/NN (r_pobj) of_14/IN (r_prep) dose_13/NN (r_pobj) of_9/IN (r_prep) effects_8/NNS (r_dobj) measured_2/VBD (l_dobj) adults_39/NNS (l_relcl) suffering_43/VBG (l_prep) from_44/IN (l_pobj) pain_49/NN
D010098_D059350 NONE oxycodone_30/NN (r_pobj) of_26/IN (r_prep) dose_25/NN (r_pobj) to_22/IN (r_prep) response_21/NN (r_pobj) in_20/IN (r_prep) changes_19/NNS (l_nmod) pain_14/NN
11642480
D015283_D004409 CID citalopram_7/NNP (r_pobj) on_6/IN (r_prep) adolescent_5/NN (r_pobj) in_2/IN (r_prep) twitching_1/VBG
D015283_D004409 CID citalopram_8/NN (r_pobj) with_7/IN (r_prep) treatment_6/NN (r_pobj) to_5/IN (r_prep) response_4/NN (l_prep) by_9/IN (l_pobj) boy_14/NN (l_relcl) exhibited_19/VBD (l_dobj) twitching_21/VBG
D015283_D003866 NONE citalopram_7/NNP (r_pobj) on_6/IN (r_prep) adolescent_5/NN (l_amod) depressed_4/JJ
D015283_D003865 NONE citalopram_8/NN (r_pobj) with_7/IN (r_prep) treatment_6/NN (r_pobj) to_5/IN (r_prep) response_4/NN (l_prep) by_9/IN (l_pobj) boy_14/NN (l_prep) with_15/IN (l_pobj) depression_17/NN
8643971
D002945_D006258 NONE cisplatin_0/NN (l_prep) as_1/IN (l_pobj) therapy_5/NN (l_prep) for_6/IN (l_pobj) cancers_10/NNS
D002945_D006258 NONE cisplatin_45/NN (r_cc) paclitaxel_43/NN (r_nmod) combination_46/NN (r_nsubjpass) used_49/VBN (r_conj) reported_27/VBD (l_dobj) rate_32/NN (l_prep) in_33/IN (l_pobj) patients_34/NNS (l_prep) with_35/IN (l_pobj) cancer_39/NN
D002945_D006258 NONE cisplatin_23/NN (r_pobj) with_19/IN (r_prep) combined_18/VBN (r_acl) doses_17/NNS (r_pobj) of_14/IN (r_prep) response_11/NN (l_prep) with_24/IN (l_pobj) support_30/NN (l_prep) in_31/IN (l_pobj) patients_32/NNS (l_prep) with_33/IN (l_pobj) carcinoma_41/NN
D002945_D006258 NONE cisplatin_2/NNP (r_appos) Paclitaxel_0/NNP (r_nsubj) is_3/VBZ (l_attr) regimen_9/NN (l_prep) for_10/IN (l_pobj) cancer_16/NN
D017239_D006258 NONE paclitaxel_13/NN (r_pobj) of_9/IN (r_prep) study_8/NN (r_pobj) of_2/IN (r_prep) results_1/NNS (r_nsubj) reported_27/VBD (l_dobj) rate_32/NN (l_prep) in_33/IN (l_pobj) patients_34/NNS (l_prep) with_35/IN (l_pobj) cancer_39/NN
D017239_D006258 NONE Taxol_15/NNP (r_appos) study_8/NN (r_pobj) of_2/IN (r_prep) results_1/NNS (r_nsubj) reported_27/VBD (l_dobj) rate_32/NN (l_prep) in_33/IN (l_pobj) patients_34/NNS (l_prep) with_35/IN (l_pobj) cancer_39/NN
D017239_D006258 NONE paclitaxel_43/NN (r_nmod) combination_46/NN (r_nsubjpass) used_49/VBN (r_conj) reported_27/VBD (l_dobj) rate_32/NN (l_prep) in_33/IN (l_pobj) patients_34/NNS (l_prep) with_35/IN (l_pobj) cancer_39/NN
D017239_D006258 NONE paclitaxel_16/NN (r_compound) doses_17/NNS (r_pobj) of_14/IN (r_prep) response_11/NN (l_prep) with_24/IN (l_pobj) support_30/NN (l_prep) in_31/IN (l_pobj) patients_32/NNS (l_prep) with_33/IN (l_pobj) carcinoma_41/NN
D017239_D006258 NONE Paclitaxel_0/NNP (r_nsubj) is_3/VBZ (l_attr) regimen_9/NN (l_prep) for_10/IN (l_pobj) cancer_16/NN
D017239_D010051 NONE paclitaxel_13/NN (r_pobj) of_9/IN (r_prep) study_8/NN (r_pobj) of_2/IN (r_prep) results_1/NNS (r_nsubj) reported_27/VBD (l_conj) used_49/VBN (l_conj) improved_54/VBN (l_dobj) duration_57/NN (l_prep) in_58/IN (l_pobj) patients_61/NNS (l_compound) cancer_60/NN
D017239_D010051 NONE Taxol_15/NNP (r_appos) study_8/NN (r_pobj) of_2/IN (r_prep) results_1/NNS (r_nsubj) reported_27/VBD (l_conj) used_49/VBN (l_conj) improved_54/VBN (l_dobj) duration_57/NN (l_prep) in_58/IN (l_pobj) patients_61/NNS (l_compound) cancer_60/NN
D017239_D010051 NONE paclitaxel_43/NN (r_nmod) combination_46/NN (r_nsubjpass) used_49/VBN (l_conj) improved_54/VBN (l_dobj) duration_57/NN (l_prep) in_58/IN (l_pobj) patients_61/NNS (l_compound) cancer_60/NN
D002945_D010051 NONE cisplatin_45/NN (r_cc) paclitaxel_43/NN (r_nmod) combination_46/NN (r_nsubjpass) used_49/VBN (l_conj) improved_54/VBN (l_dobj) duration_57/NN (l_prep) in_58/IN (l_pobj) patients_61/NNS (l_compound) cancer_60/NN
D017239_D064420 NONE paclitaxel_16/NN (r_compound) doses_17/NNS (r_pobj) of_14/IN (r_prep) response_11/NN (l_conj) toxicity_13/NN
D017239_D064420 NONE paclitaxel_5/NN (r_compound) doses_6/NNS (r_dobj) incorporate_3/VBP (l_conj) permitted_17/VBN (l_advcl) permits_20/NNS (l_nsubj) toxicity_19/NN
D002945_D064420 NONE cisplatin_23/NN (r_pobj) with_19/IN (r_prep) combined_18/VBN (r_acl) doses_17/NNS (r_pobj) of_14/IN (r_prep) response_11/NN (l_conj) toxicity_13/NN
10835440
D009553_D020521 NONE nimodipine_3/NN (r_pobj) of_1/IN (r_prep) Effect_0/NN (l_prep) after_9/IN (l_pobj) stroke_11/NN
D009553_D020521 NONE Nimodipine_2/NNP (r_compound) Trial_6/NNP (l_compound) Stroke_5/NNP
D009553_D020521 NONE Nimodipine_2/NNP (r_compound) Trial_6/NNP (r_nsubj) found_10/VBD (l_dobj) correlation_12/NN (l_prep) between_13/IN (l_pobj) reduction_17/NN (l_conj) outcome_27/NN (l_prep) in_28/IN (l_pobj) stroke_30/NN
D009553_D020521 NONE nimodipine_14/NN (r_npadvmod) induced_16/VBN (r_amod) reduction_17/NN (r_pobj) between_13/IN (r_prep) correlation_12/NN (r_dobj) found_10/VBD (l_nsubj) Trial_6/NNP (l_compound) Stroke_5/NNP
D009553_D020521 NONE nimodipine_14/NN (r_npadvmod) induced_16/VBN (r_amod) reduction_17/NN (l_conj) outcome_27/NN (l_prep) in_28/IN (l_pobj) stroke_30/NN
D009553_D020521 NONE nimodipine_20/NN (r_pobj) of_16/IN (r_prep) administration_15/NN (l_prep) after_21/IN (l_pobj) stroke_23/NN
D009553_D007022 CID Nimodipine_2/NNP (r_compound) Trial_6/NNP (r_nsubj) found_10/VBD (l_dobj) correlation_12/NN (l_prep) between_13/IN (l_pobj) reduction_17/NN (l_prep) in_18/IN (l_pobj) pressure_20/NN
D009553_D007022 CID nimodipine_14/NN (r_npadvmod) induced_16/VBN (r_amod) reduction_17/NN (l_prep) in_18/IN (l_pobj) pressure_20/NN
D009553_D007022 CID Nimodipine_0/JJ (r_compound) treatment_1/NN (r_nsubj) resulted_2/VBD (l_prep) in_3/IN (l_pobj) reduction_7/NN (l_prep) in_8/IN (l_pobj) BP_10/NNP
2312209
D007548_D009203 CID dinitrate_7/NNP (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) following_2/VBG (r_prep) infarction_1/NN
D007548_D009203 CID dinitrate_22/NNP (r_pobj) of_20/IN (r_prep) administration_19/NN (r_pobj) following_17/VBG (r_prep) suffered_8/VBD (l_dobj) infarction_12/NN
D007548_D009336 NONE dinitrate_22/NNP (r_pobj) of_20/IN (r_prep) administration_19/NN (r_pobj) following_17/VBG (r_prep) suffered_8/VBD (l_nsubj) old_3/JJ (l_prep) with_4/IN (l_pobj) necrosis_7/NN
14596845
D000661_D019966 NONE amphetamine_15/NN (r_pobj) of_14/IN (r_prep) dose_13/NN (r_pobj) to_10/IN (r_prep) causes_5/VBZ (l_nsubj) diet_1/NN (l_acl) promoting_2/VBG (l_dobj) dependency_4/NN
D000661_D006948 CID amphetamine_15/NN (r_pobj) of_14/IN (r_prep) dose_13/NN (r_pobj) to_10/IN (r_prep) causes_5/VBZ (l_dobj) sensitization_9/NN
D000661_D006948 CID amphetamine_24/NN (r_pobj) of_23/IN (r_prep) dose_22/NN (r_pobj) to_19/IN (r_prep) show_14/VB (l_dobj) sensitization_18/NN
D000661_D006948 CID amphetamine_14/NN (r_pobj) to_13/IN (r_prep) response_12/NN (r_pobj) in_11/IN (r_prep) were_9/VBD (l_acomp) hyperactive_10/JJ
D000661_D006948 CID amphetamine_30/NN (r_compound) injection_31/NN (r_pobj) by_29/IN (r_agent) followed_28/VBN (r_advcl) were_9/VBD (l_acomp) hyperactive_10/JJ
D000661_D006948 CID amphetamine_37/NN (r_compound) injection_38/NN (r_pobj) by_36/IN (r_agent) followed_35/VBN (r_acl) chow_34/NN (r_npadvmod) were_9/VBD (l_acomp) hyperactive_10/JJ
D000661_D006948 CID amphetamine_44/NN (r_pobj) with_43/IN (r_prep) chow_42/NN (r_appos) injection_38/NN (r_pobj) by_36/IN (r_agent) followed_35/VBN (r_acl) chow_34/NN (r_npadvmod) were_9/VBD (l_acomp) hyperactive_10/JJ
D013395_D006948 CID sucrose_6/NN (l_conj) were_9/VBD (l_acomp) hyperactive_10/JJ
D013395_D006948 CID sucrose_25/NN (r_prep) groups_19/NNS (r_pobj) with_16/IN (r_prep) compared_15/VBN (r_prep) were_9/VBD (l_acomp) hyperactive_10/JJ
D013395_D006948 CID sucrose_50/NN (r_conj) chow_42/NN (r_appos) injection_38/NN (r_pobj) by_36/IN (r_agent) followed_35/VBN (r_acl) chow_34/NN (r_npadvmod) were_9/VBD (l_acomp) hyperactive_10/JJ
18951540
D007980_D004409 CID levodopa_5/NN (r_npadvmod) induced_7/VBN (r_amod) dyskinesias_8/NN
D007980_D010300 NONE levodopa_5/NN (r_npadvmod) induced_7/VBN (r_amod) dyskinesias_8/NN (l_prep) in_9/IN (l_pobj) disease_12/NN
1732369
D004317_D009369 NONE doxorubicin_9/NN (r_npadvmod) treated_11/VBN (r_amod) survivors_15/NNS (l_prep) of_16/IN (l_pobj) cancer_18/NN
D004317_D009369 NONE doxorubicin_13/NN (r_pobj) due_11/IN (r_amod) test_7/NN (r_dobj) develop_1/VB (r_advcl) performed_19/VBN (l_advcl) using_20/VBG (l_xcomp) differentiate_24/VB (l_dobj) survivors_29/NNS (l_prep) of_30/IN (l_pobj) cancer_32/NN
D004317_D009369 NONE doxorubicin_35/NNS (r_pobj) with_34/IN (r_prep) treated_33/VBN (r_advcl) performed_19/VBN (l_advcl) using_20/VBG (l_xcomp) differentiate_24/VB (l_dobj) survivors_29/NNS (l_prep) of_30/IN (l_pobj) cancer_32/NN
D004317_D009202 CID Doxorubicin_0/NNP (r_nsubj) is_1/VBZ (l_attr) agent_6/NN (l_acl) known_7/VBN (l_xcomp) cause_9/VB (l_dobj) cardiomyopathy_13/NN
D004317_D006331 NONE doxorubicin_13/NN (r_pobj) due_11/IN (r_amod) test_7/NN (l_prep) for_8/IN (l_pobj) damage_10/NN
D004317_D006331 NONE doxorubicin_35/NNS (r_pobj) with_34/IN (r_prep) treated_33/VBN (r_advcl) performed_19/VBN (l_advcl) develop_1/VB (l_dobj) test_7/NN (l_prep) for_8/IN (l_pobj) damage_10/NN
D004280_D006331 NONE dobutamine_21/JJ (r_compound) infusion_22/NN (r_dobj) using_20/VBG (r_advcl) performed_19/VBN (l_advcl) develop_1/VB (l_dobj) test_7/NN (l_prep) for_8/IN (l_pobj) damage_10/NN
D004280_D009369 NONE dobutamine_21/JJ (r_compound) infusion_22/NN (r_dobj) using_20/VBG (l_xcomp) differentiate_24/VB (l_dobj) survivors_29/NNS (l_prep) of_30/IN (l_pobj) cancer_32/NN
2549018
D005473_D017109 CID Fluoxetine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) akathisia_3/NN
D005473_D017109 CID fluoxetine_3/NN (r_dobj) receiving_2/VBG (r_acl) patients_1/NNS (r_nsubj) developed_14/VBD (l_dobj) akathisia_15/NN
D005473_D017109 CID fluoxetine_2/NN (r_npadvmod) induced_4/VBN (r_amod) symptoms_5/NNS (r_nsubj) were_23/VBD (l_acomp) indistinguishable_24/JJ (l_prep) from_25/IN (l_pobj) those_26/DT (l_prep) of_27/IN (l_pobj) akathisia_31/NN
D005473_D017109 CID fluoxetine_17/NN (r_npadvmod) induced_19/VBN (r_amod) akathisia_20/NNS (r_pobj) of_16/IN (r_prep) symptoms_15/NNS (r_nsubj) were_21/VBD (r_ccomp) reported_12/VBD (l_nsubj) patients_1/NNS (l_relcl) experienced_4/VBN (l_dobj) akathisia_8/NN
D005473_D017109 CID fluoxetine_17/NN (r_npadvmod) induced_19/VBN (r_amod) akathisia_20/NNS
D005473_D017109 CID fluoxetine_9/NN (r_pobj) of_8/IN (r_prep) effect_7/NN (r_attr) be_3/VB (r_xcomp) appeared_1/VBD (l_nsubj) Akathisia_0/NNP
D005473_D017109 CID fluoxetine_4/NN (r_npadvmod) induced_6/VBN (r_amod) akathisia_7/NN
D005473_D017109 CID fluoxetine_4/NN (r_npadvmod) induced_6/VBN (r_amod) akathisia_7/NN (r_nsubjpass) caused_10/VBN (l_conj) be_36/VB (l_nsubj) pathophysiology_21/NN (l_prep) of_22/IN (l_pobj) akathisia_26/NN
D005473_D017109 CID fluoxetine_23/NN (r_npadvmod) induced_25/VBN (r_amod) akathisia_26/NN (r_pobj) of_22/IN (r_prep) pathophysiology_21/NN (r_nsubj) be_36/VB (r_conj) caused_10/VBN (l_nsubjpass) akathisia_7/NN
D005473_D017109 CID fluoxetine_23/NN (r_npadvmod) induced_25/VBN (r_amod) akathisia_26/NN
D005473_D009771 NONE fluoxetine_3/NN (r_dobj) receiving_2/VBG (l_prep) for_4/IN (l_pobj) treatment_6/NN (l_prep) of_7/IN (l_pobj) disorder_10/NN
D005473_D003865 NONE fluoxetine_3/NN (r_dobj) receiving_2/VBG (l_prep) for_4/IN (l_pobj) treatment_6/NN (l_prep) of_7/IN (l_pobj) disorder_10/NN (l_conj) depression_13/NN
D005473_D001008 NONE fluoxetine_2/NN (r_npadvmod) induced_4/VBN (r_amod) symptoms_5/NNS (l_appos) pacing_10/NN (l_conj) movements_13/NNS (l_conj) anxiety_22/NN
D011433_D017109 NONE propranolol_22/NN (r_appos) antagonist_21/NN (r_pobj) with_16/IN (r_prep) treatment_15/NN (r_pobj) to_14/IN (r_prep) responded_12/VBD (r_conj) appeared_1/VBD (l_nsubj) Akathisia_0/NNP
D000928_D017109 NONE antidepressant_29/NN (r_npadvmod) induced_31/VBN (r_amod) jitteriness_33/NN (r_conj) akathisia_26/NN (r_pobj) of_22/IN (r_prep) pathophysiology_21/NN (r_nsubj) be_36/VB (r_conj) caused_10/VBN (l_nsubjpass) akathisia_7/NN
D000928_D017109 NONE antidepressant_29/NN (r_npadvmod) induced_31/VBN (r_amod) jitteriness_33/NN (r_conj) akathisia_26/NN
1436384
D000661_D020258 CID amphetamine_2/NN (r_npadvmod) induced_4/VBN (r_amod) neurotoxicity_5/NN
D000661_D020258 CID amphetamine_10/NN (r_pobj) of_9/IN (r_prep) effect_8/NN (l_amod) neurotoxic_7/JJ
D004298_D020258 NONE dopamine_8/NN (r_compound) neurons_9/NNS (r_pobj) toward_6/IN (r_prep) neurotoxicity_5/NN
D004298_D020258 NONE dopamine_16/NN (r_compound) neurons_17/NNS (r_pobj) toward_14/IN (r_prep) effect_8/NN (l_amod) neurotoxic_7/JJ
C070935_D020258 NONE LY274614_13/NNP (r_pobj) by_12/IN (r_prep) Protection_0/NN (l_prep) against_1/IN (l_pobj) neurotoxicity_5/NN
C070935_D020258 NONE LY274614_23/NNP (r_nsubj) is_24/VBZ (r_conj) involves_18/VBZ (l_nsubj) effect_8/NN (l_amod) neurotoxic_7/JJ
D000596_D020258 NONE acid_18/NN (r_compound) antagonist_19/NN (r_appos) LY274614_13/NNP (r_pobj) by_12/IN (r_prep) Protection_0/NN (l_prep) against_1/IN (l_pobj) neurotoxicity_5/NN
D016202_D020258 NONE NMDA_19/NNP (r_compound) receptors_20/NNS (r_dobj) involves_18/VBZ (l_nsubj) effect_8/NN (l_amod) neurotoxic_7/JJ
D016202_D020258 NONE NMDA_26/NNP (r_compound) antagonist_28/NN (r_attr) is_24/VBZ (r_conj) involves_18/VBZ (l_nsubj) effect_8/NN (l_amod) neurotoxic_7/JJ
8701950
D016559_D000743 CID FK506_4/JJ (r_nmod) therapy_8/NN (r_dobj) complicating_3/VBG (l_nsubj) anemia_2/NN
D016559_D000743 CID tacrolimus_6/NN (r_nmod) therapy_8/NN (r_dobj) complicating_3/VBG (l_nsubj) anemia_2/NN
D016559_D000743 CID FK506_17/NNP (r_nmod) therapy_21/NN (r_pobj) under_16/IN (r_prep) recipients_15/NNS (r_pobj) in_11/IN (r_prep) episodes_3/NNS (l_prep) of_4/IN (l_pobj) anemia_7/NN
D016559_D000743 CID FK506_17/NNP (r_nmod) therapy_21/NN (r_pobj) under_16/IN (r_prep) recipients_15/NNS (r_pobj) in_11/IN (r_prep) episodes_3/NNS (l_prep) of_4/IN (l_pobj) anemia_7/NN (l_appos) MAHA_9/NNP
D016559_D000743 CID tacrolimus_19/NN (r_nmod) therapy_21/NN (r_pobj) under_16/IN (r_prep) recipients_15/NNS (r_pobj) in_11/IN (r_prep) episodes_3/NNS (l_prep) of_4/IN (l_pobj) anemia_7/NN
D016559_D000743 CID tacrolimus_19/NN (r_nmod) therapy_21/NN (r_pobj) under_16/IN (r_prep) recipients_15/NNS (r_pobj) in_11/IN (r_prep) episodes_3/NNS (l_prep) of_4/IN (l_pobj) anemia_7/NN (l_appos) MAHA_9/NNP
D016559_D000743 CID FK506_6/NN (r_pobj) of_5/IN (r_prep) discontinuation_4/NN (r_nsubj) led_24/VBD (l_prep) to_25/IN (l_pobj) resolution_26/NN (l_prep) of_27/IN (l_pobj) MAHA_28/NNP
D016559_D000743 CID FK506_6/NNP (r_pobj) of_5/IN (r_prep) reintroduction_4/NN (r_nsubj) led_7/VBD (l_prep) to_8/IN (l_pobj) recurrence_10/NN (l_prep) of_11/IN (l_pobj) MAHA_12/NNP
D016559_D000743 CID FK506-associated_0/NNP (r_compound) MAHA_1/NNP
D016559_D000743 CID FK506_9/NNP (r_nsubj) seem_12/VB (l_xcomp) react_16/VB (l_prep) with_17/IN (l_pobj) drug_28/NN (l_acl) known_30/VBN (l_xcomp) induce_32/VB (l_dobj) MAHA_33/NNP
D000305_D000743 NONE corticosteroids_18/NNS (r_conj) replacement_16/NN (r_conj) discontinuation_4/NN (r_nsubj) led_24/VBD (l_prep) to_25/IN (l_pobj) resolution_26/NN (l_prep) of_27/IN (l_pobj) MAHA_28/NNP
D001241_D000743 NONE aspirin_20/NN (r_conj) corticosteroids_18/NNS (r_conj) replacement_16/NN (r_conj) discontinuation_4/NN (r_nsubj) led_24/VBD (l_prep) to_25/IN (l_pobj) resolution_26/NN (l_prep) of_27/IN (l_pobj) MAHA_28/NNP
D004176_D000743 NONE dipyridamole_23/NNP (r_conj) aspirin_20/NN (r_conj) corticosteroids_18/NNS (r_conj) replacement_16/NN (r_conj) discontinuation_4/NN (r_nsubj) led_24/VBD (l_prep) to_25/IN (l_pobj) resolution_26/NN (l_prep) of_27/IN (l_pobj) MAHA_28/NNP
D016572_D000743 NONE A_19/DT (r_pobj) cyclosporin_18/NN (r_pobj) with_17/IN (l_pobj) drug_28/NN (l_acl) known_30/VBN (l_xcomp) induce_32/VB (l_dobj) MAHA_33/NNP
D016572_D000743 NONE CyA_21/NN (r_appos) A_19/DT (r_pobj) cyclosporin_18/NN (r_pobj) with_17/IN (l_pobj) drug_28/NN (l_acl) known_30/VBN (l_xcomp) induce_32/VB (l_dobj) MAHA_33/NNP
17147461
D020123_D011507 CID Sirolimus_0/NN (r_npadvmod) associated_2/VBN (r_amod) proteinuria_3/NN
D020123_D011507 CID sirolimus_11/NNP (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) proteinuria_15/NN
D020123_D011507 CID sirolimus_3/NN (r_npadvmod) associated_5/VBN (r_amod) proteinuria_6/NN
D020123_D011507 CID sirolimus_21/NN (r_pobj) of_20/IN (r_prep) effects_19/NNS (r_pobj) of_16/IN (r_prep) knowledge_15/NN (r_pobj) by_14/IN (r_agent) minimised_13/VBN (l_advcl) occur_4/VBP (l_nsubj) effects_3/NNS (l_appos) use_27/NN (l_conj) monitoring_36/NN (l_prep) of_37/IN (l_pobj) proteinuria_38/NN
D020123_D011507 CID sirolimus_21/NN (r_pobj) of_20/IN (r_prep) effects_19/NNS (r_pobj) of_16/IN (r_prep) knowledge_15/NN (r_pobj) by_14/IN (r_agent) minimised_13/VBN (l_advcl) occur_4/VBP (l_nsubj) effects_3/NNS (l_appos) use_27/NN (l_conj) monitoring_36/NN (l_conj) use_43/NN (l_advcl) occurs_57/VBZ (l_nsubj) proteinuria_56/NN
D020123_D011507 CID sirolimus_29/NN (r_pobj) of_28/IN (r_prep) use_27/NN (l_conj) monitoring_36/NN (l_prep) of_37/IN (l_pobj) proteinuria_38/NN
D020123_D011507 CID sirolimus_29/NN (r_pobj) of_28/IN (r_prep) use_27/NN (l_conj) monitoring_36/NN (l_conj) use_43/NN (l_advcl) occurs_57/VBZ (l_nsubj) proteinuria_56/NN
D020123_D007674 CID Sirolimus_0/NN (r_npadvmod) associated_2/VBN (r_amod) proteinuria_3/NN (l_conj) dysfunction_6/NN
D020123_D007674 CID Sirolimus_0/NNP (r_nsubj) represents_1/VBZ (l_dobj) advance_5/NN (l_prep) in_6/IN (l_pobj) prevention_8/NN (l_prep) of_9/IN (l_pobj) rejection_13/NN (l_conj) nephropathy_17/NN
D020123_D007674 CID sirolimus_1/NNP (r_nsubj) share_4/VB (r_advcl) designated_18/VBN (l_oprd) drug_24/NN (l_amod) nephrotoxic_23/JJ
D020123_D058186 NONE sirolimus_11/NNP (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) proteinuria_15/NN (l_conj) dysfunction_19/NN
D020123_D058186 NONE sirolimus_6/NNP (r_pobj) with_5/IN (r_prep) associated_4/VBN (r_acl) dysfunction_3/NN
D000809_D011507 NONE angiotensin_45/NN (r_npadvmod) converting_47/VBG (r_amod) inhibitors_49/NNS (r_pobj) of_44/IN (r_prep) use_43/NN (r_conj) monitoring_36/NN (l_prep) of_37/IN (l_pobj) proteinuria_38/NN
D000809_D011507 NONE angiotensin_45/NN (r_npadvmod) converting_47/VBG (r_amod) inhibitors_49/NNS (r_pobj) of_44/IN (r_prep) use_43/NN (l_advcl) occurs_57/VBZ (l_nsubj) proteinuria_56/NN
D000804_D011507 NONE II_52/NNP (r_compound) blockers_54/NNS (r_conj) inhibitors_49/NNS (r_pobj) of_44/IN (r_prep) use_43/NN (r_conj) monitoring_36/NN (l_prep) of_37/IN (l_pobj) proteinuria_38/NN
D000804_D011507 NONE II_52/NNP (r_compound) blockers_54/NNS (r_conj) inhibitors_49/NNS (r_pobj) of_44/IN (r_prep) use_43/NN (l_advcl) occurs_57/VBZ (l_nsubj) proteinuria_56/NN
322550
D009599_D007022 CID nitroprusside_8/NNP (r_npadvmod) induced_10/VBN (r_amod) hypotension_11/NN
D009599_D007022 CID nitroprusside_5/JJ (r_compound) infusion_6/NN (r_nsubj) produced_7/VBD (l_dobj) decrease_10/NN (l_prep) in_11/IN (l_pobj) pressure_14/NN
D009599_D007022 CID Nitroprusside_0/NNP (r_nsubj) caused_1/VBD (l_dobj) decreases_3/NNS (l_prep) in_4/IN (l_pobj) pressure_7/NN
D009599_D007022 NONE nitroprusside_1/JJ (r_amod) levels_4/NNS (r_pobj) During_0/IN (r_prep) alter_10/VB (l_conj) produce_31/VBP (l_dobj) decreases_33/NNS (l_prep) in_34/IN (l_pobj) pressure_37/NN (l_conj) output_40/NN
D014867_D007022 NONE H2O_2/NN (r_compound) CPAP_3/NN (l_advcl) produced_7/VBD (l_dobj) decrease_10/NN (l_prep) in_11/IN (l_pobj) pressure_14/NN
D014867_D007022 NONE H2O_22/NN (r_npadvmod) cm_21/NN (r_appos) CPAP_18/NNP (r_pobj) of_17/IN (r_prep) levels_16/NNS (r_nsubj) produce_31/VBP (l_dobj) decreases_33/NNS (l_prep) in_34/IN (l_pobj) pressure_37/NN (l_conj) output_40/NN
D014867_D002303 NONE H2O_2/NN (r_compound) CPAP_3/NN (l_advcl) produced_7/VBD (l_conj) decreased_21/VBD (l_dobj) output_23/NN
D014867_D002303 NONE H2O_22/NN (r_npadvmod) cm_21/NN (r_appos) CPAP_18/NNP (r_pobj) of_17/IN (r_prep) levels_16/NNS (r_nsubj) produce_31/VBP (l_dobj) decreases_33/NNS (l_prep) in_34/IN (l_pobj) pressure_37/NN (l_conj) output_40/NN
D009599_D002303 NONE nitroprusside_5/JJ (r_compound) infusion_6/NN (r_nsubj) produced_7/VBD (l_conj) decreased_21/VBD (l_dobj) output_23/NN
D009599_D002303 NONE nitroprusside_1/JJ (r_amod) levels_4/NNS (r_pobj) During_0/IN (r_prep) alter_10/VB (l_conj) produce_31/VBP (l_dobj) decreases_33/NNS (l_prep) in_34/IN (l_pobj) pressure_37/NN (l_conj) output_40/NN
18619688
D004317_D003643 NONE Adriamycin_0/NN (r_npadvmod) induced_2/VBN (r_amod) autophagic_3/NNP (r_compound) death_5/NN
D004317_D003643 NONE adriamycin_17/NNS (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) rats_14/NNS (r_pobj) in_13/IN (r_prep) failure_12/NN (r_pobj) of_10/IN (r_prep) pathogenesis_9/NN (r_pobj) in_7/IN (r_prep) role_6/NN (r_dobj) plays_3/VBZ (l_nsubj) death_2/NN
D004317_D006333 CID Adriamycin_0/NN (r_npadvmod) induced_2/VBN (r_amod) autophagic_3/NNP (r_compound) death_5/NN (r_nsubj) plays_6/VBZ (l_dobj) role_9/NN (l_prep) in_10/IN (l_pobj) model_13/NN (l_prep) of_14/IN (l_pobj) failure_16/NN
D004317_D006333 CID adriamycin_7/NNS (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) failure_4/NN
D004317_D006333 CID adriamycin_20/NNS (r_pobj) by_19/IN (r_agent) induced_18/VBN (r_acl) failure_17/NN
D004317_D006333 CID adriamycin_20/NNS (r_pobj) by_19/IN (r_agent) induced_18/VBN (r_acl) failure_17/NN (r_pobj) of_15/IN (r_prep) progression_14/NN (r_pobj) in_12/IN (r_prep) involved_11/VBN (r_ccomp) investigate_7/VB (l_advcl) develop_26/VB (l_dobj) strategy_30/NN (l_prep) for_31/IN (l_pobj) failure_33/NN
D004317_D006333 CID adriamycin_16/NNS (r_pobj) by_15/IN (r_agent) induced_14/VBN (r_acl) rats_13/NNS (r_pobj) of_12/IN (r_prep) model_11/NN (l_compound) failure_10/NN
D004317_D006333 CID adriamycin_17/NNS (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) rats_14/NNS (r_pobj) in_13/IN (r_prep) failure_12/NN
D004317_D006333 CID adriamycin_13/NNS (r_pobj) by_12/IN (r_agent) caused_11/VBN (r_acl) failure_10/NN
19803309
D013390_D009224 NONE suxamethonium_29/NN (r_pobj) of_27/IN (r_prep) dose_26/NN (r_pobj) following_23/VBG (r_prep) threatening_20/VBG (r_ccomp) developed_18/VBD (r_relcl) primigravida_15/NN (r_pobj) in_8/IN (r_prep) report_1/VBP (l_dobj) case_4/NN (l_prep) of_5/IN (l_pobj) congenita_7/NN
D013390_D014313 CID suxamethonium_29/NN (r_pobj) of_27/IN (r_prep) dose_26/NN (r_pobj) following_23/VBG (r_prep) threatening_20/VBG (l_dobj) spasm_22/NN
15572383
D004317_D007674 NONE adriamycin_12/NN (r_npadvmod) induced_14/VBN (r_amod) damage_16/NN
D004317_D007674 NONE adriamycin_23/NNS (r_pobj) of_22/IN (r_prep) injection_21/NN (r_pobj) by_18/IN (r_agent) induced_17/VBN (r_acl) damage_16/NN
D004317_D007674 NONE adriamycin_3/XX (r_nsubj) elicited_4/VBD (l_dobj) proteinuria_7/NN (l_conj) damage_11/NN
D004317_D007674 NONE adriamycin_10/NN (r_npadvmod) induced_12/VBN (r_amod) damage_14/NN
D004317_D011507 CID adriamycin_10/FW (r_pobj) by_9/IN (r_agent) induced_8/VBN (l_nsubjpass) proteinuria_6/NN
D004317_D011507 CID adriamycin_3/XX (r_nsubj) elicited_4/VBD (l_dobj) proteinuria_7/NN
D004317_D011507 CID adriamycin_12/NN (r_pobj) after_11/IN (r_prep) rise_8/NN (l_prep) in_9/IN (l_pobj) proteinuria_10/NN
D004317_D009404 NONE adriamycin_3/XX (r_nsubj) elicited_4/VBD (l_dobj) proteinuria_7/NN (l_compound) range_6/NN (l_amod) nephrotic_5/JJ
D004317_D005923 NONE adriamycin_3/XX (r_nsubj) elicited_4/VBD (l_dobj) proteinuria_7/NN (l_conj) damage_11/NN (l_conj) glomerulosclerosis_15/NN
19299179
D015662_D002779 NONE trimoxazole_11/JJ (r_amod) treatment_12/NN (r_pobj) after_5/IN (r_prep) cholestasis_4/NN
D015662_D011020 NONE trimoxazole_11/JJ (r_amod) treatment_12/NN (l_prep) for_13/IN (l_pobj) pneumonia_15/NN
D015662_D011020 NONE trimoxazole_25/NNP (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_pobj) with_19/IN (r_prep) treated_18/VBN (l_nsubjpass) pneumonia_1/NN
D015662_D011020 NONE trimoxazole_25/NNP (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_pobj) with_19/IN (r_prep) treated_18/VBN (l_nsubjpass) pneumonia_1/NN (l_appos) PCP_3/NNP
D015662_D011020 NONE trimoxazole_35/JJ (r_amod) treatment_36/NN (l_prep) for_37/IN (l_pobj) PCP_38/NNP
D015662_D015658 NONE trimoxazole_11/JJ (r_amod) treatment_12/NN (l_prep) for_13/IN (l_pobj) pneumonia_15/NN (l_prep) in_16/IN (l_pobj) patients_20/NNS (l_amod) infected_19/VBN
D015662_D015658 NONE trimoxazole_25/NNP (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_pobj) with_19/IN (r_prep) treated_18/VBN (l_nsubjpass) pneumonia_1/NN (l_appos) infection_9/NN (l_prep) in_10/IN (l_pobj) individuals_14/NNS (l_amod) infected_13/VBN
D015662_D015658 NONE trimoxazole_35/JJ (r_amod) treatment_36/NN (r_pobj) during_32/IN (r_prep) report_3/VBP (l_dobj) cases_5/NNS (l_prep) of_6/IN (l_pobj) patients_12/NNS (l_amod) infected_11/VBN
D015662_D009894 NONE trimoxazole_25/NNP (r_pobj) of_22/IN (r_prep) doses_21/NNS (r_pobj) with_19/IN (r_prep) treated_18/VBN (l_nsubjpass) pneumonia_1/NN (l_appos) infection_9/NN
D015662_D002780 CID trimoxazole_35/JJ (r_amod) treatment_36/NN (r_pobj) during_32/IN (r_prep) report_3/VBP (l_dobj) cases_5/NNS (l_prep) of_6/IN (l_pobj) patients_12/NNS (l_relcl) developed_14/VBD (l_dobj) cholestasis_17/NN
D015662_D008100 NONE trimoxazole_35/JJ (r_amod) treatment_36/NN (r_pobj) during_32/IN (r_prep) report_3/VBP (l_conj) in_20/IN (l_pobj) lesions_23/NNS (l_acl) mimicking_24/VBG (l_dobj) formation_27/NN (l_compound) abscess_26/NN
10091617
D012642_D007024 CID Selegiline_0/NN (r_npadvmod) induced_2/VBN (r_amod) hypotension_4/NN
D012642_D007024 CID selegiline_7/NN (r_pobj) with_6/IN (r_prep) therapy_5/NN (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) hypotension_18/NN
D012642_D007024 CID selegiline_25/NN (r_pobj) of_24/IN (r_prep) withdrawal_23/NN (r_pobj) by_22/IN (r_agent) abolished_21/VBN (r_relcl) hypotension_18/NN
D012642_D007024 CID selegiline_29/NN (r_dobj) stopping_28/VBG (l_prep) in_30/IN (l_pobj) expectation_32/NN (l_acl) shed_36/VB (l_prep) on_38/IN (l_pobj) mechanisms_40/NNS (l_relcl) causes_45/VBZ (l_dobj) hypotension_47/NN
D012642_D007024 CID selegiline_18/NN (r_pobj) on_17/IN (r_prep) patients_16/NNS (r_pobj) in_11/IN (r_prep) marked_10/VBN (r_relcl) hypotension_7/NN
D012642_D007024 CID selegiline_9/NN (r_pobj) of_8/IN (r_prep) withdrawal_7/NN (r_pobj) after_6/IN (r_prep) ameliorated_3/VBN (l_nsubjpass) hypotension_1/NN
D012642_D007024 CID selegiline_1/NN (r_dobj) Stopping_0/VBG (r_csubj) reduced_4/VBD (l_dobj) pressures_11/NNS
D012642_D007024 CID selegiline_7/NN (r_nsubjpass) associated_15/VBN (l_prep) with_16/IN (l_pobj) hypotension_19/NN
D012642_D010300 NONE Selegiline_0/NN (r_npadvmod) induced_2/VBN (r_amod) hypotension_4/NN (l_prep) in_5/IN (l_pobj) disease_8/NN
D012642_D010300 NONE selegiline_30/NN (r_dobj) receive_27/VB (r_xcomp) randomized_25/VBD (r_ccomp) found_12/VBD (l_nsubj) trial_11/NN (l_nmod) Group_7/NNP (l_compound) Disease_5/NNP
D012642_D010300 NONE selegiline_30/NN (r_dobj) receive_27/VB (r_xcomp) randomized_25/VBD (l_nsubj) mortality_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) disease_21/NN
D012642_D010300 NONE selegiline_30/NN (r_dobj) receive_27/VB (r_xcomp) randomized_25/VBD (l_nsubj) mortality_15/NN (l_prep) in_16/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) disease_21/NN (l_appos) PD_23/NNP
D012642_D010300 NONE selegiline_17/NN (r_dobj) receiving_16/VBG (r_acl) patients_15/NNS (l_compound) PD_14/NNP
D012642_D010300 NONE selegiline_18/NN (r_pobj) on_17/IN (r_prep) patients_16/NNS (l_compound) PD_15/NNP
D007980_D007024 NONE dopa_11/NNP (r_conj) selegiline_7/NN (r_pobj) with_6/IN (r_prep) therapy_5/NN (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) hypotension_18/NN
D007980_D007024 NONE dopa_13/NNP (r_pobj) with_10/IN (r_prep) combination_9/NN (r_pobj) in_8/IN (r_prep) selegiline_7/NN (r_nsubjpass) associated_15/VBN (l_prep) with_16/IN (l_pobj) hypotension_19/NN
16867021
D006632_D002375 NONE histamine_10/NN (r_amod) ligands_12/NNS (l_prep) on_13/IN (l_pobj) catalepsy_17/NN
D001058_D002375 NONE apomorphine_19/NN (r_npadvmod) induced_21/VBN (r_amod) behavior_23/NN (r_conj) ligands_12/NNS (l_prep) on_13/IN (l_pobj) catalepsy_17/NN
D001058_D002375 NONE apomorphine_12/NNP (r_nsubjpass) used_26/VBN (r_advcl) induced_2/VBN (l_nsubjpass) Catalepsy_0/NNP
D001058_D002375 NONE apomorphine_21/NN (r_npadvmod) induced_23/VBN (r_amod) climbing_24/NN (r_dobj) reducing_20/VBG (r_conj) reducing_14/VBG (r_advcl) exhibited_1/VBD (l_prep) by_7/IN (l_pcomp) potentiating_8/VBG (l_dobj) catalepsy_12/NN
D000661_D002375 NONE amphetamine_25/NN (r_npadvmod) induced_27/VBN (r_amod) activities_29/NNS (r_conj) behavior_23/NN (r_conj) ligands_12/NNS (l_prep) on_13/IN (l_pobj) catalepsy_17/NN
D000661_D002375 NONE amphetamine_19/NN (r_conj) apomorphine_12/NNP (r_nsubjpass) used_26/VBN (r_advcl) induced_2/VBN (l_nsubjpass) Catalepsy_0/NNP
D000661_D002375 NONE amphetamine_15/NN (r_npadvmod) induced_17/VBN (r_amod) hyperactivity_18/NN (r_dobj) reducing_14/VBG (r_advcl) exhibited_1/VBD (l_prep) by_7/IN (l_pcomp) potentiating_8/VBG (l_dobj) catalepsy_12/NN
D006220_D002375 CID haloperidol_4/NNP (r_pobj) by_3/IN (r_agent) induced_2/VBN (l_nsubjpass) Catalepsy_0/NNP
D006220_D002375 CID haloperidol_16/NNP (r_pobj) to_15/IN (r_prep) prior_14/RB (r_advmod) h_13/NN (r_appos) Administration_0/NN (r_nsubj) resulted_17/VBD (l_prep) in_18/IN (l_pobj) increase_23/NN (l_prep) in_24/IN (l_pobj) times_27/NNS (l_compound) catalepsy_26/NN
D006220_D002375 CID haloperidol_9/NN (r_npadvmod) induced_11/VBN (r_amod) catalepsy_12/NN
C069357_D002375 NONE methylhistamine_3/NNP (r_nsubj) cause_27/VB (l_dobj) catalepsy_28/NN
C069357_D002375 NONE RAMH_5/NNP (r_appos) methylhistamine_3/NNP (r_nsubj) cause_27/VB (l_dobj) catalepsy_28/NN
C052075_D002375 CID thioperamide_13/NNP (r_conj) methylhistamine_3/NNP (r_nsubj) cause_27/VB (l_dobj) catalepsy_28/NN
C052075_D002375 CID THP_15/NNP (r_appos) thioperamide_13/NNP (r_conj) methylhistamine_3/NNP (r_nsubj) cause_27/VB (l_dobj) catalepsy_28/NN
C052075_D002375 CID THP_2/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) resulted_17/VBD (l_prep) in_18/IN (l_pobj) increase_23/NN (l_prep) in_24/IN (l_pobj) times_27/NNS (l_compound) catalepsy_26/NN
C052075_D002375 CID THP_0/NNP (r_nsubj) exhibited_1/VBD (l_prep) by_7/IN (l_pcomp) potentiating_8/VBG (l_dobj) catalepsy_12/NN
D000661_D006948 CID amphetamine_1/NN (r_npadvmod) induced_3/VBN (r_amod) hyperactivity_4/NN
D000661_D006948 CID amphetamine_15/NN (r_npadvmod) induced_17/VBN (r_amod) hyperactivity_18/NN
C052075_D006948 NONE THP_6/NNP (r_nsubj) reduced_14/VBN (r_amod) time_16/NN (r_pobj) On_0/IN (l_pobj) hyperactivity_4/NN
C052075_D006948 NONE THP_0/NNP (r_nsubj) exhibited_1/VBD (l_advcl) reducing_14/VBG (l_dobj) hyperactivity_18/NN
D006220_D006948 NONE haloperidol_9/NN (r_npadvmod) induced_11/VBN (r_amod) catalepsy_12/NN (r_dobj) potentiating_8/VBG (r_pcomp) by_7/IN (r_prep) exhibited_1/VBD (l_advcl) reducing_14/VBG (l_dobj) hyperactivity_18/NN
D001058_D006948 NONE apomorphine_21/NN (r_npadvmod) induced_23/VBN (r_amod) climbing_24/NN (r_dobj) reducing_20/VBG (r_conj) reducing_14/VBG (l_dobj) hyperactivity_18/NN
C052075_D012559 NONE THP_3/NNP (r_pobj) of_2/IN (r_prep) effects_1/NNS (r_nsubjpass) reversed_5/VBN (l_conj) suggest_16/VBP (l_dobj) potential_18/NN (l_prep) for_19/IN (l_pobj) antagonists_21/NNS (l_prep) in_22/IN (l_pcomp) improving_23/VBG (l_dobj) cases_26/NNS (l_prep) of_27/IN (l_pobj) schizophrenia_28/NN
C069357_D012559 NONE RAMH_7/NNP (r_pobj) by_6/IN (r_agent) reversed_5/VBN (l_conj) suggest_16/VBP (l_dobj) potential_18/NN (l_prep) for_19/IN (l_pobj) antagonists_21/NNS (l_prep) in_22/IN (l_pcomp) improving_23/VBG (l_dobj) cases_26/NNS (l_prep) of_27/IN (l_pobj) schizophrenia_28/NN
D006632_D012559 NONE histamine_12/NN (r_compound) Findings_15/NNS (r_pobj) of_11/IN (r_prep) involvement_10/NN (r_dobj) indicating_8/VBG (r_acl) RAMH_7/NNP (r_pobj) by_6/IN (r_agent) reversed_5/VBN (l_conj) suggest_16/VBP (l_dobj) potential_18/NN (l_prep) for_19/IN (l_pobj) antagonists_21/NNS (l_prep) in_22/IN (l_pcomp) improving_23/VBG (l_dobj) cases_26/NNS (l_prep) of_27/IN (l_pobj) schizophrenia_28/NN
12921865
D013256_D012640 NONE steroids_4/NNS (r_pobj) of_2/IN (r_prep) efficacy_1/NN (r_nsubj) kindled_7/VBN (l_dobj) seizures_9/NNS
D013256_D012640 NONE steroid_13/NN (l_appos) receptor_26/NN (l_prep) against_27/IN (l_pobj) increase_29/NN (l_prep) in_30/IN (l_pobj) sensitivity_31/NN (l_prep) to_32/IN (l_pobj) effects_35/NNS (l_acl) engendered_38/VBN (l_agent) by_39/IN (l_pobj) administration_42/NN (l_appos) kindling_45/NN (l_compound) seizure_44/NN
D003042_D012640 CID cocaine_6/NN (r_pobj) against_5/IN (r_prep) steroids_4/NNS (r_pobj) of_2/IN (r_prep) efficacy_1/NN (r_nsubj) kindled_7/VBN (l_dobj) seizures_9/NNS
D003042_D012640 CID cocaine_37/NN (r_pobj) of_36/IN (r_prep) effects_35/NNS (l_acl) engendered_38/VBN (l_agent) by_39/IN (l_pobj) administration_42/NN (l_appos) kindling_45/NN (l_compound) seizure_44/NN
D003042_D012640 CID cocaine_41/NN (r_compound) administration_42/NN (l_appos) kindling_45/NN (l_compound) seizure_44/NN
D003042_D012640 CID cocaine_28/NN (r_npadvmod) kindled_30/VBN (r_amod) seizures_31/NNS
D003042_D012640 CID cocaine_10/NN (r_pobj) of_7/IN (r_prep) administration_6/NN (r_pobj) by_4/IN (r_agent) induced_3/VBN (l_nsubjpass) seizures_1/NNS
D013256_D009422 NONE steroids_1/NNS (r_nsubj) demonstrate_2/VBP (l_dobj) actions_4/NNS (l_relcl) have_6/VBP (l_dobj) relevance_7/NN (l_prep) for_8/IN (l_pobj) host_10/NN (l_prep) of_11/IN (l_pobj) disorders_15/NNS
D013256_D001523 NONE steroids_1/NNS (r_nsubj) demonstrate_2/VBP (l_dobj) actions_4/NNS (l_relcl) have_6/VBP (l_dobj) relevance_7/NN (l_prep) for_8/IN (l_pobj) host_10/NN (l_prep) of_11/IN (l_pobj) disorders_15/NNS
D005680_D012640 NONE acid_21/NN (r_dobj) modulate_16/VBP (r_relcl) steroid_13/NN (l_appos) receptor_26/NN (l_prep) against_27/IN (l_pobj) increase_29/NN (l_prep) in_30/IN (l_pobj) sensitivity_31/NN (l_prep) to_32/IN (l_pobj) effects_35/NNS (l_acl) engendered_38/VBN (l_agent) by_39/IN (l_pobj) administration_42/NN (l_appos) kindling_45/NN (l_compound) seizure_44/NN
D005680_D012640 NONE GABA(A_23/NN (r_appos) acid_21/NN (r_dobj) modulate_16/VBP (r_relcl) steroid_13/NN (l_appos) receptor_26/NN (l_prep) against_27/IN (l_pobj) increase_29/NN (l_prep) in_30/IN (l_pobj) sensitivity_31/NN (l_prep) to_32/IN (l_pobj) effects_35/NNS (l_acl) engendered_38/VBN (l_agent) by_39/IN (l_pobj) administration_42/NN (l_appos) kindling_45/NN (l_compound) seizure_44/NN
D005680_D012640 NONE GABA(A_4/NN (r_nmod) modulators_6/NNS (r_pobj) of_1/IN (r_prep) All_0/DT (r_nsubj) suppressed_7/VBD (l_dobj) expression_9/NN (l_prep) of_10/IN (l_pobj) seizures_12/NNS
C105051_D012640 NONE pregnan-20-one_6/NNP (r_nsubjpass) tested_9/VBN (l_prep) for_10/IN (l_pobj) ability_12/NN (l_acl) suppress_14/VB (l_dobj) expression_16/NN (l_conj) development_22/NN (l_prep) of_27/IN (l_pobj) seizures_31/NNS
C105051_D012640 NONE ganaxolone_18/NNP (r_conj) allopregnanolone_16/NN (r_nsubj) inhibited_19/VBD (r_advcl) suppressed_7/VBD (l_dobj) expression_9/NN (l_prep) of_10/IN (l_pobj) seizures_12/NNS
D011280_D012640 NONE allopregnanolone_16/NN (r_nsubj) inhibited_19/VBD (r_advcl) suppressed_7/VBD (l_dobj) expression_9/NN (l_prep) of_10/IN (l_pobj) seizures_12/NNS
17491223
D004280_D017202 CID dobutamine_14/NN (r_npadvmod) induced_16/VBN (r_amod) ischemia_18/NN
D004280_D017202 CID dobutamine_8/NN (r_npadvmod) induced_10/VBN (r_amod) ischemia_12/NN
D004280_D017202 CID dobutamine_35/NN (r_npadvmod) induced_37/VBN (r_amod) ischemia_39/NN
D004280_D007511 NONE dobutamine_35/NN (r_npadvmod) induced_37/VBN (r_amod) ischemia_39/NN (r_dobj) detecting_34/VBG (r_pcomp) for_33/IN (r_prep) assess_1/VB (r_csubj) computed_49/VBN (l_advcl) assess_58/VB (l_dobj) presence_60/NN (l_prep) of_63/IN (l_pobj) ischemia_64/NN
D017256_D017202 NONE Sestamibi_44/NNP (r_nmod) emission_48/NN (r_dobj) using_41/VBG (r_advcl) assess_1/VB (l_prep) for_33/IN (l_pcomp) detecting_34/VBG (l_dobj) ischemia_39/NN
D017256_D007511 NONE Sestamibi_44/NNP (r_nmod) emission_48/NN (r_dobj) using_41/VBG (r_advcl) assess_1/VB (r_csubj) computed_49/VBN (l_advcl) assess_58/VB (l_dobj) presence_60/NN (l_prep) of_63/IN (l_pobj) ischemia_64/NN
2266990
D008454_D020388 NONE mazindol_7/NNP (r_pobj) of_6/IN (r_prep) trial_5/NN (l_prep) in_8/IN (l_pobj) dystrophy_10/NN
D008454_D020388 NONE mazindol_7/NNP (r_pobj) of_6/IN (r_prep) trial_5/NN (r_dobj) conducted_1/VBD (l_prep) in_16/IN (l_pobj) boys_18/NNS (l_prep) with_19/IN (l_pobj) dystrophy_21/NN
D008454_D020388 NONE Mazindol_0/NNP (r_nsubj) doses_1/NNS (r_nsubj) slow_3/VB (l_dobj) progression_5/NN (l_prep) of_6/IN (l_pobj) weakness_7/NN (l_prep) in_8/IN (l_pobj) dystrophy_10/NN
D008454_D001068 CID mazindol_4/NNP (r_pobj) to_3/IN (r_prep) attributable_2/JJ (r_amod) effects_1/NNS (r_nsubj) included_5/VBN (l_dobj) appetite_7/NN
D008454_D001068 CID mazindol_35/NNP (r_compound) dosage_36/NNP (r_nsubjpass) reduced_38/VBN (l_ccomp) included_5/VBN (l_dobj) appetite_7/NN
D008454_D014987 CID mazindol_4/NNP (r_pobj) to_3/IN (r_prep) attributable_2/JJ (r_amod) effects_1/NNS (r_nsubj) included_5/VBN (l_dobj) appetite_7/NN (l_appos) mouth_14/NN
D008454_D014987 CID mazindol_35/NNP (r_compound) dosage_36/NNP (r_nsubjpass) reduced_38/VBN (l_ccomp) included_5/VBN (l_dobj) appetite_7/NN (l_appos) mouth_14/NN
D008454_D012817 CID mazindol_4/NNP (r_pobj) to_3/IN (r_prep) attributable_2/JJ (r_amod) effects_1/NNS (r_nsubj) included_5/VBN (l_dobj) appetite_7/NN (l_appos) change_21/NN (l_conj) symptoms_29/NNS
D008454_D012817 CID mazindol_35/NNP (r_compound) dosage_36/NNP (r_nsubjpass) reduced_38/VBN (l_ccomp) included_5/VBN (l_dobj) appetite_7/NN (l_appos) change_21/NN (l_conj) symptoms_29/NNS
D008454_D018908 NONE Mazindol_0/NNP (r_nsubj) doses_1/NNS (r_nsubj) slow_3/VB (l_dobj) progression_5/NN (l_prep) of_6/IN (l_pobj) weakness_7/NN
1919871
D001241_D007681 CID aspirin_20/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_pobj) during_13/IN (r_prep) developed_12/VBN (r_acl) ability_11/NN (r_conj) necrosis_2/NN
D001241_D007681 CID aspirin_20/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_pobj) during_13/IN (r_prep) developed_12/VBN (r_acl) ability_11/NN (r_conj) necrosis_2/NN (l_appos) RPN_4/NNP
D000082_D007681 CID paracetamol_22/NN (r_conj) aspirin_20/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_pobj) during_13/IN (r_prep) developed_12/VBN (r_acl) ability_11/NN (r_conj) necrosis_2/NN
D000082_D007681 CID paracetamol_22/NN (r_conj) aspirin_20/NN (r_pobj) with_19/IN (r_prep) treatment_18/NN (r_pobj) during_13/IN (r_prep) developed_12/VBN (r_acl) ability_11/NN (r_conj) necrosis_2/NN (l_appos) RPN_4/NNP
9698967
D008619_D006973 CID mepivacaine_43/NNP (r_pobj) with_42/IN (r_prep) block_41/NN (r_pobj) of_39/IN (r_prep) performance_38/NN (r_pobj) after_37/IN (r_prep) group_28/NN (r_appos) increase_1/NN (l_prep) in_2/IN (l_pobj) pressure_4/NN
D008619_D001281 CID mepivacaine_43/NNP (r_pobj) with_42/IN (r_prep) block_41/NN (r_pobj) of_39/IN (r_prep) performance_38/NN (r_pobj) after_37/IN (r_prep) group_28/NN (r_appos) increase_1/NN (l_acl) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) fibrillation_9/NN
D008619_D011595 NONE mepivacaine_43/NNP (r_pobj) with_42/IN (r_prep) block_41/NN (r_pobj) of_39/IN (r_prep) performance_38/NN (r_pobj) after_37/IN (r_prep) group_28/NN (r_appos) increase_1/NN (l_acl) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) fibrillation_9/NN (l_appos) agitation_11/NN
D008619_D019954 NONE mepivacaine_43/NNP (r_pobj) with_42/IN (r_prep) block_41/NN (r_pobj) of_39/IN (r_prep) performance_38/NN (r_pobj) after_37/IN (r_prep) group_28/NN (r_appos) increase_1/NN (l_acl) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) fibrillation_9/NN (l_appos) agitation_11/NN (l_conj) shouts_14/NNS
D008619_D014474 NONE mepivacaine_43/NNP (r_pobj) with_42/IN (r_prep) block_41/NN (r_pobj) of_39/IN (r_prep) performance_38/NN (r_pobj) after_37/IN (r_prep) group_28/NN (r_appos) increase_1/NN (l_acl) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) fibrillation_9/NN (l_appos) agitation_11/NN (l_conj) shouts_14/NNS (l_conj) loss_16/NN (l_prep) of_17/IN (l_pobj) consciousness_18/NN
D008619_D004387 NONE mepivacaine_43/NNP (r_pobj) with_42/IN (r_prep) block_41/NN (r_pobj) of_39/IN (r_prep) performance_38/NN (r_pobj) after_37/IN (r_prep) group_28/NN (l_appos) mg_45/NN (l_prep) for_51/IN (l_pobj) correction_52/NN (l_prep) of_53/IN (l_pobj) contracture_56/NN
D004837_D006973 CID adrenaline_47/NN (r_dobj) containing_46/VBG (r_acl) mg_45/NN (r_appos) group_28/NN (r_appos) increase_1/NN (l_prep) in_2/IN (l_pobj) pressure_4/NN
D004837_D001281 CID adrenaline_47/NN (r_dobj) containing_46/VBG (r_acl) mg_45/NN (r_appos) group_28/NN (r_appos) increase_1/NN (l_acl) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) fibrillation_9/NN
D004837_D011595 NONE adrenaline_47/NN (r_dobj) containing_46/VBG (r_acl) mg_45/NN (r_appos) group_28/NN (r_appos) increase_1/NN (l_acl) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) fibrillation_9/NN (l_appos) agitation_11/NN
D004837_D019954 NONE adrenaline_47/NN (r_dobj) containing_46/VBG (r_acl) mg_45/NN (r_appos) group_28/NN (r_appos) increase_1/NN (l_acl) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) fibrillation_9/NN (l_appos) agitation_11/NN (l_conj) shouts_14/NNS
D004837_D014474 NONE adrenaline_47/NN (r_dobj) containing_46/VBG (r_acl) mg_45/NN (r_appos) group_28/NN (r_appos) increase_1/NN (l_acl) accompanied_6/VBN (l_agent) by_7/IN (l_pobj) fibrillation_9/NN (l_appos) agitation_11/NN (l_conj) shouts_14/NNS (l_conj) loss_16/NN (l_prep) of_17/IN (l_pobj) consciousness_18/NN
D004837_D004387 NONE adrenaline_47/NN (r_dobj) containing_46/VBG (r_acl) mg_45/NN (l_prep) for_51/IN (l_pobj) correction_52/NN (l_prep) of_53/IN (l_pobj) contracture_56/NN
1009330
C004658_D003556 NONE choloroaniline_10/NNP (r_nsubj) is_11/VBZ (l_attr) factor_15/NN (l_prep) in_16/IN (l_pobj) cystitis_22/NN
C010882_D003556 CID digluconate_19/NN (r_compound) cystitis_22/NN
D007612_D003556 CID kanamycin_4/NNP (r_compound) colistin_6/NNP (r_pobj) of_3/IN (r_prep) percentage_2/NN (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) cystitis_16/NN
D003091_D003556 CID colistin_6/NNP (r_pobj) of_3/IN (r_prep) percentage_2/NN (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) cystitis_16/NN
D011206_D003556 CID iodine_10/NN (r_compound) irrigations_11/NNS (r_conj) colistin_6/NNP (r_pobj) of_3/IN (r_prep) percentage_2/NN (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) cystitis_16/NN
C005253_D003556 NONE Picloxydine_0/NNP (r_compound) irrigations_1/NNS (r_nsubj) appeared_2/VBD (l_xcomp) have_4/VB (l_dobj) incidence_7/NN (l_prep) of_8/IN (l_pobj) cystitis_10/NN
8170551
D000086_D053040 NONE Acetazolamide_0/NNP (r_npadvmod) induced_2/VBN (r_amod) nephrolithiasis_3/NN
D000086_D053040 NONE acetazolamide_5/NN (r_pobj) of_4/IN (r_prep) complication_3/NN (r_attr) is_1/VBZ (l_nsubj) Nephrolithiasis_0/NNP
D000086_D009468 NONE Acetazolamide_0/NNP (r_npadvmod) induced_2/VBN (r_amod) nephrolithiasis_3/NN (l_appos) implications_5/NNS (l_prep) for_6/IN (l_pobj) treatment_7/NN (l_prep) of_8/IN (l_pobj) disorders_10/NNS
D000086_D007669 CID acetazolamide_3/NNP (r_pobj) on_2/IN (r_prep) patients_1/NNS (r_nsubj) developed_8/VBN (l_dobj) calculi_10/NNS
19211690
D013739_D006973 NONE Testosterone_0/NN (r_npadvmod) dependent_2/JJ (r_amod) hypertension_3/NN
D013739_D006973 NONE Testosterone_0/NN (r_nsubj) contributes_1/VBZ (l_prep) to_2/IN (l_pobj) development_4/NN (l_prep) of_5/IN (l_pobj) hypertension_6/NN
D017673_D006973 NONE salt_11/NN (r_npadvmod) sensitive_13/JJ (r_amod) rats_14/NNS (r_pobj) in_9/IN (r_prep) hypertension_3/NN
D013739_D007674 NONE testosterone_24/NN (l_relcl) causes_27/VBZ (l_dobj) increases_28/NNS (l_prep) in_29/IN (l_pobj) BP_30/NNP (l_conj) injury_33/NN
D013739_D007674 NONE Testosterone_0/NN (r_compound) replacement_1/NN (r_nsubj) increased_6/VBD (l_dobj) BP_7/NNP (l_conj) injury_10/NN
D013739_D007674 NONE Testosterone_0/NN (r_nsubj) contributes_1/VBZ (l_prep) to_2/IN (l_pobj) development_4/NN (l_prep) of_5/IN (l_pobj) hypertension_6/NN (l_conj) injury_9/NN
D000809_D006973 NONE angiotensin_25/NN (r_compound) system_26/NN (r_pobj) of_20/IN (r_prep) upregulation_19/NN (r_pobj) through_18/IN (r_prep) contributes_1/VBZ (l_prep) to_2/IN (l_pobj) development_4/NN (l_prep) of_5/IN (l_pobj) hypertension_6/NN
D000809_D007674 NONE angiotensin_25/NN (r_compound) system_26/NN (r_pobj) of_20/IN (r_prep) upregulation_19/NN (r_pobj) through_18/IN (r_prep) contributes_1/VBZ (l_prep) to_2/IN (l_pobj) development_4/NN (l_prep) of_5/IN (l_pobj) hypertension_6/NN (l_conj) injury_9/NN
20080983
C048833_D012893 NONE modafinil_15/NN (r_pobj) of_11/IN (r_prep) effect_10/NN (l_prep) on_16/IN (l_pobj) sleep_17/NN (l_conj) sleepiness_20/NN
C048833_D012893 NONE Modafinil_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) decrease_22/NN (l_prep) in_23/IN (l_pobj) sleepiness_26/NN
C048833_D012893 NONE modafinil_3/NNP (r_nsubj) promotes_4/VBZ (l_conj) normalizes_8/VBZ (l_conj) decreases_13/VBZ (l_dobj) sleepiness_15/NN
D003042_D012893 CID cocaine_23/NN (r_compound) users_24/NNS (r_pobj) in_21/IN (r_prep) sleep_17/NN (l_conj) sleepiness_20/NN
D003042_D012893 CID cocaine_18/NN (r_compound) users_19/NNS (r_pobj) in_16/IN (r_prep) sleepiness_15/NN
19356307
D012601_D003704 NONE scopolamine_9/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) Components_0/NNS (l_prep) of_1/IN (l_pobj) dementia_6/NN
C008281_D003704 NONE limonene_8/NNP (r_pobj) of_5/IN (r_prep) effects_4/NNS (l_amod) dementia_3/JJ
C032208_D003704 NONE alcohol_13/NN (r_conj) limonene_8/NNP (r_pobj) of_5/IN (r_prep) effects_4/NNS (l_amod) dementia_3/JJ
D012601_D008569 CID scopolamine_12/NN (r_pobj) by_11/IN (r_agent) impaired_10/VBN
D012601_D008569 CID scopolamine_12/NN (r_pobj) by_11/IN (r_agent) impaired_10/VBN (r_acl) memory_9/NN (r_dobj) improve_8/VB (r_acl) ability_6/NN (r_dobj) showed_4/VBD (r_ccomp) relieved_20/VBD (l_dobj) deficit_22/NN (l_prep) of_23/IN (l_pobj) memory_25/NN
C032208_D008569 NONE alcohol_19/NN (r_nsubj) relieved_20/VBD (l_ccomp) showed_4/VBD (l_dobj) ability_6/NN (l_acl) improve_8/VB (l_dobj) memory_9/NN (l_acl) impaired_10/VBN
C032208_D008569 NONE alcohol_19/NN (r_nsubj) relieved_20/VBD (l_dobj) deficit_22/NN (l_prep) of_23/IN (l_pobj) memory_25/NN
7352670
D009599_D006973 NONE nitroprusside_4/RB (r_nsubj) prevented_5/VBN (l_nsubj) hypertensive_1/JJ
D009599_D006973 NONE SNP_2/NNP (r_compound) infusion_3/NN (r_pobj) During_0/IN (r_prep) demonstrated_7/VBD (l_dobj) increase_10/NN (l_prep) in_11/IN (l_pobj) pressure_13/NN
D012504_D006973 NONE saralasin_7/NNP (r_pobj) by_6/IN (r_agent) prevented_5/VBN (l_nsubj) hypertensive_1/JJ
D012504_D006973 NONE saralasin_20/NNP (r_npadvmod) treated_22/VBN (r_amod) animals_23/NNS (r_nsubj) showed_24/VBD (r_advcl) demonstrated_7/VBD (l_dobj) increase_10/NN (l_prep) in_11/IN (l_pobj) pressure_13/NN
D000809_D007022 NONE angiotensin_6/NN (r_compound) system_7/NN (r_appos) renin_4/NN (r_pobj) of_2/IN (r_prep) role_1/NN (r_nsubjpass) evaluated_24/VBN (l_nsubjpass) hypotension_22/NN
D000809_D007022 NONE angiotensin_8/NN (r_compound) system_9/NN (l_prep) in_10/IN (l_pcomp) antagonizing_11/VBG (l_dobj) effects_15/NNS (l_amod) hypotensive_14/JJ
D006221_D007022 CID halothane_15/NNP (r_compound) anesthesia_16/NN (r_pobj) during_14/IN (r_prep) maintenance_10/NN (r_pobj) in_8/IN (r_prep) system_7/NN (r_appos) renin_4/NN (r_pobj) of_2/IN (r_prep) role_1/NN (r_nsubjpass) evaluated_24/VBN (l_nsubjpass) hypotension_22/NN
D006221_D007022 CID halothane_17/NNP (r_pobj) of_16/IN (r_prep) effects_15/NNS (l_amod) hypotensive_14/JJ
D009599_D007022 CID nitroprusside_19/NNP (r_conj) anesthesia_16/NN (r_pobj) during_14/IN (r_prep) maintenance_10/NN (r_pobj) in_8/IN (r_prep) system_7/NN (r_appos) renin_4/NN (r_pobj) of_2/IN (r_prep) role_1/NN (r_nsubjpass) evaluated_24/VBN (l_nsubjpass) hypotension_22/NN
D009599_D007022 CID SNP)-induced_21/NNP (r_det) hypotension_22/NN
D009599_D007022 CID SNP_19/NNP (r_conj) halothane_17/NNP (r_pobj) of_16/IN (r_prep) effects_15/NNS (l_amod) hypotensive_14/JJ
9523805
D011318_D009422 CID prilocaine_11/NNP (r_pobj) with_10/IN (r_prep) incidence_9/NN (r_appos) symptoms_2/NNS
D011318_D009422 CID prilocaine_11/NNP (r_dobj) compares_10/VBZ (l_conj) bupivacaine_15/NN (l_prep) with_16/IN (l_pobj) respect_17/NN (l_prep) to_18/IN (l_pobj) duration_19/NN (l_prep) of_20/IN (l_pobj) action_21/NN (l_prep) of_25/IN (l_pobj) TNSs_26/NNS
D011318_D009422 CID prilocaine_14/NN (r_dobj) receiving_13/VBG (r_acl) patients_12/NNS (r_nsubj) had_20/VBD (l_nsubj) patients_3/NNS (l_acl) receiving_4/VBG (l_dobj) TNSs_7/NNS
D011318_D009422 CID prilocaine_14/NN (r_dobj) receiving_13/VBG (r_acl) patients_12/NNS (r_nsubj) had_20/VBD (l_conj) had_30/VBD (l_dobj) TNSs_31/NNS
D011318_D009422 CID Prilocaine_0/NNP (r_nsubj) be_2/VB (l_advcl) has_12/VBZ (l_dobj) duration_15/NN (l_conj) incidence_21/NN (l_prep) of_22/IN (l_pobj) TNSs_23/NNS
D002045_D009422 NONE bupivacaine_13/VB (r_conj) prilocaine_11/NNP (r_pobj) with_10/IN (r_prep) incidence_9/NN (r_appos) symptoms_2/NNS
D002045_D009422 NONE bupivacaine_19/NN (r_pobj) with_18/IN (r_prep) infrequent_17/JJ (r_acomp) are_16/VBP (r_conj) follow_11/VBP (l_nsubj) symptoms_6/NNS
D002045_D009422 NONE bupivacaine_19/NN (r_pobj) with_18/IN (r_prep) infrequent_17/JJ (r_acomp) are_16/VBP (r_conj) follow_11/VBP (l_nsubj) symptoms_6/NNS (l_appos) TNSs_8/NNS
D002045_D009422 NONE bupivacaine_15/NN (l_prep) with_16/IN (l_pobj) respect_17/NN (l_prep) to_18/IN (l_pobj) duration_19/NN (l_prep) of_20/IN (l_pobj) action_21/NN (l_prep) of_25/IN (l_pobj) TNSs_26/NNS
D002045_D009422 NONE bupivacaine_29/NN (r_dobj) receiving_28/VBG (r_acl) patients_27/NNS (r_pobj) of_25/IN (r_prep) none_24/NN (r_nsubj) had_30/VBD (r_conj) had_20/VBD (l_nsubj) patients_3/NNS (l_acl) receiving_4/VBG (l_dobj) TNSs_7/NNS
D002045_D009422 NONE bupivacaine_29/NN (r_dobj) receiving_28/VBG (r_acl) patients_27/NNS (r_pobj) of_25/IN (r_prep) none_24/NN (r_nsubj) had_30/VBD (l_dobj) TNSs_31/NNS
D008012_D009422 CID lidocaine_16/NN (r_pobj) with_15/IN (r_prep) than_14/IN (r_prep) incidence_9/NN (r_appos) symptoms_2/NNS
D008012_D009422 CID lidocaine_12/NN (r_compound) anesthesia_14/NN (r_dobj) follow_11/VBP (l_nsubj) symptoms_6/NNS
D008012_D009422 CID lidocaine_12/NN (r_compound) anesthesia_14/NN (r_dobj) follow_11/VBP (l_nsubj) symptoms_6/NNS (l_appos) TNSs_8/NNS
D008012_D009422 CID lidocaine_13/NN (r_pobj) with_12/IN (r_prep) compares_10/VBZ (l_conj) bupivacaine_15/NN (l_prep) with_16/IN (l_pobj) respect_17/NN (l_prep) to_18/IN (l_pobj) duration_19/NN (l_prep) of_20/IN (l_pobj) action_21/NN (l_prep) of_25/IN (l_pobj) TNSs_26/NNS
D008012_D009422 CID lidocaine_5/NN (r_nmod) TNSs_7/NNS
D008012_D009422 CID lidocaine_5/NN (r_nmod) TNSs_7/NNS (r_dobj) receiving_4/VBG (r_acl) patients_3/NNS (r_nsubj) had_20/VBD (l_conj) had_30/VBD (l_dobj) TNSs_31/NNS
D008012_D009422 CID lidocaine_5/NN (r_pobj) to_4/IN (r_prep) preferable_3/JJ (r_acomp) be_2/VB (l_advcl) has_12/VBZ (l_dobj) duration_15/NN (l_conj) incidence_21/NN (l_prep) of_22/IN (l_pobj) TNSs_23/NNS
15859940
D016572_D064420 NONE cyclosporine_7/NN (r_nmod) toxicity_11/NN
D016559_D064420 NONE tacrolimus_9/NN (r_npadvmod) cyclosporine_7/NN (r_nmod) toxicity_11/NN
D016572_D057049 CID cyclosporine_18/NN (r_pobj) to_17/IN (r_prep) secondary_15/JJ (r_acomp) was_11/VBD (l_nsubj) cause_7/NN (l_prep) of_8/IN (l_pobj) microangiopathy_10/NNP
3076126
D008148_D009135 NONE lovastatin_23/NN (r_pobj) with_22/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP
D008148_D009212 CID lovastatin_23/NN (r_pobj) with_22/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP (l_acl) associated_2/VBN (l_prep) in_3/IN (l_pobj) cases_5/NNS (l_prep) with_6/IN (l_pobj) myoglobinuria_7/NNP
D008148_D051437 CID lovastatin_23/NN (r_pobj) with_22/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP (l_acl) associated_2/VBN (l_conj) in_10/IN (l_pobj) cases_12/NNS (l_prep) with_13/IN (l_pobj) failure_16/NN
D016572_D009135 CID cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP
D016572_D009212 NONE cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP (l_acl) associated_2/VBN (l_prep) in_3/IN (l_pobj) cases_5/NNS (l_prep) with_6/IN (l_pobj) myoglobinuria_7/NNP
D016572_D051437 NONE cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP (l_acl) associated_2/VBN (l_conj) in_10/IN (l_pobj) cases_12/NNS (l_prep) with_13/IN (l_pobj) failure_16/NN
D015248_D009135 CID gemfibrozil_33/NN (r_conj) cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP
D015248_D009212 NONE gemfibrozil_33/NN (r_conj) cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP (l_acl) associated_2/VBN (l_prep) in_3/IN (l_pobj) cases_5/NNS (l_prep) with_6/IN (l_pobj) myoglobinuria_7/NNP
D015248_D051437 NONE gemfibrozil_33/NN (r_conj) cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP (l_acl) associated_2/VBN (l_conj) in_10/IN (l_pobj) cases_12/NNS (l_prep) with_13/IN (l_pobj) failure_16/NN
D009525_D009135 CID niacin_35/NN (r_conj) gemfibrozil_33/NN (r_conj) cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP
D009525_D009212 NONE niacin_35/NN (r_conj) gemfibrozil_33/NN (r_conj) cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP (l_acl) associated_2/VBN (l_prep) in_3/IN (l_pobj) cases_5/NNS (l_prep) with_6/IN (l_pobj) myoglobinuria_7/NNP
D009525_D051437 NONE niacin_35/NN (r_conj) gemfibrozil_33/NN (r_conj) cyclosporin_31/NN (r_pobj) with_30/IN (r_prep) treated_29/VBN (r_acl) patients_27/NNS (r_pobj) in_26/IN (r_prep) reported_21/VBN (l_nsubjpass) Myopathy_0/NNP (l_acl) associated_2/VBN (l_conj) in_10/IN (l_pobj) cases_12/NNS (l_prep) with_13/IN (l_pobj) failure_16/NN
17615423
D019821_D012206 CID simvastatin_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) to_7/IN (r_prep) secondary_6/JJ (r_amod) rhabdomyolysis_1/NN
D019821_D012206 CID simvastatin_9/NN (l_appos) amiodarone_11/NN (l_conj) atazanavir_14/NNS (l_acl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) rhabdomyolysis_17/NN
D019821_D012206 CID simvastatin_14/NN (r_compound) metabolism_15/NN (r_dobj) inhibit_13/VBP (r_relcl) drugs_11/NNS (r_pobj) of_9/IN (r_prep) presence_8/NN (r_pobj) in_6/IN (r_prep) increased_5/VBN (l_nsubjpass) risk_1/NN (l_prep) of_2/IN (l_pobj) rhabdomyolysis_3/NN
D019821_D058186 CID simvastatin_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) to_7/IN (r_prep) secondary_6/JJ (r_amod) rhabdomyolysis_1/NN (l_conj) failure_5/NN
D019821_D058186 CID simvastatin_9/NN (l_appos) amiodarone_11/NN (l_conj) atazanavir_14/NNS (l_acl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) rhabdomyolysis_17/NN (l_conj) failure_21/NN
D000638_D012206 CID amiodarone_13/NN (r_appos) simvastatin_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) to_7/IN (r_prep) secondary_6/JJ (r_amod) rhabdomyolysis_1/NN
D000638_D012206 CID amiodarone_11/NN (l_conj) atazanavir_14/NNS (l_acl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) rhabdomyolysis_17/NN
D000638_D058186 CID amiodarone_13/NN (r_appos) simvastatin_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) to_7/IN (r_prep) secondary_6/JJ (r_amod) rhabdomyolysis_1/NN (l_conj) failure_5/NN
D000638_D058186 CID amiodarone_11/NN (l_conj) atazanavir_14/NNS (l_acl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) rhabdomyolysis_17/NN (l_conj) failure_21/NN
C413408_D012206 CID atazanavir_16/NNS (r_conj) amiodarone_13/NN (r_appos) simvastatin_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) to_7/IN (r_prep) secondary_6/JJ (r_amod) rhabdomyolysis_1/NN
C413408_D012206 CID atazanavir_14/NNS (l_acl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) rhabdomyolysis_17/NN
C413408_D058186 CID atazanavir_16/NNS (r_conj) amiodarone_13/NN (r_appos) simvastatin_11/NN (r_pobj) of_10/IN (r_prep) use_9/NN (r_pobj) to_7/IN (r_prep) secondary_6/JJ (r_amod) rhabdomyolysis_1/NN (l_conj) failure_5/NN
C413408_D058186 CID atazanavir_14/NNS (l_acl) resulting_15/VBG (l_prep) in_16/IN (l_pobj) rhabdomyolysis_17/NN (l_conj) failure_21/NN
D019821_D015658 NONE Simvastatin_0/NNP (l_conj) medications_11/NNS (l_compound) virus_10/NN
D000638_D015658 NONE amiodarone_2/NN (r_appos) Simvastatin_0/NNP (l_conj) medications_11/NNS (l_compound) virus_10/NN
17020434
D014859_D020521 NONE warfarin_12/NN (r_nsubj) reduces_13/VBZ (l_dobj) risk_15/NN (l_prep) of_16/IN (l_pobj) stroke_17/NN
D014859_D020521 NONE warfarin_8/NN (r_nsubj) is_9/VBZ (l_xcomp) aspirin_12/NN (l_prep) in_13/IN (l_pcomp) preventing_14/VBG (l_dobj) strokes_15/NNS
D001241_D020521 NONE aspirin_24/NN (r_nsubj) reduces_26/VBZ (r_conj) reduces_13/VBZ (l_dobj) risk_15/NN (l_prep) of_16/IN (l_pobj) stroke_17/NN
D001241_D020521 NONE aspirin_12/NN (l_prep) in_13/IN (l_pcomp) preventing_14/VBG (l_dobj) strokes_15/NNS
C426686_D004617 NONE Ximelagatran_0/NN (r_nsubjpass) found_9/VBN (l_xcomp) be_11/VB (l_prep) in_19/IN (l_pobj) prevention_21/NN (l_prep) of_22/IN (l_pobj) events_24/NNS
C426686_D056486 CID Ximelagatran_0/NN (r_nsubjpass) found_9/VBN (l_conj) withdrawn_30/VBN (l_prep) because_31/IN (l_pobj) tests_36/NNS (l_compound) function_35/NN
D014812_D004617 NONE K_16/NNP (r_compound) drugs_18/NNS (r_pobj) as_14/IN (r_prep) efficient_13/JJ (r_acomp) be_11/VB (l_prep) in_19/IN (l_pobj) prevention_21/NN (l_prep) of_22/IN (l_pobj) events_24/NNS
D014812_D056486 NONE K_16/NNP (r_compound) drugs_18/NNS (r_pobj) as_14/IN (r_prep) efficient_13/JJ (r_acomp) be_11/VB (r_xcomp) found_9/VBN (l_conj) withdrawn_30/VBN (l_prep) because_31/IN (l_pobj) tests_36/NNS (l_compound) function_35/NN
C055162_D001281 NONE Clopidogrel_7/NNP (l_compound) Fibrillation_6/NNP
C055162_D001281 NONE clopidogrel_28/NN (r_appos) therapy_26/NN (r_pobj) to_24/IN (r_prep) superior_23/JJ (r_acomp) is_22/VBZ (r_ccomp) demonstrated_19/VBN (l_nsubj) study_17/NN (l_nmod) Trial_8/NNP (l_compound) Clopidogrel_7/NNP (l_compound) Fibrillation_6/NNP
C055162_D004617 NONE Clopidogrel_7/NNP (r_compound) Trial_8/NNP (r_nmod) study_17/NN (r_nsubj) demonstrated_19/VBN (l_ccomp) is_22/VBZ (l_acomp) superior_23/JJ (l_prep) in_32/IN (l_pobj) events_37/NNS
C055162_D004617 NONE clopidogrel_28/NN (r_appos) therapy_26/NN (r_pobj) to_24/IN (r_prep) superior_23/JJ (l_prep) in_32/IN (l_pobj) events_37/NNS
C081309_D001281 NONE Irbesartan_10/NNP (r_pobj) with_9/IN (r_prep) Trial_8/NNP (l_compound) Clopidogrel_7/NNP (l_compound) Fibrillation_6/NNP
C081309_D004617 NONE Irbesartan_10/NNP (r_pobj) with_9/IN (r_prep) Trial_8/NNP (r_nmod) study_17/NN (r_nsubj) demonstrated_19/VBN (l_ccomp) is_22/VBZ (l_acomp) superior_23/JJ (l_prep) in_32/IN (l_pobj) events_37/NNS
D014859_D001281 NONE warfarin_21/NN (r_nsubj) is_22/VBZ (r_ccomp) demonstrated_19/VBN (l_nsubj) study_17/NN (l_nmod) Trial_8/NNP (l_compound) Clopidogrel_7/NNP (l_compound) Fibrillation_6/NNP
D014859_D004617 NONE warfarin_21/NN (r_nsubj) is_22/VBZ (l_acomp) superior_23/JJ (l_prep) in_32/IN (l_pobj) events_37/NNS
D001241_D001281 NONE aspirin_30/NN (r_conj) clopidogrel_28/NN (r_appos) therapy_26/NN (r_pobj) to_24/IN (r_prep) superior_23/JJ (r_acomp) is_22/VBZ (r_ccomp) demonstrated_19/VBN (l_nsubj) study_17/NN (l_nmod) Trial_8/NNP (l_compound) Clopidogrel_7/NNP (l_compound) Fibrillation_6/NNP
D001241_D004617 NONE aspirin_30/NN (r_conj) clopidogrel_28/NN (r_appos) therapy_26/NN (r_pobj) to_24/IN (r_prep) superior_23/JJ (l_prep) in_32/IN (l_pobj) events_37/NNS
C479958_D001281 NONE Idraparinux_0/NNP (r_nsubjpass) evaluated_9/VBN (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) fibrillation_14/NN
D000809_D001281 NONE Angiotensin_0/NN (r_npadvmod) converting_2/VBG (r_amod) inhibitors_4/NNS (r_nsubj) hold_12/VBP (l_prep) in_14/IN (l_pobj) fibrillation_16/NN
D000809_D020257 NONE Angiotensin_0/NN (r_npadvmod) converting_2/VBG (r_amod) inhibitors_4/NNS (r_nsubj) hold_12/VBP (l_prep) through_17/IN (l_pobj) remodelling_19/NN
D000804_D001281 NONE II_7/NNP (r_conj) inhibitors_4/NNS (r_nsubj) hold_12/VBP (l_prep) in_14/IN (l_pobj) fibrillation_16/NN
D000804_D020257 NONE II_7/NNP (r_conj) inhibitors_4/NNS (r_nsubj) hold_12/VBP (l_prep) through_17/IN (l_pobj) remodelling_19/NN
11379838
D000928_D001714 CID Antidepressant_0/NN (r_npadvmod) induced_2/VBN (r_amod) mania_3/NN
D000928_D001714 CID Antidepressant_0/NN (r_npadvmod) induced_2/VBN (r_amod) mania_3/NN (l_prep) in_4/IN (l_pobj) patients_6/NNS (l_amod) bipolar_5/JJ
D000928_D001714 CID antidepressants_10/NNS (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) mania_7/NN
D000928_D001714 CID antidepressants_10/NNS (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) mania_7/NN (r_pobj) to_6/IN (r_prep) switching_5/VBG (r_pcomp) of_4/IN (r_prep) risks_3/NNS (r_pobj) about_1/IN (r_prep) Concerns_0/NNS (r_nsubj) continue_11/VBP (l_xcomp) interfere_13/VB (l_prep) with_14/IN (l_pobj) establishment_16/NN (l_prep) of_17/IN (l_pobj) paradigm_21/NN (l_prep) for_22/IN (l_pobj) depression_24/NN
D000928_D001714 CID antidepressant_14/NN (r_compound) therapy_15/NN (r_pobj) of_13/IN (r_prep) type_12/NN (r_appos) episodes_10/NNS (r_pobj) of_7/IN (r_prep) number_6/NN (r_appos) I_0/PRP (l_prep) vs._1/IN (l_pobj) II_3/NNP
D000928_D001714 CID antidepressant_14/NN (r_compound) therapy_15/NN (r_pobj) of_13/IN (r_prep) type_12/NN (r_appos) episodes_10/NNS (l_amod) manic_9/JJ
D000928_D001714 CID antidepressant_21/JJ (r_compound) drugs_22/NNS (r_pobj) vs._20/FW (r_prep) therapy_19/NN (r_oprd) used_16/VBN (r_acl) type_12/NN (r_appos) episodes_10/NNS (r_pobj) of_7/IN (r_prep) number_6/NN (r_appos) I_0/PRP (l_prep) vs._1/IN (l_pobj) II_3/NNP
D000928_D001714 CID antidepressant_21/JJ (r_compound) drugs_22/NNS (r_pobj) vs._20/FW (r_prep) therapy_19/NN (r_oprd) used_16/VBN (r_acl) type_12/NN (r_appos) episodes_10/NNS (l_amod) manic_9/JJ
D017367_D001714 CID inhibitors_31/NNS (r_appos) episodes_10/NNS (r_pobj) of_7/IN (r_prep) number_6/NN (r_appos) I_0/PRP (l_prep) vs._1/IN (l_pobj) II_3/NNP
D017367_D001714 CID inhibitors_31/NNS (r_appos) episodes_10/NNS (l_amod) manic_9/JJ
D017367_D001714 CID SSRIs_33/NNS (r_appos) inhibitors_31/NNS (r_appos) episodes_10/NNS (r_pobj) of_7/IN (r_prep) number_6/NN (r_appos) I_0/PRP (l_prep) vs._1/IN (l_pobj) II_3/NNP
D017367_D001714 CID SSRIs_33/NNS (r_appos) inhibitors_31/NNS (r_appos) episodes_10/NNS (l_amod) manic_9/JJ
D017367_D001714 CID SSRIs_29/NNS (r_pobj) with_28/IN (r_prep) treated_27/VBN (r_acl) patients_26/NNS (r_pobj) of_25/IN (r_prep) subgroup_24/NN (r_pobj) of_22/IN (r_prep) %_21/NN (r_pobj) in_19/IN (r_prep) experienced_42/JJ (r_conj) occurred_5/VBD (l_nsubj) Switches_0/NNS (l_prep) to_1/IN (l_pobj) hypomania_2/NN
D017367_D001714 CID SSRIs_29/NNS (r_pobj) with_28/IN (r_prep) treated_27/VBN (r_acl) patients_26/NNS (r_pobj) of_25/IN (r_prep) subgroup_24/NN (r_pobj) of_22/IN (r_prep) %_21/NN (r_pobj) in_19/IN (r_prep) experienced_42/JJ (r_conj) occurred_5/VBD (l_nsubj) Switches_0/NNS (l_prep) to_1/IN (l_pobj) hypomania_2/NN (l_conj) mania_4/NN
D017367_D001714 CID SSRIs_29/NNS (r_pobj) with_28/IN (r_prep) treated_27/VBN (r_acl) patients_26/NNS (r_pobj) of_25/IN (r_prep) subgroup_24/NN (r_pobj) of_22/IN (r_prep) %_21/NN (r_pobj) in_19/IN (r_prep) experienced_42/JJ (l_dobj) episodes_44/NNS (l_amod) manic_43/JJ
D017367_D001714 CID SSRIs_29/NNS (r_pobj) with_28/IN (r_prep) treated_27/VBN (r_acl) patients_26/NNS (r_pobj) of_25/IN (r_prep) subgroup_24/NN (r_pobj) of_22/IN (r_prep) %_21/NN (r_pobj) in_19/IN (r_prep) experienced_42/JJ (l_conj) experienced_54/VBN (l_dobj) episodes_56/NNS (l_amod) hypomanic_55/JJ
D008094_D001714 NONE lithium_44/NN (r_appos) stabilizers_42/NNS (r_pobj) of_40/IN (r_prep) use_37/NN (r_conj) number_6/NN (r_appos) I_0/PRP (l_prep) vs._1/IN (l_pobj) II_3/NNP
D008094_D001714 NONE lithium_44/NN (r_appos) stabilizers_42/NNS (r_pobj) of_40/IN (r_prep) use_37/NN (r_conj) number_6/NN (l_prep) of_7/IN (l_pobj) episodes_10/NNS (l_amod) manic_9/JJ
12041669
D000961_D000741 NONE globulin_1/NN (l_prep) in_2/IN (l_pobj) treatment_4/NN (l_prep) of_5/IN (l_pobj) anemia_12/NN
D000961_D000741 NONE globulin_5/NN (r_compound) therapy_6/NN (r_dobj) received_3/VBD (l_prep) for_7/IN (l_pobj) anemia_9/NN
D000961_D000741 NONE globulin_3/NN (r_pobj) of_1/IN (r_prep) Use_0/NN (r_nsubj) be_5/VB (l_attr) treatment_8/NN (l_prep) of_9/IN (l_pobj) anemia_16/NN
D010396_D000741 CID penicillamine_8/NN (r_npadvmod) induced_10/VBN (r_amod) anemia_12/NN
D010396_D000741 CID penicillamine_14/NN (r_compound) therapy_15/NN (r_nsubjpass) described_17/VBN (l_nsubjpass) patient_1/NN (l_relcl) received_3/VBD (l_prep) for_7/IN (l_pobj) anemia_9/NN
D010396_D000741 CID penicillamine_12/NN (r_npadvmod) induced_14/VBN (r_amod) anemia_16/NN
10526274
C056507_D002289 NONE Gemcitabine_0/NNP (l_prep) in_3/IN (l_pobj) patients_8/NNS (l_compound) carcinoma_7/NN
C056507_D002289 NONE GEM_12/NNP (l_prep) in_15/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) NSCLC_20/NNS
C030852_D002289 NONE vinorelbine_2/NN (r_conj) Gemcitabine_0/NNP (l_prep) in_3/IN (l_pobj) patients_8/NNS (l_compound) carcinoma_7/NN
C030852_D002289 NONE VNB_14/NNP (r_conj) GEM_12/NNP (l_prep) in_15/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) NSCLC_20/NNS
D002945_D002289 NONE cisplatin_20/NN (r_dobj) receive_19/VB (r_relcl) age_9/NN (l_nsubj) Gemcitabine_0/NNP (l_prep) in_3/IN (l_pobj) patients_8/NNS (l_compound) carcinoma_7/NN
D002945_D002289 NONE cisplatin_28/NN (r_dobj) receiving_27/VBG (r_pcomp) to_26/IN (r_prep) contraindication_25/NN (r_pobj) with_23/IN (r_prep) those_22/DT (r_conj) combination_10/NN (l_prep) of_11/IN (l_pobj) GEM_12/NNP (l_prep) in_15/IN (l_pobj) patients_17/NNS (l_prep) with_18/IN (l_pobj) NSCLC_20/NNS
C030852_D064420 NONE vinorelbine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_nsubj) obtain_18/VB (l_dobj) rate_21/NN (l_prep) with_31/IN (l_pobj) toxicity_33/NN
C030852_D064420 NONE VNB_10/NNP (r_appos) vinorelbine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_nsubj) obtain_18/VB (l_dobj) rate_21/NN (l_prep) with_31/IN (l_pobj) toxicity_33/NN
C030852_D064420 NONE VNB_14/NNP (r_conj) GEM_12/NNP (r_pobj) of_11/IN (r_prep) combination_10/NN (r_pobj) of_8/IN (r_prep) efficacy_5/NN (l_conj) toxicity_7/NN
C056507_D064420 NONE gemcitabine_13/NN (r_conj) vinorelbine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_nsubj) obtain_18/VB (l_dobj) rate_21/NN (l_prep) with_31/IN (l_pobj) toxicity_33/NN
C056507_D064420 NONE GEM_15/NNP (r_appos) gemcitabine_13/NN (r_conj) vinorelbine_8/NNP (r_pobj) with_7/IN (r_prep) therapy_6/NN (r_nsubj) obtain_18/VB (l_dobj) rate_21/NN (l_prep) with_31/IN (l_pobj) toxicity_33/NN
C056507_D064420 NONE GEM_12/NNP (r_pobj) of_11/IN (r_prep) combination_10/NN (r_pobj) of_8/IN (r_prep) efficacy_5/NN (l_conj) toxicity_7/NN
D002945_D064420 NONE cisplatin_28/NN (r_dobj) receiving_27/VBG (r_pcomp) to_26/IN (r_prep) contraindication_25/NN (r_pobj) with_23/IN (r_prep) those_22/DT (r_conj) combination_10/NN (r_pobj) of_8/IN (r_prep) efficacy_5/NN (l_conj) toxicity_7/NN
2894766
D012460_D008180 CID Sulfasalazine_0/NNP (r_npadvmod) induced_2/VBN (r_amod) erythematosus_4/NN
D012460_D008180 CID sulfasalazine_7/NN (r_npadvmod) induced_9/VBN (r_amod) lupus_10/NN
D012460_D008180 CID sulfasalazine_3/NN (r_dobj) use_2/VBP (r_relcl) Physicians_0/NNS (r_nsubj) be_12/VB (l_acomp) aware_13/JJ (l_prep) of_14/IN (l_pobj) signs_16/NNS (l_prep) of_17/IN (l_pobj) syndrome_22/NN
D012460_D008180 CID sulfasalazine_18/NN (r_npadvmod) induced_20/VBN (r_amod) syndrome_22/NN
D012460_D011014 CID sulfasalazine_29/NN (r_compound) therapy_30/NN (r_dobj) receiving_25/VBG (r_relcl) man_21/NN (r_pobj) in_16/IN (r_prep) developed_15/VBD (r_acl) autoantibodies_14/NNS (r_conj) evidence_7/NN (r_appos) Pneumonitis_0/NNP
D012460_D010996 CID sulfasalazine_29/NN (r_compound) therapy_30/NN (r_dobj) receiving_25/VBG (r_relcl) man_21/NN (r_pobj) in_16/IN (r_prep) developed_15/VBD (r_acl) autoantibodies_14/NNS (r_conj) evidence_7/NN (r_appos) Pneumonitis_0/NNP (l_appos) effusions_4/NNS
D012460_D002305 CID sulfasalazine_29/NN (r_compound) therapy_30/NN (r_dobj) receiving_25/VBG (r_relcl) man_21/NN (r_pobj) in_16/IN (r_prep) developed_15/VBD (r_acl) autoantibodies_14/NNS (r_conj) evidence_7/NN (l_prep) of_8/IN (l_pobj) tamponade_10/NN
D012460_D003093 NONE sulfasalazine_29/NN (r_compound) therapy_30/NN (l_prep) for_31/IN (l_pobj) colitis_34/NN
D012460_D012700 NONE sulfasalazine_7/NN (r_npadvmod) induced_9/VBN (r_amod) lupus_10/NN (l_relcl) manifested_13/VBD (l_prep) with_14/IN (l_pobj) involvement_19/NN (l_nmod) serositis_15/NN
D012460_D015212 NONE sulfasalazine_3/NN (r_dobj) use_2/VBP (l_xcomp) treat_5/VB (l_prep) with_7/IN (l_pobj) disease_10/NN
D012460_D015212 NONE sulfasalazine_18/NN (r_npadvmod) induced_20/VBN (r_amod) syndrome_22/NN (r_pobj) of_17/IN (r_prep) signs_16/NNS (r_pobj) of_14/IN (r_prep) aware_13/JJ (r_acomp) be_12/VB (l_nsubj) Physicians_0/NNS (l_relcl) use_2/VBP (l_xcomp) treat_5/VB (l_prep) with_7/IN (l_pobj) disease_10/NN
11431197
D011899_D009395 CID Ranitidine_0/NN (r_npadvmod) induced_2/VBN (r_amod) nephritis_5/NN
D011899_D009395 CID ranitidine_5/NN (r_npadvmod) induced_7/VBN (r_amod) nephritis_10/NN
8302922
D000527_D007022 CID E1_5/NN (l_conj) hypotension_9/NN
D000527_D007022 CID E1_6/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (r_dobj) evaluate_1/VB (r_advcl) induced_15/VBN (l_dobj) hypotension_16/NN
D000527_D007022 CID PGE1_8/NNP (r_appos) E1_6/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (r_dobj) evaluate_1/VB (r_advcl) induced_15/VBN (l_dobj) hypotension_16/NN
D000527_D007022 CID PGE1_2/NNP (r_nmod) product_10/NN (r_dobj) starting_1/VBG (r_pcomp) After_0/IN (r_prep) decreased_14/VBD (l_conj) remained_34/VBD (l_nsubj) degree_28/NN (l_prep) of_29/IN (l_pobj) hypotension_30/NN
D000527_D007022 CID PGE1_33/NNP (r_pobj) to_32/IN (r_pcomp) due_31/IN (r_prep) degree_28/NN (l_prep) of_29/IN (l_pobj) hypotension_30/NN
D000527_D007022 CID PGE1_4/NNP (r_nsubj) be_6/VB (l_prep) for_10/IN (l_pobj) anaesthesia_12/NN (l_amod) hypotensive_11/JJ
D014294_D007022 CID trimethaphan_7/NNP (r_npadvmod) induced_8/VBN (r_amod) hypotension_9/NN
D014294_D007022 CID trimethaphan_11/NNP (r_nsubj) induced_15/VBN (l_dobj) hypotension_16/NN
D014294_D007022 CID TMP_13/NNP (r_appos) trimethaphan_11/NNP (r_nsubj) induced_15/VBN (l_dobj) hypotension_16/NN
D014294_D007022 CID TMP_4/NNP (r_conj) PGE1_2/NNP (r_nmod) product_10/NN (r_dobj) starting_1/VBG (r_pcomp) After_0/IN (r_prep) decreased_14/VBD (l_conj) remained_34/VBD (l_nsubj) degree_28/NN (l_prep) of_29/IN (l_pobj) hypotension_30/NN
D014294_D007022 CID TMP_9/NNP (r_pobj) to_8/IN (r_prep) preferable_7/JJ (r_acomp) be_6/VB (l_prep) for_10/IN (l_pobj) anaesthesia_12/NN (l_amod) hypotensive_11/JJ
D014294_D007022 CID TMP_17/NNP (r_nsubj) decreased_18/VBD (r_advcl) be_6/VB (l_prep) for_10/IN (l_pobj) anaesthesia_12/NN (l_amod) hypotensive_11/JJ
D007530_D007022 NONE isoflurane_47/JJ (r_amod) anaesthesia_48/NN (r_pobj) under_46/IN (r_prep) underwent_40/VBD (r_relcl) patients_38/NNS (r_pobj) in_36/IN (r_prep) using_31/VBG (r_advcl) measured_30/VBN (l_ccomp) induced_15/VBN (l_dobj) hypotension_16/NN
15009014
D002211_D006940 CID Capsaicin_0/NN (r_nsubj) applied_7/VBN (l_prep) to_8/IN (l_pobj) increases_14/NNS (l_prep) in_15/IN (l_pobj) flow_20/NN
D001285_D006940 NONE atropine_16/NNP (r_pobj) of_15/IN (r_prep) administration_14/NN (r_pobj) by_10/IN (r_agent) abolished_9/VBN (l_nsubjpass) increases_2/NNS (l_prep) in_3/IN (l_pobj) flow_6/NN
18809400
D008063_D028361 NONE acid_3/NN (r_nsubj) prevents_4/VBZ (l_dobj) damage_6/NN
D008063_D028361 NONE acid_7/NN (r_nsubj) is_8/VBZ (l_advcl) plays_18/VBZ (l_nsubj) damage_17/NN
D008063_D028361 NONE acid_35/NN (r_pobj) of_31/IN (r_prep) effects_30/NNS (r_nsubj) depend_36/VBP (r_conj) plays_18/VBZ (l_nsubj) damage_17/NN
D008063_D028361 NONE acid_3/NN (r_nsubj) exerts_4/VBZ (r_ccomp) rescues_16/VBZ (l_dobj) toxicity_19/NN
D008063_D020258 NONE acid_3/NN (r_nsubj) prevents_4/VBZ (l_dobj) damage_6/NN (l_conj) neurotoxicity_8/NN
D008063_D020258 NONE acid_7/NN (r_nsubj) is_8/VBZ (l_acomp) neuroprotective_9/JJ (l_prep) against_10/IN (l_pobj) neurotoxicity_13/NN
D008063_D020258 NONE acid_35/NN (r_pobj) of_31/IN (r_prep) effects_30/NNS (r_nsubj) depend_36/VBP (r_conj) plays_18/VBZ (r_advcl) is_8/VBZ (l_acomp) neuroprotective_9/JJ (l_prep) against_10/IN (l_pobj) neurotoxicity_13/NN
D008063_D020258 NONE acid_3/NN (r_nsubj) exerts_4/VBZ (l_dobj) effects_6/NNS (l_prep) against_7/IN (l_pobj) neurotoxicity_10/NN
D008063_D009422 NONE acid_3/NN (r_nsubj) prevents_4/VBZ (l_dobj) damage_6/NN (l_prep) in_9/IN (l_pobj) neuropathy_12/NN
D008063_D009410 NONE acid_7/NN (r_nsubj) is_8/VBZ (l_advcl) plays_18/VBZ (l_dobj) role_21/NN (l_prep) in_22/IN (l_pobj) cascade_25/NN
D008063_D009410 NONE acid_35/NN (r_pobj) of_31/IN (r_prep) effects_30/NNS (r_nsubj) depend_36/VBP (r_conj) plays_18/VBZ (l_dobj) role_21/NN (l_prep) in_22/IN (l_pobj) cascade_25/NN
D008063_D001480 NONE acid_10/NN (r_pobj) of_6/IN (r_prep) efficacy_5/NN (l_prep) in_11/IN (l_pcomp) preventing_12/VBG (l_dobj) damage_14/NN
D008063_D001480 NONE acid_34/NN (r_conj) agents_29/NNS (r_pobj) to_27/IN (r_prep) exposure_26/NN (r_pobj) after_25/IN (r_prep) preventing_12/VBG (l_dobj) damage_14/NN
D002945_D028361 NONE cisplatin_5/NN (r_nmod) cause_8/VBP (l_appos) impairment_11/NN
D002945_D028361 NONE cisplatin_13/NN (r_npadvmod) induced_14/VBN (r_amod) neurotoxicity_15/NN (r_conj) paclitaxel_11/NN (r_pobj) in_10/IN (r_prep) event_8/NN (r_attr) is_4/VBZ (l_nsubj) toxicity_3/NN
D017239_D028361 NONE paclitaxel_7/NN (r_conj) cisplatin_5/NN (r_nmod) cause_8/VBP (l_appos) impairment_11/NN
D017239_D028361 NONE paclitaxel_11/NN (r_pobj) in_10/IN (r_prep) event_8/NN (r_attr) is_4/VBZ (l_nsubj) toxicity_3/NN
D017239_D020258 NONE paclitaxel_11/NN (l_conj) neurotoxicity_15/NN
D002945_D020258 NONE cisplatin_13/NN (r_npadvmod) induced_14/VBN (r_amod) neurotoxicity_15/NN
D008063_D010523 NONE acid_7/NN (r_nsubj) reduce_9/VB (l_dobj) risk_11/NN (l_prep) of_12/IN (l_pcomp) developing_13/VBG (l_dobj) toxicity_16/NN
10579464
C121249_D006948 NONE NRA0160_0/NNP (r_nsubj) antagonized_3/VBD (l_dobj) hyperactivity_5/NN
D003024_D006948 NONE clozapine_2/NNP (r_conj) NRA0160_0/NNP (r_nsubj) antagonized_3/VBD (l_dobj) hyperactivity_5/NN
D008694_D006948 CID methamphetamine_8/NN (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) hyperactivity_5/NN
D008694_D006948 CID MAP_10/NNP (r_appos) methamphetamine_8/NN (r_pobj) by_7/IN (r_agent) induced_6/VBN (r_acl) hyperactivity_5/NN
C121249_D002375 CID NRA0160_0/NNP (r_nsubj) induced_4/VBD (l_dobj) catalepsy_5/NN
D003024_D002375 CID clozapine_2/NNP (r_conj) NRA0160_0/NNP (r_nsubj) induced_4/VBD (l_dobj) catalepsy_5/NN
9812111
D006220_D011618 NONE haloperidol_11/NNP (r_pobj) of_10/IN (r_prep) trial_9/NN (l_prep) for_12/IN (l_pobj) psychosis_13/NN
D006220_D011618 NONE haloperidol_17/NN (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) of_13/IN (r_prep) effects_12/NNS (l_prep) in_20/IN (l_pobj) treatment_22/NN (l_prep) of_23/IN (l_pobj) psychosis_24/NN
D006220_D011618 NONE haloperidol_12/NN (r_dobj) completed_5/VBD (r_relcl) patients_3/NNS (r_pobj) For_0/IN (r_prep) was_13/VBD (l_acomp) efficacious_14/JJ (l_prep) for_25/IN (l_pobj) scores_26/NNS (l_prep) on_27/IN (l_pobj) factor_34/NN (l_compound) psychosis_33/NN
D006220_D011618 NONE haloperidol_22/NN (r_pobj) to_17/IN (r_prep) superior_16/JJ (r_conj) efficacious_14/JJ (l_prep) for_25/IN (l_pobj) scores_26/NNS (l_prep) on_27/IN (l_pobj) factor_34/NN (l_compound) psychosis_33/NN
D006220_D011618 NONE haloperidol_6/NNP (r_pobj) with_5/IN (r_prep) observed_4/VBN (r_acl) window_3/NN (r_nsubj) apply_9/VB (l_prep) to_10/IN (l_pobj) neuroleptics_12/NNS (l_acl) used_13/VBN (l_prep) with_19/IN (l_pobj) psychosis_20/NN
D006220_D019958 NONE haloperidol_11/NNP (r_pobj) of_10/IN (r_prep) trial_9/NN (l_prep) for_12/IN (l_pobj) psychosis_13/NN (l_conj) behaviors_16/NNS
D006220_D019958 NONE haloperidol_17/NN (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) of_13/IN (r_prep) effects_12/NNS (l_prep) in_20/IN (l_pobj) treatment_22/NN (l_prep) of_23/IN (l_pobj) psychosis_24/NN (l_conj) behaviors_27/NNS
D006220_D019958 NONE haloperidol_6/NNP (r_pobj) with_5/IN (r_prep) observed_4/VBN (r_acl) window_3/NN (r_nsubj) apply_9/VB (l_prep) to_10/IN (l_pobj) neuroleptics_12/NNS (l_acl) used_13/VBN (l_prep) with_19/IN (l_pobj) psychosis_20/NN (l_conj) behaviors_23/NNS
D006220_D000544 NONE haloperidol_11/NNP (r_pobj) of_10/IN (r_prep) trial_9/NN (l_prep) in_17/IN (l_pobj) disease_20/NN
D006220_D000544 NONE haloperidol_17/NN (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) of_13/IN (r_prep) effects_12/NNS (l_prep) in_20/IN (l_pobj) treatment_22/NN (l_prep) in_28/IN (l_pobj) patients_29/NNS (l_prep) with_30/IN (l_pobj) disease_33/NN
D006220_D000544 NONE haloperidol_20/NNP (r_npadvmod) dose_30/NN (r_nsubjpass) compared_48/VBN (l_prep) in_49/IN (l_pobj) outpatients_51/NNS (l_prep) with_52/IN (l_pobj) disease_55/NN
D006220_D000544 NONE haloperidol_34/NNP (r_conj) dose_30/NN (r_nsubjpass) compared_48/VBN (l_prep) in_49/IN (l_pobj) outpatients_51/NNS (l_prep) with_52/IN (l_pobj) disease_55/NN
D006220_D000544 NONE haloperidol_6/NNP (r_pobj) with_5/IN (r_prep) observed_4/VBN (r_acl) window_3/NN (r_nsubj) apply_9/VB (l_prep) to_10/IN (l_pobj) neuroleptics_12/NNS (l_acl) used_13/VBN (l_prep) in_14/IN (l_pobj) patients_18/NNS (l_compound) disease_17/NN
D006220_D011595 NONE haloperidol_12/NN (r_dobj) completed_5/VBD (r_relcl) patients_3/NNS (r_pobj) For_0/IN (r_prep) was_13/VBD (l_acomp) efficacious_14/JJ (l_prep) for_25/IN (l_conj) on_36/IN (l_pobj) agitation_38/NN
D006220_D011595 NONE haloperidol_22/NN (r_pobj) to_17/IN (r_prep) superior_16/JJ (r_conj) efficacious_14/JJ (l_prep) for_25/IN (l_conj) on_36/IN (l_pobj) agitation_38/NN
D006220_D001480 CID haloperidol_8/NNP (r_pobj) for_7/IN (r_prep) profile_6/NN (r_dobj) indicated_2/VBD (l_advcl) developed_22/VBN (l_advmod) moderate_23/JJ (l_prep) to_24/IN (l_pobj) signs_27/NNS
1468485
D010100_D006470 NONE oxygen_1/NN (r_compound) therapy_2/NN (l_prep) for_3/IN (l_pobj) control_4/NN (l_prep) of_5/IN (l_pobj) cystitis_11/NN
D010100_D003556 NONE oxygen_1/NN (r_compound) therapy_2/NN (l_prep) for_3/IN (l_pobj) control_4/NN (l_prep) of_5/IN (l_pobj) cystitis_11/NN
D003520_D006470 CID cyclophosphamide_7/NN (r_npadvmod) induced_9/VBN (r_amod) cystitis_11/NN
D003520_D006470 CID cyclophosphamide_10/NN (r_compound) therapy_11/NN (r_pobj) due_8/IN (r_prep) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) cystitis_7/NN
D003520_D006470 CID cyclophosphamide_16/NN (r_npadvmod) induced_18/VBN (r_amod) cystitis_20/NN
D003520_D003556 CID cyclophosphamide_7/NN (r_npadvmod) induced_9/VBN (r_amod) cystitis_11/NN
D003520_D003556 CID cyclophosphamide_10/NN (r_compound) therapy_11/NN (r_pobj) due_8/IN (r_prep) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) cystitis_7/NN
D003520_D003556 CID cyclophosphamide_16/NN (r_npadvmod) induced_18/VBN (r_amod) cystitis_20/NN
D003520_D014890 NONE cyclophosphamide_10/NN (r_compound) therapy_11/NN (l_prep) for_12/IN (l_pobj) granulomatosis_15/NN
D015237_D006470 NONE alpha_14/NN (r_pobj) of_11/IN (r_prep) instillation_10/NN (r_conj) saline_8/NN (r_pobj) with_6/IN (r_prep) irrigation_5/NN (r_pobj) including_3/VBG (r_prep) treatment_1/NN (r_nsubj) failed_16/VBD (l_xcomp) control_19/VB (l_dobj) hemorrhage_20/NN
9406968
D014667_D003919 NONE vasopressin_5/NN (r_compound) gene_6/NN (r_pobj) of_4/IN (r_prep) expression_3/NN (r_pobj) of_1/IN (r_prep) Upregulation_0/NNP (r_nsubj) insipidus_19/NN
D008094_D003919 NONE lithium_15/NN (r_npadvmod) induced_17/VBN (r_amod) diabetes_18/NN (r_pobj) of_13/IN (r_prep) nuclei_12/NNS (r_pobj) in_7/IN (r_prep) expression_3/NN (r_pobj) of_1/IN (r_prep) Upregulation_0/NNP (r_nsubj) insipidus_19/NN
D008094_D003919 NONE Li_35/NNP (r_npadvmod) induced_37/VBN (r_amod) diabetes_38/NN (r_pobj) of_33/IN (r_prep) SON_32/NNP (r_conj) PVN_29/NNP (r_pobj) in_27/IN (r_prep) expression_26/NN (r_pobj) of_23/IN (r_prep) upregulation_22/NN (r_conj) elevation_16/NN (r_pobj) to_14/IN (r_prep) contribute_13/VB (l_npadvmod) insipidus_39/NN
D001127_D011141 NONE vasopressin_4/NN (r_pobj) of_2/IN (r_prep) expression_1/NN (r_nsubjpass) investigated_22/VBN (l_prep) in_23/IN (l_pobj) rats_24/NNS (l_prep) with_25/IN (l_pobj) lithium_26/NN (l_appos) polyuria_29/NN
D001127_D011141 NONE AVP_6/NNP (r_nmod) gene_8/NN (r_appos) vasopressin_4/NN (r_pobj) of_2/IN (r_prep) expression_1/NN (r_nsubjpass) investigated_22/VBN (l_prep) in_23/IN (l_pobj) rats_24/NNS (l_prep) with_25/IN (l_pobj) lithium_26/NN (l_appos) polyuria_29/NN
D008094_D011141 NONE lithium_26/NN (l_appos) polyuria_29/NN
D008094_D011141 NONE Li)-induced_28/JJ (r_amod) polyuria_29/NN
D018021_D011141 CID LiCl_9/NNP (r_dobj) contained_8/VBD (r_relcl) diet_6/NN (r_dobj) consuming_4/VBG (l_advcl) developed_19/VBD (l_dobj) polyuria_21/NN
D001127_D003681 NONE AVP_19/NNP (r_pobj) of_17/IN (r_prep) elevation_16/NN (r_pobj) to_14/IN (r_prep) contribute_13/VB (l_nsubj) dehydration_4/NN
D001127_D003681 NONE AVP_24/NNP (r_compound) expression_26/NN (r_pobj) of_23/IN (r_prep) upregulation_22/NN (r_conj) elevation_16/NN (r_pobj) to_14/IN (r_prep) contribute_13/VB (l_nsubj) dehydration_4/NN
D001127_D003919 NONE AVP_19/NNP (r_pobj) of_17/IN (r_prep) elevation_16/NN (r_pobj) to_14/IN (r_prep) contribute_13/VB (l_npadvmod) insipidus_39/NN
D001127_D003919 NONE AVP_24/NNP (r_compound) expression_26/NN (r_pobj) of_23/IN (r_prep) upregulation_22/NN (r_conj) elevation_16/NN (r_pobj) to_14/IN (r_prep) contribute_13/VB (l_npadvmod) insipidus_39/NN
D008094_D003681 NONE Li_35/NNP (r_npadvmod) induced_37/VBN (r_amod) diabetes_38/NN (r_pobj) of_33/IN (r_prep) SON_32/NNP (r_conj) PVN_29/NNP (r_pobj) in_27/IN (r_prep) expression_26/NN (r_pobj) of_23/IN (r_prep) upregulation_22/NN (r_conj) elevation_16/NN (r_pobj) to_14/IN (r_prep) contribute_13/VB (l_nsubj) dehydration_4/NN
2632720
D007654_D006973 CID ketoconazole_7/NN (r_compound) treatment_8/NN (r_pobj) of_5/IN (r_prep) complication_4/NN (r_pobj) as_2/IN (r_prep) hypertension_1/NN
D007654_D006973 CID ketoconazole_16/NN (r_pobj) with_15/IN (l_pobj) hypertension_19/NN
D007654_D006973 CID ketoconazole_14/NN (r_compound) therapy_15/NN (r_pobj) following_13/VBG (r_prep) achieved_12/VBN (l_conj) demonstrated_22/VBD (l_dobj) hypertension_23/NN
D007654_D006973 CID ketoconazole_12/NN (r_pobj) of_11/IN (r_prep) doses_10/NNS (r_pobj) with_8/IN (r_prep) treatment_7/NN (r_nsubj) induce_14/VB (l_dobj) blockade_16/NN (l_acl) leading_17/VBG (l_prep) to_18/IN (l_pobj) hypertension_22/NN
D007654_D003480 NONE ketoconazole_16/NN (r_pobj) with_15/IN (r_prep) basis_14/NN (r_pobj) on_9/IN (r_prep) treated_8/VBN (l_nsubj) patients_3/NNS (l_prep) with_4/IN (l_pobj) syndrome_7/NN
D006854_D006973 NONE cortisol_8/NN (r_compound) levels_9/NNS (r_nsubjpass) achieved_12/VBN (l_conj) demonstrated_22/VBD (l_dobj) hypertension_23/NN
12369736
D003042_D009069 CID cocaine_14/NN (r_npadvmod) induced_16/VBN (r_amod) hyperactivity_18/NN
D003042_D009069 CID cocaine_34/NN (r_pobj) by_33/IN (r_agent) induced_32/VBN (r_acl) hyperactivity_31/NN
D003042_D009069 CID cocaine_18/NN (r_pobj) to_17/IN (r_prep) prior_16/RB (r_advmod) administered_11/VBN (r_acl) GR_0/NNP (r_nsubj) attenuated_23/VBN (l_dobj) hyperactivity_29/NN
D003042_D009069 CID cocaine_4/NN (r_npadvmod) induced_5/VBN (r_amod) hyperlocomotion_6/NN
C103477_D009069 NONE 55562_1/CD (r_nummod) GR_0/NNP (r_nsubj) attenuated_23/VBN (l_dobj) hyperactivity_29/NN
C103477_D009069 NONE 55562_38/CD (r_nummod) GR_37/NNP (r_appos) antagonist_35/NN (r_pobj) of_31/IN (r_prep) effects_30/NNS (r_pobj) in_26/IN (r_prep) consisting_25/VBG (r_acl) modification_24/NN (r_npadvmod) modified_8/VBN (l_nsubjpass) hyperlocomotion_6/NN
C065046_D009069 CID 93129_44/CD (r_nummod) CP_43/NNP (r_appos) agonist_41/NN (r_conj) antagonist_35/NN (r_pobj) of_31/IN (r_prep) effects_30/NNS (r_pobj) in_26/IN (r_prep) consisting_25/VBG (r_acl) modification_24/NN (r_npadvmod) modified_8/VBN (l_nsubjpass) hyperlocomotion_6/NN
12584269
D020123_D007674 CID SRL_5/NNP (r_nsubj) seems_6/VBZ (r_conj) are_1/VBP (l_attr) nephrotoxic_2/JJ
D020123_D007674 CID SRL_5/NNP (r_nsubj) seems_6/VBZ (l_xcomp) act_8/VB (l_xcomp) displaying_10/VBG (l_dobj) effects_14/NNS (l_compound) nephrotoxic_13/JJ
D020123_D007674 CID SRL_7/NNP (r_nsubjpass) combined_9/VBN (l_prep) with_10/IN (l_pobj) indications_14/NNS (l_prep) of_15/IN (l_pobj) effect_19/NN (l_compound) nephrotoxic_18/JJ
D020123_D007674 CID SRL_11/NNP (r_conj) CsA_9/NNP (r_pobj) of_8/IN (r_prep) effect_7/NN (l_compound) nephrotoxic_6/JJ
D020123_D007674 CID SRL_16/NNP (r_conj) FK506_14/NNP (r_nsubjpass) tolerated_19/VBN (r_advcl) demonstrated_3/VBD (l_dobj) effect_7/NN (l_compound) nephrotoxic_6/JJ
D016572_D005355 NONE CsA_13/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) group_10/NN (r_pobj) in_8/IN (r_prep) was_5/VBD (l_conj) showed_32/VBD (l_nsubj) analysis_24/NN (l_prep) of_25/IN (l_pobj) grade_28/NN (l_prep) of_29/IN (l_pobj) fibrosis_30/NN
D020123_D005355 NONE SRL_15/NNP (r_conj) CsA_13/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_acl) group_10/NN (r_pobj) in_8/IN (r_prep) was_5/VBD (l_conj) showed_32/VBD (l_nsubj) analysis_24/NN (l_prep) of_25/IN (l_pobj) grade_28/NN (l_prep) of_29/IN (l_pobj) fibrosis_30/NN
D020123_D005355 NONE SRL_3/NNP (r_conj) FK506_1/NNP (r_nmod) combination_4/NN (r_nsubj) showed_5/VBD (l_dobj) degree_10/NN (l_prep) of_11/IN (l_pobj) fibrosis_12/NN
D016559_D005355 NONE FK506_1/NNP (r_nmod) combination_4/NN (r_nsubj) showed_5/VBD (l_dobj) degree_10/NN (l_prep) of_11/IN (l_pobj) fibrosis_12/NN
D016572_D007674 CID CsA_9/NNP (r_pobj) of_8/IN (r_prep) effect_7/NN (l_compound) nephrotoxic_6/JJ
D016559_D007674 CID FK506_14/NNP (r_nsubjpass) tolerated_19/VBN (r_advcl) demonstrated_3/VBD (l_dobj) effect_7/NN (l_compound) nephrotoxic_6/JJ
983936
D001241_D009202 NONE acid_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_9/IN (l_pobj) injury_14/NN
D004176_D009202 NONE dipyridamole_5/NNP (r_conj) acid_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_9/IN (l_pobj) injury_14/NN
D006854_D009202 NONE hydrocortisone_8/NN (r_conj) dipyridamole_5/NNP (r_conj) acid_3/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_9/IN (l_pobj) injury_14/NN
D004837_D009202 CID epinephrine_10/NN (r_npadvmod) induced_12/VBN (r_amod) injury_14/NN
D004837_D009202 CID epinephrine_9/NN (r_compound) infusion_10/NN (r_appos) injury_7/NN
D004837_D009203 NONE epinephrine_9/NN (r_compound) infusion_10/NN (r_appos) injury_7/NN (r_dobj) producing_4/VBG (r_pcomp) for_3/IN (r_prep) model_2/NN (r_nsubjpass) developed_14/VBN (l_xcomp) study_16/VB (l_dobj) effects_19/NNS (l_prep) of_20/IN (l_pobj) agents_21/NNS (l_relcl) alter_26/VB (l_dobj) evolution_28/NN (l_prep) of_29/IN (l_pobj) infarction_32/NN
3358181
D012312_D014693 CID ritodrine_6/JJ (r_compound) therapy_7/NN (r_pobj) after_5/IN (r_prep) section_4/NN (r_pobj) during_2/IN (r_prep) tachyarrhythmias_1/NNS
D012312_D007752 NONE ritodrine_6/RB (r_dobj) receiving_5/VBG (l_prep) for_7/IN (l_pobj) labor_9/NN
D012312_D007752 NONE ritodrine_19/NN (r_pobj) of_18/IN (r_prep) effects_17/NNS (r_pobj) between_13/IN (r_prep) interactions_12/NNS (r_dobj) risk_11/VB (l_nsubj) patients_4/NNS (l_acl) receiving_5/VBG (l_prep) for_7/IN (l_pobj) labor_9/NN
D012312_D002318 NONE ritodrine_15/NN (r_pobj) of_14/IN (r_prep) infusion_13/NN (r_pobj) of_11/IN (r_prep) cessation_10/NN (r_pobj) after_9/IN (r_prep) result_3/VB (l_prep) in_4/IN (l_pobj) complications_7/NNS
D010656_D007022 NONE phenylephrine_22/NN (r_pobj) as_21/IN (r_prep) vasopressor_19/NN (r_pobj) of_14/IN (r_prep) use_13/NN (r_pobj) to_11/IN (r_prep) contraindication_10/NN (l_acl) treat_24/VB (l_dobj) patients_26/NNS (l_amod) hypotensive_25/JJ
D010656_D013610 NONE phenylephrine_22/NN (r_pobj) as_21/IN (r_prep) vasopressor_19/NN (r_pobj) of_14/IN (r_prep) use_13/NN (r_pobj) to_11/IN (r_prep) contraindication_10/NN (l_acl) treat_24/VB (l_prep) with_27/IN (l_pobj) tachycardia_28/NN
220563
C023470_D010523 CID maleate_1/NN (l_conj) neuropathy_4/NN
C023470_D010523 CID maleate_12/NNP (r_pobj) with_10/IN (r_prep) complication_7/NN (r_pobj) as_5/IN (r_prep) noted_4/VBN (l_nsubjpass) neuropathy_1/NN
C023470_D000787 NONE maleate_12/NNP (r_pobj) with_10/IN (r_prep) complication_7/NN (r_pobj) as_5/IN (r_prep) noted_4/VBN (l_conj) in_22/IN (l_pobj) for_30/IN (l_pobj) treatment_33/NN (l_prep) of_34/IN (l_pobj) pectoris_36/NN
1987816
D008094_D011141 CID Lithium_0/NN (r_npadvmod) induced_2/VBN (r_amod) polyuria_3/NN
12443032
D003042_D002637 CID Cocaine_0/NN (r_npadvmod) related_1/VBD (r_amod) pain_3/NN
D003042_D002637 CID cocaine_6/NN (r_pobj) of_5/IN (r_prep) tendency_4/NN (l_acl) produce_8/VB (l_dobj) pain_10/NN
D003042_D002637 CID cocaine_6/NN (r_pobj) of_5/IN (r_prep) tendency_4/NN (r_nsubj) ought_11/MD (l_xcomp) be_13/VB (l_advcl) faced_22/VBN (l_prep) with_23/IN (l_pobj) victim_26/NN (l_prep) of_27/IN (l_pobj) pain_29/NN
D003042_D002637 CID cocaine_7/NN (r_compound) use_8/NN (r_pobj) to_6/IN (r_prep) related_5/VBN (r_amod) pain_4/NN
18703024
D006220_D002375 CID haloperidol_3/NN (r_npadvmod) induced_5/VBN (r_amod) catalepsy_6/NN
D016291_D002375 NONE MK-801-induced_8/CD (r_nummod) locomotion_9/NN (r_conj) changes_1/NNS (l_prep) in_2/IN (l_pobj) catalepsy_6/NN
7265370
D014223_D053040 CID Triamterene_0/NNP (r_compound) nephrolithiasis_1/NN
D014223_D053040 CID triamterene_3/NNP (r_compound) nephrolithiasis_4/NNP
D014223_D053040 CID triamterene_2/NNP (r_compound) nephrolithiasis_3/NNP
C020743_D053040 NONE dyazide_3/NNP (r_compound) therapy_4/NN (r_dobj) complicating_2/VBG (r_acl) nephrolithiasis_1/NN
C020743_D053040 NONE triamterene_16/NN (r_compound) therapy_17/NN (r_pobj) of_13/IN (r_prep) years_12/NNS (r_pobj) after_10/IN (r_prep) reported_6/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) nephrolithiasis_4/NNP
D014223_D006973 NONE triamterene_3/NNP (r_compound) nephrolithiasis_4/NNP (r_pobj) of_2/IN (r_prep) case_1/NN (r_nsubjpass) reported_6/VBN (l_prep) after_10/IN (l_pobj) years_12/NNS (l_prep) of_13/IN (l_pobj) therapy_17/NN (l_prep) for_18/IN (l_pobj) hypertension_19/NN
C020743_D006973 NONE triamterene_16/NN (r_compound) therapy_17/NN (l_prep) for_18/IN (l_pobj) hypertension_19/NN
9199746
D000583_D064420 NONE amikacin_4/NNS (r_advcl) toxicity_1/NN
D000617_D009877 NONE aminoglycosides_2/NNS (r_nsubj) improved_5/VBN (l_prep) in_8/IN (l_pobj) endophthalmitis_9/NNP
D000617_D007238 NONE aminoglycosides_2/NNS (r_nsubj) improved_5/VBN (r_advcl) impair_14/VB (l_nsubj) infarction_12/NN
D000583_D012164 CID amikacin_6/NN (r_nmod) toxicity_8/NN
D000583_D012164 CID amikacin_12/NNS (r_pobj) with_11/IN (r_prep) treatment_10/NN (r_pobj) following_9/VBG (r_prep) toxicity_8/NN
D000583_D013290 NONE amikacin_6/NN (r_nmod) toxicity_8/NN (l_prep) following_9/VBG (l_pobj) treatment_10/NN (l_prep) for_15/IN (l_pobj) endophthalmitis_20/NNP
D000583_D013290 NONE amikacin_12/NNS (r_pobj) with_11/IN (r_prep) treatment_10/NN (l_prep) for_15/IN (l_pobj) endophthalmitis_20/NNP
D014640_D012164 NONE vancomycin_14/NN (r_conj) amikacin_12/NNS (r_pobj) with_11/IN (r_prep) treatment_10/NN (r_pobj) following_9/VBG (r_prep) toxicity_8/NN
D014640_D013290 NONE vancomycin_14/NN (r_conj) amikacin_12/NNS (r_pobj) with_11/IN (r_prep) treatment_10/NN (l_prep) for_15/IN (l_pobj) endophthalmitis_20/NNP
D019793_D013684 NONE fluorescein_1/NNP (r_advmod) confirmed_3/VBD (l_dobj) closure_6/NN (l_conj) telangiectasis_8/NN
16298782
D019331_D006311 NONE ester_6/NN (l_appos) protector_10/NN (l_prep) against_11/IN (l_pobj) ototoxicity_13/NN
D005839_D006311 NONE gentamicin_12/NNS (r_compound) ototoxicity_13/NN
D019331_D006316 NONE ester_7/NN (r_nsubj) act_14/VB (l_prep) as_15/IN (l_pobj) otoprotectant_17/NN (l_prep) against_18/IN (l_pobj) loss_23/NN
D019331_D006316 NONE NAME_11/NNP (r_appos) ester_7/NN (r_nsubj) act_14/VB (l_prep) as_15/IN (l_pobj) otoprotectant_17/NN (l_prep) against_18/IN (l_pobj) loss_23/NN
D005839_D006316 NONE gentamicin_26/NNS (r_pobj) by_25/IN (r_agent) caused_24/VBN (r_acl) loss_23/NN
D009569_D006311 NONE NO_17/NN (r_pobj) of_16/IN (r_prep) production_15/NN (r_dobj) involves_13/VBZ (r_advcl) need_20/VBP (r_conj) is_2/VBZ (l_nsubj) ototoxicity_1/NN
D009569_D006311 NONE NO_17/NN (r_pobj) of_16/IN (r_prep) production_15/NN (r_dobj) involves_13/VBZ (l_nsubj) mechanism_12/NN (l_compound) ototoxic_11/JJ
D009569_D006311 NONE NO_26/DT (r_det) inhibitors_27/NNS (r_pobj) of_25/IN (r_prep) use_24/NN (r_dobj) assess_22/VB (r_xcomp) need_20/VBP (r_conj) is_2/VBZ (l_nsubj) ototoxicity_1/NN
D009569_D006311 NONE NO_26/DT (r_det) inhibitors_27/NNS (r_pobj) of_25/IN (r_prep) use_24/NN (r_dobj) assess_22/VB (r_xcomp) need_20/VBP (l_advcl) involves_13/VBZ (l_nsubj) mechanism_12/NN (l_compound) ototoxic_11/JJ
D009569_D006319 NONE NO_17/NN (r_pobj) of_16/IN (r_prep) production_15/NN (r_dobj) involves_13/VBZ (r_advcl) need_20/VBP (l_xcomp) assess_22/VB (l_dobj) use_24/NN (l_prep) for_28/IN (l_pobj) prevention_30/NN (l_prep) of_31/IN (l_pobj) loss_37/NN
D009569_D006319 NONE NO_26/DT (r_det) inhibitors_27/NNS (r_pobj) of_25/IN (r_prep) use_24/NN (l_prep) for_28/IN (l_pobj) prevention_30/NN (l_prep) of_31/IN (l_pobj) loss_37/NN
D000617_D006311 NONE aminoglycoside_32/RB (r_npadvmod) induced_34/VBN (r_amod) loss_37/NN (r_pobj) of_31/IN (r_prep) prevention_30/NN (r_pobj) for_28/IN (r_prep) use_24/NN (r_dobj) assess_22/VB (r_xcomp) need_20/VBP (r_conj) is_2/VBZ (l_nsubj) ototoxicity_1/NN
D000617_D006311 NONE aminoglycoside_32/RB (r_npadvmod) induced_34/VBN (r_amod) loss_37/NN (r_pobj) of_31/IN (r_prep) prevention_30/NN (r_pobj) for_28/IN (r_prep) use_24/NN (r_dobj) assess_22/VB (r_xcomp) need_20/VBP (l_advcl) involves_13/VBZ (l_nsubj) mechanism_12/NN (l_compound) ototoxic_11/JJ
D000617_D006319 NONE aminoglycoside_32/RB (r_npadvmod) induced_34/VBN (r_amod) loss_37/NN
D019331_D034381 NONE NAME_2/NN (r_nsubj) reduced_3/VBN (l_dobj) loss_8/NN
D005839_D034381 CID gentamicin_4/NN (r_npadvmod) induced_6/VBN (r_amod) loss_8/NN
15458908
D020849_D010024 NONE Raloxifene_4/NNP (r_compound) Evaluation_5/NNP (r_pobj) of_3/IN (r_prep) Outcomes_2/NNPS (r_nsubj) enrolled_17/VBD (l_prep) with_21/IN (l_pobj) osteoporosis_22/NN
D020849_D054556 CID raloxifene_10/NNP (r_nsubjpass) associated_12/VBN (l_prep) with_13/IN (l_pobj) risk_16/NN (l_prep) for_17/IN (l_pobj) thromboembolism_19/NN
D020849_D054556 CID Raloxifene_0/NNP (r_nsubjpass) associated_2/VBN (l_prep) with_3/IN (l_pobj) risk_6/NN (l_prep) for_7/IN (l_pobj) thromboembolism_9/NN
D020849_D002386 NONE Raloxifene_0/NNP (r_nsubj) increase_3/VB (l_dobj) risk_4/NN (l_prep) for_5/IN (l_pobj) cataracts_6/NNS
D020849_D002386 NONE Raloxifene_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) was_13/VBD (l_attr) risk_16/NN (l_prep) for_17/IN (l_pobj) cataracts_18/NNS
D020849_D005705 NONE Raloxifene_0/NNP (r_nsubj) increase_3/VB (l_punct) CI_13/NNP (l_conj) disease_20/NN
D020849_D005705 NONE Raloxifene_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) was_13/VBD (l_attr) risk_16/NN (l_prep) for_17/IN (l_pobj) cataracts_18/NNS (l_conj) disease_21/NN
D020849_D004714 NONE Raloxifene_0/NNP (r_nsubj) increase_3/VB (l_punct) CI_13/NNP (l_conj) disease_20/NN (l_conj) hyperplasia_34/NN
D020849_D004714 NONE Raloxifene_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) was_13/VBD (l_attr) risk_16/NN (l_prep) for_17/IN (l_pobj) cataracts_18/NNS (l_conj) disease_21/NN (l_conj) hyperplasia_24/NN
D020849_D016889 NONE Raloxifene_0/NNP (r_nsubj) increase_3/VB (l_punct) CI_13/NNP (l_conj) disease_20/NN (l_conj) hyperplasia_34/NN (l_appos) %_40/NN (l_conj) cancer_49/NN
D020849_D016889 NONE Raloxifene_0/NNP (r_nsubjpass) associated_2/VBN (l_conj) was_13/VBD (l_attr) risk_16/NN (l_prep) for_17/IN (l_pobj) cataracts_18/NNS (l_conj) disease_21/NN (l_conj) hyperplasia_24/NN (l_conj) cancer_28/NN
603022
D005702_D062787 NONE hydrobromide_1/NNP (r_nsubjpass) used_16/VBN (l_prep) in_17/IN (l_pobj) patient_19/NN (l_acl) demonstrating_20/VBG (l_dobj) effects_22/NNS (l_prep) of_23/IN (l_pobj) overdosage_28/NN
D012601_D062787 CID scopolamine_24/NN (r_nmod) overdosage_28/NN
D012601_D062787 CID hyoscine_26/NNP (r_nmod) overdosage_28/NN
7234705
D011342_D017180 CID Procainamide_0/NNP (r_npadvmod) induced_2/VBN (r_amod) tachycardia_5/NN
D011342_D017180 CID procainamide_3/NN (r_npadvmod) induced_5/VBN (r_amod) tachycardia_8/NN
D011342_D017180 CID procainamide_17/NN (r_pobj) of_16/IN (r_prep) mg_15/NNS (r_pobj) of_11/IN (r_prep) administration_10/NN (r_pobj) after_8/IN (r_prep) appeared_7/VBD (l_nsubj) tachycardia_6/NN
D011342_D017180 CID procainamide_17/NN (r_pobj) of_16/IN (r_prep) mg_15/NNS (r_pobj) of_11/IN (r_prep) administration_10/NN (l_prep) for_18/IN (l_pobj) treatment_20/NN (l_prep) of_21/IN (l_pobj) tachycardia_24/NN
D011342_D017180 CID procainamide_16/NN (r_compound) therapy_17/NN (r_pobj) of_15/IN (r_prep) continuation_14/NN (r_pobj) despite_13/IN (r_prep) inserted_10/VBN (r_ccomp) reoccur_24/VB (l_nsubj) tachycardia_21/NN
D011342_D017180 CID procainamide_5/NN (r_nsubj) produce_7/VB (l_dobj) syndrome_14/NN (l_prep) with_15/IN (l_pobj) tachycardia_18/NN
D011342_D018879 NONE procainamide_6/NNP (r_nsubjpass) administered_8/VBN (l_prep) for_10/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) contractions_16/NNS
D011342_D001282 NONE procainamide_6/NNP (r_nsubjpass) administered_8/VBN (l_prep) for_10/IN (l_pobj) treatment_11/NN (l_prep) of_12/IN (l_pobj) contractions_16/NNS (l_conj) flutter_19/NN
D011342_D008133 NONE procainamide_5/NN (r_nsubj) produce_7/VB (l_dobj) syndrome_14/NN
11569530
D016593_D016171 CID terfenadine_19/NNP (r_appos) market_16/NN (r_pobj) from_14/IN (r_prep) withdrawal_10/NN (r_pobj) to_9/IN (r_prep) led_8/VBN (r_relcl) effect_5/NN (r_attr) is_1/VBZ (l_nsubj) TDP_0/NNP
D016593_D016171 CID terfenadine_13/FW (r_appos) investigated_11/VBN (l_nsubjpass) TDP_9/NNP
D016593_D016171 CID terfenadine_10/FW (r_appos) clinic_8/NN (r_pobj) in_6/IN (r_prep) shown_4/VBN (l_dobj) TDP_5/NNP
C010637_D016171 CID terodiline_21/NNP (r_conj) terfenadine_19/NNP (r_appos) market_16/NN (r_pobj) from_14/IN (r_prep) withdrawal_10/NN (r_pobj) to_9/IN (r_prep) led_8/VBN (r_relcl) effect_5/NN (r_attr) is_1/VBZ (l_nsubj) TDP_0/NNP
C010637_D016171 CID terodiline_15/NNP (r_conj) terfenadine_13/FW (r_appos) investigated_11/VBN (l_nsubjpass) TDP_9/NNP
C010637_D016171 CID terodiline_12/NNP (r_nmod) cisapride_14/NN (r_appos) clinic_8/NN (r_pobj) in_6/IN (r_prep) shown_4/VBN (l_dobj) TDP_5/NNP
D020117_D016171 CID cisapride_17/NN (r_conj) terodiline_15/NNP (r_conj) terfenadine_13/FW (r_appos) investigated_11/VBN (l_nsubjpass) TDP_9/NNP
D020117_D016171 CID cisapride_14/NN (r_appos) clinic_8/NN (r_pobj) in_6/IN (r_prep) shown_4/VBN (l_dobj) TDP_5/NNP
C063968_D016171 NONE E4031_19/NN (r_conj) cisapride_17/NN (r_conj) terodiline_15/NNP (r_conj) terfenadine_13/FW (r_appos) investigated_11/VBN (l_nsubjpass) TDP_9/NNP
2887062
D004967_D015175 CID estrogen_8/NN (r_npadvmod) induced_10/VBN (r_amod) prolactinomas_12/NNP
D004967_D015175 CID estrogen_21/NN (r_npadvmod) induced_23/VBN (r_amod) cells_26/NNS (r_pobj) to_20/IN (r_prep) applied_19/VBN (l_advcl) clarify_1/VB (l_dobj) effects_3/NNS (l_prep) on_6/IN (l_pobj) cells_8/NNS (l_compound) prolactinoma_7/NN
D004967_D015175 CID estrogen_21/NN (r_npadvmod) induced_23/VBN (r_amod) cells_26/NNS (l_compound) prolactinoma_25/NN
D001971_D015175 NONE bromocriptine_14/JJ (r_compound) treatment_15/NN (r_pobj) after_13/IN (r_prep) studies_6/NNS (l_prep) of_7/IN (l_pobj) prolactinomas_12/NNP
D001971_D015175 NONE bromocriptine_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (l_prep) on_6/IN (l_pobj) cells_8/NNS (l_compound) prolactinoma_7/NN
D001971_D015175 NONE bromocriptine_5/NN (r_pobj) of_4/IN (r_prep) effects_3/NNS (r_dobj) clarify_1/VB (r_advcl) applied_19/VBN (l_prep) to_20/IN (l_pobj) cells_26/NNS (l_compound) prolactinoma_25/NN
D001971_D015175 NONE bromocriptine_35/NNP (r_pobj) of_34/IN (r_prep) injection_33/NN (r_pobj) after_32/IN (r_prep) h_31/NN (r_conj) h_28/NN (r_appos) cells_26/NNS (r_pobj) to_20/IN (r_prep) applied_19/VBN (l_advcl) clarify_1/VB (l_dobj) effects_3/NNS (l_prep) on_6/IN (l_pobj) cells_8/NNS (l_compound) prolactinoma_7/NN
D001971_D015175 NONE bromocriptine_35/NNP (r_pobj) of_34/IN (r_prep) injection_33/NN (r_pobj) after_32/IN (r_prep) h_31/NN (r_conj) h_28/NN (r_appos) cells_26/NNS (l_compound) prolactinoma_25/NN
D001971_D000236 NONE bromocriptine_15/JJ (r_compound) treatment_16/NN (l_prep) of_17/IN (l_pobj) cells_20/NNS (l_compound) adenoma_19/NN
809711
D010656_D009203 NONE phenylephrine_2/NN (l_prep) of_3/IN (l_pobj) effects_6/NNS (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) infarction_15/NN
D010656_D009203 NONE phenylephrine_6/NN (r_pobj) of_5/IN (r_prep) addition_4/NN (r_nsubj) is_9/VBZ (l_acomp) beneficial_11/JJ (l_prep) in_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) infarction_20/NN
D005996_D009203 NONE nitroglycerin_9/NN (r_pobj) of_7/IN (r_prep) effects_6/NNS (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) infarction_15/NN
D005996_D009203 NONE Nitroglycerin_0/NN (r_nsubjpass) shown_3/VBN (l_xcomp) reduce_5/VB (l_prep) during_10/IN (l_pobj) infarction_13/NN
D005996_D009203 NONE nitroglycerin_25/NN (r_npadvmod) induced_27/VBN (r_amod) hypotension_28/NN (r_dobj) reverse_24/VBP (r_relcl) agents_22/NNS (r_pobj) by_21/IN (r_agent) potentiated_17/VBN (r_acl) effect_16/NN (r_npadvmod) shown_3/VBN (l_xcomp) reduce_5/VB (l_prep) during_10/IN (l_pobj) infarction_13/NN
D005996_D009203 NONE nitroglycerin_9/NN (r_dobj) received_7/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) infarctions_6/NNS
D005996_D009203 NONE nitroglycerin_8/NN (r_pobj) to_7/IN (r_prep) addition_4/NN (r_nsubj) is_9/VBZ (l_acomp) beneficial_11/JJ (l_prep) in_12/IN (l_pobj) treatment_14/NN (l_prep) of_15/IN (l_pobj) patients_16/NNS (l_prep) with_17/IN (l_pobj) infarction_20/NN
D005996_D007022 CID Nitroglycerin_0/NN (r_nsubjpass) shown_3/VBN (l_npadvmod) effect_16/NN (l_acl) potentiated_17/VBN (l_agent) by_21/IN (l_pobj) agents_22/NNS (l_relcl) reverse_24/VBP (l_dobj) hypotension_28/NN
D005996_D007022 CID nitroglycerin_25/NN (r_npadvmod) induced_27/VBN (r_amod) hypotension_28/NN
10669626
D014859_D061205 CID Warfarin_0/NN (r_npadvmod) induced_2/VBN (r_amod) calcification_4/NN
D014859_D061205 CID Warfarin_22/NNP (r_pobj) of_21/IN (r_prep) doses_20/NNS (r_dobj) given_18/VBN (r_acl) rats_17/NNS (r_pobj) in_16/IN (r_prep) calcification_15/NN
D014859_D061205 CID Warfarin_17/NN (r_npadvmod) treated_19/VBN (r_amod) rats_20/NNS (r_pobj) in_16/IN (r_prep) calcification_15/NN
D014859_D061205 CID Warfarin_5/NN (r_pobj) with_4/IN (r_prep) Treatment_0/NN (r_nsubj) caused_6/VBD (l_dobj) calcification_9/NN (l_prep) of_10/IN (l_pobj) media_13/NNS (l_compound) artery_12/NN
D014859_D061205 CID Warfarin_20/NNP (r_compound) treatment_21/NN (r_pobj) of_19/IN (r_prep) weeks_18/NNS (r_pobj) after_16/IN (r_prep) detected_8/VBN (l_nsubjpass) calcification_5/NN
D014859_D061205 CID Warfarin_8/NN (r_npadvmod) induced_10/VBN (r_amod) calcification_12/NN
D014859_D061205 CID Warfarin_7/NNP (r_pobj) with_6/IN (r_prep) treatment_1/NN (r_nsubj) produced_8/VBD (l_dobj) calcification_11/NN (l_prep) of_12/IN (l_pobj) media_15/NNS (l_compound) artery_14/NN
D014859_D061205 CID Warfarin_7/NNP (r_pobj) with_6/IN (r_prep) treatment_1/NN (r_nsubj) produced_8/VBD (l_dobj) rats_22/NNS (l_conj) calcification_27/NN
D014859_D061205 CID Warfarin_61/NN (r_advmod) induced_63/VBN (r_amod) calcification_65/NN (r_pobj) to_60/IN (r_prep) resistant_59/JJ (r_acomp) was_58/VBD (r_relcl) groups_56/NNS (r_pobj) of_54/IN (r_prep) either_53/DT (r_pobj) with_52/IN (r_prep) compared_51/VBN (r_prep) rats_50/NNS (r_conj) levels_39/NNS (r_pobj) with_35/IN (r_prep) was_22/VBD (l_advcl) determined_15/VBN (l_nsubjpass) explanation_2/NN (l_prep) for_3/IN (l_pobj) association_5/NN (l_prep) between_6/IN (l_pobj) calcification_8/NN
D014859_D061205 CID Warfarin_61/NN (r_advmod) induced_63/VBN (r_amod) calcification_65/NN (r_pobj) to_60/IN (r_prep) resistant_59/JJ (r_acomp) was_58/VBD (r_relcl) groups_56/NNS (r_pobj) of_54/IN (r_prep) either_53/DT (r_pobj) with_52/IN (r_prep) compared_51/VBN (r_prep) rats_50/NNS (r_conj) levels_39/NNS (r_pobj) with_35/IN (r_prep) was_22/VBD (l_attr) relationship_24/NN (l_prep) to_31/IN (l_pobj) calcification_33/NN
D014859_D061205 CID Warfarin_61/NN (r_advmod) induced_63/VBN (r_amod) calcification_65/NN
D014859_D061205 CID Warfarin_7/NN (r_advmod) induced_9/VBN (r_amod) calcification_11/NN
D014859_D061205 CID Warfarin_0/NN (l_prep) in_1/IN (l_pobj) calcification_3/NN
D014859_D061205 CID Warfarin_4/NNP (r_appos) antagonist_3/NN (r_nsubjpass) known_7/VBN (l_xcomp) cause_9/VB (l_dobj) calcification_10/NN (l_prep) of_11/IN (l_pobj) media_14/NNS (l_compound) artery_13/NN
D014859_D061205 CID Warfarin_20/NNP (r_conj) D_18/NN (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) rats_14/NNS (r_pobj) in_13/IN (r_prep) calcification_12/NN
D014807_D061205 NONE D._11/NNP (r_conj) growth_8/NN (r_pobj) by_7/IN (r_agent) accelerated_6/VBN (l_nsubjpass) calcification_4/NN
D014807_D061205 NONE D_8/NN (r_conj) growth_5/NN (r_nmod) treatment_9/NN (r_nsubj) enhance_10/VB (l_dobj) extent_12/NN (l_prep) of_13/IN (l_pobj) calcification_15/NN
D014807_D061205 NONE D_4/NN (r_pobj) of_2/IN (r_prep) doses_1/NNS (r_nsubjpass) known_6/VBN (l_xcomp) cause_8/VB (l_dobj) calcification_9/NN (l_prep) of_10/IN (l_pobj) media_13/NNS (l_compound) artery_12/NN
D014807_D061205 NONE D_10/NN (r_compound) dose_11/NN (l_prep) on_12/IN (l_pobj) calcification_14/NN
D014807_D061205 NONE D_10/NN (r_compound) dose_11/NN (r_pobj) of_8/IN (r_prep) effect_7/NN (l_conj) effect_17/NN (l_prep) of_18/IN (l_pobj) dose_21/NN (l_prep) on_22/IN (l_pobj) elevation_24/NN (l_prep) of_25/IN (l_pobj) calcium_27/NN (l_relcl) suggests_30/VBZ (l_ccomp) induce_35/VB (l_dobj) calcification_37/NN
D014807_D061205 NONE D_20/NN (r_compound) dose_21/NN (r_pobj) of_18/IN (r_prep) effect_17/NN (r_conj) effect_7/NN (l_prep) of_8/IN (l_pobj) dose_11/NN (l_prep) on_12/IN (l_pobj) calcification_14/NN
D014807_D061205 NONE D_20/NN (r_compound) dose_21/NN (l_prep) on_22/IN (l_pobj) elevation_24/NN (l_prep) of_25/IN (l_pobj) calcium_27/NN (l_relcl) suggests_30/VBZ (l_ccomp) induce_35/VB (l_dobj) calcification_37/NN
D014807_D061205 NONE D_33/NN (r_nsubj) induce_35/VB (r_ccomp) suggests_30/VBZ (r_relcl) calcium_27/NN (r_pobj) of_25/IN (r_prep) elevation_24/NN (r_pobj) on_22/IN (r_prep) dose_21/NN (r_pobj) of_18/IN (r_prep) effect_17/NN (r_conj) effect_7/NN (l_prep) of_8/IN (l_pobj) dose_11/NN (l_prep) on_12/IN (l_pobj) calcification_14/NN
D014807_D061205 NONE D_33/NN (r_nsubj) induce_35/VB (l_dobj) calcification_37/NN
D014807_D061205 NONE D_18/NN (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) rats_14/NNS (r_pobj) in_13/IN (r_prep) calcification_12/NN
D014807_D002114 NONE D_8/NN (r_conj) growth_5/NN (r_nmod) treatment_9/NN (r_nsubj) enhance_10/VB (l_advcl) inhibit_24/VB (l_dobj) carboxylation_27/NN (l_prep) of_28/IN (l_pobj) protein_31/NN (l_appos) inhibitor_35/NN (l_compound) calcification_34/NN
D014807_D002114 NONE D_30/NN (r_npadvmod) treated_32/VBN (r_amod) rats_33/NNS (r_pobj) of_28/IN (r_prep) media_27/NNS (r_pobj) in_25/IN (r_prep) calcification_24/NN
D014807_D002114 NONE D_15/NN (r_pobj) by_13/IN (r_agent) produced_12/VBN (r_acl) calcium_11/NN (r_pobj) in_9/IN (r_prep) elevation_8/NN (r_pobj) on_6/IN (r_prep) effect_5/NN (r_dobj) had_3/VBD (r_advcl) explained_27/VBN (l_prep) by_28/IN (l_pobj) hypothesis_30/NN (l_acl) inhibits_33/VBZ (l_prep) as_40/IN (l_pobj) inhibitor_43/NN (l_compound) calcification_42/NN
D014807_D002114 NONE D_23/NN (r_conj) Warfarin_20/NNP (r_pobj) between_19/IN (r_prep) synergy_18/NN (r_appos) D_15/NN (r_pobj) by_13/IN (r_agent) produced_12/VBN (r_acl) calcium_11/NN (r_pobj) in_9/IN (r_prep) elevation_8/NN (r_pobj) on_6/IN (r_prep) effect_5/NN (r_dobj) had_3/VBD (r_advcl) explained_27/VBN (l_prep) by_28/IN (l_pobj) hypothesis_30/NN (l_acl) inhibits_33/VBZ (l_prep) as_40/IN (l_pobj) inhibitor_43/NN (l_compound) calcification_42/NN
D014859_D002114 NONE Warfarin_22/NNP (r_pobj) of_21/IN (r_prep) doses_20/NNS (r_dobj) given_18/VBN (r_acl) rats_17/NNS (r_pobj) in_16/IN (r_prep) calcification_15/NN (r_pobj) of_13/IN (r_prep) extent_12/NN (r_dobj) enhance_10/VB (l_advcl) inhibit_24/VB (l_dobj) carboxylation_27/NN (l_prep) of_28/IN (l_pobj) protein_31/NN (l_appos) inhibitor_35/NN (l_compound) calcification_34/NN
D014859_D002114 NONE Warfarin_5/NN (r_pobj) with_4/IN (r_prep) Treatment_0/NN (r_nsubj) caused_6/VBD (l_prep) in_14/IN (l_pobj) rats_18/NNS (l_conj) calcification_23/NN
D014859_D002114 NONE Warfarin_17/NNP (r_compound) administration_18/NN (r_nsubj) increased_20/VBD (l_dobj) extent_22/NN (l_prep) of_23/IN (l_pobj) calcification_24/NN
D014859_D002114 NONE Warfarin_1/NNP (r_amod) treatment_2/NN (r_nsubj) had_3/VBD (r_advcl) explained_27/VBN (l_prep) by_28/IN (l_pobj) hypothesis_30/NN (l_acl) inhibits_33/VBZ (l_prep) as_40/IN (l_pobj) inhibitor_43/NN (l_compound) calcification_42/NN
D014859_D002114 NONE Warfarin_20/NNP (r_pobj) between_19/IN (r_prep) synergy_18/NN (r_appos) D_15/NN (r_pobj) by_13/IN (r_agent) produced_12/VBN (r_acl) calcium_11/NN (r_pobj) in_9/IN (r_prep) elevation_8/NN (r_pobj) on_6/IN (r_prep) effect_5/NN (r_dobj) had_3/VBD (r_advcl) explained_27/VBN (l_prep) by_28/IN (l_pobj) hypothesis_30/NN (l_acl) inhibits_33/VBZ (l_prep) as_40/IN (l_pobj) inhibitor_43/NN (l_compound) calcification_42/NN
D014859_D002114 NONE Warfarin_32/NNP (r_nsubj) inhibits_33/VBZ (l_prep) as_40/IN (l_pobj) inhibitor_43/NN (l_compound) calcification_42/NN
D010710_D061205 NONE phosphate_28/NN (r_pobj) between_25/IN (r_prep) relationship_24/NN (r_attr) was_22/VBD (l_advcl) determined_15/VBN (l_nsubjpass) explanation_2/NN (l_prep) for_3/IN (l_pobj) association_5/NN (l_prep) between_6/IN (l_pobj) calcification_8/NN
D010710_D061205 NONE phosphate_28/NN (r_pobj) between_25/IN (r_prep) relationship_24/NN (l_prep) to_31/IN (l_pobj) calcification_33/NN
D010710_D061205 NONE phosphate_28/NN (r_pobj) between_25/IN (r_prep) relationship_24/NN (r_attr) was_22/VBD (l_prep) with_35/IN (l_pobj) levels_39/NNS (l_conj) rats_50/NNS (l_prep) compared_51/VBN (l_prep) with_52/IN (l_pobj) either_53/DT (l_prep) of_54/IN (l_pobj) groups_56/NNS (l_relcl) was_58/VBD (l_acomp) resistant_59/JJ (l_prep) to_60/IN (l_pobj) calcification_65/NN
D010710_D061205 NONE phosphate_42/NN (r_pobj) of_40/IN (r_prep) levels_39/NNS (r_pobj) with_35/IN (r_prep) was_22/VBD (l_advcl) determined_15/VBN (l_nsubjpass) explanation_2/NN (l_prep) for_3/IN (l_pobj) association_5/NN (l_prep) between_6/IN (l_pobj) calcification_8/NN
D010710_D061205 NONE phosphate_42/NN (r_pobj) of_40/IN (r_prep) levels_39/NNS (r_pobj) with_35/IN (r_prep) was_22/VBD (l_attr) relationship_24/NN (l_prep) to_31/IN (l_pobj) calcification_33/NN
D010710_D061205 NONE phosphate_42/NN (r_pobj) of_40/IN (r_prep) levels_39/NNS (l_conj) rats_50/NNS (l_prep) compared_51/VBN (l_prep) with_52/IN (l_pobj) either_53/DT (l_prep) of_54/IN (l_pobj) groups_56/NNS (l_relcl) was_58/VBD (l_acomp) resistant_59/JJ (l_prep) to_60/IN (l_pobj) calcification_65/NN
D010710_D061205 NONE phosphate_18/NN (r_compound) levels_19/NNS (r_pobj) to_15/IN (r_prep) related_14/VBN (l_nsubjpass) susceptibility_5/NN (l_prep) to_6/IN (l_pobj) calcification_11/NN
D014812_D061205 NONE K_2/NNP (r_compound) antagonist_3/NN (r_nsubjpass) known_7/VBN (l_xcomp) cause_9/VB (l_dobj) calcification_10/NN (l_prep) of_11/IN (l_pobj) media_14/NNS (l_compound) artery_13/NN
D002118_D061205 NONE calcium_27/NN (r_pobj) of_25/IN (r_prep) elevation_24/NN (r_pobj) on_22/IN (r_prep) dose_21/NN (r_pobj) of_18/IN (r_prep) effect_17/NN (r_conj) effect_7/NN (l_prep) of_8/IN (l_pobj) dose_11/NN (l_prep) on_12/IN (l_pobj) calcification_14/NN
D002118_D061205 NONE calcium_27/NN (l_relcl) suggests_30/VBZ (l_ccomp) induce_35/VB (l_dobj) calcification_37/NN
D002118_D061205 NONE calcium_43/NN (r_pobj) on_41/IN (r_prep) effect_40/NN (r_pobj) through_38/IN (r_prep) induce_35/VB (r_ccomp) suggests_30/VBZ (r_relcl) calcium_27/NN (r_pobj) of_25/IN (r_prep) elevation_24/NN (r_pobj) on_22/IN (r_prep) dose_21/NN (r_pobj) of_18/IN (r_prep) effect_17/NN (r_conj) effect_7/NN (l_prep) of_8/IN (l_pobj) dose_11/NN (l_prep) on_12/IN (l_pobj) calcification_14/NN
D002118_D061205 NONE calcium_43/NN (r_pobj) on_41/IN (r_prep) effect_40/NN (r_pobj) through_38/IN (r_prep) induce_35/VB (l_dobj) calcification_37/NN
D002118_D002114 NONE calcium_11/NN (r_pobj) in_9/IN (r_prep) elevation_8/NN (r_pobj) on_6/IN (r_prep) effect_5/NN (r_dobj) had_3/VBD (r_advcl) explained_27/VBN (l_prep) by_28/IN (l_pobj) hypothesis_30/NN (l_acl) inhibits_33/VBZ (l_prep) as_40/IN (l_pobj) inhibitor_43/NN (l_compound) calcification_42/NN
D015055_D061205 NONE carboxylated_36/JJ (r_acomp) was_31/VBD (r_ccomp) showed_25/VBD (r_conj) found_7/VBN (l_prep) at_8/IN (l_pobj) sites_9/NNS (l_prep) of_10/IN (l_pobj) calcification_12/NN
D015055_D002114 NONE carboxyglutamate_8/JJ (r_compound) residues_9/NNS (r_nsubjpass) required_16/VBN (l_prep) for_17/IN (l_pobj) function_19/NN (l_prep) as_20/IN (l_pobj) inhibitor_23/NN (l_compound) calcification_22/NN
D015055_D002114 NONE carboxyglutamate_8/JJ (r_compound) residues_9/NNS (r_nsubjpass) required_16/VBN (r_advcl) required_28/VBN (l_prep) for_29/IN (l_pobj) accumulation_31/NN (l_prep) at_32/IN (l_pobj) sites_34/NNS (l_compound) calcification_33/NN
3780846
D009020_D009127 CID morphine_14/NN (r_pobj) by_13/IN (r_agent) produced_12/VBN (r_acl) rigidity_11/NN
D009020_D009127 CID morphine_10/NN (r_pobj) by_9/IN (r_agent) produced_8/VBN (r_acl) rigidity_7/NN
D009020_D009127 CID morphine_9/NN (r_pobj) of_8/IN (r_prep) dose_7/NN (r_dobj) given_4/VBN (l_conj) showed_15/VBD (l_dobj) rigidity_18/NN
D009020_D009127 CID morphine_6/NN (r_pobj) with_5/IN (r_prep) treated_1/VBN (r_csubj) showed_14/VBD (r_ccomp) showed_27/VBD (l_dobj) rigidity_29/NN
D009020_D009127 CID morphine_35/NN (r_pobj) of_34/IN (r_prep) dose_33/NN (r_pobj) after_30/IN (r_prep) showed_27/VBD (l_dobj) rigidity_29/NN
D009020_D009127 CID morphine_16/NN (r_pobj) of_15/IN (r_prep) action_14/NN (r_pobj) to_12/IN (r_prep) due_11/IN (r_acomp) be_10/VB (r_xcomp) assumed_8/VBN (r_relcl) rigidity_4/NN
D009020_D018476 CID morphine_6/NN (r_pobj) with_5/IN (r_prep) treated_1/VBN (r_csubj) showed_14/VBD (r_ccomp) showed_27/VBD (l_prep) after_30/IN (l_pobj) dose_33/NN (l_relcl) was_37/VBD (l_conj) were_46/VBD (l_attr) akinetic_47/JJ
D009020_D018476 CID morphine_35/NN (r_pobj) of_34/IN (r_prep) dose_33/NN (l_relcl) was_37/VBD (l_conj) were_46/VBD (l_attr) akinetic_47/JJ
D006220_D009127 CID haloperidol_7/NNP (r_nsubjpass) used_14/VBN (l_prep) in_15/IN (l_pobj) order_16/NN (l_acl) block_18/VB (l_conj) estimate_24/VB (l_dobj) degree_27/NN (l_prep) of_28/IN (l_pobj) tolerance_30/NN (l_prep) to_31/IN (l_pobj) rigidity_33/NN
D006220_D009127 CID Haloperidol_0/NNP (r_nsubj) enhanced_1/VBD (l_dobj) rigidity_3/NN
17261653
D003000_D001919 CID Clonidine_0/NN (r_npadvmod) induced_2/VBN (r_amod) bradycardia_3/NNS
2950248
D004176_D017202 NONE Dipyridamole_0/NNP (r_npadvmod) induced_2/VBN (r_amod) ischemia_4/NN
D004176_D017202 NONE dipyridamole_16/NN (r_compound) therapy_17/NN (r_pobj) of_14/IN (r_prep) effect_13/NN (r_pobj) as_10/IN (r_prep) reported_9/VBN (l_advcl) demonstrated_27/VBN (l_nsubjpass) ischemia_24/NN
D004176_D017202 NONE dipyridamole_20/NNP (r_npadvmod) induced_22/VBN (r_amod) ischemia_24/NN
D004176_D000787 CID dipyridamole_10/NNP (r_pobj) of_8/IN (r_prep) administration_7/NN (r_pobj) after_6/IN (r_prep) occurred_5/VBD (l_nsubj) Angina_0/NN
D004176_D003324 NONE dipyridamole_16/NN (r_compound) therapy_17/NN (r_pobj) of_14/IN (r_prep) effect_13/NN (r_pobj) as_10/IN (r_prep) reported_9/VBN (l_advcl) demonstrated_27/VBN (l_xcomp) occur_29/VB (l_prep) with_34/IN (l_pobj) disease_37/NN
D004176_D003324 NONE dipyridamole_20/NNP (r_npadvmod) induced_22/VBN (r_amod) ischemia_24/NN (r_nsubjpass) demonstrated_27/VBN (l_xcomp) occur_29/VB (l_prep) with_34/IN (l_pobj) disease_37/NN
D004176_D007511 NONE dipyridamole_23/NN (r_npadvmod) induced_25/VBN (r_amod) ischemia_26/NN
3031535
D013759_D002375 CID 9-tetrahydrocannabinol_7/CD (r_nummod) delta_6/NNP (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) catalepsy_3/NN
D013759_D002375 CID THC_17/NNP (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) catalepsy_14/NN
D013759_D002375 CID THC_17/NNP (r_pobj) by_16/IN (r_agent) induced_15/VBN (r_acl) catalepsy_14/NN (r_pobj) of_13/IN (r_prep) manifestation_12/NN (r_pobj) in_10/IN (r_prep) role_9/NN (r_dobj) have_6/VBP (l_advcl) are_22/VBP (l_prep) in_24/IN (l_pobj) catalepsy_25/NN
D006220_D002375 CID haloperidol_28/NNP (r_pobj) by_27/IN (r_agent) induced_26/VBN (r_acl) catalepsy_25/NN (r_pobj) in_24/IN (r_prep) are_22/VBP (r_advcl) have_6/VBP (l_dobj) role_9/NN (l_prep) in_10/IN (l_pobj) manifestation_12/NN (l_prep) of_13/IN (l_pobj) catalepsy_14/NN
D006220_D002375 CID haloperidol_28/NNP (r_pobj) by_27/IN (r_agent) induced_26/VBN (r_acl) catalepsy_25/NN
2265898
C009265_D004827 CID carbidopa_6/NNP (r_compound) administration_7/NNP (r_pobj) by_3/IN (r_agent) caused_2/VBN (r_acl) epilepsy_1/NN
C009265_D007676 NONE levodopa_38/NN (r_compound) preparation_39/NN (r_dobj) receiving_34/VBG (l_ccomp) had_11/VBD (l_dobj) failure_14/NN
C009265_D001523 NONE levodopa_38/NN (r_compound) preparation_39/NN (r_dobj) receiving_34/VBG (l_conj) had_43/VBD (l_dobj) onset_45/NN (l_prep) of_46/IN (l_pobj) hallucinosis_47/NN
C009265_D012640 NONE levodopa_38/NN (r_compound) preparation_39/NN (r_dobj) receiving_34/VBG (l_conj) had_43/VBD (l_dobj) onset_45/NN (l_prep) of_46/IN (l_pobj) hallucinosis_47/NN (l_conj) seizures_50/NNS
9522143
D011318_D034381 CID prilocaine_2/NNP (r_dobj) given_1/VBN (r_acl) Patients_0/NNS (r_nsubj) were_3/VBD (l_acomp) likely_5/JJ (l_xcomp) develop_7/VB (l_xcomp) hearing_8/NN (l_dobj) loss_9/NN
D011318_D034381 CID prilocaine_12/NNP (r_pobj) after_11/IN (r_prep) was_7/VBD (l_nsubj) loss_3/NN
D002045_D034381 CID bupivacaine_19/NN (r_pobj) given_18/VBN (r_prep) those_17/DT (r_pobj) than_16/IN (r_prep) were_3/VBD (l_acomp) likely_5/JJ (l_xcomp) develop_7/VB (l_xcomp) hearing_8/NN (l_dobj) loss_9/NN
D002045_D034381 CID bupivacaine_17/NN (r_pobj) after_16/IN (r_prep) was_7/VBD (l_nsubj) loss_3/NN
12090760
D015215_D000740 CID azidothymidine_9/NN (r_npadvmod) induced_11/VBN (r_amod) anemia_12/NN
D015215_D000740 CID Azidothymidine_0/NNP (l_parataxis) reversed_8/VBN (l_nsubjpass) anemia_3/NN
D015215_D000740 CID AZT)-induced_2/JJ (r_nummod) anemia_3/NN
2578334
D001374_D011230 CID 5-azacytidine_0/CD (r_nsubj) potentiates_1/VBZ (l_dobj) initiation_2/NN (l_acl) induced_3/VBN (l_agent) by_4/IN (l_pobj) carcinogens_5/NNS
D001374_D011230 CID 5-azacytidine_22/CD (r_appos) initiation_17/NN (l_prep) of_18/IN (l_pobj) process_20/NN
D001374_D011230 CID 5-AzC_24/CD (r_appos) 5-azacytidine_22/CD (r_appos) initiation_17/NN (l_prep) of_18/IN (l_pobj) process_20/NN
D001564_D011230 CID benzo[a]-pyrene_53/NNP (r_appos) carcinogens_51/NNS (r_pobj) by_48/IN (r_agent) induced_47/VBN (r_acl) synthesis_46/NN (r_pobj) of_44/IN (r_prep) phase_43/NN (r_pobj) during_41/IN (r_prep) given_38/VBN (l_advcl) test_1/VB (l_dobj) validity_3/NN (l_prep) of_4/IN (l_pobj) hypothesis_6/NN (l_acl) plays_11/VBZ (l_prep) in_15/IN (l_pobj) initiation_17/NN (l_prep) of_18/IN (l_pobj) process_20/NN
3782049
D008972_D012206 CID molindone_6/NNP (r_compound) administration_7/NN (r_pobj) following_5/VBG (r_prep) case_1/NN (l_prep) of_2/IN (l_pobj) rhabdomyolysis_4/NN
D008972_D012206 CID molindone_18/NNP (r_compound) administration_19/NN (r_pobj) following_17/VBG (r_prep) illustrate_9/VB (l_dobj) rhabdomyolysis_11/NN
D008972_D012559 NONE molindone_18/NNP (r_compound) administration_19/NN (r_pobj) following_17/VBG (r_prep) illustrate_9/VB (r_xcomp) reported_7/VBN (l_nsubjpass) case_1/NN (l_prep) of_2/IN (l_pobj) patient_5/NN (l_amod) schizophrenic_4/JJ
D008972_D058186 CID molindone_18/NNP (r_compound) administration_19/NN (r_pobj) following_17/VBG (r_prep) illustrate_9/VB (l_dobj) rhabdomyolysis_11/NN (l_conj) failure_16/NN
20621845
D002122_D017545 CID CaCl2-induced_5/JJ (r_amod) aneurysm_8/NN
D002122_D017545 CID chloride_18/NN (r_pobj) by_16/IN (r_prep) establish_5/VB (l_dobj) model_8/NN (l_prep) of_9/IN (l_pobj) aneurysm_12/NN
D002122_D017545 CID chloride_18/NN (r_pobj) by_16/IN (r_prep) establish_5/VB (l_dobj) model_8/NN (l_prep) of_9/IN (l_pobj) aneurysm_12/NN (l_appos) TAA_14/NNP
D002122_D017545 CID chloride_18/NN (r_pobj) by_16/IN (r_prep) establish_5/VB (l_conj) explore_25/VB (l_dobj) role_28/NN (l_prep) of_29/IN (l_pobj) disintegrin_31/NN (l_conj) metalloproteinase_33/NN (l_conj) metalloproteinases_39/NNS (l_conj) inhibitors_46/NNS (l_prep) in_50/IN (l_pobj) formation_52/NN (l_compound) TAA_51/NNP
D002122_D017545 CID CaCl(2))-induced_20/VBN (r_appos) chloride_18/NN (r_pobj) by_16/IN (r_prep) establish_5/VB (l_dobj) model_8/NN (l_prep) of_9/IN (l_pobj) aneurysm_12/NN
D002122_D017545 CID CaCl(2))-induced_20/VBN (r_appos) chloride_18/NN (r_pobj) by_16/IN (r_prep) establish_5/VB (l_dobj) model_8/NN (l_prep) of_9/IN (l_pobj) aneurysm_12/NN (l_appos) TAA_14/NNP
D002122_D017545 CID CaCl(2))-induced_20/VBN (r_appos) chloride_18/NN (r_pobj) by_16/IN (r_prep) establish_5/VB (l_conj) explore_25/VB (l_dobj) role_28/NN (l_prep) of_29/IN (l_pobj) disintegrin_31/NN (l_conj) metalloproteinase_33/NN (l_conj) metalloproteinases_39/NNS (l_conj) inhibitors_46/NNS (l_prep) in_50/IN (l_pobj) formation_52/NN (l_compound) TAA_51/NNP
D002122_D017545 CID )_9/-RRB- (r_punct) exposure_10/NN (r_appos) model_5/NN (l_compound) TAA_4/NNP
D002122_D014652 NONE chloride_18/NN (l_appos) injury_22/NN
D002122_D014652 NONE CaCl(2))-induced_20/VBN (r_appos) chloride_18/NN (l_appos) injury_22/NN
11206082
C036150_D012640 CID carboline_10/NN (r_npadvmod) induced_12/VBN (r_amod) seizures_13/NNS
C036150_D012640 CID carboline-3-carboxylate_32/NN (r_pobj) of_28/IN (r_prep) injection_27/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) seizures_21/NNS
C036150_D012640 CID CCM_36/NNP (r_appos) carboline-3-carboxylate_32/NN (r_pobj) of_28/IN (r_prep) injection_27/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) seizures_21/NNS
D005680_D012640 NONE GABA(A_24/DT (r_pobj) of_22/IN (r_prep) effects_21/NNS (r_pobj) to_18/IN (r_prep) sensitive_17/JJ (r_acomp) are_14/VBP (l_nsubj) lines_2/NNS (l_acl) selected_3/VBN (l_prep) to_7/IN (l_pobj) seizures_13/NNS
D005680_D012640 NONE GABA(A_44/NN (r_pobj) of_42/IN (r_prep) agonist_41/NN (r_appos) injection_27/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) seizures_21/NNS
D001569_D012640 NONE benzodiazepine_47/NN (r_compound) site_48/NN (r_appos) agonist_41/NN (r_appos) injection_27/NN (r_pobj) by_23/IN (r_agent) induced_22/VBN (r_acl) seizures_21/NNS
D003975_D012640 NONE diazepam_2/NN (r_npadvmod) induced_4/VBN (r_amod) anxiolysis_5/NN (r_dobj) measured_1/VBD (l_prep) by_18/IN (l_pcomp) recording_19/VBG (l_dobj) states_22/NNS (l_conj) seizures_30/NNS
D003975_D012640 NONE diazepam_14/NN (r_npadvmod) induced_16/VBN (r_amod) sedation_17/NN (r_appos) test_12/NN (r_pobj) with_6/IN (r_prep) measured_1/VBD (l_prep) by_18/IN (l_pcomp) recording_19/VBG (l_dobj) states_22/NNS (l_conj) seizures_30/NNS
D010852_D012640 CID picrotoxin-_25/NN (r_dep) and_26/CC (r_cc) induced_29/VBN (r_amod) seizures_30/NNS
D010433_D012640 CID pentylenetetrazol_27/JJ (r_amod) induced_29/VBN (r_amod) seizures_30/NNS
1420741
D005672_D003424 NONE acid_7/NN (r_pobj) with_5/IN (r_prep) disease_4/NN
D005672_D003424 NONE acid_28/NN (r_compound) treatment_29/NN (r_pobj) of_26/IN (r_prep) pharmacodynamics_23/NNS (r_dobj) estimate_21/VB (r_advcl) undertaken_19/VBN (l_prep) Because_0/IN (l_pobj) need_3/NN (l_prep) for_4/IN (l_pobj) development_6/NN (l_prep) of_7/IN (l_pobj) treatments_9/NNS (l_prep) for_10/IN (l_pobj) disease_13/NN
D005672_D003424 NONE acid_9/NN (r_nsubj) be_11/VB (l_prep) of_12/IN (l_pobj) benefit_13/NN (l_prep) in_14/IN (l_pobj) patients_21/NNS (l_compound) disease_20/NN
D016572_D003424 NONE cyclosporin_16/NN (r_pobj) to_15/IN (r_prep) similar_14/JJ (r_amod) properties_13/NNS (r_pobj) with_11/IN (r_prep) antibiotic_10/NN (r_appos) Treatment_0/NN (l_prep) of_1/IN (l_pobj) disease_4/NN
D005672_D015212 NONE acid_13/NN (r_pobj) of_11/IN (r_prep) use_10/NN (l_prep) at_14/IN (l_pobj) level_17/NN (l_prep) in_18/IN (l_pobj) disease_21/NN
84204
D002927_D003221 CID cimetidine_7/NN (r_npadvmod) associated_9/VBN (r_amod) confusion_11/NN
D002927_D003221 CID cimetidine_3/NN (r_npadvmod) associated_5/VBN (r_amod) confusion_7/NN
D002927_D051437 NONE cimetidine_19/NN (r_compound) concentrations_22/NNS (r_conj) dysfunction_8/NN
D002927_D008107 NONE cimetidine_19/NN (r_compound) concentrations_22/NNS (r_conj) dysfunction_8/NN
234669
D000628_D014693 CID aminophylline_2/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_3/IN (l_pobj) threshold_5/NN (l_prep) for_6/IN (l_pcomp) initiating_7/VBG (l_dobj) fibrillation_9/NN
D000628_D014693 CID aminophylline_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_4/IN (l_pobj) threshold_8/NN (l_compound) fibrillation_7/NN
D000628_D014693 CID aminophylline_4/NNP (r_pobj) of_3/IN (r_prep) infusion_2/NN (r_pobj) During_0/IN (r_prep) reduced_11/VBN (l_nsubjpass) threshold_9/NN (l_compound) fibrillation_8/NN
D000628_D014693 CID aminophylline_12/NNP (r_pobj) of_11/IN (r_prep) infusion_10/NN (r_nsubj) resulted_13/VBD (l_prep) in_14/IN (l_pobj) decrease_18/NN (l_prep) in_19/IN (l_pobj) threshold_22/NN (l_compound) fibrillation_21/NN
D000628_D012131 NONE aminophylline_2/NN (r_pobj) of_1/IN (r_prep) Effects_0/NNS (l_prep) on_3/IN (l_pobj) threshold_5/NN (l_prep) for_6/IN (l_pcomp) initiating_7/VBG (l_prep) during_10/IN (l_pobj) failure_12/NN
D000628_D012131 NONE aminophylline_3/NN (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) during_9/IN (l_conj) during_16/IN (l_pobj) failure_18/NN
D000628_D012131 NONE aminophylline_24/NN (r_appos) agents_21/NNS (r_dobj) contribute_8/VB (l_prep) to_9/IN (l_pobj) incidence_12/NN (l_prep) of_13/IN (l_pobj) arrhythmias_15/NNS (l_prep) in_16/IN (l_pobj) failure_18/NN
D010100_D014693 NONE oxygen_26/NN (r_pobj) of_25/IN (r_prep) pressures_24/NNS (r_nsubjpass) kept_37/VBN (r_conj) reduced_11/VBN (l_nsubjpass) threshold_9/NN (l_compound) fibrillation_8/NN
C093415_D014693 NONE PO2_28/NNP (r_appos) oxygen_26/NN (r_pobj) of_25/IN (r_prep) pressures_24/NNS (r_nsubjpass) kept_37/VBN (r_conj) reduced_11/VBN (l_nsubjpass) threshold_9/NN (l_compound) fibrillation_8/NN
D002245_D014693 NONE dioxide_32/NN (r_conj) PO2_28/NNP (r_appos) oxygen_26/NN (r_pobj) of_25/IN (r_prep) pressures_24/NNS (r_nsubjpass) kept_37/VBN (r_conj) reduced_11/VBN (l_nsubjpass) threshold_9/NN (l_compound) fibrillation_8/NN
D002245_D014693 NONE CO2_34/NNP (r_appos) dioxide_32/NN (r_conj) PO2_28/NNP (r_appos) oxygen_26/NN (r_pobj) of_25/IN (r_prep) pressures_24/NNS (r_nsubjpass) kept_37/VBN (r_conj) reduced_11/VBN (l_nsubjpass) threshold_9/NN (l_compound) fibrillation_8/NN
D000628_D001145 NONE aminophylline_24/NN (r_appos) agents_21/NNS (r_dobj) contribute_8/VB (l_prep) to_9/IN (l_pobj) incidence_12/NN (l_prep) of_13/IN (l_pobj) arrhythmias_15/NNS
7881871
D011692_D007674 CID aminonucleoside_7/RB (r_advmod) induced_9/VBN (r_amod) nephropathy_10/NN
D011692_D007674 CID aminonucleoside_12/RB (l_appos) nephropathy_15/NN
D011692_D007674 CID PAN)-induced_14/VBN (r_nummod) nephropathy_15/NN
D011692_D007674 CID PAN_14/NNP (r_compound) nephropathy_15/NN
D010100_D007674 NONE oxygen_1/NN (r_compound) species_2/NNS (r_nsubjpass) implicated_5/VBN (l_prep) in_6/IN (l_pobj) pathogenesis_8/NN (l_prep) of_9/IN (l_pobj) puromycin_11/NNP (l_advmod) aminonucleoside_12/RB (l_appos) nephropathy_15/NN
D010100_D011507 NONE oxygen_1/NN (r_compound) species_2/NNS (r_nsubjpass) implicated_5/VBN (l_prep) in_6/IN (l_pobj) pathogenesis_8/NN (l_prep) of_9/IN (l_pobj) puromycin_11/NNP (l_advmod) aminonucleoside_12/RB (l_appos) nephropathy_15/NN (l_prep) with_17/IN (l_pcomp) reducing_20/VBG (l_dobj) proteinuria_22/NN
D011692_D011507 CID aminonucleoside_12/RB (l_appos) nephropathy_15/NN (l_prep) with_17/IN (l_pcomp) reducing_20/VBG (l_dobj) proteinuria_22/NN
D011692_D011507 CID PAN)-induced_14/VBN (r_nummod) nephropathy_15/NN (l_prep) with_17/IN (l_pcomp) reducing_20/VBG (l_dobj) proteinuria_22/NN
D011692_D011507 CID PAN_14/NNP (r_compound) nephropathy_15/NN (r_pobj) in_13/IN (r_prep) injury_12/NN
2385256
D008274_D009157 CID magnesium_6/NN (r_compound) administration_7/NN (r_pobj) after_5/IN (r_prep) weakness_4/NN (r_pobj) as_3/IN (r_prep) presenting_2/VBG (l_nsubj) gravis_1/XX
D008274_D009157 CID magnesium_3/NN (r_compound) administration_4/NNP (r_nsubjpass) described_7/VBN (l_prep) in_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) gravis_13/NN
D008274_D009468 NONE magnesium_17/NNP (r_compound) administration_18/NN (r_pobj) after_15/IN (r_prep) became_12/VBD (r_relcl) history_7/NN (l_prep) of_8/IN (l_pobj) disease_10/NN
D008274_D011782 NONE magnesium_17/NNP (r_compound) administration_18/NN (r_pobj) after_15/IN (r_prep) became_12/VBD (l_acomp) quadriplegic_14/JJ
D008274_D011225 NONE magnesium_17/NNP (r_compound) administration_18/NN (l_prep) for_19/IN (l_pobj) preeclampsia_20/NN
D008274_D010243 NONE magnesium_3/NN (r_compound) administration_4/NNP (r_nsubjpass) described_7/VBN (l_nsubjpass) paralysis_1/NN
D008274_D020511 NONE magnesium_10/NN (r_pobj) of_9/IN (r_prep) effects_8/NNS (r_pobj) to_5/IN (r_prep) sensitive_4/JJ (r_acomp) are_2/VBP (r_relcl) Patients_0/NNS (r_nsubjpass) suspected_13/VBN (l_prep) of_14/IN (l_pcomp) having_15/VBG (l_dobj) disorder_18/NN (l_prep) of_19/IN (l_pobj) transmission_21/NN
12198388
D000109_D012640 NONE acetylcholine_4/NN (r_compound) release_5/NN (l_conj) sensitivity_9/NN (l_prep) in_10/IN (l_pobj) lines_22/NNS (l_amod) prone_14/JJ (l_npadvmod) seizure_12/NN
D000109_D012640 NONE acetylcholine_4/NN (r_compound) release_5/NN (l_conj) sensitivity_9/NN (l_prep) in_10/IN (l_pobj) lines_22/NNS (l_amod) resistant_19/JJ (l_npadvmod) seizure_17/NN
D000109_D012640 NONE ACh_1/NNP (r_nsubjpass) measured_4/VBN (l_prep) during_5/IN (l_pobj) testing_6/VBG (l_prep) for_7/IN (l_pobj) convulsions_11/NNS
D000109_D012640 NONE ACh_2/NNP (r_nsubjpass) measured_4/VBN (l_prep) during_5/IN (l_pobj) testing_6/VBG (l_prep) for_7/IN (l_pobj) convulsions_11/NNS
D000109_D012640 NONE ACh_14/NNP (r_nsubj) was_15/VBD (l_advcl) measured_4/VBN (l_prep) during_5/IN (l_pobj) testing_6/VBG (l_prep) for_7/IN (l_pobj) convulsions_11/NNS
D009538_D014202 NONE nicotine_3/NN (r_oprd) administered_2/VBN (l_conj) recorded_25/VBN (l_nsubjpass) latencies_17/NNS (l_prep) to_18/TO (l_pobj) onset_19/NN (l_prep) of_20/IN (l_pobj) tremor_21/NN
D002217_D014202 NONE carbachol_5/NNP (r_conj) nicotine_3/NN (r_oprd) administered_2/VBN (l_conj) recorded_25/VBN (l_nsubjpass) latencies_17/NNS (l_prep) to_18/TO (l_pobj) onset_19/NN (l_prep) of_20/IN (l_pobj) tremor_21/NN
D009388_D014202 NONE neostigmine_8/NNP (r_conj) carbachol_5/NNP (r_conj) nicotine_3/NN (r_oprd) administered_2/VBN (l_conj) recorded_25/VBN (l_nsubjpass) latencies_17/NNS (l_prep) to_18/TO (l_pobj) onset_19/NN (l_prep) of_20/IN (l_pobj) tremor_21/NN
D009538_D012640 CID nicotine_7/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) endpoints_4/NNS (l_compound) convulsion_3/NN
D002217_D012640 CID carbachol_9/NNP (r_conj) nicotine_7/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) endpoints_4/NNS (l_compound) convulsion_3/NN
D009388_D012640 CID neostigmine_12/NNP (r_conj) carbachol_9/NNP (r_conj) nicotine_7/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (r_acl) endpoints_4/NNS (l_compound) convulsion_3/NN
D000431_D012640 NONE ethanol_18/NN (r_compound) severity_20/NN (r_pobj) with_17/IN (r_prep) associated_16/VBN (l_nsubjpass) differences_4/NNS (l_prep) to_11/IN (l_pobj) convulsants_13/NNS
D000431_D012640 NONE alcohol_26/NN (r_compound) withdrawal_27/NN (r_pobj) in_25/IN (r_prep) mechanisms_24/NNS (r_dobj) implicate_22/VB (r_conj) associated_16/VBN (l_nsubjpass) differences_4/NNS (l_prep) to_11/IN (l_pobj) convulsants_13/NNS
9754849
D008691_D002819 CID methadone_7/NN (r_pobj) to_6/IN (r_prep) adjustment_5/NN (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) movements_1/NNS
D008691_D002819 CID methadone_24/NN (r_acl) report_4/NN (l_prep) of_5/IN (l_pobj) movements_9/NNS
D003042_D002819 CID cocaine_12/NN (r_pobj) with_11/IN (r_prep) intoxications_10/NNS (r_pobj) during_9/IN (r_prep) be_5/VB (r_xcomp) known_3/VBN (l_nsubjpass) hyperkinesias_1/NNS
D003042_D002819 CID cocaine_32/NN (r_conj) heroine_30/NN (r_dobj) abusing_29/VBG (r_acl) inpatient_27/NN (r_pobj) in_25/IN (r_prep) methadone_24/NN (r_acl) report_4/NN (l_prep) of_5/IN (l_pobj) movements_9/NNS
D003042_D006948 CID cocaine_12/NN (r_pobj) with_11/IN (r_prep) intoxications_10/NNS (r_pobj) during_9/IN (r_prep) be_5/VB (r_xcomp) known_3/VBN (l_nsubjpass) hyperkinesias_1/NNS
D003042_D020820 NONE cocaine_12/NN (r_pobj) with_11/IN (r_prep) intoxications_10/NNS (r_pobj) during_9/IN (r_prep) be_5/VB (l_attr) abnormalities_8/NNS
D003932_D002819 NONE heroine_30/NN (r_dobj) abusing_29/VBG (r_acl) inpatient_27/NN (r_pobj) in_25/IN (r_prep) methadone_24/NN (r_acl) report_4/NN (l_prep) of_5/IN (l_pobj) movements_9/NNS
9284778
-1_D008107 NONE hydrochlorofluorocarbons_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) disease_3/NN
D010126_D008107 NONE ozone_9/NN (r_npadvmod) sparing_11/VBG (r_amod) substitutes_12/NNS (r_pobj) as_8/IN (r_prep) used_7/VBN (r_acl) hydrochlorofluorocarbons_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) disease_3/NN
D017402_D008107 NONE chlorofluorocarbons_14/NNS (r_pobj) of_13/IN (r_prep) substitutes_12/NNS (r_pobj) as_8/IN (r_prep) used_7/VBN (r_acl) hydrochlorofluorocarbons_6/NNS (r_pobj) by_5/IN (r_agent) caused_4/VBN (r_acl) disease_3/NN
C067411_D008107 CID 1,1-dichloro-2,2,2-trifluoroethane_21/CD (r_pobj) of_20/IN (r_prep) mixture_19/NN (r_pobj) to_17/IN (r_prep) exposure_16/NN (r_dobj) repeated_14/VBN (r_relcl) workers_10/NNS (r_pobj) in_7/IN (r_prep) disease_6/NN
C067411_D008107 CID 123_24/CD (r_nummod) HCFC_23/NNP (r_npadvmod) repeated_14/VBN (r_relcl) workers_10/NNS (r_pobj) in_7/IN (r_prep) disease_6/NN
C067411_D008107 CID 124_8/CD (r_conj) HCFCs_5/NNS (r_nsubj) result_10/VB (l_prep) in_11/IN (l_pobj) disease_14/NN
C072959_D008107 CID 1-chloro-1,2,2,2-tetrafluoroethane_27/CD (r_conj) investigated_1/VBD (l_dobj) epidemic_3/NN (l_prep) of_4/IN (l_pobj) disease_6/NN
C072959_D008107 CID 124_30/CD (r_npadvmod) HCFC_29/NNP (r_appos) 1-chloro-1,2,2,2-tetrafluoroethane_27/CD (r_conj) investigated_1/VBD (l_dobj) epidemic_3/NN (l_prep) of_4/IN (l_pobj) disease_6/NN
C072959_D008107 CID 124_8/CD (r_conj) HCFCs_5/NNS (r_nsubj) result_10/VB (l_prep) in_11/IN (l_pobj) disease_14/NN
D006221_D056486 NONE 1-bromo-1-chloro-2,2,2-trifluoroethane_9/CD (r_pobj) as_8/IN (r_prep) way_7/NN (r_pobj) in_4/IN (r_prep) metabolised_3/VBN (l_advcl) form_14/VB (l_dobj) intermediates_18/NNPS (l_relcl) implicated_23/VBN (l_prep) in_24/IN (l_pobj) hepatotoxicity_26/NN
D006221_D056486 NONE halothane_11/NNP (r_appos) way_7/NN (r_pobj) in_4/IN (r_prep) metabolised_3/VBN (l_advcl) form_14/VB (l_dobj) intermediates_18/NNPS (l_relcl) implicated_23/VBN (l_prep) in_24/IN (l_pobj) hepatotoxicity_26/NN
D006221_D056486 NONE halothane_28/NNP (r_pobj) of_27/IN (r_prep) hepatotoxicity_26/NN
D014269_D056486 NONE trifluoroacetyl_16/NNP (r_compound) intermediates_18/NNPS (l_relcl) implicated_23/VBN (l_prep) in_24/IN (l_pobj) hepatotoxicity_26/NN
D014269_D056486 NONE trifluoroacetyl_17/NN (r_npadvmod) altered_19/VBN (r_amod) proteins_21/NNS (r_nsubjpass) involved_23/VBN (r_ccomp) suggest_15/VBP (l_advcl) known_11/VBN (l_nsubjpass) mechanism_3/NN (l_prep) of_4/IN (l_pobj) hepatotoxicity_5/NN
C067411_D056486 NONE 124_9/CD (r_conj) HCFCs_6/NNS (r_pobj) to_5/IN (r_prep) exposure_1/NN (r_nsubj) result_11/VB (l_prep) in_12/IN (l_pobj) injury_15/NN
C072959_D056486 NONE 124_9/CD (r_conj) HCFCs_6/NNS (r_pobj) to_5/IN (r_prep) exposure_1/NN (r_nsubj) result_11/VB (l_prep) in_12/IN (l_pobj) injury_15/NN
8387218
D016049_D064420 NONE didanosine_5/NNP (r_pobj) of_4/IN (r_prep) use_1/NN (l_conj) toxicity_3/NN
D016049_D064420 NONE ddI_7/NNP (r_appos) didanosine_5/NNP (r_pobj) of_4/IN (r_prep) use_1/NN (l_conj) toxicity_3/NN
D016049_D015658 NONE didanosine_5/NNP (l_prep) in_9/IN (l_pobj) individuals_14/NNS (l_amod) positive_13/JJ
D016049_D015658 NONE ddI_7/NNP (r_appos) didanosine_5/NNP (l_prep) in_9/IN (l_pobj) individuals_14/NNS (l_amod) positive_13/JJ
D015215_D064420 NONE zidovudine_17/JJ (r_nmod) AZT_19/NNP (r_pobj) to_16/IN (r_prep) intolerant_15/JJ (r_amod) individuals_14/NNS (r_pobj) in_9/IN (r_prep) didanosine_5/NNP (r_pobj) of_4/IN (r_prep) use_1/NN (l_conj) toxicity_3/NN
D015215_D064420 NONE AZT_19/NNP (r_pobj) to_16/IN (r_prep) intolerant_15/JJ (r_amod) individuals_14/NNS (r_pobj) in_9/IN (r_prep) didanosine_5/NNP (r_pobj) of_4/IN (r_prep) use_1/NN (l_conj) toxicity_3/NN
D015215_D015658 NONE zidovudine_17/JJ (r_nmod) AZT_19/NNP (r_pobj) to_16/IN (r_prep) intolerant_15/JJ (r_amod) individuals_14/NNS (l_amod) positive_13/JJ
D015215_D015658 NONE AZT_19/NNP (r_pobj) to_16/IN (r_prep) intolerant_15/JJ (r_amod) individuals_14/NNS (l_amod) positive_13/JJ
11587867
D014750_D001927 NONE vincristin_6/NNP (r_compound) administration_7/NN (r_pobj) due_2/IN (r_amod) myeloencephalopathy_1/NNS
D014750_D054198 NONE vincristine_9/NN (r_compound) instillation_10/NN (r_pobj) of_6/IN (r_prep) cases_5/NNS (l_prep) in_11/IN (l_pobj) girl_15/NN (l_prep) with_16/IN (l_pobj) leucemia_20/NN
D014750_D054198 NONE vincristine_9/NN (r_compound) instillation_10/NN (r_pobj) of_6/IN (r_prep) cases_5/NNS (l_prep) in_11/IN (l_pobj) girl_15/NN (l_prep) with_16/IN (l_pobj) leucemia_20/NN (l_conj) man_25/NN (l_prep) with_26/IN (l_pobj) lymphoma_28/NN
D014750_D003711 CID vincristine_24/NN (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) areas_21/NNS (r_pobj) in_20/IN (r_prep) degeneration_10/NN (l_prep) of_11/IN (l_pobj) myelin_12/NN (l_conj) axons_14/NNS
D014750_D009410 CID vincristine_24/NN (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) areas_21/NNS (r_pobj) in_20/IN (r_prep) degeneration_10/NN (l_prep) of_11/IN (l_pobj) myelin_12/NN (l_conj) axons_14/NNS
D014750_-1 NONE vincristine_24/NN (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) areas_21/NNS (r_pobj) in_20/IN (r_prep) degeneration_10/NN (l_prep) of_11/IN (l_pobj) myelin_12/NN (l_conj) transformation_19/NN
8595686
D013874_D010146 NONE Thiopentone_0/NN (r_compound) pretreatment_1/NN (l_prep) for_2/IN (l_pobj) pain_5/NN
D013874_D010146 NONE thiopentone_17/NNP (r_nsubj) reduces_19/VBZ (r_advcl) reduces_4/VBZ (l_dobj) incidence_6/NN (l_prep) of_9/IN (l_pobj) pain_12/NN
D015742_D010146 CID propofol_3/NN (r_compound) injection_4/NN (r_compound) pain_5/NN
D015742_D010146 CID propofol_3/NN (r_nmod) pain_5/NN
D015742_D010146 CID propofol_10/NN (r_compound) injection_11/NN (r_compound) pain_12/NN
D008012_D010146 NONE lidocaine_3/NN (r_nsubj) reduces_4/VBZ (l_dobj) incidence_6/NN (l_prep) of_9/IN (l_pobj) pain_12/NN
3437726
D013034_D064420 NONE sparteine_11/NNP (r_nmod) debrisoquine_13/NN (r_compound) polymorphism_14/NN (r_pobj) of_10/IN (r_prep) phenotype_9/NN (r_pobj) to_4/IN (r_prep) belonging_3/VBG (r_acl) patients_2/NNS (r_nsubj) experience_29/VB (l_dobj) reactions_32/NNS
D003647_D064420 NONE debrisoquine_13/NN (r_compound) polymorphism_14/NN (r_pobj) of_10/IN (r_prep) phenotype_9/NN (r_pobj) to_4/IN (r_prep) belonging_3/VBG (r_acl) patients_2/NNS (r_nsubj) experience_29/VB (l_dobj) reactions_32/NNS
3714122
C005238_D020258 NONE mipafox_7/NNP (r_npadvmod) induced_9/VBN (r_amod) damage_11/NN (r_conj) inhibition_5/NN (l_amod) neurotoxic_3/JJ
C005238_D020258 NONE Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN (l_prep) of_7/IN (l_pobj) esterase_9/NN (l_amod) neurotoxic_8/JJ
C005238_D020258 NONE Mipafox_24/NNP (l_appos) organophosphate_33/NN (l_amod) neurotoxic_32/JJ
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28/NNP (r_appos) N_26/NNP (r_appos) Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN (l_prep) of_7/IN (l_pobj) esterase_9/NN (l_amod) neurotoxic_8/JJ
C005238_D020258 NONE N'-diisopropylphosphorodiamidofluoridate_28/NNP (r_appos) N_26/NNP (r_appos) Mipafox_24/NNP (l_appos) organophosphate_33/NN (l_amod) neurotoxic_32/JJ
C005238_D009422 NONE mipafox_7/NNP (r_npadvmod) induced_9/VBN (r_amod) damage_11/NN
C005238_D009422 NONE Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN
C005238_D009422 NONE Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN (l_prep) of_7/IN (l_pobj) esterase_9/NN (l_conj) enzyme_13/NNS (l_compound) target_12/NN (l_compound) neuropathy_11/NN
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28/NNP (r_appos) N_26/NNP (r_appos) Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN
C005238_D009422 NONE N'-diisopropylphosphorodiamidofluoridate_28/NNP (r_appos) N_26/NNP (r_appos) Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN (l_prep) of_7/IN (l_pobj) esterase_9/NN (l_conj) enzyme_13/NNS (l_compound) target_12/NN (l_compound) neuropathy_11/NN
C005238_D009422 NONE Mipafox_18/NNP (r_compound) exposure_19/NN (r_nsubj) predict_21/VB (l_dobj) damage_23/NN
D010755_D009422 NONE organophosphate_33/NN (r_appos) Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN
D010755_D009422 NONE organophosphate_33/NN (r_appos) Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN (l_prep) of_7/IN (l_pobj) esterase_9/NN (l_conj) enzyme_13/NNS (l_compound) target_12/NN (l_compound) neuropathy_11/NN
D010755_D020258 NONE organophosphate_33/NN (r_appos) Mipafox_24/NNP (r_pobj) to_23/IN (r_prep) exposed_22/VBN (r_acl) rats_20/NNS (r_pobj) in_19/IN (r_prep) examined_18/VBN (l_nsubjpass) correlation_1/NN (l_prep) between_2/IN (l_pobj) damage_4/NN (l_prep) of_7/IN (l_pobj) esterase_9/NN (l_amod) neurotoxic_8/JJ
D010755_D020258 NONE organophosphate_33/NN (l_amod) neurotoxic_32/JJ
C005238_D013118 CID Mipafox_5/NNP (r_pobj) of_4/IN (r_prep) dosages_3/NNS (l_relcl) inhibited_16/VBD (l_advcl) produced_39/VBD (l_dobj) degree_41/NN (l_prep) of_42/IN (l_pobj) damage_44/NN
19445921
C066201_D009203 NONE A_5/NNP (l_prep) on_6/IN (l_pobj) infarction_11/NN
C066201_D009203 NONE A_13/NNP (l_prep) on_14/IN (l_pobj) infarction_19/NN
D007545_D009203 CID isoproterenol_7/NN (r_npadvmod) induced_9/VBN (r_amod) infarction_11/NN
D007545_D009203 CID isoproterenol_15/NN (r_npadvmod) induced_17/VBN (r_amod) infarction_19/NN
D007545_D009203 CID isoproterenol_10/NN (r_npadvmod) induced_12/VBN (r_amod) infarction_14/NN
D000244_D012131 NONE ADP_13/NNP (r_nmod) O_15/NNP (r_conj) ratio_11/NN (r_pobj) by_7/IN (r_agent) characterized_6/VBN (r_acl) dysfunction_5/NN
D007545_D012131 NONE isoproterenol_19/NN (r_npadvmod) treated_21/VBN (r_amod) rats_22/NNS (r_pobj) in_18/IN (r_prep) observed_17/VBN (l_nsubjpass) dysfunction_5/NN
C066201_D006331 NONE A_4/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) attenuated_12/VBD (l_dobj) dysfunction_17/NN
C066201_D009202 NONE A_4/NNP (r_pobj) of_1/IN (r_prep) Administration_0/NN (r_nsubj) attenuated_12/VBD (l_dobj) dysfunction_17/NN (l_conj) injury_20/NN
C066201_D009202 NONE A_6/NNP (l_prep) against_7/IN (l_pobj) damage_12/NN
D007545_D006331 NONE isoproterenol_13/NN (r_npadvmod) induced_15/VBN (r_amod) dysfunction_17/NN
D007545_D009202 NONE isoproterenol_13/NN (r_npadvmod) induced_15/VBN (r_amod) dysfunction_17/NN (l_conj) injury_20/NN
D007545_D009202 NONE isoproterenol_8/NN (r_npadvmod) induced_10/VBN (r_amod) damage_12/NN
19308880
D014635_D003221 CID acid_10/NN (r_pobj) with_8/IN (r_prep) reaction_7/NN (r_appos) Confusion_0/NN
D014635_D003221 CID acid_10/NN (r_pobj) with_8/IN (r_prep) observed_7/VBN (r_acl) reaction_5/NN (r_attr) is_1/VBZ (l_nsubj) Confusion_0/NN
D014635_D003221 CID acid_17/NN (r_pobj) with_15/IN (r_prep) reported_12/VBN (r_acl) cases_9/NNS (l_prep) of_10/IN (l_pobj) confusion_11/NN
D014635_D003221 CID acid_8/NN (r_pobj) with_6/IN (r_prep) reported_5/VBN (l_nsubjpass) cases_1/NNS (l_prep) of_2/IN (l_pobj) confusion_3/NN
D014635_D003221 CID acid_10/NN (r_compound) exposure_11/NN (r_pobj) following_8/VBG (r_prep) occurred_2/VBD (l_nsubj) Confusion_0/NN
D014635_D003221 CID acid_7/NN (r_pobj) with_5/IN (r_prep) confusion_4/NN
3173179
D014700_D009203 CID Verapamil_0/NN (r_compound) withdrawal_1/NN (l_prep) as_2/IN (l_pobj) cause_5/NN (l_prep) of_6/IN (l_pobj) infarction_8/NN
D014700_D009203 CID verapamil_18/NN (r_pobj) of_17/IN (r_prep) withdrawal_16/NN (r_conj) introduction_11/NN (r_pobj) with_9/IN (r_prep) coincided_8/VBD (l_nsubj) infarction_7/NN
D014700_D006973 NONE Verapamil_0/NN (r_compound) withdrawal_1/NN (l_prep) as_2/IN (l_pobj) cause_5/NN (l_prep) of_6/IN (l_pobj) infarction_8/NN (l_prep) in_9/IN (l_pobj) woman_12/NN (l_amod) hypertensive_11/JJ
D014700_D006973 NONE verapamil_18/NN (r_pobj) of_17/IN (r_prep) withdrawal_16/NN (l_prep) in_19/IN (l_pobj) woman_23/NN (l_prep) with_24/IN (l_pobj) hypertension_26/NN
D002216_D009203 NONE captopril_13/NNP (r_pobj) of_12/IN (r_prep) introduction_11/NN (r_pobj) with_9/IN (r_prep) coincided_8/VBD (l_nsubj) infarction_7/NN
D002216_D006973 NONE captopril_13/NNP (r_pobj) of_12/IN (r_prep) introduction_11/NN (l_conj) withdrawal_16/NN (l_prep) in_19/IN (l_pobj) woman_23/NN (l_prep) with_24/IN (l_pobj) hypertension_26/NN
6773726
D005996_D007022 CID nitroglycerin_5/NN (r_pobj) by_4/IN (r_prep) Provocation_0/NN (l_prep) of_1/IN (l_pobj) hypotension_3/NN
D005996_D003929 NONE nitroglycerin_5/NN (l_prep) in_6/IN (l_pobj) neuropathy_9/NN
D005996_D003920 NONE nitroglycerin_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) compared_12/VBN (l_prep) in_13/IN (l_pobj) subjects_16/NNS (l_appos) subjects_20/NNS (l_amod) diabetic_19/JJ
D005996_D003920 NONE nitroglycerin_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) compared_12/VBN (l_prep) in_13/IN (l_pobj) subjects_16/NNS (l_appos) subjects_20/NNS (l_conj) subjects_28/NNS (l_amod) diabetic_27/JJ
D005996_D003920 NONE nitroglycerin_19/NN (r_pobj) after_18/IN (r_mark) were_20/VBD (l_acomp) similar_21/JJ (l_prep) in_22/IN (l_pobj) subjects_27/NNS (l_amod) normal_24/JJ (l_conj) diabetic_26/JJ
D005996_D003920 NONE nitroglycerin_19/NN (r_pobj) after_18/IN (r_mark) were_20/VBD (l_advcl) occurred_47/VBD (l_prep) in_48/IN (l_pobj) subjects_51/NNS (l_amod) diabetic_50/JJ
D005996_D009422 NONE nitroglycerin_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) compared_12/VBN (l_prep) in_13/IN (l_pobj) subjects_16/NNS (l_appos) subjects_20/NNS (l_prep) without_21/IN (l_pobj) neuropathy_23/NN
D005996_D009422 NONE nitroglycerin_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (r_nsubjpass) compared_12/VBN (l_prep) in_13/IN (l_pobj) subjects_16/NNS (l_appos) subjects_20/NNS (l_conj) subjects_28/NNS (l_prep) with_29/IN (l_pobj) neuropathy_31/NN
D005996_D009422 NONE nitroglycerin_19/NN (r_pobj) after_18/IN (r_mark) were_20/VBD (l_acomp) similar_21/JJ (l_prep) in_22/IN (l_pobj) subjects_27/NNS (l_prep) without_28/IN (l_pobj) neuropathy_30/NN
D005996_D009422 NONE nitroglycerin_19/NN (r_pobj) after_18/IN (r_mark) were_20/VBD (l_advcl) occurred_47/VBD (l_prep) in_48/IN (l_pobj) subjects_51/NNS (l_prep) with_52/IN (l_pobj) neuropathy_54/NN
2425813
D011239_D006529 CID prednisolone_14/NNP (r_pobj) of_13/IN (r_prep) administration_12/NN (r_pobj) following_9/VBG (r_prep) occurred_5/VBD (l_nsubj) enlargement_1/NN
D011239_D009133 CID prednisolone_14/NNP (r_pobj) of_13/IN (r_prep) administration_12/NN (r_pobj) following_9/VBG (r_prep) occurred_5/VBD (l_nsubj) enlargement_1/NN (l_conj) wastage_4/NN
11928786
D016642_D064420 NONE Bupropion_0/NNP (r_nmod) toxicity_4/NN
D016642_D064420 NONE Zyban_2/NNP (r_nmod) toxicity_4/NN
D003975_D012640 NONE diazepam_5/NN (r_pobj) with_4/IN (r_prep) treated_3/VBN (l_nsubjpass) seizures_1/NNS
D003975_D013610 NONE diazepam_5/NN (l_conj) tachycardia_9/NN
D000241_D012640 NONE adenosine_14/NN (r_pobj) with_13/IN (r_prep) treated_12/VBN (r_conj) treated_3/VBN (l_nsubjpass) seizures_1/NNS
D000241_D013610 NONE adenosine_14/NN (r_pobj) with_13/IN (r_prep) treated_12/VBN (r_conj) treated_3/VBN (l_prep) with_4/IN (l_pobj) diazepam_5/NN (l_conj) tachycardia_9/NN
D016642_D020258 NONE Zyban_0/NNP (r_nsubj) caused_1/VBD (l_dobj) toxicity_6/NN
D016642_D002318 NONE Zyban_0/NNP (r_nsubj) caused_1/VBD (l_dobj) toxicity_6/NN
D016642_D062787 NONE Zyban_0/NNP (r_nsubj) caused_1/VBD (l_dobj) toxicity_6/NN (l_prep) in_7/IN (l_pobj) overdose_8/NN
3560096
D013467_D006947 CID sulindac_3/NN (r_compound) therapy_4/NN (r_pobj) with_2/IN (r_prep) associated_1/VBN (r_acl) Hyperkalemia_0/NNP
D013467_D006947 CID sulindac_22/NNP (r_compound) administration_23/NN (r_pobj) of_21/IN (r_prep) days_20/NNS (r_pobj) within_16/IN (r_prep) developed_15/VBD (r_advcl) describe_1/VBP (l_dobj) patients_3/NNS (l_relcl) ranging_7/VBG (l_nsubj) hyperkalemia_6/NN
D013467_D006947 CID sulindac_29/NNS (l_conj) hyperkalemia_31/NN
D007213_D006947 CID indomethacin_17/NN (r_pobj) as_16/IN (r_prep) agents_11/NNS (r_pobj) of_8/IN (r_prep) complication_7/NN (r_pobj) as_5/IN (r_prep) recognized_4/VBN (l_nsubjpass) Hyperkalemia_0/NNP
D011188_D006947 NONE potassium_8/NN (r_dobj) effect_6/VB (r_xcomp) known_4/VBN (r_acl) medications_3/NNS (r_nsubjpass) given_11/VBN (r_advcl) is_18/VBZ (l_acomp) suggestive_19/JJ (l_prep) of_20/IN (l_pobj) relationship_27/NN (l_prep) between_28/IN (l_pobj) sulindac_29/NNS (l_conj) hyperkalemia_31/NN
891050
D003276_D006463 CID contraceptives_17/NNS (r_dobj) taking_15/VBG (r_acl) woman_14/NN (r_pobj) in_12/IN (r_prep) syndrome_8/NN
D003276_D006463 CID contraceptives_17/NNS (r_dobj) taking_15/VBG (r_acl) woman_14/NN (r_pobj) in_12/IN (r_prep) syndrome_8/NN (l_appos) HUS_10/NNP
D006493_D001002 NONE heparin_4/NN (r_pobj) with_3/IN (r_prep) treated_2/VBN (l_conj) rose_20/VBD (l_advmod) after_28/IN (l_pobj) onset_30/NN (l_prep) of_31/IN (l_pobj) anuria_32/NNP
D004176_D001002 NONE dipyridamole_6/NN (r_conj) heparin_4/NN (r_pobj) with_3/IN (r_prep) treated_2/VBN (l_conj) rose_20/VBD (l_advmod) after_28/IN (l_pobj) onset_30/NN (l_prep) of_31/IN (l_pobj) anuria_32/NNP
8386779
D017693_D004414 NONE bicarbonate_1/NN (r_nsubj) alleviates_2/VBZ (l_dobj) pain_4/NN
D017693_D004414 NONE bicarbonate_43/NN (r_pobj) of_41/IN (r_prep) addition_40/NN (r_pobj) without_38/IN (r_conj) with_36/IN (r_prep) injections_35/NNS (r_pobj) following_33/VBG (r_prep) incidence_29/NN (r_dobj) comparing_27/VBG (r_acl) study_26/NN (r_dobj) performed_23/VBD (l_prep) In_0/IN (l_pobj) attempt_2/NN (l_acl) determine_4/VB (l_ccomp) be_13/VB (l_nsubj) pain_7/NN
D017693_D004414 NONE bicarbonate_43/NN (r_pobj) of_41/IN (r_prep) addition_40/NN (r_pobj) without_38/IN (r_conj) with_36/IN (r_prep) injections_35/NNS (r_pobj) following_33/VBG (r_prep) incidence_29/NN (l_prep) of_30/IN (l_pobj) pain_32/NN
D017693_D004414 NONE bicarbonate_6/NN (r_pobj) without_4/IN (r_prep) patients_3/NNS (r_pobj) Of_0/IN (r_prep) complained_16/VBD (l_prep) of_17/IN (l_pobj) pain_19/NN
D017693_D004414 NONE bicarbonate_6/NN (r_pobj) without_4/IN (r_prep) patients_3/NNS (r_pobj) Of_0/IN (r_prep) complained_16/VBD (l_advcl) 1_27/CD (l_prep) of_28/IN (l_pobj) men_31/NNS (l_relcl) received_37/VBD (l_dobj) bicarbonate_39/NN (l_acl) complained_40/VBD (l_prep) of_41/IN (l_pobj) pain_43/NN
D017693_D004414 NONE bicarbonate_39/NN (r_dobj) received_37/VBD (r_relcl) men_31/NNS (r_pobj) of_28/IN (r_prep) 1_27/CD (r_advcl) complained_16/VBD (l_prep) of_17/IN (l_pobj) pain_19/NN
D017693_D004414 NONE bicarbonate_39/NN (l_acl) complained_40/VBD (l_prep) of_41/IN (l_pobj) pain_43/NN
D017693_D007172 NONE bicarbonate_1/NN (r_nsubj) alleviates_2/VBZ (l_dobj) pain_4/NN (l_acl) induced_5/VBN (l_agent) by_6/IN (l_pobj) injections_8/NNS (l_prep) for_9/IN (l_pobj) dysfunction_11/NN
D010208_D007172 NONE papaverine_25/NN (r_appos) drugs_21/NNS (r_pobj) of_19/IN (r_prep) combination_18/NN (r_pobj) of_16/IN (r_prep) ml._15/NNS (r_dobj) received_13/VBD (l_nsubj) total_1/NN (l_prep) of_2/IN (l_pobj) patients_5/NNS (l_relcl) presented_7/VBD (l_prep) with_11/IN (l_pobj) impotence_12/NN
3107448
D005905_D056486 CID Glyburide_0/NNP (r_npadvmod) induced_2/VBN (r_amod) hepatitis_3/NN
D005905_D056486 CID glyburide_1/NN (r_pobj) For_0/IN (r_prep) exist_15/VBP (l_nsubj) reports_12/NNS (l_prep) of_13/IN (l_pobj) hepatotoxicity_14/NN
D005905_D056486 CID glyburide_18/NN (r_compound) therapy_19/NN (r_pobj) of_17/IN (r_prep) initiation_16/NN (r_pobj) after_15/IN (r_prep) developed_7/VBD (l_dobj) syndrome_13/NN
D005905_D056486 CID Glyburide_0/NNP (r_nsubj) produce_2/VB (l_dobj) illness_8/NN
D013453_D056486 NONE sulfonylureas_14/NNP (r_pobj) with_13/IN (r_prep) reported_10/VBN (l_nsubjpass) hepatotoxicity_3/NN
D013453_D056486 NONE sulfonylurea_7/NNP (r_pobj) For_0/IN (r_prep) exist_15/VBP (l_nsubj) reports_12/NNS (l_prep) of_13/IN (l_pobj) hepatotoxicity_14/NN
D005905_D003924 NONE glyburide_18/NN (r_compound) therapy_19/NN (r_pobj) of_17/IN (r_prep) initiation_16/NN (r_pobj) after_15/IN (r_prep) developed_7/VBD (l_nsubj) patients_1/NNS (l_prep) with_2/IN (l_pobj) mellitus_6/NN
11147747
D018490_D014549 CID antidepressants_1/NNS (l_conj) incontinence_4/NN
D018490_D014549 CID antidepressants_8/NNS (r_pobj) to_6/IN (r_prep) secondary_5/JJ (r_amod) incontinence_4/NN
C047426_D014549 CID venlafaxine_10/NN (r_dobj) taking_9/VBG (r_advcl) experienced_6/VBD (l_dobj) incontinence_7/NN
C047426_D014549 CID venlafaxine_35/NN (r_pobj) on_34/IN (r_prep) developed_30/VBD (r_relcl) third_28/NN (r_conj) serotonin_17/NN (r_pobj) to_14/IN (r_prep) secondary_13/JJ (r_amod) incontinence_12/NN
D012701_D014549 NONE serotonin_17/NN (r_pobj) to_14/IN (r_prep) secondary_13/JJ (r_amod) incontinence_12/NN
D017374_D014549 CID paroxetine_20/NNP (r_appos) serotonin_17/NN (r_pobj) to_14/IN (r_prep) secondary_13/JJ (r_amod) incontinence_12/NN
D020280_D014549 CID sertraline_22/NN (r_conj) paroxetine_20/NNP (r_appos) serotonin_17/NN (r_pobj) to_14/IN (r_prep) secondary_13/JJ (r_amod) incontinence_12/NN
D016651_D014549 CID carbonate_12/NN (r_dobj) taking_10/VBG (r_relcl) cases_5/NNS (l_relcl) contributed_23/VBN (l_prep) to_24/IN (l_pobj) incontinence_26/NN
14513889
D007654_D009422 NONE Ketoconazole_0/NN (r_npadvmod) induced_2/VBN (r_amod) sequelae_4/NNS
D007654_D018908 CID ketoconazole_23/NN (r_pobj) of_20/IN (r_prep) ingestion_19/NN (r_pobj) after_18/IN (r_prep) weakness_6/NN (l_prep) of_7/IN (l_pobj) extremities_8/NNS
D007654_D010243 CID ketoconazole_23/NN (r_pobj) of_20/IN (r_prep) ingestion_19/NN (r_pobj) after_18/IN (r_prep) weakness_6/NN (l_prep) of_7/IN (l_pobj) extremities_8/NNS (l_conj) paralysis_11/NN
D007654_D004401 CID ketoconazole_23/NN (r_pobj) of_20/IN (r_prep) ingestion_19/NN (r_pobj) after_18/IN (r_prep) weakness_6/NN (l_prep) of_7/IN (l_pobj) extremities_8/NNS (l_conj) paralysis_11/NN (l_conj) dysarthria_13/NN
D007654_D014202 CID ketoconazole_23/NN (r_pobj) of_20/IN (r_prep) ingestion_19/NN (r_pobj) after_18/IN (r_prep) weakness_6/NN (l_prep) of_7/IN (l_pobj) extremities_8/NNS (l_conj) paralysis_11/NN (l_conj) dysarthria_13/NN (l_conj) tremor_15/NN
3615541
D000661_D006948 CID amphetamine_6/NN (r_npadvmod) induced_8/VBN (r_amod) hyperactivity_9/NN
D002116_D006948 NONE calcitonin_12/NN (r_compound) injections_13/NNS (r_pobj) by_10/IN (r_prep) antagonism_4/NN (l_prep) of_5/IN (l_pobj) hyperactivity_9/NN
7834920
D012293_D005921 CID rifampin_6/NN (r_compound) therapy_7/NN (r_pobj) with_4/IN (r_prep) associated_3/VBN (r_acl) glomerulonephritis_2/NN
D012293_D005921 CID rifampin_17/NN (r_pobj) with_16/IN (r_prep) treated_15/VBN (r_acl) patient_14/NN (r_pobj) in_12/IN (r_prep) finding_6/NN (l_prep) of_7/IN (l_pobj) glomerulonephritis_11/NN
D012293_D005921 CID rifampin_20/NN (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_acl) patient_17/NN (r_pobj) in_15/IN (r_prep) occurrence_5/NN (l_prep) of_6/IN (l_pobj) glomerulonephritis_9/NN
D012293_D005921 CID rifampin_20/NN (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_acl) patient_17/NN (r_pobj) in_15/IN (r_prep) occurrence_5/NN (l_prep) with_10/IN (l_pobj) crescents_11/NNS (l_conj) glomerulonephritis_14/NN
D012293_D014397 NONE rifampin_6/NN (r_compound) therapy_7/NN (l_prep) for_8/IN (l_pobj) tuberculosis_10/NN
D012293_D014397 NONE rifampin_7/NN (l_conj) isoniazid_9/NN (l_prep) for_10/IN (l_pobj) tuberculosis_12/NN
D012293_D051437 CID rifampin_7/NN (r_pobj) of_6/IN (r_prep) regimen_5/NN (r_dobj) underwent_2/VBD (l_conj) discovered_15/VBN (l_xcomp) developed_18/VBN (l_dobj) signs_19/NNS (l_prep) of_20/IN (l_pobj) failure_23/NN
D007538_D014397 NONE isoniazid_9/NN (l_prep) for_10/IN (l_pobj) tuberculosis_12/NN
D007538_D051437 NONE isoniazid_9/NN (r_conj) rifampin_7/NN (r_pobj) of_6/IN (r_prep) regimen_5/NN (r_dobj) underwent_2/VBD (l_conj) discovered_15/VBN (l_xcomp) developed_18/VBN (l_dobj) signs_19/NNS (l_prep) of_20/IN (l_pobj) failure_23/NN
19657887
D000431_D005483 CID alcohol_9/NN (r_pobj) of_8/IN (r_prep) ingestion_7/NN (r_pobj) after_5/IN (r_prep) developed_12/VBD (l_prep) with_14/IN (l_pobj) flushing_15/NN (l_prep) of_16/IN (l_pobj) face_18/NN
D000431_D013610 CID alcohol_9/NN (r_pobj) of_8/IN (r_prep) ingestion_7/NN (r_pobj) after_5/IN (r_prep) developed_12/VBD (l_prep) with_14/IN (l_pobj) flushing_15/NN (l_conj) tachycardia_20/NN
D000431_D004417 CID alcohol_9/NN (r_pobj) of_8/IN (r_prep) ingestion_7/NN (r_pobj) after_5/IN (r_prep) developed_12/VBD (l_prep) with_14/IN (l_pobj) flushing_15/NN (l_conj) tachycardia_20/NN (l_conj) dyspnea_23/NN
D004221_D005483 NONE disulfiram_7/NN (r_npadvmod) like_9/JJ (r_amod) syndrome_10/NN (r_dobj) developed_6/VBD (l_prep) with_11/IN (l_pobj) flushing_12/NN
D004221_D013610 NONE disulfiram_7/NN (r_npadvmod) like_9/JJ (r_amod) syndrome_10/NN (r_dobj) developed_6/VBD (l_prep) with_11/IN (l_pobj) flushing_12/NN (l_conj) tachycardia_14/NN
D004221_D007022 NONE disulfiram_7/NN (r_npadvmod) like_9/JJ (r_amod) syndrome_10/NN (r_dobj) developed_6/VBD (l_prep) with_11/IN (l_pobj) flushing_12/NN (l_conj) tachycardia_14/NN (l_conj) hypotension_18/NN
18004067
D000431_D017114 NONE alcohol_8/NN (r_compound) consumption_9/NN (r_pobj) with_6/IN (r_prep) patients_5/NNS (r_pobj) in_3/IN (r_prep) failure_2/NN
D000082_D017114 NONE paracetamol_11/NNS (r_dobj) ingesting_10/VBG (r_acl) failure_2/NN
D000431_D056486 NONE alcohol_4/NN (r_pobj) of_3/IN (r_prep) role_2/NN (l_prep) in_5/IN (l_pobj) development_7/NN (l_prep) of_8/IN (l_pobj) hepatotoxicity_9/NN
D000082_D056486 CID paracetamol_15/NN (r_pobj) of_14/IN (r_prep) doses_13/NNS (r_pobj) with_11/IN (r_prep) associated_10/VBN (r_acl) hepatotoxicity_9/NN
D000082_D056486 CID acetaminophen_17/NNP (r_appos) paracetamol_15/NN (r_pobj) of_14/IN (r_prep) doses_13/NNS (r_pobj) with_11/IN (r_prep) associated_10/VBN (r_acl) hepatotoxicity_9/NN
D000082_D056486 CID paracetamol_15/NNS (r_pobj) of_14/IN (r_prep) doses_13/NNS (r_pobj) with_11/IN (r_prep) treated_10/VBN (r_acl) patients_9/NNS (r_pobj) in_8/IN (r_prep) development_5/NN (l_prep) of_6/IN (l_pobj) hepatotoxicity_7/NN
D000431_D017093 NONE alcohol_9/NN (r_pobj) of_8/IN (r_prep) consumers_7/NNS (r_attr) were_5/VBD (l_conj) developed_12/VBD (l_dobj) failure_14/NN
D000431_D017093 NONE alcohol_24/NN (r_compound) consumption_25/NN (r_dobj) stopping_23/VBG (r_conj) developed_12/VBD (l_dobj) failure_14/NN
D000431_D017093 NONE alcohol_10/NN (r_pobj) of_9/IN (r_prep) consumption_8/NN (r_appos) factors_4/NNS (r_pobj) with_2/IN (r_prep) patients_1/NNS (r_pobj) In_0/IN (r_prep) is_14/VBZ (l_nsubj) failure_13/NN
D000082_D017093 CID paracetamol_32/NN (r_pobj) with_29/IN (r_prep) treated_28/VBN (r_advcl) stopping_23/VBG (r_conj) developed_12/VBD (l_dobj) failure_14/NN
8558192
C030852_C562729 NONE vinorelbine_4/NNP (l_prep) in_5/IN (l_pobj) carcinoma_10/NN
C030852_C562729 NONE vinorelbine_11/NN (r_pobj) of_10/IN (r_prep) rate_6/NN (r_dobj) evaluate_3/VB (r_advcl) administered_15/VBN (l_prep) as_16/IN (l_pobj) agent_19/NN (l_prep) in_20/IN (l_pobj) carcinoma_25/NN
C030852_C562729 NONE VNB_13/NNP (r_appos) vinorelbine_11/NN (r_pobj) of_10/IN (r_prep) rate_6/NN (r_dobj) evaluate_3/VB (r_advcl) administered_15/VBN (l_prep) as_16/IN (l_pobj) agent_19/NN (l_prep) in_20/IN (l_pobj) carcinoma_25/NN
C030852_C562729 NONE VNB_4/NNP (r_nsubj) is_5/VBZ (l_attr) agent_8/NN (l_prep) in_9/IN (l_pobj) carcinoma_14/NN
D002945_D064420 NONE cisplatin_9/NN (r_npadvmod) based_11/VBN (r_amod) chemotherapy_12/NN (r_pobj) with_8/IN (r_prep) pretreated_7/VBN (r_acl) 16_6/CD (r_conj) chemotherapy_4/NN (r_pobj) without_2/IN (r_prep) patients_1/NNS (r_nsubj) were_13/VBD (l_acomp) assessable_14/JJ (l_prep) for_15/IN (l_pobj) toxicity_16/NN
C030852_D064420 NONE VNB_12/NNP (r_pobj) of_11/IN (r_prep) evaluation_10/NN (r_nsubjpass) warranted_17/VBN (l_prep) Given_0/VBN (l_pobj) profile_4/NN (l_conj) toxicity_7/NN
6466532
D006024_D001919 NONE glycopyrrolate_3/NN (r_pobj) of_1/IN (r_prep) Comparison_0/NN (l_prep) in_6/IN (l_pobj) prevention_8/NN (l_prep) of_9/IN (l_pobj) bradycardia_10/NNS
D006024_D001145 NONE glycopyrrolate_3/NN (r_pobj) of_1/IN (r_prep) Comparison_0/NN (l_prep) in_6/IN (l_pobj) prevention_8/NN (l_prep) of_9/IN (l_pobj) bradycardia_10/NNS (l_conj) arrhythmias_12/NNS
D001285_D001919 NONE atropine_5/NN (r_conj) glycopyrrolate_3/NN (r_pobj) of_1/IN (r_prep) Comparison_0/NN (l_prep) in_6/IN (l_pobj) prevention_8/NN (l_prep) of_9/IN (l_pobj) bradycardia_10/NNS
D001285_D001919 NONE atropine_1/NN (r_nsubj) prevent_16/VB (l_dobj) arrhythmia_17/NN (l_conj) bradycardia_19/NN
D001285_D001145 NONE atropine_5/NN (r_conj) glycopyrrolate_3/NN (r_pobj) of_1/IN (r_prep) Comparison_0/NN (l_prep) in_6/IN (l_pobj) prevention_8/NN (l_prep) of_9/IN (l_pobj) bradycardia_10/NNS (l_conj) arrhythmias_12/NNS
D001285_D001145 NONE atropine_1/NN (r_nsubj) prevent_16/VB (l_dobj) arrhythmia_17/NN
D013390_D001919 CID suxamethonium_17/NN (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) following_13/VBG (r_prep) prevention_8/NN (l_prep) of_9/IN (l_pobj) bradycardia_10/NNS
D013390_D001919 CID suxamethonium_24/NN (r_pobj) of_23/IN (r_prep) doses_22/NNS (r_pobj) following_20/VBG (r_prep) prevent_16/VB (l_dobj) arrhythmia_17/NN (l_conj) bradycardia_19/NN
D013390_D001145 NONE suxamethonium_17/NN (r_pobj) of_16/IN (r_prep) doses_15/NNS (r_pobj) following_13/VBG (r_prep) prevention_8/NN (l_prep) of_9/IN (l_pobj) bradycardia_10/NNS (l_conj) arrhythmias_12/NNS
D013390_D001145 NONE suxamethonium_24/NN (r_pobj) of_23/IN (r_prep) doses_22/NNS (r_pobj) following_20/VBG (r_prep) prevent_16/VB (l_dobj) arrhythmia_17/NN
12820454
D016729_D000740 CID acetate_6/NN (r_appos) CAB_3/NN (r_dobj) received_2/VBD (l_conj) evaluated_32/VBN (l_prep) for_33/IN (l_pobj) anemia_34/NN
D016729_D000740 CID A_10/NNP (r_appos) acetate_6/NN (r_appos) CAB_3/NN (r_dobj) received_2/VBD (l_conj) evaluated_32/VBN (l_prep) for_33/IN (l_pobj) anemia_34/NN
D005485_D000740 CID flutamide_23/NN (r_conj) days_19/NNS (r_appos) acetate_6/NN (r_appos) CAB_3/NN (r_dobj) received_2/VBD (l_conj) evaluated_32/VBN (l_prep) for_33/IN (l_pobj) anemia_34/NN
12615818
D017373_D054556 CID acetate_9/NN (r_dobj) prescribed_7/VBD (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) thromboembolism_4/NN
D017373_D054556 CID CPA_15/NNP (r_nmod) EE_17/NNP (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) VTE_11/NNP (r_appos) risk_6/NN (l_prep) of_7/IN (l_pobj) thromboembolism_9/NN
D017373_D054556 CID CPA_15/NNP (r_nmod) EE_17/NNP (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) VTE_11/NNP
D017373_D054556 CID CPA_42/NNP (r_nmod) EE_44/NN (r_pobj) with_41/IN (r_prep) associated_40/VBN (r_acl) VTE_39/NNP
D017373_D054556 CID CPA_13/NN (r_nmod) EE_15/NNP (r_pobj) of_12/IN (r_prep) use_11/NN (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) risk_5/NN (l_prep) of_6/IN (l_pobj) VTE_7/NNP
D004997_D054556 CID estradiol_14/NN (r_pobj) with_12/IN (r_prep) combination_11/NN (r_pobj) in_10/IN (r_prep) prescribed_7/VBD (l_nsubj) risk_1/NN (l_prep) of_2/IN (l_pobj) thromboembolism_4/NN
D004997_D054556 CID EE_17/NNP (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) VTE_11/NNP (r_appos) risk_6/NN (l_prep) of_7/IN (l_pobj) thromboembolism_9/NN
D004997_D054556 CID EE_17/NNP (r_pobj) with_14/IN (r_prep) associated_13/VBN (r_acl) VTE_11/NNP
D004997_D054556 CID EE_44/NN (r_pobj) with_41/IN (r_prep) associated_40/VBN (r_acl) VTE_39/NNP
D004997_D054556 CID EE_15/NNP (r_pobj) of_12/IN (r_prep) use_11/NN (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) risk_5/NN (l_prep) of_6/IN (l_pobj) VTE_7/NNP
D017373_D000152 NONE acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) women_20/NNS (l_prep) with_21/IN (l_pobj) acne_22/NN
D017373_D000152 NONE CPA_7/NNP (r_nmod) EE_9/NNP (r_appos) estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) women_20/NNS (l_prep) with_21/IN (l_pobj) acne_22/NN
D017373_D000152 NONE CPA_42/NNP (r_nmod) EE_44/NN (r_pobj) with_41/IN (r_prep) associated_40/VBN (r_acl) VTE_39/NNP (r_pobj) of_38/IN (r_prep) risk_37/NN (r_dobj) estimate_35/VB (r_advcl) conducted_7/VBD (l_dobj) study_15/NN (l_acl) nested_16/VBN (l_prep) within_17/IN (l_pobj) population_19/NN (l_prep) of_20/IN (l_pobj) women_21/NNS (l_acl) aged_22/VBN (l_prep) between_23/IN (l_pobj) years_27/NNS (l_prep) with_28/IN (l_pobj) acne_29/NN
D017373_D000152 NONE CPA_13/NN (r_nmod) EE_15/NNP (r_pobj) of_12/IN (r_prep) use_11/NN (l_prep) in_16/IN (l_pobj) women_17/NNS (l_prep) with_18/IN (l_pobj) acne_19/NN
D017373_D006628 NONE acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) women_20/NNS (l_prep) with_21/IN (l_pobj) acne_22/NN (l_conj) hirsutism_24/NN
D017373_D006628 NONE CPA_7/NNP (r_nmod) EE_9/NNP (r_appos) estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) women_20/NNS (l_prep) with_21/IN (l_pobj) acne_22/NN (l_conj) hirsutism_24/NN
D017373_D006628 NONE CPA_42/NNP (r_nmod) EE_44/NN (r_pobj) with_41/IN (r_prep) associated_40/VBN (r_acl) VTE_39/NNP (r_pobj) of_38/IN (r_prep) risk_37/NN (r_dobj) estimate_35/VB (r_advcl) conducted_7/VBD (l_dobj) study_15/NN (l_acl) nested_16/VBN (l_prep) within_17/IN (l_pobj) population_19/NN (l_prep) of_20/IN (l_pobj) women_21/NNS (l_acl) aged_22/VBN (l_prep) between_23/IN (l_pobj) years_27/NNS (l_prep) with_28/IN (l_pobj) acne_29/NN (l_conj) hirsutism_31/NN
D017373_D006628 NONE CPA_13/NN (r_nmod) EE_15/NNP (r_pobj) of_12/IN (r_prep) use_11/NN (l_prep) in_16/IN (l_pobj) women_17/NNS (l_prep) with_18/IN (l_pobj) acne_19/NN (l_conj) hirsutism_21/NN
D017373_D011085 NONE acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_conj) is_26/VBZ (l_attr) option_30/NN (l_prep) for_31/IN (l_pobj) syndrome_34/NN
D017373_D011085 NONE acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_conj) is_26/VBZ (l_attr) option_30/NN (l_prep) for_31/IN (l_pobj) syndrome_34/NN (l_appos) PCOS_36/NNP
D017373_D011085 NONE CPA_7/NNP (r_nmod) EE_9/NNP (r_appos) estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_conj) is_26/VBZ (l_attr) option_30/NN (l_prep) for_31/IN (l_pobj) syndrome_34/NN
D017373_D011085 NONE CPA_7/NNP (r_nmod) EE_9/NNP (r_appos) estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_conj) is_26/VBZ (l_attr) option_30/NN (l_prep) for_31/IN (l_pobj) syndrome_34/NN (l_appos) PCOS_36/NNP
D017373_D011085 NONE CPA_42/NNP (r_nmod) EE_44/NN (r_pobj) with_41/IN (r_prep) associated_40/VBN (r_acl) VTE_39/NNP (r_pobj) of_38/IN (r_prep) risk_37/NN (r_dobj) estimate_35/VB (r_advcl) conducted_7/VBD (l_dobj) study_15/NN (l_acl) nested_16/VBN (l_prep) within_17/IN (l_pobj) population_19/NN (l_prep) of_20/IN (l_pobj) women_21/NNS (l_acl) aged_22/VBN (l_prep) between_23/IN (l_pobj) years_27/NNS (l_prep) with_28/IN (l_pobj) acne_29/NN (l_conj) hirsutism_31/NN (l_conj) PCOS_33/NNP
D017373_D011085 NONE CPA_13/NN (r_nmod) EE_15/NNP (r_pobj) of_12/IN (r_prep) use_11/NN (l_prep) in_16/IN (l_pobj) women_17/NNS (l_prep) with_18/IN (l_pobj) acne_19/NN (l_conj) hirsutism_21/NN (l_conj) PCOS_23/NNP
D004997_D000152 NONE estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) women_20/NNS (l_prep) with_21/IN (l_pobj) acne_22/NN
D004997_D000152 NONE EE_9/NNP (r_appos) estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) women_20/NNS (l_prep) with_21/IN (l_pobj) acne_22/NN
D004997_D000152 NONE EE_44/NN (r_pobj) with_41/IN (r_prep) associated_40/VBN (r_acl) VTE_39/NNP (r_pobj) of_38/IN (r_prep) risk_37/NN (r_dobj) estimate_35/VB (r_advcl) conducted_7/VBD (l_dobj) study_15/NN (l_acl) nested_16/VBN (l_prep) within_17/IN (l_pobj) population_19/NN (l_prep) of_20/IN (l_pobj) women_21/NNS (l_acl) aged_22/VBN (l_prep) between_23/IN (l_pobj) years_27/NNS (l_prep) with_28/IN (l_pobj) acne_29/NN
D004997_D000152 NONE EE_15/NNP (r_pobj) of_12/IN (r_prep) use_11/NN (l_prep) in_16/IN (l_pobj) women_17/NNS (l_prep) with_18/IN (l_pobj) acne_19/NN
D004997_D006628 NONE estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) women_20/NNS (l_prep) with_21/IN (l_pobj) acne_22/NN (l_conj) hirsutism_24/NN
D004997_D006628 NONE EE_9/NNP (r_appos) estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_prep) for_16/IN (l_pobj) treatment_18/NN (l_prep) of_19/IN (l_pobj) women_20/NNS (l_prep) with_21/IN (l_pobj) acne_22/NN (l_conj) hirsutism_24/NN
D004997_D006628 NONE EE_44/NN (r_pobj) with_41/IN (r_prep) associated_40/VBN (r_acl) VTE_39/NNP (r_pobj) of_38/IN (r_prep) risk_37/NN (r_dobj) estimate_35/VB (r_advcl) conducted_7/VBD (l_dobj) study_15/NN (l_acl) nested_16/VBN (l_prep) within_17/IN (l_pobj) population_19/NN (l_prep) of_20/IN (l_pobj) women_21/NNS (l_acl) aged_22/VBN (l_prep) between_23/IN (l_pobj) years_27/NNS (l_prep) with_28/IN (l_pobj) acne_29/NN (l_conj) hirsutism_31/NN
D004997_D006628 NONE EE_15/NNP (r_pobj) of_12/IN (r_prep) use_11/NN (l_prep) in_16/IN (l_pobj) women_17/NNS (l_prep) with_18/IN (l_pobj) acne_19/NN (l_conj) hirsutism_21/NN
D004997_D011085 NONE estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_conj) is_26/VBZ (l_attr) option_30/NN (l_prep) for_31/IN (l_pobj) syndrome_34/NN
D004997_D011085 NONE estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_conj) is_26/VBZ (l_attr) option_30/NN (l_prep) for_31/IN (l_pobj) syndrome_34/NN (l_appos) PCOS_36/NNP
D004997_D011085 NONE EE_9/NNP (r_appos) estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_conj) is_26/VBZ (l_attr) option_30/NN (l_prep) for_31/IN (l_pobj) syndrome_34/NN
D004997_D011085 NONE EE_9/NNP (r_appos) estradiol_5/NN (r_pobj) with_3/IN (r_prep) combined_2/VBN (r_acl) acetate_1/NN (r_nsubjpass) licensed_12/VBN (l_conj) is_26/VBZ (l_attr) option_30/NN (l_prep) for_31/IN (l_pobj) syndrome_34/NN (l_appos) PCOS_36/NNP
D004997_D011085 NONE EE_44/NN (r_pobj) with_41/IN (r_prep) associated_40/VBN (r_acl) VTE_39/NNP (r_pobj) of_38/IN (r_prep) risk_37/NN (r_dobj) estimate_35/VB (r_advcl) conducted_7/VBD (l_dobj) study_15/NN (l_acl) nested_16/VBN (l_prep) within_17/IN (l_pobj) population_19/NN (l_prep) of_20/IN (l_pobj) women_21/NNS (l_acl) aged_22/VBN (l_prep) between_23/IN (l_pobj) years_27/NNS (l_prep) with_28/IN (l_pobj) acne_29/NN (l_conj) hirsutism_31/NN (l_conj) PCOS_33/NNP
D004997_D011085 NONE EE_15/NNP (r_pobj) of_12/IN (r_prep) use_11/NN (l_prep) in_16/IN (l_pobj) women_17/NNS (l_prep) with_18/IN (l_pobj) acne_19/NN (l_conj) hirsutism_21/NN (l_conj) PCOS_23/NNP
D003276_D054556 NONE contraceptives_23/NNS (r_pobj) with_19/IN (r_prep) compared_18/VBN (r_prep) demonstrated_3/VBN (l_dobj) risk_6/NN (l_prep) of_7/IN (l_pobj) thromboembolism_9/NN
D003276_D054556 NONE contraceptives_23/NNS (r_pobj) with_19/IN (r_prep) compared_18/VBN (r_prep) demonstrated_3/VBN (l_dobj) risk_6/NN (l_appos) VTE_11/NNP
12596116
D015282_D000860 NONE Octreotide_0/NN (r_npadvmod) induced_2/VBN (r_amod) hypoxemia_3/NN
D015282_D006976 CID Octreotide_0/NN (r_npadvmod) induced_2/VBN (r_amod) hypoxemia_3/NN (l_conj) hypertension_6/NN
D015282_D006976 CID octreotide_10/NN (r_appos) analogue_8/NN (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) after_3/IN (r_prep) developed_2/VBD (r_acl) hypertension_1/NN
D015282_D005402 NONE octreotide_10/NN (r_appos) analogue_8/NN (r_pobj) of_5/IN (r_prep) administration_4/NN (r_pobj) after_3/IN (r_prep) developed_2/VBD (l_advcl) enhance_13/VB (l_dobj) resolution_14/NN (l_prep) of_15/IN (l_pobj) fistula_17/NN
6634932
C002616_D017180 NONE UM-272_0/NNP (r_dep) dimethylpropranolol_6/NNP (r_nsubjpass) administered_15/VBN (l_prep) to_17/IN (l_pobj) dogs_18/NNS (l_prep) with_19/IN (l_pobj) tachycardias_24/NNS
C002616_D017180 NONE dimethylpropranolol_6/NNP (r_nsubjpass) administered_15/VBN (l_prep) to_17/IN (l_pobj) dogs_18/NNS (l_prep) with_19/IN (l_pobj) tachycardias_24/NNS
C002616_D017180 NONE UM-272_1/NNP (r_dep) converted_2/VBD (l_dobj) tachycardia_4/NN
D010042_D017180 CID ouabain_20/NN (r_npadvmod) induced_22/VBN (r_amod) tachycardias_24/NNS
9672936
D008614_D012640 CID Pethidine_0/NNP (r_npadvmod) associated_2/VBN (r_amod) seizure_3/NN
D008614_D012640 CID pethidine_9/NN (r_pobj) in_4/IN (r_prep) seizure_3/NN
D008614_D010149 NONE Pethidine_0/NNP (r_npadvmod) associated_2/VBN (r_amod) seizure_3/NN (l_prep) for_10/IN (l_pobj) control_13/NN (l_compound) pain_12/NN
D008614_D010149 NONE pethidine_9/NN (r_pobj) in_4/IN (r_prep) seizure_3/NN (l_prep) for_10/IN (l_pobj) control_13/NN (l_compound) pain_12/NN
D008614_D010149 NONE pethidine_11/NN (r_pobj) of_10/IN (r_prep) doses_9/NNS (r_dobj) received_6/VBD (l_conj) pump_21/VB (l_prep) for_22/IN (l_pobj) management_23/NN (l_prep) of_24/IN (l_pobj) control_27/NN (l_compound) pain_26/NN
17344566
D019821_D003161 CID Simvastatin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) syndrome_6/NN
D019821_D003161 CID simvastatin_9/NN (r_conj) male_5/NN (r_nsubj) presented_10/VBN (l_prep) with_11/IN (l_pobj) syndrome_15/NN
D019821_D009135 NONE Simvastatin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) syndrome_6/NN (l_conj) myonecrosis_8/NNP
D019821_D009135 NONE simvastatin_9/NN (r_conj) male_5/NN (r_nsubj) presented_10/VBN (l_prep) with_11/IN (l_pobj) syndrome_15/NN (l_conj) myonecrosis_17/NNP
D019821_D007037 NONE Simvastatin_0/NNP (r_npadvmod) induced_2/VBN (r_amod) syndrome_6/NN (l_acl) associated_9/VBN (l_prep) with_10/IN (l_pobj) hypothyroidism_11/NN
D019821_D007037 NONE simvastatin_9/NN (r_conj) male_5/NN (l_amod) hypothyroid_4/JJ
D013974_D007037 NONE thyroxine_7/NN (r_dobj) taking_6/VBG (r_acl) male_5/NN (l_amod) hypothyroid_4/JJ
D013974_D003161 NONE thyroxine_7/NN (r_dobj) taking_6/VBG (r_acl) male_5/NN (r_nsubj) presented_10/VBN (l_prep) with_11/IN (l_pobj) syndrome_15/NN
D013974_D009135 NONE thyroxine_7/NN (r_dobj) taking_6/VBG (r_acl) male_5/NN (r_nsubj) presented_10/VBN (l_prep) with_11/IN (l_pobj) syndrome_15/NN (l_conj) myonecrosis_17/NNP
14659530
D009569_D008881 NONE NO_0/RB (r_advmod) induced_2/VBN (r_amod) attack_4/NN (l_compound) migraine_3/NN
D015740_D008881 NONE peptide_14/NN (r_nmod) concentration_18/NN (r_pobj) in_8/IN (r_prep) increase_7/NN (r_appos) attack_4/NN (l_compound) migraine_3/NN
D015740_D008881 NONE CGRP_16/NNP (r_nmod) concentration_18/NN (r_pobj) in_8/IN (r_prep) increase_7/NN (r_appos) attack_4/NN (l_compound) migraine_3/NN
D015740_D008881 NONE peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN (l_conj) attack_40/NN (l_compound) migraine_39/NN
D015740_D008881 NONE CGRP_19/NNP (r_nmod) concentration_21/NN (r_appos) peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN (l_conj) attack_40/NN (l_compound) migraine_39/NN
D015740_D008881 NONE CGRP_1/NNP (r_compound) concentration_2/NN (r_nsubj) increased_3/VBD (l_prep) during_8/IN (l_pobj) attack_11/NN (l_compound) migraine_10/NN
D015740_D008881 NONE CGRP_1/NNP (r_compound) concentration_2/NN (r_nsubj) increased_3/VBD (l_conj) returned_13/VBD (l_prep) after_16/IN (l_pobj) cessation_18/NN (l_prep) of_19/IN (l_pobj) migraine_21/NN
D015740_D008881 NONE CGRP_3/NNP (r_compound) concentrations_4/NNS (r_nsubj) failed_5/VBD (l_xcomp) change_7/VB (l_prep) during_8/IN (l_conj) in_12/IN (l_pobj) subjects_14/NNS (l_prep) with_15/IN (l_pobj) attack_18/NN (l_compound) migraine_17/JJ
D015740_D008881 NONE CGRP_1/NNP (r_compound) concentration_2/NN (r_nsubj) was_3/VBD (l_conj) tended_10/VBD (l_xcomp) be_12/VB (l_prep) in_14/IN (l_pobj) subjects_15/NNS (l_relcl) experienced_17/VBD (l_dobj) attack_20/NN (l_compound) migraine_19/NN
D015740_D008881 NONE CGRP_7/NNP (r_compound) concentration_8/NN (r_nsubj) correlates_9/VBZ (l_prep) with_10/IN (l_pobj) timing_12/NN (l_prep) of_15/IN (l_pobj) headache_18/NN (l_compound) migraine_17/NN
D015740_D008881 NONE CGRP_7/NNP (r_compound) concentration_8/NN (r_nsubj) correlates_9/VBZ (r_acl) fact_4/NN (r_nsubj) suggests_19/VBZ (l_dobj) relationship_22/NN (l_prep) between_23/IN (l_pobj) CGRP_24/NNP (l_conj) migraine_26/NN
D015740_D008881 NONE CGRP_24/NNP (r_pobj) between_23/IN (r_prep) relationship_22/NN (r_dobj) suggests_19/VBZ (l_nsubj) fact_4/NN (l_acl) correlates_9/VBZ (l_prep) with_10/IN (l_pobj) timing_12/NN (l_prep) of_15/IN (l_pobj) headache_18/NN (l_compound) migraine_17/NN
D015740_D008881 NONE CGRP_24/NNP (l_conj) migraine_26/NN
D015740_D008881 NONE CGRP_21/NN (r_compound) release_22/NN (r_conj) headache_17/NN (r_dobj) counteract_15/VB (l_ccomp) provoke_9/VB (l_dobj) migraine_10/NN
D012701_D008881 NONE serotonin_24/NN (r_compound) release_25/NN (r_pobj) with_22/IN (r_prep) correlation_21/NN (r_conj) concentration_18/NN (r_pobj) in_8/IN (r_prep) increase_7/NN (r_appos) attack_4/NN (l_compound) migraine_3/NN
D012701_D008881 NONE serotonin_24/NNS (r_conj) concentration_21/NN (r_appos) peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN (l_conj) attack_40/NN (l_compound) migraine_39/NN
D012701_D008881 NONE 5-hydroxytriptamine_26/CD (r_appos) peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN (l_conj) attack_40/NN (l_compound) migraine_39/NN
D012701_D008881 NONE 5-HT_28/CD (r_appos) peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN (l_conj) attack_40/NN (l_compound) migraine_39/NN
D012701_D008881 NONE 5-HT_8/CD (r_nummod) content_9/NN (r_nsubj) tended_10/VBD (l_xcomp) be_12/VB (l_prep) in_14/IN (l_pobj) subjects_15/NNS (l_relcl) experienced_17/VBD (l_dobj) attack_20/NN (l_compound) migraine_19/NN
D012701_D008881 NONE serotonin_1/NN (r_compound) content_2/NN (r_nsubj) decreased_3/VBD (l_prep) after_8/IN (l_pobj) nitroglycerin_9/NN (l_prep) in_10/IN (l_pobj) subjects_11/NNS (l_prep) with_12/IN (l_pobj) attack_15/NN (l_compound) migraine_14/JJ
D012701_D008881 NONE serotonin_1/NN (r_compound) content_2/NN (r_nsubj) decreased_3/VBD (l_conj) observed_21/VBN (l_prep) in_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) attack_26/NN (l_compound) migraine_25/NN
D012701_D008881 NONE serotonin_3/NN (r_compound) release_4/NN (r_nsubj) provoke_9/VB (l_dobj) migraine_10/NN
D015740_D006261 NONE peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN
D015740_D006261 NONE CGRP_19/NNP (r_nmod) concentration_21/NN (r_appos) peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN
D015740_D006261 NONE CGRP_3/NNP (r_compound) concentrations_4/NNS (r_nsubj) failed_5/VBD (l_xcomp) change_7/VB (l_prep) during_8/IN (l_pobj) headache_10/NN
D015740_D006261 NONE CGRP_7/NNP (r_compound) concentration_8/NN (r_nsubj) correlates_9/VBZ (l_prep) with_10/IN (l_pobj) timing_12/NN (l_prep) of_15/IN (l_pobj) headache_18/NN
D015740_D006261 NONE CGRP_24/NNP (r_pobj) between_23/IN (r_prep) relationship_22/NN (r_dobj) suggests_19/VBZ (l_nsubj) fact_4/NN (l_acl) correlates_9/VBZ (l_prep) with_10/IN (l_pobj) timing_12/NN (l_prep) of_15/IN (l_pobj) headache_18/NN
D015740_D006261 NONE CGRP_21/NN (r_compound) release_22/NN (r_conj) headache_17/NN
D012701_D006261 NONE serotonin_24/NNS (r_conj) concentration_21/NN (r_appos) peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN
D012701_D006261 NONE 5-hydroxytriptamine_26/CD (r_appos) peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN
D012701_D006261 NONE 5-HT_28/CD (r_appos) peptide_17/NN (r_nmod) content_30/NN (r_pobj) in_10/IN (r_prep) changes_9/NNS (r_dobj) investigate_8/VB (l_prep) during_31/IN (l_pobj) headache_34/NN
D012701_D006261 NONE serotonin_3/NN (r_compound) release_4/NN (r_nsubj) provoke_9/VB (r_ccomp) counteract_15/VB (l_dobj) headache_17/NN
D005996_D006261 NONE nitroglycerin_43/NN (r_pobj) by_42/IN (r_agent) provoked_41/VBN (r_acl) attack_40/NN (r_conj) headache_34/NN
D005996_D008881 NONE nitroglycerin_43/NN (r_pobj) by_42/IN (r_agent) provoked_41/VBN (r_acl) attack_40/NN (l_compound) migraine_39/NN
D005996_D008881 NONE nitroglycerin_16/NN (r_compound) application_17/NN (r_pobj) after_14/IN (r_conj) before_12/IN (r_advmod) collected_2/VBN (l_prep) after_24/IN (l_pobj) beginning_26/NN (l_prep) of_27/IN (l_pobj) attack_30/NN (l_compound) migraine_29/NN
D005996_D008881 NONE nitroglycerin_9/NN (l_prep) in_10/IN (l_pobj) subjects_11/NNS (l_prep) with_12/IN (l_pobj) attack_15/NN (l_compound) migraine_14/JJ
D005996_D008881 NONE nitroglycerin_9/NN (r_pobj) after_8/IN (r_prep) decreased_3/VBD (l_conj) observed_21/VBN (l_prep) in_22/IN (l_pobj) patients_23/NNS (l_prep) with_24/IN (l_pobj) attack_26/NN (l_compound) migraine_25/NN
19300402
D001920_D006930 NONE Bradykinin_0/NN (r_amod) antagonists_2/NNS (r_nsubj) induced_12/VBN (l_dobj) hyperalgesia_13/NN
D001920_D006930 NONE bradykinin_9/JJ (r_amod) receptors_10/NNS (r_pobj) of_8/IN (r_prep) inhibition_7/NN (r_nsubj) reduces_21/VBZ (l_dobj) hyperalgesia_23/NN
D001920_D006930 NONE bradykinin_19/NN (r_conj) activation_15/NN (r_conj) synthase_10/NN (r_pobj) of_7/IN (r_prep) products_6/NNS (r_nsubjpass) involved_21/VBN (l_prep) in_22/IN (l_pobj) hyperalgesia_23/NN
D001920_D006930 NONE bradykinin_14/NN (r_pobj) of_13/IN (r_prep) activity_12/NN (r_pobj) in_10/IN (r_prep) participates_9/VBZ (l_prep) In_0/IN (l_pobj) hyperalgesia_4/NN
D001920_D006930 NONE bradykinin_14/NN (r_pobj) of_13/IN (r_prep) activity_12/NN (r_pobj) in_10/IN (r_prep) participates_9/VBZ (l_advcl) seemed_23/VBD (l_prep) in_17/IN (l_pobj) bradykinin_22/VBN (l_compound) hyperalgesia_21/NN
D001920_D006930 NONE bradykinin_22/VBN (r_pobj) in_17/IN (r_prep) seemed_23/VBD (r_advcl) participates_9/VBZ (l_prep) In_0/IN (l_pobj) hyperalgesia_4/NN
D001920_D006930 NONE bradykinin_22/VBN (l_compound) hyperalgesia_21/NN
D001920_D003929 NONE Bradykinin_0/NN (r_amod) antagonists_2/NNS (r_nsubj) induced_12/VBN (l_prep) in_14/IN (l_pobj) chemotherapy_15/NN (l_conj) model_20/NN (l_compound) neuropathy_18/NN
D001920_D003929 NONE bradykinin_57/NN (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
D009569_D006930 NONE oxide_5/NN (r_compound) inhibitors_7/NNS (r_conj) antagonists_2/NNS (r_nsubj) induced_12/VBN (l_dobj) hyperalgesia_13/NN
D009569_D006930 NONE NO_13/DT (r_compound) synthase_14/NN (r_conj) inhibition_7/NN (r_nsubj) reduces_21/VBZ (l_dobj) hyperalgesia_23/NN
D009569_D006930 NONE NO_18/DT (r_det) activity_20/NN (r_conj) synthase_14/NN (r_conj) inhibition_7/NN (r_nsubj) reduces_21/VBZ (l_dobj) hyperalgesia_23/NN
D009569_D006930 NONE NO_9/DT (r_compound) synthase_10/NN (r_pobj) of_7/IN (r_prep) products_6/NNS (r_nsubjpass) involved_21/VBN (l_prep) in_22/IN (l_pobj) hyperalgesia_23/NN
D009569_D006930 NONE NO_13/DT (r_compound) activation_15/NN (r_conj) synthase_10/NN (r_pobj) of_7/IN (r_prep) products_6/NNS (r_nsubjpass) involved_21/VBN (l_prep) in_22/IN (l_pobj) hyperalgesia_23/NN
D009569_D006930 NONE NO_7/DT (r_det) synthase_8/NN (r_nsubj) participates_9/VBZ (l_prep) In_0/IN (l_pobj) hyperalgesia_4/NN
D009569_D006930 NONE NO_7/DT (r_det) synthase_8/NN (r_nsubj) participates_9/VBZ (l_advcl) seemed_23/VBD (l_prep) in_17/IN (l_pobj) bradykinin_22/VBN (l_compound) hyperalgesia_21/NN
D009569_D006930 NONE NO_27/DT (r_compound) pathway_29/NN (r_dobj) activate_25/VB (r_xcomp) seemed_23/VBD (r_advcl) participates_9/VBZ (l_prep) In_0/IN (l_pobj) hyperalgesia_4/NN
D009569_D006930 NONE NO_27/DT (r_compound) pathway_29/NN (r_dobj) activate_25/VB (r_xcomp) seemed_23/VBD (l_prep) in_17/IN (l_pobj) bradykinin_22/VBN (l_compound) hyperalgesia_21/NN
D009569_D003929 NONE oxide_5/NN (r_compound) inhibitors_7/NNS (r_conj) antagonists_2/NNS (r_nsubj) induced_12/VBN (l_prep) in_14/IN (l_pobj) chemotherapy_15/NN (l_conj) model_20/NN (l_compound) neuropathy_18/NN
D009569_D003929 NONE NO_11/DT (r_compound) synthase_12/NN (r_pobj) of_9/IN (r_prep) inhibitor_8/NN (r_appos) ip_2/NNS (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
D009569_D003929 NONE NO_29/DT (r_compound) synthase_30/NN (r_pobj) of_27/IN (r_prep) inhibitor_26/NN (r_conj) inhibitor_8/NN (r_appos) ip_2/NNS (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
D014750_D006930 CID vincristine_9/NN (r_pobj) in_8/IN (r_prep) inhibitors_7/NNS (r_conj) antagonists_2/NNS (r_nsubj) induced_12/VBN (l_dobj) hyperalgesia_13/NN
D014750_D006930 CID vincristine_26/NN (r_pobj) by_25/IN (r_agent) produced_24/VBN (r_acl) hyperalgesia_23/NN
D014750_D006930 CID vincristine_18/NN (r_npadvmod) induced_20/VBN (r_amod) hyperalgesia_21/NN (r_compound) bradykinin_22/VBN (r_pobj) in_17/IN (r_prep) seemed_23/VBD (r_advcl) participates_9/VBZ (l_prep) In_0/IN (l_pobj) hyperalgesia_4/NN
D014750_D006930 CID vincristine_18/NN (r_npadvmod) induced_20/VBN (r_amod) hyperalgesia_21/NN
D014750_D003929 NONE vincristine_9/NN (r_pobj) in_8/IN (r_prep) inhibitors_7/NNS (r_conj) antagonists_2/NNS (r_nsubj) induced_12/VBN (l_prep) in_14/IN (l_pobj) chemotherapy_15/NN (l_conj) model_20/NN (l_compound) neuropathy_18/NN
D013311_D006930 CID streptozotocin_11/NNS (r_conj) vincristine_9/NN (r_pobj) in_8/IN (r_prep) inhibitors_7/NNS (r_conj) antagonists_2/NNS (r_nsubj) induced_12/VBN (l_dobj) hyperalgesia_13/NN
D013311_D006930 CID streptozotocin_1/NN (r_npadvmod) induced_3/VBN (r_amod) hyperalgesia_4/NN
D013311_D006930 CID streptozotocin_1/NN (r_npadvmod) induced_3/VBN (r_amod) hyperalgesia_4/NN (r_pobj) In_0/IN (r_prep) participates_9/VBZ (l_advcl) seemed_23/VBD (l_prep) in_17/IN (l_pobj) bradykinin_22/VBN (l_compound) hyperalgesia_21/NN
D013311_D003929 CID streptozotocin_11/NNS (r_conj) vincristine_9/NN (r_pobj) in_8/IN (r_prep) inhibitors_7/NNS (r_conj) antagonists_2/NNS (r_nsubj) induced_12/VBN (l_prep) in_14/IN (l_pobj) chemotherapy_15/NN (l_conj) model_20/NN (l_compound) neuropathy_18/NN
D009569_D010523 NONE NO_11/DT (r_compound) synthase_12/NN (r_pobj) of_9/IN (r_prep) inhibitor_8/NN (r_appos) ip_2/NNS (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
D009569_D010523 NONE NO_29/DT (r_compound) synthase_30/NN (r_pobj) of_27/IN (r_prep) inhibitor_26/NN (r_conj) inhibitor_8/NN (r_appos) ip_2/NNS (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
D001920_D010523 NONE bradykinin_57/NN (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
C065679_D003929 NONE 140_60/CD (r_nummod) HOE_59/NNP (r_appos) bradykinin_57/NN (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
C065679_D010523 NONE 140_60/CD (r_nummod) HOE_59/NNP (r_appos) bradykinin_57/NN (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
C078665_D003929 NONE 140_72/CD (r_nummod) ip_78/NN (r_appos) HOE_71/NNP (r_conj) bradykinin_57/NN (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
C078665_D010523 NONE 140_72/CD (r_nummod) ip_78/NN (r_appos) HOE_71/NNP (r_conj) bradykinin_57/NN (r_nsubjpass) investigated_100/VBN (l_nsubjpass) neuropathy_98/NN
D001920_D009437 NONE bradykinin_8/NN (r_amod) antagonists_10/NNS (r_pobj) of_7/IN (r_prep) doses_6/NNS (r_pobj) of_4/IN (r_prep) administration_3/NN (r_nsubj) be_16/VB (l_acomp) effective_17/JJ (l_prep) in_18/IN (l_pobj) alleviation_19/NN (l_prep) of_20/IN (l_pobj) pain_22/NN
D009569_D009437 NONE NO_12/JJ (r_det) inhibitors_14/NNS (r_conj) administration_3/NN (r_nsubj) be_16/VB (l_acomp) effective_17/JJ (l_prep) in_18/IN (l_pobj) alleviation_19/NN (l_prep) of_20/IN (l_pobj) pain_22/NN
3496378
D014217_D002779 CID troleandomycin_3/NN (r_npadvmod) induced_5/VBN (r_amod) hepatitis_7/NN (r_pobj) after_2/IN (r_prep) cholestasis_1/NN
D014217_D002779 CID troleandomycin_9/NN (r_npadvmod) induced_11/VBN (r_amod) hepatitis_12/NN (r_nsubjpass) followed_14/VBN (l_agent) by_15/IN (l_pobj) cholestasis_18/NN
D014217_D002779 CID troleandomycin_8/NN (r_npadvmod) induced_10/VBN (r_amod) hepatitis_12/NN (r_dobj) follow_7/VB (l_nsubj) cholestasis_5/NN
D014217_D056486 CID troleandomycin_3/NN (r_npadvmod) induced_5/VBN (r_amod) hepatitis_7/NN
D014217_D056486 CID troleandomycin_9/NN (r_npadvmod) induced_11/VBN (r_amod) hepatitis_12/NN
D014217_D056486 CID troleandomycin_8/NN (r_npadvmod) induced_10/VBN (r_amod) hepatitis_12/NN
D014217_D007565 CID troleandomycin_5/NNP (r_pobj) of_4/IN (r_prep) administration_3/NN (r_pobj) after_2/IN (r_prep) occurred_1/VBD (l_nsubj) Jaundice_0/NN
D014217_D004802 CID troleandomycin_5/NNP (r_pobj) of_4/IN (r_prep) administration_3/NN (r_pobj) after_2/IN (r_prep) occurred_1/VBD (l_conj) associated_11/VBN (l_prep) with_12/IN (l_pobj) hypereosinophilia_13/NNP
14765563
D011803_D020922 NONE quinine_23/NN (r_nsubj) is_24/VBZ (l_advcl) banned_8/VBD (l_dobj) use_10/NN (l_prep) for_11/IN (l_pobj) cramps_14/NNS
D011803_D002493 NONE quinine_7/NN (r_dobj) containing_6/VBG (r_acl) products_5/NNS (r_nsubj) produce_9/VB (l_dobj) complications_11/NNS
D011803_D003221 CID quinine_7/NN (r_dobj) containing_6/VBG (r_acl) products_5/NNS (r_nsubj) produce_9/VB (l_dobj) complications_11/NNS (l_prep) including_13/VBG (l_pobj) confusion_14/NN
D011803_D012640 CID quinine_7/NN (r_dobj) containing_6/VBG (r_acl) products_5/NNS (r_nsubj) produce_9/VB (l_dobj) complications_11/NNS (l_prep) including_13/VBG (l_pobj) confusion_14/NN (l_conj) status_18/NN (l_conj) seizures_20/NNS
D011803_D003128 CID quinine_7/NN (r_dobj) containing_6/VBG (r_acl) products_5/NNS (r_nsubj) produce_9/VB (l_dobj) complications_11/NNS (l_prep) including_13/VBG (l_pobj) confusion_14/NN (l_conj) status_18/NN (l_conj) seizures_20/NNS (l_conj) coma_23/NN
17854040
D019259_D006509 NONE lamivudine_7/NN (r_npadvmod) resistant_9/JJ (r_amod) virus_12/NN (l_compound) B_11/NN
D019259_D006509 NONE lamivudine-_19/NN (r_pobj) in_17/IN (r_prep) strains_16/NNS (r_appos) virus_12/NN (l_compound) B_11/NN
D019259_D006509 NONE lamivudine_3/NN (r_compound) na_5/NNP (r_nsubj) ve_6/NNP (l_dobj) patients_9/NNS (l_amod) infected_8/VBD
D019259_D006509 NONE lamivudine_3/NN (r_compound) na_5/NNP (r_nsubj) ve_6/NNP (l_appos) patients_26/NNS (l_amod) infected_25/JJ
D019259_D006509 NONE lamivudine_3/NN (r_compound) na_5/NNP (r_nsubj) ve_6/NNP (l_appos) patients_26/NNS (l_conj) patients_35/NNS (l_amod) infected_34/JJ
D019259_D006509 NONE lamivudine_1/NN (r_npadvmod) resistant_3/JJ (r_amod) strains_4/NNS (r_nsubjpass) detected_6/VBN (l_prep) in_7/IN (l_pobj) patients_17/NNS (l_compound) B_16/NN
D019259_D006509 NONE lamivudine_1/NN (r_npadvmod) resistant_3/JJ (r_amod) strains_4/NNS (r_nsubjpass) detected_6/VBN (l_conj) patients_28/NNS (l_amod) infected_27/JJ
D012964_D015658 NONE na_0/NNP (r_aux) ve_1/NNP (l_dobj) carriers_3/NNS (l_prep) with_4/IN (l_conj) without_6/IN (l_pobj) virus_9/NN
D012964_D015658 NONE na_5/NNP (r_nsubj) ve_6/NNP (l_prep) with_10/IN (l_conj) without_12/IN (l_pobj) infection_16/NN
D012964_D015658 NONE na_5/NNP (r_nsubj) ve_6/NNP (l_appos) patients_26/NNS (l_conj) patients_35/NNS (l_amod) infected_34/JJ
D019259_D015658 NONE lamivudine_3/NN (r_compound) na_5/NNP (r_nsubj) ve_6/NNP (l_prep) with_10/IN (l_conj) without_12/IN (l_pobj) infection_16/NN
D019259_D015658 NONE lamivudine_3/NN (r_compound) na_5/NNP (r_nsubj) ve_6/NNP (l_appos) patients_26/NNS (l_conj) patients_35/NNS (l_amod) infected_34/JJ
D019259_D015658 NONE lamivudine_1/NN (r_npadvmod) resistant_3/JJ (r_amod) strains_4/NNS (r_nsubjpass) detected_6/VBN (l_conj) patients_28/NNS (l_amod) infected_27/JJ
D012964_D006509 NONE na_5/NNP (r_nsubj) ve_6/NNP (l_dobj) patients_9/NNS (l_amod) infected_8/VBD
D012964_D006509 NONE na_5/NNP (r_nsubj) ve_6/NNP (l_appos) patients_26/NNS (l_amod) infected_25/JJ
D012964_D006509 NONE na_5/NNP (r_nsubj) ve_6/NNP (l_appos) patients_26/NNS (l_conj) patients_35/NNS (l_amod) infected_34/JJ
17244258
D003520_D003556 CID cyclophosphamide_9/NN (r_npadvmod) induced_11/VBN (r_amod) cystitis_12/NN
D003520_D003556 CID cyclophosphamide_1/RB (r_npadvmod) induced_3/VBN (r_amod) cystitis_4/NN
12464714
C093622_D008881 NONE rizatriptan_7/NNP (r_pobj) for_6/IN (r_prep) efficacy_3/NN (r_pobj) of_2/IN (r_prep) comparison_1/NN (l_appos) mg_9/NNS (l_prep) versus_10/IN (l_pobj) caffeine_13/NN (l_prep) in_14/IN (l_pobj) migraine_15/NN
C093622_D008881 NONE Rizatriptan_0/NNP (r_nsubj) is_1/VBZ (l_attr) agonist_7/NN (l_prep) with_8/IN (l_pobj) absorption_11/NN (l_conj) onset_14/NN (l_prep) of_15/IN (l_pobj) action_16/NN (l_prep) in_17/IN (l_pobj) treatment_20/NN (l_prep) of_21/IN (l_pobj) migraine_22/NN
D004878_D008881 NONE ergotamine_11/NNP (r_nmod) caffeine_13/NN (l_prep) in_14/IN (l_pobj) migraine_15/NN
D002110_D008881 NONE caffeine_13/NN (l_prep) in_14/IN (l_pobj) migraine_15/NN
D012701_D008881 NONE 5-HT(1B/1D_4/CD (r_meta) agonist_7/NN (l_prep) with_8/IN (l_pobj) absorption_11/NN (l_conj) onset_14/NN (l_prep) of_15/IN (l_pobj) action_16/NN (l_prep) in_17/IN (l_pobj) treatment_20/NN (l_prep) of_21/IN (l_pobj) migraine_22/NN
C093622_D006261 NONE rizatriptan_19/NNP (r_dobj) preferring_18/VBG (r_acl) patients_17/NNS (r_pobj) of_16/IN (r_prep) %_15/NN (r_pobj) by_13/IN (r_agent) cited_12/VBN (r_acl) reason_8/NN (r_attr) was_4/VBD (l_nsubj) relief_1/NN (l_prep) of_2/IN (l_pobj) headache_3/NN
C093622_D006261 NONE rizatriptan_9/NNP (r_pobj) for_8/IN (r_prep) %_7/NN (r_attr) was_5/VBD (l_nsubj) relief_1/NN (l_compound) Headache_0/NN
C093622_D006261 NONE rizatriptan_26/NNP (r_nsubj) being_27/VBG (r_pcomp) with_25/IN (r_prep) was_5/VBD (l_nsubj) relief_1/NN (l_compound) Headache_0/NN
D004878_D006261 NONE ergotamine_27/NN (r_nmod) caffeine_29/NN (r_dobj) preferred_26/VBD (r_relcl) patients_24/NNS (r_pobj) of_23/IN (r_prep) %_22/NN (r_conj) %_15/NN (r_pobj) by_13/IN (r_agent) cited_12/VBN (r_acl) reason_8/NN (r_attr) was_4/VBD (l_nsubj) relief_1/NN (l_prep) of_2/IN (l_pobj) headache_3/NN
D004878_D006261 NONE ergotamine_14/NN (r_nmod) caffeine_16/NN (r_pobj) for_13/IN (r_prep) %_12/NN (r_conj) %_7/NN (r_attr) was_5/VBD (l_nsubj) relief_1/NN (l_compound) Headache_0/NN
D004878_D006261 NONE ergotamine_30/NN (r_nmod) caffeine_32/NN (r_pobj) to_29/IN (r_prep) superior_28/JJ (r_acomp) being_27/VBG (r_pcomp) with_25/IN (r_prep) was_5/VBD (l_nsubj) relief_1/NN (l_compound) Headache_0/NN
D002110_D006261 NONE caffeine_29/NN (r_dobj) preferred_26/VBD (r_relcl) patients_24/NNS (r_pobj) of_23/IN (r_prep) %_22/NN (r_conj) %_15/NN (r_pobj) by_13/IN (r_agent) cited_12/VBN (r_acl) reason_8/NN (r_attr) was_4/VBD (l_nsubj) relief_1/NN (l_prep) of_2/IN (l_pobj) headache_3/NN
D002110_D006261 NONE caffeine_16/NN (r_pobj) for_13/IN (r_prep) %_12/NN (r_conj) %_7/NN (r_attr) was_5/VBD (l_nsubj) relief_1/NN (l_compound) Headache_0/NN
D002110_D006261 NONE caffeine_32/NN (r_pobj) to_29/IN (r_prep) superior_28/JJ (r_acomp) being_27/VBG (r_pcomp) with_25/IN (r_prep) was_5/VBD (l_nsubj) relief_1/NN (l_compound) Headache_0/NN
C093622_D010146 NONE rizatriptan_17/NNP (r_pobj) of_16/IN (r_prep) favor_15/NN (r_pobj) in_14/IN (r_prep) was_12/VBD (l_nsubj) endpoint_4/NN (l_prep) of_5/IN (l_pcomp) being_6/VBG (l_acomp) free_8/JJ (l_npadvmod) pain_7/NN
C093622_D010146 NONE rizatriptan_12/NNP (r_pobj) after_11/IN (r_prep) free_8/JJ (l_npadvmod) pain_7/NN
C093622_D010146 NONE rizatriptan_31/NNP (r_nsubj) being_32/VBG (r_advcl) were_6/VBD (l_acomp) free_8/JJ (l_npadvmod) pain_7/NN
C093622_D010146 NONE rizatriptan_6/NNP (r_dobj) taking_5/VBG (r_acl) patients_4/NNS (r_pobj) of_3/IN (r_prep) %_2/NN (r_nsubj) were_7/VBD (l_acomp) free_9/JJ (l_npadvmod) pain_8/NN
D004878_D010146 NONE ergotamine_20/NN (r_nmod) caffeine_22/NN (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_pcomp) with_15/IN (r_prep) compared_14/VBN (r_prep) were_6/VBD (l_acomp) free_8/JJ (l_npadvmod) pain_7/NN
D004878_D010146 NONE ergotamine_33/NN (r_nmod) caffeine_35/NN (r_pobj) on_32/IN (r_prep) patients_31/NNS (r_pobj) of_30/IN (r_prep) %_29/NN (r_pobj) to_27/IN (r_prep) compared_26/VBN (r_prep) were_7/VBD (l_acomp) free_9/JJ (l_npadvmod) pain_8/NN
D002110_D010146 NONE caffeine_22/NN (r_pobj) with_19/IN (r_prep) treated_18/VBN (r_pcomp) with_15/IN (r_prep) compared_14/VBN (r_prep) were_6/VBD (l_acomp) free_8/JJ (l_npadvmod) pain_7/NN
D002110_D010146 NONE caffeine_35/NN (r_pobj) on_32/IN (r_prep) patients_31/NNS (r_pobj) of_30/IN (r_prep) %_29/NN (r_pobj) to_27/IN (r_prep) compared_26/VBN (r_prep) were_7/VBD (l_acomp) free_9/JJ (l_npadvmod) pain_8/NN
C093622_D009325 CID Rizatriptan_0/NNP (r_nsubj) was_1/VBD (l_acomp) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN
C093622_D009325 CID rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN (l_conj) nausea_34/NN
C093622_D014839 NONE Rizatriptan_0/NNP (r_nsubj) was_1/VBD (l_acomp) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN
C093622_D012001 NONE Rizatriptan_0/NNP (r_nsubj) was_1/VBD (l_acomp) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN (l_conj) phonophobia_19/NNP
C093622_D020795 NONE Rizatriptan_0/NNP (r_nsubj) was_1/VBD (l_acomp) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN (l_conj) phonophobia_19/NNP (l_conj) photophobia_21/NN
D004878_D009325 NONE ergotamine_5/NN (r_nmod) caffeine_7/NN (r_pobj) to_4/IN (r_prep) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN
D004878_D009325 NONE ergotamine_19/NNP (r_nmod) caffeine_21/NN (r_conj) rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN (l_conj) nausea_34/NN
D004878_D014839 NONE ergotamine_5/NN (r_nmod) caffeine_7/NN (r_pobj) to_4/IN (r_prep) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN
D004878_D012001 NONE ergotamine_5/NN (r_nmod) caffeine_7/NN (r_pobj) to_4/IN (r_prep) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN (l_conj) phonophobia_19/NNP
D004878_D020795 NONE ergotamine_5/NN (r_nmod) caffeine_7/NN (r_pobj) to_4/IN (r_prep) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN (l_conj) phonophobia_19/NNP (l_conj) photophobia_21/NN
D002110_D009325 NONE caffeine_7/NN (r_pobj) to_4/IN (r_prep) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN
D002110_D009325 NONE caffeine_21/NN (r_conj) rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN (l_conj) nausea_34/NN
D002110_D014839 NONE caffeine_7/NN (r_pobj) to_4/IN (r_prep) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN
D002110_D012001 NONE caffeine_7/NN (r_pobj) to_4/IN (r_prep) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN (l_conj) phonophobia_19/NNP
D002110_D020795 NONE caffeine_7/NN (r_pobj) to_4/IN (r_prep) superior_3/JJ (l_prep) in_8/IN (l_pobj) proportions_10/NNS (l_prep) of_11/IN (l_pobj) patients_12/NNS (l_prep) with_13/IN (l_pobj) nausea_15/NN (l_conj) vomiting_17/NN (l_conj) phonophobia_19/NNP (l_conj) photophobia_21/NN
C093622_D004244 CID rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN
C093622_D006970 NONE rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN (l_conj) nausea_34/NN (l_conj) somnolence_42/NN
D004878_D004244 NONE ergotamine_19/NNP (r_nmod) caffeine_21/NN (r_conj) rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN
D004878_D006970 NONE ergotamine_19/NNP (r_nmod) caffeine_21/NN (r_conj) rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN (l_conj) nausea_34/NN (l_conj) somnolence_42/NN
D002110_D004244 NONE caffeine_21/NN (r_conj) rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN
D002110_D006970 NONE caffeine_21/NN (r_conj) rizatriptan_17/NNP (r_pobj) after_16/IN (r_prep) events_4/NNS (r_nsubj) were_25/VBD (l_attr) dizziness_26/NN (l_conj) nausea_34/NN (l_conj) somnolence_42/NN
6518066
D008094_D004437 CID lithium_1/NN (r_nmod) anomaly_6/NN
D008094_D006331 NONE lithium_9/NN (r_pobj) to_8/IN (r_prep) exposed_7/VBN (r_acl) screening_4/NN (r_nsubj) provide_13/VB (l_dobj) assessment_18/NN (l_prep) of_19/IN (l_pobj) presence_21/NN (l_prep) of_24/IN (l_pobj) malformations_29/NNS
D008094_D006331 NONE lithium_25/NN (r_npadvmod) induced_27/VBN (r_amod) malformations_29/NNS
18023325
D004221_D014826 CID disulfiram_6/NN (r_compound) intoxication_7/NN (r_pobj) after_4/IN (r_prep) palsy_3/NN
D004221_D014826 CID disulfiram_6/NN (r_compound) overdose_7/NN (r_pobj) by_4/IN (r_agent) caused_3/VBN (r_acl) neuropathy_2/NN (r_nsubj) is_8/VBZ (l_conj) is_13/VBZ (l_attr) report_15/NN (l_acl) leading_18/VBG (l_prep) to_19/IN (l_pobj) palsy_22/NN
D004221_D010523 CID disulfiram_6/NN (r_compound) overdose_7/NN (r_pobj) by_4/IN (r_agent) caused_3/VBN (r_acl) neuropathy_2/NN
D004221_D062787 NONE disulfiram_6/NN (r_compound) overdose_7/NN
D004221_D010243 NONE disulfiram_24/NN (r_compound) intoxication_25/NN (r_pobj) by_20/IN (r_agent) caused_19/VBN (r_acl) polyneuropathy_18/NNS (r_dobj) superimposed_13/VBN (r_conj) was_1/VBD (l_attr) case_3/NN (l_prep) of_4/IN (l_pobj) palsy_6/NN
D004221_D011115 NONE disulfiram_24/NN (r_compound) intoxication_25/NN (r_pobj) by_20/IN (r_agent) caused_19/VBN (r_acl) polyneuropathy_18/NNS
15602202
D017963_D009395 CID azithromycin_6/NNS (r_pobj) by_5/IN (r_agent) induced_4/VBN (r_acl) nephritis_3/NN
D017963_D009395 CID azithromycin_10/NN (r_npadvmod) induced_12/VBN (r_amod) nephritis_16/NN
17175308
D020123_D011507 CID sirolimus_4/VB (r_pobj) to_3/IN (r_prep) conversion_2/NN (r_pobj) after_1/IN (r_prep) Proteinuria_0/NNP
D020123_D011507 CID sirolimus_11/NN (r_compound) therapy_12/NN (r_pobj) of_10/IN (r_prep) consequence_9/NN (r_pobj) as_7/IN (r_prep) reported_6/VBN (l_nsubjpass) proteinuria_3/NN
D020123_D011507 CID SRL_18/NNP (r_compound) conversion_19/NN (r_pobj) after_17/IN (r_prep) displayed_14/VBD (l_dobj) proteinuria_16/NN
D020123_D011507 CID SRL_8/NNP (r_pobj) of_7/IN (r_prep) use_6/NN (r_pobj) after_4/IN (r_prep) was_2/VBD (l_nsubj) proteinuria_1/NN
D020123_D051436 NONE SRL_13/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (l_prep) due_18/IN (l_pobj) nephropathy_22/NN
D020123_D007674 NONE SRL_13/NNP (r_pobj) with_12/IN (r_prep) treated_11/VBN (l_prep) due_18/IN (l_pobj) nephropathy_22/NN (l_appos) CAN_24/MD
3865016
D005047_D054218 NONE etoposide_4/NN (r_pobj) of_3/IN (r_prep) effect_2/NN (r_nsubjpass) observed_9/VBN (l_prep) in_10/IN (l_pobj) patient_12/NN (l_prep) with_13/IN (l_pobj) leukemia_18/NN
D016572_D054218 NONE A_7/NNP (r_conj) effect_2/NN (r_nsubjpass) observed_9/VBN (l_prep) in_10/IN (l_pobj) patient_12/NN (l_prep) with_13/IN (l_pobj) leukemia_18/NN
D005047_D017254 NONE etoposide_4/NN (r_pobj) of_3/IN (r_prep) administration_2/NN (r_nsubj) resulted_8/VBD (l_prep) in_9/IN (l_pobj) eradication_10/NN (l_prep) of_11/IN (l_pobj) infiltration_15/NN
D016572_D017254 NONE A_7/DT (r_conj) administration_2/NN (r_nsubj) resulted_8/VBD (l_prep) in_9/IN (l_pobj) eradication_10/NN (l_prep) of_11/IN (l_pobj) infiltration_15/NN
12707296
D001120_D006973 NONE arginine_2/NN (r_compound) transport_3/NN (l_prep) with_6/IN (l_pobj) hypertension_10/NN
D001120_D006973 NONE arginine_4/NN (r_nmod) system_8/NN (r_nsubjpass) implicated_10/VBN (l_prep) in_11/IN (l_pobj) hypertension_15/NN
D001120_D006973 NONE arginine_19/NN (r_compound) system_21/NN (r_pobj) in_15/IN (r_prep) abnormalities_14/NNS (r_pobj) with_13/IN (r_prep) associated_12/VBN (l_nsubjpass) increases_6/NNS (l_prep) in_7/IN (l_pobj) pressure_9/NN
D006854_D006973 NONE cortisol_7/NN (r_npadvmod) induced_9/VBN (r_amod) hypertension_10/NN
D006854_D006973 NONE cortisol_12/NN (r_npadvmod) induced_14/VBN (r_amod) hypertension_15/NN
D006854_D006973 NONE cortisol_3/NN (r_npadvmod) induced_5/VBN (r_amod) increases_6/NNS (l_prep) in_7/IN (l_pobj) pressure_9/NN
D009569_D006973 NONE oxide_7/NN (r_compound) system_8/NN (r_nsubjpass) implicated_10/VBN (l_prep) in_11/IN (l_pobj) hypertension_15/NN
3693336
D014229_D001714 CID Triazolam_0/NNP (r_npadvmod) induced_2/VBN (r_amod) episodes_4/NNS (l_prep) of_5/IN (l_pobj) mania_7/NN
D014229_D001714 CID triazolam_3/NN (r_pobj) of_2/IN (l_pobj) episodes_7/NNS (l_prep) of_8/IN (l_pobj) mania_9/NN
D014229_D001714 CID triazolam_10/NNP (r_pobj) of_9/IN (r_prep) action_8/NN (r_pobj) of_7/IN (r_prep) duration_6/NN (r_pobj) with_4/IN (r_prep) coincident_3/JJ (r_acomp) was_2/VBD (l_nsubj) excitement_1/NN (l_amod) Manic_0/JJ
D014229_D003866 NONE Triazolam_0/NNP (r_npadvmod) induced_2/VBN (r_amod) episodes_4/NNS (l_prep) in_8/IN (l_pobj) patient_11/NN (l_amod) depressed_10/JJ
D014229_D003866 NONE triazolam_3/NN (r_pobj) of_2/IN (l_pobj) episodes_7/NNS (l_prep) in_10/IN (l_pobj) woman_14/NN (l_amod) depressed_12/JJ
8682684
D000082_D007022 CID Acetaminophen_0/NN (r_advmod) induced_2/VBN (r_amod) hypotension_3/NN
D000082_D007022 CID acetaminophen_2/NN (r_nsubjpass) demonstrated_5/VBN (l_xcomp) produce_7/VB (l_dobj) symptoms_8/NNS (l_prep) including_12/VBG (l_pobj) hypotension_13/NN
D000082_D007022 CID acetaminophen_18/NNP (r_pobj) of_17/IN (r_prep) administration_16/NN (r_pobj) after_15/IN (r_prep) developed_14/VBN (r_acl) hypotension_12/NN
D000082_D007022 CID acetaminophen_9/NN (r_dobj) consider_8/VB (l_prep) in_10/IN (l_pobj) patients_11/NNS (l_prep) with_12/IN (l_pobj) hypotension_13/NN
D000082_D002318 NONE acetaminophen_3/NN (r_nsubj) produce_5/VB (l_dobj) toxicities_7/NNS
D000082_D000707 NONE acetaminophen_2/NN (r_nsubjpass) demonstrated_5/VBN (l_xcomp) produce_7/VB (l_dobj) symptoms_8/NNS (l_prep) of_9/IN (l_pobj) anaphylaxis_10/NN
D000082_D016638 NONE acetaminophen_18/NNP (r_pobj) of_17/IN (r_prep) administration_16/NN (r_pobj) after_15/IN (r_prep) developed_14/VBN (r_acl) hypotension_12/NN (r_pobj) of_11/IN (r_prep) episodes_10/NNS (r_relcl) patients_6/NNS (l_amod) ill_5/JJ
18442015
D014700_D006471 NONE verapamil_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) on_4/IN (l_pobj) ulcers_7/NNS (l_amod) hemorrhagic_6/JJ
D014700_D006471 NONE verapamil_15/NN (r_pobj) by_12/IN (r_agent) ameliorated_11/VBN (r_xcomp) were_7/VBD (l_nsubj) ulcer_2/NN (l_amod) hemorrhagic_1/JJ
D014700_D006471 NONE verapamil_28/NN (r_pobj) by_27/IN (r_agent) ameliorated_26/VBN (r_relcl) release_19/NN (r_conj) generation_16/NN (r_npadvmod) produce_2/VB (l_dobj) ulcer_5/NN (l_amod) hemorrhagic_4/JJ
D014700_D014456 NONE verapamil_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) on_4/IN (l_pobj) ulcers_7/NNS
D014700_D014456 NONE verapamil_6/NN (r_pobj) of_5/IN (r_prep) effect_4/NN (l_prep) on_7/IN (l_pobj) model_10/NN (l_compound) ulcer_9/NN
D014700_D014456 NONE verapamil_15/NN (r_pobj) by_12/IN (r_agent) ameliorated_11/VBN (r_xcomp) were_7/VBD (l_nsubj) ulcer_2/NN
D014700_D014456 NONE verapamil_28/NN (r_pobj) by_27/IN (r_agent) ameliorated_26/VBN (r_relcl) release_19/NN (r_conj) generation_16/NN (r_npadvmod) produce_2/VB (l_dobj) ulcer_5/NN
D014700_D050197 NONE verapamil_3/NN (r_pobj) of_2/IN (r_prep) effect_1/NN (l_prep) in_8/IN (l_pobj) rats_11/NNS (l_amod) atherosclerotic_10/JJ
D014700_D050197 NONE verapamil_28/NN (r_pobj) by_27/IN (r_agent) ameliorated_26/VBN (r_relcl) release_19/NN (r_conj) generation_16/NN (r_npadvmod) produce_2/VB (l_nsubj) Atherosclerosis_0/NN
D006632_D006471 NONE histamine_19/NN (r_compound) release_20/NN (l_conj) generation_27/NN (l_prep) in_32/IN (l_pcomp) modulating_33/VBG (l_dobj) hemorrhage_35/NN
D006632_D006471 NONE histamine_6/NN (r_pobj) of_5/IN (r_prep) correlation_4/NN (l_prep) to_7/IN (l_pobj) hemorrhage_9/NN
D006632_D006471 NONE histamine_18/JJ (r_compound) release_19/NN (r_conj) generation_16/NN (r_npadvmod) produce_2/VB (l_dobj) ulcer_5/NN (l_amod) hemorrhagic_4/JJ
D006632_D014456 NONE histamine_19/NN (r_compound) release_20/NN (l_conj) generation_27/NN (l_prep) in_32/IN (l_pcomp) modulating_33/VBG (l_dobj) hemorrhage_35/NN (l_conj) ulcer_37/NN
D006632_D014456 NONE histamine_10/NN (r_compound) concentration_11/NN (l_conj) permeability_14/NN (l_conj) content_18/NN (l_conj) areas_21/NNS (l_compound) ulcer_20/NN
D006632_D014456 NONE histamine_16/NN (r_compound) release_17/NN (r_conj) diffusion_14/NN (r_pobj) including_9/VBG (r_prep) factors_7/NNS (r_pobj) with_4/IN (r_prep) accompanied_3/VBN (l_nsubj) ulcers_2/NNS
D006632_D014456 NONE histamine_6/NN (r_pobj) of_5/IN (r_prep) correlation_4/NN (l_prep) to_7/IN (l_conj) to_11/IN (l_pobj) ulcer_12/NN
D006632_D014456 NONE histamine_18/JJ (r_compound) release_19/NN (r_conj) generation_16/NN (r_npadvmod) produce_2/VB (l_dobj) ulcer_5/NN
D006632_D050197 NONE histamine_19/NN (r_compound) release_20/NN (l_conj) generation_27/NN (l_prep) in_32/IN (l_pcomp) modulating_33/VBG (l_prep) in_38/IN (l_pobj) rats_39/NNS (l_prep) with_40/IN (l_pobj) atherosclerosis_41/NN
D006632_D050197 NONE histamine_6/NN (r_pobj) of_5/IN (r_prep) correlation_4/NN (r_nsubjpass) found_14/VBN (l_prep) in_15/IN (l_pobj) rats_18/NNS (l_amod) atherosclerotic_17/JJ
D006632_D050197 NONE histamine_18/JJ (r_compound) release_19/NN (r_conj) generation_16/NN (r_npadvmod) produce_2/VB (l_nsubj) Atherosclerosis_0/NN
D004872_D006471 CID D2_47/NN (r_pobj) of_45/IN (r_prep) coadministration_44/NN (r_pobj) by_43/IN (r_agent) induced_42/VBN (r_acl) atherosclerosis_41/NN (r_pobj) with_40/IN (r_prep) rats_39/NNS (r_pobj) in_38/IN (r_prep) modulating_33/VBG (l_dobj) hemorrhage_35/NN
D004872_D014456 CID D2_47/NN (r_pobj) of_45/IN (r_prep) coadministration_44/NN (r_pobj) by_43/IN (r_agent) induced_42/VBN (r_acl) atherosclerosis_41/NN (r_pobj) with_40/IN (r_prep) rats_39/NNS (r_pobj) in_38/IN (r_prep) modulating_33/VBG (l_dobj) hemorrhage_35/NN (l_conj) ulcer_37/NN
D004872_D050197 CID D2_47/NN (r_pobj) of_45/IN (r_prep) coadministration_44/NN (r_pobj) by_43/IN (r_agent) induced_42/VBN (r_acl) atherosclerosis_41/NN
D004872_D050197 CID D2_21/NN (r_dobj) containing_19/VBG (r_acl) oil_18/NN (r_pobj) of_16/IN (r_prep) kg_15/NNS (r_pobj) with_11/IN (r_prep) days_10/NNS (r_pobj) for_8/IN (r_prep) challenged_4/VBN (l_advcl) induce_25/VB (l_dobj) atherosclerosis_26/NN
D002784_D006471 CID cholesterol_49/NN (r_conj) D2_47/NN (r_pobj) of_45/IN (r_prep) coadministration_44/NN (r_pobj) by_43/IN (r_agent) induced_42/VBN (r_acl) atherosclerosis_41/NN (r_pobj) with_40/IN (r_prep) rats_39/NNS (r_pobj) in_38/IN (r_prep) modulating_33/VBG (l_dobj) hemorrhage_35/NN
D002784_D014456 CID cholesterol_49/NN (r_conj) D2_47/NN (r_pobj) of_45/IN (r_prep) coadministration_44/NN (r_pobj) by_43/IN (r_agent) induced_42/VBN (r_acl) atherosclerosis_41/NN (r_pobj) with_40/IN (r_prep) rats_39/NNS (r_pobj) in_38/IN (r_prep) modulating_33/VBG (l_dobj) hemorrhage_35/NN (l_conj) ulcer_37/NN
D002784_D050197 CID cholesterol_49/NN (r_conj) D2_47/NN (r_pobj) of_45/IN (r_prep) coadministration_44/NN (r_pobj) by_43/IN (r_agent) induced_42/VBN (r_acl) atherosclerosis_41/NN
D002784_D050197 CID cholesterol_23/NN (r_conj) D2_21/NN (r_dobj) containing_19/VBG (r_acl) oil_18/NN (r_pobj) of_16/IN (r_prep) kg_15/NNS (r_pobj) with_11/IN (r_prep) days_10/NNS (r_pobj) for_8/IN (r_prep) challenged_4/VBN (l_advcl) induce_25/VB (l_dobj) atherosclerosis_26/NN
D002784_D050197 CID cholesterol_10/NN (r_conj) calcium_7/NN (r_pobj) as_5/IN (r_prep) parameters_2/NNS (l_amod) atherosclerotic_1/JJ
D002784_D050197 CID cholesterol_10/NN (r_conj) calcium_7/NN (r_pobj) as_5/IN (r_prep) parameters_2/NNS (r_nsubjpass) obtained_18/VBN (l_prep) in_19/IN (l_pobj) rats_21/NNS (l_amod) atherosclerotic_20/JJ
D010634_D014456 NONE luminal_16/JJ (r_amod) content_18/NN (l_conj) areas_21/NNS (l_compound) ulcer_20/NN
D010634_D014456 NONE luminal_22/JJ (r_amod) hemoglobin_23/NN (r_conj) generation_20/NN (r_nmod) content_24/NN (r_nsubjpass) observed_27/VBN (l_ccomp) accompanied_3/VBN (l_nsubj) ulcers_2/NNS
D002118_D050197 NONE calcium_7/NN (r_pobj) as_5/IN (r_prep) parameters_2/NNS (l_amod) atherosclerotic_1/JJ
D002118_D050197 NONE calcium_7/NN (r_pobj) as_5/IN (r_prep) parameters_2/NNS (r_nsubjpass) obtained_18/VBN (l_prep) in_19/IN (l_pobj) rats_21/NNS (l_amod) atherosclerotic_20/JJ
12523465
C022189_D006212 CID zonisamide_4/NNP (r_pobj) with_3/IN (r_prep) associated_2/VBN (r_acl) hallucinations_1/NNS
C022189_D006212 CID zonisamide_29/NNP (r_compound) treatment_30/NN (r_nsubjpass) begun_32/VBN (r_advcl) altered_25/VBN (r_conj) experienced_20/VBD (r_relcl) patients_18/NNS (r_dobj) describe_16/VBP (l_advcl) reported_6/VBN (l_nsubjpass) hallucinations_2/NNS
C022189_D006212 CID zonisamide_29/NNP (r_compound) treatment_30/NN (r_nsubjpass) begun_32/VBN (r_advcl) altered_25/VBN (r_conj) experienced_20/VBD (l_dobj) hallucinations_23/NNS
C022189_D012640 NONE Zonisamide_0/NNP (r_nsubj) is_1/VBZ (l_attr) drug_7/NN (l_acl) used_8/VBN (l_xcomp) treat_10/VB (l_dobj) types_12/NNS (l_prep) of_13/IN (l_pobj) seizures_14/NNS
18631865
D020123_D051436 NONE rapamycin_16/NN (r_amod) inhibitors_20/NNS (l_prep) in_25/IN (l_pobj) recipients_28/NNS (l_prep) with_29/IN (l_pobj) nephropathy_32/NN
D020123_D051436 NONE sirolimus_23/NNP (r_appos) inhibitors_20/NNS (l_prep) in_25/IN (l_pobj) recipients_28/NNS (l_prep) with_29/IN (l_pobj) nephropathy_32/NN
D020123_D011507 CID sirolimus_5/NNP (r_pobj) to_4/IN (r_prep) due_3/JJ (r_acomp) was_2/VBD (l_nsubj) proteinuria_1/NN
D020123_D011507 CID sirolimus_5/NNP (r_pobj) to_4/IN (r_prep) due_3/JJ (r_acomp) was_2/VBD (l_advcl) remained_14/VBD (l_advcl) observed_22/VBN (l_nsubjpass) proteinuria_19/NN
D020123_D011507 CID sirolimus_24/NN (r_compound) therapy_25/NN (r_pobj) during_23/IN (r_prep) observed_22/VBN (r_advcl) remained_14/VBD (r_advcl) was_2/VBD (l_nsubj) proteinuria_1/NN
D020123_D011507 CID sirolimus_24/NN (r_compound) therapy_25/NN (r_pobj) during_23/IN (r_prep) observed_22/VBN (l_nsubjpass) proteinuria_19/NN
D020123_D011507 CID sirolimus_34/NNP (r_nmod) novo_36/NNP (r_dobj) received_33/VBD (r_relcl) patients_31/NNS (r_pobj) in_30/IN (r_conj) in_26/IN (r_prep) therapy_25/NN (r_pobj) during_23/IN (r_prep) observed_22/VBN (r_advcl) remained_14/VBD (r_advcl) was_2/VBD (l_nsubj) proteinuria_1/NN
D020123_D011507 CID sirolimus_34/NNP (r_nmod) novo_36/NNP (r_dobj) received_33/VBD (r_relcl) patients_31/NNS (r_pobj) in_30/IN (r_conj) in_26/IN (r_prep) therapy_25/NN (r_pobj) during_23/IN (r_prep) observed_22/VBN (l_nsubjpass) proteinuria_19/NN
2234245
D003676_D014786 NONE desferrioxamine_8/NN (r_dobj) receiving_7/VBG (r_acl) patients_6/NNS (r_pobj) in_4/IN (r_prep) toxicity_3/NN
D003676_D014786 NONE desferrioxamine_10/NN (r_dobj) receiving_9/VBG (r_acl) patients_8/NNS (r_pobj) of_4/IN (r_prep) period_3/NN (r_pobj) During_0/IN (r_prep) monitored_25/VBN (l_prep) for_26/IN (l_pobj) detection_27/NN (l_prep) of_28/IN (l_pobj) toxicity_30/NN
D003676_D014786 NONE desferrioxamine_15/NN (r_dobj) receiving_14/VBG (r_acl) patients_13/NNS (r_pobj) in_11/IN (r_prep) complication_10/NN (r_attr) is_6/VBZ (l_nsubj) toxicity_5/NN
D003676_D006311 NONE desferrioxamine_8/NN (r_dobj) receiving_7/VBG (r_acl) patients_6/NNS (r_pobj) in_4/IN (r_prep) toxicity_3/NN
D003676_D006311 NONE desferrioxamine_10/NN (r_dobj) receiving_9/VBG (r_acl) patients_8/NNS (r_pobj) of_4/IN (r_prep) period_3/NN (r_pobj) During_0/IN (r_prep) monitored_25/VBN (l_prep) for_26/IN (l_pobj) detection_27/NN (l_prep) of_28/IN (l_pobj) toxicity_30/NN
D003676_D006311 NONE desferrioxamine_15/NN (r_dobj) receiving_14/VBG (r_acl) patients_13/NNS (r_pobj) in_11/IN (r_prep) complication_10/NN (r_attr) is_6/VBZ (l_nsubj) toxicity_5/NN
D003676_D034381 NONE Desferrioxamine_0/NNP (r_compound) withdrawal_1/NN (r_nsubj) resulted_2/VBD (l_conj) reversal_22/NN (l_prep) of_23/IN (l_pcomp) hearing_24/NN (l_dobj) loss_25/NN
D003676_D064420 NONE desferrioxamine_10/NN (r_pobj) of_9/IN (r_prep) doses_8/NNS (r_dobj) receiving_5/VBG (r_acl) patients_4/NNS (r_pobj) in_3/IN (r_prep) appeared_2/VBD (l_nsubj) toxicity_1/NN
-1_D064420 NONE aluminium_19/NN (r_compound) serum_20/NN (r_compound) levels_21/NNS (r_pobj) of_16/IN (r_prep) normalization_15/NN (r_pobj) with_13/IN (r_prep) coincided_12/VBD (r_conj) appeared_2/VBD (l_nsubj) toxicity_1/NN
16181582
D014635_D001927 CID Valproate_0/RB (r_advmod) induced_2/VBN (r_amod) encephalopathy_3/NN
D014635_D001927 CID Valproate_0/RB (r_advmod) induced_2/VBN (r_amod) encephalopathy_3/NN
D014635_D001927 CID valproate_3/NN (r_advmod) induced_5/VBN (r_amod) encephalopathy_6/NN
D014635_D004827 NONE Valproate_0/RB (r_advmod) induced_2/VBN (r_amod) encephalopathy_3/NN (r_nsubj) is_4/VBZ (l_attr) syndrome_7/NN (l_relcl) manifest_10/VB (l_prep) in_11/IN (l_pobj) individuals_15/NNS (l_amod) epileptic_14/JJ
8829025
D016559_D006973 CID tacrolimus_5/NN (r_dobj) receiving_4/VBG (r_acl) patients_3/NNS (r_pobj) of_2/IN (r_prep) groups_1/NNS (r_nsubjpass) compared_7/VBN (l_npadvmod) group_16/NN (l_acl) comprising_17/VBG (l_dobj) patients_19/NNS (l_amod) hypertensive_18/JJ
D016559_D006973 CID tacrolimus_12/NN (r_pobj) with_11/IN (r_prep) associated_10/VBN (r_acl) nephrotoxicity_9/NN (r_dobj) reducing_7/VBG (r_pcomp) on_6/IN (r_prep) impact_3/NN (r_nsubj) be_18/VB (l_attr) factor_21/NN (l_prep) in_22/IN (l_pcomp) selecting_23/VBG (l_advcl) treat_27/VB (l_dobj) hypertension_28/NN
D009543_D006973 NONE nifedipine_23/NN (r_dobj) receiving_22/VBG (r_relcl) patients_19/NNS (l_amod) hypertensive_18/JJ
D009543_D006973 NONE nifedipine_33/NN (r_dobj) receiving_32/VBG (r_acl) other_27/JJ (r_conj) group_16/NN (l_acl) comprising_17/VBG (l_dobj) patients_19/NNS (l_amod) hypertensive_18/JJ
D009543_D006973 NONE nifedipine_5/NN (r_pobj) of_4/IN (r_prep) impact_3/NN (r_nsubj) be_18/VB (l_attr) factor_21/NN (l_prep) in_22/IN (l_pcomp) selecting_23/VBG (l_advcl) treat_27/VB (l_dobj) hypertension_28/NN
D009543_D007674 NONE nifedipine_5/NN (r_pobj) of_4/IN (r_prep) impact_3/NN (l_prep) on_6/IN (l_pcomp) reducing_7/VBG (l_dobj) nephrotoxicity_9/NN
D016559_D007674 NONE tacrolimus_12/NN (r_pobj) with_11/IN (r_prep) associated_10/VBN (r_acl) nephrotoxicity_9/NN
12627929
C067311_D054556 CID docetaxel_9/NN (r_pobj) of_8/IN (r_prep) combination_7/NN (r_pobj) with_5/IN (r_prep) frequency_1/NN (l_prep) of_2/IN (l_pobj) thromboembolism_4/NN
C067311_D054556 CID docetaxel_23/NNP (r_pobj) with_22/IN (r_prep) treated_21/VBN (r_relcl) cancer_18/NN (r_pobj) with_12/IN (r_prep) patients_11/NNS (r_pobj) in_10/IN (r_prep) evaluate_1/VB (l_dobj) frequency_3/NN (l_prep) of_4/IN (l_pobj) thromboembolism_6/NN
C067311_D054556 CID docetaxel_23/NNP (r_pobj) with_22/IN (r_prep) treated_21/VBN (r_relcl) cancer_18/NN (r_pobj) with_12/IN (r_prep) patients_11/NNS (r_pobj) in_10/IN (r_prep) evaluate_1/VB (l_npadvmod) VTE_8/NNP
C067311_D054556 CID docetaxel_6/NNP (r_dobj) received_5/VBD (r_relcl) patients_3/NNS (r_pobj) of_1/IN (r_prep) None_0/NN (r_nsubj) developed_8/VBD (l_dobj) VTE_9/NNP
C067311_D054556 CID docetaxel_6/NNP (r_dobj) received_5/VBD (r_relcl) patients_3/NNS (r_pobj) of_1/IN (r_prep) None_0/NN (r_nsubj) developed_8/VBD (l_advcl) developed_25/VBD (l_dobj) VTE_26/NNP
C067311_D054556 CID docetaxel_22/NNP (r_dobj) received_21/VBD (r_relcl) 9_12/CD (r_nummod) thalidomide_24/NN (r_nsubj) developed_25/VBD (r_advcl) developed_8/VBD (l_dobj) VTE_9/NNP
C067311_D054556 CID docetaxel_22/NNP (r_dobj) received_21/VBD (r_relcl) 9_12/CD (r_nummod) thalidomide_24/NN (r_nsubj) developed_25/VBD (l_dobj) VTE_26/NNP
C067311_D054556 CID docetaxel_5/NN (r_acl) addition_1/NN (r_nsubj) increases_13/VBZ (l_dobj) frequency_15/NN (l_prep) of_16/IN (l_pobj) VTE_17/NNP
C067311_D011471 NONE docetaxel_9/NN (r_pobj) of_8/IN (r_prep) combination_7/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) cancer_20/NN
C067311_D011471 NONE docetaxel_23/NNP (r_pobj) with_22/IN (r_prep) treated_21/VBN (r_relcl) cancer_18/NN
C067311_D011471 NONE docetaxel_5/NN (l_prep) in_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) cancer_11/NN
D013792_D054556 CID thalidomide_11/NN (r_conj) docetaxel_9/NN (r_pobj) of_8/IN (r_prep) combination_7/NN (r_pobj) with_5/IN (r_prep) frequency_1/NN (l_prep) of_2/IN (l_pobj) thromboembolism_4/NN
D013792_D054556 CID thalidomide_29/NN (r_pobj) with_28/IN (r_prep) combination_27/NN (r_pobj) in_26/IN (r_conj) treated_21/VBN (r_relcl) cancer_18/NN (r_pobj) with_12/IN (r_prep) patients_11/NNS (r_pobj) in_10/IN (r_prep) evaluate_1/VB (l_dobj) frequency_3/NN (l_prep) of_4/IN (l_pobj) thromboembolism_6/NN
D013792_D054556 CID thalidomide_29/NN (r_pobj) with_28/IN (r_prep) combination_27/NN (r_pobj) in_26/IN (r_conj) treated_21/VBN (r_relcl) cancer_18/NN (r_pobj) with_12/IN (r_prep) patients_11/NNS (r_pobj) in_10/IN (r_prep) evaluate_1/VB (l_npadvmod) VTE_8/NNP
D013792_D054556 CID thalidomide_24/NN (r_nsubj) developed_25/VBD (r_advcl) developed_8/VBD (l_dobj) VTE_9/NNP
D013792_D054556 CID thalidomide_24/NN (r_nsubj) developed_25/VBD (l_dobj) VTE_26/NNP
D013792_D054556 CID thalidomide_3/NN (r_pobj) of_2/IN (r_prep) addition_1/NN (r_nsubj) increases_13/VBZ (l_dobj) frequency_15/NN (l_prep) of_16/IN (l_pobj) VTE_17/NNP
D013792_D011471 NONE thalidomide_11/NN (r_conj) docetaxel_9/NN (r_pobj) of_8/IN (r_prep) combination_7/NN (l_prep) in_12/IN (l_pobj) patients_13/NNS (l_prep) with_14/IN (l_pobj) cancer_20/NN
D013792_D011471 NONE thalidomide_29/NN (r_pobj) with_28/IN (r_prep) combination_27/NN (r_pobj) in_26/IN (r_conj) treated_21/VBN (r_relcl) cancer_18/NN
D013792_D011471 NONE thalidomide_3/NN (r_pobj) of_2/IN (r_prep) addition_1/NN (l_acl) docetaxel_5/NN (l_prep) in_6/IN (l_pobj) treatment_8/NN (l_prep) of_9/IN (l_pobj) cancer_11/NN
18208574
D006493_D013927 CID heparin_12/NN (r_npadvmod) induced_14/VBN (r_amod) thrombocytopenia_15/NN (r_pobj) with_11/IN (r_prep) patients_10/NNS (r_pobj) in_9/IN (r_prep) thrombosis_8/NN
D006493_D013927 CID heparin_12/NN (r_npadvmod) induced_14/VBN (r_amod) thrombocytopenia_15/NN (l_appos) assay_20/NN (l_prep) with_21/IN (l_pobj) thrombosis_22/NN
D006493_D013927 CID heparin_33/NN (r_compound) concentration_34/NN (r_pobj) of_30/IN (r_prep) characteristics_29/NNS (r_dobj) utilizes_26/VBZ (l_advcl) correlate_1/VB (l_dobj) density_3/NN (l_prep) of_7/IN (l_pobj) thrombocytopenia_15/NN (l_appos) assay_20/NN (l_prep) with_21/IN (l_pobj) thrombosis_22/NN
D006493_D013921 CID heparin_12/NN (r_npadvmod) induced_14/VBN (r_amod) thrombocytopenia_15/NN
D006493_D013921 CID heparin_12/NN (r_npadvmod) induced_14/VBN (r_amod) thrombocytopenia_15/NN
D006493_D013921 CID heparin_12/NN (r_npadvmod) induced_14/VBN (r_amod) thrombocytopenia_15/NN (l_appos) assay_20/NN (l_nmod) HIT_17/NN
D006493_D013921 CID heparin_33/NN (r_compound) concentration_34/NN (r_pobj) of_30/IN (r_prep) characteristics_29/NNS (r_dobj) utilizes_26/VBZ (l_advcl) correlate_1/VB (l_dobj) density_3/NN (l_prep) of_7/IN (l_pobj) thrombocytopenia_15/NN
D006493_D013921 CID heparin_33/NN (r_compound) concentration_34/NN (r_pobj) of_30/IN (r_prep) characteristics_29/NNS (r_dobj) utilizes_26/VBZ (l_advcl) correlate_1/VB (l_dobj) density_3/NN (l_prep) of_7/IN (l_pobj) thrombocytopenia_15/NN (l_appos) assay_20/NN (l_nmod) HIT_17/NN
D006493_D013921 CID heparin_21/NN (r_pobj) to_20/IN (r_prep) exposure_19/NN (r_pobj) after_18/IN (r_prep) Patients_0/NNS (l_prep) with_1/IN (l_pobj) decrease_6/NN (l_prep) in_7/IN (l_pobj) count_9/NN (l_conj) thrombocytopenia_11/NN
1867351
D015767_D008288 NONE mefloquine_10/NNP (r_pobj) with_9/IN (r_prep) prophylaxis_6/NN (l_compound) malaria_5/NN
2515254
D005996_D008881 CID nitroglycerin_11/NN (r_pobj) of_10/IN (r_prep) application_9/NN (r_dobj) received_4/VBD (l_nsubj) patients_3/NNS (l_compound) migraine_2/NN
D005996_D008881 CID nitroglycerin_7/NN (r_pobj) by_6/IN (r_agent) induced_5/VBN (l_nsubjpass) attacks_3/NNS (l_compound) migraine_2/NN
D005996_D008881 CID nitroglycerin_13/NN (r_pobj) with_11/IN (r_prep) attack_10/NN (r_dobj) developed_6/VBD (r_relcl) patients_3/NNS (l_compound) migraine_2/NN
D005996_D008881 CID nitroglycerin_7/NN (r_pobj) of_6/IN (r_prep) effect_5/NN (l_amod) inducing_4/VBG (l_npadvmod) migraine_2/NN
D005996_D008881 CID nitroglycerin_7/NN (r_pobj) of_6/IN (r_prep) effect_5/NN (r_nsubj) seems_8/VBZ (l_advcl) suggesting_21/VBG (l_ccomp) is_26/VBZ (l_prep) in_30/IN (l_pobj) development_32/NN (l_prep) of_33/IN (l_pobj) crisis_36/NN (l_compound) migraine_35/NN
D005996_D010146 NONE nitroglycerin_7/NN (r_pobj) of_6/IN (r_prep) effect_5/NN (r_nsubj) seems_8/VBZ (l_xcomp) depend_10/VB (l_prep) on_11/IN (l_pobj) stimulation_13/NN (l_prep) of_14/IN (l_pobj) site_17/NN (l_prep) of_18/IN (l_pobj) pain_19/NN
17639754
D014859_D006470 CID warfarin_18/NNP (r_pobj) between_17/IN (r_prep) interaction_16/NN (r_pobj) of_14/IN (r_prep) result_13/NN (r_attr) be_11/VB (r_xcomp) appear_9/VBP (r_relcl) complications_7/NNS (l_amod) bleeding_6/NN
D064704_D006470 CID levofloxacin_20/NNS (r_conj) warfarin_18/NNP (r_pobj) between_17/IN (r_prep) interaction_16/NN (r_pobj) of_14/IN (r_prep) result_13/NN (r_attr) be_11/VB (r_xcomp) appear_9/VBP (r_relcl) complications_7/NNS (l_amod) bleeding_6/NN
10365197
D003042_D019964 CID Cocaine_0/NN (r_npadvmod) induced_2/VBN (r_amod) disorder_4/NN
D003042_D019964 CID cocaine_1/NN (r_npadvmod) dependent_3/JJ (r_amod) outpatients_4/NNS (l_prep) with_5/IN (l_pobj) disorder_10/NN
D003042_D019964 CID cocaine_1/NN (r_npadvmod) dependent_3/JJ (r_amod) outpatients_4/NNS (l_prep) with_5/IN (l_pobj) disorder_10/NN (l_conj) disorders_17/NNS
D003042_D019964 CID cocaine_1/NN (r_npadvmod) dependent_3/JJ (r_amod) outpatients_4/NNS (l_prep) with_5/IN (l_pobj) disorder_10/NN (l_conj) disorders_17/NNS (l_conj) disorder_22/NN
D003042_D019964 CID cocaine_6/NN (r_npadvmod) induced_8/VBN (r_amod) disorder_10/NN
D003042_D019964 CID cocaine_6/NN (r_npadvmod) induced_8/VBN (r_amod) disorder_10/NN (l_conj) disorders_17/NNS
D003042_D019964 CID cocaine_6/NN (r_npadvmod) induced_8/VBN (r_amod) disorder_10/NN (l_conj) disorders_17/NNS (l_conj) disorder_22/NN
D003042_D001523 NONE cocaine_8/NN (r_npadvmod) dependent_10/JJ (r_amod) sample_11/NN (r_pobj) in_5/IN (r_prep) rates_1/NNS (l_conj) symptoms_4/NNS (l_amod) psychiatric_3/JJ
D003042_D001523 NONE cocaine_1/NN (r_npadvmod) dependent_3/JJ (r_amod) outpatients_4/NNS (r_nsubjpass) compared_24/VBN (l_prep) on_25/IN (l_pobj) measures_26/NNS (l_prep) of_27/IN (l_pobj) symptoms_29/NNS (l_amod) psychiatric_28/JJ
D003042_D001523 NONE cocaine_6/NN (r_npadvmod) induced_8/VBN (r_amod) disorder_10/NN (r_pobj) with_5/IN (r_prep) outpatients_4/NNS (r_nsubjpass) compared_24/VBN (l_prep) on_25/IN (l_pobj) measures_26/NNS (l_prep) of_27/IN (l_pobj) symptoms_29/NNS (l_amod) psychiatric_28/JJ
D003042_D019970 NONE cocaine_1/NN (r_npadvmod) dependent_3/JJ (r_amod) outpatients_4/NNS (l_prep) with_5/IN (l_pobj) disorder_10/NN (l_appos) CIMD_12/NNP
D003042_D019970 NONE cocaine_6/NN (r_npadvmod) induced_8/VBN (r_amod) disorder_10/NN (l_appos) CIMD_12/NNP
19957053
D010656_D002534 CID Phenylephrine_0/NNP (r_nsubj) reduces_4/VBZ (l_dobj) oxygenation_7/NN
D010656_D007022 NONE Phenylephrine_0/NNP (r_nsubj) reduces_4/VBZ (l_dobj) oxygenation_7/NN (l_prep) following_8/VBG (l_pobj) hypotension_12/NN
D010656_D007022 NONE phenylephrine_5/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (r_dobj) describe_1/VBP (l_prep) following_16/VBG (l_pobj) hypotension_20/NN
D010656_D007022 NONE phenylephrine_3/NN (r_pobj) of_2/IN (r_prep) utilization_1/NN (l_acl) correct_5/VB (l_dobj) hypotension_6/NN
D004809_D002534 NONE ephedrine_3/JJ (r_conj) Phenylephrine_0/NNP (r_nsubj) reduces_4/VBZ (l_dobj) oxygenation_7/NN
D004809_D007022 NONE ephedrine_3/JJ (r_conj) Phenylephrine_0/NNP (r_nsubj) reduces_4/VBZ (l_dobj) oxygenation_7/NN (l_prep) following_8/VBG (l_pobj) hypotension_12/NN
D004809_D007022 NONE ephedrine_7/NN (r_conj) phenylephrine_5/NN (r_pobj) of_4/IN (r_prep) effect_3/NN (r_dobj) describe_1/VBP (l_prep) following_16/VBG (l_pobj) hypotension_20/NN
6727060
D008787_D004409 CID metoclopramide_7/NN (r_pobj) by_6/IN (r_agent) caused_5/VBN (r_acl) dyskinesia_4/NN
D008787_D004409 CID metoclopramide_23/NN (r_dobj) took_22/VBD (r_advcl) appeared_3/VBD (l_nsubj) movements_2/NNS
D008787_D004409 CID metoclopramide_2/NNP (r_compound) administration_3/NN (r_nsubjpass) discontinued_5/VBN (r_advcl) improved_11/VBN (l_nsubj) movements_9/NNS
D008787_D005767 NONE metoclopramide_23/NN (r_dobj) took_22/VBD (l_prep) for_24/IN (l_pobj) disorder_26/NN
15325671
D003520_D066126 NONE cyclophosphamide_9/NN (r_npadvmod) based_11/VBN (r_amod) chemotherapy_12/NN (r_pobj) with_5/IN (r_prep) association_4/NN (r_pobj) in_3/IN (r_prep) observed_2/VBN (l_nsubj) toxicity_1/NN
D003520_D066126 NONE cyclophosphamide_3/RB (r_npadvmod) related_5/VBN (r_amod) toxicity_7/NN
D003520_D001943 NONE cyclophosphamide_9/NN (r_npadvmod) based_11/VBN (r_amod) chemotherapy_12/NN (l_prep) for_13/IN (l_pobj) cancer_16/NN
D003520_D001943 NONE cyclophosphamide_9/NN (r_conj) melphalan_4/NNP (r_conj) paclitaxel_2/XX (l_prep) in_15/IN (l_pobj) regimen_22/NN (l_prep) for_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) cancer_28/NN
D003520_D001943 NONE cyclophosphamide_16/NN (r_dobj) receiving_13/VBG (r_acl) cancer_12/NN
D017239_D001943 NONE paclitaxel_2/XX (l_prep) in_15/IN (l_pobj) regimen_22/NN (l_prep) for_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) cancer_28/NN
D008558_D001943 NONE melphalan_4/NNP (r_conj) paclitaxel_2/XX (l_prep) in_15/IN (l_pobj) regimen_22/NN (l_prep) for_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) cancer_28/NN
D013852_D001943 NONE thiotepa_11/NNP (r_conj) cyclophosphamide_9/NN (r_conj) melphalan_4/NNP (r_conj) paclitaxel_2/XX (l_prep) in_15/IN (l_pobj) regimen_22/NN (l_prep) for_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) cancer_28/NN
D016190_D001943 NONE carboplatin_14/NNP (r_conj) thiotepa_11/NNP (r_conj) cyclophosphamide_9/NN (r_conj) melphalan_4/NNP (r_conj) paclitaxel_2/XX (l_prep) in_15/IN (l_pobj) regimen_22/NN (l_prep) for_23/IN (l_pobj) patients_24/NNS (l_prep) with_25/IN (l_pobj) cancer_28/NN
D003520_D006333 CID cyclophosphamide_16/NN (r_dobj) receiving_13/VBG (l_prep) as_17/IN (l_pobj) part_18/NN (l_prep) of_19/IN (l_pobj) regimen_26/NN (l_relcl) assess_28/VB (l_dobj) association_29/NN (l_prep) between_30/IN (l_pobj) presence_31/NN (l_prep) of_32/IN (l_pobj) failure_36/NN
D003520_D006333 CID cyclophosphamide_16/NN (r_dobj) receiving_13/VBG (l_prep) as_17/IN (l_pobj) part_18/NN (l_prep) of_19/IN (l_pobj) regimen_26/NN (l_relcl) assess_28/VB (l_dobj) association_29/NN (l_prep) between_30/IN (l_pobj) presence_31/NN (l_prep) of_32/IN (l_pobj) failure_36/NN (l_appos) CHF_38/NNP
D003520_D006333 CID cyclophosphamide_16/NN (r_pobj) following_14/VBG (r_prep) developed_8/VBD (l_dobj) CHF_13/NNP
D003520_D006333 CID cyclophosphamide_5/NN (r_pobj) during_3/IN (r_prep) monitoring_2/NN (r_nsubj) predict_8/VB (l_dobj) development_10/NN (l_compound) CHF_9/NNP
D003520_D006973 NONE cyclophosphamide_16/NN (r_dobj) receiving_13/VBG (l_prep) as_17/IN (l_pobj) part_18/NN (l_prep) of_19/IN (l_pobj) regimen_26/NN (l_relcl) assess_28/VB (l_dobj) association_29/NN (l_prep) between_30/IN (l_pobj) presence_31/NN (l_conj) characteristics_44/NNS (l_appos) presence_46/NN (l_prep) of_47/IN (l_pobj) abnormalities_52/NNS (l_conj) age_54/NN (l_conj) hypertension_56/NN
D003520_D003920 NONE cyclophosphamide_16/NN (r_dobj) receiving_13/VBG (l_prep) as_17/IN (l_pobj) part_18/NN (l_prep) of_19/IN (l_pobj) regimen_26/NN (l_relcl) assess_28/VB (l_dobj) association_29/NN (l_prep) between_30/IN (l_pobj) presence_31/NN (l_conj) characteristics_44/NNS (l_appos) presence_46/NN (l_prep) of_47/IN (l_pobj) abnormalities_52/NNS (l_conj) age_54/NN (l_conj) hypertension_56/NN (l_conj) history_60/NN (l_conj) smoking_62/NN (l_conj) mellitus_65/NN
D018943_D001943 NONE anthracyclines_70/NNS (r_pobj) of_69/IN (r_prep) use_68/NN (r_appos) characteristics_44/NNS (r_conj) presence_31/NN (r_pobj) between_30/IN (r_prep) association_29/NN (r_dobj) assess_28/VB (r_relcl) regimen_26/NN (r_pobj) of_19/IN (r_prep) part_18/NN (r_pobj) as_17/IN (r_prep) receiving_13/VBG (r_acl) cancer_12/NN
D018943_D006333 NONE anthracyclines_70/NNS (r_pobj) of_69/IN (r_prep) use_68/NN (r_appos) characteristics_44/NNS (r_conj) presence_31/NN (l_prep) of_32/IN (l_pobj) failure_36/NN
D018943_D006333 NONE anthracyclines_70/NNS (r_pobj) of_69/IN (r_prep) use_68/NN (r_appos) characteristics_44/NNS (r_conj) presence_31/NN (l_prep) of_32/IN (l_pobj) failure_36/NN (l_appos) CHF_38/NNP
D018943_D006973 NONE anthracyclines_70/NNS (r_pobj) of_69/IN (r_prep) use_68/NN (r_appos) characteristics_44/NNS (l_appos) presence_46/NN (l_prep) of_47/IN (l_pobj) abnormalities_52/NNS (l_conj) age_54/NN (l_conj) hypertension_56/NN
D018943_D003920 NONE anthracyclines_70/NNS (r_pobj) of_69/IN (r_prep) use_68/NN (r_appos) characteristics_44/NNS (l_appos) presence_46/NN (l_prep) of_47/IN (l_pobj) abnormalities_52/NNS (l_conj) age_54/NN (l_conj) hypertension_56/NN (l_conj) history_60/NN (l_conj) smoking_62/NN (l_conj) mellitus_65/NN
12907309
C121465_D020258 NONE MPEP_3/NNP (l_appos) antagonist_8/NN (l_prep) in_10/IN (l_pobj) neurotoxicity_15/NN
C121465_D005334 NONE MPEP_3/NNP (r_pobj) of_2/IN (r_prep) action_1/NN (r_nsubjpass) associated_17/VBN (l_prep) with_18/IN (l_pobj) decrease_20/NN (l_prep) in_21/IN (l_pobj) outflow_23/NN (l_prep) of_26/IN (l_pobj) hyperthermia_27/NN
C121465_D005334 NONE MPEP_3/NNP (r_pobj) by_2/IN (r_agent) rendered_1/VBN (r_acl) Neuroprotection_0/NN (r_nsubjpass) associated_6/VBN (l_conj) with_29/IN (l_pobj) decrease_31/NN (l_prep) in_32/IN (l_pobj) hyperthermia_33/NN
D008694_D020258 NONE methamphetamine_11/NN (r_npadvmod) induced_13/VBN (r_amod) neurotoxicity_15/NN
D008694_D005334 CID methamphetamine_11/NN (r_npadvmod) induced_13/VBN (r_amod) neurotoxicity_15/NN (r_pobj) in_10/IN (r_prep) antagonist_8/NN (r_appos) MPEP_3/NNP (r_pobj) of_2/IN (r_prep) action_1/NN (r_nsubjpass) associated_17/VBN (l_prep) with_18/IN (l_pobj) decrease_20/NN (l_prep) in_21/IN (l_pobj) outflow_23/NN (l_prep) of_26/IN (l_pobj) hyperthermia_27/NN
D008694_D005334 CID methamphetamine_6/NN (l_appos) hyperthermia_11/NN
D008694_D005334 CID methamphetamine_12/NN (r_npadvmod) induced_14/VBN (r_amod) efflux_16/NN (r_pobj) of_10/IN (r_prep) reduction_9/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (l_conj) with_29/IN (l_pobj) decrease_31/NN (l_prep) in_32/IN (l_pobj) hyperthermia_33/NN
D004298_D020258 NONE dopamine_22/NN (r_compound) outflow_23/NN (r_pobj) in_21/IN (r_prep) decrease_20/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (l_nsubjpass) action_1/NN (l_prep) of_2/IN (l_pobj) MPEP_3/NNP (l_appos) antagonist_8/NN (l_prep) in_10/IN (l_pobj) neurotoxicity_15/NN
D004298_D005334 NONE dopamine_22/NN (r_compound) outflow_23/NN (l_prep) of_26/IN (l_pobj) hyperthermia_27/NN
D004298_D005334 NONE dopamine_15/NN (r_compound) efflux_16/NN (r_pobj) of_10/IN (r_prep) reduction_9/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (l_conj) with_29/IN (l_pobj) decrease_31/NN (l_prep) in_32/IN (l_pobj) hyperthermia_33/NN
C121465_D064420 NONE MPEP_12/NNP (r_pobj) by_11/IN (r_prep) blockade_8/NN (r_nsubj) protect_14/VB (l_dobj) neurones_16/NNS (l_prep) against_17/IN (l_pobj) toxicity_21/NN
D008694_D064420 NONE methamphetamine_18/NN (r_npadvmod) induced_20/VBN (r_amod) toxicity_21/NN
3425586
D003622_D000743 CID Dapsone_0/NNP (r_npadvmod) associated_2/VBN (r_amod) anemia_6/NN
D003622_D000743 CID dapsone_23/NN (r_pobj) of_22/IN (r_prep) dose_21/NN (r_dobj) taking_19/VBG (r_advcl) developed_12/VBD (l_dobj) anemia_17/NN
D003622_D000743 CID dapsone_21/NNP (r_nsubj) cause_24/VB (l_dobj) anemia_26/NN
D003622_D007918 NONE dapsone_23/NN (r_pobj) of_22/IN (r_prep) dose_21/NN (r_dobj) taking_19/VBG (r_advcl) developed_12/VBD (l_nsubj) woman_2/NN (l_prep) with_3/IN (l_pobj) trait_6/NN (l_conj) leprosy_11/NN
D003622_D006461 NONE dapsone_23/NN (l_acl) associated_32/VBN (l_prep) with_33/IN (l_pobj) hemolysis_35/NN
18439803
C108761_D012640 NONE N-(2-propylpentanoyl)urea_3/NNP (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) in_9/IN (l_pobj) seizure_13/NN
C108761_D012640 NONE VPU_0/NNP (r_nsubj) was_1/VBD (l_advcl) exhibiting_7/VBG (l_dobj) dose_11/NN (l_prep) of_16/IN (l_pobj) mg/kg_18/CD (l_prep) in_19/IN (l_pcomp) protecting_20/VBG (l_dobj) rats_21/NNS (l_prep) against_22/IN (l_pobj) seizure_26/NN
C108761_D012640 NONE VPU_5/NNP (r_nsubj) protect_9/VB (l_prep) against_12/IN (l_pobj) seizure_16/NN
C108761_D012640 NONE VPU_8/NNP (r_nsubj) reduce_11/VB (r_acl) finding_6/NN (r_nsubj) account_21/VB (l_prep) for_27/IN (l_pobj) activity_30/NN (l_acl) observed_31/VBN (l_prep) in_32/IN (l_pobj) seizure_36/NN
D000596_D012640 NONE acid_7/NN (r_compound) neurotransmitters_8/NNS (r_pobj) on_4/IN (r_prep) effects_1/NNS (l_prep) in_9/IN (l_pobj) seizure_13/NN
D000596_D012640 NONE acid_26/NN (r_compound) neurotransmitters_27/NNS (r_pobj) of_23/IN (r_prep) reduction_22/NN (r_nsubj) was_28/VBD (r_ccomp) suggested_19/VBN (l_prep) Based_0/VBN (l_prep) on_1/IN (l_pobj) finding_3/NN (l_acl) protect_9/VB (l_prep) against_12/IN (l_pobj) seizure_16/NN
D010862_D012640 CID pilocarpine_10/NN (r_npadvmod) induced_12/VBN (r_amod) seizure_13/NN
D010862_D012640 CID pilocarpine_23/NN (r_npadvmod) induced_25/VBN (r_amod) seizure_26/NN
D010862_D012640 CID pilocarpine_13/NN (r_npadvmod) induced_15/VBN (r_amod) seizure_16/NN
D010862_D012640 CID pilocarpine_12/NN (r_npadvmod) induced_14/VBN (r_amod) increases_15/NNS (r_dobj) reduce_11/VB (r_acl) finding_6/NN (r_nsubj) account_21/VB (l_prep) for_27/IN (l_pobj) activity_30/NN (l_acl) observed_31/VBN (l_prep) in_32/IN (l_pobj) seizure_36/NN
D010862_D012640 CID pilocarpine_33/NNP (r_npadvmod) induced_35/VBN (r_amod) seizure_36/NN
D014635_D012640 NONE VPA_5/NNP (r_pobj) than_4/IN (r_prep) potent_3/JJ (r_acomp) was_1/VBD (l_advcl) exhibiting_7/VBG (l_dobj) dose_11/NN (l_prep) of_16/IN (l_pobj) mg/kg_18/CD (l_prep) in_19/IN (l_pcomp) protecting_20/VBG (l_dobj) rats_21/NNS (l_prep) against_22/IN (l_pobj) seizure_26/NN
D014635_D012640 NONE VPA_32/NNP (r_pobj) for_31/IN (r_prep) value_30/NN (r_nsubj) was_33/VBD (r_advcl) was_1/VBD (l_advcl) exhibiting_7/VBG (l_dobj) dose_11/NN (l_prep) of_16/IN (l_pobj) mg/kg_18/CD (l_prep) in_19/IN (l_pcomp) protecting_20/VBG (l_dobj) rats_21/NNS (l_prep) against_22/IN (l_pobj) seizure_26/NN
D014635_D012640 NONE VPA_7/NNP (r_conj) VPU_5/NNP (r_nsubj) protect_9/VB (l_prep) against_12/IN (l_pobj) seizure_16/NN
D014635_D012640 NONE VPA_3/NNP (r_pobj) like_2/IN (r_prep) account_21/VB (l_prep) for_27/IN (l_pobj) activity_30/NN (l_acl) observed_31/VBN (l_prep) in_32/IN (l_pobj) seizure_36/NN
D018698_D012640 NONE glutamate_38/NN (r_pobj) of_37/IN (r_prep) reduction_36/NN (r_pobj) by_33/IN (r_agent) offset_32/VBN (r_conj) was_28/VBD (r_ccomp) suggested_19/VBN (l_prep) Based_0/VBN (l_prep) on_1/IN (l_pobj) finding_3/NN (l_acl) protect_9/VB (l_prep) against_12/IN (l_pobj) seizure_16/NN
D018698_D012640 NONE glutamate_17/NN (r_pobj) in_16/IN (r_prep) increases_15/NNS (r_dobj) reduce_11/VB (r_acl) finding_6/NN (r_nsubj) account_21/VB (l_prep) for_27/IN (l_pobj) activity_30/NN (l_acl) observed_31/VBN (l_prep) in_32/IN (l_pobj) seizure_36/NN
D001224_D012640 NONE aspartate_40/NN (r_conj) glutamate_38/NN (r_pobj) of_37/IN (r_prep) reduction_36/NN (r_pobj) by_33/IN (r_agent) offset_32/VBN (r_conj) was_28/VBD (r_ccomp) suggested_19/VBN (l_prep) Based_0/VBN (l_prep) on_1/IN (l_pobj) finding_3/NN (l_acl) protect_9/VB (l_prep) against_12/IN (l_pobj) seizure_16/NN
D001224_D012640 NONE aspartate_19/NN (r_conj) glutamate_17/NN (r_pobj) in_16/IN (r_prep) increases_15/NNS (r_dobj) reduce_11/VB (r_acl) finding_6/NN (r_nsubj) account_21/VB (l_prep) for_27/IN (l_pobj) activity_30/NN (l_acl) observed_31/VBN (l_prep) in_32/IN (l_pobj) seizure_36/NN
15275829
D009538_D012640 CID nicotine_5/NN (r_npadvmod) induced_7/VBN (r_amod) seizures_8/NNS
D009538_D012640 CID nicotine_2/NN (r_pobj) of_1/IN (r_prep) Binding_0/VBG (r_nsubj) elicits_10/VBZ (l_dobj) series_12/NN (l_prep) of_13/IN (l_pobj) behaviors_17/NNS (l_relcl) go_19/VBP (l_prep) to_29/IN (l_pobj) seizures_30/NNS
D009538_D012640 CID nicotine_9/NN (r_npadvmod) induced_11/VBN (r_amod) seizures_12/NNS
D009538_D012640 CID nicotine_8/NN (r_pobj) of_7/IN (r_prep) effects_6/NNS (l_acl) measured_28/VBN (l_prep) as_29/IN (l_pobj) sensitivity_30/NN (l_prep) to_31/IN (l_pobj) seizures_35/NNS
D009538_D012640 CID nicotine_32/NN (r_npadvmod) induced_34/VBN (r_amod) seizures_35/NNS
D009538_D012640 CID nicotine_6/NN (r_npadvmod) induced_8/VBN (r_amod) seizures_9/NNS
D009538_D012640 CID nicotine_15/NN (r_npadvmod) induced_17/VBN (r_amod) seizures_18/NNS
D009538_D006948 NONE nicotine_5/NN (r_npadvmod) induced_7/VBN (r_amod) seizures_8/NNS (l_conj) hypolocomotion_10/NN
D009538_D006948 NONE nicotine_9/NN (r_npadvmod) induced_11/VBN (r_amod) seizures_12/NNS (l_conj) hypolocomotion_14/NN
D009538_D006948 NONE nicotine_15/NN (r_npadvmod) induced_17/VBN (r_amod) seizures_18/NNS (l_conj) hypolocomotion_20/NN
D009538_D014202 NONE nicotine_2/NN (r_pobj) of_1/IN (r_prep) Binding_0/VBG (r_nsubj) elicits_10/VBZ (l_dobj) series_12/NN (l_prep) of_13/IN (l_pobj) behaviors_17/NNS (l_relcl) go_19/VBP (l_prep) from_20/IN (l_pobj) exploration_22/NN (l_conj) sedation_24/NN (l_conj) tremors_27/NNS
D009538_D003643 NONE nicotine_2/NN (r_pobj) of_1/IN (r_prep) Binding_0/VBG (r_nsubj) elicits_10/VBZ (l_dobj) series_12/NN (l_prep) of_13/IN (l_pobj) behaviors_17/NNS (l_relcl) go_19/VBP (l_prep) to_29/IN (l_pobj) seizures_30/NNS (l_conj) death_32/NN
D000109_D014202 NONE acetylcholine_5/NN (r_compound) receptors_6/NNS (r_pobj) to_3/IN (r_prep) Binding_0/VBG (r_nsubj) elicits_10/VBZ (l_dobj) series_12/NN (l_prep) of_13/IN (l_pobj) behaviors_17/NNS (l_relcl) go_19/VBP (l_prep) from_20/IN (l_pobj) exploration_22/NN (l_conj) sedation_24/NN (l_conj) tremors_27/NNS
D000109_D012640 NONE acetylcholine_5/NN (r_compound) receptors_6/NNS (r_pobj) to_3/IN (r_prep) Binding_0/VBG (r_nsubj) elicits_10/VBZ (l_dobj) series_12/NN (l_prep) of_13/IN (l_pobj) behaviors_17/NNS (l_relcl) go_19/VBP (l_prep) to_29/IN (l_pobj) seizures_30/NNS
D000109_D003643 NONE acetylcholine_5/NN (r_compound) receptors_6/NNS (r_pobj) to_3/IN (r_prep) Binding_0/VBG (r_nsubj) elicits_10/VBZ (l_dobj) series_12/NN (l_prep) of_13/IN (l_pobj) behaviors_17/NNS (l_relcl) go_19/VBP (l_prep) to_29/IN (l_pobj) seizures_30/NNS (l_conj) death_32/NN
3341566
D009599_D006470 NONE nitroprusside_10/RB (r_npadvmod) induced_12/VBN (r_amod) hypotension_13/NN (r_pobj) than_7/IN (r_prep) greater_4/JJR (l_prep) during_5/IN (l_pobj) hemorrhage_6/NN
D009599_D006470 NONE SNP_21/NNP (r_compound) group_22/NN (r_pobj) in_19/IN (r_prep) that_18/DT (r_pobj) with_17/IN (r_prep) compared_16/VBN (r_prep) higher_15/RBR (r_acomp) was_8/VBD (l_prep) During_0/IN (l_pobj) hypotension_4/NN (l_amod) induced_3/VBN (l_npadvmod) HEM_1/NNP
D009599_D006470 NONE SNP_17/NNP (r_compound) group_18/NN (r_pobj) in_15/IN (r_prep) Hg_14/NNP (r_appos) mm_13/NN (r_pobj) with_9/IN (r_prep) compared_8/VBN (r_prep) Hg_2/NNP (l_prep) in_3/IN (l_pobj) group_6/NN (l_compound) HEM_5/NNP
D009599_D006470 NONE SNP_7/NNP (r_conj) HEM_5/NNP
D009599_D007022 CID nitroprusside_10/RB (r_npadvmod) induced_12/VBN (r_amod) hypotension_13/NN
D009599_D007022 CID SNP_21/NNP (r_compound) group_22/NN (r_pobj) in_19/IN (r_prep) that_18/DT (r_pobj) with_17/IN (r_prep) compared_16/VBN (r_prep) higher_15/RBR (r_acomp) was_8/VBD (l_prep) During_0/IN (l_pobj) hypotension_4/NN
D009599_D007022 CID SNP_7/NNP (r_conj) HEM_5/NNP (r_nmod) groups_8/NNS (r_pobj) in_3/IN (r_prep) Hg_2/NNP (l_prep) during_12/IN (l_pobj) hypotension_13/NN
2070391
D008012_D010146 CID lidocaine_6/NN (r_dobj) using_4/VBG (r_acl) Reduction_0/NN (l_prep) in_1/IN (l_pobj) pain_3/NN
D008012_D010146 CID lidocaine_11/NN (r_pobj) of_10/IN (r_prep) injection_9/NN (r_pobj) with_7/IN (r_prep) associated_6/VBN (r_acl) pain_5/NN
D008012_D010146 CID lidocaine_14/NN (r_pobj) of_13/IN (r_prep) pH_12/NN (r_dobj) adjust_10/VB (r_relcl) solution_8/NN (r_pobj) of_5/IN (r_prep) addition_4/NN (r_nsubj) reduce_20/VB (l_dobj) pain_21/NN
D008012_D010146 CID lidocaine_13/NN (r_dobj) receiving_11/VBG (r_pcomp) after_10/IN (r_prep) quantify_5/VB (l_dobj) severity_7/NN (l_prep) of_8/IN (l_pobj) pain_9/NN
D008012_D010146 CID lidocaine_20/NN (r_pobj) after_10/IN (r_prep) quantify_5/VB (l_dobj) severity_7/NN (l_prep) of_8/IN (l_pobj) pain_9/NN
D008012_D010146 CID lidocaine_6/NN (r_pobj) for_4/IN (r_prep) score_3/NN (l_compound) pain_2/NN
D008012_D010146 CID lidocaine_16/NN (r_pobj) for_14/IN (r_prep) score_13/NN (r_pobj) than_10/IN (r_prep) lower_9/JJR (r_acomp) was_7/VBD (l_nsubj) score_3/NN (l_compound) pain_2/NN
D008012_D010146 CID lidocaine_5/NN (r_pobj) of_3/IN (r_prep) adjustment_2/NN (r_nsubjpass) accomplished_8/VBN (l_prep) before_14/IN (l_pobj) injection_15/NN (l_conj) results_17/NNS (l_prep) in_18/IN (l_pobj) reduction_20/NN (l_prep) of_21/IN (l_pobj) pain_23/NN
26094
D008750_D003866 CID dopa_13/NN (r_pobj) in_11/IN (r_prep) occurring_10/VBG (r_acl) depressions_9/NNS
D008750_D001523 NONE dopa_13/NN (r_pobj) in_11/IN (r_prep) occurring_10/VBG (r_acl) depressions_9/NNS (r_pobj) of_8/IN (r_prep) number_7/NN (r_pobj) by_4/IN (r_agent) accounted_2/VBN (l_conj) treated_14/VBD (l_dobj) patients_15/NNS (l_prep) with_16/IN (l_pobj) histories_18/NNS (l_amod) psychiatric_17/JJ
17532790
D007980_D004409 CID DOPA_12/NNP (r_npadvmod) induced_14/VBN (r_amod) dyskinesia_15/NN
D007980_D004409 CID DOPA_2/NNP (r_npadvmod) induced_4/VBN (r_amod) dyskinesia_5/NN
D007980_D004409 CID DOPA_2/NNP (r_npadvmod) induced_4/VBN (r_amod) dyskinesia_5/NN (l_appos) LID_7/NN
D007980_D004409 CID DOPA_31/NNP (r_pobj) with_28/IN (r_prep) treatment_27/NN (r_pobj) after_24/IN (r_prep) arise_15/VBP (r_relcl) complications_13/NNS (r_pobj) among_10/IN (r_prep) is_9/VBZ (l_nsubj) dyskinesia_5/NN
D007980_D004409 CID DOPA_31/NNP (r_pobj) with_28/IN (r_prep) treatment_27/NN (r_pobj) after_24/IN (r_prep) arise_15/VBP (r_relcl) complications_13/NNS (r_pobj) among_10/IN (r_prep) is_9/VBZ (l_nsubj) dyskinesia_5/NN (l_appos) LID_7/NN
D007980_D004409 CID DOPA_5/NNP (r_pobj) with_2/IN (r_prep) treated_1/VBN (l_conj) allocated_7/VBN (l_prep) to_8/IN (l_pobj) groups_10/NNS (l_acl) based_11/VBN (l_prep) on_12/IN (l_pobj) presence_14/NN (l_prep) of_17/IN (l_pobj) LID_18/NN
D007980_D010300 NONE DOPA_2/NNP (r_npadvmod) induced_4/VBN (r_amod) dyskinesia_5/NN (r_nsubj) is_9/VBZ (l_prep) among_10/IN (l_pobj) complications_13/NNS (l_relcl) arise_15/VBP (l_prep) in_16/IN (l_pobj) patients_23/NNS (l_nmod) disease_19/NN
D007980_D010300 NONE DOPA_2/NNP (r_npadvmod) induced_4/VBN (r_amod) dyskinesia_5/NN (r_nsubj) is_9/VBZ (l_prep) among_10/IN (l_pobj) complications_13/NNS (l_relcl) arise_15/VBP (l_prep) in_16/IN (l_pobj) patients_23/NNS (l_nmod) disease_19/NN (l_appos) PD_21/NNP
D007980_D010300 NONE DOPA_31/NNP (r_pobj) with_28/IN (r_prep) treatment_27/NN (r_pobj) after_24/IN (r_prep) arise_15/VBP (l_prep) in_16/IN (l_pobj) patients_23/NNS (l_nmod) disease_19/NN
D007980_D010300 NONE DOPA_31/NNP (r_pobj) with_28/IN (r_prep) treatment_27/NN (r_pobj) after_24/IN (r_prep) arise_15/VBP (l_prep) in_16/IN (l_pobj) patients_23/NNS (l_nmod) disease_19/NN (l_appos) PD_21/NNP
D007980_D010300 NONE DOPA_34/NNP (r_conj) saline_30/NN (r_pobj) with_29/IN (r_prep) treated_28/VBN (r_acl) changes_8/NNS (l_acl) occurring_9/VBG (l_prep) at_10/IN (l_pobj) level_13/NN (l_prep) in_14/IN (l_pobj) samples_16/NNS (l_acl) obtained_17/VBN (l_prep) from_18/IN (l_pobj) model_25/NN (l_prep) of_26/IN (l_pobj) PD_27/NNP
D016627_D010300 NONE 6-hydroxydopamine_21/CD (r_nummod) lesion_23/NN (r_compound) model_25/NN (l_prep) of_26/IN (l_pobj) PD_27/NNP
D001971_D010300 NONE bromocriptine_36/NN (r_conj) DOPA_34/NNP (r_conj) saline_30/NN (r_pobj) with_29/IN (r_prep) treated_28/VBN (r_acl) changes_8/NNS (l_acl) occurring_9/VBG (l_prep) at_10/IN (l_pobj) level_13/NN (l_prep) in_14/IN (l_pobj) samples_16/NNS (l_acl) obtained_17/VBN (l_prep) from_18/IN (l_pobj) model_25/NN (l_prep) of_26/IN (l_pobj) PD_27/NNP
11745184
D002945_D001943 NONE cisplatin_5/NN (r_pobj) of_4/IN (r_prep) trial_3/NN (l_conj) amifostine_9/NNP (l_prep) for_11/IN (l_pobj) carcinoma_14/NN
D002945_D001943 NONE Cisplatin_0/NNP (r_nsubj) has_1/VBZ (l_advcl) used_6/VBN (l_prep) as_7/IN (l_pobj) treatment_13/NN (l_prep) of_14/IN (l_pobj) carcinoma_17/NN
D002945_D001943 NONE cisplatin_10/NN (r_pobj) with_9/IN (r_prep) observed_8/VBN (r_advcl) limited_31/VBN (l_prep) as_34/IN (l_pobj) treatment_36/NN (l_prep) for_37/IN (l_pobj) carcinoma_39/NN
D002945_D001943 NONE cisplatin_19/NN (r_nmod) nephrotoxicity_23/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) toxicities_16/NNS (r_appos) cisplatin_10/NN (r_pobj) with_9/IN (r_prep) observed_8/VBN (r_advcl) limited_31/VBN (l_prep) as_34/IN (l_pobj) treatment_36/NN (l_prep) for_37/IN (l_pobj) carcinoma_39/NN
D002945_D001943 NONE cisplatin_8/NNP (r_pobj) of_7/IN (r_prep) combination_6/NN (r_pobj) of_4/IN (r_prep) study_3/NN (r_nsubjpass) conducted_12/VBN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) carcinoma_19/NN
D004999_D001943 NONE WR-2721_7/NNP (r_nmod) amifostine_9/NNP (l_prep) for_11/IN (l_pobj) carcinoma_14/NN
D004999_D001943 NONE amifostine_9/NNP (l_prep) for_11/IN (l_pobj) carcinoma_14/NN
D004999_D001943 NONE amifostine_10/NNP (r_conj) cisplatin_8/NNP (r_pobj) of_7/IN (r_prep) combination_6/NN (r_pobj) of_4/IN (r_prep) study_3/NN (r_nsubjpass) conducted_12/VBN (l_prep) in_13/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) carcinoma_19/NN
D002945_D064420 NONE cisplatin_10/NN (l_appos) toxicities_16/NNS
D002945_D064420 NONE cisplatin_19/NN (r_nmod) nephrotoxicity_23/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) toxicities_16/NNS
D002945_D064420 NONE cisplatin_20/NN (r_pobj) to_19/IN (r_prep) amifostine_18/NNP (r_pobj) of_17/IN (r_prep) addition_16/NN (r_pobj) with_14/IN (r_prep) observed_13/VBN (l_nsubjpass) effect_5/NN (l_conj) toxicity_8/NN
D002945_D007674 CID cisplatin_10/NN (l_appos) toxicities_16/NNS (l_acl) associated_17/VBN (l_prep) with_18/IN (l_pobj) nephrotoxicity_23/NN
D002945_D007674 CID cisplatin_19/NN (r_nmod) nephrotoxicity_23/NN
D002945_D007674 CID cisplatin_3/NN (r_pobj) of_2/IN (r_prep) trials_1/NNS (r_nsubj) suggested_7/VBD (l_ccomp) reduced_24/VBN (l_nsubjpass) incidence_10/NN (l_prep) of_13/IN (l_pobj) nephrotoxicity_17/NN
D002945_D007674 CID cisplatin_14/NN (r_npadvmod) induced_16/VBN (r_amod) nephrotoxicity_17/NN
D002945_D006311 CID cisplatin_10/NN (l_appos) toxicities_16/NNS (l_acl) associated_17/VBN (l_prep) with_18/IN (l_pobj) nephrotoxicity_23/NN (l_conj) ototoxicity_25/NN
D002945_D006311 CID cisplatin_19/NN (r_nmod) nephrotoxicity_23/NN (l_conj) ototoxicity_25/NN
D002945_D006311 CID cisplatin_3/NN (r_pobj) of_2/IN (r_prep) trials_1/NNS (r_nsubj) suggested_7/VBD (l_ccomp) reduced_24/VBN (l_nsubjpass) incidence_10/NN (l_prep) of_13/IN (l_pobj) nephrotoxicity_17/NN (l_conj) ototoxicity_19/NN
D002945_D006311 CID cisplatin_14/NN (r_npadvmod) induced_16/VBN (r_amod) nephrotoxicity_17/NN (l_conj) ototoxicity_19/NN
D002945_D020258 NONE cisplatin_10/NN (l_appos) toxicities_16/NNS (l_acl) associated_17/VBN (l_prep) with_18/IN (l_pobj) nephrotoxicity_23/NN (l_conj) ototoxicity_25/NN (l_conj) neurotoxicity_28/NN
D002945_D020258 NONE cisplatin_19/NN (r_nmod) nephrotoxicity_23/NN (l_conj) ototoxicity_25/NN (l_conj) neurotoxicity_28/NN
D002945_D009422 CID cisplatin_3/NN (r_pobj) of_2/IN (r_prep) trials_1/NNS (r_nsubj) suggested_7/VBD (l_ccomp) reduced_24/VBN (l_nsubjpass) incidence_10/NN (l_prep) of_13/IN (l_pobj) nephrotoxicity_17/NN (l_conj) ototoxicity_19/NN (l_conj) neuropathy_22/NN
D002945_D009422 CID cisplatin_14/NN (r_npadvmod) induced_16/VBN (r_amod) nephrotoxicity_17/NN (l_conj) ototoxicity_19/NN (l_conj) neuropathy_22/NN
D004999_D007674 NONE amifostine_5/NNP (r_conj) cisplatin_3/NN (r_pobj) of_2/IN (r_prep) trials_1/NNS (r_nsubj) suggested_7/VBD (l_ccomp) reduced_24/VBN (l_nsubjpass) incidence_10/NN (l_prep) of_13/IN (l_pobj) nephrotoxicity_17/NN
D004999_D006311 NONE amifostine_5/NNP (r_conj) cisplatin_3/NN (r_pobj) of_2/IN (r_prep) trials_1/NNS (r_nsubj) suggested_7/VBD (l_ccomp) reduced_24/VBN (l_nsubjpass) incidence_10/NN (l_prep) of_13/IN (l_pobj) nephrotoxicity_17/NN (l_conj) ototoxicity_19/NN
D004999_D009422 NONE amifostine_5/NNP (r_conj) cisplatin_3/NN (r_pobj) of_2/IN (r_prep) trials_1/NNS (r_nsubj) suggested_7/VBD (l_ccomp) reduced_24/VBN (l_nsubjpass) incidence_10/NN (l_prep) of_13/IN (l_pobj) nephrotoxicity_17/NN (l_conj) ototoxicity_19/NN (l_conj) neuropathy_22/NN
D004999_D009369 NONE amifostine_18/NNP (r_pobj) of_17/IN (r_prep) addition_16/NN (r_pobj) with_14/IN (r_prep) observed_13/VBN (l_nsubjpass) effect_5/NN (l_amod) protective_4/JJ (l_npadvmod) tumor_2/NN
D004999_D064420 NONE amifostine_18/NNP (r_pobj) of_17/IN (r_prep) addition_16/NN (r_pobj) with_14/IN (r_prep) observed_13/VBN (l_nsubjpass) effect_5/NN (l_conj) toxicity_8/NN
D002945_D009369 NONE cisplatin_20/NN (r_pobj) to_19/IN (r_prep) amifostine_18/NNP (r_pobj) of_17/IN (r_prep) addition_16/NN (r_pobj) with_14/IN (r_prep) observed_13/VBN (l_nsubjpass) effect_5/NN (l_amod) protective_4/JJ (l_npadvmod) tumor_2/NN
3800626
D010423_D009408 CID pentazocine_8/NN (r_npadvmod) induced_10/VBN (r_amod) myopathy_12/NN (r_pobj) due_6/IN (r_amod) neuropathy_1/NN (l_prep) of_2/IN (l_pobj) nerve_5/NN
D010423_D009408 CID pentazocine_10/NN (r_npadvmod) induced_12/VBN (r_amod) myopathy_13/NN (r_pobj) by_9/IN (r_agent) affected_8/VBN (r_acl) muscle_7/NN (r_pobj) due_4/JJ (r_prep) neuropathy_3/NN
D010423_D020425 CID pentazocine_8/NN (r_npadvmod) induced_10/VBN (r_amod) myopathy_12/NN (r_pobj) due_6/IN (r_amod) neuropathy_1/NN (l_prep) of_2/IN (l_pobj) nerve_5/NN
D010423_D005355 CID pentazocine_8/NN (r_npadvmod) induced_10/VBN (r_amod) myopathy_12/NN
D010423_D005355 CID pentazocine_13/JJ (r_compound) injection_14/NN (r_pobj) of_11/IN (r_prep) effect_10/NN (r_attr) is_2/VBZ (l_nsubj) myopathy_1/NN
D010423_D005355 CID pentazocine_8/NN (r_npadvmod) induced_10/VBN (r_amod) myopathy_12/NN
D010423_D005355 CID pentazocine_8/NN (r_npadvmod) induced_10/VBN (r_amod) myopathy_12/NN (r_pobj) with_6/IN (r_prep) woman_5/NN (r_pobj) In_0/IN (r_prep) showed_32/VBD (l_prep) in_51/IN (l_pobj) addition_52/NN (l_prep) to_53/IN (l_pobj) myopathy_56/NN
D010423_D009135 CID pentazocine_8/NN (r_npadvmod) induced_10/VBN (r_amod) myopathy_12/NN
D010423_D009135 CID pentazocine_13/JJ (r_compound) injection_14/NN (r_pobj) of_11/IN (r_prep) effect_10/NN (r_attr) is_2/VBZ (l_nsubj) myopathy_1/NN
D010423_D009135 CID pentazocine_10/NN (r_npadvmod) induced_12/VBN (r_amod) myopathy_13/NN
D010423_D009135 CID pentazocine_8/NN (r_npadvmod) induced_10/VBN (r_amod) myopathy_12/NN
D010423_D009135 CID pentazocine_8/NN (r_npadvmod) induced_10/VBN (r_amod) myopathy_12/NN (r_pobj) with_6/IN (r_prep) woman_5/NN (r_pobj) In_0/IN (r_prep) showed_32/VBD (l_prep) in_51/IN (l_pobj) addition_52/NN (l_prep) to_53/IN (l_pobj) myopathy_56/NN
3412544
D000082_D014523 NONE paracetamol_1/NN (r_nsubj) cause_2/VB (l_dobj) cancer_4/NN
D000082_D007681 NONE paracetamol_1/NN (r_nsubj) cause_2/VB (l_dobj) cancer_4/NN (l_conj) necrosis_8/NN
D000082_D007681 NONE paracetamol_24/NNP (r_conj) phenacetin_22/NNP (r_pobj) of_20/IN (r_prep) consumption_19/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) pelvis_12/NNS (r_pobj) of_9/IN (r_prep) necrosis_6/NN
D000082_D007681 NONE paracetamol_12/JJ (r_compound) consumption_13/NN (l_prep) for_14/IN (l_pobj) necrosis_17/NN
D010615_D007681 CID phenacetin_22/NNP (r_pobj) of_20/IN (r_prep) consumption_19/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) pelvis_12/NNS (r_pobj) of_9/IN (r_prep) necrosis_6/NN
D010615_D007681 CID phenacetin_13/NNP (r_pobj) of_12/IN (r_prep) consumption_11/NN (r_pobj) by_10/IN (r_agent) increased_7/VBN (l_nsubjpass) risk_1/NN (l_prep) of_2/IN (l_pobj) necrosis_5/NN
D010615_D007680 CID phenacetin_13/NNP (r_pobj) of_12/IN (r_prep) consumption_11/NN (l_relcl) increased_17/VBD (l_dobj) risk_19/NN (l_prep) for_20/IN (l_pobj) cancer_21/NN (l_prep) of_22/IN (l_pobj) pelvis_25/NNS (l_conj) bladder_27/NN
D010615_D007680 NONE phenacetin_22/NNP (r_pobj) of_20/IN (r_prep) consumption_19/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) pelvis_12/NNS (l_conj) ureter_14/NN (l_conj) bladder_16/NN
D010615_D014516 NONE phenacetin_22/NNP (r_pobj) of_20/IN (r_prep) consumption_19/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) pelvis_12/NNS (l_conj) ureter_14/NN (l_conj) bladder_16/NN
D010615_D014516 NONE phenacetin_13/NNP (r_pobj) of_12/IN (r_prep) consumption_11/NN (l_relcl) increased_17/VBD (l_conj) for_30/IN (l_pobj) cancer_32/NN
D010615_D001749 CID phenacetin_13/NNP (r_pobj) of_12/IN (r_prep) consumption_11/NN (l_relcl) increased_17/VBD (l_dobj) risk_19/NN (l_prep) for_20/IN (l_pobj) cancer_21/NN (l_prep) of_22/IN (l_pobj) pelvis_25/NNS (l_conj) bladder_27/NN
D010615_D001749 NONE phenacetin_22/NNP (r_pobj) of_20/IN (r_prep) consumption_19/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) pelvis_12/NNS (l_conj) ureter_14/NN (l_conj) bladder_16/NN
D000082_D007680 NONE paracetamol_24/NNP (r_conj) phenacetin_22/NNP (r_pobj) of_20/IN (r_prep) consumption_19/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) pelvis_12/NNS (l_conj) ureter_14/NN (l_conj) bladder_16/NN
D000082_D014516 NONE paracetamol_24/NNP (r_conj) phenacetin_22/NNP (r_pobj) of_20/IN (r_prep) consumption_19/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) pelvis_12/NNS (l_conj) ureter_14/NN (l_conj) bladder_16/NN
D000082_D014516 NONE paracetamol_12/JJ (r_compound) consumption_13/NN (r_pobj) from_11/IN (r_prep) risk_10/NN (r_dobj) substantiate_7/VB (r_xcomp) unable_5/JJ (r_acomp) were_4/VBD (l_advcl) was_25/VBD (l_attr) suggestion_27/NN (l_prep) of_28/IN (l_pobj) association_30/NN (l_prep) with_31/IN (l_pobj) cancer_32/NN (l_prep) of_33/IN (l_pobj) ureter_35/NN
D000082_D001749 NONE paracetamol_24/NNP (r_conj) phenacetin_22/NNP (r_pobj) of_20/IN (r_prep) consumption_19/NN (r_pobj) with_18/IN (r_prep) associated_17/VBN (r_acl) pelvis_12/NNS (l_conj) ureter_14/NN (l_conj) bladder_16/NN
D000082_D009369 NONE paracetamol_12/JJ (r_compound) consumption_13/NN (l_conj) any_19/DT (l_prep) of_20/IN (l_pobj) cancers_22/NNS
1786266
D000928_D001480 NONE antidepressant_3/JJ (r_compound) use_4/NN (r_conj) syndrome_1/NN
11672959
D012460_D003872 CID sulphasalazine_27/NN (r_pobj) of_25/IN (r_prep) course_24/NN (r_pobj) of_22/IN (r_prep) day_21/NN (r_pobj) on_18/IN (r_prep) beginning_17/VBG (r_advcl) developed_5/VBD (l_dobj) constellation_7/NN (l_prep) of_8/IN (l_pobj) dermatitis_9/NN
D012460_D005334 CID sulphasalazine_27/NN (r_pobj) of_25/IN (r_prep) course_24/NN (r_pobj) of_22/IN (r_prep) day_21/NN (r_pobj) on_18/IN (r_prep) beginning_17/VBG (r_advcl) developed_5/VBD (l_dobj) constellation_7/NN (l_prep) of_8/IN (l_pobj) dermatitis_9/NN (l_conj) fever_11/NN
D012460_D008206 CID sulphasalazine_27/NN (r_pobj) of_25/IN (r_prep) course_24/NN (r_pobj) of_22/IN (r_prep) day_21/NN (r_pobj) on_18/IN (r_prep) beginning_17/VBG (r_advcl) developed_5/VBD (l_dobj) constellation_7/NN (l_prep) of_8/IN (l_pobj) dermatitis_9/NN (l_conj) fever_11/NN (l_conj) lymphadenopathy_13/JJ
D012460_D056486 CID sulphasalazine_27/NN (r_pobj) of_25/IN (r_prep) course_24/NN (r_pobj) of_22/IN (r_prep) day_21/NN (r_pobj) on_18/IN (r_prep) beginning_17/VBG (r_advcl) developed_5/VBD (l_dobj) constellation_7/NN (l_prep) of_8/IN (l_pobj) dermatitis_9/NN (l_conj) fever_11/NN (l_conj) lymphadenopathy_13/JJ (l_conj) hepatitis_15/NN
D012460_D001172 NONE sulphasalazine_27/NN (r_pobj) of_25/IN (r_prep) course_24/NN (l_prep) for_28/IN (l_pobj) arthritis_33/NN
16403073
D007654_D016171 CID Ketoconazole_0/NNP (r_nsubj) induced_1/VBD (l_dobj) pointes_4/FW
D007654_D016171 CID ketoconazole_24/NN (r_dobj) taking_23/VBG (r_pcomp) after_22/IN (r_prep) developed_9/VBD (l_dobj) interval_14/NN (l_conj) pointes_18/FW
D007654_D016171 CID ketoconazole_24/NN (r_dobj) taking_23/VBG (r_pcomp) after_22/IN (r_prep) developed_9/VBD (l_dobj) interval_14/NN (l_conj) pointes_18/FW (l_appos) TdP_20/NNP
D007654_D016171 CID ketoconazole_13/NNP (r_nsubj) prolong_16/VB (l_conj) induce_20/VB (l_punct) TdP._21/NNP
D007654_D016171 CID ketoconazole_27/NNP (r_nsubjpass) administered_29/VBN (r_advcl) calls_23/VBZ (r_dobj) induce_20/VB (l_punct) TdP._21/NNP
D007654_D003324 NONE ketoconazole_24/NN (r_dobj) taking_23/VBG (r_pcomp) after_22/IN (r_prep) developed_9/VBD (r_relcl) disease_7/NN
D007654_D008133 CID ketoconazole_24/NN (r_dobj) taking_23/VBG (r_pcomp) after_22/IN (r_prep) developed_9/VBD (l_dobj) interval_14/NN
D007654_D008133 CID ketoconazole_13/NNP (r_nsubj) prolong_16/VB (l_conj) induce_20/VB (l_dobj) calls_23/VBZ (l_advcl) administered_29/VBN (l_prep) with_32/IN (l_pobj) factors_34/NNS (l_prep) for_35/IN (l_pobj) syndrome_39/NN
D007654_D008133 CID ketoconazole_27/NNP (r_nsubjpass) administered_29/VBN (l_prep) with_32/IN (l_pobj) factors_34/NNS (l_prep) for_35/IN (l_pobj) syndrome_39/NN
D007654_D009181 NONE ketoconazole_24/NN (r_dobj) taking_23/VBG (l_prep) for_25/IN (l_pobj) treatment_26/NN (l_prep) of_27/IN (l_pobj) infection_29/NN
3985451
D014859_D006470 NONE Warfarin_0/NN (r_npadvmod) induced_2/VBN (r_amod) hemorrhage_4/NN
D014859_D020428 CID Warfarin_0/NN (r_npadvmod) induced_2/VBN (r_amod) hemorrhage_4/NN (l_prep) with_5/IN (l_pobj) palsy_9/NN
D014859_D020428 CID warfarin_12/NN (r_advmod) induced_14/VBN (r_amod) neuropathy_16/NN (r_pobj) of_11/IN (r_prep) form_10/NN (r_dobj) represents_6/VBZ (l_nsubj) palsy_5/NN
D014859_D009135 CID warfarin_12/NN (r_amod) therapy_13/NN (r_pobj) on_10/IN (r_prep) man_9/NN (l_relcl) sustained_15/VBD (l_dobj) tear_19/NN
D014859_D010146 NONE warfarin_12/NN (r_amod) therapy_13/NN (r_pobj) on_10/IN (r_prep) man_9/NN (l_relcl) sustained_15/VBD (l_conj) developed_21/VBD (l_dobj) pain_23/NN
D014859_D010146 NONE warfarin_12/NN (r_advmod) induced_14/VBN (r_amod) neuropathy_16/NN (r_pobj) of_11/IN (r_prep) form_10/NN (r_dobj) represents_6/VBZ (r_ccomp) characterized_20/VBN (l_agent) by_21/IN (l_pobj) pain_23/NN
D014859_D003286 NONE warfarin_12/NN (r_amod) therapy_13/NN (r_pobj) on_10/IN (r_prep) man_9/NN (l_relcl) sustained_15/VBD (l_conj) developed_21/VBD (l_dobj) pain_23/NN (l_conj) contracture_27/NN
D014859_D003286 NONE warfarin_12/NN (r_advmod) induced_14/VBN (r_amod) neuropathy_16/NN (r_pobj) of_11/IN (r_prep) form_10/NN (r_dobj) represents_6/VBZ (r_ccomp) characterized_20/VBN (l_advcl) varying_29/VBG (l_dobj) degrees_30/NNS (l_conj) contracture_39/NN
D014859_D010523 NONE warfarin_12/NN (r_advmod) induced_14/VBN (r_amod) neuropathy_16/NN
D014859_D015417 NONE warfarin_12/NN (r_advmod) induced_14/VBN (r_amod) neuropathy_16/NN (r_pobj) of_11/IN (r_prep) form_10/NN (r_dobj) represents_6/VBZ (r_ccomp) characterized_20/VBN (l_advcl) varying_29/VBG (l_dobj) degrees_30/NNS (l_prep) of_31/IN (l_pobj) impairment_35/NN
2870085
C047847_D013610 NONE Flestolol_0/NNS (r_nsubj) produced_1/VBD (l_dobj) attenuation_6/NN (l_prep) of_7/IN (l_pobj) tachycardia_11/NN
D007545_D013610 CID isoproterenol_8/NN (r_npadvmod) induced_10/VBN (r_amod) tachycardia_11/NN
C047847_D013617 NONE Flestolol_0/NNS (r_nsubj) reduced_2/VBD (l_prep) in_5/IN (l_pobj) patients_6/NNS (l_prep) with_7/IN (l_pobj) tachyarrhythmia_9/NN
C047847_D000789 NONE flestolol_6/NNS (r_compound) infusion_7/NN (r_nsubjpass) found_9/VBN (l_prep) In_0/IN (l_pobj) patients_1/NNS (l_prep) with_2/IN (l_pobj) angina_4/NN
C047847_D002637 NONE flestolol_6/NNS (r_compound) infusion_7/NN (r_nsubjpass) found_9/VBN (l_xcomp) be_11/VB (l_acomp) safe_12/JJ (l_conj) effective_14/JJ (l_prep) in_15/IN (l_pcomp) controlling_16/VBG (l_dobj) pain_18/NN
8421099
D015282_D042882 CID octreotide_12/NN (r_appos) analog_10/NN (r_pobj) of_8/IN (r_prep) effects_7/NNS (l_prep) on_14/IN (l_pobj) function_16/NN (l_conj) formation_19/NN (l_compound) gallstone_18/NN
D015282_D042882 CID octreotide_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_pobj) During_0/IN (r_prep) developed_7/VBD (l_conj) had_11/VBD (l_dobj) gallstones_12/NNS
D015282_D042882 CID octreotide_3/NN (r_pobj) of_2/IN (r_prep) withdrawal_1/NN (l_prep) in_4/IN (l_pobj) patients_6/NNS (l_prep) without_7/IN (l_pobj) gallstones_8/NNS
D015282_D042882 CID octreotide_25/NN (r_compound) therapy_26/NN (r_pobj) during_24/IN (r_prep) formation_15/NN (l_prep) of_16/IN (l_pobj) sludge_18/NN (l_conj) gallstones_20/NNS
D015282_D000172 NONE octreotide_12/NN (r_appos) analog_10/NN (r_pobj) of_8/IN (r_prep) effects_7/NNS (l_prep) on_14/IN (l_pobj) function_16/NN (l_prep) in_20/IN (l_pobj) patients_23/NNS (l_compound) acromegalic_22/JJ
D015282_D000172 NONE octreotide_26/NN (r_pobj) of_22/IN (r_prep) injection_21/NN (r_pobj) with_19/IN (r_prep) treated_18/VBN (l_nsubj) changes_4/NNS (l_prep) in_5/IN (l_pobj) function_7/NN (l_acl) examined_8/VBN (l_prep) in_11/IN (l_pobj) patients_14/NNS (l_prep) with_15/IN (l_pobj) acromegaly_17/NNS
D015282_D000172 NONE octreotide_25/NN (r_compound) therapy_26/NN (l_prep) in_27/IN (l_pobj) patients_30/NNS (l_compound) acromegalic_29/JJ
D015282_D000172 NONE octreotide_16/IN (r_compound) therapy_17/NN (l_prep) of_18/IN (l_pobj) patients_20/NNS (l_compound) acromegalic_19/JJ
D015282_D041881 CID octreotide_3/NN (r_pobj) with_2/IN (r_prep) treatment_1/NN (r_pobj) During_0/IN (r_prep) developed_7/VBD (l_conj) had_11/VBD (l_conj) cholecystitis_18/NN
D015282_D002764 NONE octreotide_25/NN (r_compound) therapy_26/NN (r_pobj) during_24/IN (r_prep) formation_15/NN (l_prep) of_16/IN (l_pobj) sludge_18/NN (l_conj) gallstones_20/NNS (l_conj) cholecystitis_23/NN
20619828
D002997_D001008 CID Clomipramine_0/NN (r_compound) exposure_1/NN (r_nsubj) produced_5/VBD (l_dobj) changes_10/NNS (l_relcl) include_12/VBP (l_dobj) anxiety_14/NN
D002997_-1 NONE Clomipramine_0/NN (r_compound) exposure_1/NN (r_nsubj) produced_5/VBD (l_dobj) changes_10/NNS (l_relcl) include_12/VBP (l_dobj) anxiety_14/NN (l_conj) inflexibility_25/NN
D002997_-1 NONE Clomipramine_0/NN (r_compound) exposure_1/NN (r_nsubj) produced_5/VBD (l_dobj) changes_10/NNS (l_relcl) include_12/VBP (l_dobj) anxiety_14/NN (l_appos) impairment_41/NN (l_conj) hoarding_51/NN (l_conj) dysfunction_55/NN
D002997_D008569 CID Clomipramine_0/NN (r_compound) exposure_1/NN (r_nsubj) produced_5/VBD (l_dobj) changes_10/NNS (l_relcl) include_12/VBP (l_dobj) anxiety_14/NN (l_appos) impairment_41/NN
D002997_D060845 CID Clomipramine_0/NN (r_compound) exposure_1/NN (r_nsubj) produced_5/VBD (l_dobj) changes_10/NNS (l_relcl) include_12/VBP (l_dobj) anxiety_14/NN (l_appos) impairment_41/NN (l_conj) hoarding_51/NN
16428221
D008774_D020293 CID methylphenidate_4/NN (r_compound) intake_5/NN (r_pobj) following_2/VBG (r_prep) vasculitis_1/JJ
D008774_D020293 CID methylphenidate_20/NN (r_compound) intake_21/NN (r_pobj) after_19/IN (r_prep) reported_18/VBN (r_conj) documented_8/VBN (l_nsubjpass) vasculitis_1/NN
D008774_D019969 NONE methylphenidate_20/NN (r_compound) intake_21/NN (r_pobj) after_19/IN (r_prep) reported_18/VBN (r_conj) documented_8/VBN (l_nsubjpass) vasculitis_1/NN (l_acl) associated_2/VBN (l_prep) with_3/IN (l_pobj) abuse_5/NN
D008774_D002544 NONE methylphenidate_20/NN (r_compound) intake_21/NN (r_pobj) after_19/IN (r_prep) reported_18/VBN (l_nsubjpass) stroke_15/NN
D008774_D002544 NONE methylphenidate_14/NN (r_pobj) with_13/IN (r_prep) treated_12/VBN (l_conj) suffered_19/VBD (l_prep) from_20/IN (l_pobj) strokes_23/NNS
D008774_D006948 NONE methylphenidate_14/NN (r_pobj) with_13/IN (r_prep) treated_12/VBN (l_prep) due_15/IN (l_pobj) hyperactivity_17/NN
D008774_D014657 NONE methylphenidate_3/NN (r_npadvmod) mediated_4/VBN (r_amod) vasculitis_5/NN
D008774_D014657 NONE methylphenidate_18/NN (r_compound) therapy_19/NN (r_pobj) of_17/IN (r_prep) history_16/NN (r_conj) symptoms_13/NNS (r_pobj) with_11/IN (r_prep) patients_10/NNS (r_pobj) in_9/IN (r_prep) considered_8/VBN (l_nsubjpass) vasculitis_5/NN
4071154
D007213_D051437 NONE Indomethacin_0/NN (r_npadvmod) induced_2/VBN (r_amod) insufficiency_4/NN
D007213_D051437 NONE indomethacin_24/NN (r_compound) therapy_25/NN (r_pobj) after_23/IN (r_prep) cirrhosis_16/NN (r_pobj) with_15/IN (r_prep) patient_14/NN (r_pobj) in_12/IN (r_prep) failure_9/NN
D007213_D006947 CID indomethacin_24/NN (r_compound) therapy_25/NN (r_pobj) after_23/IN (r_prep) cirrhosis_16/NN (r_pobj) with_15/IN (r_prep) patient_14/NN (r_pobj) in_12/IN (r_prep) failure_9/NN (l_prep) with_10/IN (l_pobj) hyperkalemia_11/NN
D007213_D005355 CID indomethacin_24/NN (r_compound) therapy_25/NN (r_pobj) after_23/IN (r_prep) cirrhosis_16/NN
D007213_D001201 CID indomethacin_24/NN (r_compound) therapy_25/NN (r_pobj) after_23/IN (r_prep) cirrhosis_16/NN (l_conj) ascites_18/NNS
D007213_D011660 CID indomethacin_24/NN (r_compound) therapy_25/NN (r_pobj) after_23/IN (r_prep) cirrhosis_16/NN (l_conj) ascites_18/NNS (l_conj) pulmonale_22/NN
D007213_D009846 CID indomethacin_18/NN (r_pobj) of_17/IN (r_prep) dose_16/NN (r_pobj) to_13/IN (r_prep) exposure_12/NN (r_nsubj) caused_19/VBN (l_dobj) recurrence_20/NN (l_prep) of_21/IN (l_pobj) oliguria_24/NN
6747681
D002330_D005910 NONE BCNU_3/NNP (r_compound) chemotherapy_4/NN (l_prep) for_5/IN (l_pobj) treatment_6/NN (l_prep) of_7/IN (l_pobj) gliomas_9/NNS
D002330_D005910 NONE BCNU_7/NNP (r_pobj) of_6/IN (r_prep) clearance_5/NN (r_pobj) Because_0/IN (r_prep) provide_17/VB (l_dobj) advantage_20/NN (l_prep) over_21/IN (l_pobj) administration_23/NN (l_prep) for_24/IN (l_pobj) treatment_26/NN (l_prep) of_27/IN (l_pobj) gliomas_29/NNS
D002330_D005910 NONE 1,3-bis-(2-chloroethyl)-1-nitrosourea_9/CD (r_appos) BCNU_7/NNP (r_pobj) of_6/IN (r_prep) clearance_5/NN (r_pobj) Because_0/IN (r_prep) provide_17/VB (l_dobj) advantage_20/NN (l_prep) over_21/IN (l_pobj) administration_23/NN (l_prep) for_24/IN (l_pobj) treatment_26/NN (l_prep) of_27/IN (l_pobj) gliomas_29/NNS
D002330_D001254 NONE BCNU_29/NNP (r_compound) therapy_30/NN (r_pobj) of_25/IN (r_prep) courses_24/NNS (r_dobj) received_20/VBD (l_nsubj) patients_3/NNS (l_prep) to_8/IN (l_pobj) astrocytomas_10/NNPS
D000431_D014786 NONE ethanol_11/NN (r_compound) diluent_12/NN (r_pobj) of_9/IN (r_prep) concentration_8/NN (r_nsubjpass) lowered_14/VBN (r_advcl) decreased_5/VBD (l_nsubj) frequency_1/NN (l_prep) of_2/IN (l_pobj) loss_4/NN
12574103
D003907_D006973 CID dexamethasone_1/NN (r_compound) programs_2/NNS (l_dobj) hypertension_3/NN
D003907_D006973 CID dexamethasone_11/NN (r_nsubj) programmed_12/VBD (l_dobj) increase_15/NN (l_prep) in_16/IN (l_pobj) pressure_18/NN
D003907_D006973 CID dexamethasone_5/NN (r_dobj) received_3/VBD (r_relcl) rats_1/NNS (r_nsubj) elevated_23/VBN (l_dobj) pressures_25/NNS
D003907_D006973 CID dexamethasone_5/NN (r_nsubj) results_8/NNS (l_prep) in_9/IN (l_pobj) reduction_11/NN (l_prep) in_12/IN (l_pobj) number_14/NN (l_conj) glomerulosclerosis_16/NNP (l_conj) hypertension_19/NN
D003907_D007674 CID dexamethasone_1/NN (r_compound) programs_2/NNS (l_dobj) hypertension_3/NN (l_conj) injury_6/NN
D003907_D007674 CID dexamethasone_11/NN (r_nsubj) programmed_12/VBD (l_dobj) increase_15/NN (l_prep) in_16/IN (l_pobj) pressure_18/NN (l_conj) injury_21/NN
D003907_D007674 CID dexamethasone_4/NN (r_dobj) administered_3/VBD (l_conj) had_11/VBD (l_dobj) reduction_15/NN (l_prep) in_16/IN (l_pobj) number_18/NN
D003907_D007674 CID dexamethasone_5/NN (r_dobj) received_3/VBD (r_relcl) rats_1/NNS (r_nsubj) elevated_23/VBN (r_ccomp) have_37/VB (l_dobj) reduction_39/NN (l_prep) in_40/IN (l_pobj) number_42/NN
D003907_D007674 CID dexamethasone_5/NN (r_nsubj) results_8/NNS (l_prep) in_9/IN (l_pobj) reduction_11/NN (l_prep) in_12/IN (l_pobj) number_14/NN
D003907_D005921 NONE dexamethasone_3/NN (r_dobj) given_2/VBN (l_conj) had_11/VBD (l_dobj) glomeruli_13/NNS (l_prep) with_14/IN (l_pobj) glomerulosclerosis_15/NNP
D003907_D005921 NONE dexamethasone_5/NN (r_nsubj) results_8/NNS (l_prep) in_9/IN (l_pobj) reduction_11/NN (l_prep) in_12/IN (l_pobj) number_14/NN (l_conj) glomerulosclerosis_16/NNP
8752018
D008094_D003072 CID Lithium_0/NN (r_npadvmod) associated_2/VBN (r_amod) deficits_6/NNS
D008094_D003072 CID lithium_15/NN (l_prep) as_18/IN (l_pobj) polyuria_19/NN (l_conj) effects_27/NNS (l_prep) as_29/IN (l_pobj) deficits_31/NNS
D008094_D003072 CID lithium_15/NN (l_prep) as_18/IN (l_pobj) polyuria_19/NN (l_conj) effects_27/NNS (l_prep) as_29/IN (l_pobj) deficits_31/NNS (l_conj) loss_33/NN (l_prep) of_34/IN (l_pobj) creativity_35/NN
D008094_D003072 CID lithium_15/NN (r_pobj) of_14/IN (r_prep) effects_13/NNS (r_pobj) of_8/IN (r_prep) management_7/NN (r_pobj) about_5/IN (r_prep) written_4/VBN (r_advcl) remain_40/VBP (l_nsubj) impairments_39/NNS
D008094_D003072 CID lithium_25/NN (r_compound) side_26/NN (r_compound) effects_27/NNS (l_prep) as_29/IN (l_pobj) deficits_31/NNS
D008094_D003072 CID lithium_25/NN (r_compound) side_26/NN (r_compound) effects_27/NNS (l_prep) as_29/IN (l_pobj) deficits_31/NNS (l_conj) loss_33/NN (l_prep) of_34/IN (l_pobj) creativity_35/NN
D008094_D003072 CID lithium_25/NN (r_compound) side_26/NN (r_compound) effects_27/NNS (r_conj) polyuria_19/NN (r_pobj) as_18/IN (r_prep) lithium_15/NN (r_pobj) of_14/IN (r_prep) effects_13/NNS (r_pobj) of_8/IN (r_prep) management_7/NN (r_pobj) about_5/IN (r_prep) written_4/VBN (r_advcl) remain_40/VBP (l_nsubj) impairments_39/NNS
D008094_D003072 CID lithium_10/NN (r_pobj) from_9/IN (r_prep) switching_6/VBG (l_advcl) alleviate_15/VB (l_dobj) impairments_20/NNS
D008094_D003072 CID lithium_7/NN (r_pobj) of_6/IN (r_prep) substitution_5/NN (r_nsubj) was_17/VBD (l_acomp) helpful_19/JJ (l_prep) in_20/IN (l_pcomp) reducing_21/VBG (l_dobj) deficits_29/NNS
D008094_D003072 CID lithium_32/NN (r_pobj) to_31/IN (r_prep) attributed_30/VBN (r_acl) deficits_29/NNS
D008094_D003072 CID lithium_12/NN (r_pobj) to_11/IN (r_prep) alternative_10/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_acl) experiencing_16/VBG (l_dobj) deficits_18/NNS
D008094_D003072 CID lithium_12/NN (r_pobj) to_11/IN (r_prep) alternative_10/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_acl) experiencing_16/VBG (l_dobj) deficits_18/NNS (l_conj) loss_20/NN (l_prep) of_21/IN (l_pobj) creativity_22/NN
D008094_D003072 CID lithium_12/NN (r_pobj) to_11/IN (r_prep) alternative_10/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_acl) experiencing_16/VBG (l_dobj) deficits_18/NNS (l_conj) loss_20/NN (l_conj) impairments_26/NNS
D014635_D003072 NONE sodium_13/NN (r_pobj) to_11/IN (r_prep) switch_10/NN (r_pobj) by_8/IN (r_agent) reduced_7/VBN (r_acl) deficits_6/NNS
D014635_D003072 NONE sodium_13/NN (r_pobj) to_11/IN (r_prep) switching_6/VBG (l_advcl) alleviate_15/VB (l_dobj) impairments_20/NNS
D014635_D003072 NONE sodium_16/NN (r_pobj) with_14/IN (r_prep) substitution_5/NN (r_nsubj) was_17/VBD (l_acomp) helpful_19/JJ (l_prep) in_20/IN (l_pcomp) reducing_21/VBG (l_dobj) deficits_29/NNS
D014635_D003072 NONE sodium_6/NN (r_nsubj) was_7/VBD (l_attr) alternative_10/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_acl) experiencing_16/VBG (l_dobj) deficits_18/NNS
D014635_D003072 NONE sodium_6/NN (r_nsubj) was_7/VBD (l_attr) alternative_10/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_acl) experiencing_16/VBG (l_dobj) deficits_18/NNS (l_conj) loss_20/NN (l_prep) of_21/IN (l_pobj) creativity_22/NN
D014635_D003072 NONE sodium_6/NN (r_nsubj) was_7/VBD (l_attr) alternative_10/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_acl) experiencing_16/VBG (l_dobj) deficits_18/NNS (l_conj) loss_20/NN (l_conj) impairments_26/NNS
D008094_D001714 NONE Lithium_0/NN (r_nsubj) remains_1/VBZ (l_attr) treatment_6/NN (l_prep) for_7/IN (l_pobj) treatment_12/NN (l_prep) of_13/IN (l_pobj) disorder_15/NN
D008094_D001714 NONE lithium_10/NN (r_pobj) from_9/IN (r_prep) switching_6/VBG (l_dobj) patients_8/NNS (l_amod) bipolar_7/JJ
D008094_D001714 NONE lithium_7/NN (r_pobj) of_6/IN (r_prep) substitution_5/NN (r_nsubj) was_17/VBD (l_acomp) helpful_19/JJ (l_prep) in_20/IN (l_pcomp) reducing_21/VBG (l_dobj) deficits_29/NNS (l_acl) attributed_30/VBN (l_prep) in_33/IN (l_pobj) patients_36/NNS (l_amod) bipolar_35/JJ
D008094_D001714 NONE lithium_32/NN (r_pobj) to_31/IN (r_prep) attributed_30/VBN (l_prep) in_33/IN (l_pobj) patients_36/NNS (l_amod) bipolar_35/JJ
D008094_D001714 NONE lithium_12/NN (r_pobj) to_11/IN (r_prep) alternative_10/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_amod) bipolar_14/JJ
D008094_D011141 NONE lithium_15/NN (l_prep) as_18/IN (l_pobj) polyuria_19/NN
D008094_D011141 NONE lithium_25/NN (r_compound) side_26/NN (r_compound) effects_27/NNS (r_conj) polyuria_19/NN
D008094_D014202 NONE lithium_15/NN (l_prep) as_18/IN (l_pobj) polyuria_19/NN (l_conj) tremor_21/NN
D008094_D014202 NONE lithium_25/NN (r_compound) side_26/NN (r_compound) effects_27/NNS (r_conj) polyuria_19/NN (l_conj) tremor_21/NN
D014635_D001714 NONE sodium_13/NN (r_pobj) to_11/IN (r_prep) switching_6/VBG (l_dobj) patients_8/NNS (l_amod) bipolar_7/JJ
D014635_D001714 NONE sodium_16/NN (r_pobj) with_14/IN (r_prep) substitution_5/NN (r_nsubj) was_17/VBD (l_acomp) helpful_19/JJ (l_prep) in_20/IN (l_pcomp) reducing_21/VBG (l_dobj) deficits_29/NNS (l_acl) attributed_30/VBN (l_prep) in_33/IN (l_pobj) patients_36/NNS (l_amod) bipolar_35/JJ
D014635_D001714 NONE sodium_6/NN (r_nsubj) was_7/VBD (l_attr) alternative_10/NN (l_prep) in_13/IN (l_pobj) patients_15/NNS (l_amod) bipolar_14/JJ
2375138
D008874_D006323 CID midazolam_2/NN (r_advmod) associated_4/VBN (r_amod) arrest_6/NN
D008874_D006323 CID midazolam_17/NNP (r_pobj) of_16/IN (r_prep) administration_15/NN (r_pobj) with_13/IN (r_prep) associated_12/VBN (r_acl) arrest_9/NN
D008874_D003643 NONE midazolam_2/NN (r_advmod) associated_4/VBN (r_amod) arrest_6/NN (l_conj) death_8/NN
D008874_D003643 NONE midazolam_17/NNP (r_pobj) of_16/IN (r_prep) administration_15/NN (r_pobj) with_13/IN (r_prep) associated_12/VBN (r_acl) arrest_9/NN (l_conj) death_11/NN
15649445
D012110_D004409 CID reserpine_1/NN (r_nmod) change_6/VBP (l_conj) elicit_12/VB (l_dobj) dyskinesia_14/NN
D012110_D004409 CID reserpine_12/NN (r_pobj) by_10/IN (r_prep) induced_7/VBD (l_dobj) dyskinesia_9/NN
D006220_D004409 CID haloperidol_4/NNP (r_conj) reserpine_1/NN (r_nmod) change_6/VBP (l_conj) elicit_12/VB (l_dobj) dyskinesia_14/NN
D006220_D004409 CID haloperidol_1/NNP (r_npadvmod) induced_3/VBN (r_amod) dyskinesia_5/NN
D006220_D004409 CID haloperidol_1/NNP (r_npadvmod) induced_3/VBN (r_amod) dyskinesia_5/NN (r_nsubj) are_6/VBP (l_attr) models_9/NNS (l_prep) of_10/IN (l_pobj) dyskinesia_12/NN
D006220_D004409 CID haloperidol_1/NNP (r_npadvmod) induced_3/VBN (r_amod) dyskinesia_5/NN (r_nsubj) are_6/VBP (l_attr) models_9/NNS (l_prep) of_10/IN (l_pobj) dyskinesia_12/NN (l_appos) TD_14/NN
D006220_D004409 CID haloperidol_15/NNP (r_compound) administration_16/NN (r_conj) reserpine_12/NN (r_pobj) by_10/IN (r_prep) induced_7/VBD (l_dobj) dyskinesia_9/NN
D018698_D004409 NONE glutamate_9/NN (r_compound) uptake_10/NN (r_dobj) change_6/VBP (l_conj) elicit_12/VB (l_dobj) dyskinesia_14/NN
D018698_D004409 NONE glutamate_5/NN (r_compound) uptake_6/NN (r_pobj) in_4/IN (r_prep) decrease_3/NN (r_nsubj) correlates_7/VBZ (l_prep) with_9/IN (l_pobj) increase_11/NN (l_prep) in_12/IN (l_pobj) incidence_14/NN (l_prep) of_15/IN (l_pobj) diskinesia_17/NNP
16274958
D017255_D055154 CID acitretin_3/NNP (r_conj) dysphonia_1/NNP
D017255_D055154 CID acitretin_15/NNP (r_pobj) by_14/IN (r_agent) treated_13/VBN (r_advcl) report_1/VBP (l_dobj) case_3/NN (l_prep) of_4/IN (l_pobj) woman_6/NN (l_acl) complaining_7/VBG (l_prep) of_8/IN (l_pobj) dysphonia_9/NN
D017255_D055154 CID acitretin_10/NNP (r_npadvmod) induced_12/VBN (r_amod) dysphonia_13/NN
7802851
D000525_D016584 NONE alprazolam_3/NN (r_pobj) of_2/IN (r_prep) efficacy_1/NN (l_prep) in_6/IN (l_pobj) disorder_8/NN
D000525_D016584 NONE alprazolam_20/NN (r_pobj) to_19/IN (r_prep) randomised_18/JJ (l_prep) In_0/IN (l_pobj) London_1/NNP (l_conj) patients_5/NNS (l_relcl) met_7/VBD (l_dobj) criteria_11/NNS (l_prep) for_12/IN (l_pobj) disorder_14/NN
D000525_D000379 NONE alprazolam_3/NN (r_pobj) of_2/IN (r_prep) efficacy_1/NN (l_prep) with_9/IN (l_pobj) agoraphobia_10/NNP
D000525_D000379 NONE alprazolam_20/NN (r_pobj) to_19/IN (r_prep) randomised_18/JJ (l_prep) In_0/IN (l_pobj) London_1/NNP (l_conj) patients_5/NNS (l_relcl) met_7/VBD (l_dobj) criteria_11/NNS (l_prep) for_12/IN (l_pobj) disorder_14/NN (l_prep) with_15/IN (l_pobj) agoraphobia_16/NNP
D000525_D003866 CID alprazolam_5/NNP (r_compound) patients_6/NNS (r_nsubj) developed_7/VBD (l_dobj) reactions_10/NNS (l_appos) %_13/NN (l_prep) of_18/IN (l_pobj) depression_19/NN
D000525_D004775 CID alprazolam_5/NNP (r_compound) patients_6/NNS (r_nsubj) developed_7/VBD (l_dobj) reactions_10/NNS (l_appos) %_13/NN (l_prep) of_18/IN (l_pobj) depression_19/NN (l_conj) enuresis_21/NN
D000525_D001523 NONE alprazolam_5/NNP (r_compound) patients_6/NNS (r_nsubj) developed_7/VBD (l_dobj) reactions_10/NNS (l_appos) %_13/NN (l_prep) of_18/IN (l_pobj) depression_19/NN (l_conj) enuresis_21/NN (l_conj) disinhibition_23/NN (l_conj) aggression_25/NN
D000525_D001523 NONE alprazolam_5/NNP (r_compound) patients_6/NNS (r_nsubj) developed_7/VBD (l_dobj) reactions_10/NNS (l_conj) effects_31/NNS (l_appos) sedation_34/NN (l_conj) irritability_36/NN
D000525_D008569 CID alprazolam_5/NNP (r_compound) patients_6/NNS (r_nsubj) developed_7/VBD (l_dobj) reactions_10/NNS (l_conj) effects_31/NNS (l_appos) sedation_34/NN (l_conj) irritability_36/NN (l_conj) memory_39/NN
D000525_D015431 CID alprazolam_5/NNP (r_compound) patients_6/NNS (r_nsubj) developed_7/VBD (l_dobj) reactions_10/NNS (l_conj) effects_31/NNS (l_appos) sedation_34/NN (l_conj) irritability_36/NN (l_conj) memory_39/NN (l_conj) loss_42/NN
D000525_D001259 CID alprazolam_5/NNP (r_compound) patients_6/NNS (r_nsubj) developed_7/VBD (l_dobj) reactions_10/NNS (l_conj) effects_31/NNS (l_appos) sedation_34/NN (l_conj) irritability_36/NN (l_conj) memory_39/NN (l_conj) loss_42/NN (l_conj) ataxia_44/NN
6666578
D010396_D001018 CID penicillamine_2/NNP (r_npadvmod) induced_4/VBN (r_amod) angiopathy_5/NNP
12589964
D004317_D009202 CID doxorubicin_14/NN (r_npadvmod) induced_16/VBN (r_amod) rats_18/NNS (r_pobj) in_13/IN (r_prep) damage_12/NN
D004317_D009202 CID doxorubicin_14/NN (r_npadvmod) induced_16/VBN (r_amod) rats_18/NNS (l_compound) cardiomyopathy_17/NN
D004317_D009202 CID doxorubicin_20/NNS (r_pobj) of_19/IN (r_prep) model_18/NN (r_pobj) in_15/IN (r_prep) damage_14/NN
D004317_D009202 CID doxorubicin_20/NNS (l_appos) cardiomyopathy_23/NN
D004317_D009202 CID DOX)-induced_22/VBN (r_amod) cardiomyopathy_23/NN (r_appos) doxorubicin_20/NNS (r_pobj) of_19/IN (r_prep) model_18/NN (r_pobj) in_15/IN (r_prep) damage_14/NN
D004317_D009202 CID DOX)-induced_22/VBN (r_amod) cardiomyopathy_23/NN
D004317_D009202 CID DOX_6/NNP (r_pobj) after_5/IN (r_prep) markers_1/NNS (r_pobj) Among_0/IN (r_prep) showed_11/VBD (l_dobj) ability_14/NN (l_acl) detect_16/VB (l_dobj) damage_18/NN
D004317_D006331 NONE doxorubicin_20/NNS (r_pobj) of_19/IN (r_prep) model_18/NN (r_pobj) in_15/IN (r_prep) damage_14/NN (r_pobj) of_12/IN (r_prep) diagnosis_11/NN (r_pobj) for_9/IN (r_prep) investigated_1/VBD (l_conj) examined_27/VBD (l_dobj) relationship_29/NN (l_prep) with_35/IN (l_pobj) development_37/NN (l_prep) of_38/IN (l_pobj) disorders_40/NNS
D004317_D006331 NONE DOX)-induced_22/VBN (r_amod) cardiomyopathy_23/NN (r_appos) doxorubicin_20/NNS (r_pobj) of_19/IN (r_prep) model_18/NN (r_pobj) in_15/IN (r_prep) damage_14/NN (r_pobj) of_12/IN (r_prep) diagnosis_11/NN (r_pobj) for_9/IN (r_prep) investigated_1/VBD (l_conj) examined_27/VBD (l_dobj) relationship_29/NN (l_prep) with_35/IN (l_pobj) development_37/NN (l_prep) of_38/IN (l_pobj) disorders_40/NNS
D004317_D064420 NONE DOX_3/NNP (r_pobj) of_1/IN (r_prep) Eighteen_0/CD (r_nsubj) died_5/VBD (l_prep) of_7/IN (l_pobj) toxicity_9/NN
D004317_D005355 NONE DOX_8/NNP (r_pobj) given_7/VBN (r_prep) rats_6/NNS (r_pobj) from_4/IN (r_prep) hearts_3/NNS (r_pobj) of_2/IN (r_prep) evaluation_1/NN (r_nsubj) revealed_9/VBD (l_dobj) degrees_12/NNS (l_prep) of_13/IN (l_pobj) perivascular_14/NN (l_conj) fibrosis_17/NN
D004317_D017202 NONE DOX_6/NNP (r_pobj) after_5/IN (r_prep) markers_1/NNS (l_prep) of_2/IN (l_pobj) injury_4/NN
D004317_D066126 NONE DOX_13/NNP (r_pobj) after_12/IN (r_prep) amount_7/NN (r_pobj) between_5/IN (r_prep) discrepancy_4/NN (r_attr) was_2/VBD (r_advcl) is_33/VBZ (l_acomp) likely_34/JJ (l_ccomp) indicates_41/VBZ (l_conj) be_55/VB (l_attr) marker_58/NN (l_prep) for_59/IN (l_pobj) prediction_61/NN (l_prep) of_62/IN (l_pobj) cardiotoxicity_65/NN
D004317_D066126 NONE DOX_40/NNP (r_nsubj) indicates_41/VBZ (l_conj) be_55/VB (l_attr) marker_58/NN (l_prep) for_59/IN (l_pobj) prediction_61/NN (l_prep) of_62/IN (l_pobj) cardiotoxicity_65/NN
227508
D003000_D006973 NONE clonidine_17/NN (r_pobj) by_15/IN (r_agent) produced_14/VBN (r_acl) rate_13/NN (r_conj) pressure_10/NN (r_pobj) in_8/IN (r_prep) decrease_7/NN (r_pobj) In_0/IN (l_pobj) rats_5/NNS (l_amod) hypertensive_4/JJ
D003000_D006973 NONE clonidine_7/NN (r_intj) rats_6/NNS (l_amod) hypertensive_5/JJ
D003000_D006973 NONE clonidine_42/NN (r_compound) suppressible_44/JJ (r_compound) binding_45/NN (r_dobj) influence_41/VB (r_conj) influence_18/VB (l_prep) In_0/IN (l_pobj) membranes_2/NNS (l_prep) from_3/IN (l_pobj) rats_6/NNS (l_amod) hypertensive_5/JJ
-1_D006973 NONE nalozone_31/NN (r_pobj) by_30/IN (r_agent) reversed_29/VBN (r_conj) inhibited_27/VBN (l_prep) In_0/IN (l_pobj) rats_5/NNS (l_amod) hypertensive_4/JJ
-1_D006973 NONE 3H]-naloxone_23/CD (r_pobj) of_21/IN (r_prep) binding_20/NN (r_dobj) influence_18/VB (l_prep) In_0/IN (l_pobj) membranes_2/NNS (l_prep) from_3/IN (l_pobj) rats_6/NNS (l_amod) hypertensive_5/JJ
-1_D006973 NONE 3H]-dihydroergocryptine_48/CD (r_pobj) of_46/IN (r_prep) binding_45/NN (r_dobj) influence_41/VB (r_conj) influence_18/VB (l_prep) In_0/IN (l_pobj) membranes_2/NNS (l_prep) from_3/IN (l_pobj) rats_6/NNS (l_amod) hypertensive_5/JJ
D008750_D007022 CID methyldopa_8/NNP (r_nsubjpass) reversed_12/VBN (l_nsubjpass) effect_2/NN (l_amod) hypotensive_1/JJ
D009270_D007022 NONE naloxone_14/NN (r_pobj) by_13/IN (r_agent) reversed_12/VBN (l_nsubjpass) effect_2/NN (l_amod) hypotensive_1/JJ
D009270_D006973 NONE naloxone_30/NN (r_conj) 3H]-naloxone_23/CD (r_pobj) of_21/IN (r_prep) binding_20/NN (r_dobj) influence_18/VB (l_prep) In_0/IN (l_pobj) membranes_2/NNS (l_prep) from_3/IN (l_pobj) rats_6/NNS (l_amod) hypertensive_5/JJ
16330766
C040029_D009437 NONE gabapentin_11/NN (l_appos) drug_14/NN (l_amod) effective_15/JJ (l_prep) in_16/IN (l_pobj) patients_19/NNS (l_compound) pain_18/NN
C040029_D006930 NONE gabapentin_15/NN (r_npadvmod) induced_17/VBN (r_amod) modulation_18/NN (r_dobj) studied_13/VBD (l_prep) in_22/IN (l_pobj) response_23/NN (l_prep) to_24/IN (l_pobj) stimulation_27/NN (l_prep) of_28/IN (l_pobj) skin_30/NN (l_conj) hyperalgesia_36/NN
D002211_D006930 CID capsaicin_32/NN (r_npadvmod) induced_34/VBN (r_amod) hyperalgesia_36/NN
11256525
D019808_D001002 CID losartan_4/NNP (r_compound) administration_5/NNP (r_dobj) following_3/VBG (r_acl) anuria_2/NNP
D019808_D001002 CID losartan_27/NNP (r_compound) administration_28/NNP (r_pobj) after_26/IN (r_prep) developed_20/VBD (l_dobj) episodes_22/NNS (l_prep) of_23/IN (l_pobj) anuria_25/NN
D019808_D001002 CID losartan_9/NNP (r_pobj) of_8/IN (r_prep) mg_7/NNS (r_pobj) of_5/IN (r_prep) dose_4/NN (r_nsubj) resulted_10/VBD (l_prep) in_11/IN (l_pobj) anuria_14/NN
D019808_D001002 CID losartan_7/NNP (r_nsubjpass) prescribed_9/VBN (l_conj) developed_22/VBD (l_dobj) episode_25/NN (l_prep) of_26/IN (l_pobj) anuria_28/NN
D019808_D006973 NONE losartan_27/NNP (r_compound) administration_28/NNP (r_pobj) after_26/IN (r_prep) developed_20/VBD (r_relcl) man_10/NN (l_amod) hypertensive_9/JJ
D019808_D051436 NONE losartan_27/NNP (r_compound) administration_28/NNP (r_pobj) after_26/IN (r_prep) developed_20/VBD (r_relcl) man_10/NN (l_prep) with_11/IN (l_pobj) kidney_14/NN (l_conj) insufficiency_18/NN
D019808_D006331 NONE losartan_5/NNP (l_compound) dysfunction_4/NN
D005665_D001002 NONE furosemide_24/NN (r_nmod) infusion_27/NN (r_pobj) despite_20/IN (r_prep) lasted_17/VBD (r_relcl) anuria_14/NN
D000588_D001002 NONE amine_26/NN (r_conj) furosemide_24/NN (r_nmod) infusion_27/NN (r_pobj) despite_20/IN (r_prep) lasted_17/VBD (r_relcl) anuria_14/NN
D000809_D012078 NONE angiotensin_24/NN (r_compound) system_25/NN (r_pobj) of_20/IN (r_prep) activation_19/NN (r_pobj) in_16/IN (r_prep) resulted_15/VBD (l_nsubj) stenosis_6/NN
D000809_D006333 NONE angiotensin_24/NN (r_compound) system_25/NN (r_pobj) of_20/IN (r_prep) activation_19/NN (r_pobj) in_16/IN (r_prep) resulted_15/VBD (l_nsubj) stenosis_6/NN (l_acl) combined_7/VBN (l_prep) with_8/IN (l_pobj) failure_10/NN
D000804_D014652 NONE II_9/NNP (r_compound) antagonist_11/NN (r_compound) losartan_12/NNP (r_nsubj) cause_14/VB (l_dobj) complications_17/NNS (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) disease_22/NN
D019808_D014652 NONE losartan_12/NNP (r_nsubj) cause_14/VB (l_dobj) complications_17/NNS (l_prep) in_18/IN (l_pobj) patients_19/NNS (l_prep) with_20/IN (l_pobj) disease_22/NN
12789195
D008914_D004194 NONE minoxidil_9/NN (r_pobj) of_8/IN (r_prep) use_7/NN (r_pobj) by_2/IN (r_agent) induced_1/VBN (r_acl) Pseudoacromegaly_0/NNP
D008914_D004194 NONE minoxidil_15/NN (r_pobj) of_14/IN (r_prep) use_13/NN (r_pobj) from_8/IN (r_prep) resulted_7/VBD (r_relcl) pseudoacromegaly_5/NNP
D008914_D004194 NONE minoxidil_13/NN (r_compound) use_14/NN (r_pobj) of_12/IN (r_prep) effect_11/NN (r_pobj) as_8/IN (r_prep) report_5/NN (l_prep) of_6/IN (l_pobj) pseudoacromegaly_7/NNP
18308784
C035054_D007859 NONE Rg1_1/NN (r_nsubj) restores_2/VBZ (l_dobj) impairment_4/NN (l_prep) of_5/IN (l_pobj) learning_6/NN
C035054_D007859 NONE Rg1_0/NNP (r_nsubj) ameliorate_11/VB (l_dobj) impairment_14/NN
C035054_D007859 NONE Rg1_11/NN (r_pobj) of_10/IN (r_prep) effect_9/NN (l_prep) on_12/IN (l_pcomp) learning_13/VBG (l_dobj) impairment_14/NN
D009020_D007859 CID morphine_10/NNP (r_compound) administration_11/NN (r_pobj) by_8/IN (r_agent) induced_7/VBN (r_acl) learning_6/NN
D009020_D007859 CID morphine_17/NNP (r_compound) administration_18/NNP (r_pobj) by_15/IN (r_prep) impairment_14/NN
D036145_D007859 NONE ginsenoside_4/NN (r_pobj) as_2/IN (r_prep) ameliorate_11/VB (l_dobj) impairment_14/NN
12617329
D006170_D007674 NONE Arabic_6/NNP (r_pobj) with_4/IN (r_prep) treatment_3/NN (l_prep) on_7/IN (l_pobj) nephrotoxicity_9/NN
D006170_D007674 NONE Arabic_14/NNP (r_pobj) with_12/IN (r_prep) rats_11/NNS (r_pobj) of_10/IN (r_prep) treatment_9/NN (r_pobj) of_8/IN (r_prep) effect_7/NN (r_dobj) assessed_5/VBD (l_prep) on_15/IN (l_pobj) failure_18/NN (l_acl) induced_19/VBN (l_agent) by_20/IN (l_pobj) gentamicin_21/NNS (l_appos) nephrotoxicity_25/NN
D006170_D007674 NONE Arabic_6/JJ (r_amod) treatment_7/NN (r_nsubj) induced_9/VBN (l_dobj) amelioration_12/NN (l_prep) of_13/IN (l_pobj) some_14/DT (l_prep) of_15/IN (l_pobj) indices_20/NNS (l_prep) of_21/IN (l_pobj) nephrotoxicity_23/NN
D005839_D007674 NONE gentamicin_8/NNS (r_compound) nephrotoxicity_9/NN
D005839_D007674 NONE gentamicin_21/NNS (l_appos) nephrotoxicity_25/NN
D005839_D007674 NONE GM_23/NNP (r_nmod) nephrotoxicity_25/NN
D005839_D007674 NONE GM_22/NNP (r_compound) nephrotoxicity_23/NN
D006170_D058186 CID Arabic_14/NNP (r_pobj) with_12/IN (r_prep) rats_11/NNS (r_pobj) of_10/IN (r_prep) treatment_9/NN (r_pobj) of_8/IN (r_prep) effect_7/NN (r_dobj) assessed_5/VBD (l_prep) on_15/IN (l_pobj) failure_18/NN
D005839_D058186 CID gentamicin_21/NNS (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) failure_18/NN
D005839_D058186 CID GM_23/NNP (r_nmod) nephrotoxicity_25/NN (r_appos) gentamicin_21/NNS (r_pobj) by_20/IN (r_agent) induced_19/VBN (r_acl) failure_18/NN
D003404_D007674 NONE creatinine_8/NN (r_pobj) of_7/IN (r_prep) concentrations_6/NNS (r_dobj) measuring_4/VBG (r_pcomp) by_3/IN (r_prep) assessed_2/VBN (l_nsubjpass) Nephrotoxicity_0/NNP
D014508_D007674 NONE urea_10/NN (r_conj) creatinine_8/NN (r_pobj) of_7/IN (r_prep) concentrations_6/NNS (r_dobj) measuring_4/VBG (r_pcomp) by_3/IN (r_prep) assessed_2/VBN (l_nsubjpass) Nephrotoxicity_0/NNP
D005978_D007674 NONE glutathione_16/NN (r_conj) measuring_4/VBG (r_pcomp) by_3/IN (r_prep) assessed_2/VBN (l_nsubjpass) Nephrotoxicity_0/NNP
D005978_D007674 NONE GSH_18/NNP (r_appos) glutathione_16/NN (r_conj) measuring_4/VBG (r_pcomp) by_3/IN (r_prep) assessed_2/VBN (l_nsubjpass) Nephrotoxicity_0/NNP
D005839_D007683 NONE GM_1/NNP (r_npadvmod) induced_3/VBN (r_amod) necrosis_6/NN
D005839_D007683 NONE GM_16/NNP (r_dobj) given_15/VBN (r_acl) rats_14/NNS (r_pobj) in_13/IN (r_prep) severe_12/JJ (r_acomp) be_9/VB (r_xcomp) appeared_7/VBD (l_nsubj) necrosis_6/NN
D005839_D007683 NONE GM_25/NNP (r_pobj) given_24/VBN (r_acl) those_23/DT (r_pobj) in_22/IN (r_prep) than_21/IN (r_prep) given_15/VBN (r_acl) rats_14/NNS (r_pobj) in_13/IN (r_prep) severe_12/JJ (r_acomp) be_9/VB (r_xcomp) appeared_7/VBD (l_nsubj) necrosis_6/NN
D006170_D007683 NONE Arabic_20/JJ (r_pobj) with_18/IN (r_prep) given_15/VBN (r_acl) rats_14/NNS (r_pobj) in_13/IN (r_prep) severe_12/JJ (r_acomp) be_9/VB (r_xcomp) appeared_7/VBD (l_nsubj) necrosis_6/NN
9587734
D013390_D006323 CID Suxamethonium_0/NN (r_npadvmod) induced_2/VBN (r_amod) arrest_4/NN
D013390_D006323 CID suxamethonium_21/NN (r_pobj) of_20/IN (r_prep) use_19/NN (r_pobj) following_17/VBG (r_acl) hyperkalaemia_16/NN (r_pobj) of_15/IN (r_prep) result_14/NN (r_pobj) as_12/IN (r_prep) describes_3/VBZ (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) arrest_8/NN
D013390_D006323 CID suxamethonium_5/NN (l_conj) bradycardia_7/JJ (l_conj) arrest_10/NN
D013390_D003643 NONE Suxamethonium_0/NN (r_npadvmod) induced_2/VBN (r_amod) arrest_4/NN (l_conj) death_6/NN
D013390_D003643 NONE suxamethonium_21/NN (r_pobj) of_20/IN (r_prep) use_19/NN (r_pobj) following_17/VBG (r_acl) hyperkalaemia_16/NN (r_pobj) of_15/IN (r_prep) result_14/NN (r_pobj) as_12/IN (r_prep) describes_3/VBZ (l_dobj) case_5/NN (l_prep) of_6/IN (l_pobj) arrest_8/NN (l_conj) death_11/NN
D013390_D003643 NONE suxamethonium_11/NNP (r_pobj) to_10/IN (r_prep) hypersensitivity_9/NN (r_pobj) by_8/IN (r_agent) caused_7/VBN (l_nsubjpass) death_5/NN
D013390_D006947 CID suxamethonium_21/NN (r_pobj) of_20/IN (r_prep) use_19/NN (r_pobj) following_17/VBG (r_acl) hyperkalaemia_16/NN
D013390_D006947 CID suxamethonium_35/NNP (r_pobj) of_34/IN (r_prep) administration_33/NN (r_pobj) following_31/VBG (r_acl) signs_15/NNS (l_conj) of_21/IN (l_pobj) any_22/DT (l_prep) of_23/IN (l_pobj) conditions_28/NNS (l_prep) for_29/IN (l_pobj) hyperkalaemia_30/NN
D013390_D001919 CID suxamethonium_5/NN (l_conj) bradycardia_7/JJ
D013390_D004342 CID suxamethonium_11/NNP (r_pobj) to_10/IN (r_prep) hypersensitivity_9/NN
17343925
D012906_D034381 CID smoking_3/NN (r_pobj) of_2/IN (r_prep) influence_1/NN (r_nsubjpass) estimated_13/VBN (l_advcl) associated_20/VBN (l_prep) with_21/IN (l_pcomp) hearing_22/NN (l_dobj) loss_23/NN
D012906_D034381 CID smoking_16/NN (r_nsubjpass) associated_20/VBN (l_prep) with_21/IN (l_pcomp) hearing_22/NN (l_dobj) loss_23/NN
6861444
D009638_D006973 CID noradrenaline_3/NN (r_pobj) of_2/IN (r_prep) infusion_1/NN (r_nsubj) caused_4/VBD (l_dobj) hypertension_5/NN
D009638_D006973 CID noradrenaline_8/NN (r_compound) infusion_9/NN (r_nsubjpass) produced_11/VBN (l_nsubjpass) hypertension_4/NN
D009638_D006973 CID noradrenaline_18/NN (r_dobj) circulating_17/VBG (r_pcomp) of_16/IN (r_prep) levels_15/NNS (r_pobj) by_12/IN (r_agent) produced_11/VBN (l_nsubjpass) hypertension_4/NN
17400887
D013726_D020078 NONE terbutaline_6/JJ (r_compound) treatment_7/NN (r_pobj) after_4/IN (r_prep) Neuroinflammation_0/NN
D013726_D001523 NONE terbutaline_6/JJ (r_compound) treatment_7/NN (r_pobj) after_4/IN (r_prep) Neuroinflammation_0/NN (l_conj) abnormalities_3/NNS
D013726_D001321 CID terbutaline_6/JJ (r_compound) treatment_7/NN (r_pobj) after_4/IN (r_prep) Neuroinflammation_0/NN (l_appos) implications_11/NNS (l_prep) for_12/IN (l_pobj) autism_13/NN
D013726_D001321 CID Terbutaline_0/NNP (r_nsubjpass) associated_13/VBN (l_prep) with_14/IN (l_pobj) concordance_16/NN (l_prep) for_17/IN (l_pobj) autism_18/NN
D013726_D007752 NONE Terbutaline_0/NNP (l_appos) agonist_4/NN (l_acl) used_5/VBN (l_xcomp) arrest_7/VB (l_dobj) labor_9/NN
2054792
D004317_D005334 NONE adriamycin_2/NNS (r_pobj) of_1/IN (r_prep) Effect_0/NN (l_acl) combined_3/VBN (l_prep) with_4/IN (l_pobj) hyperthermia_7/NN
D004317_D005334 NONE Adriamycin_3/NN (r_npadvmod) mediated_5/VBN (r_amod) activity_7/NN (l_conj) toxicities_11/NNS (l_prep) by_12/IN (l_pobj) hyperthermia_15/NN
D004317_D005334 NONE Adriamycin_13/NNP (r_npadvmod) mediated_15/VBN (r_amod) activity_17/NN (r_dobj) enhanced_11/VBN (l_nsubj) hyperthermia_2/NN
D004317_D005334 NONE Adriamycin_7/NN (r_npadvmod) mediated_9/VBN (r_amod) effect_11/NN (r_dobj) enhances_6/VBZ (l_nsubj) hyperthermia_5/NN
D004317_D009369 NONE adriamycin_2/NNS (r_pobj) of_1/IN (r_prep) Effect_0/NN (l_acl) combined_3/VBN (l_prep) with_4/IN (l_pobj) hyperthermia_7/NN (l_prep) on_8/IN (l_pobj) tumor_9/NN
D004317_D064420 NONE Adriamycin_3/NN (r_npadvmod) mediated_5/VBN (r_amod) activity_7/NN (l_conj) toxicities_11/NNS
D004317_D064420 NONE Adriamycin_7/NN (r_npadvmod) mediated_9/VBN (r_amod) effect_11/NN (r_dobj) enhances_6/VBZ (r_advcl) increased_18/VBN (l_nsubjpass) toxicity_15/NN
15036754
D010755_D012640 NONE Organophosphate_0/NN (r_npadvmod) induced_2/VBN (r_amod) convulsions_3/NNS
D010755_D004194 NONE Organophosphate_0/NN (r_npadvmod) induced_2/VBN (r_amod) convulsions_3/NNS (l_prep) of_6/IN (l_pobj) damages_8/NNS
D010755_D064420 NONE OPs_4/NNS (r_pobj) of_3/IN (r_prep) toxicity_2/NN
D010755_D064420 NONE OP_10/NN (r_npadvmod) induced_12/VBN (r_amod) signs_14/NNS (l_compound) toxicity_13/NN
D000109_D064420 NONE acetylcholine_25/NN (r_nmod) levels_29/NNS (r_dobj) elevates_24/VBZ (r_relcl) binding_11/NN (r_pobj) of_8/IN (r_prep) result_7/NN (r_attr) is_5/VBZ (l_nsubj) toxicity_2/NN
D000109_D064420 NONE ACh_27/NNP (r_nmod) levels_29/NNS (r_dobj) elevates_24/VBZ (r_relcl) binding_11/NN (r_pobj) of_8/IN (r_prep) result_7/NN (r_attr) is_5/VBZ (l_nsubj) toxicity_2/NN
D007531_D064420 NONE DFP_4/NNP (r_compound) atropine_6/NN (r_pobj) with_3/IN (r_prep) treated_2/VBN (r_acl) rats_1/NNS (r_nsubj) showed_7/VBD (l_dobj) signs_14/NNS (l_compound) toxicity_13/NN
D007531_D064420 NONE DFP_10/NNP (r_compound) toxicity_11/NN
D007531_D064420 NONE DFP_26/NNP (r_pobj) of_25/IN (r_prep) toxicity_24/NN
D001285_D064420 NONE atropine_6/NN (r_pobj) with_3/IN (r_prep) treated_2/VBN (r_acl) rats_1/NNS (r_nsubj) showed_7/VBD (l_dobj) signs_14/NNS (l_compound) toxicity_13/NN
D001285_D064420 NONE Atropine_0/NN (r_compound) MK801_2/NN (r_nsubj) offer_5/VB (l_dobj) protection_8/NN (l_prep) against_9/IN (l_pobj) toxicity_11/NN
D001285_D064420 NONE atropine_11/NN (r_pobj) with_10/IN (r_prep) combination_9/NN (r_pobj) in_8/IN (r_prep) CPA_3/NN (r_nsubj) prevented_12/VBD (l_conj) reduced_22/VBD (l_dobj) toxicity_24/NN
C048599_D011041 NONE CPA_1/NN (r_nsubjpass) given_7/VBN (r_advcl) prevented_16/VBD (l_conj) delayed_18/VBN (l_conj) shortened_20/VBN (l_dobj) occurrence_22/NN (l_prep) of_23/IN (l_pobj) signs_25/NNS (l_prep) of_26/IN (l_pobj) poisoning_27/NN
C048599_D011041 NONE CPA_3/NN (r_nsubj) prevented_12/VBD (l_dobj) occurrence_14/NN (l_prep) of_15/IN (l_pobj) signs_17/NNS (l_prep) of_18/IN (l_pobj) poisoning_19/NN
D003975_D011041 NONE diazepam_3/NN (r_appos) CPA_1/NN (r_nsubjpass) given_7/VBN (r_advcl) prevented_16/VBD (l_conj) delayed_18/VBN (l_conj) shortened_20/VBN (l_dobj) occurrence_22/NN (l_prep) of_23/IN (l_pobj) signs_25/NNS (l_prep) of_26/IN (l_pobj) poisoning_27/NN
D003975_D011041 NONE diazepam_5/NN (r_conj) CPA_3/NN (r_nsubj) prevented_12/VBD (l_dobj) occurrence_14/NN (l_prep) of_15/IN (l_pobj) signs_17/NNS (l_prep) of_18/IN (l_pobj) poisoning_19/NN
D011220_D011041 NONE 2PAM_5/NNP (r_conj) diazepam_3/NN (r_appos) CPA_1/NN (r_nsubjpass) given_7/VBN (r_advcl) prevented_16/VBD (l_conj) delayed_18/VBN (l_conj) shortened_20/VBN (l_dobj) occurrence_22/NN (l_prep) of_23/IN (l_pobj) signs_25/NNS (l_prep) of_26/IN (l_pobj) poisoning_27/NN
D011220_D011041 NONE 2PAM_7/NN (r_conj) diazepam_5/NN (r_conj) CPA_3/NN (r_nsubj) prevented_12/VBD (l_dobj) occurrence_14/NN (l_prep) of_15/IN (l_pobj) signs_17/NNS (l_prep) of_18/IN (l_pobj) poisoning_19/NN
D007531_D011041 NONE DFP_10/NNP (r_compound) atropine_12/NN (r_pobj) after_9/IN (r_prep) given_7/VBN (r_advcl) prevented_16/VBD (l_conj) delayed_18/VBN (l_conj) shortened_20/VBN (l_dobj) occurrence_22/NN (l_prep) of_23/IN (l_pobj) signs_25/NNS (l_prep) of_26/IN (l_pobj) poisoning_27/NN
D007531_D011041 NONE DFP_26/NNP (r_pobj) of_25/IN (r_prep) toxicity_24/NN (r_dobj) reduced_22/VBD (r_conj) prevented_12/VBD (l_dobj) occurrence_14/NN (l_prep) of_15/IN (l_pobj) signs_17/NNS (l_prep) of_18/IN (l_pobj) poisoning_19/NN
D001285_D011041 NONE atropine_12/NN (r_pobj) after_9/IN (r_prep) given_7/VBN (r_advcl) prevented_16/VBD (l_conj) delayed_18/VBN (l_conj) shortened_20/VBN (l_dobj) occurrence_22/NN (l_prep) of_23/IN (l_pobj) signs_25/NNS (l_prep) of_26/IN (l_pobj) poisoning_27/NN
D001285_D011041 NONE atropine_11/NN (r_pobj) with_10/IN (r_prep) combination_9/NN (r_pobj) in_8/IN (r_prep) CPA_3/NN (r_nsubj) prevented_12/VBD (l_dobj) occurrence_14/NN (l_prep) of_15/IN (l_pobj) signs_17/NNS (l_prep) of_18/IN (l_pobj) poisoning_19/NN
D016291_D064420 NONE MK801_2/NN (r_nsubj) offer_5/VB (l_dobj) protection_8/NN (l_prep) against_9/IN (l_pobj) toxicity_11/NN
C048599_D064420 NONE CPA_3/NN (r_nsubj) prevented_12/VBD (l_conj) reduced_22/VBD (l_dobj) toxicity_24/NN
D003975_D064420 NONE diazepam_5/NN (r_conj) CPA_3/NN (r_nsubj) prevented_12/VBD (l_conj) reduced_22/VBD (l_dobj) toxicity_24/NN
D011220_D064420 NONE 2PAM_7/NN (r_conj) diazepam_5/NN (r_conj) CPA_3/NN (r_nsubj) prevented_12/VBD (l_conj) reduced_22/VBD (l_dobj) toxicity_24/NN
18020536
D001569_D004244 CID BZDs_4/NNP (r_nmod) RDs_6/NNP (r_pobj) of_3/IN (r_prep) use_2/NN (r_nsubjpass) associated_8/VBN (l_prep) with_9/IN (l_pobj) dizziness_10/NN
D001569_D007319 CID BZDs_4/NNP (r_nmod) RDs_6/NNP (r_pobj) of_3/IN (r_prep) use_2/NN (r_nsubjpass) associated_8/VBN (l_conj) inability_12/NN (l_acl) sleep_14/VB
D001569_D005221 CID BZDs_4/NNP (r_nmod) RDs_6/NNP (r_pobj) of_3/IN (r_prep) use_2/NN (r_nsubjpass) associated_8/VBN (l_conj) inability_12/NN (l_acl) sleep_14/VB (l_prep) after_15/IN (l_pcomp) awaking_16/VBG (l_prep) at_17/IN (l_pobj) night_18/NN (l_conj) tiredness_20/NN
D001569_D003866 CID BZDs_4/NNP (r_nmod) RDs_6/NNP (r_pobj) of_3/IN (r_prep) use_2/NN (r_nsubjpass) associated_8/VBN (l_conj) inability_12/NN (l_acl) sleep_14/VB (l_prep) after_15/IN (l_pcomp) awaking_16/VBG (l_prep) during_24/IN (l_conj) with_31/IN (l_pobj) symptoms_34/NNS
11706060
D019344_D009202 NONE lactate_8/NN (r_dobj) elevates_6/VBZ (r_conj) causes_3/NNS (l_dobj) cardiomyopathy_4/NN
D019344_D009202 NONE lactate_18/NN (r_pobj) in_15/IN (r_conj) in_9/IN (l_pobj) cardiomyopathy_10/NN
D019344_D009202 NONE lactate_18/NN (r_pobj) in_15/IN (r_conj) in_9/IN (l_pobj) cardiomyopathy_10/NN (l_appos) CM_12/NN
D019344_D009202 NONE LA_20/NNP (r_appos) lactate_18/NN (r_pobj) in_15/IN (r_conj) in_9/IN (l_pobj) cardiomyopathy_10/NN
D019344_D009202 NONE LA_20/NNP (r_appos) lactate_18/NN (r_pobj) in_15/IN (r_conj) in_9/IN (l_pobj) cardiomyopathy_10/NN (l_appos) CM_12/NN
D019344_D009202 NONE LA_10/NNP (r_pobj) with_8/IN (r_prep) CM_7/NN
D019344_D000163 NONE lactate_8/NN (l_prep) in_9/IN (l_pobj) mice_12/NNS (l_compound) AIDS_11/NNP
D019344_D000163 NONE lactate_18/NN (r_pobj) in_15/IN (l_prep) in_22/IN (l_pobj) AIDS_23/NNP
D019344_D000163 NONE LA_20/NNP (r_appos) lactate_18/NN (r_pobj) in_15/IN (l_prep) in_22/IN (l_pobj) AIDS_23/NNP
D019344_D000163 NONE LA_10/NNP (l_prep) in_11/IN (l_pobj) mice_14/NNS (l_compound) transgenic_13/JJ (l_compound) AIDS_12/NNP
D019344_D028361 NONE lactate_18/NN (r_pobj) in_15/IN (r_conj) in_9/IN (r_prep) implicated_8/VBN (l_prep) through_24/IN (l_pobj) mechanisms_25/NNS (l_prep) of_26/IN (l_pobj) dysfunction_28/NN
D019344_D028361 NONE LA_20/NNP (r_appos) lactate_18/NN (r_pobj) in_15/IN (r_conj) in_9/IN (r_prep) implicated_8/VBN (l_prep) through_24/IN (l_pobj) mechanisms_25/NNS (l_prep) of_26/IN (l_pobj) dysfunction_28/NN
7930386
D002997_D012893 CID Clomipramine_0/NN (r_npadvmod) induced_2/VBN (r_amod) disturbance_4/NN
D002997_D012893 CID clomipramine_15/NNP (r_compound) administration_16/NNP (r_pobj) by_14/IN (r_agent) induced_13/VBN (r_acl) disturbance_11/NN
16167916
D020849_D054556 CID raloxifene_11/JJ (r_compound) treatment_12/NN (r_nsubjpass) related_15/VBN (l_nsubjpass) risk_5/NN (l_prep) of_6/IN (l_pobj) thromboembolism_8/NN
1728522
D019980_D006099 CID acid_9/NN (r_conj) amoxicillin_6/NNP (r_pobj) of_5/IN (r_prep) combination_4/NN (r_pobj) due_2/IN (r_prep) hepatitis_1/NN
D019980_D006099 CID acid_11/NN (r_npadvmod) induced_13/VBN (r_amod) hepatitis_14/NN (l_prep) with_15/IN (l_pobj) granulomas_18/NNS
D019980_D056486 CID acid_9/NN (r_conj) amoxicillin_6/NNP (r_pobj) of_5/IN (r_prep) combination_4/NN (r_pobj) due_2/IN (r_prep) hepatitis_1/NN
D019980_D056486 CID acid_11/NN (r_npadvmod) induced_13/VBN (r_amod) hepatitis_14/NN
18503483
D016559_D020968 CID tacrolimus_2/NN (r_npadvmod) associated_4/VBN (r_amod) neuritis_6/NN
C107135_D020968 NONE everolimus_10/VB (r_pobj) to_9/IN (r_prep) conversion_8/NN (r_pobj) after_7/IN (r_prep) Recovery_0/NN (l_prep) of_1/IN (l_pobj) neuritis_6/NN
7858459
D005472_D003221 CID 5-fluorouracil_10/CD (r_pobj) of_9/IN (r_prep) infusion_8/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) confusion_1/NN
D005472_D003221 CID 5-fluorouracil_35/CD (r_pobj) of_34/IN (r_prep) day_31/NN (r_appos) dose_29/NN (r_pobj) during_26/IN (r_prep) lasting_21/VBG (r_advcl) lapsed_15/VBD (r_conj) developed_1/VBD (l_dobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) confusion_7/NN
D005472_D003221 CID 5-fluorouracil_35/CD (r_pobj) of_34/IN (r_prep) day_31/NN (r_appos) dose_29/NN (r_pobj) during_26/IN (r_prep) lasting_21/VBG (r_advcl) lapsed_15/VBD (r_conj) developed_1/VBD (l_dobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) confusion_7/NN (l_conj) disorientation_9/NN
D002955_D003221 CID acid_13/NN (r_conj) infusion_8/NN (r_pobj) by_3/IN (r_agent) induced_2/VBN (r_acl) confusion_1/NN
D002955_D003221 CID acid_38/NN (r_compound) infusion_39/NN (r_conj) day_31/NN (r_appos) dose_29/NN (r_pobj) during_26/IN (r_prep) lasting_21/VBG (r_advcl) lapsed_15/VBD (r_conj) developed_1/VBD (l_dobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) confusion_7/NN
D002955_D003221 CID acid_38/NN (r_compound) infusion_39/NN (r_conj) day_31/NN (r_appos) dose_29/NN (r_pobj) during_26/IN (r_prep) lasting_21/VBG (r_advcl) lapsed_15/VBD (r_conj) developed_1/VBD (l_dobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) confusion_7/NN (l_conj) disorientation_9/NN
D002945_D013274 NONE cisplatinum_11/NN (r_dobj) incorporating_10/VBG (l_prep) for_29/IN (l_pobj) adenocarcinoma_33/NN
D005047_D013274 NONE etoposide_13/NN (r_appos) cisplatinum_11/NN (r_dobj) incorporating_10/VBG (l_prep) for_29/IN (l_pobj) adenocarcinoma_33/NN
D005472_D013274 NONE 5-fluorouracil_18/CD (r_punct) cisplatinum_11/NN (r_dobj) incorporating_10/VBG (l_prep) for_29/IN (l_pobj) adenocarcinoma_33/NN
D002955_D013274 NONE acid_28/NN (r_conj) hours_24/NNS (r_appos) cisplatinum_11/NN (r_dobj) incorporating_10/VBG (l_prep) for_29/IN (l_pobj) adenocarcinoma_33/NN
D005472_D001523 NONE 5-fluorouracil_35/CD (r_pobj) of_34/IN (r_prep) day_31/NN (r_appos) dose_29/NN (r_pobj) during_26/IN (r_prep) lasting_21/VBG (r_advcl) lapsed_15/VBD (r_conj) developed_1/VBD (l_dobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) confusion_7/NN (l_conj) disorientation_9/NN (l_conj) irritability_11/NN
D005472_D003128 CID 5-fluorouracil_35/CD (r_pobj) of_34/IN (r_prep) day_31/NN (r_appos) dose_29/NN (r_pobj) during_26/IN (r_prep) lasting_21/VBG (r_advcl) lapsed_15/VBD (l_prep) into_16/IN (l_pobj) coma_19/NN
D002955_D001523 NONE acid_38/NN (r_compound) infusion_39/NN (r_conj) day_31/NN (r_appos) dose_29/NN (r_pobj) during_26/IN (r_prep) lasting_21/VBG (r_advcl) lapsed_15/VBD (r_conj) developed_1/VBD (l_dobj) symptoms_4/NNS (l_prep) of_5/IN (l_pobj) confusion_7/NN (l_conj) disorientation_9/NN (l_conj) irritability_11/NN
D002955_D003128 CID acid_38/NN (r_compound) infusion_39/NN (r_conj) day_31/NN (r_appos) dose_29/NN (r_pobj) during_26/IN (r_prep) lasting_21/VBG (r_advcl) lapsed_15/VBD (l_prep) into_16/IN (l_pobj) coma_19/NN
D002955_D020258 NONE acid_2/NN (r_nsubj) was_3/VBD (r_advcl) was_19/VBD (l_nsubj) neurotoxicity_12/NN
D005472_D020258 NONE 5-fluorouracil_18/CD (r_pobj) due_13/IN (r_prep) neurotoxicity_12/NN
D005472_D020258 NONE 5-fluorouracil_3/CD (r_punct) neurotoxicity_4/NN
D005463_D020258 NONE fluoroacetate_14/NNP (r_pobj) by_13/IN (r_prep) blockade_12/NN (r_pobj) to_8/IN (r_prep) due_7/IN (r_acomp) be_6/VB (l_nsubj) pathogenesis_1/NN (l_prep) of_2/IN (l_pobj) neurotoxicity_4/NN
C007744_D020258 NONE fluorocitrate_16/NN (r_conj) fluoroacetate_14/NNP (r_pobj) by_13/IN (r_prep) blockade_12/NN (r_pobj) to_8/IN (r_prep) due_7/IN (r_acomp) be_6/VB (l_nsubj) pathogenesis_1/NN (l_prep) of_2/IN (l_pobj) neurotoxicity_4/NN
D013831_D020258 NONE thiamine_18/NN (r_compound) deficiency_19/NN (r_conj) fluoroacetate_14/NNP (r_pobj) by_13/IN (r_prep) blockade_12/NN (r_pobj) to_8/IN (r_prep) due_7/IN (r_acomp) be_6/VB (l_nsubj) pathogenesis_1/NN (l_prep) of_2/IN (l_pobj) neurotoxicity_4/NN
C007419_D020258 NONE dihydrouracil_22/NN (r_compound) dehydrogenase_23/NN (r_compound) deficiency_24/NN (r_conj) deficiency_19/NN (r_conj) fluoroacetate_14/NNP (r_pobj) by_13/IN (r_prep) blockade_12/NN (r_pobj) to_8/IN (r_prep) due_7/IN (r_acomp) be_6/VB (l_nsubj) pathogenesis_1/NN (l_prep) of_2/IN (l_pobj) neurotoxicity_4/NN
D005472_D009369 NONE 5-fluorouracil_3/CD (r_dep) /_4/SYM (r_punct) dose_2/NN (r_amod) therapy_8/NN (r_nsubj) become_11/VBN (l_attr) regimen_14/NN (l_prep) for_15/IN (l_pobj) cancers_17/NNS
D002955_D009369 NONE acid_6/NN (r_compound) therapy_8/NN (r_nsubj) become_11/VBN (l_attr) regimen_14/NN (l_prep) for_15/IN (l_pobj) cancers_17/NNS
15278670
C009250_D012640 NONE sevoflurane_3/NNP (r_pobj) of_2/IN (r_prep) effects_1/NNS (l_prep) on_4/IN (l_pobj) convulsions_8/NNS
C009250_D012640 NONE sevoflurane_3/NNP (l_prep) on_4/IN (l_pobj) convulsions_8/NNS
C009250_D012640 NONE sevoflurane_10/NNP (r_pobj) between_9/IN (r_prep) threshold_8/NN (l_amod) convulsive_7/JJ
C009250_D012640 NONE sevoflurane_12/NNP (r_pobj) of_11/IN (r_prep) concentrations_10/NNS (r_nsubjpass) administered_16/VBN (l_conj) decreased_23/VBD (l_nsubj) pressure_20/NN (l_prep) at_21/IN (l_pobj) convulsions_22/NNS
C009250_D012640 NONE sevoflurane_28/NNP (r_pobj) in_25/IN (r_prep) decreased_23/VBD (l_nsubj) pressure_20/NN (l_prep) at_21/IN (l_pobj) convulsions_22/NNS
C009250_D012640 NONE sevoflurane_4/NNP (r_nsubj) reduces_5/VBZ (l_dobj) effect_8/NN (l_amod) convulsive_7/JJ
D008012_D012640 CID lidocaine_5/NN (r_npadvmod) induced_7/VBN (r_amod) convulsions_8/NNS
D008012_D012640 CID lidocaine_5/NN (r_npadvmod) induced_7/VBN (r_amod) convulsions_8/NNS
D008012_D012640 CID lidocaine_16/NN (r_compound) infusion_17/NN (r_pobj) with_15/IN (r_prep) was_8/VBD (l_nsubj) threshold_2/NN (l_amod) convulsive_1/JJ
D008012_D012640 CID lidocaine_10/NN (r_compound) toxicity_11/NN (r_pobj) of_9/IN (r_prep) effect_8/NN (l_amod) convulsive_7/JJ
D004737_D012640 NONE enflurane_12/NNP (r_conj) sevoflurane_10/NNP (r_pobj) between_9/IN (r_prep) threshold_8/NN (l_amod) convulsive_7/JJ
D004737_D012640 NONE enflurane_14/NNP (r_conj) sevoflurane_12/NNP (r_pobj) of_11/IN (r_prep) concentrations_10/NNS (r_nsubjpass) administered_16/VBN (l_conj) decreased_23/VBD (l_nsubj) pressure_20/NN (l_prep) at_21/IN (l_pobj) convulsions_22/NNS
D004737_D012640 NONE enflurane_37/NNP (r_conj) %_33/NN (r_pobj) in_31/IN (r_prep) decreased_23/VBD (l_nsubj) pressure_20/NN (l_prep) at_21/IN (l_pobj) convulsions_22/NNS
D001030_D012640 NONE Apamin_0/NNP (r_nsubj) had_5/VBD (l_dobj) tendency_7/NN (l_acl) decrease_9/VB (l_dobj) threshold_12/NN (l_amod) convulsive_11/JJ
C009250_D064420 NONE sevoflurane_4/NNP (r_nsubj) reduces_5/VBZ (l_dobj) effect_8/NN (l_prep) of_9/IN (l_pobj) toxicity_11/NN
C009250_D003866 NONE sevoflurane_4/NNP (r_nsubj) reduces_5/VBZ (l_conj) carries_13/VBZ (l_prep) due_16/IN (l_pcomp) to_17/IN (l_pobj) depression_19/NN
D008012_D064420 NONE lidocaine_10/NN (r_compound) toxicity_11/NN
D008012_D003866 NONE lidocaine_10/NN (r_compound) toxicity_11/NN (r_pobj) of_9/IN (r_prep) effect_8/NN (r_dobj) reduces_5/VBZ (l_conj) carries_13/VBZ (l_prep) due_16/IN (l_pcomp) to_17/IN (l_pobj) depression_19/NN
3560095
D005480_D001171 NONE Flurbiprofen_0/NN (l_prep) in_1/IN (l_pobj) treatment_3/NN (l_prep) of_4/IN (l_pobj) arthritis_7/NN
D005480_D001171 NONE flurbiprofen_13/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_relcl) patients_3/NNS (l_prep) with_4/IN (l_pobj) arthritis_7/NN
D005480_D001168 NONE flurbiprofen_13/NN (r_pobj) with_12/IN (r_prep) treated_11/VBN (r_relcl) patients_3/NNS (r_nsubj) had_26/VBD (l_dobj) decreases_29/NNS (l_prep) in_32/IN (l_pobj) indices_35/NNS (l_compound) arthritis_34/NN
7423039
D004317_D066126 CID adriamycin_3/NN (r_compound) cardiotoxicity_4/NN
D004317_D066126 CID adriamycin_4/NNS (r_pobj) of_3/IN (r_prep) effects_2/NNS (l_amod) cardiotoxic_1/JJ
3970039
D000477_D015470 CID agents_4/NNS (r_pobj) with_2/IN (r_prep) treated_1/VBN (r_acl) Patients_0/NNS (r_nsubj) have_5/VBP (l_dobj) risk_8/NN (l_prep) of_9/IN (l_pobj) development_10/NN (l_prep) of_11/IN (l_pobj) leukemia_14/NN
D000477_D015470 CID agents_19/NNS (r_conj) have_5/VBP (l_dobj) risk_8/NN (l_prep) of_9/IN (l_pobj) development_10/NN (l_prep) of_11/IN (l_pobj) leukemia_14/NN
D000477_D008228 CID agents_4/NNS (r_pobj) with_2/IN (r_prep) treated_1/VBN (r_acl) Patients_0/NNS (r_nsubj) have_5/VBP (l_conj) associated_23/VBN (l_prep) with_24/IN (l_pobj) development_26/NN (l_prep) of_27/IN (l_pobj) lymphoma_32/NN
D000477_D008228 CID agents_19/NNS (r_conj) have_5/VBP (l_conj) associated_23/VBN (l_prep) with_24/IN (l_pobj) development_26/NN (l_prep) of_27/IN (l_pobj) lymphoma_32/NN
D001379_D015470 NONE azathioprine_21/NN (r_conj) agents_19/NNS (r_conj) have_5/VBP (l_dobj) risk_8/NN (l_prep) of_9/IN (l_pobj) development_10/NN (l_prep) of_11/IN (l_pobj) leukemia_14/NN
D001379_D008228 CID azathioprine_21/NN (r_conj) agents_19/NNS (r_conj) have_5/VBP (l_conj) associated_23/VBN (l_prep) with_24/IN (l_pobj) development_26/NN (l_prep) of_27/IN (l_pobj) lymphoma_32/NN
D003520_D001749 CID Cyclophosphamide_0/NNP (r_compound) therapy_1/NN (r_nsubj) increases_2/VBZ (l_dobj) risk_4/NN (l_prep) of_5/IN (l_pobj) carcinoma_6/NN (l_prep) of_7/IN (l_pobj) bladder_9/NN
D003520_D002277 CID Cyclophosphamide_0/NNP (r_compound) therapy_1/NN (r_nsubj) increases_2/VBZ (l_dobj) risk_4/NN (l_prep) of_5/IN (l_pobj) carcinoma_6/NN (l_prep) of_7/IN (l_pobj) bladder_9/NN
D001379_D001172 NONE azathioprine_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) studies_7/NNS (l_prep) of_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) arthritis_12/NN
D001379_D009369 NONE azathioprine_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) studies_7/NNS (l_conj) incidence_20/NN (l_prep) of_21/IN (l_pobj) most_22/JJS (l_prep) of_23/IN (l_pobj) cancers_26/NNS
D003520_D001172 NONE cyclophosphamide_17/NN (r_conj) azathioprine_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) studies_7/NNS (l_prep) of_8/IN (l_pobj) patients_9/NNS (l_prep) with_10/IN (l_pobj) arthritis_12/NN
D003520_D009369 NONE cyclophosphamide_17/NN (r_conj) azathioprine_15/NN (r_pobj) with_14/IN (r_prep) treated_13/VBN (r_acl) studies_7/NNS (l_conj) incidence_20/NN (l_prep) of_21/IN (l_pobj) most_22/JJS (l_prep) of_23/IN (l_pobj) cancers_26/NNS
D000477_D009369 NONE agents_31/NNS (r_appos) drugs_27/NNS (r_pobj) of_25/IN (r_prep) use_24/NN (r_nsubjpass) reserved_41/VBN (r_conj) collected_14/VBN (l_nsubjpass) Data_0/NNS (l_prep) on_1/IN (l_pobj) risk_5/NN (l_prep) of_6/IN (l_pobj) malignancy_7/NN
D000477_D001172 NONE agents_31/NNS (r_appos) drugs_27/NNS (r_pobj) of_25/IN (r_prep) use_24/NN (r_nsubjpass) reserved_41/VBN (r_conj) collected_14/VBN (l_nsubjpass) Data_0/NNS (l_prep) on_1/IN (l_pobj) risk_5/NN (l_prep) in_8/IN (l_pobj) arthritis_10/NN
D000477_D001172 NONE agents_31/NNS (r_appos) drugs_27/NNS (r_pobj) of_25/IN (r_prep) use_24/NN (l_prep) in_33/IN (l_pobj) treatment_35/NN (l_prep) of_36/IN (l_pobj) arthritis_38/NN
3503576
D003676_D006311 NONE deferoxamine_8/JJ (r_compound) therapy_9/NN (r_dobj) receiving_7/VBG (r_acl) patients_6/NNS (r_pobj) in_5/IN (r_prep) studies_1/NNS (l_prep) of_2/IN (l_pobj) neurotoxicity_4/NN
D003676_D006311 NONE deferoxamine_26/NN (r_pobj) with_23/IN (r_prep) receiving_19/VBG (r_relcl) patients_11/NNS (r_pobj) in_7/IN (r_prep) documented_6/VBN (l_nsubjpass) neurotoxicity_3/NN
D003676_D006311 NONE deferoxamine_9/JJ (r_compound) doses_10/NNS (r_dobj) receiving_8/VBG (r_advcl) restarted_24/VBN (l_prep) depending_36/VBG (l_prep) on_37/IN (l_pobj) degree_39/NN (l_prep) of_40/IN (l_pobj) abnormality_42/NN
D003676_D006311 NONE deferoxamine_14/NNP (r_dobj) receiving_13/VBG (r_conj) receiving_10/VBG (r_acl) patients_9/NNS (r_pobj) in_7/IN (r_prep) demonstrated_5/VBD (l_prep) provided_18/VBD (l_dobj) evidence_20/NN (l_prep) for_21/IN (l_pobj) relation_28/NN (l_prep) between_29/IN (l_pobj) administration_31/NN (l_conj) ototoxicity_33/NNP
D003676_D006311 NONE deferoxamine_30/NNP (r_compound) administration_31/NN (l_conj) ototoxicity_33/NNP
D007501_D014786 NONE iron_20/NN (r_compound) chelation_21/NN (r_compound) therapy_22/NN (r_dobj) receiving_19/VBG (r_relcl) patients_11/NNS (r_pobj) in_7/IN (r_prep) documented_6/VBN (l_nsubjpass) neurotoxicity_3/NN
D007501_D006311 NONE iron_20/NN (r_compound) chelation_21/NN (r_compound) therapy_22/NN (r_dobj) receiving_19/VBG (r_relcl) patients_11/NNS (r_pobj) in_7/IN (r_prep) documented_6/VBN (l_nsubjpass) neurotoxicity_3/NN
D007501_D000740 NONE iron_20/NN (r_compound) chelation_21/NN (r_compound) therapy_22/NN (r_dobj) receiving_19/VBG (r_relcl) patients_11/NNS (l_prep) with_12/IN (l_pobj) anemia_16/NN
D003676_D014786 NONE deferoxamine_26/NN (r_pobj) with_23/IN (r_prep) receiving_19/VBG (r_relcl) patients_11/NNS (r_pobj) in_7/IN (r_prep) documented_6/VBN (l_nsubjpass) neurotoxicity_3/NN
D003676_D000740 NONE deferoxamine_26/NN (r_pobj) with_23/IN (r_prep) receiving_19/VBG (r_relcl) patients_11/NNS (l_prep) with_12/IN (l_pobj) anemia_16/NN
D003676_D064420 NONE deferoxamine_9/JJ (r_compound) doses_10/NNS (r_dobj) receiving_8/VBG (r_advcl) restarted_24/VBN (l_conj) demonstrated_55/VBN (l_nsubjpass) toxicity_53/NN
18261172
D020123_D011507 CID sirolimus_6/NN (r_npadvmod) based_8/VBN (r_amod) immunosuppression_9/NN (r_pobj) to_5/IN (r_prep) switch_4/NN (r_pobj) after_3/IN (r_prep) Development_0/NN (l_prep) of_1/IN (l_pobj) proteinuria_2/NN
D020123_D011507 CID sirolmus_7/NNP (r_intj) novel_1/JJ (r_nsubj) lacks_11/VBZ (l_ccomp) reported_23/VBN (l_nsubjpass) proteinuria_17/NN
D020123_D011507 CID Srl_9/NNP (r_appos) sirolmus_7/NNP (r_intj) novel_1/JJ (r_nsubj) lacks_11/VBZ (l_ccomp) reported_23/VBN (l_nsubjpass) proteinuria_17/NN
D020123_D011507 CID Srl_20/NNP (r_pobj) with_19/IN (r_prep) associated_18/VBN (r_acl) proteinuria_17/NN
D020123_D011507 CID Srl_10/NNP (r_pobj) with_9/IN (r_prep) associated_8/VBN (r_acl) proteinuria_7/NN
D020123_D011507 CID Srl_12/NNP (r_pobj) to_11/IN (r_prep) switch_10/NN (r_pobj) after_9/IN (r_prep) develop_4/VB (l_nsubj) proteinuria_2/NN
D020123_D011507 CID Srl_0/NNP (r_nsubjpass) used_3/VBN (l_prep) with_4/IN (l_pobj) therapy_8/NN (l_conj) patients_10/NNS (l_acl) monitored_11/VBN (l_prep) for_12/IN (l_pobj) proteinuria_13/NN
D020123_D007674 NONE sirolmus_7/NNP (r_intj) novel_1/JJ (r_nsubj) lacks_11/VBZ (l_dobj) effects_13/NNS (l_compound) nephrotoxic_12/NNP
D020123_D007674 NONE Srl_9/NNP (r_appos) sirolmus_7/NNP (r_intj) novel_1/JJ (r_nsubj) lacks_11/VBZ (l_dobj) effects_13/NNS (l_compound) nephrotoxic_12/NNP
D020123_D007674 NONE Srl_20/NNP (r_pobj) with_19/IN (r_prep) associated_18/VBN (r_acl) proteinuria_17/NN (r_nsubjpass) reported_23/VBN (r_ccomp) lacks_11/VBZ (l_dobj) effects_13/NNS (l_compound) nephrotoxic_12/NNP
D020123_D007674 NONE Srl_0/NNP (r_nsubjpass) used_3/VBN (l_prep) with_4/IN (l_pobj) therapy_8/NN (l_appos) dysfunction_17/NN
D000806_D011507 NONE inhibitor_1/NN (r_nsubj) reduced_11/VBD (l_dobj) development_13/NN (l_compound) proteinuria_12/NN
D000806_D011507 NONE ACEi_5/NNP (r_nmod) ARB_7/NN (r_compound) therapy_8/NN (l_conj) patients_10/NNS (l_acl) monitored_11/VBN (l_prep) for_12/IN (l_pobj) proteinuria_13/NN
D057911_D011507 NONE blocker_6/NN (r_nmod) therapy_10/NN (r_conj) inhibitor_1/NN (r_nsubj) reduced_11/VBD (l_dobj) development_13/NN (l_compound) proteinuria_12/NN
D057911_D011507 NONE ARB_8/NNP (r_nmod) therapy_10/NN (r_conj) inhibitor_1/NN (r_nsubj) reduced_11/VBD (l_dobj) development_13/NN (l_compound) proteinuria_12/NN
D057911_D011507 NONE ARB_7/NN (r_compound) therapy_8/NN (l_conj) patients_10/NNS (l_acl) monitored_11/VBN (l_prep) for_12/IN (l_pobj) proteinuria_13/NN
D000806_D007674 NONE ACEi_5/NNP (r_nmod) ARB_7/NN (r_compound) therapy_8/NN (l_appos) dysfunction_17/NN
D057911_D007674 NONE ARB_7/NN (r_compound) therapy_8/NN (l_appos) dysfunction_17/NN
19037603
D019259_D012216 NONE lamivudine_3/NNP (r_pobj) of_2/IN (r_prep) use_1/NN (l_prep) with_4/IN (l_pobj) therapy_7/NN (l_prep) for_8/IN (l_pobj) disorders_10/NNS
D019259_D012216 NONE lamivudine_18/NNP (r_pobj) of_17/IN (r_prep) administration_16/NNP (r_pobj) of_13/IN (r_prep) effectiveness_12/NN (l_prep) in_19/IN (l_pobj) patients_30/NNS (l_prep) with_31/IN (l_pobj) disease_33/NN
D019259_D012216 NONE lamivudine_23/JJ (r_compound) therapies_24/NNS (r_pobj) on_18/IN (r_prep) were_17/VBD (r_relcl) diseases_14/NNS
D006514_D012216 NONE antigen_24/NN (r_nmod) patients_30/NNS (l_prep) with_31/IN (l_pobj) disease_33/NN
D006514_D012216 NONE Ag_27/NNP (r_nmod) patients_30/NNS (l_prep) with_31/IN (l_pobj) disease_33/NN
D006514_D012216 NONE Ag_9/NNP (r_nmod) patients_11/NNS (l_prep) with_12/IN (l_pobj) diseases_14/NNS
8690168
D006497_D003928 NONE sulphate_3/NN (r_npadvmod) associated_5/VBN (r_amod) sites_7/NNS (l_prep) with_15/IN (l_pobj) nephropathy_20/NN
D013311_D003928 CID streptozotocin_16/NNS (r_npadvmod) induced_18/VBN (r_amod) nephropathy_20/NN
D006497_D003920 NONE sulphate_1/NN (r_npadvmod) associated_3/VBN (r_amod) sites_5/NNS (r_dobj) Heparan_0/NNP (r_nsubjpass) studied_12/VBN (l_prep) after_17/IN (l_pobj) induction_18/NN (l_prep) of_19/IN (l_pobj) diabetes_20/NN
D006497_D003920 NONE sulphate_18/NN (r_compound) density_22/NN (r_nsubjpass) found_24/VBN (l_prep) in_3/IN (l_pobj) rats_7/NNS (l_amod) diabetic_6/JJ
D013311_D003920 NONE streptozotocin_22/NNS (r_pobj) by_21/IN (r_prep) induction_18/NN (l_prep) of_19/IN (l_pobj) diabetes_20/NN
D013311_D003920 NONE streptozotocin_4/NNP (r_npadvmod) diabetic_6/JJ
C015445_D003920 NONE blue_38/NN (r_dobj) employing_33/VBG (r_advcl) studied_12/VBN (l_prep) after_17/IN (l_pobj) induction_18/NN (l_prep) of_19/IN (l_pobj) diabetes_20/NN
18417364
D009538_D009759 CID Nicotine_0/NN (r_npadvmod) induced_2/VBN (r_amod) nystagmus_3/NN
D009538_D009759 CID nicotine_3/NN (r_npadvmod) induced_5/VBN (r_amod) nystagmus_6/NN
D009538_D009759 CID nicotine_3/NN (r_npadvmod) induced_5/VBN (r_amod) nystagmus_6/NN (l_appos) NIN_8/NNP
D010100_D009759 NONE oxygen_4/NN (r_nmod) levels_12/NNS (r_pobj) with_2/IN (r_prep) correlated_1/VBD (l_nsubj) NIN_0/NNP
